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Backgrounds: The prognostic significance of additional lung nodules in the setting of 
lung cancer is important as the impact on survival is often considered for the justification 
of surgical selection in the management of patients with synchronous nodules. TNM 7 
down staged the impact on T category but did not distinguish between second primary 
versus metastasis. Traditional distinctions such as the Martini criteria do not take the 
same histological type into account and classification continues to improve (e.g. IASLC 
classification of adenocarcinoma). The aim of our study is to determine if it is possible 
to distinguish between second primary versus metastases in patients with the same 
histological type and quantity any difference in survival. Methods: We retrospectively 
analysed data from a prospectively collated database at our institution. We collected 
all the records which included two resected nodules. The detailed pathology reports 
of these patients were retrieved and the histology, subtype and pTNM of tumours 
documented. Slides were re-reviewed to determine the histological subtypes according 
to the current IASLC adenocarcinoma classification. Survival was calculated using Kaplan 
Meier methods and adjusted survival compared using Cox regression on R (statistical 
software). Results: From April 1999 to February 2013, a total of 2925 lung cancer 
resection were performed. Of these, 379 (14%) operations fulfilled the inclusion criteria 
of multiple nodules with 316 having synchronous tumours (83.3%) and 63 having 
metachronous tumours (16.6%). The tumours were ipsilateral in 87.3% and the vast 
majority were in the same lobe (70.9%). For synchronous tumours, patients with the 
same histological type had a poorer 5-years survival rate compared to tumours with 
different histology (p=0.041). The pathologist’s designation between second primary 
versus intra-pulmonary metastasis distinguished between overall survival (p= 0.001) and 
this remained statistically significant in the tumours of the same cell type (p= 0.035). 
 
Figure 1. Survival outcomes between patients with multiple nodules classified as second 
primary versus intra-pulmonary metastasis 
 
 
Conclusion: Our results suggest that distinction between second primary and intra-
pulmonary metastasis remains important for staging as appreciable differences in survival 
were observed in patients with synchronous nodules. Survival was poorer in patients 
with multiple nodules of the same histologic type (compared to different histology) and 
within the same histological subtype it is possible for pathologists to distinguish between 
second primary and intra-pulmonary metastasis. As this is currently confirmed only on 
pathologic stage in the majority, it presently does not influence the selection for surgery. 
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MINI01.03 Pathology-Imaging Agreement in Distinguishing Separate Primary 
Tumours and Intrapulmonary Metastasis in Staging of Multiple Lung Cancers 
Patrizia Viola1, Anand Devaraj2, Eric Lim3, Giulia Luciano3, Sanjay Popat4, Andrew G. 
Nicholson5 1Histopathology, Royal Brompton Hospital, London/United Kingdom, 2Department 
of Imaging, Royal Brompton Hospital, London/United Kingdom, 3Thoracic Surgery, Royal 
Brompton Hospital, London/United Kingdom, 4Medical Oncology, Royal Marsden Hospital, 
London/United Kingdom, 5Pathology, Royal Brompton and Harefield NHS Foundation Trust 
and National Heart and Lung Institute, London/United Kingdom
Background: The 7th TNM staging system for lung cancer recommended staging 
for cases with multiple nodules viewed as intrapulmonary metastases (IM) as T3 
(same lobe), T4 (ipsilateral different lobe) and M1a (contralateral lobe), whilst those 
classified as separate primary tumours (SPTs) as T(x)NM where “x” is the number of 
primary tumours, either as a number or “m” for multiple. With an increase in patients 
presenting with multiple nodules, we sought to develop a set of criteria for c-staging 
on imaging and to determine the agreement between clinical and pathological staging 
in a cohort of resected lung cancers who had multiple nodules. Methods: In 2013 and 
2014, there were a total of 48 consecutive cases with available imaging resected with 
multiple tumours, ranging from 2 to 5 nodules. Of these, one case was excluded as it 
was a carcinoid with background DIPNECH. These cases were classified as SPT or IM 
based on previously published criteria (Girard et al. Am J Surg Pathol 2009;33:1752-
64). Imaging criteria were generated based on clinical experience in similar fashion with 
indicators of SPT being 1) Lesions of equivalent size (one not more than 100% of the 
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MINI01.01 Immunohistochemical Distinction between Primary Lung Squamous 
Cell Carcinoma and Pulmonary Metastasis of Head and Neck Squamous Cell 
Carcinoma Junji Ichinose1, Aya Shinozaki-Ushiku2, Kazuhiro Nagayama1, Jun-Ichi 
Nitadori1, Masaki Anraku1, Masashi Fukayama2, Jun Nakajima1, Daiya Takai3 1Department 
of Thoracic Surgery, University of Tokyo Hospital, Tokyo/Japan, 2Department of Pathology, 
University of Tokyo Hospital, Tokyo/Japan, 3Department of Clinical Laboratory, University of 
Tokyo Hospital, Tokyo/Japan
Background: It is extremely difficult to distinguish between primary lung squamous cell 
carcinoma (LUSq) and pulmonary metastasis of head and neck squamous cell carcinoma 
(HNSq) in patients with a past history of HNSq, even by histological examination of the 
resected specimen. This study aimed to establish an immunohistochemical scoring 
system for discrimination between LUSq and pulmonary metastasis of HNSq. Methods: We 
selected genes that were expressed in a markedly different manner in LUSq and HNSq 
using the results of expression microarrays and chose the antibodies for four proteins 
(CK19, MMP3, ZNF830, PI3) that had immunohistochemical results shown in the Human 
Protein Atlas (http://www.proteinatlas.org) that were distinguishable between LUSq and 
HNSq. We constructed the tissue microarrays using the resected specimens of 39 LUSqs 
and 48 HNSqs as the training set and evaluated the tendency of HNSq using the 16-grade 
system according to the positive staining of the four antibodies. Twenty-seven of the 
patients with pulmonary tumors that were resected and pathologically diagnosed as 
squamous cell carcinoma between 1999 and 2014 had a past history of HNSq. Their 
pulmonary tumors and primary HNSqs were analyzed immunohistochemically as the test 
set. We defined LU-associated recurrence as postoperative recurrence in the thoracic 
cavity, mediastinum, brain, bone, and liver and defined HN-associated recurrence as 
recurrence in the other sites. We compared the diagnosis of our immunohistochemical 
scoring system to the preoperative clinical diagnosis and the pathological diagnosis 
according to the predictive power of HN-associated recurrence. Results: The sensitivity, 
specificity, and accuracy of our immunohistochemical scoring system were 90%, 67%, 
and 79%, respectively in the training set, and our system correctly diagnosed 96% of 
HNSq specimens in the test set. Twenty-three out of 27 pulmonary tumors in the test set 
were diagnosed as pulmonary metastasis of HNSq, and four were diagnosed as LUSq. 
Eleven of 23 patients (48%) with pulmonary metastasis of HNSq developed HN-associated 
recurrence (3-year HN-associated recurrence-free probability was 46%), and 10 died 
because of HNSq, while none of the four patients with LUSq had HN-associated 
recurrence. Compared with the clinical diagnosis (five LUSq, 14 pulmonary metastasis of 
HNSq, eight uncertain) and the pathological diagnosis (two LUSq, 17 pulmonary 
metastasis of HNSq, eight uncertain), our immunohistochemical scoring system could 
predict the risk of HN-associated recurrence more accurately.
 
 
Conclusion: Immunohistochemical analysis of four proteins (CK19, MMP3, ZNF830, PI3) 
was clinically useful for discrimination between LUSq and pulmonary metastasis of HNSq. 
Keywords: Immunohistochemistry, Squamous cell carcinoma, pulmonary metastasis, 
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MINI01.02 Is It Possible to Distinguish between Second Primary vs. Metastasis 
in Resectable Synchronous Nodules with the Same Histotype of Lung Cancer? 
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other) 2) Smaller lesion is spiculated , 3) At least one lesion is subsolid, 4) Presence 
of field change. (For signs 1 and 2, if the lesions were in different lungs, an absence 
of mediastinal disease on imaging was required). Cases with at least one positive 
sign were classified as SPTs. The interobserver agreement between radiologists and 
pathologist were then generated. Results: Of the 47 cases, the additional nodules 
were not identifiable on CT in 7 cases. In the remaining 40 cases, there was agreement 
in 28 cases, of which 16 were SPTs and 12 were IM. Of 12 cases where there was 
disagreement, only 3 were SPTS and the majority were cases classified on pathology 
as IM. There was 70% agreement, greater than that expected by chance (p = 0.002) 
with a kappa value of 0.41. Conclusion: Moderate agreement can be achieved in terms 
of clinical and pathological staging of lung cancers presenting with multiple nodules 
using imaging and pathologic criteria. Using pathology as the gold standard, there 
was greater agreement in categorisation of SPTs (84% (16/19)) than IM (57% (12/21)). 
Keywords: separate primary tumours (SPTs), intrapulmonary metastasis (IMs), Staging, 
lung cancer
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MINI01.05 Local Diagnostic Practices for Advanced Non-Small-Cell Lung 
Cancer in Europe and Japan: ASSESS Study Nicola Normanno1, Koichi Hagiwara2, 
Baohui Han3, Sergei Tjulandin4, Christian Grohé5, Takashi Yokoi6, Alessandro Morabito7, 
Silvia Novello8, Edurne Arriola9, Olivier Molinier10, Rose Mccormack11, Marianne Ratcliffe11, 
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Giovanni Pascale’, IRCCS, Naples/Italy, 2Jichi Medical University, Saitama Medical Center, 
Saitama-Ken/Japan, 3Department of Respiratory Medicine, Shanghai Chest Hospital, Jiao 
Tong University, Shanghai/China, 4Department of Clinical Pharmacology and Chemotherapy, 
Russian Cancer Research Center, Moscow/Russian Federation, 5Arzt Fur Innere Medizin, 
Pneumologie and Kardiologie, Evangelische Lungenklinik Berlin, Berlin/Germany, 6The 
Department of Thoracic Oncology, Kansai Medical University Hirakata Hospital, Osaka/
Japan, 7Thoraco-Pulmonary Department, Instituto Nazionale Tumori-Fondazione Pascale, 
Naples/Italy, 8Thoracic Oncology Unit, Department of Clinical and Biological Sciences, 
University of Torino, Torino/Italy, 9Oncology Department, Hospital Del Mar, Barcelona/
Spain, 10Centre Hospitalier General Du Mans, Le Mans/France, 11Personalised Healthcare and 
Biomarkers, Astrazeneca, Macclesfield/United Kingdom,12Department of Thoracic Oncology, 
Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German 
Center for Lung Research (DZL), Grosshansdorf/Germany
Background: ASSESS (a large, multicentre, non-interventional, diagnostic study; 
NCT01785888) evaluated local diagnostic practices for patients with advanced non-
small-cell lung cancer (aNSCLC) in Europe/Japan. Methods: Eligible patients: local/
metastatic aNSCLC; chemotherapy-naïve, newly diagnosed/recurrent disease after 
resection; ineligible for curative treatment. We report diagnostic assessments and 
epidermal growth factor receptor (EGFR ) mutation test turnaround times (secondary 
endpoints) associated with tissue/cytology samples from patients in Europe/Japan. 
Results: 1311 patients enrolled (300 Japan). Immunohistochemistry (IHC) was used 
to confirm pathological diagnosis in 727/960 (76%) and 142/146 (97%) patients in 
Europe and Japan, respectively (where data were available); the following markers were 
assessed using IHC: TTF-1 (Europe 96% and Japan 79%); p65 (4% and 8%); and p40 (9% 
and 24%). EGFR mutation tests were not performed on samples from 110 patients and 
tested samples from 17 patients did not yield results. The most common reason for not 
testing was insufficient material provided (Europe 60% [47/78 responses]; Japan 56% 
[5/9 responses]). The percentages of neoplastic cells in samples (data available: Europe 
n=281; Japan n=20) were: <20% tumour cells: Europe 15% vs Japan 35%; 20–50% 
tumour cells: 23% vs 45%; >50% tumour cells: 61% vs 20%. Considering sampling 
methodologies, the most common sampling sites (data available: Europe n=996; Japan 
n=291) were the lung parenchyma (Europe 73%; Japan 79%) or lymph nodes (Europe 
9%; Japan 9%); the most common sample collection method was bronchoscopy (Europe 
39%; Japan 68%; Table 1). Median EGFR mutation test turnaround time was longer in 
Europe (11 days) versus Japan (8 days; Table 2). Mutation test success rates for Europe 
and Japan were 98.3% and 99.6%, respectively. Conclusion: Diagnostic assessments, 
sampling methodologies and EGFR mutation testing practices vary between and within 
Europe and Japan; further understanding of local practices will drive improvements and 
enable more patients to receive appropriate personalised treatment. 
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MINI01.07 Comparison of Grading Systems Based on Histologic Patterns and 
Mitotic Activity to Predict Recurrence in Stage I Lung Adenocarcinoma (ADC)  
Kay See Tan1, Kyuichi Kadota2, Andre Moreira1, Prasad S. Adusumilli1, William D. Travis1 
1Memorial Sloan-Kettering Cancer Center, New York/NY/United States of 
America, 2Department of Diagnostic Pathology, Kagawa University, Kagawa/Japan
Background: An established grading system for lung adenocarcinoma does not exist but 
is greatly needed. The histologic classification proposed by the International Association 
for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS) and the 
European Respiratory Society (ERS) has been shown to define prognostically significant 
subgroups of lung adenocarcinoma (ADC). Since then, various grading systems based 
on histologic patterns have emerged as promising methods to further discriminate 
patient risk of clinical outcomes. The aim of this work is to quantitatively assess the 
discrimination properties of a set of grading systems proposed in recent years to identify 
the best grading scale(s) independent of other clinical factors to predict recurrence. 
Methods: We considered five grading systems: (1) single predominant pattern as six 
subtypes; (2) as three grades of low (lepidic), intermediate (acinar, papillary) and high 
(micropapillary, solid); (3) two most predominant grades; (4) predominant grade with 
mitotic grade; and (5) predominant grade with cribriform pattern and mitotic activity 
criteria. We evaluated the performance of each grading system with the concordance 
predictive estimate (CPE). The CPE represents the probability that for any pair of 
patients, the patient with the better predicted outcome from the Cox model had the 
longer survival time. CPE > 0.80 demonstrates strong performance. To compare the 
performance of the grading systems, we determined the significance of the differences 
between the CPEs. Five-year recurrence-free probability (RFP) was derived using the 
Kaplan-Meier method. Results: We applied the grading systems to a uniform large cohort 
of stage I lung ADC (N=909). The scale based on the single predominant pattern as five 
subtypes yielded a CPE of 0.63 (95% CI, 0.59-0.67), indicating moderate discrimination. 
Our analysis showed that grading systems (1), (2), and (3) were not significantly different 
from each other, suggesting that identifying finer subtypes and second predominant 
pattern may not improve discrimination. Grading system (4) [CPE, 0.67; 95% CI, 0.63-
0.71] yielded a significantly higher CPE than (1), (2) and (3) [p<0.01]. Grading system 
(5) [CPE, 0.67; 95% CI, 0.63-0.71] was significantly better than (1), (2) and (3) but not 
(4) [p=0.776]. The lack of improvement in discrimination with the inclusion of cribriform 
between (4) and (5) can be attributed to the significant relationship between cribriform 
pattern and mitoses. As the proportion of cribriform pattern increased, the amount of 
mitotic activity also increased (p<0.001). Under (2), the 5-year RFP of the intermediate 
grade was 0.81. The addition of cribriform and mitotic counts further classified the 
intermediate (acinar, papillary) grade such that those with <10% cribriform and low 
mitotic count had 5-year RFP of 0.89, while the 5-year RFP for the other combinations 
are between 0.73-0.75. Conclusion: Grading systems based on histologic patterns and 
mitotic activity out-perform those with only histologic pattern. This comparison study 
suggests that proposed grading systems (4) or (5) provide valuable information in 
discriminating patients with different risks of disease-recurrence in patients with lung ADC. 
Keywords: Adenocarcinoma, Pathology, grading, histology
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MINI01.06 Pathological Second-Predominant Component Predicts Recurrence 
in Lung Adenocarcinoma Masaoki Ito1, Yoshihiro Miyata1, Yasuhiro Tsutani1, 
Takeshi Mimura1, Shuji Murakami2, Hiroyuki Ito2, Haruhiko Nakayama3, Morihito Okada1 
1Department of Thoracic Surgery, Hiroshima University Hospital, Hiroshima/Japan, 2Thoracic 
Oncology, Kanagawa Cancer Center, Yokohama/Japan, 3Thoracic Surgery, Kanagawa Cancer 
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Background: Lung adenocarcinoma is pathologically subdivided according to its 
predominant component. Approximately 50–70% of invasive adenocarcinomas are 
diagnosed as adenocarcinomas of either papillary or acinar predominant subtype. 
The prognostic difference between these subtypes has not been revealed, and these 
2 similar subtypes may further be classified. This study aimed to investigate whether 
the pathological second-predominant component that follows the most predominant 
component predict recurrence in adenocarcinoma. Methods: We retrospectively 
reviewed 347 consecutive cN0 lung adenocarcinoma cases resected between April 2006 
and December 2010 at Hiroshima University Hospital and Kanagawa Cancer Center. We 
further classified papillary and acinar predominant adenocarcinomas into either the 
papillary/acinar-lepidic type (Pap/Aci-Lep type) or the papillary/acinar-nonlepidic type 
(Pap/Aci-NonLep type). Tumor recurrence and the frequency of each invasion status 
such as lymphatic, vascular, and pleural invasion were compared between Pap/Aci-
Lep type and Pap/Aci-NonLep type adenocarcinomas. In addition, we estimated the 
correlation between the radiological and pathological characteristics of these subtypes. 
Whole-tumor size, ground-glass opacity (GGO) ratio, solid size, and tumor disappearance 
ratio (TDR) on high-resolution computed tomography and maximum standardized uptake 
value (SUVmax) on positron emission tomography (CT) were measured as radiological 
parameters. Results: Papillary (n = 70) and acinar predominant adenocarcinomas (n = 
61) were subdivided into the Pap/Aci-Lep type (n = 72) and Pp/Aci-NonLep type (n = 59). 
Compared with the Pap/Aci-NonLep type, the Pap/Aci-Lep type showed a significantly 
higher disease-free survival rate (5-year DFS: 89.4% vs 70.6%, p = 0.0374) and fewer 
cases of lymphatic invasion (15.3% vs 30.5%, p = 0.037), vascular invasion (15.3% vs 
33.9%, p = 0.013), and pleural invasion (9.72% vs 25.4%, p = 0.031). Furthermore, 
radiological findings significantly differ between the Pap/Aci-Lep and Pap/Aci-NonLep 
types as follows: GGO ratio (µ ± 1 ´ SD: 34.4% ± 25.2% vs 3.81% ± 18.0%, p < 0.01), 
CT solid size (µ ± 1 ´ SD: 1.35 ± 0.65 cm vs 1.73 ± 0.55 cm, p = 0.015), TDR (µ ± 1 
´ SD: 41.8% ± 26.7% vs 17.5% ± 22.6%, p < 0.01), and SUVmax (µ ± 1 ´ SD: 2.37 ± 
2.15 vs 3.96 ± 3.06, p < 0.01). Significant recurrence-free survival and prevalences 
of lymphatic and vascular invasion were observed between the lepidic predominant 
type (n = 109) and Pap/Aci-Lep type. Conclusion: The pathological second-
predominant component allows for subclassification of papillary and acinar predominant 
adenocarcinomas with prognostic significance. Pathological features of these subtypes 
can be represented on clinical imaging. Not only the most predominant component 
but also the second-predominant component should be given clinical and pathological 
attention in order to predict malignant potential or decide indication for adjuvant therapy. 
Keywords: clinical image, Pathology, Prognosis, Staging
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Background: Both the response and the therapeutic ratio of targeted agents in 
NSCLC may depend on the expression of the target molecules in the tumor and the 
surrounding non-malignant lung tissue. We therefore performed transcriptome analysis 
and investigated correlations with histology, gender, age, CRP level and smoking status 
as well as evaluated the differential pathway expression in primary resected NSCLC 
and the surrounding non-malignant lung of the same patient. Methods: Transcriptome 
sequencing was performed on the primary tumor and distant lung tissue of the same 
patient from resection specimens of NSCLC patients. Differential gene expression 
between different conditions was identified using the statistical algorithms Cufflinks, 
EdgeR and DeSeq. Differential expression with P-values <0.05 after Benjamini-Hochberg 
correction was considered significant. Pathway analysis for overall tumor versus distant 
lung tissue was performed with the PANTHER gene classification platform using the 
Cufflinks, DeSeq and EdgeR differentially expressed gene sets as input. Results: Twenty-
five patients were studied, 19 males and 6 females, with a median age of 69 years. Ten 
were current smokers, 14 former smokers (>4 weeks before surgery) and 1 non-smoker. 
Eleven patients had squamous cell carcinoma, 14 adenocarcinoma. A heat map with 
the results for the most commonly targeted genes in NSCLC is represented in figure 
1. When compared to distant lung tissue, PD-L1 was downregulated in tumor tissue of 
adenocarcinoma and active smokers, but not in squamous cell carcinoma or ex-smokers. 
Internal control of tumor tissue of squamous vs. adenocarcinoma and ex-smokers vs. 
active smokers shows an important trend towards a higher expression of PD-L1 in 
squamous cell carcinoma and ex-smokers in both Cufflinks and EdgeR algorithms. 
Additional pathway analysis revealed 188 differentially regulated pathways. The most 
notable were downregulation of VEGF signaling, angiogenesis and B and T cell activation 
in tumor tissue when compared to distant lung tissue.
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Background: Gene expression profiling can provide valuable information beyond the 
morphologic diagnosis. A previously validated 52-gene Lung Subtype Panel (LSP) for 
differentiating lung tumors into Adenocarcinoma (AD), Squamous Cell Carcinoma(SQ), 
and Neuroendocrine (NE) was explored in several publically available lung tumor datasets, 
including the TCGA RNAseq dataset. Methods:  The LSP 3-class nearest centroid 
predictor developed in array data was applied to AD and SQ samples in TCGA (RNAseq, 
n=1,160), the Director’s Challenge (Affy array, n=442), and Tomida et al. (Agilent array, 
n=117) datasets. Each sample was predicted as AD, SQ, or NE. Kaplan Meier plots and 
log rank tests were used to assess and compare 5-year overall survival in two gene 
expression groups, AD predicted AD (AD-AD) and AD predicted SQ or NE (AD-notAD). 
Cox models were used to assess survival differences while controlling for T stage, N 
stage, and proliferation (as measured by the PAM50 score). The distribution of samples 
among the AD subtypes (Terminal Respiratory Unit(TRU), Proximal Proliferative(PP), and 
Proximal Inflammatory(PI) was investigated. Results:  The predictor confirmed AD in 
80% of the AD samples. AD samples were called SQ and NE by the LSP in 8% and 
12% of cases, respectively. The AD-notAD group (AD by histology and SQ or NE by 
gene expression LSP) had worse survival than the AD-AD group (AD by both histology 
and LSP) in each data set (logrank p-value in TCGA, Director’s Challenge, and Tomida 
were 1.17e-06, 0.0009, and 0.0001, respectively). Pooling the 3 data sets and using 
a stratified cox model that allowed for different baseline hazards in each study, the 
hazard ratio comparing AD-notAD to AD-AD was 2.14 (95% CI 1.70-2.70). When we fit 
the model adjusting for T stage, N stage, and proliferation score, the HR was 1.70 (95% 
CI 1.31-2.20). Adenosubtype profiling of AD-notAD samples indicated that tumors were 
overwhelmingly of the PP or PI gene expression subtypes (209/213). Conclusion:  Gene 
expression tumor subtyping may provide valuable clinical information identifying a subset 
of AD samples with poor prognosis. Poor prognosis adenocarcinoma samples belong to 
the PI and PP expression subtypes, and demonstrate elevated proliferation scores. This 
subset of AD tumors may be less responsive to standard adenocarcinoma management. 
Keywords: Prognosis, Diagnostics, Gene Expression, Tumor classification
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MINI01.10 Analysis of the Status of Lymphocyte Infiltration in Patients with 
NSCLC Eduardo A. Richardet1, Martin E. Richardet1, Patricia A. Hernandez1, Evelin 
Pets2, Matias Cortes1, Matias Molina1, Aldo A. Riso1, Cecilia Di Tada2, Luciana P. Acosta1, 
Pablo Companys1, Martin Paradelo2 1Capital, IONC (Instituto Oncologico de Cordoba), 
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Background: Current evidence highlights the potential role of tumor-infiltrating 
lymphocytes (TILs) as a prognostic factor in many types of tumors; in non-small cell 
lung cancer (NSCLC), this relationship is not well determined. TILs are being studied 
with different methods such as immunohistochemistry and optical microscopy. The 
primary endpoint is to identify TILs in patients with NSCLC, classified as present or 
absent, and its relation to progression-free survival (PFS) and overall survival (OS). Our 
secondary endpoint is to establish the relationship between the TILs and treatment 
received. Methods: Retrospective and analytical case study of Instituto Oncológico de 
Córdoba, from 2004 to 2014. 166 patients with stage IIIB and IV NSCLC were analyzed. 
TILs are descriptively classified as present or absent. Survival curves were calculated 
using the Kaplan-Meier method. Results: 59% of patients had adenocarcinoma and 41% 
squamous cell carcinoma. 70% were men. 82% were smokers. 58% of patients with 
squamous histology and 65% with adenocarcinoma, showed TILs. In relation to first-
line chemotherapy, 63,8% of patients received carboplatin-paclitaxel (CP) and 36,2% 
gemcitabine-cisplatin (GC). Patients with adenocarcinom with TILs present had higher 
PFS and OS; 8.86 and 13.43 months respectively, compared to patients with absent, 
3.78 and 7.9 months. These differences were statistically significant (PFS: p = 0.000002 
and OS: p = 0.003). The patients with squamous cell carcinoma with TILs had 6.78 and 
12 months PFS and OS respectively. Those who had infiltrated absent had a PFS of 3.96 
months and OS of 6.37 months. These differences were also statistically significant (PFS: 
p = 0.003 OS p = 0.001). Conclusion: Our study shows that patients whose pathological 
samples presented inflammatory infiltrate had higher OS and PFS. The presence 
of TILs could be used as an important prognostic factor in this patient population. 
Keywords: TILs, NSCLC, PFS, OS
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Studies, University of Leicester, Leicester/United Kingdom, 2MRC Toxicology Unit, HN/United 
Kingdom
Background: Early lung adenocarcinomas have previously been successfully sub-
classified by Noguchi et al on the basis of histopathological characteristics, in particular 
the pattern of growth exhibited by the tumour and the response of the adjacent stroma. 
A wholly in situ pattern of growth characterises preinvasive lung lesions, namely atypical 
adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS). It is not uncommon 
for large areas of an invasive tumour to show this in situ pattern of growth. Metastases 
to the lung from other organs can also show areas of in situ spread, and this shows 
that truly invasive malignant clones of cells can grow along the alveolar surface. This 
study aimed to identify whether the characteristics of in situ growth in an individual 
tumour may give an indication of the underlying tumour biology, and be of prognostic 
value. Methods: We reviewed all small (sub 35 mm) lung adenocarcinomas resected with 
curative intent over a 4 year period from our thoracic surgical centre. Nodal metastasis 
data was also collected, which the reviewing pathologists were blinded to. All tumour 
sections were reviewed by 2 thoracic histopathologists, who separated these into 4 
categories, based on the patterns of growth, stromal changes, cytological changes 
between in situ and invasive components and overall symmetry of the lepidic growth. On 
the basis of these appearances early lung adenocarcinomas were divided into 4 groups. 
Type 1 showed minimal stromal reaction analogous to Noguchi A/B tumours. Types 2 
and 3 are subdivisions of mixed in situ/invasive adenocarcinomas (equivalent to the 
Noguchi C group). Type 2 showed marked stromal changes in the invasive component 
and a cytologically lower grade asymmetrical lepidic component. Type 3 showed a 
concentric rim of lepidic growth cytologically similar to the invasive disease. Type 4 
were wholly invasive tumours. Tumour type was subsequently correlated to pathological 
lymph node staging. Results: 156 tumours were included and sub-classified. Of these 
12 were type 1, 30 were type 2, 46 were type 3 and 68 were type 4. The rate of nodal 
metastasis was increased across the tumour types from 1 to 4, at 0%, 7%, 24% and 
29% respectively. Conclusion: We find that partly invasive lung adenocarcinomas fall 
into two histologically and biologically distinct groups with different potential toward 
nodal metastasis. We suggest the type 2 tumours represent the emergence of an 
invasive subclone in an in situ adenocarcinoma lacking this property. The type 3 tumours 
have a lepidic region at their edge which represents infiltration of normal structures 
by migratory malignant cells but may have no truly biologically ‘in situ’ disease. This 
group also shows more tendency toward metastasis. Type 4 lesions without any kind 
of lepidic growth have the highest rate of nodal involvement, and their destructive 
pattern of growth represents the most aggressive form of early tumours. Future 
molecular characterisation of these lesions and their various components may further 
inform our understanding of the pathways of tumorigenesis in lung adenocarcinoma. 
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Conclusion: Our first results show a higher expression of PD-L1 in squamous tumors 
than in adenocarcinoma and a higher expression in tumors of ex-smokers than in those 
of active smokers. This may have consequences for the therapeutic ratio with anti-
PD-L1 treatment. Downregulation of VEGFR-genes in tumor tissue was observed across 
almost all conditions. We will make this data more complete by adding methylation data 
as well as immunohistochemistry for protein localization.  
Keywords: PD-L1, Transcriptome sequencing, non-small cell lung cancer, Targeted 
agents
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MINI01.12 Implementation of a Molecular Tumor Board: The Impact on 
Treatment Decisions for NSCLC Patients Evaluated at Dartmouth-Hitchcock 
in One Year Laura J. Tafe1, Ivan P. Gorlov2, Francine De Abreu1, Joel A. Lefferts1, 
Xiaoying Liu1, Jason R. Pettus1, Jonathan D. Marotti1, Katarzyna J. Bloch2, Vincent A. 
Memoli1, Arief A. Suriawinata1, Camilo E. Fadul3, Gary N. Schwartz3, Clinton R. Morgan3, 
Britt M. Holderness3, Jason D. Peterson1, Gregory J. Tsongalis1, Todd W. Miller2, Mary 
D. Chamberlin3, Konstantin H. Dragnev3 1Department of Pathology, Dartmouth-Hitchcock 
Medical Center, Lebanon/NH/United States of America, 2Norris Cotton Cancer Center, 
Lebanon/NH/United States of America, 3Medical Oncology, Dartmouth-Hitchcock Medical 
Center, Lebanon/NH/United States of America
Background: Genetic profiling of tumors is a powerful approach to predict drug 
sensitivity and resistance. Definitive interpretation of the clinical significance of 
somatic mutations is possible for only a few well studied mutations. For the majority, 
prediction of clinical significance is challenging. We established a Molecular Tumor 
Board (MTB) at our Cancer Center to interpret individual patients’ tumor genetic profiles 
and provide treatment recommendations. Methods: DNA from tumor specimens 
was sequenced in a Clinical Laboratory Improvement Amendments (CLIA) -certified 
laboratory to identify coding mutations in a 50-gene panel. Cases were evaluated by 
a MTB composed of molecular and anatomic pathologists, medical oncologists, basic 
research scientists, and genetic counselors. Results: 35 cases were evaluated in 1 
year by the MTB including 8 metastatic NSCLC cases. The most common reason for 
MTB referral was for recommendations on targeted therapies (91.9%), and for potential 
germline mutations. Tumors exhibited genetic heterogeneity: 71 different mutations 
were found across 300 genes (for NSCLC 18 mutations across 10 genes). In 18/32 
of advanced/metastatic cases, MTB recommended non-standard therapy with a 
specific targeted agent (11 clinical trials; 7 off-label use), 4 of the 18 patients were 
subsequently treated with a MTB-recommended targeted therapy. The remaining 14 
patients continued on current therapy because disease was stable (n=4), were treated 
with non-MTB-recommended standard therapy (n=4), declined conventional therapy 
(n=5), or died prior to receiving further therapy (n=1). For 4 out of the 8 NSCLC cases 
MTB recommended a BRAF inhibitor (1), RET inhibitor (1), or MET inhibitor (2). One 
patient received a BRAF inhibitor, 6 continued on current standard of care therapy, one 
declined therapy. Conclusion: Case evaluation by a multidisciplinary group of individuals 
in the context of a MTB frequently shapes treatment options and decisions. Importantly, 
anticipated obstacles to capitalizing on the benefits of a MTB such as access to drugs 
were rarely encountered in the entire cohort and in the NSCLC patients. Instead, the most 
commonly encountered reasons that MTB-recommended therapy was not administered 
stemmed from patient preferences, and genetic profiling at a very late stage of disease. 
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%) exhibited PD-L1 expression in the primary tumor, which was significantly associated 
with smaller tumor size, lower pT stage, nodal disease, solid-predominant pattern, 
the presence of tumor islands, necrosis and lymphovascular invasion, and increased 
CD8+ TILs (grade 2-3). Upon multivariate analysis, only increased CD8+ TILs remained 
significant (p=0.039). As for the primary – lymph node correlation, PD-L1 expression was 
seen in 57.6% of 59 N1 nodes, 53.1% of 32 N2 nodes, and 100% of one N3 node available 
for evaluation. The PD-L1 expression status was the same between the primary tumor 
and nodal metastases in the majority (76.3 % of N1 nodes, and 75.0% of N2; p<0.001 
and p=0.005, respectively), and the upregulation of PD-L1 expression (positive expression 
was present in nodal metastasis with negative primary) was seen in only small fractions 
of the cohort (6.8% of N1 nodes and 9.3% of L2 nodes). Interestingly, PD-L1 expression 
in the primary tumor was associated with longer RFS in patients who underwent platinum-
based adjuvant therapy (mean 84 months vs. 41 months in PD-L1 negative patients, 
p=0.016), but not in those without adjuvant therapy. Conclusion: PD-L1 expression in 
the primary tumor was associated with prominent CD8+ TILs as well as several adverse 
clinicopathological parameters including nodal disease, but PD-L1 expression in the nodal 
metastasis was similar to that in the primary tumor in the majority of cases. Although 
the evaluation was limited due to a small size of the cohort, PD-L1 expression in the 
primary tumor appears to be predictive of response to platinum-based adjuvant therapy. 
Keywords: PD-L1, lung adenocarcinoma, Adjuvant therapy, lymph node
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MINI02.03 Overexpression of CD47, Decrease of Apoptosis and Phagocytosis 
of Neutrophils in Advanced Non-Small Cell Lung Cancer Patients Lourdes 
Barrera1, Oscar Arrieta Rodriguez2, Renato Morales-Flores3, Angeles Garcia-Vicente4, 
Edgar Montes-Servín2, Fernanda Salinas-Parra3, Alejandra Ramirez-Tirado2 1Business 
Oncology Unit, Astrazeneca, Mexico City/Mexico, 2Laboratory of Experimental Oncology 
and Thoracic Oncology Unit, National Institute of Cancer, Mexico City/Mexico, 3Laboratory 
of Experimental Oncology, National Institute of Cancer, Mexico City/Mexico, 4Faculty of 
Sciences, National Autonomous University of Mexico, Mexico City/Mexico
Background: Lung cancer is the leading cause of cancer death worldwide and most of 
the patients are diagnosed with advanced disease. Inflammatory components play a key 
role in tumor progression and survival. Neutrophils are increased in blood of patients 
with lung cancer and they are associated with poor clinical outcomes. CD47 is a protein 
which control cell communication, apoptosis, adhesion and proliferation and it has been 
found increased in cancer and related with phagocytosis evasion mechanism.The aim 
of this study was to evaluate CD47 expression levels on peripheral neutrophils, also 
assess the phenotype, apoptosis, activation state, reactive oxygen species production 
of neutrophils between patients with Non-Small Cell Lung Cancer (NSCLC) and healthy 
subjects. Methods: Fifty NSCLC patients (stage IIIB and IV) naive to treatment and 
25 healthy subjects were analized for: CD47 peripheral blood expression, neutrophils 
phenotype and activation state, evaluation of apoptosis and phagocytosis by flow 
cytometry. Reactive oxygen species (ROS) production by circulating neutrophils upon 
stimulation with PMA was assessed by flow cytometry. For the phagocytosis assay, 
PMNC were labeled with CMFDA and were cultured in RPMI for 24 hrs. To obtain apoptotic 
target cells, 24h PMNC were labeled with Annexin-V. For the evaluation of phagocytosis, 
the neutrophils from NSCLC patients were co-cultured with THP-1 cells. The percentage 
of phagocytosis was assessed by flow cytometry. Results: Our results showed a lower 
percentage of total CD47 in peripheral blood cells in NSCLC patients compared to controls 
[P=0.042]. Mean Fluorescence Intensity (MFI) of CD47 was higher in patients [P<0.001]. 
The percentage of CD66b+ cells characterized as neutrophils was higher in patients as 
well as their MFI of CD47 [P< 0.001]. MFI of CD66b was higher in patients [P< 0.0178]. This 
would be related with a more activated state. We found that a higher disease stage (IIIB vs. 
IV) associated with a higher MFI of CD47 [P=0.020]. Plasma pro-inflammatory cytokines, 
was increased in patients compare to controls IL-6 (P<0.002), IL-8 (P<0.001), IL-12p70 
(P<0.008), TNF (0.010) and IFN-g (P<0.001). MFI of CD47 >1635.5 was associated with 
a higher median Overall survival (P= 0.007). We found a decrease of AnnexinV+/7AAD+ 
in neutrophils of patients [P=0.0317]. Caspases 3 and 7 were found decreased in 
neutrophils of patients [P= 0.049]. Oxygen species (ROS) production of neutrophils upon 
PMA stimulation was increased in patients [P=0.029], suggesting it might play a role in 
immune effector function. Phagocytosis of apoptotic neutrophils by differentiated THP-1 
cells was decrease in cancer patients cells (P=0.0445). Mean fluorescence Intensity 
of CD47 was increased after 24 hrs in patients [P=0.0408]. This result suggests 
that neutrophils from patients avoid being engulfed and this may be associated with 
overexpression of CD47. Conclusion: Taken together, these findings suggest that 
these are altered mechanisms by which neutrophils evade anti-tumor immune response 
and their increased expression of CD47 is a potential therapeutic target for NSCLC. 
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MINI02.04 Sequential Assessment of DNA Damage Response and PD-
L1 Expression in Circulating Tumor Cells of Lung Cancer Patients during 
Radiotherapy Steven H. Lin1, Jianzhong He1, Martin Edelman2, Ting Xu1, Hui Gao3, 
James Reuben3, Yawei Qiao1, Holly Liu1, Pete Amstutz4, Stephen Hahn1, Ritsuko 
U. Komaki1, Zhongxing Liao1, Cha-Mei Tang4, Daniel Adams4 1Radiation Oncology, 
The University of Texas MD Anderson Cancer Center, Houston/TX/United States of 
America, 2Greenebaum Cancer Center, University of Maryland, Baltimore/United States of 
America, 3Hematopathology, The University of Texas MD Anderson Cancer Center, Houston/
TX/United States of America, 4Creatv Microtech, Inc., Potomac/MD/United States of America
Background: Recent evidence suggests that PD-L1 expression can be induced with 
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MINI02.01 Pulmonary Large Cell Carcinoma and Solid Adenocarcinoma 
Are Highly Mutated with Frequent Expression of PDL1 David H. Hwang1, 
Anthony Perry2, Frank Kuo1, Scott J. Rodig1, Lynette Sholl1, Jason L. Hornick1 
1Department of Pathology, Brigham and Women’s Hospital, Boston/MA/United States of 
America, 2Department of Pathology, Utah Valley Regional Medical Center, Provo/UT/United 
States of America
Background: Large cell carcinoma (LCC) is an uncommon lung tumor that arises 
predominantly in smokers and shares many features of solid adenocarcinoma (ADC). 
40% of LCC/solid ADC harbor mutations in KRAS; EGFR and ALK alterations are rare in this 
tumor type. The majority of these tumors, however, lack one of the commonly queried 
oncogenic driver alterations, thus therapeutic options are limited for patients with this 
tumor type. Immunomodulatory therapies, including targeting PDL1, have shown promise 
in a variety of tumor types. Tumor neo-antigens, including those induced by smoking, 
are associated with mutational burden and may predict susceptibility to cytolytic 
immune response; in addition, high PDL1 expression in non small cell lung carcinoma 
has been associated with response to anti-PDL1 drugs. Given the high prevalence of 
smoking in patients with LCC and solid ADC, we hypothesize that these tumors may be 
amenable to immunomodulatory therapy and sought to define the frequency of PDL1 
expression in tumors lacking an oncogenic driver mutation. Methods: This study was 
restricted to 27 LCC and solid ADC known to be negative for KRAS, EGFR, ALK and 
ROS1 alterations. Hybrid capture targeted next generation sequencing (NGS) on an 
Illumina HiSeq 2500 was performed using a cancer genomic assay to detect mutations, 
copy number variations (CNVs) and structural variants. The assay captures exonic 
sequences of 275 cancer genes and 91 introns across 30 genes for rearrangement 
detection. Findings were compared to an institutional cohort of 732 consecutive 
lung tumors sequenced on the same platform. Immunohistochemistry for PDL1 was 
performed using a rabbit monoclonal antibody (Cell Signaling Technologies) at 1:100 
dilution following pretreatment with citrate buffer/pressure cooker and detected using 
the Envision + polymer system (DAKO). Immunostaining was considered positive 
in the tumor component or the inflammatory component if ≥5% of the cells showed 
membranous staining. Results: Of the 27 tumors tested, 26 were resected from 
smokers. NGS revealed an average of 14.9 mutations per case for LCC/solid ADC 
cohort versus 8.1 mutations in the overall cohort of lung tumors (p<0.0001). 11 cases 
(41%) were positive for PD-L1. 7 cases (26%) showed strong, diffuse staining (≥70% 
of cells) for PD-L1. The inflammatory component was positive for PD-L1 in 25 cases 
(93%). Two cases with strong expression of PD-L1 by immunohistochemistry (>90% of 
cells) showed focal amplification of CD274 by NGS. Conclusion: LCC and solid ADC are 
strongly associated with a smoking history and harbor a significantly higher average 
mutational burden than other lung tumors. 41% of LCC/solid ADC are positive for PDL1 
by immunohistochemistry with 26% showing very strong PDL1 expression and nearly 
all cases showing some degree of positivity in the associated inflammatory infiltrate. In 
some cases, high PDL1 expression is associated with focal amplification of CD274, the 
gene encoding PDL1. These findings suggest that LCC/solid ADC is likely to have smoking-
associated neo-antigen expression and that PDL1-directed immunotherapies may be 
a promising therapeutic approach in this otherwise poorly-characterized lung tumor. 
Keywords: large cell carcinoma, solid adenocarcinoma, next generation sequencing, 
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MINI02.02 Programmed Cell Death Ligand (PD-L1) Expression in Stage II 
and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga1, Emine 
Bozkurtlar1, Tiffany Huynh1, Alona Muzikansky2, Aaron Hata2, Justin F. Gainor2, Eugene 
Mark1, Jeffrey A. Engelman2, Michael Lanuti3, Mari Mino-Kenudson1 1Pathology, 
Massachusetts General Hospital, Boston/MA/United States of America, 2Cancer Center, 
Massachusetts General Hospital, Boston/MA/United States of America, 3Thoracic Surgery, 
Massachusetts General Hospital, Boston/MA/United States of America
Background: Inhibition of PD-L1 can lead to reactivation of tumor immunity and assist 
in cancer therapy. PD-L1 expression in tumor cells has been reported to correlate with 
clinicopathological parameters and prognosis in a variety of cancers including lung 
adenocarcinomas (ADC). However, it has not been well studied whether PD-L1 expression 
is altered along with tumor progression. In addition, little is known about the role of 
PD-L1 expression in predicting response to chemotherapy in ADC. Thus, we sought to 
compare PD-L1 expression in the main tumor and lymph node metastases of stage II and 
III ADC, and correlate PD-L1 expression with survival in patients who underwent adjuvant 
chemotherapy. Methods: The study cohort consisted of 109 ADC who underwent 
curative resection without neoadjuvant therapy and were diagnosed to have stage II or III 
disease. Of those, 60 cases received platinum-based adjuvant therapy and were followed 
at our institution. Immunohistochemistry for PD-L1 (E1L3N, 1:200, CST) was performed 
on sections of the primary tumor and/or metastatic lymph nodes and the primary tumor 
sections were also stained with CD8 (4B11, RTU, Leica Bond). Membranous staining of 
any intensity present in 5% or more of the tumor cells was deemed positive for PD-L1 
expression. CD8+ tumor infiltrating lymphocytes (TILs) were evaluated using a 4-tier 
grading system (0-3). The PD-L1 expression in the primary tumor was correlated with 
that in lymph node metastases as well as clinicopathological parameters, including 
CD8+ TILs, and recurrence free survival (RFS). Results: Of the 109 cases, 53 (48.6 
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MINI02.07 Preclinical Rationale for a Phase I/II Study of Pembrolizumab (P) 
and Vorinostat (V) in Immune Therapy Naïve and Pretreated Stage IV NSCLC  
Nishan Tchekmedyian1, Hong Zheng2, Amer A. Beg2, Eric Haura1, Dung-Tsa Chen3, 
Scott J. Antonia1, Jhanelle Gray1 1Dept of Thoracic Oncology, Moffitt Cancer Center and 
Research Institute, Tampa/FL/United States of America, 2Dept of Immunology, Moffitt Cancer 
Center and Research Institute, Tampa/United States of America, 3Dept of Biostatistics 
and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa/United States of 
America
Background: The WHO estimated that 1.6 million people died of lung cancer in 2012. 
Nivolumab, an anti-PD-1 immune checkpoint inhibitor, was FDA approved on March 4, 2015 
for platinum-refractory, metastatic, squamous-cell NSCLC, based upon a RR to single 
agent nivolumab of ~15% and improved OS. Combinatorial strategies may enhance these 
outcomes. Increased tumor expression of T cell chemokines, such as CCL5 and CXCL10, 
is associated with a better response to immunotherapy. Furthermore, expression of T 
cell chemokines is strongly and positively associated with increased T cell infiltration and 
improved patient survival. Therefore, enhancement of expression of T cell chemokines 
may augment response to PD-1 blockade immunotherapy. Methods: FDA-approved 
oncology agents were utilized from the Approved Oncology Drugs Set (97 agents) from 
the Developmental Therapeutics program of NCI. LKR cells were plated in 96-well plates, 
and a viability assay was performed 48 hours after drug administration (Cell Counting Kit-
8, Dojindo Laboratories). Mice were bred and housed in the animal facility at Moffitt Cancer 
Center. Cells were harvested in logarithmic growth phase after being cultured for less 
than 2 weeks. 1x106 LKR or 344SQ cells were injected s.c. and tumors were monitored 
for growth by measurements 2-3 times per week. Romidepsin was injected i.p. (2mg/
kg) on days 14,16, and 18 after tumor inoculation. Anti-PD-1 was injected i.p. (300µg/
mouse) on days 15, 17, and 19 after tumor inoculation. Relative tumor size between 
treatment groups was analyzed using the t test with Welch’s correction. Results: Histone 
deacetylase inhibitors (HDACi), including vorinostat, emerged as the only class of agents 
in a 97-drug screen capable of inducing expression of multiple T cell chemokines, 
including CCL5, CXCL9, and CXCL10, in mouse and human lung cancer cell lines and 
primary tumors. HDACi’s ability to induce T cell chemokine expression was dependent 
on both JAK-STAT and NF-kB pathways. HDACi (romidepsin) treatment of mice bearing 
LKR tumors did not substantially cause tumor shrinkage but significantly reduced growth 
(p<0.0001; final tumor volume). This effect of HDACi was completely T cell dependent. 
LKR tumor cells had low cell surface expression of PD-L1 but which was substantially 
increased by IFN-g. PD-1 blockade with mAb reduced tumor growth but rarely induced 
rejection. However, when PD-1 blockade was combined with HDACi, 9 out of 11 mice 
demonstrated complete tumor rejection. HDACi anti-tumor response correlated with T cell 
chemokine induction in tumors and greater presence of tumor-infiltrating lymphocytes 
(TILs). We next used a mouse tumor model (344SQ) that was relatively resistant to anti-
PD-1 treatment. PD-1 blockade combined with HDACi significantly reduced growth of 
these tumors compared to untreated (p=0.0003), anti-PD-1 alone (p=0.01), or HDACi 
(p=0.004) alone treated mice. Conclusion: HDACi not only enhanced anti-tumor 
response against PD-1 blockade sensitive tumors (LKR), but also induced response 
against PD-1 blockade resistant tumors (344SQ). HDACi induces JAK-STAT and NF-kB 
dependent chemokine expression and may induce tumor-infiltrating lymphocytes. Thus, 
a Phase I/randomized Phase II clinical trial of vorinostat, an orally active, small molecule 
HDACi, plus pembrolizumab, an anti-PD-1 humanized monoclonal IgG4-kappa antibody, 
is planned in patients with immune therapy naïve and pre-treated metastatic NSCLC. 
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MINI02.08 Bidirectional Cross-Talk between CD14+ Monocytes and Human 
Lung Cancer Cell Lines Results in Different Phenotypic and Functional 
Outcomes Erin Schenk1, Aaron Mansfield1, Allan Dietz2 1Medical Oncology, Mayo 
Clinic, Rochester/MN/United States of America, 2Department of Laboratory Medicine and 
Pathology, Mayo Clinic, Rochester/MN/United States of America
Background: Myeloid cell infiltration of the tumor microenvironment is associated with 
decreased overall survival in multiple tumor types, including lung cancer. This myeloid 
cell infiltration represents a tissue component of the heterogeneous group of cells 
termed myeloid derived suppressor cells (MDSC), which can inhibit the endogenous 
anti-tumor response, direct angiogenesis, and promote tumor progression. In several 
studies of patients with non-small cell lung cancer (NSCLC), there is wide variation in 
the presence of myeloid cells in the tumor with increasing levels peripheral blood MDSC 
associated with poor survival. We have previously shown that CD14+ monocytes can 
be converted by the tumor microenvironment to an immune suppressive phenotype 
in non-Hodgkin lymphoma and glioblastoma. In this work, we expand on our earlier 
observations to include recruitment of CD14+ cells by lung cancer cell lines and their 
conversion to an immune suppressive phenotype. While most models of myeloid cells in 
the microenvironment describe the effects of these cells on non-malignant systems, we 
show that myeloid cells may have profound direct effects on the tumor. Methods: Human 
lung cancer cell lines were cultured and supernatants collected for ELISA. CD14+ 
cells were isolated from the peripheral blood of healthy volunteers using anti-CD14 
immunomagnetic beads. Lung cancer cell lines and CD14+ cells were cocultured under 
a variety of low serum conditions with or without cisplatin. Changes in CD14+ cell HLA-
DR expression and tumor cell survival were measured by flow cytometry. CD14+ cell 
migration through a permeable transwell membrane was measured in real time with 
live cell imaging. Results: Under normal culture conditions, 7 of 8 human lung cancer 
cell lines secreted detectable levels of CCL2, a major chemoattractant for monocytes, 
ranging from 30 to 10,000 pg/ml of CCL2 found in culture supernatants. CD14+ cells 
radiotherapy and may be a mechanism for resistance to radiotherapy and immunotherapy. 
Sequentially assessing PD-L1 expression on cancer associated cells in circulation 
during treatment regimens may be a way to assess the efficacy of radiotherapy and 
immunotherapy in clinical trials. For this feasibility study, we evaluated the association of 
RAD50 induction, and PD-L1 expression, on CTCs and Cancer Associated Macrophage-
Like Cells (CAMLs) in lung cancer patients (pts) before and during radiotherapy to 
determine expression changes of these markers. Methods: Eleven pts with stage I-IV 
lung cancer were included in this pilot study. Three pts received Stereotactic Body 
Radiation Therapy (SBRT) for stage I disease and 8 other pts received chemoradiation 
for stage II-IV disease. Baseline blood samples (7.5 ml) were drawn prior to the start 
of radiotherapy (T0) and a second blood sample was drawn at a follow up visit during 
radiotherapy; or for three pts, after completing SBRT (T1); for a total of 22 samples. 
Blood was processed using CellSieve™ microfiltration (Creatv Microtech), stained for 
cytokeratin 8, 18 & 19 and CD45, and imaged. Using the QUAS-R (Quench, Underivatize, 
Amine-Strip and Restain) technique to remove fluoresce signal, all cells were restained 
for RAD50-AlexaFluor550 and PD-L1-AlexaFluor 488, along with DAPI nuclear stain. The 
RAD50 foci numbers within nuclear regions were quantified. PD-L1 pixel intensity was 
measured by the ZenBlue software and grouped into 4 IHC groups: 0-negative (pixel 
average 0-215), 1-low (pixel average 216-300), 2-medium (pixel average 301-750), and 
3-high (pixel average 751+). Results: There was at least one cytokeratin positive cell 
(i.e. CTC or CAMLs) found in each of the samples. Specifically CTCs were found in 82% 
of T0 and 64% of T1 samples, and CAMLs were found in 91% of T0 and 100% of T1 
samples. RAD50 foci ranged from 0-16 per cell, with an average of 0.69 at T0 that 
increased to 3.46 at T1 (p=0.002) during radiotherapy. Distinctively, there were 6 pts 
with greater than 2 fold RAD50 foci increase at T1 and 5 pts with ≤ 2 fold induction. 
PD-L1 expression ranged from 34-2004 pixel intensity, with an average of 170 at T0 
and 336 at T1 (p=0.08). Interestingly, 4 pts had no PD-L1 expression at T0 but an 
increase to 2 to 3+ at T1, 4 pts with low/no PD-L1 expression remained low at T1, and 
3 pts had high PD-L1 expression that remained high or decreased at T1. There was no 
correlation between RAD50 induction and PD-L1 expression. Conclusion: Both RAD50 
foci and PD-L1 expression were quantifiable in both CTCs and CAMLs, and had variable 
responses to radiotherapy +/- chemotherapy. These data suggest that sequential 
tracking of CTCs or immune-related cells from the primary lung tumor is feasible using 
microfiltration and potentially can serve as predictive biomarkers for cancer therapy. 
Keywords: circulating tumor cells, cancer associated macrophage like cells, PD-L1, 
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Jonathan W. Riess2, James Keck1, Karolina Palucka3, Lenord Shultz4, Mingshan Cheng1, 
Danying Cai1, Carol Bult4, David R. Gandara2, Philip C. Mack2 1In Vivo Service, The Jackson 
Laboratory, Sacramento/CA/United States of America, 2UC Davis Comprehensive Cancer 
Center, Sacramento/United States of America, 3The Jackson Laboratory, Farmington/United 
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Background: Preclinical modeling of immunotherapeutics in PDX-bearing mice has 
been limited by the absence of a relevant immune microenvironment, as a highly 
immunosuppressive environment is often required for the implanted tumor to grow. 
Checkpoint inhibitors including anti-PD-1 and anti-PD-L1 antibodies (mAbs) are promising 
new treatments in non-small cell lung cancer (NSCLC). The creation of a PDX model 
system that supports human tumor growth and recapitulates the relevant genomics 
in NSCLC while providing the immune microenvironment necessary for anti-PD-1 and 
anti-PD-L1 mAb activity is critical for validation of combination checkpoint inhibitor 
strategies in NSCLC. Methods: Hematopoietic CD34+ progenitor stem cells (CD34+ 
HPC) were engrafted into the tail vein of sublethally irradiated NSG mice. A KRAS 
G12D PDX was assayed for PD-L1 expression by FACS (Biolegend; clone 29E. 2A3, 
San Diego CA) and implanted into Hu-CD34 NSG mice with > 25% Hu-CD45+ cells 12 
weeks post CD34+ HPC injection. Multilineage engraftment of immune cell subsets 
was assayed in peripheral blood, spleen and tumor by FACS (CD45, CD3, CD4, CD8, 
CD19). PDX were treated with vehicle Q5D x 6, pembrolizumab (Merck, Whitehorse 
Station PA) 5 mg/kg Q5D x 6, and combination pembrolizumab and docetaxel (Hospira, 
Lake Forest) 10 mg/kg Q7D x4 at the same single agent dosages. Body weight and 
tumor growth were assessed twice weekly. Results: Hu-CD45+ cells were detected in 
peripheral blood, spleen and tumor by flow cytometry on single cell suspension. The 
majority of Hu-CD45+ cells were T-cells: CD3CD4+ (mean blood 50%, spleen 53%, 
tumor 52%) and CD3CD8+ (mean blood 14%, spleen 15%, tumor 39%). KRAS G12D 
tumor had 89% surface expression of PD-L1. No significant change in Hu-CD45+ cell 
composition was noted between the different treatment groups. Pembrolizumab both 
alone and in combination with docetaxel showed activity in KRAS G12D PDX with 
substantial tumor growth inhibition and decreased mean tumor volume at day 24 post-
treatment. Conclusion: Multilineage engraftment of relevant immune cell subsets for 
PD-1 inhibition is present in the humanized immune-mouse (Hu-CD34 NSG). PD-1 inhibition 
in a KRAS G12D Hu-CD34 NSG with high PD-L1 expression demonstrated substantial 
tumor growth inhibition both alone and in combination with chemotherapy. Additional 
studies are underway exploiting the Hu-CD34 NSG mouse model for study of anti-PD-1/
PD-L1 therapies in KRAS mutant and other important molecular subsets of NSCLC. 
Keywords: NSCLC, Humanized model, KRAS, PD-1
S268 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
ratio were proved as predictors of prognosis in various cancers. Squamous non-small 
cell lung cancer (NSCLC) revealed to be divergent clinical and molecular phenotypes 
compared with non-squamous NSCLC. Significantly, combining application of 
appropriate biomarkers in prognosis prediction is emerging its high importance in cancer 
research. Methods: Chart review was performed on 1286 consecutive patients, 156 of 
these patients were enrolled in the final analysis. Patients with squamous NCSLC were 
randomly assigned (2:1) centrally by computer into training group and validation group. 
Monocyte ratio, Neutrophils to Lymphocytes Ratio, PD-L1 immunostaining score and PD-
1-positive stained tumor-infiltrating lymphocytes counts were assessed by Fisher’s linear 
discriminant analysis to discriminate if OS would exceeding 5 years. The final model was 
used to calculate the discriminant score in each study participant. And this prediction 
model was validated in a second set of squamous NCSLC patients. We internally validated 
the model using a cross-validation procedure. Results: 4 independent predictors of OS 
were identified by using FLDA with stepwise variant-selection. The clinical classifying 
model was described by the following equation: Y = −1.212 + 0.211 × NLR ratio + 
0.437 × monocyte ratio - 0.390 × PD-L1 + 0.035 × PD-1 (eigenvalue 0.673, canonical 
correlation 0.634, P < 0.001). In this equation, PD-L1 represented PD-L1 immunostaining 
score; and PD-1 represented PD-1 positive TILs counts. For the training set of 104 leave-
one-out-cross-validated cases, 27 of 29 OS > 5 years (93.1% sensitivity) and 61 of 75 OS 
<= 5 years (81.3% specificity) were correctly classified with an overall accuracy of 84.6% 
(88 of 104) and an AUC of 0.938 [P < 0.001, 95% confidence interval (CI) 0.864–1] Next, 
the predicting model consisting of the 4 predictors (NLR ratio, monocyte ratio, PD-L1 and 
PD-1) were applied to the validation set of 52 patients (14 OS > 5 years and 38 OS <= 5 
years). A survival prediction for 38 of the 52 patients (73.1%) with an AUC of 0.908 (P < 
0.001, 95% CI 0.806–1) was achieved. Also, 12 of 14 OS > 5 years (85.7% sensitivity) and 
26 of 38 OS <= 5 years (68.4% specificity) were correctly identified. Conclusion: The 
analysis of a set of immunological markers could effectively and reproducibly classify 
patients with squamous NCSLC according to their overall survival. Further prospective 
validation in larger independent cohorts of patients with similar or different regimens 
is warranted to fully assess its predictive power. The 4-immunological-marker 
model offers a novel tool for survival prediction and could have important clinical 
implications for the consideration of differential treatment strategies in patients 
with squamous NCSLC, thus providing a framework for future individualized therapy. 
Keywords: Prediction model, Squamous non-small cell lung cancer, Immunological 
markers
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MINI02.12 Distribution of Immune Markers and Their Association with Overall 
Survival and Time to Progression in Non-Small-Cell Lung Cancer (NSCLC) 
Andrew T. Kuykendall1, Farah Khalil2, Eric Haura2, Scott J. Antonia2, Matthew Schabath2, 
Dmitry Gabrilovich3, Ben Creelan2 1Internal Medicine, University of South Florida Graduate 
Medical Education, Tampa/FL/United States of America, 2Dept of Thoracic Oncology, Moffitt 
Cancer Center and Research Institute, Tampa/FL/United States of America, 3Wistar Institute, 
Philadelphia/PA/United States of America
Background: Inducible nitric oxide synthase (iNOS) and reactive nitrosylation are 
important mediators of tumor immunosuppression by myeloid-derived suppressor 
cells (MDSCs). However, the role of CD33+ peritumoral PMN-MDSCs in these pathways 
remains unclear. We conducted a retrospective cohort study of NSCLC subjects 
treated with surgery, with the primary objective to determine the association of MDSC 
biomarkers with time to progression (TTP) and overall survival (OS). Methods: Inclusion 
criteria: Surgically treated NSCLC of all stages at a single institution between 1996 
and 2010. Somatic mutations tested by PCR. Anti-human antibodies optimized for 
immunohistochemistry. Samples scored by blinded pathologist based on intensity and 
percentage of peritumoral cells. Peritumoral nitrotyrosine (NT) and iNOS used Allred 
scoring. Time to progression (TTP) defined as time from resection to progression event 
or censored at last evaluation. Overall survival (OS) defined as time from resection to 
death. Results: Of 458 tumor samples, 366 lung primaries, 38 soft tissue metastases, 
and 39 brain metastases. Demographics: median age 67 yrs, 54% female, 96% 
Caucasian. Of 151 tested for somatic mutations, 36% KRASm, 8.6% EGFRm, 25% p53m, 
respectively. Histology: adenocarcinoma 76%, squamous 10%. Higher % CD3+ tumor 
infiltrating lymphocytes (TILs) and CD33+ myeloid cells were observed in tumors than 
normal tissue (p < .0001 and p = .002, respectively). More CD3+ TILs observed in 
soft tissue metastases than primary lung tumors (p < .0001). No difference in iNOS 
expression between tumor and normal lung tissue. More CD3+ TIL was observed in p53 
mutant tumors (p=.03). iNOS was positively correlated with CD3+ TIL (p < .001) and 
CD73+ epithelial cells (p <.001), but not CD33+ myeloid cells. NT expression correlated 
with the absence of CD3+ TIL (p = .02), consistent with its putative immunosuppressive 
activity. Median TTP: 10.4 months; 320 (69.7%) events. Median OS: 35.4 months; 353 
(77.1%) events. Expectedly, presence of CD3+ TIL was associated with favorable OS; 
HR 0.5 [0.4 – 0.7], p < .0001, and TTP; HR 0.7 [.5 – .9], p =.009. CD33+ myeloid cells 
were associated with favorable OS; HR 0.6 [0.5-0.8], p = .0002. Presence of peritumoral 
iNOS trended toward favorable OS; HR 0.81 [0.6-1.0], p = .07. Peritumoral iNOS was not 
associated with TTP. 
more robustly migrated towards cell lines with higher production of CCL2. The coculture 
system showed a differential impact on monocytes by the tested lung cancer cell lines 
which either reliably upregulated or downregulated CD14+ cell expression of HLA-DR. 
In 3 of 8 lung cancer cell lines, CD14+ cell HLA-DR was downregulated in a manner 
expected to promote local immune suppression. Under serum starvation conditions, 
one lung cancer cell line showed improved survival when cocultured with CD14+ cells. 
Similarly, coculture with CD14+ cells enhanced tumor survival of two cell lines after 
exposure to cisplatin. Conclusion: The studied lung cancer cell lines differ in the degree 
of CD14+ cell recruitment, CD14+ cell HLA-DR expression after coculture, and level 
of conferred survival benefit under stressful conditions. Taken together these results 
suggest that the variable myeloid involvement in lung cancer patients can be modeled 
using lung cancer lines. In addition, we have identified that for some tumors, monocytes 
confer a significant survival advantage that is not associated with immune or angiogenic 
responses. Future work is needed to explore the impact of CD14+ cells on lung tumor 
invasiveness, angiogenesis, and the mechanisms underlying these pro-tumor effects. 
Keywords: lung cancer, Monocytes, Myeloid derived suppressor cells, tumor 
microenvironment
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MINI02.09 ERK Activation Mediates Increased PD-L1 Expression in KRAS 
Mutated Premalignant Human Bronchial Epithelial Cells Mi-Heon Lee1, Jane 
Yanagawa1, Shumin Wu1, Tonya Walser1, Gerald Wang1, Jonathan W. Goldman1, Edward 
B. Garon1, Gang Zeng1, Sherven Sharma1, John Minna2, David P. Carbone3, Steven 
M. Dubinett1, Jay M. Lee1 1University of California, Los Angeles, Los Angeles/CA/United 
States of America, 2UT Southwestern, Dallas/TX/United States of America, 3The Ohio State 
University, Columbus/OH/United States of America
Background: Immune checkpoint pathways including the PD-1/PD-L1 pathway are 
involved in tumor evasion from the immune system. Elevated PD-L1 expression in tumor 
cells inhibits tumor-infiltrating T cell function and may be associated with poor prognosis 
in lung cancer patients. There is increasing interest in developing immunotherapies 
that block the immunosuppressive effects of checkpoint pathways such as PD-L1, 
and identifying patients who may benefit from PD-L1 blockade. Activating KRAS 
mutations are common driver mutations in non-small cell lung carcinoma. Patients with 
mutated KRAS demonstrate less benefit from adjuvant chemotherapy and resistance 
to tyrosine kinase inhibitors. The effect of cancer cell driver mutations on immune 
checkpoint immune regulation is poorly understood. While recent clinical trials have 
suggested better response to PD-1 blockade in KRAS mutation subjects, it is unclear 
if this clinical finding is directly driven by KRAS regulating the PD-1/PD-L1 pathway 
with resultant improved efficacy to anti-PD-L1 immunotherapy or if the presence of a 
KRAS mutation is merely a surrogate marker of the overall mutational load and tumor 
immunogenicity. KRAS mutations are known to activate the RAF-MEK-ERK pathway. We 
hypothesize that KRAS mutation directly regulates the PD-1/PD-L1 pathway through 
ERK activation. Methods:Immortalized human bronchial epithelial cells (HBEC-vector 
control), KRAS–mutated (KRASv12) HBEC cells (HBEC-KRAS), p53 knockdown HBEC cells 
(HBEC-p53), and p53 knockdown/KRAS mutated cells (HBEC-p53/KRAS) were used to 
assess mRNA and/or surface protein expression levels of immune checkpoints including 
Lag-3, Tim-3, PD-L1 and PD-L2 by real time-qPCR (RT-qPCR) and flow cytometry, 
respectively. HBEC-vector and HBEC-KRAS cells were treated with MEK (ERK kinase) 
inhibitor (PD0325901) at 1µM for 24hrs and evaluated for mRNA and surface protein 
expression of PD-L1. The premalignant HBEC cell lines were used instead of human lung 
cancer cell lines in order to assess the role of KRAS mutation in isolation without other 
mutations. Results: PD-L1 and PD-L2 mRNA levels increased 2.4 fold (p<0.001) and 
3.6 (p<0.001) fold in comparing HBEC-KRAS to HBEC-vector (wild-type) cells, while Lag-
3 and Tim-3 mRNA expression levels were unchanged. Based on mean fluorescence 
intensity on flow cytometry, cell surface PD-L1 protein expression level was 2.2 and 1.6 
fold higher in HBEC-KRAS and HBEC-p53/KRAS, respectively, compared to HBEC-vector 
cells. There was no increase in surface PD-L1 expression in HBEC-p53 cells compared 
to HBEC-vector control, suggesting that p53 mutation did not alter PD-L1 expression 
in HBEC-p53/KRAS cells. With MEK inhibition, PD-L1 mRNA levels decreased 10 and 
11 fold in HBEC-vector and HBEC-KRAS cells, respectively. Analogously, PD-L1 surface 
protein levels were reduced 2.7 fold in HBEC-vector and HBEC-KRAS cells, respectively. 
These findings suggest that ERK activation mediates intrinsic expression and KRAS 
mutation mediates over-expression of PD-L1 mRNA and protein. Conclusion: Here, 
we demonstrate that PD-L1 expression is elevated in premalignant KRAS mutated 
human bronchial epithelial cells, and ERK activation mediates constitutive and KRAS 
mutation driven up-regulation of PD-L1 in these cells. Our findings suggest that KRAS 
mutation may directly regulate the PD-1/PD-L1 immune checkpoint pathway. Further 
understanding of KRAS driven molecular pathways that modulate immune checkpoints 
may elucidate therapeutic targets for potential combinational drugs to PD-L1 inhibition. 
Keywords: KRAS, PD-L1, PD-1
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MINI02.11 Immunological Markers Predict the Prognosis of Patients with 
Squamous Non-Small Cell Lung Cancer Long Jiang, Shanshan Jiang, Hao Long 
Sun Yat-Sen University Cancer Center, Guangzhou/China
Background: As one of the novel therapy strategies, PD-L1 has been shown the function 
of down-regulating T-cell activation through receptor PD-1. Moreover, prognosis of cancer 
patients are based not only on tumor-related factors but also on host-related factors, 
particularly systemic inflammatory response. As significant indicators of patients’ 
inflammation status, circulating monocyte count, neutrophil ratio and lymphocyte 
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MINI03.01 Prior TKI Therapy in NSCLC EGFR Mutant Patients Associates with 
Lack of Response to Anti-PD-1 Treatment 
Edward B. Garon, Brian Wolf, Aaron Lisberg, Kevin Y. Kim, John M. Horton, Naeimeh 
Kamranpour, Kevin Chau, Phillip Abarca, Marshall L. Spiegel, Mary Han, William Sago, 
Siwen Hu-Lieskovan, Kingshuk Das, William D. Wallace, Dennis J. Slamon, Steven M. 
Dubinett, Jonathan W. Goldman David Geffen School of Medicine at University of California, 
Los Angeles/Translational Research in Oncology-US Network, Santa Monica/CA/United 
States of America
Background: Programmed cell death-1 (PD-1) inhibitors have shown signifi cant 
potential to induce durable responses in non-small cell lung cancer (NSCLC). Although 
responses have been seen in patients (pts) whose tumors harbor epidermal growth 
factor receptor (EGFR) mutations (EGFRm), data to date with inhibitors of PD-1, or its 
ligand PD-L1, suggest that responses are less frequent in EGFRm NSCLC. Studies in 
which EGFRm pts receive EGFR tyrosine kinase inhibitors (TKIs) and PD-1 inhibitors in 
sequence or concurrently are being conducted. However, based on the high response 
rate with EGFR TKIs in EGFRm pts, PD-1 inhibition does not precede the EGFR TKIs in 
these study designs. Methods: We evaluated data from our experience at UCLA as part 
of the KEYNOTE-001 clinical trial, in which pts received pembrolizumab 2 mg/kg every 
3 weeks or 10 mg/kg every 2 or 3 weeks. Early in the trial, an amendment excluded 
EGFRm, EGFR TKI naïve pts, however a subsequent amendment allowed such pts if their 
mutation was non-sensitizing to approved EGFR TKIs. Although the trial employed central 
radiographic assessment by RECIST v1.1 (available to the sponsor but not the sites), 
clinical decisions and the assessment we describe were based on investigator-assessed 
immune-related response criteria. Groups were compared using Fisher’s exact test. 
Western blot was performed using standard techniques, exposing human non-small cell 
lung cancer cell lines HCC-827, H1975, Calu3 and H460 to erlotinib or afatinib at 1µM 
or control using the antibody PD-L1 mAb #1368 (Cell Signaling) and α-tubulin antibody 
#2144 (Cell Signaling). Results: We enrolled 29 EGFRm pts. 2 of 3 EGFR TKI naïve pts 
experienced a partial response (PR) compared to 1 of 26 enrolled after a prior EGFR 
TKI (p<0.001). 18 of these 29 pts had a 9 week scan. Of these, PR was seen in both 
EGFR TKI naïve pts (one L858R mutation and one exon 20 insertion) compared to 1 
of 16 enrolled after a prior EGFR TKI (p<0.001). Of note, a similar trend of increased 
responses in EGFR TKI naïve pts was not seen in EGFR wild type pts. In vitro experiments 
using erlotinib and afatinib showed unchanged PD-L1 levels in cell lines not inhibited by 
the EGFR TKI used, but reduced PD-L1 in EGFRm cell lines inhibited by the TKI. Of note, 
the only responder among the EGFR TKI-treated EGFRm pts was one of only 4 of the 16 
scanned post-TKI pts who had a non-sensitizing mutation. So, 0 of 22 EGFRm pts with a 
sensitizing mutation responded after an EGFR TKI. Conclusion: A retrospective analysis 
in EGFRm NSCLC showed a strong correlation between response and lack of prior EGFR 
TKI treatment. PD-L1 levels decrease in response to an EGFR TKI in cell lines sensitive 
to the TKI. Immunohistochemistry evaluating the presence and location of relevant 
proteins and immune effector cells are ongoing as is whole exome sequencing. These 
results have implications for the design of clinical trials of PD-1 inhibitors in EGFRm pts. 
Supported by: 1K23CA149079, One Ball Matt Memorial Golf Tournament, Kasdan Family 
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MINI03.02 PD-L1 Displays a Funtional Effect in the Acquired Chemoresistance 
in Lung Cancer Panpan Zhang Peking University Cancer Hospital, Beijing/China
Background: Although neoadjuvant chemotherapy (NAC) for advanced lung cancer can 
improve operability and local disease control, the duration of benefi t is limited before 
resistance develops. PD-L1, which was a co-stimulatory molecule,interacting with PD-1, 
has a crucial role in T-cell regulation in immune response. Interest remains in combining 
chemotherapy and immune therapies to overcome resistance. Methods: In the study, 
we used immunohistochemistry, real-time PCR and fl ow cytometry techniques to 
investigatethe correlation between overall survival (OS) and disease free survival (DFS) 
of lung cancer patients and the expression of programmed cell death ligand1 (PD-L1) and 
the effect of NAC on the expression of PD-L1 in lung cancer cells. Results: Firstly, we 
identifi ed PD-L1 was uprelugated in the SD lung cancer patient by the RNA-seq analysis. 
Therefore, we performed IHC evaluation in the total 194 patients of NSCLC. The patients 
with PD-L1 (−) had much better OS compared to those who were PD-L1 (+), and a high 
PD-L1 expression level in the cancer cells was signifi cantly correlated with a shorter OS 
and DFS in patients with NAC from the 194 patient (n=78). Meanwhile,in patients who 
had stable disease (SD) to NAC, there was a rise in the expression of PD-L1, and patients 
with NAC (n=78) had signifi cantly high rate of positive PD-L1 expression compared with 
those without NAC (n=116, p= 0.001). The chemotherapy of lung cancer can induce the 
expression of PD-L1, which may be one of the resistance mechanisms of NAC. Changes 
in PD-L1 expression were examined in vitro and vivo. Inhibition of the PI3K/AKT pathway 
reduced the up-regulation of PD-L1 induced by cisplatin, suggesting an involvement 
of PI3K/AKT pathway in up-regulation of PD-L1.Moreover, knock down of PD-L1 can 
lead to an increase in apoptosis, as well as cisplatin-induced apoptosis. And caspase7 
might play an important role in the apoptosis of lung cancer cells after the knockdown 
of PD-L1. Conclusion: These fi ndings support provide a relationship between PD-L1 
expression and chemoresistance. All in all, these results suggest the use of PD-L1 
inhibitor with chemotherapy after surgery, in lung cancer patients who received NAC. 
Conclusion: Increased presence of TILs in p53 mutant tumors has been reported in 
other cancers, and may be related to somatic mutational load. An infl amed tumor 
phenotype was associated with improved overall survival. Unexpectedly, iNOS was 
positively correlated with both CD3+ infi ltration and overall survival. 
Keywords: Myeloid-derived suppressor cells, Nitrosylation, Immunotherapy, Immune 
Markers
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MINI02.13 Immune Related Gene Signature Reveal Potential Role for 
Leukocyte-Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer 
Regulation Dalam Ly1, Chang-Qi Zhu2, Ming S. Tsao2, Li Zhang1 1Department of 
Laboratory Medicine and Pathobiology, University Health Network, Toronto General Research 
Institute and University of Toronto, Toronto/ON/Canada, 2Departments of Pathology, 
University Health Network, Princess Margaret Cancer Centre and University of Toronto, 
Toronto/ON/Canada
Background: Cancer development and biology is infl uenced by the host immune system. 
Emerging data indicate that the context of immune cell infi ltrates within the tumor is 
associated with cancer prognosis. Both the activation state and type of immune cells 
present can provide mediators that either promote or inhibit tumor growth. While the 
presence of activated cytotoxic T lymphocytes (CTL) may correlate with better patient 
survival, the presence of tumor associated macrophages and effector lymphocytes that 
lack cytotoxic properties may promote tumor growth. Thus, in established tumors, a 
balance between pro and anti-tumor mediators are present, but as advanced tumors 
rarely regress without therapeutic intervention, this balance is likely skewed towards 
tumor-promoting infl ammation. In attempts to gain insight into the immune networks 
that regulate tumorigenesis, we used genome wide gene expression datasets of primary 
lung cancer tissues to identify and functionally validate immune related genes that are 
associated with patient survival. Methods: Gene expression analysis was conducted 
on microarray datasets from 128 early-stage NSCLC resected tumor samples. Limiting 
analysis to immune-related gene sets curated by NIAID ImmPortal, we identifi ed a 
minimum gene set using MAximizing R Square Algorithm (MARSA) that selected for 
the greatest separation between good and poor prognostic patient subgroups. The 
prognostic value of this gene signature was validated in nine additional independently 
published microarray datasets of NSCLC. From the gene signature, we functionally 
characterized the potential role of the soluble protein LAIR2 in immune regulation of 
lung cancer. Results:We identify a 9-gene signature that separate patients into high and 
low-risk subgroups for 5-year cancer-free survival (hazard ratio 10.26, 95% confi dence 
interval 4.32-24.34, p<0.0001). The prognostic accuracy of this signature was validated 
in additional NSCLC datasets (total 1095 patients without adjuvant treatment). Amongst 
the 9-genes, the gene encoding the soluble protein LAIR2 was highly expressed within 
the high-risk patient subgroup. Functionally, we found that addition of recombinant LAIR2 
resulted in increased NK cell expression of cytotoxicity receptors and secretion of pro-
infl ammatory cytokines in the presence of lung cancer cell lines. Conclusion: By limiting 
gene expression analysis to immune related genes, we identify a 9-gene prognostic 
immune signature in resected early stage NSCLC patients. The signature identifi es a 
role for the soluble protein LAIR2 in the modulation of immune cell activation during 
lung cancer development and may suggest that LAIR2 induce a pro-infl ammatory 
microenvironment which promote tumorigenesis and poor patient outcome. 
Keywords: Immunology, Gene signature, infl ammation
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assessed every 9 weeks per RECIST v1.1 by central review. Patients evaluable for PD-L1 
were those whose slides were prepared within 6 months of staining and for which a 
proportion score could be assigned. Results: ORR in the 550 patients who received ≥1 
pembrolizumab dose was 18.9%. ORR was generally similar across subgroups (Table), 
although there may be a difference between ever and never smokers. Among the 409 
patients evaluable for PD-L1 expression, ORR was highest in those with PS ≥50% as 
compared with PS 1%-49% or <1% (36.8%, 11.9%, and 10.0%, respectively). Within all 
subgroups, ORR was highest in patients with PS ≥50% (Table). 
 
Conclusion: Pembrolizumab provides antitumor activity in a broad selection of 
subgroups of patients with advanced NSCLC. Improved response in patients whose 
tumors express PD-L1 in ≥50% of cells was observed for all subgroups. Ongoing analyses 
are investigating the interdependency between PD-L1 status, mutational status, and 
smoking. Keywords: pembrolizumab
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MINI03.06 Phase II Studies of Nivolumab in Patients with Advanced Squamous 
(SQ) or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC) 
Kazuhiko Nakagawa1, Makoto Nishio2, Toyoaki Hida3, Hiroshi Sakai4, Naoyuki 
Nogami5, Shinji Atagi6, Toshiaki Takahashi7, Hiroshi Nokihara8, Hideo Saka9, Mitsuhiro 
Takenoyama10, Shiro Fujita11, Hiroshi Tanaka12, Koji Takeda13, Miyako Satouchi14, 
Hiroshi Isobe15, Makoto Maemondo16, Koichi Goto17, Tomonori Hirashima18, Koichi 
Minato19, Tomohide Tamura20 1Medical Oncology, Kinki University Faculty of Medicine, 
Osaka-Sayama,Osaka/Japan, 2The Cancer Institute Hospital of the Japanese Foundation for 
Cancer Research, Tokyo/Japan, 3Aichi Cancer Center Hospital, Nagoya/Japan, 4Saitama 
Cancer Center, Saitama/Japan, 5National Hospital Organization Shikoku Cancer Center, 
Matsuyama/Japan, 6National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka/
Japan, 7Shizuoka Cancer Center, Shizuoka/Japan, 8National Cancer Center Hospital, Tokyo/
Japan, 9National Hospital Organization Nagoya Medical Center, Nogoya/Japan, 10National 
Kyushu Cancer Center, Fukuoka/Japan, 11Institute of Biomedical Research and Innovation, 
Kobe/Japan, 12Niigata Cancer Center Hospital, Niigata/Japan, 13Osaka City General Hospital, 
Osaka/Japan, 14Hyogo Cancer Center, Akashi/Japan, 15KKR Sapporo Medical Center, 
Sapporo/Japan, 16Miyagi Cancer Center, Natori/Japan, 17National Cancer Center Hospital 
East, Chiba/Japan, 18Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 
Osaka/Japan, 19Gunma Prefectural Cancer Center, Ohta/Japan, 20St.Luke’s International 
Hospital, Tokyo/Japan
Background: Nivolumab (anti-PD-1, ONO-4538, BMS-936558), a fully human IgG4, 
PD-1 immune-checkpoint inhibitor antibody, has shown durable clinical activity in 
previous[MS誠1] phase I and II trials in several tumor types. In March 2015, U.S. Food 
and Drug Administration (FDA) has approved Nivolumab for the treatment of patients 
with metastatic squamous (SQ) non-small-cell lung cancer (NSCLC) with progression 
on or after platinum-based chemotherapy. Here, we report the results of two phase II 
studies to evaluate the effi cacy and safety of nivolumab in previously treated advanced 
SQ (JapicCTI-No.132072) and NSQ (JapicCTI-No.132073) NSCLC pts. Methods: Both 
studies required pts aged ≥ 20 years with an ECOG performance status of 0 or 1, stage 
IIIB/IV, or recurrent NSCLC and at least one prior chemotherapy including platinum 
containing regimen. Pts received nivolumab 3 mg/kg IV Q2W until disease progression or 
unacceptable toxicity. The primary endpoint in both studies was the objective response 
rate (ORR) (RECIST v1.1). Planned sample size was 30 pts for SQ and 67 pts for NSQ, 
respectively (P0[MS誠1] =0.09 &[MS誠2] P1=0.26, P0=0.09 & P1=0.20 ; α=0.025 
(one-side), 1-β=0.8). Results: From April 2013 to April 2014, a total of 111 NSCLC pts 
were enrolled in both studies (35 pts with SQ, 76 pts with NSQ, male/female: 81/30; 
PS 0/1: 46/55; aged 31 to 84 [median: 65.0] years; Stage IIIB/Stage IV/recurrence: 
6/86/19). Objective response rates (ORRs) were 25.7% (9/35) [95% CI: 14.2, 42.1] in SQ 
and 19.7% (15/76) [95% CI: 12.3, 30.0] in NSQ, respectively. Complete Response was 
observed in 2.6% with NSQ. Median progression-free survival (mPFS) was 4.2 months 
(95% CI: 1.4, 7.1) for SQ and 2.8 months (95% CI: 1.4, 3.4) for NSQ, respectively. Median 
follow-up periods were 10.4 months and 8.4 months, respectively. Median duration of 
Keywords: chemoresistance, non small lung cancer, PD-L1, Target therapy
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MINI03.03 Pembrolizumab 2 mg/kg Q3W for Previously Treated, PD-L1–
Positive Advanced NSCLC Øystein Fløtten1, Edward B. Garon2, Hendrik-Tobias 
Arkenau3, Rina Hui4, Leena Gandhi5, Enriqueta Felip6, Herve Lena7, Federico Cappuzzo8, 
Leora Horn9, Matthew Gubens10, Jin Zhang11, Gregory Lubiniecki11, Ellie Im11, Matthew 
Hellmann12 1Haukeland University Hospital, Bergen/Norway, 2David Geffen School of 
Medicine at UCLA, Los Angeles/CA/United States of America, 3Sarah Cannon Research 
Institute UK, London/United Kingdom, 4Westmead Hospital, University of Sydney, Westmead/
NSW/Australia, 5Dana-Farber Cancer Institute, Boston/MA/United States of America, 6Vall 
D’Hebron University Hospital, Barcelona/Spain, 7Centre Hospitalier Universitaire, Hopital 
Pontchaillou, Rennes/France, 8Istituto Toscano Tumori, Livorno/Italy, 9Vanderbilt Ingram 
Cancer Center, Nashville/TN/United States of America, 10University of California, San 
Francisco, San Francisco/CA/United States of America, 11Merck & Co., Inc., Kenilworth/NJ/
United States of America, 12Memorial Sloan Kettering Cancer Center, New York/NY/United 
States of America
Background: In patients with previously treated NSCLC enrolled in KEYNOTE-001 
(NCT01295827), the anti–PD-1 antibody pembrolizumab (MK-3475) has demonstrated 
promising effi cacy and manageable safety when given at dosages of 10 mg/kg once 
every 2 weeks (Q2W) or once every 3 weeks (Q3W). In a prospectively defi ned validation 
set from KEYNOTE-001, the greatest effi cacy was observed in patients whose tumors 
expressed PD-L1 in ≥50% of tumor cells. Here, we present data for patients with previously 
treated, PD-L1–positive advanced NSCLC enrolled in a KEYNOTE-001 expansion cohort 
added to evaluate pembrolizumab 2 mg/kg Q3W. Methods: Patients had measurable 
disease, ECOG performance status of 0 or 1, and adequate organ function. Prior 
therapy with ≥1 platinum-doublet chemotherapy regimen was required; an appropriate 
tyrosine kinase inhibitor was required for patients with sensitizing EGFR mutations 
or ALK translocations. All patients had PD-L1–positive tumors, defi ned as staining in 
≥1% of tumor cells as determined by a prototype IHC assay using the 22C3 antibody. 
The percentage of PD-L1–stained tumor cells was also determined by a clinical trial 
IHC assay using the same antibody. Patients received pembrolizumab 2 mg/kg Q3W 
until investigator-determined progression according to immune-related response 
criteria, intolerable toxicity, patient withdrawal, or investigator decision. Response was 
assessed centrally every 9 weeks by RECIST v1.1. Results: Of the 55 patients enrolled, 
41 (74.5%) received ≥2 prior therapies. Three (5.5%) patients experienced grade 3-5 
drug-related AEs (grade 3 colitis and pneumonitis and grade 5 cardiorespiratory arrest). 
After a minimum of 27 weeks of follow-up by central radiology review of tumor imaging 
(median, 7.7 months; range, 6.4-9.7 months), confi rmed overall response rate (ORR) in 
the 52 patients with centrally evaluable disease at baseline was 15.4% (95% CI, 6.9%-
28.1%) and the disease control rate (DCR, complete response + partial response + 
stable disease) was 50.0% (95% CI, 35.8%-64.2%). At the time of analysis, all responses 
were ongoing, and the median response duration was not reached (range, 2.1+ to 
6.2+ months). Median progression-free survival (PFS) was 3.3 months (95% CI, 2.0-
6.0 months), with a 6-month PFS rate of 37.7%. Median overall survival (OS) was not 
reached, and the 6-month OS rate was 75.8%. In the 25 (45.5%) patients who had PD-L1 
expression in ≥50% of tumor cells, confi rmed ORR was 30.4% (95% CI, 13.2%-52.9%), 
DCR was 56.5% (34.5%-76.8%), median PFS was 4.2 months (95% CI, 1.9 months-NR), 
and 6-month PFS and OS rates were 49.0% and 81.8%, respectively. Conclusion: In 
this previously treated cohort of patients with PD-L1–positive advanced NSCLC, 
pembrolizumab 2 mg/kg Q3W demonstrated robust and durable antitumor activity, 
with improved effi cacy in patients with PD-L1 staining in ≥50% of tumor cells. 
Keywords: pembrolizumab
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MINI03.05 Effi cacy of Pembrolizumab in Key Subgroups of Patients with 
Advanced NSCLC Matthew D. Hellmann1, Edward B. Garon2, Leena Gandhi3, Rina Hui4, 
Jin Zhang5, Reshma Rangwala5, Gregory Lubiniecki5, Naiyer A. Rizvi6 1Memorial Sloan 
Kettering Cancer Center, New York/NY/United States of America, 2David Geffen School of 
Medicine at UCLA, Los Angeles/CA/United States of America, 3Dana-Farber Cancer Institute, 
Boston/MA/United States of America, 4Westmead Hospital, University of Sydney, Westmead/
NSW/Australia, 5Merck & Co., Inc., Kenilworth/NJ/United States of America, 6Columbia 
University, New York/NY/United States of America
Background: The humanized anti–PD-1 monoclonal antibody pembrolizumab (MK-3475) 
has demonstrated robust antitumor activity and a manageable safety profi le in patients 
with advanced cancers, including NSCLC. In the fi rst 495 patients with advanced NSCLC 
enrolled in multiple expansion cohorts of the phase 1b KEYNOTE-001 study (ClinicalTrials.
gov, NCT01295827), pembrolizumab provided an overall response rate (ORR) of 19.4%. 
In a prospectively defi ned validation set, a relationship between tumor PD-L1 expression 
and pembrolizumab effi cacy was demonstrated, such that patients with PD-L1 expression 
in ≥50% of cells had a 45.2% ORR compared with 16.5% and 10.7% in patients with PD-L1 
expression in 1%-49% and <1% of cells, respectively. Using the total population of 550 
patients with NSCLC treated with pembrolizumab in KEYNOTE-001, we assessed the 
relationship between antitumor activity and the level of PD-L1 expression in key patient 
subgroups. Methods: Patients with advanced NSCLC enrolled in the NSCLC-specifi c 
expansion cohorts of KEYNOTE-001 received pembrolizumab 2 or 10 mg/kg every 3 
weeks (Q3W) or 10 mg/kg every 2 weeks (Q2W) until confi rmed progression, intolerable 
toxicity, or investigator decision. Tumor PD-L1 expression was assessed by 
immunohistochemistry using a clinical-trial assay and scored as the proportion score 
(PS) (ie, percentage of tumor cells with membranous PD-L1 expression). Response was 
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Conclusion: Many immunotherapy clinical trials exclude patients with brain metastases, 
certain steroid use, poor PS, and autoimmune disease, yet a substantial proportion of 
community-based lung cancer patients present with these attributes. Approximately half 
of advanced stage patients have tissue specimens amenable to current SOC biomarker 
testing. Efforts to develop additional biomarker tests for lung cancer patients need to 
consider the reality of limited tissue sample availability in the community setting.
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MINI03.09 Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with 
EGFR-Mutant Advanced Non-Small Cell Lung Cancer Qiu -Yi Zhang1, E -E Ke1, Wei 
Deng1, Fei -Yu Niu1, Ning Zhao1, Jian Su2, Zhi -Hong Chen2, Jin -Ji Yang1, Chong -Rui Xu1, 
Hong -Hong Yan1, Yi -Long Wu1, Qing Zhou1 1Guangdong Lung Cancer Institute; Guangdong 
General Hospital (GGH) & Guangdong Academy of Medical Sciences, Guangzhou/
China, 2Medical Research Center, Guangdong General Hospital (GGP) & Guangdong Academy 
of Medical Sciences, Guangzhou/China
Background: Epidermal growth factor receptor (EGFR ) exon 20 T790M mutation may 
have a predictive role before EGFR-tyrosine kinase inhibitors (TKIs) treatment and it also 
might have a prognostic role after acquired resistance to EGFR-TKIs. However, its role in 
EGFR-TKI rechallenge after failure of initial EGFR-TKIs in EGFR-mutant advanced non-small 
cell lung cancer (NSCLC) remains unknown. Methods: We retrospectively evaluated 
the clinical course of 515 EGFR-mutant advanced NSCLC patients who received first 
generation EGFR-TKIs (gefitinib or erlotinib) from December 2009 to November 2014 at 
Guangdong General Hospital. Of these 515 patients, 65 patients recieved same EGFR-TKI 
rechallenge, including 51 patients who underwent rebiopsy and secondary EGFR mutation 
detection after failure of initial EGFR-TKIs. EGFR detection was performed by Sanger 
sequencing or Amplification Refractory Mutation System (ARMS) methods. Progression-
free survival (PFS) and overall survival (OS) were both calculated from commencement 
of EGFR-TKI rechallenge. Survival data were analyzed using the Kaplan-Meier method and 
log-rank test. Results: EGFR activating mutations still existed in all the 51 patients who 
received rebiopsy and 18 patients were with T790M mutation while 33 patients were 
without T790M. The median PFS for the T790M+ and T790M- groups were 1.8 months 
(95%CI 1.180~2.420) and 2.0 months (95%CI 1.100~2.900), respectively (P=0.261). 
The median OS for the two groups were 7.7 months (95%CI 6.548~8.852) and 6.8 
months (95%CI 4.730~8.870), respectively (P=0.565). No statistical difference was 
found in PFS or OS between two groups(Figure 1).
  
Fig 1. Kaplan-Meier curves of patients in two groups. (A)Progression-free survival. (B) 
Overall survival. Conclusion: EGFR T790M mutation is neither a predictive nor a prognostic 
factor for first generation EGFR-TKI rechallenge in EGFR-mutant advanced NSCLC patients, 
indicating that whether T790M occurs or not, same EGFR-TKI rechallenge could not be 
recommended as a good strategy to overcome the resistance to first generation EGFR-TKIs. 
Keywords: non-small cell lung cancer, EGFR-TKIs, T790M, Rechallenge
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MINI03.10 Rociletinib in NSCLC Patients with Negative Central Testing 
for T790M in TIGER-X Heather A. Wakelee1, Lecia V. Sequist2, Shirish Gadgeel3, 
Jean-Charles Soria4, Jonathan W. Goldman5, H. Yu6, D. R. Camidge7, Benjamin J. 
Solomon8, Shannon Matheny9, Darrin Despain10, Vassiliki Papadimitrakopoulou11 
1Department of Medicine, Division of Oncology, Stanford University, Stanford/CA/
United States of America, 2Massachusetts General Hospital, Boston/MA/United States of 
America, 3Karmanos Cancer Institute, Detroit/MI/United States of America, 4Gustave Roussy 
Cancer Center, Villejuif/France, 5University of California at Los Angeles, Santa Monica/CA/
United States of America, 6Memorial Sloan Kettering Cancer Center, New York/NY/United 
States of America, 7Medical Oncology, University of Colorado, Denver/CO/United States of 
America, 8Peter MacCallum Cancer Center, Melbourne/VIC/Australia, 9Clovis Oncology, San 
Francisco/CA/United States of America, 10Clovis Oncology, Boulder/CO/United States of 
America, 11MD Anderson Cancer Center, Houston/TX/United States of America
Background: Rociletinib (CO-1686) is a novel, oral, irreversible tyrosine kinase inhibitor 
for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-
small cell lung cancer (NSCLC). Rociletinib has demonstrated efficacy against activating 
mutations (L858R and Del19) and the dominant acquired resistance mutation (T790M), 
response was not reached in each study. Of 9 SQ pts and 15 NSQ pts who responded 
to nivolumab, durable and ongoing response was observed in 77.8% (7/9) and 80.0% 
(12/15), respectively. Median overall survival was not reached in either study. All Grade 
drug-related adverse events across both studies were 79.3% (88/111) and Grade 3-4 
drug-related adverse events (G3-4 AEs) were observed in 16.2% (18/111) pts. Most 
common G3-4 AEs were lymphocyte count decreased 3.6% (4/111), hyponatremia 
1.8% (2/111), interstitial lung disease 1.8% (2/111), pleural effusion 1.8% (2/111). 
Any grade of interstitial lung disease was observed in 4.5% (5/111) pts. No grade 5 
AEs were observed. Conclusion: In these studies, nivolumab showed encouraging 
clinical efficacy in both SQ and NSQ NSCLC with a manageable safety profile. 
Keywords: PD1 antibody, Immunotherapy, Nivolumab, advanced NSCLC
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MINI03.07 Clinical Attributes of Lung Cancer in US Community Oncology 
Practice: Implications for Immunotherapy Praveen Reddy1, Donald Richards1, Brian 
Ulrich1, Vijay Gunuganti2, Robert Jotte3, Sharon Wilks2, David Waterhouse4, Mohamed 
Mohamed5, Jason Chandler6, Lee Schwartzberg7, Dilawar Khan8, Mark Hancock9, 
Christina Bromley10, Kimary Kulig11, Maen Hussein12 1Texas Oncology, Austin/TX/United 
States of America, 2Cancer Care Centers South Texas, San Antonio/TX/United States of 
America, 3Rocky Mountain Cancer Centers, Denver/CO/United States of America, 4Oncology 
Hematology Care, Cincinnati/OH/United States of America, 5Cone Health Medical Group, 
Greensboro/NC/United States of America, 6The West Clinic, P.C., South Haven/TN/United 
States of America, 7The West Clinic, P.C., Memphis/TN/United States of America, 8Harbin 
Clinic, Rome/GA/United States of America, 9St. Mary’s Hospital & Regional Medical Center, 
Grand Junction/CO/United States of America, 10Biostat Solutions, Inc., Frederick/MD/United 
States of America, 11Bristol-Myers Squibb, Princeton/NJ/United States of America, 12Florida 
Cancer Specialists, Lady Lake/FL/United States of America
Background: The majority of lung cancer in the US is treated in the community. A 
prospective cohort study of stage IV non-small cell lung cancer (NSCLC) and extensive 
disease small cell lung cancer (ED SCLC) is being conducted in 70 US community 
oncology practices (Figure) to assess current standards of care (SOC) and outcomes in 
anticipation of immunotherapy as a new treatment modality. This study establishes a 
historical comparator cohort in a “pre-immunotherapy era” of lung cancer treatment. 
 
 
Methods: Pembrolizumab provides antitumor activity in a broad selection of subgroups 
of patients with advanced NSCLC. Improved response in patients whose tumors express 
PD-L1 in ≥50% of cells was observed for all subgroups. Ongoing analyses are investigating 
the interdependency between PD-L1 status, mutational status, and smoking. 
Results: This early analysis focused on patient clinical attributes and tumor sample 
characteristics of relevance to non-clinical trial patient populations and to biomarker 
testing (Table). Of 1,183 cases enrolled to date, at enrollment 17.6% were ECOG 
performance status (PS) 2 or 3, 18.8% of patients had brain metastases, 22.2% were on 
systemic steroids, 6.7% had history of a specific autoimmune condition, and 49.5% had 
had tissue samples from core needle or surgical specimens. 
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Conclusion: YLL and LEL values across LC histologies are substantial in both older and, 
perhaps even more noticeably, younger populations. Improvements in survival reported 
with promising new LC therapies have the potential to substantially decrease the societal 
burden caused by YLL and LEL. Keywords: metastatic lung cancer, Life expectancy, 
Lifetime earnings, Immunotherapy
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MINI04.02 Value of Innovation in Systemic Therapy for US Patients with 
Advanced/Metastatic NSCLC Jonas Nilsson1, Nahila Justo2, Beata Korytowsky3, 
Nabil Chehab3, Amy Stanford3, Alistair Mcguire4 1Sahlgrenska Cancer Center, University 
of Gothenburg, Gothenburg/Sweden, 2Optuminsight, Stockholm/Sweden, 3Bristol-Myers 
Squibb, Princeton/NJ/United States of America, 4LSE Health, London School of Economics 
and Political Science, London/United Kingdom
Background: Lung cancer remains the leading cause of cancer death in the US. Over 
the past 40 years, treatment approaches have evolved and new systemic anti-cancer 
therapies have been introduced to the standard of care. With few exceptions, the impact 
of these agents for patients with advanced/metastatic non-small cell lung cancer 
(NSCLC) has been arguably minimal, with overall survival (OS) still less than 1 year for 
most patients. This study analyzed the association of available new systemic therapies 
with median OS, 1-year OS, and 1-year conditional survival (CS: adjusted probability of 
survival, specifically probability of living to year 2, given survival at 1-year) in patients 
with advanced/metastatic NSCLC. Methods: This study enrolled adult patients with 
advanced/metastatic NSCLC diagnosed between 1973 and 2011 in the US Surveillance, 
Epidemiology, and End Results (SEER-Research) Program of the American National 
Cancer Institute. We report the data from 1973 to 2008 for this analysis. Thirty-eight 
cohorts of patients were defined by year of diagnosis. Survivor functions were estimated 
using Kaplan-Meier analysis, with death as the failure event. Median OS, 1-year OS, and 
1-year CS were derived for each year and analyzed graphically. The innovation index was 
defined as the sum of all systemic anti-cancer treatments available in the US market within 
a given year between 1973 and 2011 (Lichtenberg; Econ Hum Biol 2003;1:259–266). 
Results: Of 347,709 patients, a clear correlation was observed between the innovation 
index and survival measures (median OS, 1-year OS, and 1-year CS), with correlation 
coefficients of 77%, 92%, and 97%, respectively. Median OS, 1-year OS, 1-year CS, and 
the innovation index are plotted against time (Figure), enabling a comparison of survival 
measures between 1973 and 2008. Any change in the innovation index is reflected as 
a change in the survival curves, most notably in the 1-year CS, displaying a 1- or 2-year 
delay. From 1973 to 2008, median life expectancy of patients increased from 4 to 6 
months; 1-year OS and 1-year CS improved by 71% and 31%, respectively.
 
Conclusion: The availability of systemic anti-cancer treatments for advanced/metastatic 
NSCLC has resulted in an incremental survival benefit, albeit modest, for US patients 
diagnosed between 1973 and 2008. Despite progress in treatment, outcomes for this 
patient population are very poor. Further research is needed to explore these treatment-
survival relationships, including the resulting benefit for all patients with advanced/
metastatic NSCLC and select patient subgroups.
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MINI04.03 Real-World Patterns of Access to Cancer Specialist Care Among 
Patients With Lung Cancer in the United States: A Claims Database Analysis 
Apar K. Ganti1, Hossein Borghaei2, Fred R. Hirsch3, Murry Wynes4, Arliene Ravelo5, 
Raluca Ionescu-Ittu6, Irina Pivneva6, Peggy Lin7, Suresh S. Ramalingam8 1Internal Medicine, 
while sparing wild-type EGFR. New insights into mutEGFR NSCLC suggest clonal 
heterogeneity – activating EGFR mutations are truncal (present in all tumor clones) and 
T790M is a dominant branch mutation with variable clonal frequency between patients 
and over time. The extent of this clonal heterogeneity may relate to rociletinib efficacy. 
Here we present preliminary findings to evaluate this hypothesis from an ongoing Phase 
1/2 clinical trial. Methods: TIGER-X (NCT01526928) is a Phase I/II open-label, safety, 
pharmacokinetics and preliminary efficacy study of rociletinib in patients with metastatic 
or unresectable locally advanced EGFR mutation-positive NSCLC with progressive 
disease after ≥1 EGFR tyrosine kinase inhibitor (TKI). Screening included mandatory 
tumor biopsy and T790M testing. For Phase 1, patients could be T790M negative, 
positive or unknown. For Phase 2, T790M negative patients (by validated central testing) 
could have a contemporaneous local T790M+ result. Results: As of March 2015, 36 
patients were enrolled in TIGER-X who were T790M central negative by cobas® or 
Qiagen therascreen® and evaluable for efficacy. Sensitivity analysis indicated that the 
2 assay platforms were comparable for T790M detection. 69% (25/36) were T790M 
negative centrally but positive locally; 4/36 (11%) were negative by both central and 
local testing; and 7/36 (19%) were centrally negative with no local result. Median number 
of previous TKIs was 1 and median number of previous therapies was 2; 81% (29/36) 
were treated with a TKI as their most recent prior therapy. In central negative/local+ 
patients the ORR was 40% (10/25). In central negative/local negative patients the ORR 
was 25% (1/4). The most common treatment emergent adverse events in this subset 
(all grades) were fatigue, diarrhea, nausea and hyperglycemia. Conclusion: These 
preliminary findings suggest that patients who test negative for T790M using a sensitive 
tissue test may still benefit from treatment with rociletinib. In part, this clinical activity 
may be driven by T790M tumor heterogeneity, demonstrated by the discordant T790M 
results described. In addition, inhibition of IGF-1R/IR by the previously reported (Soria 
2014) rociletinib metabolite M502 may also be driving some of the activity observed. 
This possible explanation is important, since the response rates reported herein 
are higher than described for other T790M inhibitors in T790M-negative patients. 
Furthermore, TKI re-treatment effect is unlikely to be a major driver of these results, 
since the majority of patients came on study directly after progression on another EGFR 
TKI. To further explore these findings, the open-label TIGER-2 (NCT02147990) and the 
randomized Phase 3 TIGER-3 (NCT02322281) studies include T790M negative patients. 
Keywords: rociletinib, NSCLC, EGFR, T790M
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MINI04.01 Years of Life Lost and Lifetime Earnings Lost in Metastatic Lung 
Cancer: Potential Societal Benefits of Improved Survival by Age and Histology 
Beata Korytowsky1, Kimary Kulig1, Marc Halperin2, Mark D. Danese2 1Bristol-Myers 
Squibb, Princeton/NJ/United States of America, 2Outcomes Insights, Inc., Westlake Village/
CA/United States of America
Background: “Years of life lost” (YLL) and “lifetime earnings lost” (LEL) are used to 
describe the population burden of cancer. Lung cancer (LC) is one of the most common 
cancers in the US. While it affects older patients, the younger subgroups of LC are large. 
Approximately 57% of LC cases are metastatic at diagnosis, with a 5-year survival rate 
of approximately 5%. Nivolumab, a recently-approved fully human IgG4 programmed 
death-1 (PD-1) immune checkpoint inhibitor antibody, demonstrated a mortality risk 
reduction of 41% compared to docetaxel in patients previously treated with platinum-
based therapy for metastatic squamous, non-small cell LC (NSCLC) (hazard ratio [HR]: 
0.59; 95% CI: 0.44, 0.79). This analysis quantifies YLL and LEL prior to the introduction of 
LC immunotherapy in order to benchmark potential population-level effects of improved 
long-term survival. Methods: A simulation model was developed using real-world US 
patients with LC diagnosed 1/1/2000–12/31/2011 in the Surveillance, Epidemiology, 
and End Results Program, with follow-up through 12/31/2012. Age-, sex-, and race-
specific life expectancy were estimated using flexible parametric survival models. 
Comparable life expectancy was projected for the general US population using US vital 
statistics data. Life expectancy was combined with US Bureau of Labor Statistics income 
data to derive lifetime earnings in 2014 US dollars. Earnings reflect 18 possible income 
sources, including salary, investments, social security, and other retirement income. 
Mean YLL and LEL were estimated as the differences between patients with LC and the 
general US population. Results were stratified by age (<65; ≥65) and histology subtype 
(small cell, non-squamous NSCLC; squamous NSCLC). Results: An estimated 1,223,031 
patients in the US were diagnosed with metastatic LC from 2000–2011. Estimated 
patient counts, expected survival, and expected lifetime earnings within each age and 
histology subtype are provided (Table). For patients aged <65, YLL per patient due to 
LC varied from 22.8–23.7 years by histology subtype, while for patients aged ≥65, 
YLL varied from 9.9–11.3 years. LEL per patient ranged from $862,000–$887,000 for 
patients aged <65, and from $274,000–$313,000 for patients aged ≥65. 
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MINI04.04 Economic Burden of Lung Cancer Patients Treated in Clinical Trials: 
Experience from a Comprehensive Cancer Center in Germany Florian Kron1, 
Anna Kostenko1, Jan P. Glossmann1, Michael Hallek1, Ines Dohle2, Alexander Hoss2, 
Matthias Scheffler3, Thomas Zander1, Jürgen Wolf3 1Department I of Internal Medicine 
and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne/
Germany, 2Controlling, University Hospital of Cologne, Cologne/Germany, 3Lung Cancer 
Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne/
Germany
Background: Lung cancer leads to the highest costs among cancers in developed 
countries. Hospital inpatient care is the main cost driver. Comprehensive cancer centers 
(CCC) are designed to adopt innovative treatment methods within clinical trials. This 
analysis focuses on the economic burden of clinical trials for advanced lung cancer 
patients in a CCC in Germany. Methods: 111 consecutive patients with advanced lung 
cancer treated in clinical trials (phase I - phase II) were analyzed. We integrated medical and 
economic data from a business perspective during patients’ in- and outpatient treatment. 
Different reimbursement systems and cost calculation models are linked with an internal 
budget system for lung cancer patients. Results: 79 patients (71.2%) had at least one 
in-house stay with a total of 204 inpatient cases. 67 different diagnosis-related groups 
(DRGs) were coded for these cases. Grouping of the DRGs into 4 categories (i. Neoplasm, 
ii. Infection, iii. Radiotherapy and iv. Rest) reveals a statistically significant difference in the 
case mix index (p<0.001) and length of hospitalization (p<0.001). Cost type calculation 
demonstrated labor (46%) and infrastructure (31%) being the predominant cost factors. 
The average revenues of 1301 outpatient contacts (219 cases per quarter) of all patients 
are €144. Subgroup analysis of 44 cases with €117 revenues in average identified imaging 
procedures accounting for 74% of the costs. Conclusion: The medical development 
involves economic risks for the hospital that recommend a fully integrative cost- and sales 
controlling between the in- and outpatient treatment setting including standards care and 
clinical trials, which should be discussed with all stakeholder in the healthcare system. 
Keywords: lung cancer, economics, clinical trials, comprehensive cancer centers
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MINI04.06 During-Treatment PET Metabolic Tumor Volume (MTV) Instead 
of FDG Activity Is Predictive of Survival in Patients with Non-Small Cell Lung 
Cancer Feng-Ming (Spring) Kong1, Jennifer L. Waller2, Ling Li1, Kirk Frey3, Morand 
Piert3, Dawn Owen4, Mathew Stenmark4, Colin Huang1, Martha Matuszak4, Randall K. Ten 
Haken4, Theodore S. Lawrence4 1Department of Radiation Oncology, GRU Cancer Center/
Medical College of Georgia, Georgia Regents University; University of Michigan, Augusta/GA/
United States of America, 2Department of Biostatistics and Epidemiology, Georgia Regents 
University, Augusta/GA/United States of America, 3Department of Radiology, University 
of Michigan, Ann Arbor/MI/United States of America, 4Department of Radiation Oncology, 
University of Michigan, Ann Arbor/MI/United States of America
Background: We have previously reported that tumor reduces in activity and volume 
during the course of radiotherapy (RT), and such changes were correlated with post-
treatment “tumor response”, known as a significant factor for overall survival in patients 
with non-small cell lung cancer (NSCLC). This study aimed to determine whether the 
metabolic activity or metabolic tumor volume (MTV) obtained from the during-treatment 
FDG-PET is predictive of overall survival in NSCLC. Methods: Patients with stage I-III 
NSCLC enrolled in prospective studies with during-treatment FDG-PET were eligible 
for this study. All patients were treated with a definitive course of RT + chemotherapy. 
FDG-PET/CT scans were acquired within 2 weeks before RT (pre-RT) and at about two 
thirds of the total dose delivered (during-RT). PET-MTVs were delineated by a tumor/
aorta ratio of 1.5 autosegmentation combined with manual editing based on CT 
anatomy, as previously described (Mahasittiwat et al, 2013). FDG-activity was measured 
as maximum standard update value (SUVmax) and the average activity (SUVmean) of 
the defined MTV. Total lesion glycolysis (TLG) was computed as the product of MTV 
and SUVmean. CT gross tumor volume (CT-GTV) were also delineated in a consistent 
manner. Data are presented as mean (95% confident interval). P<0.05 is considered 
to be statistically significant. Results: A total of 129 patients with a minimum follow-
up of 24 months (for surviving patients) were included in this study. The majority of 
subjects were male (73%), white (96%), current or former smokers (87%) with an average 
age of 67 years (range 45-92). Seventy-nine percent were treated with chemotherapy 
in combination with RT (dose range 45-90 Gy). Of the pre-RT PET parameters, neither 
SUVmax nor SUVmean was significant, while CT-GTV (P=0.03), PET-MTV (p=0.008), 
and PET-TLG (p=0.005) were all significant for overall survival. After 2/3 treatments 
were delivered, the mean SUVmax, SUVmean, CT-GTV, PET-MTV, and PET-TLG all 
decreased significantly (P<0.001) and remarkably (more than 30% reduction), with the 
PET-MTV showing the greatest extent of reduction. During-RT SUVmax or SUVmean 
were not significantly associated with overall survival, either as continuous variables 
or as binominal variables (split from median). While during-RT CT-GTV was a significant 
factor for survival (P=0.04), yet during-RT PET-MTV and PET-TLG as continuous variables 
were not. However, patients with during-RT PET-MTV values greater than the median 
had significantly shorter median survival (21 months, 95%CI: 12.1-32.0) than those of 
below the median (38 months, 95%CI: 29.0-89.9, p=0.01). The absolute reductions in 
SUVmax or SUVmean or CT-GTV were not, but changes of PET-MTV and PET-TLG during-
RT were significantly associated with overall survival. Smaller reductions from Pre-RT 
to during-RT were associated with an increased risk of death for PET-MTV (HR=1.003, 
95%CI: 1.001–1.006, P=0.01) and PET-TLG (HR=1.001, 95%CI: 1.000–1.001, P=0.02), 
respectively.Conclusion: MTV instead of SUV during the course of RT are significantly 
associated with overall survival in patients with NSCLC. Larger MTV during-RT may lead to 
worse survival. RTOG1106/ACRIN6697 is ongoing to adapt radiation therapy plan to give 
Veteran’s Affairs Nebraska-Western Iowa Health Care System, University of Nebraska Medical 
Center, Omaha/NE/United States of America, 2Medical Oncology, Fox Chase Cancer Center, 
Philadelphia/PA/United States of America, 3Division of Medical Oncology, University of 
Colorado Anschutz Medical Campus, Aurora/CO/United States of America, 4IASLC, Aurora/
CO/United States of America, 5Health Economics & Outcomes Research, US Medical Affairs, 
Genentech, Inc., South San Francisco/CA/United States of America, 6Analysis Group, Inc., 
Montreal/QC/Canada, 7Analysis Group, Inc., Boston/MA/United States of America, 8Medical 
Oncology, Emory University Winship Cancer Institute, Atlanta/United States of America
Background: Timely access to specialist care is an important first step in the 
care of patients with lung cancer (LC). This study describes real-world patterns of 
access to cancer specialist (CS) care in all LC patients and those with metastatic LC 
(mLC). Methods: Adult patients diagnosed with primary LC or mLC were identified in a 
US commercial claims database (01/01/2008 - 03/31/2014). Patients’ specialist visits 
were assessed before and after their first biopsy (index date). All patients had ≥3 months 
follow-up after index date. CS was defined as oncologists or hematologists. Patients 
were divided in four mutually exclusive groups based on the specialists seen in the 6 
weeks pre-index period: patients seen by CS (± other specialists), pulmonologists (no 
CS, ± other specialists), internists or family physicians (no CS/pulmonologist, ± other 
specialists), and other. CS visits in the 8-weeks post-index were assessed for each group. 
Reversed Kaplan-Meier plots were used to describe time from index date to first CS 
visit. Results: The analysis included 75,163 LC and 25,191 mLC patients, with a median 
age of 67 [interquartile range (IQR): 59-76)] and 63 (IQR: 57-73) years and a median 
follow-up of 11 and 9 months, respectively. In the 8-week post-index period, over half 
of LC patients (54%) and nearly two-thirds of mLC patients (66%) had their first CS visit 
(Figure 1), while 38% of LC patients and 28% of mLC patients never saw a CS within 
1-year of biopsy (Figure 1). In both samples, patients in the CS and pulmonologist pre-




Conclusion: A substantial proportion of patients diagnosed with LC and mLC did not see 
any CS after biopsy, which may negatively affect access to optimal and timely treatment. 
Keywords: Access to Cancer Specialist Care, Patients with Lung Cancer, Real-World 
Patterns, Claims Database Analysis
S274 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
at the time of diagnosis or metastatic recurrence. We noted if patients developed 
T790M, a resistance mutation to targeted therapy, in EGFR+ patients. A Fisher-Exact test 
was used to determine statistical significance between metastatic site and subsequent 
PC. Results:
Table 1 - Sites of metastasis and presence of T790M mutation in patients with PC and 
without PC
Metastatic site / mutation PC No PC P value
Lung 9.1% 38.6% P = 0.06
Liver 18.2% 15.8% P = 0.689
Bone 36.4% 46.8% P = 0.549
Brain 0% 23.7% P = 0.3570
Adrenal 0% 6.4% P = 0.123
Soft tissue 9.1% 2.2% P = 0.265
Pleural effusion 100% 26.6% P = 0.0001
T790M mutation 81.1% 34.5% P = 0.0001
 
The presence of a pleural effusion was universal in all 11 EGFR+ patients who subsequently 
developed PC and this finding was statistically significant (P = 0.0001). 9 out of 11 
patients with PC were identified to have a T790M mutation, a finding that was statistically 
significant (P = 0.0001). Except one patient, all EGFR+ patients developed PC following 
targeted tyrosine kinase therapy. Conclusion: The presence of a malignant effusion is 
highly predictive of developing PC in patients with EGFR+ NSCLC. Although the underlying 
mechanism of PC is not entirely clear, it may be related to serosal communication with 
subsequent micrometastatic seeding of the peritoneal cavity. The T790M mutation, 
the most common acquired resistance mechanism to EGFR kinase inhibitors, was 
significantly more prevalent in the group that developed PC, although it remains 
unclear whether this mutation has any causative effect on spread to the peritoneum. 
Keywords: peritoneal, carcinomatosis, EGFR, metastases
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MINI04.09 The Impact of Next-Generation Sequencing on Clinical Decisions in 
Lung Cancer Anna Belilovski Rozenblum1, Maya Ilouze1, Elizabeth Dudnik1, Dov Flex1, 
Lior Soussan-Gutman2, Addie Dvir2, Nir Peled1 1Thoracic Cancer Service, Davidoff Cancer 
Center, Rabin Medical Center, Petach Tiqwa/Israel, 2Teva Pharmaceutical Industries Ltd., 
Shoam/Israel
Background: In the last decade, important advances have been made in understanding 
genetic and molecular mechanisms of Non-Small Cell Lung Cancer (NSCLC) tumor 
development. This has led to the creation of innovative, targeted drugs that significantly 
prolong survival in advanced patients. Recent data shows that 63% of NSCLC tumors 
harbor at least one activating driver mutation, including treatable mutations such as 
RET, HER2 and ROS1 gene mutations, besides the regularly screened ALK and EGFR 
genes that account for 23% of the patients. Clinical cancer genomic profiling tests based 
on Next Generation Sequencing (NGS) technologies are capable to reveal clinically 
actionable genetic alterations in up to three times the number of actionable alterations 
detected by current diagnostic tests. However, there is no data regarding the true 
impact of these tests on clinical decisions in lung cancer. In this study, our objective is to 
evaluate the impact of NGS-based genetic profiling tests on treatment strategy in NSCLC 
patients in the real life setting, considering the additional diagnostic tests performed. 
Based on clinical experience from Israel, NGS-based tests actively change treatment 
plans, but the effect size is unknown and merits further investigation. Methods: In this 
retrospective study, data is collected from patient files at the Thoracic Cancer Unit of 
Davidoff Cancer Center, Rabin Medical Center, Israel. The current study population is 78 
NSCLC patients who performed NGS-based genetic profiling tests. Results: Out of 78 
patients, 58 patient files have already been reviewed and 6 were excluded. Treatment 
decision change rate after NGS testing was 33% (17 out of 52 patients were treated with a 
targeted therapy - 24% of the current study population). Interestingly, 9 patients became 
EGFR and ALK positive by NGS after the previous standard local molecular testing was 
negative. Based on the RECIST criteria of response evaluation, 41% of the patients had a 
partial response after switching to targeted therapy, 23% had a complete response, 18% 
experienced progressive disease and 18% were not evaluated yet. Survival rates will be 
calculated further in the study based on data availability. Conclusion: The use of NGS for 
tumor classification and treatment planning holds a great potential for improving patient 
life quality and survival. In this study, we aimed to determine its clinical impact in the 
real life setting in the treatment of lung cancer. Our partial results show that in addition 
to performing standard molecular testing for NSCLC, almost a quarter of the patients 
can be identified having an actionable driver mutation and switched to targeted therapy. 
Most of these patients showed a positive response to treatment. Although this topic 
needs to be further assessed in large randomized controlled trials, these positive results 
emphasize the importance of upfront multiplex testing or suggest such technology 
as a reflex test in places where the primary kits are done first in sake of cost-benefit. 
Keywords: non-small cell lung cancer, next generation sequencing, Driver Mutations, 
personalized medicine
higher dose to residual PET-MTV during-RT to improve tumor control and overall survival. 
Keywords: GTV, During Radiotherapy, non-small cell lung cancer, Metabolic tumor 
volume
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MINI04.07 Changes in Skeletal Muscle Index and Body Mass Are Prognostic 
Factors in First Line Stage IV Non-Small Cell Lung Cancer (NCSCL) Patients 
Mary J. Fidler1, Samantha Kerns2, Fatema M. Esmail3, Maria D. Martin4, Stephanie M. 
Shors4, Neel Patel5, Rutvin R. Patel6, Selina Sayidine5, Sanjib Basu7, Ravi Pithadia5, Marta 
Batus7, Jeffrey A. Borgia6, Philip Bonomi7, Palmi N. Shah8 1Hematology, Oncology and 
Cell Therapy, Rush University Medical Center, Chicago/IL/United States of America, 2Rush 
University Medical Center, Chicago/IL/United States of America, 3Internal Medicine, Rush 
University Medical Center, Chicago/AL/United States of America, 4Diagnostic Radiology, 
Rush University Medical Center, Chicago/IL/United States of America, 5Pathology, Rush 
University Medical Center, Chicago/United States of America, 6Pathology, Rush University 
Medical Center, Chicago/IL/United States of America, 7Hematology, Oncology and Cell 
Therapy, Rush University Medical Center, Chicago/United States of America, 8Diagnostic 
Radiology, Rush University Medical Center, Chicago/United States of America
Background: Cancer cachexia is a complex metabolic syndrome affecting 60-80% of 
patients with non-small cell lung cancer (NSCLC). The characteristic involuntary weight 
loss observed in cachexia is associated with poor outcomes in advanced NSCLC; 
however, reduced muscle mass may be a more reliable prognostic indicator. In this 
study, we examine the impact of changes in weight and skeletal muscle index (SMI) in the 
first 12-weeks of therapy on clinical outcome parameters for front line stage IV NSCLC 
patients. Methods: Cancer cachexia is a complex metabolic syndrome affecting 60-
80% of patients with non-small cell lung cancer (NSCLC). The characteristic involuntary 
weight loss observed in cachexia is associated with poor outcomes in advanced 
NSCLC; however, reduced muscle mass may be a more reliable prognostic indicator. 
In this study, we examine the impact of changes in weight and skeletal muscle index 
(SMI) in the first 12-weeks of therapy on clinical outcome parameters for front line 
stage IV NSCLC patients. Results: 119 patients had serial weights available and were 
included for analysis: 49% were male, median age of males was 71, and females were 
63 years; 82% had smoking history. Histology was predominantly adenocarcinoma and 
squamous (62% and 22%). Median PFS was 159 days, and medial OS was 314 days. 
Median weights for males at baseline, 6 weeks, and 12 weeks were 77.3, 76.9, and 
77.3 kilograms respectively. Median weights for females at baseline, 6 weeks, and 12 
weeks were 67.1, 66.7, 65.8 kilograms respectively. Baseline weights were less for 
women than men (p<0.0007) but the change in weight with time was not significantly 
different at measured time points. Weight loss of greater than 10.39 pounds in the first 
six weeks of treatment was strongly associated with inferior outcomes (PFS 2.35 vs. 
6.44 months, p=2.02 x 10-7; OS 3.96 vs. 15.48 months, p=8.71 x 10-9). Persistent 
weight loss at 12 weeks was also associated with worse outcomes (PFS p=1.72x10-7 , 
OS p= 0.00286). Within this cohort, 41 patients had baseline SMI measured from their 
CT scans, 27 patients had additional CT-derived SMI available at 6- and 12- weeks. 
Patients with SMI decrease at 12 weeks of at least 2.6 units (n=9, 33%) had an inferior 
median PFS compared with those not meeting this threshold (2.79 months vs. 9.75 
months p<0.05). In a multivariate analysis, this loss, when adjusted by gender, remained 
significantly associated with PFS (HR=2.37, p < 0.05). Conclusion: This study shows 
the prognostic value of weight loss for progression on first line chemotherapy as early as 
six weeks following therapy initiation. This analysis confirms the significant association 
between weight loss on serial measurements and inferior survival in stage IV NSCLC 
pts. Additionally, this is the first report of decreasing CT-derived SMI correlating with 
inferior progression free survival on front line platinum doublet therapy for NSCLC. 
Keywords: Clinical outcome, cancer cachexia, skeletal muscle index
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MINI04.08 Malignant Pleural Effusions Are Predictive of Peritoneal 
Carcinomatosis in Patients with Advanced EGFR Positive Non-Small Cell 
Lung Cancer Tejas Patil1, Dara L. Aisner2, Sinéad A. Noonan3, Paul A. Bunn, Jr3, 
Eamon M. Berge4, William T. Purcell3, D. R. Camidge4, Laurie L. Carr5, Robert C. 
Doebele6 1Department of Internal Medicine, University of Colorado, Aurora/United 
States of America, 2Department of Pathology, University of Colorado Som, Aurora/United 
States of America, 3Medical Oncology, University of Colorado, Denver/United States 
of America, 4Medical Oncology, University of Colorado, Denver/CO/United States of 
America,5Medicine, National Jewish Health, Denver/CO/United States of America, 6Division 
of Medical Oncology, University of Colorado SOM, Aurora/United States of America
Background: Lung cancer is the most frequent cause of cancer death and metastatic 
disease at the time of initial diagnosis is common. Peritoneal carcinomatosis (PC) from 
lung cancer is a rare clinical event with a reported incidence of 1.2% (Satoh et al. 2001). 
However, there are limited data on what factors predict peritoneal progression in lung 
cancer. Over the last decade, molecular analysis of NSCLC has provided more detailed 
classification of patterns of metastatic spread. It has also been shown that oncogene-
addicted subsets of NSCLC have different patterns of metastatic spread (Doebele et 
al. 2012). We investigated whether certain baseline patterns of metastatic spread in 
patients with advanced EGFR mutation positive (EGFR+) NSCLC can predict subsequent 
PC. Methods: We identified 156 patients with EGFR+ (Exon 19 or L858R) mutations 
from 2009 - 2014, of which 139 had metastatic NSCLC. 11 patients developed PC. This 
was defined as the presence of biopsy-proven adenocarcinoma from peritoneal fluid 
or radiographic patterns consistent with omental metastases. We identified areas of 
metastatic disease in predefined sites (brain, liver, lung, adrenal, soft tissue and pleura) 
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were reported across the US, EU, and Japan. Median OS of NSCLC patients from the 
time of BRM diagnosis ranged from 5.0 to 13.1 months by country (Figure 1). The rate, 
by country, of radiation therapy among NSCLC patients with BRM ranged from 32.9% to 
90.1%, systemic therapy ranged from 5.8% to 39.7%, and surgery was used in 2.2% to 
31.6% of studies. 
Conclusion: Reported median OS and treatment patterns were highly variable. 
Exposure to risk factors associated with BRM may help explain some of the 
geographic variability in survival. The lack of published cost data underscores 
the need to quantify the economic burden of BRM on patients and society. 
Keywords: survival, epidemiology, NSCLC, brain metastases
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MINI04.13 Survival Analysis of 51 Leptomeningeal Metastatic Non Small Cell 
Lung Cancer Patients Treated with Whole Brain Radiotherapy Erkan Topkan, 
Berna Akkus Yildirim, Ozan C. Guler, Yurday Ozdemir Radiation Oncology, Baskent 
University Faculty of Medicine, Adana/Turkey
Background: Although leptomeningeal carcinomatosis (LC)in Non small cell lung cancer 
is less frequently seen in radiotherapy (RT) clinics, it is an important cause of mortality 
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MINI04.11 Incidence of Brain Metastasis in Non-Small Cell Lung Cancer 
Over Eleven Years at a Single Canadian Institution Adrijana D’Silva1, Haocheng 
Li1, Shannon Otsuka1, Don Morris2, Jackson Wu2, Gwyn Bebb2 1Oncology, University of 
Calgary, Calgary/AB/Canada, 2Alberta Health Services, Calgary/AB/Canada
Background: The highest percentage of metastasis to the brain exists among non-small 
cell lung cancer (NSCLC) patients. The exact incidence of brain metastasis (BM) in NSCLC 
is unknown, but current literature suggests that incidence for this cohort is increasing as 
cancer patients live longer. To date, only a single Canadian study reporting BM occurrence 
in lung cancer patients is available. A key limitation to this study is the method of 
incidence reporting, as number of cases, rather than number of cases as a percentage 
among lung cancer population. Reliable estimates of BM in NSCLC patients are necessary 
to further improve patient care and resource allocation. Methods: The Alberta Cancer 
Registry dataset was used to identify all NSCLC patients living in southern Alberta who 
are consulted at the Tom Baker Cancer Centre, Calgary, Alberta, Canada between 1999 
and 2010. These patients were registered and their charts were reviewed for an 
institutional lung cancer database (Glans-Look Database). NSCLC patients were 
categorized into two groups: (i) having BM at diagnosis or (ii) developing BM between 
diagnosis and death. Patient characteristics were compared to the database NSCLC 
cohort and all metastatic cases. The number of BM cases was reported for each group 
per year. Incidence was calculated as a percentage of the NSCLC and metastatic disease 
cases, where applicable. Linear trend testing was performed. Results: A total of 5297 
NSCLC patients were consulted. The percentage of BM at diagnosis in the cohort was 
11% in 1999 and 8% in 2010 (linear trend test p -value=0.010). These numbers were 26% 
in 1999 and 15% in 2010 (p=0.010) in the metastatic cohort. The percentage of BM 
developed by death in the NSCLC cohort was 20% in 1999 and 13% in 2010 (p=0.010). 
These numbers were 44% in 1999 and 26% in 2010 (p=0.009) in the metastatic cohort 
(Figure 1). Out of 2501 non-metastatic NSCLC patients, 46% developed BM by death in 
1999 compared to 62% in 2010 (p=0.14). Conclusion: Although the absolute number of 
NSCLC patients with BM at diagnosis has increased between 1999 and 2010, the 
incidence, reported as a percentage of the all NSCLC cases, is decreasing. Similar trends 
were not observed for non-metastatic patients. As a future step, a pre-specified 
multivariable analyses will be conducted to examine effects of age, gender, histology, 
smoking, and treatment on rates of BM in NSCLC.
 
Keywords: NSCLC, Brain metastasis, Incidence
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MINI04.12 Systematic Review of Brain Metastases in Non-Small Cell Lung 
Cancer (NSCLC) in the United States, European Union, and Japan D. C. Fenske, 
Gregory L. Price, Allen W. Nyhuis, Lisa M. Hess Eli Lilly and Company, Indianapolis/IN/
United States of America
Background: Prevalence of brain metastases (BRM) is increasing due to better 
detection methods and patients living longer with their disease, presenting an unmet 
need. Importantly, BRM are more common in NSCLC than most other cancers. Published 
literature offers incomplete data on prevalence, treatment, costs, and outcomes 
associated with BRM in NSCLC. This study was designed to better understand the 
epidemiology, treatment patterns, costs, and overall survival (OS) of NSCLC patients 
with BRM in the US, EU, and Japan. Methods: A systematic review was conducted by 
searching PubMed, Ovid, and Embase from January 2003 to December 2013 according 
to PRISMA guidelines. Keywords, MeSH, and Emtree terminology were used to define 
the search strategy. Eligible studies were observational, published in English, and 
peer-reviewed research of patients with NSCLC and BRM. Demographic, clinical, and 
outcomes data were extracted into Excel. Descriptive statistics were generated with 
SAS version 9.2. Demographics were summarized and treatment patterns and median 
OS were assessed by country. Results: The literature search identified 8,257 articles 
and 243 studies were eligible. There were 46,422 NSCLC cases included. Patient 
characteristics are summarized in Table 1. Treatment patterns for BRM from NSCLC 
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MINI05.01 A Progression Free Survival Score for EGFR Mutant Non-Small Cell 
Lung Cancer Patients Treat with First Line EGFR Tyrosine Kinase Inhibitors 
Yu-Mu Chen, Meng-Chih Lin, Wen-Feng Fang, Chien-Hao Lie, Huang-Chih Chang 
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung/Taiwan
Backgrounds: As epidermal growth factor receptor (EGFR) mutation a strong predictor 
of EGFR tyrosine kinase inhibitor (TKI) responsiveness, there are still around 10% TKI-
naïve patients early refractory to first line TKIs. We aimed to find clinical predictors of 
TKIs responsiveness in EGFR-mutant non-small cell lung cancer (NSCLC) patients and 
create a scoring system as progression free survival (PFS) prediction. Methods: This 
retrospective study evaluated 262 patients harboring EGFR mutation received TKIs 
as first line therapy for NSCLC between January 2011 and December 2013. Patients 
were assigned to test (N=131) and validation (N=131) by time sequence. Patients with 
age ≤ 40, uncommon EGFR mutation, poor performance status, more sites of distal 
metastasis, and lymphocyte to monocyte ratio ≤3 were independently associated with 
poor progression free survival. These five factors were included in the scoring system 
and 3 predictive groups were formed by total score. Table. 1 Univariate and Cox 





PFS (M) P value P value
Age >40 ≤40 11.6 3.3 0.001 0.002
BMI >24 ≤24 14.9 9.1 0.027 0.928
Gender Male Female 9.3 12.0 0.292
DM YES NO 9.1 11.5 0.500
Smoking Never Former / current 11.5 7.6 0.413
Performance status ECOG 0-2 ECOG 3-4 11.5 2.7 0.009 0.012
Mutation Common Uncommon 11.5 4.1 <0.001 <0.001
Tumor type Adenocarcinoma Non-adeno-
carcinoma 11.1 9.8 0.789
No. of distal metastasis 0 1-2 >2 21.4 11.3 6.1 <0.001 <0.001 0.015 <0.001
Malignant effusion Yes No 9.1 11.6 0.031 0.946
Lymphocyte to monocyte ratio >3 ≤3 13.4 7.4 <0.001 0.047
 
Results: Progression free survival in the test group were 15.7 months(m) for 0-1 points, 
9.3 m for 2 points, 4.0 m for 3-6 points (p <0.001). In the validation test, Progression free 
survival in there predictive groups each were 13.7 m, 9.5 m, 4.8 m (p <0.001). Between 
the test and validation groups, no significant differences were found in each one of the 
three predictive groups.  
and morbidity. As the median survival is limited to 2-4 months, the role of RT in treatment 
is controversial. In this Study, we try to analyze the survival rates and associated 
factors of 51 leptomeningeal brain metastatic NSCLC patients treated with whole brain 
radiotherapy (WBRT). Methods: Between January 2007 to August 2014, during follow 
up with the diagnosis of NSCLC, 51 patientswho develop LC and treated with WBRT in 
our clinic had included this study. Patients were treated with 20-30 Gy (3-4 Gy/fr) WBRT. 
Kaplan-Meier method was used for survival analysis. Bonnefoni correction was performed 
for survival analysis of groups more than two before statistical analysis. Results: Median 
age of patients were 64 (37-83) and 34(67.7%) of them are male. Patient number with 
ECOG performance status of 0-1, 2 and 3 were23 (%45.1), 15 (%29.4) and 13 (%25.5) 
respectively.%58.8 of patients had squamous cell cancer and %41.2 of them were 
adenocancer. The dose of WBRT in 31 patients was 20 Gy (4 Gy/fr; BED10=28 Gy) and 
30 Gy (3Gy/fr; BED10=39 Gy) in the other 20 patients. At the time of performing these 
analyses all the patients had died.Median survival was 3.9 ay (%95 CI: 3.3- 4.5). On 
univaryan analyses, age (≤50 vs. >50; p=0.46), gender (p=0.37),histological subtype 
(squamous cell vs. adenocancer; p= 0.74) and BED10value (39 vs. 28 Gy; p=0.26) 
did not show any statistically difference but ECOG performance status (0-1 vs. 2-3; 
p<0.001) was associated with overall survival. Median survival duration times for ECOG 
0-1 and 2-3 groups were 5.7 and 3.7 respectively. Conclusion: Median survival of 3.9 
months of our study is similar with literature but it is also querying the necessity of RT 
in this group of patients especially with poor performance status. However, the survival 
benefit of 5.8 months in ECOG performance 0-1 group may lead us to think that WBRT 
is useful. Although there has been no survival benefit between two RT dose schemes, 
20 Gy (4 Gy/fr) may be the treatment of choice because of the shorter duration. 
Keywords: NSCLC, Whole Brain Radiotherapy, Leptomeningeal Metastasis
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MINI04.14 Comparative Survival in Patients with Brain Metastases from 
Non-Small Cell Lung Cancer Treated before and after Implementation of 
Radiosurgery Anand Swaminath1, Joel Broomfield2, Gregory R. Pond3, Samantha 
Caetano4, Peter M. Ellis5, Jeffrey Greenspoon1 1Oncology, McMaster University, Hamilton/
ON/Canada, 2BC Cancer Agency, Abbotsford/BC/Canada, 3Ontario Clinical Oncology Group, 
McMaster University, Hamilton/ON/Canada, 4Mathematics, McMaster University, Hamilton/
AB/Canada, 5Oncology, McMaster University, Hamilton/Canada
Background: Survival after a diagnosis of brain metastases (BM) in non-small cell lung 
cancer (NSCLC) is generally considered poor. We previously reported median survival 
of approximately 4 months in a cohort of patients treated with whole brain radiotherapy 
(WBRT), the standard of care in many centres. Since that time, we implemented a 
program of stereotactic radiosurgery (SRS), based on randomized trials and large 
prospective series, supporting WBRT + SRS or SRS alone in selected patients. The 
current study examined survival and prognostic factors in a consecutive cohort of 
NSCLC BM patients after the introduction of an SRS program. Methods: A retrospective 
review of 167 NSCLC patients referred with BM to a tertiary cancer centre from 2010-
2012 (NEW cohort) was undertaken. These data were compared to a prior cohort of 
91 patients treated between 2005 and 2007 (OLD cohort). Summary statistics were 
used to describe the patient characteristics as well as outcomes. The Kaplan-Meier 
method was used to calculate time-to-event outcomes for overall survival (OS), from 
the time of BM diagnosis. Cox proportional hazards regression was used to investigate 
factors prognostic for outcomes. An optimal model was constructed using forward 
stepwise selection, and tests were two-sided with a p-value <0.05 deemed statistically 
significant. Results: Overall survival from diagnosis of BM (median 4.3 months NEW vs 
3.9 months OLD p=0.74) was not significantly different between cohorts. A univariate 
analysis of the NEW cohort demonstrated significant differences in OS between 
treatment groups (SRS, WBRT + SRS, WBRT or no treatment), in terms of female gender 
(p=0.034), lack of neurological symptoms (p=0.001), number of BM (p<0.001), GPA 
(p=0.001), and ECOG status at BM (p=0.009). Treatment regimen with SRS or WBRT 
+ SRS was significant as a prognostic factor for OS as well (p<0.001). Results were 
similar if one excluded the no treatment group. As some factors were not collected in 
the OLD cohort, a separate model was constructed including only data available from 
both cohorts. After adjusting for factors included in the optimal model, cohort was not 
statistically significant for OS (hazard ratio=1.03, 95% CI 0.90-1.59; p =0.88). There 
was a trend towards improved OS in the NEW vs OLD cohorts in patients <50 years of 
age (median 11.8 vs 7.5 months, p=0.39) and 50-59 years of age (median 7.8 vs 3.7 
months, p=0.052); this trend reversed to favour the OLD vs NEW cohort in patients >70 
(4.3 vs 2.8 months, p=0.01). This was coincident with increased uptake of chemotherapy 
(p<0.001) and better ECOG status (p=0.007) in younger age groups in the NEW versus 
OLD cohort. Conclusion: There has been no improvement in survival of NSCLC patients 
with BM, following the implementation of SRS. Selected patients (younger age, female 
gender, good fitness, fewer brain metastases) appear to demonstrate improved 
OS with SRS. However, this may also reflect a better natural history of the disease, 
or a greater tendency to offer them systemic therapy, in addition to receipt of SRS. 
Keywords: brain metastases, survival, radiosurgery, whole brain radiotherapy
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MINI05.03 P53 Disruptive Mutation Is a Negative Predictive Factor in EGFR 
M+ NSCLC Treated with TKI Anne C. Lueers1, Nicole Neemann2, Regina Prenzel1, 
Douglas Scriba1, Kay Wilborn1, Ursula Stropiep1, Markus Falk3, Cora Hallas3, Markus 
Tiemann3, Frank Griesinger1 1Pius-Hospital, Oldenburg/Germany, 2University of Oldenburg, 
Oldenburg/Germany, 3Haematopathology Hamburg, Hamburg/Germany
Background: p53 mutations are common in lung cancer, and have also been described 
in EGFR mutated patients. The impact of p53 mutations in EGFR M+ patients is 
controversial, especially if classified as “disruptive” and “non-disruptive” according to 
their functional effect on the p53 protein as proposed by Poeta and colleagues. The aim 
of the study was therefore to systematically analyze EGFR and p53 mutations within a 
cohort of patients with lung cancer stage IV (UICC 7), to correlate alterations with clinical 
characteristics and to investigate a potential impact of p53 mutations on treatment 
outcome. Methods: 267 patients from a single center diagnosed with lung cancer stage 
IV were studied for the presence of EGFR as well as inactivating p53 mutations. Methods 
for the detection of EGFR mutations included Sanger Sequencing and hybridization 
based COBAS testing. P53 mutations were detected by Sanger Sequencing. Clinical 
characteristics including smoking status were available for all patients. Results: 267 
consecutive patients at the lung cancer center of the Pius-Hospital Oldenburg were 
studied. The overall EGFR mutation rate was 19% (51/267) in all patients, 80% (41/51) 
showing common mutations of exon 19 or 21. P53 disruptive mutation showed in 16% 
(8/51) and p53 nondisruptive mutation occurred in 11% (22/51) whereas p53 WT was 
found in 47% (24/51). In 8/51 (16%) patients p53 analysis was not successful. OS was 
37 months in p53 disruptive mutation and p53 WT patients compared to 19 months 
in p53 nondisruptive mutation (p<0,05). PFS on 1st line TKI therapy was 18 months 
in p53 nondisruptive mutation and p53 WT patients and 6 months in p53 disruptive 
mutation (p<0,024). Similar results could be shown in the EGFR common mutation 
subgroup but not in the uncommon mutation subgroup. Conclusion: Significant 
differences in PFS and OS in EGFR M+ patients were observed depending on p53 
mutation status. P53 mutational status is only predictive when disruptive and non-
disruptive P53 mutations are differentiated. P53 should be tested prospectively 
in EGFR M+ patients as management of patients on 1st line TKI may be different. 
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MINI05.04 Survival Outcome Assessed According to Tumor Burden & 
Progression Patterns in Patients with EGFR Mutant NSCLC Undergoing 
EGFR-TKIs Yoon Ki Cha1, Ho Yun Lee2, Myung-Ju Ahn3, Yoon-La Choi4, Ji Hyun Lee2, 
Keunchil Park5, Seon-Jeong Kim6 1Radiology, Dongguk University Ilsan Hospital, Goyangsi/
Korea, 2Radiology, Samsung Medical Center, Seoul/Korea, 3Internal Medicine, Samsung 
Medical Center Sungkyunkwan University School of Medicine, Seoul/Korea, 4Pathology, 
Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul/
Korea, 5Samsung Medical Center, Seoul/Korea, 6Department of Radiology, Myongji Hospital, 
Goyang-Si/Korea
Background: Mutations in the epidermal growth factor receptor (EGFR) are associated 
with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in patients 
with advanced non-small cell lung cancer (NSCLC). However, clinical predictors of 
the survival benefit of EGFR-TKI treatment in NSCLC with EGFR activating mutations 
have not been well elucidated. Therefore, this study evaluated clinical predictors of 
survival outcome in patients with EGFR mutant NSCLC who were treated with EGFR-
TKIs. Mutations in the epidermal growth factor receptor (EGFR) are associated with a 
marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in patients with 
advanced non-small cell lung cancer (NSCLC). However, clinical predictors of the survival 
benefit of EGFR-TKI treatment in NSCLC with EGFR activating mutations have not been 
well elucidated. Therefore, this study evaluated clinical predictors of survival outcome 
in patients with EGFR mutant NSCLC who were treated with EGFR-TKIs. Methods:A 
total of 224 patients with EGFR-mutant lung adenocarcinomas that were treated with 
EGFR-TKIs were retrospectively reviewed. Treatment outcomes were evaluated based 
on clinical factors, number of metastasis site and progression patterns. Results: The 
clinical factors associated with reduced progression-free survival (PFS) and overall 
survival (OS) by univariate analysis were ECOG performance status (PS) ≥ 2, intra- 
and extrathoracic metastasis, presence of extrathoracic metastasis, high number of 
metastasis sites, metastasis to liver or adrenal gland at baseline, and rapid progression 
of primary tumor at the time of progressive disease (PD). In multivariate analysis, 
factors that remained significantly associated with shorter PFS were ECOG PS ≥ 2 
(Odds ratio [OR] 2.189 [95% CI, 1.374 – 3.437]; P < 0.001) and rapid progression of 
primary tumor at PD (OR 1.800 [95% CI, 1.059 – 3.058]; P = 0.030). Conclusion: Thus, 
tumor burden, expressed as the number of metastasis sites at the time of EGFR-TKI 
treatment, and rapid progression of primary tumor at PD are predictive of inferior 
survival in patients with lung adenocarcinoma with activating EGFR mutations. 
Keywords: predictor, Epidermal growth factor receptor, tyrosine kinase inhibitor, non-
small cell lung cancer (NSCLC)
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MINI05.06 A Phase Ib/II Study of Afainib plus Nimotuzumab in Non-Small Cell 
Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib 
Ji Yun Lee, Sung Hee Lim, Haesu Kim, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, 
Mikyong Kwak, Mijung Han, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, 
Conclusion: The score appears valid and reproducible. It can stratify NSCLC patients 
harboring EGFR mutation using first line EGFR-TKIs into long, intermediate and short PFS 
groups.  
Keywords: EGFR mutation, EGFR Tyrosine Kinase Inhibitors, NSCLC
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MINI05.02 Impact of ABCG2 Polymorphisms on the Clinical Outcome of TKIs 
Therapy in Chinese Advanced Non-Small-Cell Lung Cancer Patients Xueqin 
Chen, Dadong Chen, Shaoyu Yang, Yuelong Pan, Xin Li, Shenglin Ma Department of 
Medical Oncology, Hangzhou First People’s Hospital, Hangzhou/China
Background: ATP binding cassette superfamily G member 2 (ABCG2) has been 
demonstrated to be associated with the effect of chemotherapy/targeted therapy in 
non-small-cell lung cancer (NSCLC) and the single nucleotide polymorphisms (SNPs) 
of ABCG2 gene are supposed to affect the expression of ABCG2 protein. The purpose of this 
study was to investigate the correlation between SNPs of ABCG2 and outcome of tyrosine 
kinase inhibitions (TKIs) therapy in Chinese advanced NSCLC patients. Methods: SNP 
genotyping(34 G/A, 421 C/A, 1143 C/T and -15622 C/T)of ABCG2 gene in 100 patients 
was performed using matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry. The clinical characteristics of 100 patients were collected. A total of 
70 patients were treated with TKIs(gefitinib, erlotinib and icotinib). The association 
between ABCG2 polymorphisms and clinical characteristics was evaluated. Kaplan-Meier 
survival curves were plotted for overall survival (OS) and analyzed with the log-rank 
test. Cox proportional hazards model was applied to evaluate the association between 
OS and clinical or genomic characteristics and estimated the adjusted HR and its 95 
%CI. Results: The three polymorphisms of the ABCG2 34 G/A, 421 C/A and 1143 C/T 
occurred more frequently compared with -15622 C/T in Chinese advanced NSCLC 
patients. The allele A of 421C>A happened frequently in EGFR mutation positive patients 
(33.3% vs 9.1%, P=0.038). There was no association between ABCG2 polymorphisms 
and other clinical characteristics (p> 0.05).The median OS of patients with 34G>A 
mutant type (GA+AA) was 31.0 (95%CI: 22.9-39.1) months , which was significantly 
longer than those with wild type (GG) , 18.0 (95%CI: 14.9-21.1) months (p=0.005). 
No significant difference of OS was found in 421 C/A and 1143 C/T polymorphisms 
(p> 0.05). Conclusion: Our findings demonstrate a strong association between 
the ABCG2 34G>A polymorphism and the overall survival of NSCLC patients treated with 
TKI. It may be a possible predictor of the clinical outcome of TKIs therapy in NSCLC patients. 
Keywords: TKI, ABCG2, polymorphism, NSCLC, OS
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tissue, ECOG performance status (PS) of 0-2, adequate organ function and informed 
consent were required. Results of the two studies were previously reported individually. 
Analyses were performed by pooling patients with common EGFR activating mutations 
from both studies to compare efficacy of D versus E. Results: 121 patients with any 
EGFR mutation were enrolled into the two studies with 1 patient randomized but not 
treated; 101 (53 on D) pts had activating mutations in exon 19 or 21. For patients with 
exon19/21 mutations, the median PFS was 14.6 months (95%CI 9.0–18.2) for D and 
9.6 months (95%CI 7.4–12.7) for E and unstratified HR 0.717 (95%CI 0.458–1.124) with 
1-sided p=0.073. The median OS was 26.6 months (95%CI 21.6–41.5) for D and 23.2 
months (95%CI 16.0–31.8) for E and unstratified HR 0.737 (95%CI 0.431–1.259) with 
1-sided p=0.132. The corresponding pooled analyses were conducted separately in exon 
19 and exon 21. The adverse-event profile did not differ between the activating mutation 
subset and the overall population.
  
Conclusion: Dacomitinib may be associated with an improved PFS and 
OS compared to Erlotinib in patients with exon 19/21 EGFR mutations. 
A prospective P3 study comparing D to another EGFR TKI in 1L EGFR 
mutated NSCLC is ongoing to verify these observations (NCT01774721). 
Keywords: EGFR activating mutations, Dacomitinib, Erlotinib
EGFR MUTANT LUNG CANCER 1 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI05.10 EGFR-TKI Alone or with Concomitant Radiotherapy for Brain 
Metastases in Lung Adenocarcinoma Patients with EGFR Gene Mutations 
Yongshun Chen1, Jing Yang2, Xue Li1, Daxuan Hao1, Xiaoyuan Wu1, Yuanyuan Yang1, 
Xiaona Hu1, Chunyu He1, Wen Wang1, Jinsong Liu1, Jianhua Wang1 1Department of 
Radiation Oncology, Zhengzhou University Affiliated Cancer Hospital, Henan Cancer Hospital, 
Zhengzhou/China, 2Angang General Hospital, Anyang/China
Background: Radiotherapy is the principal treatment modality for patients with brain 
metastases (BM), however, tyrosine kinase inhibitor (TKI) of epidermal growth factor 
receptor (EGFR) shows therapeutic efficacy for brain metastases in patients with EGFR-
mutant lung adenocarcinoma. This study was conducted to compare the outcome of TKI 
alone with TKI plus concomitant radiotherapy in treatment of BM from EGFR-mutated lung 
adenocarcinoma patients.  Methods: The inclusion criteria were as following: patients 
newly diagnosed with EGFR-mutant lung adenocarcinoma, presented with BM, TKI as 
first-line therapy, and ECOG PS 0-2. Results: From January 1, 2009 to September 1, 
2014 at Zhengzhou University Affiliated Cancer Hospital, 516 lung adenocarcinoma 
patients with EGFR gene mutations were reviewed, and 132 cases (25.6%) with newly 
diagnosed BM were enrolled for the analysis. Among the 132 patients, more than half of 
them (n = 72; 54.5%) harbored a deletion in exon 19, 97 patients (73.5%) showed multiple 
intracranial lesions, and 50.8% (n = 67) had asymptomatic BM. 79 patients (59.8%) were 
treated with TKI alone, 53 with TKI plus concomitant radiotherapy (45 with whole brain 
radiotherapy, and 8 with stereotactic radiosurgery). The objective response rate of BM 
was significantly higher in TKI plus radiotherapy group (67.9%) compared with TKI alone 
group (27.8%, P<0.001). The median time to intracranial progression was 22.3 months. 
The median intracranial progression-free survival in patients who received TKI plus 
radiotherapy was 24.7 months, much longer than those treated with TKI alone which was 
19.0 months, P = 0.005. Multivariate analysis showed brain radiotherapy (P = 0.012) and 
intracranial lesion number (P = 0.070) as important prognostic factors for intracranial 
progression-free survival. In addition, the data of overall survival will be presented at the 
conference. Conclusion: For EGFR-mutated lung adenocarcinoma patients with BM, TKI 
plus concomitant radiotherapy achieved higher response rate of BM and significant 
improvement in intracranial progression-free survival compared with TKI alone.
  
Keywords: Brain metastasis, EGFR mutation, lung adenocarcinoma, Radiotherapy
Myung-Ju Ahn Division of Hematology-Oncology, Department of Medicine, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul/Korea
Background: Afatinib (A) is a potent irreversible EGFR TKI and nimotuzumab (N) is a 
humanized anti-EGFR mAb. In this phase Ib/II study, we aimed to assess the safety and 
activity of A plus N in advanced NSCLC patients with acquired resistance to gefitinib or 
erlotinib. Methods: Major inclusion criteria were advanced NSCLC with activating EGFR 
mutation or disease control for at least six months with previous gefitinib or erlotinib 
therapy. In the phase Ib study using classic 3+3 dose escalation method, patients were 
treated with A 40mg/d or 30mg/d in combination with N 100mg/w or 200mg/w. One 
cycle was composed of 4 weeks of treatment. In the phase II study, patients were treated 
with A plus N in the level of RP2D defined in the phase Ib study. Results: Overall, fifty pts 
were enrolled and treated: 13 in phase Ib and 37 in phase II. At the starting dose level (A 
40mg/d + N 100mg/w), one out of 6 pts experienced end-of-cycle 1 DLT (G3 diarrhea), 
and the dose was up to the next level of A 40mg/d + N 200mg/w. Out of 6 pts at this 
level, 2 pts experienced DLTs (G3 diarrhea and G3 neutropenia, respectively), and RP2D 
was accordingly determined as A 40mg/d + N 100mg/w. In the whole treatment duration 
of the phase II, there was no treatment related death and 10 pts (20%) experienced 
any grade 3 adverse event, including diarrhea and skin rash. Out of evaluable 50 pts 
in the phase Ib/II study, the response rate was 36% (18 achieved partial response out 
of 50) and the median PFS was 4.4 months (95% CI:3.2-5.5 months). Conclusion: A 
and N showed an acceptable safety profile and promising antitumor activity 
in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. 
Keywords: afainib, nimotuzumab, non-small cell lung cancer, Acquired resistance
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MINI05.07 Circulating Tumor Cells and Evaluation of Targeted Therapy Effect 
in EGFR Mutation/ALK Translocation Metastatic Non-Small Cell Lung Cancer 
Chunxia Su, Xuefei Li, Shengxiang Ren, Caicun Zhou Shanghai Pulmonary Hospital, 
Shanghai/China
Background: Targeted therapies have considerably improved the prognosis of patients 
with non-small cell lung cancer (NSCLC). Although not precision enough, RECIST criteria 
was still the most often used response assessment method to reflecting the clinical 
benefits. We propose a non-invasive, folate receptor (FR)–based circulating tumor cell 
(CTC) detection approach to interpret treatment response of targeted therapy between 
baseline and follow-up CTC values in EGFR mutation/ALK translocation advanced 
NSCLC. Methods: One hundred and thirty eight patients were enrolled in our study. 
Peripheral blood was analyzed for CTCs enumeration on negative enrichment by 
immunomagnetic beads. Changes of CTCs levels were correlated with radiological 
response. Sequential analyses were conducted to monitor CTC signals during therapy 
and correlate radiological effects with treatment outcome. Results: CTCs were detected 
(≥8.7CTC) in 84.8% of patients. Pretreatment and pro-treatment blood samples from 
all 118 EGFR-mutant (19deltion:56, L858R:57, G719x:3, L861Q:1, 19 deletion + 
L858R:1), 14 ALK translocation lung cancer patients and 6 EGFR wild type patients 
were collected. Of 89 eligible and evaluable patients, baseline CTC counts were not 
associated with response to treatment by RECIST (P=0.353). There is no difference 
between exon 19 deletion and L858R of baseline CTC values. (19deletion:19.4 CTCs, 
L858R:20.9 CTCs,P=0.222) The change of CTCs values increased correlation with 
radiological response (P=0.042) after treatment of targeted therapy. There is no 
significant difference between exon 19 deletion and L858R of CTCs values pre and 
pro EGFR-TKI treatment.(3.32 vs.12.1, P=0.783) Conclusion: This study confirms 
the predictive significance of CTCs in patients with EGFR mutation/ALK translocation 
NSCLC receiving targeted therapy. The change of CTCs value correlated significantly 
with radiological response. This strategy may enable non-invasive, specific biomarker 
assessment method for using CTC decreases as an early indication of response to 
targeted therapy and monitoring in patients undergoing targeted cancer therapies. 
Keywords: Targeted therapy, CTC, Gene mutation, non-small cell lung cancer
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MINI05.08 Comparison of the Efficacy of Dacomitinib v Erlotinib for NSCLC Pts 
with Del 19/L858R Suresh S. Ramalingam1, Kenneth J. O’Byrne2, Tony Mok3, Michael 
Boyer4, Pasi A. Jänne5, Zelanna Goldberg6, Cecile B. Mather6, Ian Taylor6, Hui Zhang6, 
Luis Paz-Ares7 1Winship Cancer Institute, Emory University, Atlanta/GA/United States of 
America, 2Princess Alexandra Hospital, Brisbane/QLD/Australia, 3Princess of Wales Hospital, 
The Chinese University of Hong Kong, Hong Kong/Hong Kong, 4Chris O’Brien Lifehouse, 
Camperdown/NSW/Australia, 5Dana-Farber Cancer Institute, Boston/MA/United States of 
America, 6Pfizer Oncology, New York/United States of America, 7Hospital Universitario Virgen 
Del Rocio, Sevilla/Spain
Background: To date there have been limited randomized comparisons of EGFR tyrosine 
kinase inhibitors (TKI) in EGFR mutant NSCLC. Dacomitinib is a potent, irreversible EGFR 
inhibitor that demonstrated robust activity in a phase 2 study for patients with common 
activating EGFR mutations. Additionally, preclinical data suggests greater activity 
in patients with common EGFR activating mutations in exon 19 or 21. ARCHER 1009 
(NCT01360554) and A7471028 (NCT00769067) each compared the clinical activity of 
dacomitinib (D) versus erlotinib (E) in advanced NSCLC including patients with common 
activating EGFR mutations; pooled results are presented. Methods: Patients (pts) with 
locally advanced/metastatic NSCLC were randomized following progression with 1 or 
2 prior chemotherapy regimens to treatment with dacomitinib (D) (45 mg PO QD) or 
erlotinib (E) (150 mg PO QD). The Phase 2 study (A7471028) was open label while the 
Phase 3 ARCHER 1009 study was double-blind and double dummy. Archived tumor 
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Conclusion: The combination of erlotinib and pemetrexed/cisplatin is effective 
and improved PFS as first-line treatment in Chinese lung adenocarcinoma with brain 
metastases. Toxicities are tolerable and the erlotinib-related side-effects were higher. 
Keywords: pemetrexed, lung adenocarcinoma, brain metastases, Erlotinib
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MINI05.13 Treatment of EGFR/ALK-Driven Non-Small Cell Lung Cancer 
(NSCLC) Brain Metastases: Impact of First-Line Whole Brain Radiotherapy on 
Outcome Mark K. Doherty1, Grezgorz Korpanty1, Pascale Tomasini1, Moein Alizadeh2, 
Kevin Jao1, Catherine Labbe1, Celine Mascaux1, Petra Martin1, Suzanne Kamel-Reid3, 
Melania Pintilie4, Geoffrey Liu1, Penelope Bradbury1, Ronald Feld1, Natasha Leighl1, 
Caroline Chung2, Frances Shepherd1 1Dept of Medical Oncology and Haematology, 
Princess Margaret Cancer Centre, Toronto/ON/Canada, 2Dept of Radiation Oncology, 
Princess Margaret Cancer Centre, Toronto/ON/Canada, 3Dept of Laboratory Medicine and 
Pathology, Princess Margaret Cancer Centre, Toronto/ON/Canada, 4Dept of Biostatistics, 
Princess Margaret Cancer Centre, Toronto/ON/Canada
Background: Brain metastases (mets) in EGFR/ALK-driven NSCLC are common, and 
frequently pose treatment dilemmas. Effective systemic therapy with tyrosine kinase 
inhibitors (TKIs) controls extracranial disease in up to 70% of patients, but often 
radiotherapy is required for intracranial control. As whole brain radiation (WBRT) may be 
associated with neurocognitive toxicity, we aimed to evaluate the impact of molecularly 
targeted therapy and stereotactic radiotherapy (SRS) for EGFR/ALK-driven NSCLC 
on intracranial disease control with and without WBRT. Methods: This retrospective 
analysis included patients treated with EGFR/ALK-positive NSCLC at Princess Margaret 
Cancer Centre from 1998-2015, with brain mets at lung cancer diagnosis or during 
treatment/follow-up. Demographic data were collected from electronic patient records. 
Time to intracranial progression (TTIP) and overall survival (OS) were calculated from 
date of diagnosis of brain mets, using the cumulative incidence function and Kaplan-
Meier methods respectively; differences between groups were tested with Gray’s 
or log-rank test. Results: From 1998-2015, 162 patients with brain mets from EGFR/
ALK-driven NSCLC were identified: 138 in the EGFR cohort, 23 in the ALK cohort and 
one included in both cohorts for analysis, whose tumour carries both an EGFR mutation 
and ALKrearrangement. Table 1 contains clinical characteristics and treatment details. 
In the EGFR cohort, initial brain mets treatment consisted of systemic therapy alone in 
19 patients (17 TKI, 2 chemotherapy), SRS +/- surgery in 27 patients and WBRT +/- 
SRS/surgery in 88 patients. 1-year intracranial progression rates were 26%, 32% and 
12%, respectively, and median TTIP was 18, 16 and 40 months [p=0.12]. Median OS 
was 26, 27 and 34 months respectively [p=0.49]. In the ALK cohort, initial brain mets 
treatment consisted of systemic therapy alone in 4 patients (1 TKI, 3 chemotherapy), 
SRS/surgery alone for 4 patients and WBRT +/- SRS/surgery for 15 patients. 
1-year intracranialprogression rates were 50%, 50% and 13%, respectively, and median 
TTIP was 18, 14 and 69 months [p=0.028]. Median OS was 35 months, not reached and 
51 months, respectively [p=0.75]. Multivariable analysis for the whole group showed 
that age [p=0.021], number of brain mets [p=0.012] and extracranial control [p=0.008] 
were significantly associated with OS, but not WBRT [p=0.61]. Conclusion: In this cohort 
of patients with brain mets from EGFR/ALK-driven NSCLC, patients treated with WBRT 
trended to longer TTIP. Although not statistically significant, our data also show a trend 
towards longer survival in patients who received WBRT. These observations require 
further validation in this patient population.
EGFR (N=139) ALK (N=24)
Median Age (Range) 59(29-86) 53(31-77)
Female Sex 93(67%) 15(62%)
Ethnicity Asian Caucasian Other 58(42%) 63(45%) 18(13%) 7(29%) 13(54%) 4(17%)
Smoking Never Smoker Former/
Current Smoker Unknown
108(77%) 30(22%) 
1(1%) 19(79%) 5(21%) 0
ECOG PS (Diagnosis) 0 1 2-4 66(48%) 67(48%) 6(4%) 7(29%) 14(58%) 3(13%)
Brain Mets at Stage IV diagnosis 93(67%) 13(52%)
Number of Brain Mets 1 2-4 5+ N/A 32(23%) 39(28%) 62(45%) 6(4%) 9(38%) 6(24%) 9(38%) 0
Symptomatic Brain Mets No Yes 78(56%) 61(44%) 16(67%) 8(33%)





13(54%) 3(12%) 4(17%) 
4(17%) 0
 
Keywords: brain metastases, EGFR, ALK, metastatic lung cancer
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MINI05.11 Exon 19 Deletion Prolongs Survival in Brain Metastases from Non-
Small Cell Lung Cancer Hongwei Li Radiation Therapy, Shanxi Cancer Hospital, Taiyuan/
China
Background: Approximately 20-40% of non–small–cell lung cancer (NSCLC) patients 
develop brain metastasis (BM) and the survival is very poor with a median overall survival 
of 4-6 months following whole brain radiotherapy treatment. Recent studies have shown 
that oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 
were effective for the treatment of BM from NSCLC with EGFR mutation. However, the 
relationship between EGFR mutations and prognosis of NSCLC patients with BM remains 
to be determined. In this study, we investigated the impact of EGFR mutation status on the 
survival of BM patients from NSCLC. Methods: 730 NSCLC patients were retrospectively 
reviewed. 136 patients had developed BM during their course of disease. 33 of these 
136 BM patients (24.3%) were confirmed to have exon 19 deletions, while 33 had exon 21 
point mutation (L858R) (24.3%). Overall survival was evaluated by Kaplan-Meier method. 
Log-rank test and Cox proportional hazards model were used to analyze the impact of 
pretreatment and treatment variables on survival. Results: The median survival of NSCLC 
with BM was 8 months. Log-rank test analysis showed that ECOG PS at BM (p=0.000), 
control of primary tumor (p=0.005), pathology (p=0.01), EGFR mutations (p=0.045) and 
19 exon deletion (p=0.007) were associated with a longer survival. In Cox proportional 
hazards model, EGFR exon 19 deletion (HR=0.558, 95%CI=0.325-0.957, p=0.034), 
control of primary tumor (HR=2.033, 95%CI=1.098-3.766, p=0.024), and ECOG PS at 
BM (HR=2.033,95%CI=1.145-1.287, p=0.006) were found to be independent prognostic 
factors. Moreover, there were significantly differences in the survival between different 
groups according to RTOG recursive partitioning analysis (RPA) classification system 
in this cohort of patients (p=0.000). Conclusion: Exon 19 deletion is an independent 
prognostic factor in BM from NSCLC. Our findings suggest that the status of exon 19 
deletion may be integrated into the prognostic scoring classification system for NSCLC. 
Keywords: non-small-cell lung cancer;EGFR mutation;Brain metastases;Prognosis
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MINI05.12 Erlotinib Combined with Chemotherapy versus Erlotinib 
Alone Treating Advanced Lung Adenocarcinoma with Brain Metastases 
(NCT01578668) Haihong Yang, Yalei Zhang, Meilin Zhao, Xin Xu The First Affiliated 
Hospital of Guangzhou Medical University, Guangzhou/China
Background: Erlotinib has a synergistic effect with pemetrexed when treating non-
squamous non-small cell lung cancer. The aim of our study was to confirm the efficacy 
and safety of erlotinib (E) in combination with pemetrexed/cisplatin (E-P) in Chinese 
lung adenocarcinoma with brain metastases. Methods: This study is a prospecive, 
non-randomized cocurrent controlled study. Lung adenocarcinoma patients with brain 
metastases, who were erlotinib or pemetrexed treatment-naive and had adequate organ 
functions, were assigned in parallel to receive either erlotinib 150 mg/day or erlotinib 
on days 4-21 plus pemetrexed 500 mg/m2 on day 1 and cisplatin 20 mg/m2 on day 1-3 
every 21 days up to 6 cycles and subsequent oral erlotinib, until progressive disease 
or unacceptable toxicity. The primary endpoint was intracranial overall response rate 
(ORRi). Previous data showed that about 56% of the patients treated with E and 78% of 
the patients treated with E-P, achieved an ORRi. We estimated the minimum sample size 
of 65 with 70% power (two-sided alpha 0.05). Results: 69 lung adenocarcinoma patients 
with brain metastases had received E (n=35) or E-P (n=34) from Jan 2012 through Nov 
2014. Demographics and patient characteristics were well balanced between two groups, 
including EGFR status, gender, age, smoking status, ECOG performance status, brain 
metastases and number of prior treatments. ORRi, in the E-P arm was superior to that in 
the E arm (79% vs. 48%, P=0.008) (Table S). Especially in the patients with EGFR wild 
type or treated as first-line treatment could achieve much better ORRi. Patients treated 
with E-P arm, compared with E arm as first-line treatment, were associated with better 
intracranial PFS (PFSi) (median PFSi, 9 months vs. 2 months, P=0.02) and systemic 
PFS (median PFS, 8 months vs. 2 months, P=0.006).The most frequent adverse events 
related with erlotinib were higher in the combination arm. No new safety signals were 
detected. The side effects were tolerable and no-drug related deaths. Table S The ORRi 
between the E-P and E arm.
group (n) ORRi (n,%)
Total patients E (35) 17,48.6%
E-P (34) 27, 79.4%
P value 0.008
EGFR mutation E (18) 10,55.6%
E-P (14) 12,85.7%
P value 0.124
EGFR negative E (7) 1, 14.3%
E-P (11) 7, 63.6%
P value 0.066
EGFR unknown E (10) 6,60.0%
E-P (9) 8,88.9%
P value 0.303
First-line treatment E (16) 7,43.7%
E-P (18) 14 ,77.7%
P value 0.08
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(JTO 2015), and predominant solid (SOL) (Modern Pathol 2011) histological subtype as 
poor prognostic markers in stage I lung adenocarcinomas (ADC) are reproduced by 
others. In this study, we hypothesized that presence of STAS, MIP or SOL patterns (≥5%) 
in small stage I lung ADC (≤2 cm) is a marker of invasion and poor prognosis, and can 
influence the recurrence patterns based on the type of surgical resection – lobectomy 
(LO) versus limited resection (LR). Methods: All available tumor slides from patients with 
therapy-naive, surgically resected small (≤ 2cm), solitary stage I lung ADC were reviewed 
(1995-2011; n = 909). STAS was defined as isolated tumor cells within alveolar spaces 
separate from the main tumor. MIP and SOL patterns were considered present in the 
tumor when it comprised ≥5% of the overall tumor. Cumulative incidence of recurrence 
(CIR; any types, locoregional or distant) was estimated using a cumulative incidence 
function. Differences in CIR between groups were assessed using Gray’s method. 
Results: 
 
The association of outcomes with the presence of STAS, MIP, or SOL patterns is shown 
in the table. The risk of developing any types of recurrence was significantly higher in 
patients with both STAS and MIP positive tumors than others (P < 0.001); and the risk 
of developing any types of recurrence was significantly lower in patients with both STAS 
and SOL negative tumors than others (P < 0.001). In the LR group, STAS, MIP and SOL 
patterns were independent prognostic factors for any types of recurrence (HR: 4.5, 1.4, 
and 1.3, respectively), locoregional recurrence (HR: 5.2, 1.3, and 1.3, respectively), 
and distant recurrence (HR: 3.1, 1.4, and 1.2, respectively). Conclusion: Tumor STAS, 
presence of MIP and SOL patterns are independent risk factors of recurrence especially 
in the LR group of small stage I lung ADC patients. Importantly, of these factors, 
tumor STAS was the strongest predictor of locoregional recurrence in this group. 
These results suggest that the identification of STAS in small lung ADC may identify LR 
patients who need further management, one of which may be completion lobectomy. 
Keywords: lung adenocarcinoma, spread of tumor through alveolar spaces, 
micropapillary growth pattern, solid growth pattern
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MINI06.03 Improved Survival in Patients with Stage I-II NSCLC Treated with 
Surgery or Radiotherapy in the Department of Veterans Affairs Joseph K. 
Salama1, Christina D. Williams2, Drew Moghanaki3, Michael J. Kelley2 1Radiation Oncology, 
Duke University, Durham/United States of America, 2Duke University/VA Hospital, Durham/
NC/United States of America, 3Radiation Oncology, Virginia Commonwealth University, 
Richmond/VA/United States of America
Background: Recent advancements in surgical and radiotherapy techniques for early 
stage NSCLC have demonstrated improved outcomes in clinical trials and case series. 
However, their impact on large populations remains poorly studied. We therefore 
analyzed Department of Veterans Affairs (VA) data to evaluate temporal trends in survival 
within a large integrated healthcare system during the decade these techniques were 
introduced. Methods: Using VA Central Cancer Registry and vital status data, patients 
diagnosed with stage I-II NSCLC between 1/1/2001-12/31/2010 were identified. Patient 
characteristics assessed included age, race, stage, histology, Charlson comorbidity 
index, specific comorbid conditions, and smoking status. Descriptive and chi-square 
statistics were used to compare patient characteristics and outcomes. Results: 18,442 
patients were identified with stage I-II NSCLC. The primary modality of treatment was 
surgery in 10,754 (58%), radiotherapy in 3,708 (20%), and another or no therapy in 
3,980 (22%). Patients treated with surgery were younger (median age 66 vs 72%, 
p<0.0001), were more likely to have a comorbidity index of 0 (28% vs 18%, p<0.0001), 
and were less likely to have COPD (41% vs 58%, p<0.0001), diabetes (22% vs 25%, 
p=0.0026), peripheral vascular disease (16% vs 20%,P<0.0001), and coronary vascular 
disease (9 vs 12%,p<0.0001). Surgery patients were more likely to be current (52% 
vs 45%, p<0.0001) and less likely to be former (39% vs 45%,p<0.0001) smokers. 
Equal percentages of surgery and radiation patients were black (14% vs 15%) and white 
(86% vs 85%). Compared to radiotherapy, surgery patients were more likely to have 
earlier stage disease (stage I: 79% vs 70%, p<0.0001), and adenocarcinoma (45% vs 
22%, p<0.0001). The number of stage I-II NSCLC patients treated with radiotherapy or 
surgery increased by 50% (667 to 1,001) and 35% (1,845 to 2,496), respectively. The 
percentage treated each year with surgery increased from 56% in 2001 to a peak of 
61% in 2004-2005, decreasing back to 56% in 2010. Inversely, the percentage treated 
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MINI06.01 Prognostic Impact of Visceral Pleural Invasion and Its Degrees in 
Non-Small Cell Lung Cancer: A SEER Database Analysis Lilan Zhao, Junyan Zha, 
Fangyu Zhou, Ke Fei, Chang Chen Department of General Thoracic Surgery, Shanghai 
Pulmonary Hospital, Shanghai/China
Background: Visceral pleural invasion (VPI) is reported to be associated with poor 
prognosis in non-small cell lung cancer (NSCLC). However, whether a tumor size larger 
than 3cm with VPI should be upgraded to the next T stage remains unclear. In addition, 
few studies have clarified the impact of VPI according to nodal status, and whether 
degree of VPI (PL1, PL2) affects survival is controversial. The objective of this study was 
to evaluate the influence of VPI and also develop a prognostic nomogram. Methods: We 
retrospectively reviewed the SEER database from 2004 to 2011. Inclusion criteria were 
defined as: first and only primary NSCLC treated with lobectomy; staging as T1-3N0-
2M0, no other non-size-based T factors except VPI. Tumors were divided into 10 groups: 
A, 0-2cm, non-VPI; B, 0-2cm, VPI; C, 2-3cm, non-VPI; D, 2-3cm, VPI; E, 3–5cm, non-VPI; 
F, 3–5cm, VPI; G, 5–7cm, non-VPI; H, 5–7cm, VPI; I, >7cm, non-VPI; J, >7cm, VPI. Kaplan-
Meier overall survival (OS) curves were compared using the log-rank test. A Cox 
proportional hazard model was used, and identified independent prognostic factors were 
entered into the nomogram. Results: A total of 26,315 patients were finally identified, 
5,941 patients (22.6%) had VPI. VPI showed an adverse impact in all tumor size groups in 
N0 status (p<0.001). Cox regression showed that VPI is an independent risk factor (HR 
1.25; 95%CI 1.19-1.31). In N0 status, the survival rates were significantly different 
between B with C and D with E groups (p<0.001), whereas not significantly between F 
with G (p=0.405) and H with I (p=0.506). In N1 and N2 status, only the A and B groups 
showed a distinct survival impact (p=0.001). Between 2010 and 2011, 5,632 patients 
performed the elastic stain for differentiating the degrees of VPI, and survival was not 
significantly different between PL1 and PL2 (p=0.568). The C-index of the nomogram 
was 0.68. The calibration curves showed optimal agreement between nomogram 
prediction and actual observation of OS. 
 
Conclusion: The presence of VPI, rather than the extent (PL1, PL2) has an adverse 
impact on NSCLC patients and N0 status. In a future TNM staging system, VPI should 
lead to upstaging to the next T category in current 3-7cm tumors. VPI is more aggressive 
in early-stage tumors, while its prognostic impact in node positive and locally invasive 
tumors is less significant. We further established and validated a nomogram to provide 
individual prediction of OS. The nomogram could be helpful for clinicians in decision 
making.  
Keywords: Nomogram, prognostic factor, non-small cell lung cancer, visceral pleural 
invasion
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MINI06.02 T1a Lung Adenocarcinomas: Presence of Spread of Tumor through 
Alveolar Spaces (STAS), Micropapillary and Solid Patterns Determines 
Outcomes Kyuichi Kadota1, Takashi Eguchi2, Nabil P. Rizk2, Kaitlin M. Woo3, Camelia S. 
Sima3, Bernard J. Park2, David R. Jones2, William D. Travis4, Prasad S. Adusumilli5 
1Department of Diagnostic Pathology, Kagawa University, Kagawa/Japan, 2Thoracic Service, 
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York/NY/United 
States of America, 3Department of Epidemiology & Biostatistics, Memorial Sloan Kettering 
Cancer Center, New York/NY/United States of America, 4Department of Pathology, Memorial 
Sloan Kettering Cancer Center, New York/NY/United States of America, 5Thoracic Service 
and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York/NY/
United States of America
Background: Our previous reports highlighting the significance of presence of 
micropapillary (MIP) (JNCI 2013), STAS- spread of tumor through alveolar spaces 
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variations among institutions, but the overall rate of attainment has increased over time. 
Compared with no lymph nodes examined, meeting the CoC criteria provided a 43% 
overall survival benefi t. However, more stringent measures, such as examining 20 lymph 
nodes (72%) or requiring mediastinal lymph node examination (17%), will have even 
greater survival impact. 
Keywords: patient survival, Surgical resection, non-small cell lung cancer, Commission 
on Cancer
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MINI06.06 Early-Stage Lung Cancer Treatment and Survival: Impact of Race 
Christina D. Williams, Michael J. Kelley Duke University/VA Hospital, Durham/NC/United 
States of America
Background: Lower rates of surgical resection for early-stage lung cancer among 
blacks compared to whites are well-documented and have persisted for decades. It is 
suggested that the survival disparity is largely due to lower rates of surgery among 
blacks and that equivalent outcomes are possible for blacks and whites with similar 
treatment. The objectives of this work were to utilize a decade of data to evaluate trends 
in receipt of treatment among blacks and whites and examine the impact of race on 
survival outcomes. Methods: We used data from a national cohort of patients in the 
Veterans Administration diagnosed with Stage I-II non-small cell lung cancer (NSCLC) 
between 2001 and 2010. Chi-square statistics were used to compare treatment and 
outcomes by race. Cox proportional hazards models estimated hazard ratios (HR) 
with 95% confi dence intervals (95%CI). Results: Among 18,442 patients with stage I-II 
NSCLC, the proportion of blacks and whites receiving surgery was 54% and 59% (p ≤ 
0.0001), respectively. The black-white difference in surgery rates was 8% in 2001 and 1% 
in 2010. There was no racial difference in receipt of nonsurgical therapy; however, blacks 
were more likely than whites to have no treatment (22% vs. 18%, p ≤ 0.0001). Among 
surgical patients, type of surgical resection was similar by race, the 30-day mortality 
rate was 2% in both race groups, but 90-day mortality was signifi cantly higher in whites 
than blacks (6% vs. 3%, p=0.0008). Also, 31% of blacks were diagnosed at the time of 
surgery compared to 27% of whites (p<0.0001). There was no racial difference in type 
of nonsurgical treatment, with 86% of all patients who did not have surgery receiving 
radiation therapy. Among all patients, the 4-year survival rate was 40% in blacks and 
39% in whites (p=0.38), and the adjusted HR for blacks compared to whites was 0.91 
(95%CI 0.84-0.98) among all patients. Corresponding HRs and 95% CI among patients 
receiving surgical treatment, nonsurgical treatment, or no treatment were 0.90 (0.83-
0.97), 0.83 (0.76-0.91), and 0.91 (0.82-0.996), respectively. Conclusion: The racial 
disparity in receipt of surgery for early-stage lung cancer decreased between 2001 and 
2010, with similar rates observed at the end of the study period. Previously reported 
racial differences in survival outcomes were not observed in this cohort. Despite 
overall lower surgery rates among blacks, the proportion of black and white patients 
surviving 4 years was similar although overall survival was slightly better among 
blacks, and this fi nding was consistent among patients with and without treatment. 
Keywords: survival, Race, disparity, Surgery, Radiotherapy
each year with radiation decreased from 21% in 2001, to 17% in 2005 and increased 
to 24% in 2010. The use of other/no therapy remained unchanged. The Southern 
region comprised almost half of all treated lung cancer diagnoses (46%), followed by 
the Midwest (21%), the West (17%), and the Northeastern Region (14%). Between 2001-
2010, the number of patients receiving therapy (radiation or surgery) increased each 
year (p=0.0017). The 4-year survival rate was 54% for surgery patients and 19% for 
radiotherapy patients (p<0.0001), which varied based on stage (stage I: 58% vs 22%; 
stage II: 41% vs 13%, respectively). Between 2001-2010, patients treated with either 
surgery or radiotherapy had a 12% absolute improvement in 4 year OS, representing 
a 100% survival improvement with radiotherapy (12% to 24%) and a 24% improvement 
with surgery (49% to 61%). Conclusion: The Department of Veterans Affairs is treating 
increasing numbers of patients with stage I-II NSCLC. Following a decade when 
advanced technologies were introduced for surgery and radiotherapy, survival rates 
have improved signifi cantly for both treatment modalities. The largest gains were 
observed among patients treated with radiotherapy with a doubling of 4-year survival. 
Keywords: Surgery, early stage NSCLC, radiation, Veterans Administration
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MINI06.04 Impact of Attainment of the American College of Surgeons 
Commission on Cancer Quality Measure on Patient Survival After Lung Cancer 
Resection Xinhua Yu1, Nicholas Faris2, Ransome Eke1, Matthew P. Smeltzer1, George 
Relyea1, Fedoria E. Rugless2, Carrie Fehnel2, Nibedita Chakraborty2, Cheryl Houston-
Harris2, Fujin Lu2, Edward T. Robbins2, Raymond S. Signore3, Laura Mchugh3, Brad 
Wolf4, Chris Mutrie4, Lawrence Deese5, Paul Levy6, Edward Crocker7, Lynn Wiggins8, 
Raymond U. Osarogiagbon2 1Epidemiology and Biostatistics, University of Memphis School 
of Public Health, Memphis/TN/United States of America, 2Thoracic Oncology Research 
Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis/TN/
United States of America, 3Multidisciplinary Thoracic Oncology Program, Baptist Cancer 
Center, Memphis/TN/United States of America, 4Baptist Memorial Health Care Corporation, 
Memphis/TN/United States of America, 5Baptist Memorial Health Care Corporation, Oxford/
MS/United States of America, 6Baptist Memorial Health Care Corporation, Jonesboro/AR/
United States of America, 7Baptist Memorial Health Care Corporation, Columbus/MS/United 
States of America, 8St. Bernard’s Regional Medical Center, Jonesboro/AR/United States of 
America
Background: Institution-driven survival disparities persist among non-small cell lung 
cancer (NSCLC) patients who receive curative-intent surgical resection. Recently, the 
Commission on Cancer (CoC) established an institutional quality surveillance measure: 
the proportion of resected stage IA–IIB NSCLC with examination of ≥10 lymph nodes. We 
examined the potential impact of this measure on long-term patient survival. Methods: We 
analyzed all stage IA-IIB NSCLC resections in the Mid-South Quality of Surgical Resection 
cohort, a patient-level database of all lung cancer resections performed in 11 institutions 
in 5 Dartmouth Hospital Referral Regions in Eastern Arkansas, Northern Mississippi, and 
Western Tennessee from 2004-2013. We recorded pathologic staging details. Patients 
receiving pre-operative therapy were excluded. A trend analysis of quality and survival 
disparities was performed based on a Cox proportional hazard model, adjusted for age 
and pathologic stage. Results: Of 1,877 eligible patients, 77% were stage I and 23% 
stage II. The median number of lymph nodes retrieved during surgery was 6 (interquartile 
range [IQR]: 3-10). The CoC quality measure was achieved in 27.8% of cases. Conversely, 
11% of resections had no lymph nodes examined (pNX). The proportion of cases meeting 
the CoC criteria increased from 18.8% in 2004 to 50% in 2013 (p<0.001). Large 
variations among institutions existed, ranging from 14% to 55% of institutional cases 
meeting the CoC measure. Compared to pNX resections, resections with at least one 
lymph node examined yielded some survival benefi t (Hazard ratio (HR): 0.71, 95%CI: 
0.54-0.93, p=0.014). Likewise, Patients with 10-12 lymph nodes examined had 43% 
overall survival benefi t (HR: 0.57, 95%CI: 0.40-0.81, p=0.002), but survival did not 
signifi cantly improve compared with 4-6 (the median) lymph nodes harvested (p=0.48). 
However, the survival benefi t improved as more lymph nodes were examined, reaching 
an optimal point of a 72% benefi t when 19-21 lymph nodes were harvested (HR: 0.28, 
95%CI: 0.11-0.68, p=0.005). Compared with 4-6 lymph nodes, the survival benefi t was 
17% (p=0.06) (Figure 1). Furthermore, for those with any mediastinal lymph nodes 
sampled during the surgery, the survival benefi t was 17% (HR: 0.82, 95%CI: 0.71-0.96, 
p=0.015).
Conclusion: Only 28% of NSCLC resections achieved the CoC measure, with large 
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MINI06.07 High Incidence of PD-L1 Expression in Surgically Resected 
Pulmonary Lymphoepithelioma-Like Carcinoma Is Linked to Prognosis 
Yunpeng Yang, Shaodong Hong, Wenfeng Fang, Hongyun Zhao, Yan Huang, Xin Wang, Li 
Zhang Sun Yat-Sen University Cancer Center, Guangzhou/China
Background: Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and distinct 
type of primary lung cancer which is characterized by Epstein-Barr virus (EBV) infection. 
The prognostic significance of programmed cell death ligand 1 (PD-L1) in pulmonary LELC 
remains poorly understood. Methods: A total of 113 surgically resected pulmonary LELC 
in Sun Yat-sen University Cancer Center between January 2008 and December 2012 
were included. Paraffin-embedded tumor sections were stained with PD-L1 antibody. 
H score were calculated by multiplying the percentage of positively stained cells by an 
intensity score. Tumors with >5% PD-L1 expression were deemed PD-L1 positive. The 
mRNA level of latent membrane protein 1 (LMP1) were determined by RT-PCR. Univariate 
and multivariate analyses were performed to identify prognostic factors for disease-free 
survival (DFS) and overall survival (OS). Results: The positive rate of PD-L1 was 74.3%. 
Patients with PD-L1 (+) tumor were significantly younger than those with PD-L1 (-) (median 
age, 50 vs 58 years; p = 0.008). High PD-L1 expression (H-score > 30) was associated 
with impaired DFS (median: 33.8 months vs not reached; p = 0.008) compared with low 
PD-L1 expression (Figure 1). Multivariate analysis shows that PD-L1 expression level (p 
= 0.014), N stage (p = 0.039) and M stage (p= 0.024) were independent prognostic 
factors for DFS. N stage and M stage but not PD-L1 expression level were significantly 
associated with OS (Figure 2). Also, LMP1 mRNA level was significantly associated with 
PD-L1 expression level (p < 0.001).
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significant statistical difference (p=0.016). Two of the 25 patients were deceased from 
lung cancer metastases at postoperative 23rd and 36thmonths, respectively. Statistical 
analysis revealed three predictors for lymph nodal metastasis: tumor size, preoperative 
serum carcinoembryonic antigen level, and proportion of the mix density. The ROC 
curves show cutoff values at 1.1cm, 2.75ng/ml and 21%, respectively.
Conclusion: Our results reveal higher incidence of PD-L1 expression in pulmonary LELC 
than common lung cancer, which may be linked to EBV burden. PD-L1 was a negative 
prognostic factor for DFS but was not associated with OS in surgically resected 
pulmonary LELC. These findings may provide a rationale for immunotarget therapy in this 
virus-associated lung cancer. Keywords: pulmonary Lymphoepithelioma-Like Carcinoma, 
Programmed cell death ligand 1, Prognosis
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MINI06.08 Recognition Of “Aggressive” Nodal Metastatic Behavior In “Indolent” 
Ground Glass Opacity Lesions Junyan Zha, Lilan Zhao, Dong Xie, Ke Fei, Chang Chen 
Department of General Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai/China
Background: Radiologically characteristic ground-glass opacity (GGO) represents 
a special cohort of pulmonary adenocarcinomas that has been unanimously defined 
as biologically inert. Lymph node metastasis, however, occurs occasionally in these 
biologically “indolent” cancers. The incidence and underlying risk factors of nodal 
metastasis remain unknown. Methods: All surgically removed GGO lesions between Jan. 
2008 and Dec. 2014 were reviewed from a single treatment institution. Pathologically-
confirmed adenocarcinomas with systemic lymph node dissection or sampling were 
enrolled into the present study. All the lesions were classified into three groups according 
to the proportion of solid densities: Group I, pure GGO; Group II, 1% to 50%; and Group 
III, 50% to 100%. Risk factors analysis of lymph node involvement was performed by 
multivariate logistic regression. Results: Of the 867 patients eligible for this study, there 
were 566 (65.3%) females and 301 (34.7 %) males. 553 (63.7%) presented as pure GGOs 
(Group I) and 314 (36.2%) were mixed GGOs, of which 160 (18.5%) were in Group II and 
154 (17.8%) group III. Lymph node metastasis was confirmed in 25 patients, including 12 
pN1 and 13 pN2 cases. Among these 25 cases, 11 were Group II and 14 were Group III; 
13 (13/367) had1-2cm tumors and 12 (12/136) had 2-3cm tumors, which also showed a 
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Conclusion: In p-stage-I lung adenocarcinoma patients, ASFC was frequently 
found in invasive lung adenocarcinoma cases. Therefore, characteristics 
of these lung cancers may develop a poor prognosis. PET scan might have 
effective radiological examinations to find a lung adenocarcinoma with ASFC. 
Keywords: lung cancer, Adenocarcinoma, aerogenous spread, stage I
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MINI06.11 The Influence of Body Mass Index on Overall Survival following 
Surgical Resection of Non-Small Cell Lung Cancer Kathryn A. Gold1, Boris 
Sepesi2, Arlene M. Correa2, Xi Liu3, John V. Heymach1, Ara A. Vaporciyan4, Ethan 
Dmitrovsky1 1Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson 
Cancer Center, Houston/TX/United States of America, 2Thoracic and Cardiovascular 
Surgery, University of Texas MD Anderson Cancer Center, Houston/TX/United States of 
America, 3Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson 
Cancer Center, Houston/TX/United States of America, 4Thoracic and Cardiovascular Surgery, 
University of Texas MD Anderson Cancer Center, Houston/United States of America
Background: Population studies suggest that high body mass index (BMI) correlates 
with a reduced risk of death from lung cancer. The aim of our study was to evaluate the 
influence of BMI on long term overall survival (OS) in surgical patients with non-small 
cell lung cancer (NSCLC). Methods: Study population consisted of 1935 patients who 
underwent surgical resection for lung cancer at MD Anderson Cancer Center between 
2000-2014. Patients with perioperative mortality, 90-day mortality, intraoperative 
transfusion, postoperative ICU days, postoperative pneumonia, and postoperative 
transfusion were excluded. Study variables included both patient and treatment related 
characteristics. Univariable and multivariable Cox regression analyses were performed 
to identify variables associated with overall survival. Propensity matching was performed 
to compare patients with BMI <25 and BMI≥30 matching on type of surgery, age, gender, 
histology, and pathological stage. Results: On univariable analysis, significant predictors 
of improved survival were higher BMI, pathologic tumor stage (stage I vs II, III, or IV), type 
of surgery (lobectomy/pneumonectomy vs wedge resection/segmentectomy), younger 
age, female gender, and adenocarcinoma histology (vs squamous) (all p<0.05). Patients 
considered morbidly obese (BMI≥35) had a trend towards better outcomes than those 
classified as obese (BMI ≥30 and <35), overweight (BMI ≥25 and <30), or healthy weight 
(BMI<25) (HR 0.727, 0.848, 0.926, and 1, respectively, p=NS). On multivariate analysis, 
BMI remained an independent predictor of survival (p=0.02, see Table). Propensity 
matching analysis demonstrated significantly better OS (p=0.008) in patients with 
BMI≥30 compared to BMI <25 (Figure).
Table1. Independent predictors of lymph node involvement by multivariate analysis
Variables Odds Ratio 95%CI P
Tumor size 2.544 1.271-5.092 0.008
GGO status(Ratio) 3.272 1.759-6.089 <0.001
CEA level 9.672 3.805-24.584 <0.001
 
Conclusion: Among the majority of “indolent” GGO lesions, lymph node metastasis occurs 
occasionally at 2.9%. A larger size, mixed GGOs with a higher proportion of solid component, 
and elevated serum CEA level were associated with a higher preference for nodal metastasis. 
Keywords: Lymph nodal metastatic, Early-stage Non-small-cell lung cancer, Serum CEA 
leve, ground-glass opacity
QUALITY/PROGNOSIS/SURVIVAL 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI06.09 Aerogeneous Spread Is a Predictive Factor of Recurrence in Stage I 
Lung Adenocarcinoma Satoshi Shiono1, Naoki Yanagawa2 1Thoracic Surgery, Yamagata 
Prefectural Central Hospital, Yamagata/Japan, 2Pathology, Yamagata Prefectural Central 
Hospital, Yamagata/Japan
Background: Previously, aerogeneous spread with floating cancer cell clusters (ASFC) 
was a prognostic factor and significantly related with local recurrence of the surgical 
margin after metastatic lung tumor (Shiono, Ann Thorac Surg 2005). However, ASFC 
in surgically resected lung cancer has not been investigated well. Since our institute 
examined ASFC in resected lung cancer specimens prospectively, we assessed 
the prognostic impact of ASFC and local recurrence in stage I lung adenocarcinoma 
cases. Methods: From July 2004 to November 2014, a total of 877 lung cancer 
patients underwent a surgery. Among them, 318 patients with pathological stage 
I adenocarcinoma cases were reviewed. We investigated the characteristics of ASFC 
and analyzed the relationship between ASFC and prognosis. The patients who received 
preoperative treatment or had multiple lung cancers were excluded. Results: Median 
follow-up time was 28 months. Of the 318 patients, 47 (14.8%) patients had ASFC. The 
local recurrence rate was 11 of 47 (23.4%) cases with ASFC and 10 of 271 (3.7%) cases 
without (p < 0.01). All 4 cases developing surgical stump recurrence had an ASFC. In 
patients with ASFC, the ratio of male, smoker, EGFR mutation negative, lymphovascular 
and pleural invasion were significantly high (p < 0.01). Standardized uptake value (SUV) 
(p < 0.01) was also significantly higher in ASFC positive cases. Surgical procedure did 
not influence development of ASFC. Multivariate analysis revealed that the ASFC were 
significantly related with EGFR negative mutation and lymphovascular invasion. As 
preoperative predictive factors for ASFC, SUV was a significant predictive factor (p = 
0.01). Univariate analysis showed that overall 5-year survival of cases with ASFC was 
62.7% and without was 91.1% (p < 0.01) and recurrence free 5-year survival of cases with 
ASFC was 54.4% and without 87.8% (p < 0.01). Multivariate analysis showed that age, 
pleural invasion and ASFC were significant prognostic factors for overall survival, and that 
these factors were significantly related to cancer recurrence after surgery.
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strong (HR 36.17, 95% CI 6.23 to 210.13; P<0.01). Conclusion: This study suggests that 
for pathological ‘N1’ NSCLC, overall LNR should be considered a prognostic value while 
for ‘N2’ disease, only medialstinal LNR should be included in prognostic stratification. 
Keywords: NSCLC, Cancer-involved Lymph Node Ratio, survival
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MINI06.13 Multiple Lung Cancers: Is Their Survival Better or Worse Then 
Other Lung Cancers? Jarushka Naidoo1, Kaitlin Woo2, Camelia S. Sima2, William D. 
Travis3, Maria Arcila3, David J. Finley4, Valerie W. Rusch5, David R. Jones5, Mark G. Kris1, 
Marjorie Zauderer6 1Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York/
NY/United States of America, 2Epidemiology and Biostatistics, Memorial Sloan Kettering 
Cancer Center, New York/United States of America, 3Pathology, Memorial Sloan Kettering 
Cancer Center, New York/United States of America, 4Thoracic Surgery, Dartmouth-Hitchcock 
Medical Center, New Hampshire/NH/United States of America, 5Thoracic Surgery, Memorial 
Sloan Kettering Cancer Center, New York/NY/United States of America, 6Medicine/Thoracic 
Oncology, MSKCC, New York/NY/United States of America
Background: Multiple lung cancers (MLCs) are determined using the Martini-Melamed 
clinical criteria, and comprehensive pathologic assessment. The prognosis of MLCs 
is not known. Herein, we evaluate the prognosis of patients with MLCs, one resected 
LC, and recurrent LC, to ascertain whether patients with MLCs have a distinct natural 
history compared to the other two groups. Methods: After IRB approval, we conducted a 
retrospective review of all patients who underwent an R0 resection for stage IA-IIIA LC from 
2008-2013 in our institution. Patients with carcinoid tumors, adenocarcinoma-in-situ, 
multiple ground-glass opacities, intrapulmonary metastases and cancers not originating 
from the lung, were excluded. MLCs were defined using Martini-Melamed criteria and 
comprehensive pathologic assessment. Clinicopathologic data was collected. We used 
the Kaplan-Meier method and log-rank test to assess overall survival (OS) of patients 
with MLCs, one LC, or recurrent LC, from the time of surgery/pathologic confirmation of 
their MLC, one LC, or recurrent LC, respectively. Results: 2352 patients were identified: 
one LC (n=2238), recurrent LC (n=348), MLC (n=113).Median OS and 2-year OS for 
patients in these subgroups stratified by stage, is depicted in Table 1. In patients with 
one LC, never smokers (p<0.001), adenocarcinoma histology (p<0.001), and surgery 
type (p<0.001) were associated with improved OS. In patients with recurrent LC, never 
smokers (p=0.015), and adenocarcinoma histology (p=0.009) were associated with 
favorable OS, compared to smokers and squamous histology respectively. In patients 
with MLCs, adenocarcinoma histology was associated with improved OS when compared 
to squamous histology (p=0.049).
Pathologic 
Stage (n)




One Lung Cancer 
(n=2238)
























Conclusion: Martini-Melamed criteria and comprehensive pathologic assessments 
successfully identify patients with MLCs. Prognostic data for patients with MLCs, 
one LC and recurrent LC, highlight that these patients have a long natural history. 
MLCs have a long survival stage for stage, which underscores a definitive therapeutic 
approach where possible, based on favorable prognosis of these patients. 
Keywords: multiple lung cancer, non-small cell lung cancer, Prognosis, survival
Multivariate Cox Regression Model
N (%) Overall Survival HR (95% CI)
BMI <25 (Reference) ≥25 646 (33.4%) 1289 (66.7%) 1.000 0.833(0.713-0.975)
Age Continuous variable Median 66 (13-88) 1.024 (1.015-1.032)
Gender Female (Reference) Male
984 (50.9%) 
951 (49.1%) 1.000 1.236 (1.061-1.441)
Stage I (Reference) II III IV
1149 (59.4%) 
431 (22.3%) 
299 (15.5%) 56 
(2.9%)







1737 (89.8%) 1.000 0.602 (0.479-0.755)
Pre-op 
therapy No (Reference) Yes
1604 (82.9%) 








1.000 1.225 (1.035-1.451) 0.959 
(0.747-1.231)
Conclusion: In a large, single center series, after controlling for disease stage and 
other variables, higher BMI was associated with improved OS following surgical 
resection of NSCLC. Further studies are necessary to define the complex relationship 
between BMI and treatment outcomes.  
Keywords: Obesity, non-small cell lung cancer, Surgical resection
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MINI06.12 Prognostic Impact of Cancer-involved Lymph Node Ratio in 
Resected NSCLC Differ between ‘N1’ or ‘N2’ Disease Wenhua Liang, Jianxing He 
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou/China
Background: The extent of lymph nodes (LN) involvement and the adequacy of 
systematic LN sampling are significantly correlated with the prognosis of cancer 
patients. The index combing these two factors, cancer-involved LN ratio (LNR), has 
been proved a strong prognostic factor by extensive previous studies, including non-
small cell lung cancer (NSCLC). However, intrapulmonary or mediastinal LNs associate 
with different examination strategy. It might not be appropriate to apply the LNR 
indistinguishably to all patients. Therefore, we sought to examine the performance of 
LNR separately. Methods: A consecutive cohort of patients who underwent radical 
resection with systematic lymph node sampling for NSCLC between Sep 2009 and 
Dec 2011 were collected. LNR for intrapulmonary and hilar LNs was recorded as LNR1, 
and LNR for mediastinal LNs was recorded as LNR2. LNR was incorporated in the Cox 
regression model as a continuous variable. Disease free survival (DFS) was the primary 
endpoint. Results: A total of 681 cases were included for analysis. Overall LNR was 
a significant prognostic factor in overall population (HR 11.75, 95% CI 6.99 to 19.75; 
P<0.001). For patients with ‘N2’ disease, overall LNR remained a prognostic factor (HR 
3.07, 95% CI 1.22 to 7.74; P=0.02). However, further explorations revealed that LNR2 has 
prognostic impact (HR 3.59, 95% CI 1.68 to 7.67; P<0.01) but not LNR1 (HR 0.99, 95% CI 
0.48 to 2.06; P= 0.99). For those with ‘N1’ disease, LNR1 was not a significant prognostic 
factor (HR 3.19, 95% CI 0.87 to 11.66; P=0.08) but the prognostic value of overall LNR is 
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neutropenia 9%, 17%, diarrhea 6%, 0% respectively. There were 4 and 5 treatment-
related deaths in Arms SP and VP, respectively. The quality assurance committee 
judged that 74% of radiation treatment plans had no deviation and 24% had a minor 
deviation. Conclusion: Both arms rejected the null hypothesis for 2yr-OS. In this study Arm 
SP was declared the winner in terms of 2yr-OS, PFS, treatment completion, and toxicity. 
Keywords: concurrent chemoradiotherapy, NSCLC, S-1, locally advanced
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MINI07.02 Chemoradiotherapy versus Radiotherapy Alone in Elderly Patients 
with Stage III Non-Small Cell Lung Cancer: A Systematic Review David E. Dawe1, 
David Christiansen2, Ryan Zarychanski1, Ahmed Abou-Setta2, Peter M. Ellis3, Anand 
Swaminath3, Janet Rothney2, Rasheda Rabbani2, Salah Mahmud2 1CancerCare Manitoba, 
Winnipeg/MB/Canada, 2University of Manitoba, Winnipeg/Canada, 3McMaster University, 
Hamilton/ON/Canada
Background: Approximately 30% of non-small cell lung cancer (NSCLC) patients present 
with locally advanced (stage III) disease, and half are elderly (age ≥70). Young, fit patients 
with stage III NSCLC have improved survival with the use of combined chemotherapy 
and radiation therapy (CRT) over radiation therapy (RT) alone – HR 0.74 in a 2010 
Cochrane systematic review. Elderly patients have more comorbid illnesses and suffer 
greater treatment toxicity, thus it is unclear whether they benefit more from CRT over 
RT. The objective of this systematic review is to explore the evidence base for using 
CRT in elderly patients with stage III NSCLC. Methods: We performed a systematic 
review including trials identified in MEDLINE, EMBASE and CENTRAL databases from 
inception to March 8, 2015, plus relevant conference proceedings since 2000. We 
included randomized controlled trials (RCTs) of elderly patients (≥70 years old) with 
stage III NSCLC or elderly subgroups from individual patient meta-analyses comparing 
CRT versus RT alone. We excluded studies that treated patients with palliative intent, 
included surgical patients, or in which both arms received chemotherapy. We did not 
restrict language. Two reviewers independently extracted summary outcome data. Risk 
of bias was assessed using the Cochrane Risk of Bias tool. We used a random effects 
model and inverse variance method to pool time-to-event outcomes. We calculated 
Peto Odds Ratios (POR) using RevMan 5.3 to pool dichotomous outcomes with a zero 
cell and otherwise calculated Risk Ratios (RR). Results: We screened 2951 citations 
identifying 68 articles for full text evaluation, 16 of which have not been accessible yet. 
Four reports of three studies met inclusion criteria (n = 407 elderly patients). All trials 
were evaluated as having a high risk of bias due primarily to lack of blinding. Overall 
survival in elderly patients was superior in those treated with CRT compared to RT (HR 
0.66, 95%CI 0.53 to 0.82, I2 0%, p 0.0009). Progression-free survival was also improved 
with CRT (HR 0.67, 95%CI 0.53 to 0.85, I2 0%, p 0.001). Toxicity assessments were 
available in two studies with 119 patients receiving CRT and 121 RT. Treatment-related 
death occurred in 6 (5%) with CRT and 5 (4%) with RT (RR 1.22, 95%CI 0.38 to 3.88) 
and grade ≥3 pneumonitis was seen in 6 patients in each group, (RR 1.01, 95%CI 0.34 
to 3.06) – neither was significantly different between treatments. Neutropenia – 57% 
v 2% (POR 14.38, 95%CI 8.26 to 25.04) and thrombocytopenia – 30% v 3% (RR 7.62, 
95%CI 2.09 to 27.79) were more common with CRT. Febrile neutropenia occurred in 3 
(2.5%) patients with CRT and zero patients with RT, but this did not meet significance 
(POR 7.54, 95%CI 0.78 to 72.82). No studies included patient-reported quality of 
life. Conclusion: CRT in elderly patients with stage III NSCLC results in improved 
survival as compared to RT alone, at the expense of increased treatment-related 
hematologic toxicity. Quality of life assessment should be included in any future trial 
design. CRT can be considered for fit patients ≥70 years of age with stage III NSCLC. 
Keywords: Geriatric Oncology, Chemoradiotherapy, elderly, Systematic review
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MINI07.03 The NARLAL2 Phase III Trial: Heterogeneous FDG-Guided Dose 
Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer 
Group Ditte Sloth Møller1, Jon L. Andersen2, Ane L. Appelt3, Carsten Brink4, Olfred 
Hansen4, Lone Hoffmann1, Nikolaj K. G. Jensen5, Mirjana Josipovic6, Azza Ahmed Khalil1, 
Marianne Marquard Knap1, Mikkel D. Lund3, Christina M. Lutz1, Martin S. Nielsen7, 
SvetlanaK. Nielsen7, Tine B. Nielsen4, Christa H. Nyhus3, Wiviann Ottosson2, Gitte F. 
Persson6, Patrik Sibolt2, Kim Wedervang5, Tine Schytte4 1Department of Oncology and 
Medical Physics, Aarhus University Hospital, Aarhus/Denmark, 2Radiotherapy Research Unit, 
Department of Oncology, Copenhagen University Hospital, Herlev/Denmark, 3Department of 
Oncology, Vejle Hospital, Vejle/Denmark, 4Laboratory of Radiation Physics and Department 
of Oncology, Odense University Hospital, Odense/Denmark, 5Department of Oncology, 
Naestved University Hospital, Naestved/Denmark, 6Department of Oncology, Rigshospitalet, 
Copenhagen University Hospital, Copenhagen/Denmark, 7Department of Oncology, Aalborg 
University Hospital, Aalborg/Denmark
Background: Locally advanced lung cancer lacks effective treatment options and 
requires aggressive radiotherapy (RT) with higher doses. In the light of RTOG 0617, 
multi-center dose escalation trials should avoid increasing organ at risk (OAR) toxicity 
and require strict quality assurance (QA). Exploiting the predictive value of FDG-PET, 
sub-volumes can be dose escalated, and by implementing image-guided adaptive RT, 
the total treatment volume (PTV) can be reduced. Incorporating these elements, the 
randomized multicenter trial NARLAL2 aims at increasing loco-regional control at 30 
months without increasing major toxicity. 
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MINI06.14 The Impact of Serum EGFR Levels on Survival of Resected Patients 
with Non-Small Cell Lung Cancer Elvin Hekimoglu1, Yasemin Oltulu2, Ilhan Yaylım2, 
Kamil Kaynak1, Akif Turna3 1Department of Thoracic Surgery, Istanbul University Cerrahpasa 
Medical School, Istanbul/Turkey, 2Institute for Experimental Research Department of 
Molecular Medicine, Istanbul University, Istanbul/Turkey, 3Department of Thoracic Surgery, 
Istanbul University, Cerrahpasa Medical Faculty, Istanbul/Turkey
Background: Lung cancer is an important cause of cancer mortality. Mutations of 
the EGFR gene may cause deranged activation leading to cell proliferation and the 
inhibition of apoptosis and metastases. Screening for EGFR mutation plays a key role 
for managements of lung cancer cases. The aim of our study is to determine a possible 
relationship between EGFR gene mutations in exon 19,20,21, along with serum EGFR 
levels and non small cell lung cancer. Methods: A total of 35 patients; 29 (%82.9) male 
and 6 (%17.1) female with non small cell lung cancer who underwent surgical resection 
between February 2011 and July 2013 were analyzed.Mean age of the patients was 
60.1(41-79) Mediastinoscopy was performed to all patients prior to the resection. 
Lobectomy, pneumonectomy and bilobectomy were performed to 30(%85.7), 4(%11.4) 
and 1 (%2.9) patients respectively. The most common tumour histopathology was 
adenocarcinoma(%55.6). EGFR gene mutations were analyzed for exon 19,20 and 21 
by direct sequencing. In addition, serum EGFR levels were determined by ELISA in non 
small cell lung cancer patients and control group. Results: Exon 19,20 and 21 aminoacid 
substitutions that could cause significant mutations were detected.At exon 19,20 and 
21, totally 17 mutations were detected in 10 different regions.One of these mutations 
were (2237-MT) E746- T751>V, E746-T751VA, E746-S752>V on exon 19. In one sample 
5 different regions of exon 20 mutations were detected. On exon 21 two mutations that 
cause aminoacid changes were detected which includes Leu 861 Gln ve Leu 861 Arg. 
In our study there was no significant difference in survival rates between the cases who 
have EGFR mutations or who have not(p=0.21). Serum EGFR average levels of non small 
cell lung cancer patients and healthy control groups were calculated respectively as, 
341,49±125,41 pg/ml ve 574,9±125,96 pg/ml and the difference was found statistically 
significant (p<0,001). According to the EGFR levels survival rate at 3 years was %45 
and mean survival time is 19 (%95 confidence interval :14-29 months)and 23 (%95 
confidence interval 18-29 months)month in patients with serum EGFR levels higher and 
lower than 400 pg/ml respectively. The patients with high serum EGFR levels (>400 pg/
ml) have better survival time than the ones who had low serum EGFR levels (p=0.04). 
Conclusion: EGFR mutation did not lead to survival difference in resected patients with 
lung adenocarcinoma. However, survival of patients with higher serum EGFR levels seems 
better. The modus operandi of this effect and validation of the data need further studies. 
Keywords: EGFR, non-small cell lung cancer, resection, serum EGFR
SESSION MINI 07: 
CHEMORT AND TRANSLATIONAL SCIENCE 
MONDAY, SEPTEMBER 7, 2015
CHEMORT AND TRANSLATIONAL SCIENCE 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI07.01 A Randomized Phase II Study of S-1 and Cisplatin vs. Vinorelbine 
and Cisplatin with Concurrent Radiotherapy for Locally Advanced NSCLC: 
WJOG5008L Junichi Shimizu1, Takeshi Kodaira1, Takashi Seto2, Tomonari Sasaki3, 
Takeharu Yamanaka4, Naonobu Kunitake2, Fumiyoshi Ohyanagi5, Takuyo Kozuka5, 
Masayuki Takeda6, Kiyoshi Nakamatsu6, Toshiaki Takahashi7, Hideyuki Harada7, Naruo 
Yoshimura8, Shinichi Tsutsumi8, Hiromoto Kitajima9, Masaaki Kataoka9, Kazuhiko 
Nakagawa6, Yasumasa Nishimura6, Yoichi Nakanishi3 1Aichi Cancer Center, Nagoya/
Japan, 2National Kyushu Cancer Center, Fukuoka/Japan, 3Kyushu University, Fukuoka/
Japan, 4Yokohama City University, Yokohama/Japan, 5The Cancer Institute Hospital of 
Japanese Foundation for Cancer Research, Tokyo/Japan, 6Kinki University Faculty of 
Medicine, Osaka-Sayama/Japan, 7Shizuoka Cancer Center, Shizuoka/Japan, 8Osaka City 
University Graduate School of Medicine, Osaka/Japan, 9National Hospital Organization 
Shikoku Cancer Center, Matsuyama/Japan
Background: Cisplatin-based chemotherapy and concurrent radiotherapy is the 
standard treatments for locally advanced non-small cell lung cancer ( LA-NSCLC). 
This trial evaluated two experimental regimens of chemotherapy with concurrent 
radiotherapy. Methods: Eligible patients (pts) with unresectable stage III NSCLC, 20 to 
74 years of age, and ECOG PS of 0 –1 were randomized to either Arm SP, S-1 (40 mg/
m2/dose per oral, b.i.d, on days 1-14) and cisplatin (60 mg/m2 on day 1) repeated every 
4 weeks or Arm VP, vinorelbine ( 20mg/m2 on day 1, 8) and cisplatin (80 mg/m2 on 
day) repeated every 4 weeks with early concurrent thoracic radiotherapy of 60Gy at 
2 Gy per daily fraction. The primary endpoint was overall survival rate at 2-year (2yr-
OS). A pick-the-winner design was used to identify the treatment regimen most likely 
to be superior. The planned sample size was 55 patients per arm, assuming in each 
arm that the null hypothesis for 2yr- OS was 50% versus an alternative hypothesis for 
65% with one-sided alpha of 0.10 and power of 80%. All the radiation treatment plans 
were reviewed at quality assurance committee meetings. (Study ID: UMIN000002420). 
Results: One hundred eleven patients were registered between Sep 2009 and Sep 2012. 
Of 108 patients for efficacy analysis, the 2yr-OS was 76% (95% CI, 62-85%) for SP and 
69% (95% CI, 54-79%) for VP. The hazard ratio (HR) of death between the two arms was 
0.85 (0.48-1.49). The median progression-free survival (PFS) was 14.8 months for SP 
and 12.3 months for VP with a HR of 0.92 (0.58-1.44). 80% and 48% of pts completed 
the protocol treatment in SP and VP, respectively. Common grade 3-4 toxicities of both 
SP and VP were neutropenia 33%, 75%, platelets 9%, 4%, hemoglobin 26%, 28%, febrile 
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all patients. Ten patients (38%) had no ctDNA alterations present in the post-radiotherapy 
blood sample and a trend was observed of improved PFS among patients without 
ctDNA alterations post-treatment (average PFS 52.3 vs. 75.5 months respectively) 
however this was not statistically signifi cant (p=0.1). Of note, the three patients without 
evidence of recurrence as of last contact had no ctDNA alterations identifi ed in the post-
treatment sample. This trend is anticipated to become signifi cant with larger sample 
size. Conclusion: In this interim analysis, we found that the dynamic alterations of 
specifi c mutant alleles strongly correlated with clinical response and that persistence of 
ctDNA mutant allele concentrations post-defi nitive treatment is likely a marker of early 
metastatic recurrence. Undetectable ctDNA in post-treatment sample was seen in the 
three patients with approximately three years of PFS. These initial results suggest that 
serial ctDNA analysis may be useful to monitor treatment response and identify patients 
at high risk for early recurrence who may benefi t from additional systemic therapy. 
Keywords: circulating tumor DNA, driver mutations, biomarker, non-small cell lung 
cancer
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MINI07.06 Pattern of Loco-Regional Failure after Defi nitive Chemo 
Radiotherapy for NSCLC. Results from NARLAL, a Phase II Randomized Trial 
Tine Schytte1, Tine B. Nielsen2, Marianne Knap3, Azza Khalil3, Christa Nyhus4, Tine 
Mcculloch5, Bente Holm6, Carsten Brink2, Olfred Hansen1 1Department of Oncology, 
Odense University Hospital, Odense/Denmark, 2Laboratory of Radiation Physics, Odense 
University Hospital, Odense/Denmark, 3Department of Oncology, Aarhus University Hospital, 
Aarhus/Denmark, 4Department of Oncology, Vejle Sygehus, Vejle/Denmark, 5Department 
of Oncology, Ålborg University Hospital, Ålborg/Denmark, 6Department of Oncology, Herlev 
Hospital, Herlev/Denmark
Background: Concurrent chemo-radiotherapy (CRT) is the treatment of choice in loco-
regional advanced non-small cell lung cancer (LA-NSCLC). Even though the patients are 
treated with curative intend the loco-regional control at 2 year is only about 30% in clinical 
trials. The aim of this study is to compare the loco-regional failure in patients treated with 
66 Gy vs 60 Gy in the randomized phase II trial, NARLAL. Furthermore to analyze the 
localization of relapse compared to the original treatment plan. Methods: From 2009-
2013 117 patients with LA-NSCLC were randomized in a national multicentre protocol 
between 60 Gy/ 30 F (arm A) and 66 Gy/ 33 F (Arm B), 5 FW. Navelbine® 50 mg 3 days 
a week was given as concomitant regimen. Patients were followed with CT scans every 
3rd month in 2 years and hereafter every 6th month for another 3 years. As part of the 
protocol a PET-CT scan was performed 9 months after randomization. In case recurrent 
disease was suspected a biopsy was done from the lesion if possible. The recurrence 
gross tumor volume will be delineated and registered with the original radiation treatment 
plan to identify the site of failure. Results: Fifty-nine patients were treated in arm A 
and 58 patients in arm B. The median local recurrence free interval was 10 months in 
arm A and 10.9 months in arm B (p=0.57). At the end of this analysis 22 patients were 
alive with no evidence of loco-regional disease, 16 patients had died with no evidence of 
loco-regional failure. Loco-regional failure in high-dose area was diagnosed in 60 (51%) 
patients (33 patients in arm A and 27 patients in arm B). Loco-regional failure outside 
high-dose area was diagnosed in 19 patients. Fig 1. Treatment plan 60 Gy/ 30 F and PET-
CT with relapse (verifi ed by biopsy).
Conclusion: Although this treatment was with curative intend, the loco-regional control 
was disappointingly poor in both treatment arms. This is in line with other newly published 
clinical dose-escalations trials for NSCLC. In order to improve loco-regional control and 
hopefully survival homogeneous dose-escalation is not the choice. Inhomogenous dose-
escalation may be an alternative. A phase III trial on this subject has just started enrolment 
in Denmark (NARLAL II, www.clinicaltrials.gov). Acknowledgements Supported by 
CIRRO- The Lundbeck Foundation Center for Interventional Research in Radiation 
Oncology. 
Keywords: Loco-regional control, NSCLC, Radiotherapy
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MINI07.07 Risk Factor of Morbidity and Mortality of Surgical Resection 
after Induction Therapy in Patients with Stage IIIA-N2 Lung Cancer Jong Ho 
Cho1, Jhingook Kim1, Hong Kwan Kim1, Yong Soo Choi1, Jae Ill Zo1, Young Mog Shim1, 
Kwhanmien Kim2 1Department Thoracic & Cardiovascular Surgery, Sungkyunkwan University 
School of Medicine, Samsung Medical Center, Seoul/Korea, 2Department of Thoracic 
and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National 
University College of Medicine, Seoul/Korea
Background: Surgical resection after neoadjuvant chemoradiation therapy for patients 
with stage IIIA-N2 non-small cell lung cancer (NSCLC) carries high postoperative 
Methods:
 
In the standard arm, the PTV is treated with a homogenous dose of 66 Gy/33 fractions. 
In the experimental arm, the dose is heterogeneously escalated to the FDG-PET avid 
volumes, with mean doses up to 95 Gy/33 fractions and 74 Gy/33 fractions to the 
escalated volumes in the tumor and malignant lymph nodes, respectively. The escalation 
dose will be limited in favor of OAR constraints. A standard and an experimental 
treatment plan with similar mean lung doses of maximum 20 Gy are made for each 
patient prior to randomization. Quality Assurance: FDG-PET scans of a standard phantom 
(NEMA) and PET signal processing software from all centers were compared and 
acceptable agreement achieved. Multicenter delineation of OARs was performed and 
consensus achieved. Treatment planning and adaptive strategy consensus were based 
on a study including fi ve patients with repeated CT-scans, requiring several steps before 
the achievable level of dose escalation and the number of patients needed in the trial 
could be defi ned. Daily online tumor set-up and adaptive strategies were mandatory. 
A QA committee for evaluation of RT plans and treatments and a central committee 
for evaluation of all non-biopsy-verifi ed recurrences were established. Results: A mean 
dose of 91,9 Gy to the FDG-PET avid part of the tumor and 80 Gy to the clinical target 
volume was achieved in the planning study, corresponding to 16% estimated increase 
in locoregional control at 30 months. Assuming a loco-regional control of 56% at 30 
months in the standard arm, a total of 330 patients were needed in order to resolve this 
effect with a power of 80% (95% signifi cance level). Recalculation of escalated plans 
on CT-scans acquired at fraction 20 revealed an increase in OAR doses of 4-7Gy for 
two of fi ve patients, endorsing the need for adaptive strategies. Conclusion: A dose 
escalation trial with strict QA has been set up. Patient enrollment started January 2015. 
Keywords: clinical trial, NSCLC, dose escalation
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MINI07.04 Dynamic Changes in Cell-Free Circulating Tumor DNA to Track 
Tumor Response and Risk of Recurrence in Stage III Non-Small Cell Lung 
Cancer Steven H. Lin1, Ting Xu1, Jianzhong He1, Kimberly Banks2, Richard B. Lanman2, 
Dragan Sebisanovic2, Amir A. Talasaz2, Charles Lu3, Thomas Buchholz1, Stephen Hahn1, 
Ritsuko U. Komaki1, Zhongxing Liao1 1Radiation Oncology, The University of Texas MD 
Anderson Cancer Center, Houston/TX/United States of America, 2Guardant Health, Inc, 
Redwood City/CA/United States of America, 3Thoracic Medical Oncology, The University of 
Texas MD Anderson Cancer Center, Houston/TX/United States of America
Background: While the curative management of unresectable stage III non-small cell 
lung cancer (NSCLC) is defi nitive chemoradiotherapy, clinical outcomes remain poor. 
Cellular heterogeneity in tumors is correlated with therapeutic resistance and poor 
prognosis. We hypothesize that tumor-specifi c mutant allelic frequency in cell-free DNA 
from plasma quantifi es tumor heterogeneity and that tracking allelic evolution via blood 
from patients during and after treatment can serve as a non-invasive means to monitor 
treatment response and recurrence. Methods: Between 2009-2013, 156 patients 
with unresectable NSCLC who received defi nitive radiotherapy or chemoradiotherapy 
were consented to have blood drawn at baseline before starting radiotherapy, once 
or twice during treatment, and once or twice during follow up visits. Cell-free plasma 
DNA was sequenced using a cell-free circulating tumor DNA (ctDNA) next generation 
sequencing (NGS) assay (Guardant360) that uses digital sequencing to report single 
nucleotide variants (SNVs) in 68 genes and amplifi cations in 16 genes. This ctDNA assay 
has high sensitivity (detects 85%+ of the SNVs detected in tissue in advanced cancer 
patients) and analytic specifi city (>99.9999%). Over 670 serial samples were collected 
from these patients. Here we report the initial analysis of the fi rst 26 patients of this 
ongoing study. Results: Among this initial cohort, 23 (88%) had a recurrence (PFS 
ranged from 1.2 – 27.9 months) and three (12%) had no evidence of recurrence as of 
last contact (32.8 – 42.8 months post-radiotherapy completion). Twenty-one patients 
(81%) had ctDNA alterations present pre-radiotherapy, of which six had a classic driver 
mutation: KRAS G12F x2; KRAS G12S; PIK3CA E545K x2; PIK3CA H1047R. These six patients 
had signifi cantly shorter PFS compared to patients without a driver mutation present 
pre-radiotherapy: average PFS of 4.2 months (1.2 - 8.3) vs. 18.6 months (4.4 - 42.8) 
respectively (p=0.002). All six had the driver mutation disappear during radiotherapy, 
four had new alterations appear during and/or post-treatment. One patient had the driver 
mutation reappear in ctDNA post-radiotherapy and had the shortest PFS (1.2 months) of 
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most pts die from distant failure due to preexisting occult metastases. Based on the 
premise that EGFR-TKI would improve the outcome of pts with stage III NSCLC that 
harbors sensitive EGFR mutations, as for the pts with stage IV NSCLC, we initiated a 
randomized phase II pilot trial that incorporated erlotinib (E) into CCRT treatment 
paradigms. Methods: Eligible pts over 18 years old with unresectable stage IIIA or IIIB 
NSCLC, ECOG PS 0–1, and adequate organ function were screened for EGFR mutation in 
axons 18–21 in the tumor sample. Those with EGFR mutation (+) tumors were randomized 
upfront to receive 3 cycles of 3-weekly E 150 mg/day treatment, and then either E 
x2 cycles concurrently with CCRT and x6 more cycles after CCRT (Arm A) or CCRT 
with 2 cycles of irinotecan-cisplatin (IP) but no additional therapy after CCRT (Arm B). 
When disease progression (PD) is documented during follow-up, E was re-instituted. Pts 
with EGFR mutation (-) or unknown tumors were randomized to receive either 3 cycles 
of IP induction followed by CCRT concurrently with 2 cycles of IP (Arm C) or CCRT with 
IP x2 first then consolidation with IP x3 (Arm D). IP chemo dose-schedule was irinotecan 
60 mg/m2and cisplatin 30mg/m2 iv on days 1 and 8 when given concurrently with RT 
(2.4 Gy/fx, total 60 Gy); irinotecan 65 mg/m2 and cisplatin 30 mg/m2 iv on days 1 and 
8 when given every 3 weeks as induction or consolidation. The primary endpoint was 
overall response rate (ORR), toxicity, and overall survival (OS). Results: From 02/2008 
to 03/2015, 59 pts (44 men and 8 women) with median age of 62 years (range: 37-78) 
were enrolled. There were 13 never smokers, 28 had adenocarcinoma, and 44 had IIIB 
tumors. EGFR mutation was (+) in 12, (-) in 28, and unknown in 19. There was apparent 
imbalance in histology and smoking status between the pts assigned to Arms A&B and 
C&D. ORR after induction E therapy was 75.0% for the 12 pts with EGFR mutation(+) 
tumors (Arm A, n=7; B, n=5). ORR after IP induction therapy was 63.6% for pts with 
EGFR mutation(-) or unknown tumors in Arm C (n=22). After completion of upfront CCRT 
therapy with IP in Arm D (n=25), ORR was 68.0%. There were no noticeable unusual 
side-effects. Median PFS for Arm A, B, C, and D, was 11.84, 8.09, 8.36, and 11.81 
months respectively, with a trend toward better OS for pts with EGFR mutation(+) 
tumors (Arm A: not reached, B: 31.18 mos) than those EGFR mutation(-) or unknown 
tumors (Arm C: 17.93 mos, Arm D: 25.33 mos). Conclusion: The combined-
modality treatment by molecular diagnostics is feasible in stage III NSCLC patients. 
Although the number is rather small, pts with EGFR mutation (+) tumors seem to be 
a distinct subset with better overall survival than the others, which warrants careful 
consideration in chemoradiation therapy trial design and outcome evaluation. 
Keywords: EGFR-TKI Erlotinib, Concurrent ChemorationTherapy, Combined miodality 
therapy, Molecular genetics-based therapy
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MINI07.11 Isotoxic Dose Escalation and Acceleration in Lung Cancer 
Chemoradiotherapy David Landau1, Iftekhar Khan2, Angela Baker3, Andrew T. 
Bates4, Michael C. Bayne5, Nicholas Counsell2, Angel Garcia-Alonso6, Susan V. Harden7, 
Jonathan Hicks8, Laura Hughes2, Marianne C. Illsley9, Simon R. Hughes1, Virginia 
Laurence5, Zafar Malik3, Helen Mayles3, Philip William M. Mayles3, Elizabeth Miles10, 
Nazia Mohammed8, Yenting Ngai2, Emma Parsons10, James Spicer1, Paula Wells11, Dean 
Wilkinson10, John D. Fenwick12 1Guy’s & St. Thomas’ NHS Trust and King’s College London, 
London/United Kingdom, 2Cancer Research UK & UCL Cancer Trials Centre, London/United 
Kingdom, 3Clatterbridge Cancer Centre, Wirral/United Kingdom, 4University Hospitals 
Southampton, Southampton/United Kingdom, 5Poole Hospital NHS Foundation Trust, 
Poole/United Kingdom, 6North Wales Cancer Centre, Rhyl/United Kingdom, 7Addenbrookes 
Hospital, Cambridge/United Kingdom, 8Beatson West of Scotland Cancer Centre, Glasgow/
United Kingdom, 9Royal Surrey County Hospital, Guilford/United Kingdom, 10Mount Vernon 
Hospital, Middlesex/United Kingdom, 11St. Bartholomew’s Hospital, London/United 
Kingdom, 12University of Oxford, Oxford/United Kingdom
Background: RTOG 0617 investigated standard dose radiotherapy (RT) versus higher 
dose in the context of concurrent chemoRT with no advantage to higher dose treatment. 
IDEAL CRT investigated an alternative RT dose-escalation strategy with concurrent 
chemoRT in locally advanced NSCLC. Dose-per-fraction-escalation was used to achieve 
intensification without treatment prolongation. The trial would determine the maximum 
tolerable dose (MTD) deliverable to esophagus, and assess toxicity and early clinical 
outcomes for the schedule. Methods: Patients were enrolled to 2 groups, depending on 
maximum esophageal dose. Tumor doses were determined by esophageal constraints 
in Group 1 and other normal tissue constraints in Group 2. Patients received 63-73Gy in 
30 once-daily fractions / 6 weeks with 2 concurrent cycles of cisplatin and vinorelbine. 
Group 1 esophageal dose-escalation followed a 6+6 design, increasing maximum dose 
to 1cc esophagus from 65Gy, 68Gy then 71Gy in successive cohorts, defining MTD by 
early and late toxicity. Efficacy endpoints were overall survival (OS), progression-free 
survival (PFS) and tumor response. Results: 8 centres recruited 84 patients, treating 13, 
12 and 10 in 65Gy, 68Gy and 71Gy group 1 cohorts. Prescribed RT doses are shown in 
figure 1. Median follow-up 24 months. 57 patients (68%) were stage IIIa and 21 (25%) IIIb. 
5 grade 3 esophagitis events observed across both groups and 3 grade 3 pneumonitis. 
Following 1 fatal esophageal perforation in the 71Gy cohort, 68Gy was declared as 
esophageal MTD. Overall Survival (OS) and Progression Free Survival (PFS) were 87.8% 
and 72.0% at 1 year, and 67.1% and 50.4% at 2 years, median OS 39.3 months. OS is 
shown in figure. 2.
complications. Careful selection of candidate for surgery should be based on analysis of 
proven risk factors. Methods: We retrospectively reviewed all consecutive patients with 
clinical stage IIIA-N2 non-small cell lung cancer who underwent surgical resection after 
neoadjuvant chemoradiation therapy from 1997 to 2013. Preoperative, perioperative, 
and outcome variables which related to the morbidity and mortality were assessed. 
Univariate and multivariate analysis was done to identify predictors of postoperative 
morbidity and mortality. Results: During the study period, 574 patients underwent 
major pulmonary resection after induction therapy. The median time interval between 
the end of induction therapy and surgery was 33 days (range, 5-79 days). Thirty-day 
and ninety-day postoperative mortality were 1.4% (8 patients), and 7.1% (41 patients), 
respectively. The most common cause of In-hospital mortality was acute respiratory 
distress syndrome (n=6, 4.5%). Morbidity rate was 34.7 % (199 patients). Median 
hospital stay was 8 days (interquartile range, 7-11 days). Significant predictors of 
morbidity by multivariable analysis included patient age more than 70 years (odds 
ratio- 1.82;p=0.040), low body mass index <18.5 (odds ratio - 2.62;p=0.022), and 
pneumonectomy (odds ratio – 1.8;p=0.026). Significant predictors of mortality by 
multivariable analysis included patient age more than 70 years (odds ratio – 1.82; 
p=0.022), and pneumonectomy (odds ratio – 3.256; p=0.003). Ninety-day mortality 
was 15.8 % (9/57) in patient age more than 70 years, and 17.8 % (13/73) in patients who 
underwent pneumonectomy. Conclusion: Surgical outcomes after neoadjuvant CCRT 
for patients who are older than 70 year or undergo pneumonectomy are relatively poor. 
For those patients, there should be extra concern about the respiratory complications. 
And for the elderly patients with limited pulmonary reserves, other possible alternative 
treatment options, such as definitive CCRT rather than surgery should be considered. 
Keywords: non-small cell lung cancer, Surgery
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MINI07.08 Mutation Profile Prognostic Value in Stage III Non Small Cell Lung 
Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy (CRT) Angela 
Boros1, Ludovic Lacroix2, Benjamin Lancas3, Julien Adam2, Jean-Pierre Pignon3, Caroline 
Caramella4, David Planchard5, Antonin Levy1, Vincent De Montpreville6, Eric Deutsch1, 
Benjamin Besse5, Cecile Le Pechoux1 1Radiation Oncology, Gustave Roussy, Villejuif/
France, 2Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, 
Villejuif/France, 3Biostatistics, Gustav Roussy, Villejuif/France, 4Radiology, Gustave Roussy, 
Villejuif/France, 5Medical Oncology, Gustave Roussy, Villejuif/France, 6Pathology, Centre 
Chirurgical Marie Lannelongue, Le Plessis-Robinson/France
Background: Molecular profiling is a standard procedure in advanced non squamous 
NSCLC. Gene alteration in EGFR, BRAF or ALK gene can lead to prescription of targeted 
therapies and prolongs survival. The influence of molecular abnormalities on the survival 
of stage III NSCLC patients definitely treated by CRT is unknown. Methods: We reviewed 
all consecutive patients that received CRT or RT with a curative intent for stage III 
NSCLC in a single institution. Paraffin embedded tissue block were collected. DNA was 
extracted for gene mutation analysis by next generation sequencing and ALK, ROS1 and 
RET rearrangements were detected by FISH analysis. Kaplan-Meier methods, log-rank 
test, and Cox proportional hazards models were used for survival analysis, adjusting 
for performance status (0, ≥1), stage (IIIA, IIIB) and thoracic surgery (yes, no). Median 
follow-up was estimated by the Schemper method. Results: Between January2002 and 
June 2013, clinical data from 190 patients were collected. Median dose of RT was 66 Gy 
(46-70). Platinum-based chemotherapy was administrated concomitantly in 108 patients, 
as induction/consolidation treatment in 170 patients, and 15 patients did not receive any 
chemotherapy. Seventy-eight patients were evaluable for mutation profile, 20 (26%) were 
female, 47 (60%) were current smoker, 40 (51%) had adenocarcinoma and there were 
47/31 stage IIIA/IIIB. Mutations were positive as follow: EGFR 12% (9/78), KRAS 15% 
(12/78), BRAF 5% (3/66), PI3KCA 2% (1/58), HER2 0% (0/65), NRAS 3% (1/32), CTNNB1 
3% (1/32). FISH was positive for ALK in 5% (3/56) of the NSCLC. In 32 NSCLC for which 
the test was performed, there was no alteration in ROS1, RET, HRAS and AKT1. Median 
Follow-up was 3.1 years (minimum 0.9 year). EGFR mutated or ALK+ (EGFR/ALK) group 
(n=11) and other mutation group (n=17) had a poorer progression free survival (median 
0.8[95%CI: 0.6 ; 0.9] year and 0.5 [0.4 ; 0.8] year ; multivariate hazard ratio (HR)= 1.8 
[0.8 ; 3.8] and 2.8 [1.5 ; 5.1] respectively, p=0.004) compared to the wild group (n=50) 
(median 1 year [0.9;1.3]). There was no significant difference (p=0.23, multivariate Cox) 
in overall survival: median 2.4 years [1.3 ; NR] for EGFR/ALK group, 1.1 [0.6 ; 2.5] for 
other mutation group and 1.9 [1.5 ; 2.5] for wild type. In multivariate analysis, only the 
dose of radiotherapy was significantly associated with overall survival (HR=0.5 [0.3 ; 1.0], 
p=0.04 in contrast with performance status or stage. Conclusion: This study suggests 
that selected gene alterations could be associated with a poorer survival in stage III 
NSCLC patients treated by combined modality treatment or radiotherapy alone. Their 
prognostic and/or predictive value should be further evaluated in a larger population. 
Keywords: Stage III NSCLC, chemo-radiation, Mutation profile, prognostic value
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MINI07.09 Incorporating Erlotinib Into Chemoradiation Therapy for 
Unresectable Stage IIIA/B NSCLC: Interim Results of Ongoing Phase II 
Randomized Trial Jin Soo Lee1, Sung Ho Moon2, Kun Young Lim1, Byung-Ho Nam3, 
Geon Kook Lee1, Youngjoo Lee1, Heung Tae Kim1, Tak Yun1, Kwan-Ho Cho2, Sung Jin 
Yoon1, Ji-Youn Han1 1Center for Lung Cancer, National Cancer Center Korea, Goyang/
Korea, 2Center for Lung Cancer, Center for Proton Therapy, National Cancer Center Korea, 
Goyang/Korea, 3Center for Clinical Trials, National Cancer Center Korea, Goyang/Korea
Background: Combined chemoradiotherapy (CCRT) improves long-term outcome of 
patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC). However, 
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multivariable analyses were performed to gain insight into predictive factors. Results: In 
the 219 included patients, mean age was 76 years, 78% was male and 51% had 
squamous cell carcinoma. Sixty-eight percent had a WHO Performance Status (PS) of 
0-1, 22% PS 2, and 11% PS 3. Serious co-morbidity (severe organ decompensation or 
≥2 moderate decompensations) was present in 59%, average co-morbidity (moderate 
organ compensation or ≥2 mild decompensations) in 16%, mild co-morbidity (mild organ 
decompensation) in 11% and 15% had no co-morbidities. Chemoradiation (CHRT) was 
administered in 55% of patients (33% cCHRT and 22% sequential CHRT (sCHRT)), 16% 
received only radical radiotherapy (RT) and 29% Best Supportive Care (BSC). CHRT 
was less often administered to patients aged ≥75 and those with a PS 2-3 (p<0.001). 
Also, patients with serious co-morbidity were less likely to receive CHRT, although not 
signifi cant (p=0.10). The most common motives for omitting cCHRT were co-morbidity 
and/or poor PS (57%) and patient refusal (15%). Multivariable analyses showed that 
treatment and co-morbidity were predictive for tolerance. In comparison to cCHRT, 
tolerance was signifi cantly better for RT (Odds Ratio (OR) = 5.1(95% Confi dence 
Interval (95%CI) 2.1-13)) and non-signifi cantly better for sCHRT (OR=2.2 (0.97-4.9)). 
Patients with serious co-morbidity had signifi cantly worse tolerance compared to no 
co-morbidity (OR=0.28 (0.11-0.68). Even when corrected for patient characteristics, 
survival was not signifi cantly better after cCHRT compared to sCHRT (Hazard Ratio 
(HR) = 1.1 (95%CI 0.76-1.7)) or compared to RT (HR=1.3 (0.81-2.0)). The 1-and 3-year 
Overall Survival (OS) rates for cCHRT were respectively 56% and 17%, for sCHRT 54% 
and 16%, and for RT 48 % and 9%. Conclusion: Co-morbidity, poor PS and patient 
refusal were the most common motives for omitting cCHRT. Although relatively fi t and 
younger elderly were assigned to cCHRT, treatment tolerance was worse. OS was not 
signifi cantly different between cCHRT, sCHRT and even RT. Since limited information on 
geriatric characteristics was available in this retrospective study, prospective studies 
including geriatric assessments are urgently needed to gather evidence on treatment 
options, resulting in the most optimal balance between quality of life and survival. 
Keywords: non-small cell lung cancer, elderly, treatment tolerance, survival
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MINI07.13 Clinical Impact of Frequent Surveillance Imaging in the First Year 
following Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer 
Nima K. Harandi1, Megan E. Daly2 1Radiation Oncology, University of California Davis 
Comprehensive Cancer Center, Sacramento/CA/United States of America, 2Radiation 
Oncology, University of California Davis Comprehensive Cancer Center, Sacramento/United 
States of America
Background: Uncertainty exists regarding the optimal surveillance strategy following 
defi nitive chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-
NSCLC) with regards to both frequency and modality. We sought to determine the 
effi cacy of frequent (q2-4 month) post-treatment imaging in detecting asymptomatic 
recurrent disease and document the clinical impact of frequent surveillance 
imaging. Methods: The records of all patients treated with CRT for stage IIIA/IIIB NSCLC 
between August 1999 and April 2014 at our institution were reviewed. Patients were 
included if they underwent frequent (Q2-4 month) chest computed tomography (CT) or 
positron emission tomography (PET/CT) for routine surveillance following CRT for at 
least one year following CRT or until disease progression or death. Radiographic fi ndings 
and clinical interventions from the fi rst year following CRT were identifi ed. Results: We 
identifi ed 145 patients with LA-NSCLC treated with CRT, 65 of whom underwent Q2-4 
month surveillance imaging for at least one year or until progression or death. Median 
age was 63.6 years (range, 41.0-86.9 years). Forty-nine (75.4%) also underwent an 
initial baseline CT within the fi rst 6 weeks following CRT. An asymptomatic recurrence 
was detected by surveillance imaging within the fi rst year in 40 (61.5%) patients, 31 
(77.5%) by CT and 9 (22.5%) by PET/CT. Among these patients, 21 (52.5%) initiated 
palliative systemic therapy. Three (7.5%) underwent attempted defi nitive therapy for 
isolated disease, including one patient treated with defi nitive lobectomy for what was 
found to be a histologically distinct new primary early stage NSCLC, and two patients 
treated with stereotactic ablative radiotherapy for isolated recurrences, both of 
whom subsequently developed metastatic disease. Urgent palliative local therapies 
(radiotherapy and bronchoscopy) were performed in 2 patients for impending neurologic 
and airway compromise, respectively. Ten patients (25%) with recurrences detected 
on surveillance imaging were not candidates for or declined additional cancer-directed 
therapy. Seven patients (10.8%) developed a symptomatic recurrence detected between 
planned scans. Five patients (7.7%) underwent additional diagnostic procedures for false-
positive surveillance imaging fi ndings. Conclusion: Frequent surveillance imaging within 
the fi rst year following CRT for LA-NSCLC detected asymptomatic recurrences in a high 
proportion of patients in our population. However, defi nitive interventions were attempted 
in less than 5%, and were successful in only one patient. The predominant potential 
benefi t of frequent radiographic surveillance appears to be the expedient initiation of 
palliative systemic therapy. Evidence-based algorithms for follow-up imaging among 
this population are needed, and should account for patient-specifi c factors including 
expected tolerance of, benefi t from, and willingness to undergo systemic therapies. 
Keywords: locally advanced non-small cell lung cancer, Surveillance imaging, 
chemoradiation
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MINI07.14 Endostatin Combined with Paclitaxel, Carboplatin, and Radiotherapy 
in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer 
Xiao-Jiang Sun1, Qing-Hua Deng1, Xin-Min Yu2, Yong-Lin Ji1, Yuan-Da Zheng1, Hao 
Jiang3, Yaping Xu4, Sheng-Lin Ma5 1Departments of Radiation Oncology, Zhejiang Cancer 
Hospital, Hangzhou/China, 2Departments of Medical Oncology, Zhejiang Cancer Hospital, 
 
Conclusion: Acceptable toxicity rates and promising survival were achieved. 
The isotoxic design proved practical, allowing signifi cant treatment 
intensifi cation and defi nition of MTD with relatively few patients. Results 
from longer follow-up are required and will be presented at the meeting. 
Keywords: chemoradiation, RT dose escalation, early phase trial, lung cancer
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MINI07.12 Stage III NSCLC in the Elderly: Patient Characteristics Predictive for 
Tolerance and Survival of Chemoradiation in Daily Clinical Practice Elisabeth 
Driessen1, Gerben Bootsma2, Lizza Hendriks3, Franchette Van Den Berkmortel4, Brigitte 
Bogaarts5, Judith Van Loon6, Anne-Marie Dingemans3, Maryska Janssen-Heijnen1
1Clinical Epidemiology, Viecuri Medical Centre, Venlo/Netherlands, 2Pulmonology, Atrium 
Medical Centre, Heerlen/Netherlands, 3Pulmonology, Maastricht University Medical 
Center, Maastricht/Netherlands, 4Medical Oncology, Atrium Medical Centre, Heerlen/
Netherlands, 5Pulmonology, Viecuri Medical Centre, Venlo/Netherlands, 6Radiation Oncology, 
Maastro Clinic, Maastricht/Netherlands
Background: Although the mean age at diagnosis of stage III non-small cell lung 
cancer (NSCLC) is 70 years, trials mainly include younger patients. Therefore, a lack of 
knowledge remains regarding tolerance and survival of standard treatment (concurrent 
chemoradiation (cCHRT)) and other treatment options for the elderly. The aim of this 
study was to evaluate administered treatment, assess motivations to omit cCHRT, and 
determine predictors for treatment tolerance and survival among unselected elderly with 
stage III NSCLC. Methods: In this multicenter retrospective study, all stage III NSCLC 
patients aged ≥70 and diagnosed in 2009-2013 in three Dutch teaching hospitals were 
included. Data on patient and tumor characteristics were derived from the Netherlands 
Cancer Registry and medical records regarding treatment details, geriatric patient 
characteristics, tolerance (completing treatment and/or no unplanned hospitalizations) 
and survival. Treatment and motives for omitting cCHRT were described. Univariate and 
S290 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
SESSION MINI 08: 
PROGNOSTIC/PREDICTIVE BIOMARKERS 
MONDAY, SEPTEMBER 7, 2015
PROGNOSTIC/PREDICTIVE BIOMARKERS 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI08.01 Quantitative Mass Spectrometry Proteomics Identifies FRalpha and 
GARFT as Predictive Biomarkers in NSCLC Patients Treated With Pemetrexed 
Abdulrahman A. Alshehri1, Eunkyung An2, Fabiola Cecchi2, Todd Hembrough2, Patrick C. 
Ma1, Matthew Smolkin1, Sijin Wen1, Manish Monga1 1Mary Babb Randolph Cancer Center., 
West Virginia University., Morgantown/United States of America, 2Oncoplex Diagnostics, 
Rockville/MD/United States of America
Background: Lung cancer remains the leading cause of cancer mortality in United States 
and globally. Pemetrexed combined with platinum chemotherapy is specifically indicated 
for treatment of non-squamous non-small cell lung cancer (non-sq NSCLC). Pemetrexed 
is a folate-analog metabolic inhibitor that disrupts folate-dependent processes essential 
for cell replication. Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate 
reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are 
folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine 
nucleotides. Folate receptor alpha (FRalpha) is a folate/antifolate transporter protein that 
is overexpressed by a number of epithelial tumors. The purpose of this study is to identify 
proteomic biomarkers predictive of response to pemetrexed-based chemotherapy in non-
sq NSCLC. Methods: Patients with advanced non-sq NSCLC who received pemetrexed-
based chemotherapy at West Virginia University from 2009 to 2014 were retrospectively 
identified. Formalin-fixed, paraffin-embedded tumor biopsies were laser microdissected, 
solubilized, enzymatically digested and subjected to quantitative proteomic analysis. A 
multiplexed, selected reaction monitoring (SRM) mass spectrometry (MS) assay was 
used to determine the absolute levels of 46 different candidate proteomic markers, 
including those in the folate receptor pathway. The Kaplan-Meier method and log-rank 
test were used in statistical analysis of overall survival (OS) and progression-free survival 
(PFS). Results: The 74 patients included in the study had a median follow-up of 26 months, 
a median OS of 16.6 months (95%CI: 11.6 - 43.4), and a median PFS of 9.61 months 
(95%CI: 8.43, 12.98). There were 65 patients who received pemetrexed-based regimen 
as a first line therapy and 9 patients as subsequent salvage treatment. In a comparison 
between patients who survived >24 months and < 8 months, there were no significant 
differences between the two groups in terms of sex, age, ECOG performance status, TNM 
stage at diagnosis, and smoking history. Among the 37 patients with sufficient tumor 
specimens available for multiplexed proteomic analysis, 30 biomarkers were detected 
with varying levels of expression. Sixteen additional biomarkers were undetectable. TS 
protein expression was detected in only 2 patients. Patients whose tumors expressed 
low levels of GARFT protein (≤900 amol/µg; n=7) had statistically significantly longer 
median PFS than those whose tumors expressed high levels of GARFT (>900 amol/µg; 
n=30) (40.6 vs. 11.4 months; p= 0.014). Patients with high FRalpha protein expression 
(>1510 amol/µg, n=9) had significantly longer median PFS than those with low FRalpha 
expression (≤1510 amol/µg; n=28) (>50 vs. 11.4 months; p= 0.021). Moreover, the 23 
patients with both high GARFT expression (>900 amol/µg) and low FRalpha expression 
(≤1510 amol/µg) faired considerably worse than the remainder of patients (median PFS 
10.1 vs. 40.6 months; p=0.0003). Conclusion:Multiplexed mass spectrometry-based 
proteomics offers a feasible and promising approach for tumor biomarker profiling and 
quantification to predict therapeutic response. Of note, our results show that FRalpha and 
GARFT protein expression may be predictive of response to pemetrexed-based treatment 
in patients with non-sq NSCLC. Further investigation is needed to validate the utility of 
these biomarkers for guiding personalized treatment decisions in clinical practice. 
Keywords: pemetrexed, proteomics, FRalpha, GARFT
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MINI08.02 Prediction of Response to Pemetrexed in NSCLC by 
Immunohistochemical Phenotyping Based on Gene Expression Profiles 
Sabine Visser1, Jun Hou2, Koen Bezemer1, L. De Vogel3, Bruno Stricker4, J. Philipsen5, 
Joachim G. Aerts1 1Pulmonary Diseases, Erasmus MC Cancer Centre, Rotterdam/
Netherlands, 2Gastroenterology and Hepatology, Erasmus Medical Centre, Rotterdam/
Netherlands, 3Pathology, Erasmus Medical Centre, Rotterdam/Netherlands, 4Epidemiology, 
Erasmus Medical Centre, Rotterdam/Netherlands, 5Cell Biology, Erasmus Medical Centre, 
Rotterdam/Netherlands
Background: A major challenge in the treatment of advanced non-small cell lung cancer 
(NSCLC) is to identify specific tumor properties that predict response to chemotherapy. 
Although thymidylate synthase (TS) immunohistochemical (IHC) staining has been 
extensively studied as a predictive marker for pemetrexed (PEM) sensitivity, its clinical 
value remains limited. We investigated IHC stainings of different molecular markers linked 
to the folate metabolic pathway (FMP) identified with gene expression profiling (Hou et al, 
JTO 2012;7:105-114). We used a population with advanced NSCLC treated with PEM for 
external validation. Methods: Resected tumor samples from PEM-naïve NSCLC patients 
were collected. Gene expression profiling with respect to predicted sensitivity to PEM was 
based on genes related to FMP. Based on differentially expressed genes, patients were 
divided into predicted responders (Rs) and non-responders (NRs). Genes showing a strong 
correlation with these FMP genes and for which IHC stainings were commercially available, 
were selected for measurement of corresponding protein expressions by IHC stainings. A 
semiquantitative scoring method was applied, which was used to construct a prediction 
model for response to PEM. Subsequently, a retrospective cohort of patients with advanced 
NSCLC was selected, who had received at least two cycles of PEM-based chemotherapy as 
first-line treatment. IHC staining scores for the same proteins were obtained from tumor 
Hangzhou/China, 3Departments of Medical Oncology, Zhejiang Hospital, Hangzhou/
China, 4Zhejiang Cancer Hospital, Zhejiang/China, 5Department of Radiation Oncology, 
Hangzhou First People’s Hospital, Hangzhou/China
Background: Endostatin inhibits the pro-angiogenic action of basic fibroblast growth 
factor and vascular endothelial growth factor in different human cancers. This study 
assessed the efficacy of endostatin combined with concurrent chemoradiotherapy of 
non-small cell lung cancer (NSCLC). Methods: Nineteen patients with unresectable stage 
III NSCLC, ECOG performance status 0-l, and adequate organ function were treated with 
60–66 Gy thoracic radiation therapy over 30–33 fractions concurrent with weekly 7.5 
mg/m2 endostatin for 14 days, 50 mg/m2 paclitaxel, and 2 mg/mL/min carboplatin over 
30 min. Patients were then treated with 7.5 mg/m2 endostatin for 14 days, 150 mg/
m2paclitaxel, and 5 mg/mL/min carboplatin every 3 weeks for 2 cycles as the 
consolidation treatment (Fig.1). The objective response rate was recorded according to 
the RECIST criteria, and the toxicity was evaluated using the NCI Common Toxicity 
Criteria.
Results: Six patients were unable to complete the consolidation treatment (4 pulmonary 
toxicity, 1 tracheoesophageal fistulae, and 1 progressive disease). Seventeen patients 
were included for data analysis. Specifically, one (5.9%) patient had a complete response 
and 13 (70.6%) had a partial response, whereas two patients had stable disease and the 
other two had disease progression. The overall response rate was 76% [95% CI, 51%–
97%]. The median progression-free survival was 10 months (95% CI, 7.6–12.3 months), 
and the median overall survival was 14 months (95% CI, 10.7–17.2 months) (Tab.1). The 
toxicity analysis of 10 patients who completed the treatment regimen showed that four 
patients experienced grade III pulmonary toxicity.
Conclusion: The results demonstrated no evidence of the efficacy of endostatin 
concurrent with chemoradiotherapy of locally advanced unresectable NSCLC. The real 
impact of endostatin as the first-line treatment combined with chemoradiotherapy on the 
survival of NSCLC patients remains to be determined.
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Background: EML4-ALK is a new driver gene of non-small cell lung cancer (NSCLC) and 
is associated with response to inhibition with crizotinib. ALK break apart fluorescence in 
situ hybridization (FISH) assay, Ventana immunohistochemistry (IHC), and reverse 
transcriptase polymerase chain reaction (RT-PCR) can all be used as the primary assay 
for detecting ALK fusion events in tumor samples of lung cancer patients with SFDA 
approval in China. The objective of this study was to analyze the association of ALK 
rearrangements with clinical outcomes in different ALK testing methods, including FISH, 
Ventana IHC, and RT-PCR. Methods: ALK status was assessed by FISH, IHC and RT-PCR 
in 75 patients with advanced ALK-positive lung adenocarcinoma who had received 
crizotinib treatment from 2011, May to 2014, Nov in China. Clinicopathologic data and 
survival outcomes were analyzed. Kaplan-Meier cumulative probability was used to 
assess different testing methods for survival. Results: Of all 75 ALK-positive lung 
adonocarcinoma, there are 23 FISH-positive ALK patients (23/75, 30.7%), 35 IHC-
positive ALK patients (35/75, 46.7%) and 17 RT-PCR-positive ALK patients (17/75, 
22.7%). 75 patients received crizotinib treatment with IHC-positive and FISH-positive had 
better progression-free survival (PFS) (P=0.049, Fig A), compared with those with RT-
PCR-positive, but not for overall survival (OS) (P=0.074). The median PFS survival for all 
these 75 patients was 16m, 14m, 8m, respectively, based on the IHC, FISH, and RT-PCR 
test (Fig A). 23 patients received first-line crizotinib treatment with IHC-positive and FISH-
positive had better PFS (P=0.030), compared with those with RT-PCR-positive, but not for 
OS (P=0.061), either. The median PFS survival for these 23 patients with first-line 
crizotinib treatment was 12m, 18m, 4.8m, respectively, based on the IHC, FISH, and RT-
PCR test. Of all 17 RT-PCR-positive ALK patients, there are 10 E13:A20 fusion type 
(10/17, 58.8%), 4 E6:A20 fusion type (4/17, 23.5%), 2 E18:A20 fusion type (2/17, 
11.8%), and 1 E2:A20 fusion type (1/17, 5.9%). 4 different fusion-type ALK-positive 
patients detected by RT-PCR received crizotinib treatment with no crizotinib-related PFS 
significant difference (P=0.312) and no OS difference (P=0.149).
Conclusion: ALK-positive patients confirmed by IHC and FISH assay, compared with RT-
PCR, maybe have better crizotinib-related PFS. RT-PCR method needs to be further 
evaluated in clinical practice to identify its role in guiding targeted therapy using crizotinib. 
And there is no survival difference for different ALK fusion type detected by RT-PCR in our 
cohort, which need further validation in a large group. 
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MINI08.06 Prognostic Significance of FGFR1 Amplification in Patients with 
Lung Squamous Cell Carcinoma Qi Zhang1, Xu -Chao Zhang2, Zhi Xie2, Jian Su2, 
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Background: The Fibroblast Growth Factor Receptor (FGFR) pathway 
especially FGFR1 gene copy number gain have attracted continuous attention of 
researchers for several years. Whereas due to different test methods and distinguishing 
criteria whether FGFR1 amplification related to patients smoking status or prognosis 
is still controversial. Methods: We used fluorescence in situ hybridization (FISH) to 
detect the gene copy number in paraffin-embedded tissue sections from 200 cases 
of pulmonary squamous cell carcinoma patients who underwent surgery in Guangdong 
Lung Cancer Institute (GLCL) from 2008 to 2013. All samples had been identified as 
primary squamous cell carcinoma by postoperative pathology and informed consent. 
A tumor is defined as FGFR1 amplification positive when FISH results meet one of the 
following criteria after reviewing at least 100 tumor cells: (1) FGFR1/CEP-8 ratio≥2; 
(2) mean number of FGFR1 signals≥6; or if (3) ≥10% tumor cell containing more than 
15 FGFR1 signals or large clusters. Among them, sample accord with the 3rd standard 
was defined as focal amplification. 
tissue. The performance of the prediction model was tested in this population. Results: 
From 91 patients resected tumor samples were collected. The majority of patients had 
early or locally advanced NSCLC (96.3%). Gene expression profiling revealed five markers 
that showed mRNA levels strongly correlating to FMP genes mRNA levels: TPX2, CPA3, 
EZH2, MCM2 and TOPO2a. Of 63 patients IHC staining scores of these markers were 
obtained, which all correlated to their corresponding mRNA levels. The scores were 
significantly different between predicted NRs and Rs (p<0.05). Testing the IHC markers 
showed an optimized prediction model with CPA3 (OR=1.71, 95%CI (0.94-3.08)), EZH2 
(OR=0.57, 95%CI (0.35-.093)) and TPX2 (OR=0.55, 95%CI (0.29-1.03)) included. With this 
model 86.5% of the predicted Rs and 72.7% of the predicted NRs were correctly classified. 
The ROC showed an AUC of 0.883 representing a good discriminatory performance. 
In the external study population (n=23) the majority of patients had metastatic NSCLC 
(95.7%). Partial response (PR) was established in 26.1%. Considering patients with PR 
as responders the prediction model classified 16.7% of the observed Rs and 88.2% of 
the observed NRs correctly. The ROC showed an AUC of 0.750. Conclusion: Using 
external validation this prediction model with IHC staining of FMP correlated markers 
shows a good specificity, but lacks sensitivity. Again this study shows the limited value 
of IHC markers as response predictors for PEM in clinical practice. This may be ascribed 
to the poor relation between IHC and protein activity but the biological significance of 
FMP genes may also be less important than other factors influencing PEM activity, like 
pharmacodynamics of PEM e.g. the formation of metabolites. Metabolomics may offer 
better understanding in cellular processing of PEM and could provide new insights for 
tailored chemotherapy. Supported by an unrestricted grant from Eli-Lilly, the Netherlands 
Keywords: pemetrexed sensitivity, gene expression profiling, NSCLC, 
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MINI08.04 VeriStrat® and Epidermal Growth Factor Receptor Mutation 
Status in a Phase 1b/2 Study of Cabozantinib +/- Erlotinib in Non-Small Cell 
Lung Cancer Sukhmani K. Padda1, Primo Lara Jr.2, Scott N. Gettinger3, Jeffrey A. 
Engelman4, Pasi A. Jänne5, Howard West6, Lisa Y. Zhou1, Deepa S. Subramaniam7, 
Joseph W. Leach8, Michael B. Wax9, Joel W. Neal1, Douglas O. Clary10, Laurie J. 
Goodman11, Heather A. Wakelee1 1Stanford Cancer Institute/Stanford University School of 
Medicine, Stanford/CA/United States of America, 2UC Davis Medical Center, Sacramento/
CA/United States of America, 3Yale University School of Medicine, New Haven/CT/
United States of America, 4Massachusetts General Hospital Cancer Center, Boston/MA/
United States of America, 5Dana-Farber Cancer Institute, Boston/MA/United States of 
America, 6Swedish Cancer Institute, Seattle/WA/United States of America, 7Lombardi Cancer 
Center/Georgetown University, Washington DC/CA/United States of America, 8Minnesota 
Onc, Minneapolis/MN/United States of America, 9Summit Medical Group, Berkeley Heights/
NJ/United States of America, 10Exelixis Inc, South San Francisco/CA/United States of 
America, 11Biodesix, Boulder/CO/United States of America
Background: VeriStrat is a blood-based multivariate proteomic test that predicts response 
to second line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) 
therapy in non-small cell lung cancer (NSCLC). We report a retrospective blinded analysis 
of VeriStrat classification in plasma samples from a phase 1b/2 trial of cabozantinib (C) 
+/- erlotinib (E) in metastatic NSCLC patients who had all progressed after benefiting 
from EGFR TKI therapy. Cabozantinib inhibits the MET/hepatocyte growth factor (HGF) 
pathway, and VeriStrat may be a surrogate marker for this pathway. Methods: Patients 
enrolled into phase 1b (1A:60 mg C+150 mg E, 2A:60 mg C+100 mg E, 3A:100 mg C+100 
mg E, 4A:100 mg C+50 mg E, 2B:40 mg C+150 mg E) and phase 2 (Arm A:100 mg C, 
Arm B:100 mg C+50 mg E). EGFR mutation (EGFRm) status was tested on archival tissue 
and/or plasma when available. The primary objective was to determine if pre-treatment 
VeriStrat (VS) classification, good or poor, was prognostic for patients treated with 
cabozantinib +/- erlotinib. Kaplan-Meier method and log-rank test was used to compare 
progression-free survival (PFS) of VS-good v. VS-poor patients. Outcomes were stratified 
by EGFRm status (mutated v. wild type WT/unknown UNK). Results: Of 79 evaluable 
patients, 71 were classified as VS-good and 8 as VS-poor. 55.7% had an activating EGFRm 
(majority exon 19 del/exon 21 L858R) and 12.7% had UNK EGFRm status. There were 
no significant differences in patient characteristics between VeriStrat-groups. VS-good 
patients had a statistically improved PFS: VS-good 3.7 mo. (95% CI 3.5-5.4) v. VS-poor 
1.9 mo. (95% CI 1.1-3.4), p=0.014. This was still true after excluding 14 patients who 
had received cabozantinib alone (p=0.005). There was no difference in PFS for VS-good 
patients when stratified by EGFRm status. There was also no difference in PFS for VS-poor 
patients with WT/UNK EGFR v. VS-good patients irrespective of EGFRm status. However, 
VS-poor patients with WT/UNK EGFR had improved PFS compared to VS-poor patients 
with an EGFRm (3.1 mo. v. 1.6 mo., HR 0.15, 95% CI 0.03-0.68). Conclusion: VeriStrat is 
a strong prognostic marker in this study. This study suggests cabozantinib neutralized 
the worse prognosis of VS-poor patients with WT/UNK EGFR. Given the heterogeneity 
of treatment dosing, the small number of VS-poor patients, and a high proportion of 
unknown EGFRm (including T790M) status, this analysis should be considered exploratory. 
Keywords: epidermal growth factor receptor mutation, EGFR, VeriStrat, cabozantinib
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MINI08.05 A Survival Comparison Study of Chinese Patients with Primary 
Lung Adenocarcinoma Harboring ALK Rearrangements Detected in Different 
Methods with Crizotinib Treatment Shun Lu1, Xiaomin Niu2, Zhiwei Chen2, Zhen 
Zhou2, Ziming Li2, Xiangyun Ye2, Yongfeng Yu2, Yunhua Xu2, Meilin Liao2 1Shanghai Lung 
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effects, but may be due to direct effects at the promoter level. Direct histone acetylation 
of histones H3 and H4 was observed, indicating an increase in histone hyperacetylation 
of VEGFR1 and VEGR2 promoters. A significant trend in the modulation of the VEGF 
receptors similar to that seen in response to TSA was shown when treated with Vorinostat 
(SAHA). Conclusion: Epigenetic targeting of the Neuropilin receptors may offer an effective 
treatment for NSCLC patients in the clinical setting. The possibility of novel targeted 
agents decreasing the levels, or function, of tumour VEGF receptors, in particular NP1, 
may lead to more successful treatments and prolonged overall survival in these patients. 
Keywords: VEGF, VEGFR, HDAC, Epigenetics
PROGNOSTIC/PREDICTIVE BIOMARKERS 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI08.09 Anti-Tumor Efficacy of Interleukin-27 in Non Small Cell Lung Cancer 
Giuseppe Cipollone1, Irma Airoldi2, Maria Grazia Tupone3, Silvia Esposito3, Marco 
Vincenzo Russo3, Giulia Barbarito4, Emma Di Carlo3 1General and Thoracic Surgery, 
Chieti University Scholl of Medicine, Chieti/Italy, 2Laboratory of Oncology, “Giannina Gaslini” 
Institute, Genoa/Italy, 3Anatomic Pathology and Molecular Medicine, Department of Medicine 
and Science of Aging, “G.D’Annunzio” University, Chieti, Italy; Ce.S.I. Biotech, Aging Research 
Center, “G.D’Annunzio” University Foundation, Chieti, Italy, Chieti/Italy, 4Laboratory of 
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Background: Adenocarcinoma (AC) and Squamous Cell Carcinoma (SCC) constitute the 
commonest lung cancer histotypes, but current therapies still fail to significantly increase 
their survival rate. An effective immunotherapy to apply alternatively or together with 
specific treatments may be of great value. Here we asked whether Interleukin (IL) -27, which 
has revealed powerful antitumor activity in different tumor types and is toxicity-free in 
humans, is a promising therapeutic choice for NSCLC patients. Methods: Human lung 
AC and SCC cell lines were used to assess IL-27’s effect on cancer cell viability, by flow 
cytometry, and on malignancy-related gene expression, by qRT-PCR. Its effects on tumor 
growth were assessed in pre-clinical models and examined histopathologically. Expression 
of IL-27Receptor(R) in clinical samples was assessed by laser capture microdissection 
followed by qRT-PCR, and by immunohistochemistry. Results: In vitro, IL-27 was ineffective 
on cancer cell proliferation or apoptosis, but fostered CXCL3/GROg/MIP2b expression. In 
vitro and in vivo, IL-27 down-regulated stemness-related genes, namely SONIC HEDGEHOG in 
AC cells, and OCT4A, SOX2, NOTCH1, KLF4 along with the Epithelial to Mesenchymal Transition 
(EMT)-related genes NESTIN, SNAI1/Snail, SNAI2/Slug and ZEB1, in SCC cells. In vivo, IL-27 
hampered both AC and SCC tumor growth in association with a prominent granulocyte- and 
macrophage-driven colliquative necrosis, CXCL3 production, and a reduced pluripotency- 
and EMT-related gene expression. Myeloablation of tumor-bearing hosts mostly abolished 
IL-27’s antitumor effects. In clinical samples, IL-27R was expressed by the majority of AC, 
90%, and SCC, 84%. Its expression by the primary tumor was significantly associated 
with advanced stages of disease (P = 0,02) as assessed by Fisher’s exact test. IL-27R was 
also expressed by pre-cancerous lesions, microvessels, and by infiltrating immune cells 
as CD15+granulocytes, CD68+monocytes/macrophages and CD11c+myeloid dendritic 
cells scattered in the stroma or within the lymph node–like structures, known as tertiary-
lymphoid-structures (TLS). Conclusion: Altogether, our results highlight novel aspects of 
IL-27’s antitumor potential, specifically in NSCLC, such as the ability to drive myeloid cells 
towards antitumor activities, and down-regulate stemness genes, particularly in SCC cells, 
thus suppressing their self-renewal potential. IL-27 may thus be proposed for clinical trials 
with the prospect of its clinical use in immune-defective or advanced NSCLC patients. 
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MINI08.10 Co-Occurrence of Driver Mutations of MAPK and PI3K Pathways in 
Non Small Cell Lung Cancer: A Report from Lung Cancer Genomics Ireland 
(LCGI) Study Shereen Rafee1, Yasir Elamin2, Sinead Toomey3, Kathy Gately4, Aoife 
Carr3, Sinead Cuffe4, Siobhan Nicholson5, Stephen P. Finn6, Ronan Ryan7, Vincent Young7, 
John Crown8, Oscar Breathnach9, Patrick Morris9, Elaine Kay9, Anthony O’Grady9, Bryan 
Hennessy3, Kenneth J. O’Byrne10 1St.James’s Hospital, Dublin/Ireland, 2Royal College of 
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Research Group, Trinity College Dublin/St. James’s Hospital, Dublin/Ireland, 5Department 
of Histopathology, St. James’s Hospital, Dublin/Ireland, 6Trinity College and St. James’s 
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Background: The mitogen-activated protein kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K) pathways are frequently altered in human cancers. Targeting these 
pathways is an attractive therapeutic strategy in malignant disease. The frequency of 
single and dual pathway alterations varies substantially across various cancers. Co-
occurrence of the MAPK and PI3K pathway aberrations is reported in 5-7% of melanomas, 
gastric and colorectal cancers, and is associated with a worse clinical outcome. In this 
report we aim to determine the co-occurrence of the MAPK and PI3K pathway mutations 
in a large cohort of surgically resected NSCLC tumors. Methods: We used the platform 
of Sequenom’s MassArray to perform genotyping for 548 somatic hotspot mutations in 
49 genes including genes in the MAPK and PI3K pathways in surgically resected NSCLC 
tumors. MAPK pathway genes that were screened include: KRAS, HRAS, BRAF, RAF1, 
MAP3K1, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MAP2K1, MAP2K2, MAP2K3, and PTPN11. PI3K 
pathway genes that were screened include: PIK3CA, PIK3R1, PIK3R2, PTEN, PDPK1, AKT1, 
AKT2, and MTOR. Fisher’s exact test was used to determine the statistical significance of 
association between the MAPK and PI3K pathway mutations. The strength of association 
was determined in the form of odds ratio. Results: NSCLC tumors from 356 patients 
Results: 
 
We used fluorescence in situ hybridization (FISH) to detect the gene copy number in paraffin-
embedded tissue sections from 200 cases of pulmonary squamous cell carcinoma patients 
who underwent surgery in Guangdong Lung Caner Institute (GLCL) from 2008 to 2013. All 
samples had been identified as primary squamous cell carcinoma by postoperative pathology 
and informed consent. A tumor is defined as FGFR1 amplification positive when FISH results 
meet one of the following criteria after reviewing at least 100 tumor cells: (1) FGFR1/CEP-8 
ratio≥2; (2) mean number of FGFR1 signals≥6; or if (3) ≥10% tumor cell containing more than 
15 FGFR1 signals or large clusters. Among them, sample accord with the 3rd standard was 
defined as focal amplification. Conclusion: Our results suggested that FGFR1 focal 
amplification might be an independent risk factor for patients overall survival. Patients with 
FGFR1 amplification were more likely to disease recurrence. Clinical characteristic including 
smoking status were not found in association with FGFR1 amplification, suggesting patients 
with FGFR1 amplification might not be fully enriched through only clinical factors. 
Keywords: FGFR1 amplification, lung squmous cell carcinoma
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MINI08.08 VEGF-Mediated Cell Survival in NSCLC: Implications for Epigenetic 
Targeting of VEGF Receptors as a Therapeutic Approach Martin P. Barr1, Kenneth 
J. O’Byrne2, Nael Al Sarraf1, Sinead Cuffe1, Stephen Finn3, Steven G. Gray1 1Thoracic 
Oncology, St. James’s Hospital & Trinity College Dublin, Dublin/Ireland, 2Cancer & Ageing 
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Background: We have recently shown that VEGF, at least in part, is an autocrine growth 
factor for NSCLC cells, mediating its survival effects via VEGFR2 (KDR) in addition to the 
more novel receptor, Neuropilin-1 (Barr et al., Mol Cancer, 2015). In this study, we evaluated 
the potential therapeutic utility of histone deacetylase (HDAC) inhibitors in targeting the 
VEGF-VEGFR signalling axis in non-small cell lung cancer (NSCLC) cells. Methods: The 
effect of the HDAC inhibitor, Trichostatin-A (TSA) on modulating the expression of the VEGF 
receptors, VEGFR1, VEGFR2, NP1 and NP2, in A549 and SKMES-1 cells was examined and 
validated at the mRNA level and protein levels using RT-PCR and Western blot analysis. Gene 
expression was further validated by quantitative real-time PCR. To investigate the effect of 
TSA on the viability of NSCLC cells, these were treated with increasing concentrations of 
TSA (2.5 ng/ml-250 ng/ml) for 24h. Cell proliferation and apoptosis was measured by 
BrdU and Annexin V/PI (FACS), respectively. VEGF protein secretion in response to TSA 
was assessed in conditioned media from lung tumour cells by ELISA. To determine if the 
effects of TSA on VEGFR receptors were mediated through immediate to early responses, 
cells were pre-treated with cycloheximide (10 µg/ml) for 2 h followed by treatment with 
TSA (250 ng/ml) for 24 h. To confirm whether the observed effects of HDAC inhibition 
by TSA were due to increased histone hyperacetylation at the VEGFR1 and VEGFR2 gene 
promoters, chromatin immunoprecipitation (ChIP) analysis was carried out following 
treatment with TSA. Results: NP1 and NP2 mRNA levels were decreased in both A549 and 
SKMES-1 lung cancer cells in response to TSA and induced the expression of VEGFR1 and 
VEGFR2 at higher concentrations. TSA however, had no effect on VEGF mRNA expression. 
Critically, the effect of TSA was more marked at the protein level, with complete loss 
of Neuropilin-1 protein. HDAC inhibition resulted in a significant decrease in the viability 
of A549 and SKMES-1 cells in a dose-dependent fashion. While TSA induced significant 
apoptosis of both lung tumour cell lines, VEGF was unable to rescue cells from TSA-induced 
cell death. VEGF secretion was significantly decreased in both cell lines. Treatment with 
cycloheximide was unable to abrogate the TSA-mediated increase in the VEGF receptors 
examined, indicating that de novo protein synthesis is not required for these observed 
S293Copyright © 2015 by the International Association for the Study of Lung Cancer
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
PROGNOSTIC/PREDICTIVE BIOMARKERS 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI08.12 Proteomic Profiling of Pulmonary Cancer with Squamous Cell 
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Thomas Oellerich2 1Institute of Pathology, University Medical Center, Goettingen/
Germany, 2Department of Medicine, Hematology/Oncology, Goethe University, Frankfurt/
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Background: Pathologic differentiation of neoplastic lesions in the lung with squamous 
cell histology is challenging as appropriate diagnostic immunohistochemical biomarkers 
are lacking. In particular patients with head and neck cancer and a smoking history 
can develop both lung metastases and primary lung cancer. Differentiation of primary 
lung cancer and lung metastases of head and neck cancer is clinically important for 
therapy and risk stratification. Furthermore, molecular targeted therapies for squamous 
cell carcinoma of the lung are largely lacking to date. Recent genetic studies uncovered 
multiple genetic subgroups of squamous cell carcinoma of the lung and moreover 
potential drug targets. However, the correlation between protein-expression/signaling 
activation patterns and genetic alterations is strongly influenced by co- and post-
transcriptional as well as post-translational regulation. We characterized a broad panel 
of primary patient-derived formalin-fixed squamous cell carcinomas from lung and head 
and neck cancer by quantitative mass spectrometry to identify proteomic diagnostic 
biomarkers, signaling patterns and potential novel drug targets. Methods: Proteins were 
extracted from formalin-fixed paraffin-embedded (FFPE) microdissected patient-derived 
cancer tissues by using the “filter-aided sample preparation (FASP)” method. Purified 
proteins were subsequently mixed with a cancer-matched isotope labeled quantification 
standard (Super-SILAC standard) that allows for identification and quantification of 
thousands of proteins and their phosphorylation sites by high-end mass spectrometry. 
Using bioinformatics we determined the protein expression and signaling patterns. The 
biomarkers discovered were validated by immunohistochemistry in additional independent 
tumor tissues. Results: In this study we quantitatively characterized the proteomes of 
60 primary patient-derived non-small cell lung cancer specimens with squamous cell 
histology and 25 squamous cell carcinomas from the head and neck region derived from 
patients that developed lung tumors with similar histology in the course of their disease. 
Using the Super-SILAC-based mass spectrometric approach we were able to identify 
and quantify around 2500 proteins per sample. Unsupervised clustering- and principal 
component analyses revealed that the detected protein expression patterns show a 
strong correlation with the cellular origin of the analyzed carcinomas. Furthermore, 
secondary lesions with similar histological morphology in the lung in patients with 
squamous cell carcinoma of the head and neck region could be classified as primary 
or metastatic cancer according to their protein expression profiles. Conclusion: 
Collectively, this study provides a large set of proteomic biomarkers that can be used to 
improve lung cancer diagnostics in the future. In particular the differential diagnosis of 
squamous cell carcinoma/metastases in the lung, that has so far been difficult due to the 
lack of biomarkers, will be improved by the biomarker panels presented here. Moreover, 
the expression and activation patterns of kinases discovered in our study is of interest 
regarding potential novel lung cancer therapies as overexpression or hyperactivation of 
certain kinases can potentially contribute to the malignant phenotype of lung cancer cells. 
Keywords: Squamous cell carcinoma, Pathology, mass spectrometry, proteomics
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Correlation with Radiographic CT Findings HaiyuY. Zhou1, CarolC. Wu2, Mari 
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Background: To indentify the correlation of chest computed tomography 
appearance and the presence of oncogenic driver mutations in resected stage I lung 
adenocarcinoma. Methods: Patients with resected stage I lung adenocarcinoma were 
analyzed from 2008-2012 and categorized into 3 groups: pure ground glass (GGO), 
mix-solid and ground glass, and solid patterns. All patients underwent driver mutation 
analysis (26 genes and 89 point mutations) using a multiplex PCR-based assay from 
paraffin embedded tumors. Disease free survival (DFS) and overall survival (OS) were 
compared between patients with EGFR, KRAS and the wild-type tumors using Kaplan-
Meier methods and Cox regression models. Results: 237 patients who underwent 
curative resection for stage I lung adenocarcinoma were analyzed with a median follow-
up 34 months. Female gender was observed in 68% (160/237) and 21% (50/237) were 
nonsmokers. Pure GGO was indentified in 9% (n=21), mixed solid in 69% (n=164), 
and solid in 22% (n=52) of cases. EGFR and KRAS mutation rates were 18.6% (n= 
44) and 34.6% (n= 82), respectively. Univariate analysis showed that KRAS-mutated 
tumors (HR 1.91, 95% CI 1.37-2.67; p<0.01), solid component > 50%, (HR 2.65, 95% 
CI 1.03-6.8; p=0.04), and smoking status (HR 3.59, 95% CI 1.1-11.8; p=0.03) were 
associated with worse DFS. In multivariate analysis only KRAS-mutated tumor (HR 
1.84, 95% CI 1.31-2.59; p<0.01) was significant for worse DFS. KRAS-mutated tumor 
(258 squamous cell, 98 adenocarcinomas) were tested using Sequenom’s MassArray. 
The frequency of mutations in the MAPK and PI3K pathways was 22.5% (n=80) and 
22.8% (n=81) respectively. Among these patients, 38 patients had mutations in both 
pathways (i.e: 47.5% of patients with a MAPK pathway mutation also had a mutation in the 
PI3K pathway, and 46.9% of patients with a PI3K pathway mutation also had a mutation 
in the MAPK pathway, see table 1). Fisher’s exact test revealed that mutations in the 
MAPK and the PI3K pathways are mutually inclusive (p<0.0001, odds ratio=4.95, 95% 
CI 2.9-8.5) Table 1: The co-occurrence of MAPK and PI3K pathway mutations in NSCLC.
Pathway/no of patients PI3K WT PI3K MT
MAPK WT 235 43
MAPK MT 42 38
 
Conclusion: 38 (10.7%) of 356 NSCLC patients included in the LCGI study 
had hotspot somatic mutations in both the MAPK and PI3K pathways. Contrary 
to previous reports, we observed that activating mutations of the MAPK and 
PI3K pathways are mutually inclusive in NSCLC. These findings may have 
implications in designing clinical trials of targeted therapies in lung cancer. 
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Hwang1, Ho Young Son2, Yoo Jin Jung3, Sae Bom Lee3, Yun Ho Kim3, Hyun Joo Lee4, In 
Kyu Park1, Chang Hyun Kang1, Jong-Il Kim2, Young Tae Kim1 1Thoracic and Cardiovascular 
Surgery, Seoul National University Hospital, Seoul/Korea, 2Biochemistry and Molecular 
Biology, Seoul National University, Seoul/Korea, 3Cancer Research Institute, Seoul National 
University, Seoul/Korea, 4Thoracic Ad Cardiovascular Surgery, Seoul National University 
Hospital, Seoul/Korea
Background: Non-small cell lung cancer (NSCLC) is characterized by poor prognosis, 
and few molecular markers were proven to be associated with cancer metastasis. The 
aim of the study is to identify the associations between single-nucleotide polymorphisms 
(SNPs) and distant metastasis of adenocarcinoma of the lung in Korean population. 
Methods: We conducted a genome-wide association study (GWAS) of in 499 Korean lung 
adenocarcinomas comparing 4,653,588 SNPs genotypes. Analyses were performed 
to investigate the association between the germline variations in all genes and cancer 
metastasis, survival and cancer recurrence. Results: We undertook a gene-metastasis 
interaction analysis in a GWAS of lung cancer using a case-control study. (18cases and 
481controls) The combined analyses identified two susceptibility loci for metastasis risk 
in lung adenocarcinoma: SYNE1 [rs117050208, p-value = 1.91 x 10-14, odds ratio (OR) = 
87] and QSOX1 (rs148150589, p-value = 4.46 x 10-9, OR = 56.5). SYNE1 was known to 
play crucial roles in the dynamics of genetic progression in colorectal adenocarcinoma 
and QSOXI was considered a prognostic indicator of metastatic potential in the breast 
cancer. (Figure1) However, no significant association was found between SNPs and either 
survival or recurrence.
Conclusion: Our data suggest that the SYNE1 rs117050208 and the QSOX1 
rs148150589 may serve as potential biomarkers to influence cancer metastasis in the 
Korean lung adenocarcinoma. The analysis of the rs117050208 and rs148150589 
polymorphism can help identify patients at high risk of distant metastasis of lung 
adenocarcinoma. Keywords: metastasis, GWAS, lung cancer, SNP
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(pts) with EGFR mutations. Nonetheless, emergence of acquired resistance to therapy 
invariably occurs despite effective initial response. Classical rebiopsy studies of EGFR-
mutant pts at clinical tumor progression based on RECIST criteria have identified diverse 
resistance mechanisms involving T790M-EGFR, MET amplification or activation and AXL 
upregulation. Tumor cells within minimal or microscopic residual disease during drug 
response may constitute founder cells for future disease relapse. The mechanisms 
of molecular changes intrinsic to these early therapeutic survivors are not yet well-
understood. Our studies focus on tumor cells adaptation early during therapy to map the 
initial course of molecular drug resistance emergence and evolution. Methods: Drug-
sensitive model studies of EGFR-mutant lung cancer were performed using HCC827 
and PC-9 cells (exon 19 deletions EGFR) under erlotinib, and H1975 (T790M/L858R-
EGFR) cells under CL-387,785 inhibition. Affymetrix microarray profiling was performed in 
triplicate at 0h, 8h, 9d and 9d tyrosine kinase inhibitor (TKI) followed by 7d drug-washout. 
Both in vitro and in vivo xenograft analyses, immunofluorescence, immunohistochemistry, 
time-lapse video microscopy analysis were conducted. Mass-spectrometry based 
global metabolomics profiling was also conducted under similar conditions as in gene 
expression profiling. Results: We identified an early adaptive and reversible drug-escape 
within EGFR-mutant cells that could emerge as early as 9 days during course of effective 
therapy with molecular drug resistance. Principal component analysis (PCA) of gene 
expression profiling data identified distinct transcriptome signatures in each cell state. 
Of note, the prosurvival cell state was independent of MET pathway activation, and had a 
TKI cytotoxicity escape at 100x higher IC50. The drug resistant cell state was associated 
with reversible cellular quiescence, suppressed Ki-67 expression, and profoundly 
inhibited cellular motility and migration. Transcriptome gene expression profiling 
revealed a remarkable adaptive genome-wide signature reprogramming, centered on the 
autocrine TGFβ2 cascade that involved pathways of cell adhesion, cell cycle regulation, 
cell division, glycolysis, and gluconeogenesis. Global metabolomic profiling of cellular 
metabolites in HCC827 cells under erlotinib inhibition also revealed a concurrent adaptive 
reprogramming of cellular metabolism during the early drug-resistant cell state, with 
suppression of glycolysis, TCA cycle, amino acids metabolism, and lipid bioenergetics. 
Our studies identified a direct link of TGFβ2 within the drug escaping cells, with the 
metabolic-bioenergetics quiescence, reverse Warburg metabolism and mitochondrial 
BCL-2/BCL-xL priming. Furthermore, this adaptive drug-resistant cell state also displayed 
an increased EMT and cancer stem cell signaling as adaptation to the drug treatment 
and that could be overcome by broad BCL-2/BCL-xL BH3 mimetic ABT-263, but not BCL-2 
only mimetic ABT-199. Conclusion: We identified and characterized the emergence of 
early adaptive drug-escape within EGFR-mutant NSCLC cells amid an overall precision 
therapy excellent response, through a MET-independent mechanism. The profoundly 
drug-resisting prosurvival cell state undertook remarkable cellular transcriptome-
metabolome adaptive reprogramming coorindated through autocrine TGFβ2 signaling 
augmentation. Our study results have important implications in lung cancer drug-resistant 
minimal/microscopic disease and future therapeutic remedies in precision therapy. 
Keywords: EGFR-mutant NSCLC, Precision therapy, Adaptive drug resistance, 
Reprogramming
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MINI09.03 Characterization of Afatinib or EGFR T790M Specific Inhibitor 
(WZ8040 or AZD9291) Resistant Lung Cancer Cells (PC9) Anya Maan-Yuh Lin1, 
Ming-Hung Huang2, Ta-Wen Yu1, Hsin-Hui Tsai2, Jih-Hsiang Lee2, James Chih-Hsin Yang2 
1Institute of Pharmacology, National Yang-Ming University, Taipei/Taiwan, 2National Taiwan 
University, Graduate Institute of Oncology, Taipei/Taiwan
Background: Non-small cell lung cancer patients harboring epidermal growth factor 
receptor (EGFR) mutation respond well to EGFR tyrosine kinase inhibitors (TKI). However, 
all patients develop resistance to EGFR TKI after long term use. EGFR T790M mutation can 
be found in about half of the resistant re-biopsy tumors. Afatinib is an irreversible EGFR TKI 
with in vitro activity against resistant T790M mutation. However, afatinib has little activity 
in EGFR TKI resistant patients whose tumors developed T790M mutation. A novel alinino-
pyrimidine based WZ8040 has been developed to specifically inhibit phosphorylation 
of EGFR with T790M mutation and not on wild type EGFR. Similar compounds such as 
CO1686 or AZD9291 has demonstrated high activity against T790M mutations. We 
plan to develop afatinib or AZD9291, WZ8040 resistant PC9 cells to study afatinib 
or AZD9291 resistance. Methods: PC9 cells were grown in culture media containing 
escalating concentrations of afatinib, WZ8040 or AZD9291. When cells can grow in high 
concentrations of drugs, cells were cloned, expanded and grew in drug-free media for 
more than two weeks to obtain stable afatinib, WZ8040 or AZD9291 resistant clones. 
Gefitinib, afatinib, WZ8040, AZD9291. Cells viability were determined by surforodamine 
bromide method. PC9 parental and EGFR TKI resistant cells were treated with gefitnib, 
afatinib, WZ8040 or AZD9291 for one hour and EGFR, AKT, ERK phosphorylation were 
determined by Western blot. DNA repair capacity were compared between sensitive and 
resistant cells after exposure of cells to ultraviolet light and measured by pGL3-luciferase 
plasmid transfection methods. Epithelial mesenchyma transition of these cells were 
tested by snail, slug, vimentin and E-cadherin western blot. Autophagy was measured by 
LC3-II levels by Western blot. EGFR exon 18-21 sequence of each clones were determined 
by Sanger’s direct sequencing. Results: We developed afatinib resistant PC9 cells, 
PC9/AFAb2, PC9/AFAc3 and WZ8040 resistant PC9/WZd7, PC9/WZf6. PC9/AFA cells 
were more than 100-fold resistant to afatinib and PC9/WZ cells were more than 50-
fold resistant to WZ8040. 10nM of afatinib treatment inhibits EGF-induced EGFR, AKT 
and EKR phosphorylation in PC9 cells, but phosphorylation of these kinases were only 
partially inhibited in PC9/AFA cells. Phosphorylation was completely blocked at 100nM 
afatinib. MEK inhibitor plus afatinib did not reverse resistance to afatinib in PC9/AFA cells. 
On the other hand, WZ8040 or AZD9291 alone completely reversed resistance in PC9/
AFA cells. EGFR, AKT and ERK phosphorylation can be blocked by 100nM WZ8040 in PC9 
and PC9/WZd7 cells. However, it is curious that phosphorylation of these proteins can 
be inhibited by 100nM gefitinib as well. EGFR T790M mutation was only detected in PC9/
was also associated with worse OS in both univariate (HR 1.72, 95% CI 1.14-2.59; 
p=0.009) and multivariate (HR 1.65, 95% CI 1.09-2.49; p=0.018) analysis. Tumors that 
harbored >50% solid component on CT chest with a KRAS mutation were associated 
with worse DFS (HR 2.87, 95% CI 1.4-5.92; p=0.004) and OS (HR 2.51, 95% CI 1.03-
6.1; p=0.04) in multivariate analysis compared to wild type tumors that were < 50% 
solid. Conclusion: KRAS mutation status and percent solid component on chest CT 
were predictive of worse outcome in surgically resected stage I lung adenocarcinoma 
Keywords: KRAS, Ground glass opacity, non small cell lung cancer, EGFR
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MINI09.01 Inhibiting Tankyrase Prevents Epithelial-To-Mesenchymal Transition 
and Synergizes with EGFR-Inhibition in Wnt-Dependent NSCLC Lines 
Hannah A. Scarborough1, Barb A. Helfrich2, Matias Casas-Selves1, Zhiyong Zhang2, 
Daniel C. Chan2, Alwin Schuller3, Shaun Grosskurth3, Paul A. Bunn, Jr2, James V. 
Degregori1 1Biochemistry and Molecular Biology, University of Colorado Denver, Denver/CO/
United States of America, 2Medical Oncology, University of Colorado Denver, Denver/United 
States of America, 3Astrazeneca, Boston/MA/United States of America
Background: Despite their promise, therapies targeting driver receptor tyrosine 
kinases (RTKs) rarely produce complete responses and have shown modest clinical 
benefit in NSCLC. This suggests the presence of escape mechanisms that allow cells 
to survive and proliferate despite inhibition of an oncogenic driver. Methods: Using a 
genome-wide shRNA screen, we identified that the canonical Wnt/β-catenin pathway 
contributes to the survival of NSCLC cells during inhibition of the epidermal growth 
factor receptor (EGFR). In order to evaluate the effects of inhibiting the Wnt pathway 
on EGFR-inhibited cells, we categorized NSCLC cell lines as “Wnt-responsive” or “Wnt-
non-responsive” based on their ability to upregulate β-catenin-dependent targets in 
response to treatment with exogenous Wnt3a. Using both shRNA knockdown and a novel 
tankyrase inhibitor, AZ1366, we evaluated the ability of tankyrase inhibition to synergize 
with EGFR-inhibition in multiple Wnt-responsive and Wnt-non-responsive cell lines. We then 
evaluated the effects of the combination of gefitinib and AZ1366 on the survival and 
tumor progression in an orthotopic mouse model. In order to comprehensively query 
transcriptional changes brought about by treatment, we performed RNA-seq on cells 
treated with gefitinib, AZ1366, or the combination of the two drugs. Results: We have 
demonstrated that inhibition of tankyrase, a key player in the canonical Wnt pathway, 
significantly increases the induction of senescense and/or apoptosis mediated by 
EGFR-inhibitors in cell lines with a Wnt-responsive phenotype, and that the ability of 
the tankyrase inhibitor to synergistically eliminate NSCLC cells is dependent on its 
actions within the canonical Wnt pathway. In Wnt-non-responsive cell lines, tankyrase 
inhibition did not synergize with inhibition of EGFR. We have further demonstrated that 
Wnt-responsive cell lines show evidence of EMT in response to Wnt ligand stimulation, 
and that this can be prevented with tankyrase-inhibitor treatment. Additionally, we have 
shown that mice orthotopically implanted with Wnt-responsive cell lines and treated with 
a combination of a tankyrase inhibitor and an EGFR inhibitor have a substantially reduced 
tumor burden and a significant improvement in survival when compared to treatment 
with an EGFR inhibitor alone. When Wnt-non-responsive cell lines were used, we noted 
no improvement in survival or reduction in tumor burden. RNA-seq analysis revealed that 
while most transcriptional changes present in the combination were driven by gefitinib, 
AZ1366 had the effect of significantly amplifying many of the changes thought to be 
instrumental in resistance to EGFR inhibition including increased expression of TP53 and 
apoptosis signaling machinery, increased expression of NF-kB signaling components, 
and a strong decrease in cell cycle drivers. Furthermore, treatment with AZ1366 alone 
resulted in decreased expression of Axl and its ligand, Gas6, a known mechanism of 
resistance to EGFR inhibition. Conclusion: Taken together, these results indicate that 
tankyrase inhibition impinges on multiple mechanisms of escape from EGFR-inhibition, 
and that its ability to synergize with EGFR-inhibition is dependent on its actions within the 
canonical Wnt pathway. As the goal of these studies is the development of combination 
therapies with EGFR inhibition, this suggest tankyrase as a promising target in the subset 
of NSCLC with known dependencies on signaling through the canonical Wnt pathway. 
Keywords: combinatorial therapy, Wnt pathway, EMT, TKI resistance
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MINI09.02 Transcriptome-Metabolome Reprogramming of EGFR-Mutant 
NSCLC Contributes to Early Adaptive Drug-Escape via BCL-xL Mitochondrial 
Priming Patrick C. Ma1, Praveena Thiagarajan2, Wei Zhang1, Xiaoliang Wu1, Patrick 
Leahy3, Ivy Shi1, Yan Feng4, Martina L. Veigl3, Daniel Lindner2, David Danielpour3, Lihong 
Yin2, Zhenfeng Zhang5, Rafael Rosell6, Trever Bivona7 1Mary Babb Randolph Cancer 
Center., West Virginia University., Morgantown/WV/United States of America, 2Taussig 
Cancer Institute, Cleveland Clinic, Cleveland/OH/United States of America, 3Case 
Comprehensive Cancer Center, Case Western Reserve Unviersity, Cleveland/OH/United 
States of America, 4Medicine, Case Western Reserve Unviersity, Cleveland/OH/United States 
of America, 5Sun Yat-Sen University Cancer Center, Guangzhou/China, 6Catalan Institute of 
Oncology, Barcelona/Spain, 7Medicine, UCSF, San Francisco/United States of America
Background: Precision therapy using EGFR small molecular inhibitors is the current 
standard-of-care in treatment of advanced non-small cell lung cancer (NSCLC) patients 
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Background: The Lung Cancer Mutation Consortium (LCMC) 1.0 demonstrated 
multiplexed genomic platforms can assay 10 oncogenic drivers in tumor specimens from 
patients with lung adenocarcinomas. 28% of the patients with oncogenic drivers could be 
effectively targeted. The survival of these 275 patients treated with targeted agents was 
longer than the patients who were not treated with a targeted agent (Kris and Johnson 
JAMA 2014). The efficiency of Next-Generation Sequencing enables more comprehensive 
testing of additional aberrations with less tumor tissue. LCMC 2.0 was initiated to test 
tumor specimens for 12 oncogenic drivers and to provide the results to clinicians for 
treatment decisions and research purposes. Methods: The 16 site LCMC 2.0 is testing 
tumors from 1000 patients with lung adenocarcinomas in CLIA laboratories for mutations 
in KRAS, EGFR, HER2, BRAF, PIK3CA, AKT1, and NRAS, MET DNA amplification, and 
rearrangements in ALK as done in LCMC 1.0. The new genes that were added because of 
emerging information about potential therapeutic targets include MAP2K1 mutations, RET 
and ROS1 rearrangements, PTEN (MAb 138G4) loss and MET (MAb SP44) overexpression 
by immunohistochemistry (IHC). All patients were diagnosed with stage IIIB/IV lung 
adenocarcinoma after May 2012, had a performance status 0-2, and available tumor 
tissue. Results: Of 1073 patients registered, data is now reported for 759. The median 
age of the patients is 65 (23-90). The population includes 369 (55%) women; 164 (24%) 
never smokers, 399 (59%) former smokers, and 73 (11%) current smokers; 26 (4%) 
Asians, 58 (9%) African American, 548 (81%) Caucasian, and 43 (6%) of other races. 
As of April 2015 information on genomic and immunohistochemical changes for 675 
eligible patients were recorded in our database. Alterations in oncogenic drivers were 
found in 45% of samples as follows: 159 KRAS (24%), 88 EGFR (13%), 25 ALK (4%), 
19 BRAF (3%), 17 PIK3CA (3%), 9 HER2 (1%), 4 NRAS (1%) 0 AKT1, 28 had ≥ 2 findings 
(4%) and 25 MET DNA amplification (4%). The new genes studied in LCMC 2.0 revealed 
1 MAP2K1 mutation (<1%), 19 RET (3%) and 9 ROS (1%) rearrangements, 94 had PTEN 
loss (14%), and 362 with MET overexpression (54%). As expected, PIK3CA mutations 
and PTEN loss by IHC were mutually exclusive in 109 of 111 (98%) patients’ tumors. 
Seventeen of the 23 (74%) with MET DNA amplification studied thus far with IHC had 
MET overexpression. Next-Generation platforms were used at 13 of 16 LCMC 2.0 sites. 
Conclusion: Next-Generation Sequencing is rapidly becoming routine practice at LCMC 
2.0 centers with use going from 0 to 81% of sites since 2012. LCMC 2.0 identified 
additional targets (RET and ROS1 rearrangements and PTEN loss). PIK3CA and PTEN 
were largely mutually exclusive and an actionable oncogenic driver has been identified 
in the 45% of initial lung adenocarcinoma specimens. Supported by Free to Breathe 
Keywords: next generation sequencing, Oncogenic driver, Adenocarcinoma
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MINI09.07 Activation of the MET Kinase Confers Acquired Resistance to FGFR-
Targeted Therapy in FGFR-Dependent Squamous Cell Carcinoma of the Lung 
Yong Wha Moon1, Sung-Mu Kim2, Hwan Kim2, Hye Ryun Kim1, Sun Min Lim1, Byoung Chul 
Cho1 1Medical Oncology, Yonsei Cancer Center, Seoul/Korea, 2JE-UK Laboratory of Molecular 
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Background: Fibroblast growth factor receptor (FGFR) tyrosine kinase plays a crucial 
role in cancer cell growth, survival, and resistance to chemotherapy. FGFR1 amplification 
occurs at a frequency of 10-20% and is a novel druggable target in squamous cell 
carcinoma of the lung (SCCL). A number of FGFR-targeted agents are currently being 
developed in SCCL harboring FGFR alterations. The aim of the study is to evaluate the 
activity of selective FGFR inhibitors (AZD4547, BAY116387) and the mechanisms of 
intrinsic and acquired resistance to these agents in SCCL. Methods: The antitumor 
activity of AZD4547 and BAY116387 was screened in a panel of 12 SCCL cell lines, 
among which 4 cell lines harbored FGFR1 amplification. To investigate mechanisms 
of acquired resistance, FGFR1-amplified H1581 cells which were exquisitely sensitive 
to FGFR inhibitors, were exposed to AZD4547 or BAY116387 to generate polyclonal 
resistant clones (H1581-AR, H1581-BR). Characterization of these resistant clones was 
performed using receptor tyrosine kinase (RTK) array, immunoblotting and microarray. 
Migration and invasion assays were also performed. Results: Among 12 SCCL cell 
lines, two FGFR1-amplified cells, H1581 and DMS114, were sensitive to FGFR inhibitors 
(IC50<250 nmol/L). Compared with resistant cells, sensitive cells showed increased 
phosphorylation of FRS2 and PLC-γ, but decreased phosphorylation of STAT3. There 
was no noticeable difference in FGFR1-3 protein expression level between sensitive and 
resistant cells. Importantly, phosphorylation of ERK1/2 was significantly suppressed 
upon treatment of FGFR inhibitors only in sensitive cells, suggesting phospho-ERK1/2 as 
a pharmacodynamic marker of downstream FGFR signaling. RTK array and immunoblots 
demonstrated strong overexpression and activation of MET in H1581-AR and H1581-BR, 
in comparison to almost nil expression in parental cells. Four different SCCL cells with 
intrinsic resistance to FGFR inhibitors also showed intermediate to high MET expression, 
suggesting that MET may be involved in both intrinsic and acquired resistance to FGFR 
inhibitors. Gene-set enrichment analysis against KEGG database showed that cytokine-
cytokine receptor interaction pathway was significantly enriched, with MET contributing 
significantly to the core enrichment, in H1581-AR and H1581-BR, as compared with 
parental cells. Stimulation with HGF strongly activated downstream FGFR signaling or 
enhanced cell survival in the presence of FGFR inhibitors in both acquired and intrinsic 
resistant cells. Quantitative PCR on genomic DNA and fluorescent in situ hybridization 
revealed MET amplification in H1581-AR, but not in H1581-BR. MET amplification led to 
acquired resistance to AZD4547 in H1581-AR by activating ERBB3. The combination of 
FGFR inhibitors with ALK/MET inhibitor, crizotinib, or small interfering RNA targeting 
MET synergistically inhibited cell proliferation in both H1581-AR and H1581-BR, 
whereas it resulted in additive effects in SCCL cells with intrinsic resistance to FGFR 
inhibitors. Acquisition of resistance to FGFR inhibitors not only led to a morphologic 
change, but also promoted migration and invasion of resistant clones via inducing 
epithelial to mesenchymal transition phenotype, as documented by a decrease in 
AFA cells and not in PC9/gef, PC9/WZ cells. None of the PC9/WZ cells have EGFR C797S 
mutation. We did not detect any other EGFR resistance mechanism in PC9/AFA cells. 
Other of comparing EMT, autophagy and DNA repair capacity of PC9 and their resistant 
cells are ongoing. Conclusion: We developed multiple gefitinib, afatinib, WZ8040, 
AZD9291 resistant PC9 cells. Only afatinib resistant cells develop EGFR T790M. We 
demonstrated that EGFR T790M was the predominant resistant mechanism in PC9/AFA 
cells. The characteristics of PC9/WZ and PC9/AZD9291 are still under investigation. 
Keywords: EGFRTKI resistance, afatinib, WZ8040, AZD9291
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Resistance to the EGFR Mutant Selective Inhibitor Rociletinib (CO-1686) 
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Thomas C. Harding Translational Medicine, Clovis Oncology, San Francisco/United States 
of America
Background: Rociletinib (CO-1686) is a novel, oral, irreversible tyrosine kinase inhibitor 
for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-
small cell lung cancer (NSCLC) that has demonstrated efficacy against the activating 
mutations (L858R and del19) and the dominant acquired resistance mutation (T790M), 
while sparing wild-type (WT) EGFR. Although rociletinib has generated compelling 
objective responses in heavily-pretreated T790M positive and negative NSCLC 
patients, acquired resistance to rociletinib monotherapy has also been observed. 
We are currently exploring preclinical combinations to delay or prevent resistance to 
rociletinib. Methods: To study acquired resistance in an unbiased fashion, rociletinib 
resistant populations and clones were generated from the EGFR mutant NSCLC cell lines 
PC-9 (del19 EGFR), HCC827 (del19 EGFR), and NCI-H1975 (L858R/T790M EGFR) by 
chronic in vitro and/or in vivo exposure of rociletinib. Compound library screening was 
performed with rociletinib resistant cell lines to identify drug combinations that could 
restore rociletinib sensitivity. In vitro and in vivo validation, mechanism of action, and 
combination studies were performed to evaluate the potency of these combinations in 
rociletinib sensitive and resistant preclinical models. In addition, combination studies 
with therapies commonly used in NSCLC, including radiotherapy (RT), an anti-EGFR 
antibody, and anti-PD-1/L1 antibodies were also explored. Results: Multiple mechanisms 
of resistance were observed in rociletinib resistant cell lines, including MET amplification 
and an epithelial-mesenchymal transition (EMT). In a PC-9 resistant population 
(designated 2A10) generated by in vitro and in vivo selection, multiple agents including 
the aurora kinase inhibitor MLN8237, the MEK inhibitor trametinib, and an anti-EGFR 
antibody restored rociletinib sensitivity in cell viability assays. Western blot analysis 
demonstrated that the levels of p-ERK in the parental PC-9 cell line were comparable to 
p-ERK levels in 2A10 cells grown in the presence of 1 mM rociletinib. The combination of 
rociletinib and trametinib in the 2A10 cell line suppressed p-ERK signaling, concomitant 
with increased levels of apoptotic markers such as PARP cleavage. The combination of 
rociletinib and trametinib also demonstrated potent in vivo activity in the 2A10 xenograft 
model. In vitroand in vivo studies performed with additional cell lines and combinations 
are ongoing and will also be presented. Conclusion: Resistance to all 3rd generation 
EGFR inhibitors is likely to be observed, and identifying tolerable and effective 
combinations to delay or prevent resistance is critical in extending the clinical benefit of 
these therapies. In vitroand in vivo studies reported here highlight multiple combinations 
that restore the activity of rociletinib in rociletinib resistant models. In particular, the 
combination of trametinib and rociletinib restored MAPK pathway suppression and anti-
tumor activity in the rociletinib resistant 2A10 model. These nonclinical data support 
the ongoing Phase 1/2 evaluation of the combination of trametinib and rociletinib. 
Keywords: EGFR, T790M, Resistance, NSCLC
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MINI09.06 Oncogenic Drivers including RET and ROS1 plus PTEN Loss and 
MET by IHC in Patients with Lung Adenocarcinomas: Lung Cancer Mutation 
Consortium 2.0 Bruce E. Johnson1, Mark G. Kris2, IgnacioI. Wistuba3, Lynne Berry4, 
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type and LKB1 mutant NSCLC (p<0.05 and fold-change ≥ or ≤1.5). LKB1 mutant cell 
lines showed higher protein expression of phospho-cKIT, a tyrosine-kinase receptor 
involve in cell proliferation and angiogenesis, and CA12 (Carbonic anhydrase 12), a 
known HIF-1α regulated molecule, involved in maintaining cellular pH homeostasis. Also, 
LKB1 mutant cells exhibit different quantitative vascular patterns in matrigel assays like 
number of nodes, junctions, length and branching of the endothelial matrix (p<0.05). 
Human endothelial cells exhibited an increase rate of proliferation and migration when 
incubated with conditioned medium from LKB1 mutant NSCLC cell lines compared with 
conditioned media from LKB1-wild type NSCLC cell lines (p<0.05). Conclusion: There 
are biological differences in vasculature patterns in LKB1 mutant NSCLC tumors 
and in LKB1 mutant cell lines comparing with wild-type LKB1. These differences are 
translated in biological alterations of human endothelial cells in vitrosuggesting 
an important role of LKB1 in resistance to anti-angiogenic treatments in vivo. 
Keywords: angiogenesis, LKB1, NSCLC, Bevacizumab resistance
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MINI09.11 Adaptor Re-Programming and Acquired Resistance in RET-Fusion 
Positive NSCLC Sarah Nelson, Laura Schubert, Anh T. Le, Karen A. Ryall, Severine 
Kako, Aik-Choon Tan, Marileila Varella-Garcia, Robert C. Doebele Division of Medical 
Oncology, University of Colorado Som, Aurora/CO/United States of America
Background: RET gene fusions were identified as a novel oncogenic driver of ~1-2% 
of non-small cell lung cancer (NSCLC) patients and clinical trials investigating the use 
RET TKI therapy are underway. Like all NSCLC patients treated with TKI therapies, it is 
expected that drug resistance will emerge in this patient population. The mechanisms 
that drive acquired resistance to RET TKI therapy are still unknown. The objective of this 
study is to advance current understanding of RET signaling in NSCLC and to identify the 
cellular mechanisms of acquired RET TKI resistance that will eventually emerge in RET 
fusion positive NSCLC patients by using in vitro models of drug resistance. Methods: 
The LC-2/ad is a lung adenocarcinoma cell line that harbors the CCDC6-RET fusion. 
We created three distinct ponatinib resistant (PR) LC-2/ad cell lines (PR1, PR2, PR3) 
derived from three different dose-escalation strategies. RET break-apart fluorescence in 
situ hybridization (FISH) was performed on the parental LC-2/ad and PR-derivatives. 
Interactions between the RET kinase domain and known adaptor signaling molecules were 
assessed via proximity ligation assay (PLA) in parental LC-2/ad cells and resistant lines. 
Formation of RET-adaptor signaling complexes were confirmed via immunoprecipitation 
and western blot analysis. Next-generation RNA sequencing in conjunction with a high-
throughput small molecule inhibitor screen were performed to elucidate the signaling 
pathways that drive resistance to RET-inhibition. Pathways and candidate molecules 
identified by these screens were validated using siRNA knockdown and pharmacologic 
inhibition in the context of a cell-proliferation MTS assay. Western blot analysis was 
utilized to identify the downstream signaling programs responsible for proliferation and 
survival in the RET-inhibition resistant cell lines. Results: MTS cell proliferation assay 
confirmed that all three ponatinib resistant cell lines are significantly less sensitive to 
ponatinib than parental LC-2/ad cells. RET FISH analysis demonstrated that the CCDC6-
RET gene was retained in the PR1 and PR2 cell lines, but lost in the PR3 cell line. RT-PCR 
and western blot analysis confirmed the loss of the CCDC6 -RET fusion in the PR3 cell line. 
DNA sequencing demonstrated no RET kinase domain mutations in either the PR1 or PR2 
derivatives. Further, profound changes in the RET-signaling program have emerged in the 
PR1 and PR2 cell lines. Using a RET-GRB7 PLA, we have demonstrated that PR1 cells no 
longer form RET-GRB7 signaling complexes, while PR2 cells retain RET-GRB7 complexes 
even in the presence of ponatinib. Next-generation RNA sequencing of the PR1 cell line 
revealed an increase in expression of several known EMT markers including caveolin-1, 
vimentin, and ADAMTS1. Conclusion: Like many other targeted therapeutic strategies, 
resistance to small molecule Ret-inhibition in RET-fusion positive lung cancer cells can 
be driven by multiple mechanisms. Changes in the RET-adaptor programming appear 
to mitigate resistance in both the PR1 and PR2 cell lines, suggesting that RET-resistant 
cells may have successfully undergone an oncogenic switch to rely upon another known 
oncogenic driver in lieu of the CCDC6-RET fusion. Further, EMT reprogramming of the 
LC-2/ad cell may have contributed to the resistance phenotype in the PR1 cell line. 
Keywords: Ponatinib, RET, Acquired resistance, fusion oncogene
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MINI09.12 HDAC Inhibitors Overcome New Generation EGFR-TKI-Resistance 
Caused by Homozygous BIM Polymorphism in EGFR Mutant Lung Cancer  
Seiji Yano1, Azusa Tanimoto1, Shoko Arai1, Koji Fukuda1, Sin T. Ong2, Shinji Takeuchi1 
1Kanazawa University Cancer Research Institute, Kanazawa/Japan, 2Duke National University 
of Singapore, Singapore/Singapore
Background: The BIM deletion polymorphism in intron 2 was found in a significant 
percent (~13%) of the Asian population, with 0.5% of individuals being homozygous for 
this deletion. Patients with EGFR mutant lung cancers harboring this BIM polymorphism 
have shorter progression free survival and overall response rates to 1st generation 
EGFR-TKIs, gefitinib and erlotinib. We recently reported that the histone deacetylase 
(HDAC) inhibitor vorinostat can epigenetically restore BIM function and death sensitivity 
of EGFR-TKI, in cases of EGFR mutant lung cancer where resistance to 1st generation 
EGFR-TKI is associated with a heterozygous BIM polymorphism. Here, we examined 1) 
whetherBIM polymorphism associated with resistance to new generation EGFR-TKIs and 
2) whether vorinostat could overcome EGFR-TKI resistance in EGFR mutant lung cancer 
cells with a homozygous BIM polymorphism. Methods: We used EGFR mutant lung cancer 
cells lines, PC-9, PC-9i2BIM-/- (a genetically engineered subclone that was homozygous 
for BIM deletion polymorphism), and PC-3 (heterozygous for BIM deletion polymorphism). 
E-cadherin and an increase in N-cadherin and vimentin. Conclusion: MET activation 
is sufficient to bypass dependency on FGFR signaling and concurrent inhibition 
of these two pathways may be desirable when targeting FGFR-dependent SCCL. 
Keywords: FGFR inhibitor, Acquired resistance, Squamous cell carcinoma of the lung, 
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MINI09.08 Secondary C805S Mutation in HER2 Gene Confers Acquired 
Resistance to HER2 Kinase Inhibitors in HER2 Mutant Lung Cancer Takayuki 
Kosaka, Hideki Endoh, Claire Repellin, Junko Tanizaki, Dalia Ercan, Marzia Capelletti, 
Pasi A. Jänne Department of Medical Oncology, Dana-Farber Cancer Institute, Boston/MA/
United States of America
Background: Activating mutations in the HER2 kinase domain are detected in 2-4% 
of non-small cell lung cancers (NSCLC), and are oncogenic in both in vitro and in vivo 
models. Current clinical strategies to target mutant HER2 include the use of covalent 
HER2 inhibitors afatinib, dacomitinib and neratinib; all of which have limited single 
agent activity. We evaluated how drug sensitive models of HER2 mutant lung cancer 
develop acquired resistance in vitro to gain biological insights and to predict how 
acquired resistance may develop in the clinic. Methods: Murin Ba/F3 cells expressing 
duplication/insertion of four amino acids (YVMA) between codon 775 and 776 in exon 
20 of HER2gene (A775_G776insYVMA (insYVMA)) were exposed to N-ethyl-N-nitrosourea 
mutagenesis and expanded in the presence of neratinib and dacomitinib. Total RNAs were 
extracted from resistant clones and sequencing of the HER2 tyrosine kinase domain was 
performed. Drug resistance was confirmed with cell growth assays and western blotting. 
Results: Total 5 clones for Neratinib and 7 clones for Dacomitinib were expanded from 
each 300 wells. Sequencing analysis revealed that all resistant clones retained original 
insertion mutation and acquired same substitution of Cysteine to Serine change in codon 
805 (C805S) in exon 20 of HER2 gene. This mutation is analogous to the EGFRC797S 
mutation that mediates resistance to 3rd generation EGFR inhibitors. Next, we 
generated Ba/F3 cells co-expressing activating mutations; insYVMA and a dacomitinib 
hypersensitive insertion mutation (insertion of three amino acids (WLV) after codon 774 
with deletion of M774 (M774del insWLV (insWLV))), in cis with the C805S mutation. Cell 
growth assay revealed these double mutants were resistant to all three second generation 
inhibitors for EGFR family; neratinib, dacomitinib, and afatinib, compared to parental 
cells which only have activating mutation. They were also resistant to 3rd generation 
EGFR inhibitors; WZ40002 and AZD9291. Phosphorylation of HER2 was not completely 
inhibited by these drugs. Resistant cells showed moderate sensitivity to mTOR inhibitor; 
rapamycin alone. Combination treatment with afatinib and rapamycin effectively 
inhibited growth of these cells. Conclusion: The C805S secondary HER2 mutation 
results in acquired resistance to covalent HER2 inhibitors in HER2 mutant NSCLC. 
Our results provide insights into drug resistance mechanisms and help predict likely 
clinical mechanisms of resistance to HER2 targeted therapies in HER2 mutant NSCLC. 
Keywords: HER2, NSCLC, Acquired resistance, Target therapy
DRUG RESISTANCE 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI09.10 Tumor Angiogenesis in LKB1-Mutant Non-Small Cell Lung Cancer 
(NSCLC) Irene Guijarro1, Monique Nilsson1, Alissa Poteete1, Pan Tong2, Huiying Sun1, 
Warren Denning1, Dianren Xia1, Ferdinandos Skoulidis1, Jing Wang2, Emily Roarty1, John 
V. Heymach1 1Thoracic, Head & Neck Medical Oncology, The University of Texas M. D. 
Anderson Cancer Center, Houston/TX/United States of America, 2Bioinformatics & Comp 
Biology, The University of Texas M. D. Anderson Cancer Center, Houston/TX/United States 
of America
Background: LKB1 is a critical regulator of cell growth, metabolism and EMT, and it is 
mutated in 20-30% of non-small cell lung cancers (NSCLC). LKB1 mutations co-occur 
with KRAS-activating mutations in 7%-10% of all NSCLC and results in an aggressive 
phenotype and a worse response to chemotherapy compared to KRAS-mutated tumors. 
Because LKB1 activates AMPK (AMP-activated protein kinase) which functions as a 
cellular energy sensor, LKB1-deficient cells are unable to appropriately sense metabolic 
and energetic stress. LKB1 is also known to regulate angiogenesis, but the mechanism(s) 
by which this occurs remains unclear. Bevacizumab, the human anti-VEGF antibody 
approved for the treatment of NSCLC, improves the progression-free and overall survival 
of NSCLC patients combined with chemotherapy, but often the benefit is transient, and 
therapeutic resistance occurs. Our laboratory has previously identified phenotypical 
differences in vasculature patterns in A549 NSCLC tumors resistant to bevacizumab 
(LKB1 mutant), when compared to H1975 tumors, (LKB1 wild-type). In addition, LKB1 
mutant NSCLC cell lines are highly vulnerable to agents acting on energetic pathways. 
These results may indicate that loss of LKB1 in NSCLC could alter the tumor vasculature 
and regulate sensitivity to anti-angiogenic therapies. Here, we investigate the hypothesis 
that combinations of energetic-depleting compounds along with blockade of tumor 
angiogenesis would be more effective in NSCLC LKB1 mutant tumors. Methods: mRNA 
and protein expression of 584 angiogenesis-related genes were analyzed in wild-type 
and LKB1 mutant NSCLC (TCGA, RPPA and PROSPECT databases). In vitrovalidation 
was performed using qPCR, immunohistochemistry and western blot analysis as well 
as pairs of isogenic LKB1 mutant cell lines with overexpressed or silenced LKB1. 
Endothelial cells were incubated with conditioned medium of wild-type and LKB1 mutant 
NSCLC cell lines, and tube formation matrigel, proliferation and migration (Boyden 
chamber) assays were performed. Results: We identify a group of new and classic 
angiogenesis-related molecules: VEGFA, VEGFR1, KDR, NRP1, PDGFB, PDGFRA-B, HIF-1A, 
C-KIT, VCAM1, hypoxia related molecules: HIF1AN, EGLN1, HIF3A, CA12, EPAS1 and immune 
related molecules: TNFSF11, NFKB1, CD47, PDL1 differentially expressed in LKB1-wild 
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Background: Epidermal growth factor receptor (EGFR) and KRAS mutations, and 
echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase 
(ALK) translocation are generally considered to be mutually exclusive. However, some 
reports show that a number of patients may have concomitant mutations, and it is 
not yet clear what impact these double mutations could have on response to targeted 
therapy. Methods: We took into consideration 380 NSCLC patients who underwent non-
sequential testing for EGFR and KRAS mutations and EML4-ALK translocation between 
January 2010 and December 2013. EGFR mutation and EML4-ALK translocation analysis 
were performed on the entire case series and KRAS mutation analysis was performed 
on 282 cases. Results: EGFR mutation and EML4-ALK translocation were present in 44 
(11.6%) and 32 (8.4%) of patients, respectively. Ninety-two patients (32.6%) showed a 
KRAS mutation. Two concomitant mutations among EGFR, KRAS or EML4-ALK genes 
were observed in 16 patients. In particular, 6 of the 380 (1.6%) patients analyzed had 
concomitant EGFR mutation and EML4-ALK translocation. Of the 282 patients who also 
underwent KRAS mutation, 3 (1.1%) showed a concomitant EGFR and KRAS mutation 
and 7 (2.5%) a concomitant EML4-ALK and KRAS alteration. Of the 44 EGFR-mutated 
patients, 28 received a TKI-based treatment (24 with gefitinib and 4 with erlotinib) as 
first-line therapy, and 6 of these also had an EML4-ALK translocation. Among the 22 
patients with EGFR mutation only, we observed 2 complete response (CR) (9%), 16 
partial response (PR) (72.7%) and 4 progressive disease (PD) (18%). Of the 6 patients 
who also had an EML4-ALK translocation, one had CR (17%), 3 PR (50%) and 2 PD 
(33%). No differences were seen in terms of overall survival (OS). Of the 32 patients 
harboring the EML4-ALK translocation, 6 (those also carrying the EGFR mutation) 
were treated with a TKI as first-line therapy, while the others received chemotherapy. 
Twelve patients received crizotinib as second-line treatment and 7 progressed within 
3 months of starting therapy. Of these, 2 showed a concomitant KRAS mutation 
(G12C) and one a concomitant EGFR mutation (exon 19 del). Two patients had stable 
disease, one of whom also showed a KRAS mutation (G12V). Two patients had PR and 
one had CR, all of whom showed a EML4-ALK translocation only. The median OS of the 
patients carrying an EML4-ALK translocation alone or a concomitant KRAS mutation 
was 57.1 (range 10.7-nr) and 10.7 (range 4.6-nr) months, respectively. Conclusion: The 
concomitant presence of EGFR, EML4-ALK or KRAS mutations is a possible event 
in NSCLC. KRAS mutation in patients with EML4-ALK translocation represents 
the most common double mutation and seems to confer a poor prognosis. 
Keywords: KRAS, EML4-ALK, Double mutations, EGFR
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MINI10.02 Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR 
Co-Altered Lung Adenocarcinoma Weijing Cai1, Caicun Zhou1, Dongmei Lin2, 
Chunyan Wu3, Xuefei Li1, Chao Zhao1, Limou Zheng4, Ke Fei5, Fred R. Hirsch6 1Medical 
Oncology, Shanghai Pulmonary Hospital, Shanghai/China, 2Beijing Cancer Hospital, Beijing/
China, 3Pathology, Shanghai Pulmonary Hospital, Shanghai/China, 4Translational Medical 
Center, Xiamen University, Xiamen/China, 5Thoracic Surgery, Shanghai Pulmonary Hospital, 
Shanghai/China, 6Departments of Medicine and Pathology, University of Colorado Cancer 
Center, Aurora/CO/United States of America
Background: Genetic intratumoral heterogeneity has a profound influence on the 
selection of clinical treatment strategies and addressing resistance to targeted 
therapy. The purpose of our study is to explore the potential effect of intratumoral 
heterogeneity on both the genetic and pathologic characteristics of ALK-rearranged 
lung adenocarcinoma (LADC). Methods: We tested ALK fusions and EGFR mutations in 
629 LADC patients by using laser capture microdissection (LCM) to capture spatially 
separated tumor cell subpopulations in various adenocarcinoma subtypes and test 
for ALK fusions and EGFR mutations in ALK-rearranged, EGFR-mutated, and ALK/EGFR co-
altered LADCs in order to compare the oncogenic driver status between different tumor 
cell subpopulations in the same primary tumor. Results: Among the 629 patients, 
30 (4.8%) had ALK fusions, 364 (57.9%) had EGFR mutations, and 2 had ALK fusions 
coexisting with EGFR mutations. Intratumoral heterogeneity of ALK fusions was identified 
in 9 patients by RT-PCR. In the 2 ALK/EGFR co-altered patients, intratumoral genetic 
heterogeneity was observed both between different growth patterns and within the same 
growth pattern. Genetic intratumoral heterogeneity of EGFR mutations was also identified 
in EGFR-mutated NSCLC. ALK fusions were positively associated with a micropapillary 
pattern (P=0.002) and negatively associated with a lepidic pattern (P=0.008) in a 
statistically-expanded analysis of 900 individual adenocarcinoma components, although 
they appeared to be more common in acinar-predominant LADCs in the analysis of 629 
patients. Conclusion: Intratumoral genetic heterogeneity was demonstrated to co-exist 
with histologic heterogeneity in both single-driver and EGFR/ALK co-altered LADCs. 
As for the latter, one of the dual altered drivers may be the trunk-driver for the tumor. 
Keywords: ALK rearrangement, ALK/EGFR co-alteration, lung adenocarcinoma, 
Intratumoral Heterogeneity
These cell lines were treated with gefitinib, afatinib (2nd generation), and AZD9291 
(3rd generation). Apoptosis was evaluated by FACS and expression of cleaved-caspase 
3/7 and PARP by western blot. Results: While PC-9 cells were sensitive to all EGFR-TKIs 
in terms of apoptosis induction, both of PC-3 and PC-9i2BIM-/- cells were resistant to 
1st generation EGFR-TKIs and new generation EGFR-TKIs as well. Vorinostat combined with 
new generation EGFR-TKIs induced apoptosis of PC-3 and PC-9i2BIM-/- cells in vitro. In the 
subcutaneous tumor model, AZD9291 regressed the tumors produced PC-9 cells but not 
PC-9i2BIM-/- cells, indicating in vivo resistance of PC-9i2BIM-/- cells to EGFR-TKIs. Combined 
use of vorinostat with AZD9291 successfully decreased the size of tumors produced 
by PC-9i2BIM-/- cells by inducing tumor cell apoptosis. Conclusion: These observations 
indicated that BIM deletion polymorphism is associated with apoptosis resistance caused 
not only by 1st generation EGFR-TKIs but also by new generation EGFR-TKIs. Moreover, 
combined use of HDAC inhibitor may overcome EGFR-TKI resistance associated not 
only with heterozygous deletion but also with homozygous deletion in the BIM gene. 
Keywords: EGFR-TKI resistance, HDAC inhibitors, EGFR mutation, BIM polymorphism
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MINI09.13 Neuropilin-2 Promotes Acquired Resistance to EGFR-TKI Associated 
with the Epithelial–Mesenchymal Transition in Lung Cancer Patrick Nasarre1, 
Joyce Nair-Menon1, Anastasios Dimou1, Takeshi Yoshida2, Hidetaka Uramoto3, Eric 
Haura4, Robert M. Gemmill1, Harry A. Drabkin5 1Medicine, Medical Univ. of South Carolina, 
Charleston/SC/United States of America, 2Medical Oncology, Kinki University Faculty of 
Medicine, Osaka-Sayama/Japan, 3Surgery, Univ. of Occupational & Environ. Health, Fukuoka/
Japan, 4Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa/United 
States of America, 5Medicine, Medical Univ. of South Carolina, Charleston/United States of 
America
Background: Lung cancer accounts for one-fifth of cancer deaths worldwide with 
invasion, metastases and drug resistance representing major causes of mortality and 
barriers to cure. While lung cancers with activating mutations in the EGF receptor (EGFR) 
are susceptible to tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib, the 
efficacy of these agents is limited by the inevitable development of resistance. The 
epithelial-mesenchymal transition (EMT), by which epithelial cells acquire a mesenchymal 
and invasive phenotype, is one mechanism promoting EGFR-TKI resistance, including 
resistance to 3rd generation T790M-specific inhibitors. However, the molecular 
connections between EMT and resistance are not well understood. Here we report that 
upregulation of Neuropilin-2 (NRP2) is crucial for development of EGFR-TKI resistance 
associated with the EMT. NRP2 is a cell surface receptor for SEMA3F, a secreted 
semaphorin with tumor suppressor activity that is down-regulated during EMT. NRP1 
and NRP2 are also co-receptors and signaling enhancers for several growth-promoting 
ligands such as VEGF, HGF and FGF. We previously reported that NRP2 was induced by 
TGFβ as part of an EMT response in lung cancers and that NRP2 knockdown suppressed 
the EMT phenotype, including local tumor invasion in a subcutaneous xenograft 
model. Methods:Immunohistochemistry (IHC) was performed for NRP2 on patient 
biopsies, before and after development of gefitinib resistance. EGFR mutant NSCLC cell 
lines, transfected with control or NRP2-specific shRNAs, were selected for gefitinib/
erlotinib resistance in vitro, using progressively increasing concentrations or continuous 
exposure to IC50 levels of EGFR TKIs. Western blot analysis confirmed changes in NRP2 
expression along with selected markers of EMT. MTS viability assays determined 
drug sensitivity while migration and invasion were assessed using Boyden chambers. 
Growth as spheroids was assessed in 1% methylcellulose medium in low-adherence 
plates. Results: Increased NRP2 was observed in lung tumor biopsies following acquisition 
of EMT-associated gefitinib-resistance, and in HCC4006-ER cells, which acquired a stable 
erlotinib-resistant EMT phenotype. In vitro, using multiple EGFR mutant cell lines, NRP2 
knockdown blocked acquired gefitinib-resistance, arising both spontaneously following 
growth in IC50concentrations or after exposure to TGFβ. Of interest, spontaneously-
resistant cells exhibited increased migration similar to cells stimulated with TGFβ. 
NRP2 knockdown also blocked tumorsphere formation, which has been associated 
with stem-cell characteristics and drug resistance. Conclusion: Collectively, our 
results demonstrate that NRP2 is a mediator of acquired EGFR-TKI resistance. The 
results also suggest that NRP2 blocking antibodies could be useful for enhancing the 
duration of response to EGFR inhibitors, including those targeting the T790M mutation. 
Keywords: neuropilin-2, SEMA3F, EGFR-TKI resistance, epithelial-mesenchymal transition
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MINI10.01 Frequency of Concomitant EGFR, EML4-ALK or KRAS Alterations in 
NSCLC Patients and Correlation with Response to Treatment Paola Ulivi1, Elisa 
Chiadini1, Claudio Dazzi2, Alessandra Dubini3, Matteo Costantini3, Laura Medri3, Maurizio 
Puccetti4, Laura Capelli1, Daniele Calistri1, Alberto Verlicchi2, Alessandro Gamboni5, 
Maximilian Papi6, Marita Mariotti7, Nicoletta De Luigi7, Emanuela Scarpi8, Sara 
Bravaccini1, Gian Michele Turolla9, Dino Amadori7, Lucio Crinò10, Angelo Delmonte7 
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showed positive protein expression. High ALK gene expression was observed in all four 
ALK-FISH rearranged samples with matching microarray or RNA-seq data. Of five patients 
with positive protein expression, only three (83%) showed high gene expression levels 
according to gene expression microarray and RNA-seq data. RNA-seq revealed that 
2/202 samples were ALK rearranged, both of which were detected by FISH and IHC. One 
sample that was not rearranged according to RNA-seq-data did, however, demonstrate 
rearrangement with FISH. Conclusion: The overall frequency of ALK rearrangements in 
this NSCLC cohort was lower than previously reported, with a significant but variable 
correlation on different molecular levels. It is possible that technical issues with regard 
to the use of TMAs, where only a fraction of the whole tumor is represented, may have 
hampered the results. Therefore, the FISH and IHC analysis will be complemented with 
assessments on whole tissue sections. The discordant results also stress the need for 
careful validation of these methods before they can be implemented in the clinical practice. 
Keywords: NSCLC, ALK, IHC, Gene Expression
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MINI10.06 Incidence of ALK Gene Rearrangements in a Prospectively, 
Consecutively Collected Caucasian Population with Pulmonary 
Adenocarcinomas Birgit G. Skov1, Jens B. Soerensen2, Klaus R. Larsen3, Paul 
Clementsen4, Anders Mellemgaard5 1Department of Pathology, Copenhagen University 
Hospital, Rigshospitalet, Copenhagen/Denmark, 2Department of Oncology, Copenhagen 
University Hospital, Rigshospitalet, Copenhagen/Denmark, 3Department of Pulmonary 
Medicine, Bispebjerg University Hospital, Copenhagen/Denmark, 4Department of Pulmonary 
Medicine, Copenhagen University Hospital, Gentofte/Denmark, 5Department of Oncology, 
Herlev University Hospital, Herlev/Denmark
Background: EML4-ALK oncogene fusion in non- small cell lung cancer, identifies 
patients sensitive to ALK-targeted inhibitors. Estimates of the frequency of this fusion 
oncogene rearrangement are primarily available from selected patient cohorts. The 
true incidence in an unselected Caucasian population is unknown. This study assess the 
incidence of ALK rearrangement in a population based cohort, together with correlation 
to gender, age, smoking habits, as well as pathological and clinical. Methods: All patients 
in a well-defined catchment area of 1.7 million people in the capital region of Denmark 
diagnosed with pulmonary adenocarcinomas from April 1. 2013 to July 31. 2014 were 
prospectively included. The type and location of the diagnostic material, and data on 
smoking and clinical characteristics were registered. The rearrangement analyses 
were investigated by up-front analysis with immunohistochemistry (IHC) using clone 
5A4 Novocastra and all IHC positive tests were also subsequently tested by FISH using 
Zytovision, spec. ALK Dual Color Break Apart. Results: Among 797 patients included in 
this study, 777 patients (97.5%) patients had sufficient material for mutation analysis. 
Fourteen patients (1.8%, 95% CI 1.1-3.0) were IHC positive, all with 3+ reaction. All but 
one of these were also FISH positive. Eight patients (57%) were women. Median age was 
62.7 years. All tumors were strongly TTF1 positive with mucin present in the cytoplasm 
of the malignant cells without dominance of any subtype. Ten patients (71.4) were 
diagnosed in stage IIIa or higher. Nine patients (64.3%) were never smokers, 3 (21.4%) 
were light smokers (0.5-10 yrs), 2 (14.3 %) were heavy smokers (25-40 yrs). More than 
1/3 (36%) of the analyses were done on cytological, cellblock material. Seven patients 
had localized or locally advanced disease and did not receive crizotinib. Among seven 
patients with advanced disease, six received crizotinib with one complete response in 
a light smoker (male) and three partial responses in two never and one light smoker 
(response rate 67%). One out of three females receiving crizotinib achieved a response 
while it was three out of three males. No heavy smokers received crizotinib despite an 
ALK translocation was identified. Median progression free survival for patients receiving 
crizotinib was 3.4 months (range 0-20 months). Conclusion: ALK rearrangement 
analysis was possible in 97.5% of all patients with pulmonary adenocarcinomas. 1.8% 
had a positive test. Rearrangements were primarily found in never/light smokers. No 
difference in gender regarding rearrangement status was observed. Response rate 
to crizotinib was 67% and was in this study more frequent in males than in females 
(not significant). Chance of response was equal in light and in never smokers. 
Keywords: Pulmonary adenocarcinom, ALK translocation, Incidence, unselected 
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MINI10.07 Lung Adenocarcinomas Co-Expressing TTF-1, MUC5B and/or 
MUC5AC Show a High Incidence of ALK Rearrangement and a Poor Prognosis 
Dongmei Lin1, Wei Sun2 1Key Laboratory of Carcinogenesis and Translational Research 
(Ministry of Education), Department of Pathology, Peking University Cancer Hospital & 
Institute, Beijing/China, 2Peking Union Medical College, Cancer Institute and Hospital of the 
Chinese Academy of Medical Sciences, Beijing/China
Background: The lung adenocarcinomas can be divided into terminal respiratory unit 
(TRU) and non-TRU types, as these tumors frequently show distinctive morphologic and 
gene expression characteristics. Tumors co-expressing thyroid transcription factor-1 
(TTF-1) and mucins MUC5B and/or MUC5AC exhibit intermediate morphology between 
TRU-type and non-TRU-type adenocarcinomas. Few studies have focused on this type of 
adenocarcinoma. Methods: 176 patients with lung adenocarcinoma were retrospectively 
reviewed. The tumors were divided into TRU type, non-TRU and the intermediate type by 
morphology and immunohistochemistry (TTF-1, MUC5B, MUC5AC). The expression of 
Napsin-A, CK20, epidermal growth factor receptor (EGFR) mutation and anaplastic 
lymphoma kinase (ALK) rearrangement were also evaluated. Results: TTF-1, MUC5B, 
MUC5AC, Napsin-A and CK20 were detected in 157 (89.2%), 52 (29.5%), 10 (5.7%), 143 
(81.3%), and 10 (5.7%) patients, respectively. EGFR mutation and ALK rearrangement 
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MINI10.03 Evolution of Concurrent Driver Mutations in Lung Adenocarcinoma 
Patients on EGFR TKI Therapy Uncovered by Comprehensive Molecular 
Profiling Collin M. Blakely1, Saurabh Asthana1, Evangelos Pazarentzos1, Victor Olivas1, 
Luping Lin1, Jennifer Flanagan1, Aleah Caulin2, Petros Giannikopoulos2, Trever Bivona1 
1Medicine, UCSF, San Francisco/United States of America, 2Driver Group, San Francisco/CA/
United States of America
Background: Lung adenocarcinoma (LAC) patients (p) with EGFR mutations respond 
initially to EGFR tyrosine kinase inhibitors (TKIs) but invariably develop acquired EGFR 
TKI resistance. Prior studies identified the EGFR T790M mutation and activation of 
MET, NF-kB, PI3K, AXL, HER2 and the MAPK pathway as drivers of acquired EGFR TKI 
resistance. We hypothesized that tumor cell populations present pre-treatment harbor 
mechanisms of EGFR TKI resistance that are subsequently selected for by EGFR TKI 
therapy. Methods: We performed longitudinal comprehensive molecular tumor profiling 
on 10 p with metastatic EGFR-mutant LAC throughout the course of their disease. Exome 
sequencing to a mean depth of coverage of 100 X, was performed on FFPE or frozen 
patient tumor specimens as well as matched normal control specimens collected from 
patients prior to initiating standard erlotinib (erl) treatment, upon the development of 
erl resistance, and upon resistance to subsequent 2nd line therapy when available. One 
case of a patient with acquired resistance to the 3rd generation EGFR TKI Rociletinib 
was analyzed. We performed functional analysis of select mutations identified using 
established cellular models of EGFR-mutant LAC. Results: We constructed phylogenetic 
trees based on somatic mutations and copy number alterations identified by exome 
sequencing of longitudinally acquired patient specimens. Activating mutations (L858R 
or exon 19 deletion) were present in all tumor specimens analyzed, indicating that this 
is a ‘truncal’ event. We identified on-target mutation in EGFR (T790M) in ~ 50% of erl 
resistant specimens as expected. However, in three patients we identified concurrent low 
frequency oncogenic driver events pre-EGFR TKI treatment that subsequently increased 
in frequency upon erlotinib resistance. This included: 1) a BRAF V600E mutation that 
was detected pre-treatment at a low frequency that expanded in the erlotinib resistant 
tumor specimen; 2) a PIK3CA G106V mutation that was not present in a patient’s primary 
tumor, but developed in a lymph node metastasis at a low frequency and subsequently 
expanded in the erlotinib resistant tumor, and 3) a pre-treatment KRAS amplification that 
was found in a patient with de novo resistance to erlotinib. The functional significance 
of these mutations in driving tumor growth and EGFR TKI resistance will be discussed. 
We will also present exome sequencing analysis from multiple tumors (including a CNS 
and spinal metastasis) collected from the autopsy of a patient with initial response, but 
rapid development of acquired resistance to Rociletinib. Conclusion: These results 
indicate that EGFR-mutant LAC can harbor additional oncogenic driver mutations at low 
frequencies prior to therapy. EGFR TKI treatment can lead to expansion of these subclonal 
populations likely contributing to EGFR TKI resistance in patients with or without the 
EGFR T790M resistance mutation. These data demonstrate the utility of comprehensive 
molecular profiling of LAC p on targeted therapy beyond assessing EGFR T790M 
mutational status, and suggest that pre-treatment tumor analyses can in some cases 
predict mechanisms of EGFR TKI resistance before they become clinically significant. 
Keywords: Tumor heterogeneity, TKI resistance, tumor evolution, EGFR
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MINI10.05 ALK Rearrangements in Non-Small Cell Lung Cancer: 
Comprehensive Integration of Genomic, Gene Expression and Protein Analysis 
Johanna S. M. Mattsson1, Maria A. Svensson2, Björn Hallström3, Hirsh Koyi4, Eva 
Brandén4, Hans Brunnström5, Karolina Edlund6, Simon Ekman7, Linnéa La Fleur7, 
Marianna Grinberg8, Jörg Rahnenführer8, Karin Jirström5, Fredrik Pontén7, Mats G. 
Karlsson2, Christina Karlsson2, Gisela Helenius2, Mathias Uhlén3, Johan Botling7, Patrick 
Micke1 1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala/
Sweden, 2Dept. of Pathology, Faculty of Medicine and Health, Örebro University, Örebro/
Sweden, 3Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm/
Sweden, 4Dept. of Respiratory Medicine, Gävle Hospital, Gävle/Sweden, 5Dept. of Clinical 
Sciences Lund, Division of Oncology and Pathology, Lund University, Lund/Sweden, 6Leibniz 
Research Centre for Working Environment and Human Factors (IfADo), Dortmund TU, 
Dortmund/Germany, 7Dept. of Immunology, Genetics and Pathology, Uppsala University, 
Uppsala/Sweden, 8Dept. of Statistics, Dortmund TU, Dortmund/Germany
Background: Identification of EML4-ALK fusion proteins has revolutionized the treatment 
of a subgroup of non-small cell lung cancer (NSCLC) patients. Although the gene inversion 
is regarded as the relevant event for therapy response, the relation between gene 
rearrangement, mRNA and protein levels has not been evaluated in detail. Thus, the 
objective of this study was to comprehensively define the molecular relations induced 
by ALK rearrangements in a large representative Swedish NSCLC cohort incorporating 
genomic, gene expression and protein data, as well as corresponding clinical 
correlates. Methods: ALK protein analysis was performed on 860 NSCLC patients (551 
adenocarcinoma, 224 squamous cell carcinomas, 85 large cell carcinomas/NOS) using 
immunohistochemistry (IHC) on tissue microarrays (TMAs), applying an established 
monoclonal ALK antibody (clone D5F3, Cell signaling). In parallel, ALK rearrangement was 
determined by fluorescent in situ hybridization (FISH, Abbott, Vysis ALK Break Apart FISH 
Probe Kit) on the same TMAs. A subgroup of patients was additionally analyzed utilizing 
gene expression microarrays (Affymetrix, n=194) or RNA-sequencing (n=202). The 
RNA sequencing data was also used to identify ALK gene fusions. Results: ALK protein 
expression was observed in 12/860 (1.4%). ALK rearrangement was detected in 11/860 
samples (1.3%) by FISH analysis. Of 194 patients evaluated by microarray, six (3.1%) 
showed high ALK gene expression and of 202 patients analyzed by RNA-seq, nine (4.5%) 
demonstrated high ALK transcript levels. Of the 11 FISH rearranged patients, eight (73%) 
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obtained through standard of care testing at multiple different institutions available 
for review. Of these 71 cases, 12 (17%) were negative for EGFR alterations, but were 
identified by CGP as harboring an exon 19 deletion. Of 14 cases with deletions affecting 
the C-Helix (753-761), 6 had previous EGFR testing results available for review, with 
5 (83%) cases having a prior negative result. For select cases clinical histories were 
reviewed, and the clinical benefit from treatment with small molecule inhibitors of EGFR 
was observed, consistent with historic norms, including EGFR 746-750 deleted patients 
responding to erlotinib and afatinib, a patient with EGFR T751_I759>N responding to 
afatinib, and a patient with EGFR S752_I759del having an ongoing 18 month response 
to erlotinib. Conclusion: CGP in the course of clinical care can identify EGFR exon 19 
deletions in NSCLC that may be missed by standard of care testing, including both the 
canonical 746-750 deletion as well as the less characterized C- Helix deletions. Tumors 
with either of these alterations that go undetected by standard testing but are identified 
by CGP can respond to anti-EGFR therapy. Given the proven improved extent and duration 
of tumor response and patient survival benefit conferred by anti-EGFR targeted therapy 
in patients whose NSCLC harbor EGFR exon 19 deletions, the 17% false negative rate 
in patients tested by standard hot spot assays is a concern. Further evaluation of 
the impact of the increased range and sensitivity of CGP to uncover EGFR alterations 
in NSCLC that have been missed by non-hybrid capture assays appears warranted. 
Keywords: exon 19 deletion, molecular testing, EGFR, NSCLC
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MINI10.10 A Multicenter Prospective Biomarker Study in Afatinib-Treated 
Patients with EGFR-Mutation Positive Non-Small Cell Lung Cancer Koichi 
Azuma1, Eiji Iwama2, Kazuko Sakai3, Kaname Nozaki4, Daijiro Harada5, Katsuyuki Hotta6, 
Fumiyoshi Ohyanagi7, Takayasu Kurata8, Hiroaki Akamatsu9, Koichi Goto10, Tatsuro 
Fukuhara11, Yoichi Nakanishi2, Isamu Okamoto12, Kazuto Nishio3 1Division of Respirology, 
Department of Internal Medicine, Kurume University School of Medicine, Kurume/Japan, 
2Kyushu University, Fukuoka/Japan, 3Department of Genome Biology, Kinki University Faculty 
of Medicine, Osaka-Sayama/Japan, 4Department of Thoracic Oncology, National Hospital 
Organization, Kyushu Cancer Center, Fukuoka/Japan, 5Department of Thoracic Oncology 
and Medicine, NHO Shikoku Cancer Center, Matsuyama/Japan, 6Department of Respiratory 
Medicine, Okayama University Hospital, Okayama/Japan, 7The Cancer Institute Hospital of 
Japanese Foundation for Cancer Research, Tokyo/Japan, 8Kansai Medical University Hirakata 
Hospital, Hirakata/Japan, 9Wakayama Medical University, Wakayama/Japan, 10Division of 
Thoracic Oncology, National Cancer Center Hospital East, Kashiwa/Japan, 11Department 
of Respiratory Medicine, Miyagi Cancer Center, Natori/Japan, 12Center for Clinical and 
Translational Research, Kyushu University Hospital, Fukuoka/Japan
Background: Afatinib is an oral, irreversible ErbB family blocker and one of the key drugs 
for patients with EGFR mutation positive advanced non-small cell lung cancer (NSCLC). 
Although treatment with afatinib has a clinical benefit for these patients, such individuals 
inevitably develop drug resistance as with other TKIs. This is a multicenter prospective 
biomarker study to inform the usefulness of noninvasive liquid biopsy in the treatment 
of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and explore the molecular mechanism of 
acquired-resistance against afatinib. Methods: Eligible patients were EGFR-TKIs naïve 
and had histologically and cytologically confirmed stage IIIB/IV adenocarcinoma of 
the lung with activating EGFR mutations. Patients remained on afatinib treatment until 
disease progression or unacceptable toxicity. Tumor samples were collected upon 
before afatinib treatment and after disease progression. Plasma samples were collected 
upon before and during afatinib treatment (4 and 24 weeks after initiation) and after 
disease progression. DNA derived both from tumors and plasma was analyzed using 
Scorpion-ARMS (ARMS), digital PCR (dPCR) and next generation sequencing (NGS). We 
used a nanofluidic dPCR system (BioMark HD System; Fluidigm) with a digital chip to 
detect activating or resistance mutations of EGFR in a quantitative and highly sensitive 
manner. NGS on an Ion Torrent PGM device (Thermo Fisher Scientific) was applied to 
detect target molecules which contribute to the survival and growth of lung cancer 
cells. We compared the sensitivity of these methods in detection of EGFR activating 
mutations in plasma DNA. Results: A total of 35 EGFR mutation positive NSCLC 
patients were enrolled. Twenty one patients harbored a deletion in exon 19 and fourteen 
patients had an L858R missense mutation in exon 21. Twenty seven (77.1%) patients 
had an objective response. In plasma DNA obtained before afatinib treatment, dPCR 
and NGS detected EGFR activating mutations more sensitively compared with ARMS 
(83.9% v 58.1%; p <0.005, 74.2% v 58.1%; p =0.059, respectively). Concordance 
of EGFR activating mutations detected by dPCR and NGS was 26/31 (84%) (kappa 
value: 0.52). All of the mutation type detected by NGS on plasma DNA completely 
corresponded to that found in matching tumor tissue by NGS. As of March 2015, serial 
plasma DNA was analyzed in 9 patients. The copy number of activating mutation was 
markedly decreased in 5 of 9 patients. Conclusion: EGFR activating mutations in 
plasma DNA were frequently detected by dPCR or NGS. We will present the detailed 
data for monitoring mutation load in plasma DNA during the afatinib treatment. 
Keywords: afatinib, plasma DNA, biomarker
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MINI10.11 Classification of EGFR Gene Mutation Status Using Serum Proteomic 
Profiling Predicts Tumor Response in Patients with Stage IIIB or IV NSCLC Lin 
Yang1, Chuanhao Tang1, Bin Xu2, Weixia Wang1, Jianjie Li1, Xiaoyan Li1, Haifeng Qin1, 
Hongjun Gao1, Kun He2, Santai Song3, Xiaoqing Liu1 1Department of Pulmonary Oncology, 
307 Hospital, PLA, Beijing/China, 2Institute of Basic Medical Sciences, National Center of 
Biomedical Analysis, Beijing/China, 3Cancer Center, 307 Hospital, PLA, Beijing/China
Background: Epidermal growth factor receptor (EGFR) gene mutations in tumors predict 
were present in 56 (31.8%) and 13 (7.4%) patients, respectively. 99, 44 and 33 patients, 
respectively, were defined as TRU-type, intermediate-type, and non-TRU-type by 
morphology and immunohistochemistry (Fig 1). A cribriform pattern and extracellular 
mucus were present in 44 (25.0%) and 38 (21.6%) patients, and the intermediate type 
was associated with a cribriform pattern and extracellular mucus morphologically, a 
transitional phenotype in Napsin-A and EGFR mutations (Fig 2). ALK rearrangement 
tumors were significantly associated with the expression of MUC5B (P = 0.026). The 
intermediate type present a higher incidence of ALK rearrangement compared with the 
other types (P = 0.005), which ALK rearrangement were detected in 8 of 44(18.2%) 
cases. There was no significant difference in prognosis between the morphological TRU 
and non-TRU types (P = 0.076). However, when the tumors were classfied into 3 groups, 
TRU type showed better prognosis than the other types (P = 0.038).
Conclusion: Tumors co-expressed TTF-1, MUC5B, and/or MUC5AC had a high incidence 
of ALK rearrangement and exhibited distinctive features in comparison with TRU-type and 
non-TRU-type adenocarcinomas.
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MINI10.09 Comprehensive Genomic Profiling Identifies EGFR Exon 19 Deletions 
in NSCLC Not Identified by Standard of Care Testing Alexa B. Schrock1, Siraj 
M. Ali1, Dana Herndon2, Garrett M. Frampton1, Joel Greenbowe1, Kai Wang1, Doron 
Lipson1, Roman Yelensky1, Zachary Chalmers1, Juliann Chmielecki1, Julia A. Elvin1, 
Mariane Wolner3, Rodolfo Bordoni4, Fadi Braiteh5, Addie Dvir3, Rachel Erlich1, Mohamed 
Mohamed2, Jeffrey S. Ross1, Philip J. Stephens1, Vincent Miller1 
1Foundation Medicine, Cambridge/MA/United States of America, 2Cone Health, Greensboro/
NC/United States of America, 3Teva Oncology, Petah Tikva/Israel, 4Georgia Cancer 
Specialists, Marietta/GA/United States of America, 5Comprehensive Cancer Centers of 
Nevada, Las Vegas/NV/United States of America
Background: Non-small cell carcinoma (NSCLC) cases harboring deletions in exon 19 
of EGFR typically respond to treatment with small molecule inhibitors of EGFR. Detection 
of EGFR deletions in routine clinical practice is performed using a large variety of assays 
and testing platforms, with varying performance characteristics that are often not readily 
available. Using a hybrid capture based comprehensive genomic profiling (CGP) assay we 
identified 250 consecutive NSCLC cases, obtained from a range of clinical institutions, 
harboring deletions in EGFR exon 19 and compared data from these cases with available 
prior EGFR testing results. Methods: DNA was extracted from 40 microns of FFPE 
sections and CGP was performed on hybridization-captured, adaptor ligation based 
libraries to a mean coverage depth of 678X for 3,769 exons of 236 cancer-related genes 
plus 47 introns from 19 genes frequently rearranged in cancer. The results were evaluated 
for all classes of genomic alterations (GA). Clinically relevant genomic alterations (CRGA) 
were defined as GA linked to drugs on the market or under evaluation in mechanism 
driven clinical trials. Results: Of the 250 cases with exon 19 deletions excluding the 
C-Helix, consisting primarily of 746-750, 71 (28%) had previous EGFR testing results 
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China, 2Clinical Pharmacology, Early Clinical Development, Astrazeneca, Alderley Park/United 
Kingdom, 3Astrazeneca Translational Centre, Personal Healthcare and Biomarkers Imed, 
Astrazeneca R&D, Karolinska Institutet, Department of Clinical Neuroscience, Stockholm/
Sweden, 4Global Medicine Development, Shanghai/China
Background: Increasing incidences of brain metastases (BM) and leptomeningeal 
metastases (LM) in lung cancer, especially in those patients with activating mutations 
of the epidermal growth factor receptor (EGFR) have been reported recently. However, 
there are currently no approved drugs available for the treatment of these diseases. 
AZD3759 is an oral EGFR TKI specifically designed to penetrate blood brain barrier 
(BBB) for the treatment of BM and LM. Methods: Efflux liability at BBB was assessed 
by using in vitro MDCKII-MDR1 and MDCKII-BCRP substrate assay, and central nervous 
system (CNS) penetration was evaluated in rats and mice and quantitatively measured 
by free brain to free blood ratio (Kp,uu,brain) and CSF to free blood ratio (Kp,uu,CSF). Brain 
uptake of [11C]-AZD3759 related radioactivity was also evaluated in two Cynomolgus 
monkeys by positron emission tomography (PET). Human clearance was predicted 
by different methods including In vitro In vivo extrapolation, liver blood flow method 
with fu correction and fu correction intercept method (FCIM). Human volume of 
distribution was projected from Oie-Tozer and PBPK methods. Human efficacious 
dose was predicted by achieving free brain concentration at steady state continuously 
covering the IC50 of pEGFR(Tyr1068) in PC-9(Exon19Del) cells. Results: AZD3759 has 
high passive permeability (29.5x10-6 cm/sec) and is not a substrate of Pgp or BCRP. 
AZD3759 reached distribution equilibrium in rats and mice (Kpuu,brain and Kpuu,CSF > 0.5), 
suggesting good BBB penetration. The distribution of [11C]-AZD3759 related radioactivity 
to monkey brain was fast and homogenous. Estimated Kpuu,brain in monkeys is greater 
than 0.5. In the animal model bearing EGFRm+ brain tumor, AZD3759 induced profound 
tumor regression and significantly improved animal survival. Predicted half-life in human 
PK is 13.3 hr and clinically observed t1/2 ranges from 10 to 15 hr. Median Kpuu,CSF value 
among six valuable BM patients is 1.2, suggesting good CNS penetration in human and 
consistent with the preclinical data. The predicted efficacious dose for AZD3759 in man 
is 100 mg bid. In an ongoing Phase I study, AZD3759 was well tolerated with no DLTs at 
50 mg or 100 mg bid and some preliminary evidence of intracranial tumor shrinkage was 
observed. Conclusion: So far the preclinical predictions of CNS penetration of AZD3759 
appear to be valid. Predicted and observed half-life of AZD3759 in human is consistent 
to date. Some preliminary evidence of intracranial tumor shrinkage was observed in 
clinical setting.
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MINI10.14 Brain Metastasis at Diagnosis and EGFR Mutational Status in 
Non-Small Cell Lung Cancer Vijaya R. Bhatt1, Sanyo P. D`Souza2, Lynette Smith1, 
Allison M. Cushman-Vokoun1, Vanita Noronha2, Vivek Verma1, Amit Joshi2, Anuradha 
Chougule2, Nirmala Jambekar2, Apar K. Ganti3, Kumar Prabhash2 1University of Nebraska 
Medical Center, Omaha/NE/United States of America, 2Tata Memorial Hospital, Mumbai/
India, 3Veteran’s Affairs Nebraska-Western Iowa Health Care System, University of Nebraska 
Medical Center, Omaha/NE/United States of America
Background: Prior studies have indicated higher epidermal growth factor receptor 
(EGFR) mutation rate in non-small cell lung cancer (NSCLC) patients (pts) with brain 
metastases; however, these studies did not adjust for the effects of potential confounding 
variables. Methods: This was a retrospective study of NSCLC pts diagnosed between 
2007-2014 at the University of Nebraska Medical Center, USA and Tata Memorial 
Hospital, India. After excluding 87 pts due to missing data, a total of 1522 pts were 
included. Univariate analysis (Chi-square or Fisher’s exact tests) and multivariate logistic 
regression were used to determine any association between EGFR status and clinical 
factors. Results: EGFR mutations were more common in females than males (38% vs. 
24%, p<.0001), Asians than Caucasians (31% vs. 13%, p<.0001), non-smokers than 
smokers (40% vs. 14%, p<.0001), alcohol non-consumers than consumers (32% vs. 
15%, p<.0001), adenocarcinoma than other histologies (32% vs. 10%, p<.0001) and in 
pts with brain metastasis than extracranial metastases or no metastasis (39% vs. 29% 
vs. 15%, p<.0001). The type of EGFR mutation (exon 19 vs. 21) did not correlate with 
the presence of brain metastasis. Multivariate analysis demonstrated a higher likelihood 
of an EGFR mutation among Asians vs. Whites/other ethnic groups (odds ratio, OR 
2.1, p=0.015), non-smokers vs. smokers (OR 2.8, p<0.0001), alcohol non-consumers 
vs. consumers (OR 1.6, p=0.022) and adenocarcinoma vs. other histologies (OR 3.1, 
p<0.0001). Pts with brain metastasis were 1.9 times more likely to have an EFGR mutation 
than pts with extracranial metastasis (p=0.0002). Pts with brain metastasis were 1.8 
times more likely to have an EFGR mutation (p=0.0002) compared to those without. 
The distribution of EGFR mutations was similar between pts with brain metastasis vs. 
non-metastatic disease (p=0.86) and pts with extracranial metastasis vs. non-metastatic 
disease (p=0.44). Conclusion: Our study is the largest study to demonstrate almost 
two-fold higher likelihood of an EFGR mutation among newly diagnosed NSCLC pts 
with brain metastases vs. those without. Studies of prophylactic cranial irradiation 
in pts with earlier stages of EGFR mutation positive NSCLC may be warranted. 
Keywords: non-small cell lung cancer, epidermal growth factor receptor mutation, Brain 
metastasis
tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer 
(NSCLC). However, obtaining tumor tissue for mutation analysis is challenging. Recently, 
peptide mass fingerprinting based on matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF-MS) has been widely used to detect diagnostic, 
prognostic, and predictive proteomic biomarkers. Here, we aimed to detect serum 
peptides/proteins associated with EGFR gene mutation status, and test whether a 
classification algorithm based on serum proteomic profiling could be developed to 
analyze EGFR gene mutation status to aid therapeutic decision-making. Methods: Serum 
collected from 223 stage IIIB or IV NSCLC patients with known EGFR gene mutation 
status in their tumors prior to therapy was analyzed by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and ClinProTools software. 
Differences in serum peptides/proteins between patients with EGFR gene TKI-sensitive 
mutations and wild-type EGFR genes were detected in a training group of 100 patients; 
based on this analysis, a serum proteomic classification algorithm was developed to 
classify EGFR gene mutation status and tested in an independent validation group of 123 
patients. The correlation between EGFR gene mutation status, as identified with the serum 
proteomic classifier and response to EGFR-TKIs was analyzed. Results: Nine peptide/
protein peaks were significantly different between NSCLC patients with EGFR gene TKI-
sensitive mutations and wild-type EGFR genes in the training group. A genetic algorithm 
model consisting of five peptides/proteins (m/z 4092.4, 4585.05, 1365.1, 4643.49 and 
4438.43) was developed from the training group to separate patients with EGFR gene 
TKI-sensitive mutations and wild-type EGFR genes. The classifier exhibited a sensitivity 
of 84.6% and a specificity of 77.5% in the validation group. In the 81 patients from the 
validation group treated with EGFR-TKIs, 28 (59.6%) of 47 patients whose matched 
samples were labeled as “mutant” by the classifier and 3 (8.8%) of 34 patients whose 
matched samples were labeled as “wild” achieved an objective response (p<0.0001). 
Patients whose matched samples were labeled as “mutant” by the classifier had a 
significantly longer progression-free survival (PFS) than patients whose matched samples 
were labeled as “wild” (p=0.001). Conclusion: Peptides/proteins related to EGFR gene 
mutation status were found in the serum. Classification of EGFR gene mutation status 
using the serum proteomic classifier established in the present study in patients 
with stage IIIB or IV NSCLC is feasible and may predict tumor response to EGFR-TKIs. 
Keywords: Epidermal growth factor receptor, mass spectrometry, proteomics, non–
Small-Cell Lung Cancer
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MINI10.12 Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain 
Metastases Peter Ballard1, Pamela Yang2, Darren Cross3, James Yates3, M. Raymond 
V. Finlay3, Matthew Grist1, Matthew Box1, Peter Johnström4, Katerina Varnäs5, Jonas 
Malmquist5, Christer Halldin5, Lars Farde4, Kenneth Thress6 1Astrazeneca, Macclesfield/
United Kingdom, 2Asia and Emerging Markets, Astrazeneca, Shanghai/China, 3Astrazeneca, 
Cambridge/United Kingdom, 4Astrazeneca Translational Science Centre and Department 
of Clinical Neuroscience, Karolinska Institutet, Stockholm/Sweden, 5Department of Clinical 
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States of America
Background: AZD9291 is an oral, potent, irreversible epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR-TKI) selective for the EGFR-TKI-sensitizing (EGFRm) and 
T790M resistance mutations. We examined how the level of AZD9291 brain penetration 
and activity compared to that of other EGFR-TKIs in preclinical models of EGFRm non-small 
cell lung cancer (NSCLC) brain metastases (BM). Methods: Brain exposure of AZD9291 
and an active circulating metabolite of AZD9291 (AZ5104), CO-1686 (rociletinib), gefitinib, 
erlotinib, and afatinib were evaluated in mouse models. Brain distribution following 
intravenous administration of microdoses (<3 micrograms) of [11C]AZD9291 and [11C]
CO-1686 were compared in healthy cynomolgus macaques using positron emission 
tomography (PET) imaging. In vivo efficacy of AZD9291 and CO-1686 were assessed 
in a mouse EGFRm (exon 19 deletion) BM xenograft (PC9) model. Human doses that 
could potentially deliver BM efficacy were predicted using a preclinical pharmacokinetic/
pharmacodynamic (PK/PD) mathematical model, adapted to account for the differential 
exposure and binding of AZD9291 and AZ5104 in brain compared with plasma. Results: In 
preclinical studies, AZD9291 showed significant exposure in the brain with concentrations 
in mouse brain tissue approximately 2-fold higher than plasma, although the metabolite, 
AZ5104, did not show similar levels of exposure to parent. AZD9291 also showed higher 
brain exposure than other tested EGFR-TKIs. Furthermore, under microdosing conditions 
[11C]AZD9291 showed marked exposure in a cynomolgus macaques brain PET study 
in contrast to [11C]CO-1686. At clinically relevant doses, AZD9291 distribution to the 
mouse brain was approximately 10-fold higher than gefitinib. In the PC9 BM model, 
AZD9291 showed tumor growth inhibition at 5 mg/kg/day. Using an adapted preclinical 
PK/PD model, simulations with clinical AZD9291/AZ5104 PK data predicted that a 
human dose of 80 mg may be sufficient to target EGFRm BM. Conclusion: Preclinical 
studies indicate AZD9291 has significant exposure in the brain and activity against 
EGFRm BM, compared with the other EGFR-TKIs tested. In light of early clinical activity 
of AZD9291 observed in patients with EGFRm NSCLC BM, further investigation into 
the potential benefit of AZD9291 in patients with EGFRm NSCLC BM is warranted. 
Keywords: T790M, EGFR-TKI, brain metastases
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MINI10.13 Prediction of Human Pharmacokinetics, Efficacious Dose and BBB 
Penetration of a Novel EGFR Inhibitor for Treating NSCLC with CNS Metastasis 
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MINI11.03 Switching to Smokeless Tobacco Use as a Smoking Cessation 
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Background: Smoking is the dominant form of tobacco globally. However in many Asian 
countries such as India, the use of smokeless tobacco (SLT) is common. The adverse 
health and economic effects of smokeless tobacco are as harmful as that of smoking. In 
India, 75% of the tobacco users were smokeless tobacco users. Limited information is 
available at the population level on smokeless tobacco as a smoking cessation method in 
India. The present study examined the use of smokeless tobacco as a smoking cessation 
method and its determinants among adults in India. Methods: We used raw data on 
the nationally representative household survey Global Adult Tobacco Survey (GATS) 
2009-2010 India for the present study. GATS India covered 29 states and two Union 
Territories (Chandigarh and Puducherry) covering 99.92% of the total population of India 
using a multistage sampling. A total sample of 69,296 adults aged 15 years and above 
(men 52%, rural 71%) was analyzed. We studied the smoking cessation method for those 
who quit smoking within one year. We did logistic regression analysis to find out the 
determinants of switching to smokeless tobacco as a smoking cessation method among 
adult Indian men. Results: Prevalence of smokeless tobacco use (26%) was nearly two 
times higher than that of smoking (14%) in India. Among the total tobacco users in India 
75% were smokeless tobacco users (men 69%, women 91%). Quit ratio (defined as 
former tobacco users among ever daily users within one year) was low among smokeless 
tobacco users (5%) compared to smokers (13%). Forty five percent of the ever smokers 
tried some method to quit in the last 12 months. Among former smokers (ever-smokers 
who stopped smoking within one year) 20% tried to switch to smokeless tobacco as 
a smoking cessation method. Among the different methods of smoking cessation, 
switching to smokeless tobacco was the highest used method (45%). Employed [Odds 
Ratio (OR) 7.34, 95% CI 7.23-7.45] and adults with formal education (OR 2.26, CI 2.25-
2.28) were more likely to switch to smokeless tobacco as a smoking cessation method 
compared to their counterparts. Conclusion: The low quit rate among smokeless 
tobacco users and a high proportion of smokers switching to smokeless tobacco 
predict the future burden of SLT in India. Smokers in India need to be educated regarding 
the risks of different tobacco products especially the use of smokeless tobacco. The 
public policies related to tobacco have been focusing on smoking form of tobacco and 
there is a need to include smokeless tobacco in all tobacco control programs in India. 
Keywords: Smokeless Tobacco, Switching, Smoking Cessation Method, India
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MINI11.04 A New Preclinical Model of Airway Progenitor Cells to Identify 
Responders to Iloprost-Mediated Chemoprevention Jennifer B. Kwon1, Ichiro 
Nakachi2, Robert L. Keith3, Daniel T. Merrick4, Michael Edwards4, Sonia Leach5, Wilbur 
A. Franklin2, York E. Miller3, Moumita Ghosh1 1Pediatrics, National Jewish Health, Denver/
United States of America, 2Pathology, University of Colorado Anschutz Medical Campus, 
Aurora/CO/United States of America, 3Pulmonary Medicine, Denver Veteran Affairs Medical 
Center, Denver/CO/United States of America, 4Pathology, University of Colorado Anschutz 
Medical Campus, Aurora/United States of America, 5Genes and Environment, National Jewish 
Health, Denver/CO/United States of America
Background: Lung cancer is the leading cause of cancer related deaths worldwide. The 
5-year survival rate for this cancer is only 16%. Chemoprevention can improve prognosis 
in these patients. However, previous attempts at lung cancer chemoprevention that 
were soley based on epidemiological data were ineffective. Squamous cell lung cancer 
develops through a series of bronchial lesions or dysplasia. Persistent dysplasia harbors 
similar genetic changes as the tumor and has significantly higher chance of progression. 
Thus, bronchial dysplasia is a risk biomarker for SCC and improvement in dysplasia grade 
can be used as an outcome for chemoprevention trials. The long-acting prostacyclin 
analogue, iloprost is the only drug that has improved dysplasia in former smokers (p 
= 0.006). Despite this positive outcome we have little insight into the mechanisms of 
iloprost function. Understanding these mechanisms would be essential to identify people 
who have the highest chance to benefit from iloprost treatment. We propose that this 
endeavor will require a preclinical model that recapitulates the human disease and is 
amenable to mechanistic studies. Methods: Airway progenitor cells are critical for the 
maintenance of normal airways, because of their ability to self-renew (i.e. replicate) 
and differentiate into all cell-types of the airway (i.e. multipotentiality). Together these 
properties allow progenitors to return injured tissue to normal structure and function. 
In dysplasia, normal bronchial epithelium is changed into one that contains increased 
numbers of basal cells and lacks ciliated cells. These findings led to our hypothesis that 
‘airway progenitors are malfunctioning in dysplasia’. Previously we showed that Keratin (K) 
5/p63-expressing basal cells are the multipotential progenitors of the airway epithelium. 
During in vitro culture these cells form a unique 3-deimensional structure called the rim 
clone, which allows them to be distinguished from non-progenitors. To investigate a 
role of epithelial progenitors in dysplasia, we have collected bronchial biopsies from 
high-risk smokers and purified rim clone forming basal progenitor cells. Results: We 
demonstrate that both self-renewal and multipotentiality of progenitors is significantly 
(p < 0.001 for both) decreased in dysplasia. During differentiation in vitro at the air-liquid 
interface, progenitors from normal biopsies generated a normal epithelium. In contrast, 
progenitors from dysplasia made a squamous epithelium containing only basal cells and 
lacking ciliated cells. Mutational analyses of paired samples from epithelial brushings and 
biopsy-derived progenitors identified the same somatic mutations in p53, Notch 1, Notch 
3, Survivin and FGFR1. Thus, epithelial progenitor culture reflects the histologic and 
genetic changes of dysplasia and therefore can be used as a personalized, preclinical 
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MINI11.01 The Upshot of Passive Smoke (ETS) Exposure on Pneumonia Risk in 
Children Under 7 Years in Nigeria Blessing Obiazi-Odiase Paediatrics, University of 
Abuja, Abuja/Nigeria
Background: This study considers pneumonia risk on children under age 7 in Northern 
Nigeria exposed to ETS. The numerous adverse effects of Environmental Tobacco 
Smoke (ETS) on the non-smoking public have being evidenced through decades of 
research. This does not only affect adults but children. ETS effects on children have 
shown to be grave as it worsens asthma conditions, increases pneumonia cases and 
causes Sudden Infant Death Syndrome (SIDS). Methods: Most residents in all 44 Local 
Government Areas (LGAs) in Kano State of Northern Nigeria took part in a population-
based large-scale cross-sectional survey in Kano state from 2007-2010. Demographic 
information coupled with socioeconomic status, smoking status and house environment 
of each household member, was collected from participants. Pneumonia case reported 
among children aged 7 years and below in each household in the previous 18 months 
were recorded based on parent’s/guardian’s report. Results: Out of a total of 528, 800 
people resident in 102,334 homes indentified in the survey areas and visible/present as 
at the time of the study, 52,888 (10%) were children aged 7 years and below. While the 
prevalence of ETS exposure on children was 81%, the prevalence of reported pneumonia 
cases was 3.5%. Multiple logistic regression analysis showed that exposure to ETS 
was independently associated with reports of pneumonia cases (adjusted odds ratio 
1.55, 95% CI 1.25 to 1.92). The prevalence of tobacco smoking was higher among men 
than women (63.5% vs 44.1%). It is estimated that 32.7% of childhood pneumonia in 
the northern region of Nigeria is attributable to ETS. Conclusion: Attention should be 
given to reduction to children’s exposure to ETS not only in Nigeria but in all affected 
areas mostly all parts of the world. If nothing is done to protect children, there will be 
millions of avoidable deaths attributable to Pneumonia heightened by ETS exposure. 
This is a case of concern for any one involved in lung cancer/tobacco control. 
Keywords: tobacco, ETS, children
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MINI11.02 Frizzled 9 as a Predictor of Response to Iloprost Chemoprevention 
of Lung Cancer Meredith Tennis1, Daniel T. Merrick2, Lori Nield3, Robert L. Keith4 
1Pulmonary, University of Colorado Denver Anschutz, Aurora/CO/United States of 
America, 2Pathology, University of Colorado Anschutz Medical Campus, Aurora/CO/United 
States of America, 3School of Pharmacy, University of Colorado Anschutz Medical Campus, 
Aurora/CO/United States of America, 4Pulmonary Medicine, Denver Veteran Affairs Medical 
Center, Denver/CO/United States of America
Background: Lung cancer remains the leading cause of cancer death in the United 
States and chemoprevention offers an appealing area of investigation in the face of 
limited therapeutic success. Improvement in endobronchial histology was recently 
demonstrated in former smokers after oral iloprost treatment. Of the 48 patients who 
received iloprost in the chemoprevention trial, 23 had regressive histology and 25 had 
stable or progressive histology. Identifying markers that predict which patients will 
respond to treatment will help refine target populations for future trials and clinical 
applications. In vitro studies of NSCLC indicate that iloprost, a prostacyclin analogue, 
acts through the G-protein coupled receptor Frizzled 9 (Fzd9) instead of the prostacyclin 
receptor. We hypothesize that Fzd9 expression status predicts response to iloprost 
chemoprevention and that current smokers may not respond to iloprost treatment due 
to carcinogen-induced decreases in Fzd9 expression. Prostacyclin may also induce 
expression of Fzd9, leading to increased anti-tumor signaling. Methods: Fzd9 expression 
was measured by quantitative real-time PCR in RNA extracted from mouse and human 
tissues, cultured dysplastic cell lines, and cultured human bronchial epithelial cells 
(HBEC). In the urethane model, FVB wild type and transgenic mice were exposed to a 
single dose of urethane and sacrificed after 20 weeks. In the smoking model, FVB wild 
type and transgenic mice were sacrificed after one week of cigarette smoke exposure. 
Human matched tumor and normal tissue and dysplastic cell lines were acquired from the 
University of Colorado SPORE in Lung Cancer Tissue Bank. HBEC were exposed to 5ug/
ml cigarette smoke condensate and 10uM iloprost in culture media. Results: Human 
lung tumors demonstrated reduced Fzd9 mRNA expression compared to matched 
normal lung tissue. Fzd9 expression is also decreased in human primary dysplastic 
cell lines, suggesting that loss of Fzd9 expression occurs early in early lung lesions. 
In a urethane mouse model of lung cancer, Fzd9 mRNA expression is reduced in lung 
tumors compared to matched, uninvolved lung tissue. Tumors from urethane exposed 
prostacyclin synthase overexpressing (PGIStg) mice have higher Fzd9 expression 
compared to tumors from wild type mice. In a one-week smoking model, Fzd9 expression 
is decreased in lung from wild type smoked mice but higher in PGIStg smoked mice. In 
HBEC exposed to cigarette smoke, Fzd9 expression decreases and remains low with 
continued exposure from 1 to 28 weeks. After two weeks of exposure to iloprost alone, 
HBEC cells demonstrated increased Fzd9 expression. Conclusion: These initial studies 
suggest that Fzd9 expression is lost lung epithelial cells with early smoking-induced 
damage. Fzd9 expression will be measured in baseline and follow up biopsy tissues from 
the iloprost clinical trial. This study has the potential to improve iloprost lung cancer 
chemoprevention by allowing future trials to more effectively target high-risk patients 
and by providing a clinical biomarker for identification of chemoprevention candidates. 
Keywords: Lung cancer, Frizzled9, lloprost, chemoprevention
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cancer incidence (1 study), and reduced lung cancer (3 studies) and smoking-attributable 
cancer (1 study) mortality. Results indicated that increased program funding was 
associated with greater impact on the examined tobacco-related outcomes (16 studies). 
Stratified analysis showed CTCPs were effective across population groups with diverse 
racial and ethnic backgrounds (5 studies) and varied education or socioeconomic status 
(6 studies). Conclusion: Based on CG criteria, there is strong evidence that CTCPs are 
effective for reducing tobacco use prevalence among adults and young people, reducing 
tobacco product consumption, increasing quitting, reducing SHS exposure, and reducing 
tobacco-related diseases and deaths, especially lung cancer. These findings are broadly 
applicable to the U.S. settings and population groups at the state, city, and local levels. 
Keywords: interventions, tobacco, control, prevention
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MINI11.07 The Relationship between Smoking Status and Prognostic Factors 
after Surgery in Lung Cancer Patients with Chronic Obstructive Pulmonary 
Disease Masaya Yotsukura1, Takashi Ohtsuka1, Yasoo Sugiura1, Yuichiro Hayashi2, 
Ikuo Kamiyama1, Hisao Asamura1 1Division of Thoracic Surgery, Keio University School of 
Medicine, Tokyo/Japan, 2Department of Pathology, Keio University Hospital, Tokyo/Japan
Background: Cigarette smoking is the leading cause of chronic obstructive pulmonary 
disease (COPD), which frequently coexists with lung cancer. For non-small cell lung 
cancer (NSCLC) patients with COPD, the poor prognostic factors after curative surgery 
and their association with smoking status are unclear. Methods: We enrolled 858 
patients who underwent curative surgical resection for pathological stage I or II NSCLC in 
our institute between January 2002 and December 2012. Of these patients, those with 
COPD, as determined by a fixed post-bronchodilator ratio of forced expiratory volume in 1 
second and forced vital capacity (FEV1/FVC) below 0.7, were evaluated (n = 302). Clinical 
and pathological characteristics of the patients were retrospectively analyzed using the 
Cox regression hazards model to determine those that serve as poor prognostic factors 
after surgery. Results: The mean follow-up time was 49.3 months (±30.8 months; range, 
1 to 135 months). The five-year disease-free survival rate was 70.2%, and the overall 
survival rate was 81.5%. Of 302 COPD patients, 243 (80.5%) had a smoking habit, 
whereas 59 (19.5%) did not. According to the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) criterion, 143 patients (47.5%) were diagnosed with stage I COPD 
and 159 patients (52.6%) were diagnosed with stage II COPD. The presence of a smoking 
habit (p = 0.010, hazard ratio [HR] 3.340, 95% confidence interval [CI] 1.334-8.359), 
lymphatic permeation (p = 0.001, HR 2.352, 95% CI 1.450-3.814), pathological T2 
or T3 disease (p = 0.005, HR 1.666, 95% CI 1.165-2.381), and a preoperative serum 
carcinoembryonic antigen (CEA) value > 0.5 ng/ml (p = 0.041, HR 1.637, 95% CI 1.021-
2.625) were determined to be indicators of poor recurrence-free survival in multivariate 
analysis. For overall survival rates, a smoking habit (p = 0.048, HR 7.527, 95% CI 1.017-
55.738), a preoperative serum CEA value > 0.5 ng/ml (p = 0.001, HR 2.782, 95% CI 
1.495-5.175), a histology of squamous cell carcinoma (p = 0.014, HR 2.220, 95% CI 
1.175-4.193), and pathological N1 disease (p = 0.031, HR 2.505, 95% CI 1.089-5.762) 
were determined to be poor prognostic indicators in multivariate analysis. The disease 
stage as determined by the GOLD criterion was associated with neither recurrence-free 
nor overall survival rates. With regard to smokers, the number of pack-years did not 
significantly influence prognosis. Conclusion: We identified poor prognostic indicators 
for resected NSCLC in COPD patients. It should be noted that COPD patients who did not 
smoke had a better prognosis after surgery than those who did. Neither the number of 
pack-years in smokers nor the stage of COPD was related to prognosis after surgery. 
Keywords: Chronic obstructive pulmonary disease, Early-stage lung cancer, smoking 
status
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MINI11.08 Smoking Cessation Results in a Clinical Lung Cancer Screening 
Program Andrea K. Borondy Kitts1, Andrea Mckee2, Shawn Regis1, Brady Mckee3, 
Sebastian Flacke4 1Rescue Lung Rescue Life, Lahey Hospital & Medical Center, Burlington/
MA/United States of America, 2Radiation Oncology, Lahey Hospital & Medical Center, 
Burlington/MA/United States of America, 3Thoracic Imaging, Lahey Hospital & Medical 
Center, Burlington/MA/United States of America, 4Interventional Radiology, Lahey Hospital & 
Medical Center, Burlington/MA/United States of America
Background: Published results, to date, on smoking cessation and lung cancer screening 
have been from lung cancer screening clinical trials and/or lung cancer screening studies. 
Most were done before publication of National Lung Screening Trail (NLST) results. To 
our knowledge, this is the first report on smoking cessation and smoking relapse rates 
in a clinical lung cancer screening program to assess the influence of initial screening 
results on smoking behavior. Methods: Self-reported smoking status for all individuals 
enrolled in a clinical CT lung screening program undergoing a follow-up CT lung screening 
exam between February 1, 2014 and July 31, 2014 was retrospectively reviewed and 
compared to self-reported smoking status using a standardized questionnaire at time of 
program entry. Point smoking cessation and relapse rates were calculated across the 
entire population and compared with exam results. Results: 682 participants all of which 
met NCCN high-risk criteria for lung cancer were included in the study. 45% (309/682) 
were active smokers at program entry. The smoking cessation rate was 18.4%. Overall 
relapse rate was 9.9% with a relapse rate for former smokers quit for less than or equal 
to one year (24 of 64) of 37.5%, 14.8% for those quit for more than one year and up 
to two years (4 of 27), and 3.2% for those quit for more than two years (9 of 282). 
Initial screening exam results were not predictive of smoking status at the most recent 
scan (OR = 0.779, 95% CI = 0.415-1.460, p=0.435). In the group of smokers at the 
initial scan, screening results did not result in increased rates of smoking cessation 
model. A proof of concept study where dysplastic progenitor cells were treated with 
iloprost resulted in decreased dysplasia in 2 out of 3 cases. Conclusion: Thus our data 
indicate that progenitor cell cultures from a patient’s dysplasia may be used to identify 
responders versus non-responders to iloprost, as well as other chemopreventives. 
Future studies could focus on identifying downstream mechanisms via which iloprost 
exerts its beneficial effect.
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MINI11.05 Prevalence Use of Others Tobacco Products: Findings from the ITC 
Brazil Survey Cristina D.A. Perez, Tania M. Cavalcante, Felipe L. Mendes 
Tobacco Control, National Cancer Institute of Brazil, Rio de Janeiro/Brazil
Background: Tobacco use is responsible for 5.4 million deaths every year worldwide 
and a leading cause of preventable death. Brazil is widely regarded as an international 
leader in tobacco control. The WHO FCTC aims to protect individuals from the 
consequences of tobacco use by providing a framework for tobacco control measures. 
Parties are obligated to implement measures to prevent and reduce all tobacco 
consumption and to monitor the magnitude and patterns of tobacco use. The ITC Brazil 
Survey includes several measures to assess smokers’ tobacco use behaviour, such as 
cigarette consumption and types of products used. Methods: The International Tobacco 
Control Policy Evaluation Survey (ITC) Brazil Survey is a longitudinal cohort survey and 
was conducted in Brazil with 1,200 adult smokers and 600 adult non-smokers living in 
three cities. Telephone-administered surveys were conducted using an area stratified 
random sampling strategy, yielding a representative sample of the four largest cities 
in Brazil (Rio de Janeiro, Porto Alegre, and Sao Paulo). The Wave 1 Survey (in 2009) 
and Wave 2 (2012-2013) included questions a variety of tobacco control measures, 
including use of tobacco products. Results: Brazilian smokers in the ITC Survey smoked 
mainly factory-made cigarettes and five percent reported that they regularly smoke 
a flavored brand (including menthol). In Wave 2, all respondents were asked about 
their use of other tobacco products, and the results show evidence of other tobacco 
product use even among non-cigarette smokers. Thirteen percent of the overall sample 
(smokers and non-smokers combined) have smoked clove cigarettes, 10% have smoked 
cigars, 8% smoked shisha, 5% smoked pipes, and 4% smoked bidis. The percentage 
of smokers and non-smokers in the sample who have tried various tobacco products, 
by city, shows a significantly higher use of shisha among smokers in São Paulo (18%) 
compared to Rio de Janeiro (5%) and Porto Alegre (8%), and non-smokers in São Paulo 
were significantly more likely to smoke cigars than in the other two cities. Despite the 
prohibition of electronic cigarettes (e-cigarettes) sale, importation, and advertising in 
Brazil since August 2009, in the ITC Brazil Wave 2 Survey, respondents were asked “Have 
you ever heard of electronic cigarettes or e-cigarettes?”. The results showed that 35% 
of smokers and 29% of non-smokers had heard of them. The highest level of awareness 
of the product was in Porto Alegre where 39% of smokers and 29% of non-smokers 
had heard of them. Among smokers who had heard of e-cigarettes, 38 smokers (12%) 
and one non-smoker reported trying these products. Conclusion: Daily consumption 
of cigarettes is relatively high in Brazil for both male and female daily smokers, based 
on a comparison of the average number of cigarettes smoked per day among 20 ITC 
countries and an average consumption of 17 cigarettes per day — twice the average 
consumption of smokers in Mexico, so its recommended to reinforce educational 
campaigns about the dangers of smoking, and the electronic cigarette use, increase its 
inspections and mainly reinforce educational campaigns about the dangers of shisha. 
Keywords: Tobacco Control, Tobacco products, smoking
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MINI11.06 Comprehensive Tobacco Control Programs Reduce Tobacco Use 
and Secondhand Smoke Exposure: A Systematic Review Jeffrey A. Reynolds, 
Yinan Peng, Namita Vaidya, Cristian G. Dumitru, David P. Hopkins Community Guide 
Branch, Centers for Disease Control and Prevention, Atlanta/GA/United States of America
Background: Tobacco use is the single greatest cause of preventable disease, 
disability, and death in the U.S. Over the last few decades, several states have 
implemented comprehensive tobacco control programs (CTCP) to reduce tobacco use 
and secondhand smoke (SHS) exposure. This Community Guide (CG) systematic review 
was conducted to examine CTCP effectiveness in reducing tobacco use and tobacco-
related diseases and deaths. Methods: A systematic search was conducted (search 
period Jan 2000-July 2014) to identify and abstract qualifying studies using standard 
CG systematic review methods. Studies published prior to 2000 were identified from 
a previous Community Guide review and added. Summary measures were calculated 
when possible and narrative results were provided when effect estimates could not 
be pooled. The review team worked under the guidance of the Community Preventive 
Services Task Force (CPSTF), a non-federal, independent, volunteer body of public health 
and prevention experts. Results: The review team identified 60 eligible studies; only 
results from the U.S. studies are reported here (55 studies). Most of the U.S. studies 
evaluated CTCP at the state level (48 studies from 10 states) with the remaining studies 
at the city (3 studies) and local or community level (4 studies). States with a CTCP 
reduced tobacco use prevalence among adults by a median of 2.8 percentage points 
(pct pts) [Interquartile interval (IQI): -3.5 to -2.4 pct pts; 12 studies]; reduced tobacco 
use prevalence among young people by a median of 4.5 pct pts (IQI: -6.0 to -0.7 pct pts; 
9 studies); reduced cigarette pack sales by a median of 12.7% (IQI: -20.8% to -5.5%; 7 
studies); and reduced daily tobacco product consumption by a median of 17.1% (IQI: 
-43.4% to -13.5%; 6 studies). Narrative results showed that states with a CTCP increased 
cessation (6 studies) and reduced SHS exposure (4 studies). States with a CTCP 
decreased tobacco-related diseases and deaths (6 studies), specifically in reduced lung 
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Stage, sex and period specific relative survival was rather similar between countries. 
When restricting the analysis to patients with recorded treatment, stage-specific 
relative survival differences in 2007-2009 nearly disappeared. Conclusion: Improved 
data quality and comparability are needed, especially by lowering the proportion of 
cases only reported via death certificates in Germany. This would diminish the survival 
differences as a high proportion of such cases leads to an over-estimation of survival. 
Smoking is a strong risk factor for lung cancer and smoking prevalence 10 years before 
our study was high, specifically 37% in men and 22% in women in Germany and 45% 
in men and 38% in women in Denmark respectively. Smoking prevalence dropped to 
24% in men and 21% in women in Denmark 2010, but only to 31% in men and 24% in 
women respectively in Germany. Such dramatic changes over a short period of time in 
Denmark are over time expected to be reflected in the overall incidence, mortality and 
even survival. International benchmarking studies are needed to understand lung cancer 
trends and to improve prevention and treatment of this serious cancer disease. Research 
presented here was partly funded by EU INTERREG 4a Fehmarn Belt 2011-2014. 
Keywords: population based, stage specific, survival-benchmarking, lung cancer
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MINI11.11 Lung Cancer and Smoking in Nepal Sandhya C. Acharya, Madan K. Piya 
Clinical Oncology, National Hospital and Cancer Research Center, Kathmandu/Nepal
Background: Smoking and Tobacco kills 15,000 people in Nepal every year. The 
combined prevalence of smoking and tobacco use is 56.5% in men and 19.5% in 
women, of whom 32.5% of men and 15.2% of women smoked cigarettes. The estimated 
incidence of lung cancer is 8000 per year, making it the first commonest cancer in both 
sexes. Lung cancer accounts for 15.4% of total cancer as per the hospital based cancer 
registry for both genders in Nepal. Methods: This prospective observational study was 
conducted at National Hospital and Cancer Research Centre, Nepal. Following informed 
consent, patients with lung cancer attending the hospital for appointments completed 
pre-set questionnaires about smoking only, and their stage of cancer and histological 
type were obtained from case notes. Results: A total of 116 patients completed the 
questionnaire between March 2012 and February 2015. 59% of the respondents were 
male and 41% were female. The mean age was 64 years with ranging from 31 to 81 years. 
The proportion of patients presenting in the different stages of lung cancer were IB (3%), 
IIA (2%), IIB (4%), IIIA (30%), IIIB (41%), and IV (23%). The histological type of cancer 
showed that 53% were Squamous Cell Carcinoma, followed by Adenocarcinoma 28%, 
Small cell lung Cancer 13% and Neuroendocrine tumors 4%. 85% were smokers. Of the 
smokers, 14% started smoking before the age of 10, 53% when they were between 11-20 
years of age, 13% when they were 21-30 years and only 5% started when they were 40 
years or older. Only 4% smoked more than 30 cigarettes per day, 13% smoked 21-30 per 
day, 32% smoked 10-20 per day and 36% patient smoked less than 10 per day. 68% used 
local cigarettes, 7% foreign and 10% used both. Further analysis showed that 27% used 
cigarettes without filters, 50% filtered and 8% used both. 28% were relighting the butt 
ends, 5% did this occasionally and 52% did not practice this. 13% of patients were still 
smoking after their diagnosis, 24% quit less than a month later, 11% quit less than a year 
later, 19% had already quit smoking 5 years before the diagnosis of cancer, 12% had quit 
10 years before and 8% had quit 20 years before. Out of 28% of relighting, 48% patient 
developed cancer in compare to 52% who never relight the butt end. Conclusion: The 
results shows that majority of patients are presenting at stage III and IV. NSCLC is still on 
the rise in Nepal. This late presentation suggests a lack of education in the community as 
well as a delayed diagnosis and referral to the specialist. Focus should be given to make 
the population in Nepal aware about smoking and tobacco use and its link to cancer, as 
well as the high prevalence of lung cancer in both genders in Nepal. Focus should also be 
given to educating the population and non-specialist health care professionals about the 
symptoms of lung cancer and the importance of early presentation to improve prognosis. 
Keywords: Developing Country, lung cancer, smoking
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MINI11.12 Is There Any Role for Residential Radon in Patients with Non Small 
Cell Lung Cancer (NSCLC) Harbouring Molecular Alterations? Preliminary 
Results Laura Mezquita1, Maria Eugenia Olmedo1, Alberto Ruano-Ravina2, Jose Maria 
Fraile3, Amparo Benito4, Almudena Santon4, Sagrario Mayoralas5, Luis Gorospe6, 
Alfonso Cortes1, Silvia Patricia Cortez1, Jacobo Munoz1, Ana Gomez1, Eduardo Roberts1, 
Alfredo Carrato1, Pilar Garrido1 1Medical Oncology Department, Hospital Universitario 
Ramón Y Cajal, Madrid/Spain, 2Preventive Medicine & Public Health, University of Santiago 
de Compostela, Santiago de Compostela/Spain, 3Internal Medicine Department, Hospital 
General Villalba, Madrid/Spain, 4Pathology Department, Hospital Universitario Ramón Y 
Cajal, Madrid/Spain 5Pneumology Department, Hospital Universitario Ramón Y Cajal, Madrid/
Spain, 6Radiology Department, Hospital Universitario Ramón Y Cajal, Madrid/Spain
Background: World Health Organization (WHO) recommends radon concentration 
lower than 100 Bq/m3. Previous studies have demonstrated the correlation between 
high level of residential radon exposure and lung cancer especially in non-smokers 
patients (p.). Similarly, most of the advances in personalized therapy in NSCLC 
p. also occurred in non-smoker. We hypothesized that residential radon could be 
associated to some specific molecular alterations in NSCLC p. Methods: A detector 
alpha-track was delivered to each p. to measure radon concentration in residence 
for 3 months and a questionnarie to fill out. The elegible population were NSCLC p. 
harbouring molecular alterations (EGFR, KRAS or BRAF mutations (m)), ALK or ROS1 
rearrangements (r)) and non-smoker p. treated in the Medical Oncology Department, 
at Hospital Universitario Ramon y Cajal, Madrid. Incident cases and prevalent cases 
collected from lung cancer patients database have been included from September 2014 
(OR = 0.704, 95% CI = 0.308 – 1.610, p=0.405). In the group of former smokers 
at the initial scan, negative initial exam results did not result in increased smoking 
relapse rates (OR = 1.021, 95% CI = 0.364-2.860, p=0.969). Conclusion: Smoking 
cessation and relapse rates in a clinical CT lung screening program significantly exceed 
rates observed in the general population and do not correlate with exam results. 
Keywords: Smoking Cessation, Clinical lung cancer screening program, Low Dose CT 
Scan, Smoking Relapse
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MINI11.09 Trends in Lung Cancer Mortality Attributable to Smoking, Years of 
Potential Life Lost and Financial Cost, Puerto Rico 1983-2010 Juan C. Orengo1, 
Vivian Green2, Homero Monsanto3, Cecile Marques-Goyco3, Felipe Arbelaez3 1Medical 
Department, Merck & Co, Carolina/Puerto Rico, 2Public Health, Ponce Health Sciences 
University, Ponce/Puerto Rico, 3Medical Affairs, Merck & Co, Carolina/Puerto Rico
Background: During 1983, 2000 and 2004 the lung cancer deaths attributable to 
smoking (LCDAS) were 64.1% (>15 years old), 76% (> 35 years old) and 71% (34-65 
years old), respectively. Objectives: a) LCDAS; b) Years of Potential Life Lost (YPLL) due 
LCDAS; c) cost associated with YPLL for the LCDAS. Methods: Mortality data of lung 
cancer (ICD-10, C33-C34) from the National Center for Health Statistics for Puerto Rico 
(2010) was analyzed. The prevalence of current, former and never smoking by gender 
was obtained from the Behavioral Risk Factor Surveillance System (2010) (CDC, US) 
and the Relative Risk of death dues to smoking by gender from the Cancer Prevention 
Study-II. The Smoke Attributable Fraction (SAF) was calculated as [p0 + pcs * RRcs + pfs * 
RRfs ] – 1 / [p0 + pcs * RRcs + pfs * RRfs ], where p0 = prevalence of never smoker, pcs = 
prevalence current smoker, pfs = prevalence of former smoker, RRcs, = Relative Risk 
of current smoker and RRfs = Relative Risk of former smoker. The LCDAS (Das) were 
calculated as Do*SAF, where Do = deaths observed of lung cancer 2010. To compare the 
data of 1983, 2000 and 2010, SAF was calculated by sex for the total population (not 
by age groups), with correspondent same death-risk LCDAS. YPLL used life expectancy 
(women=82.56 years old; men=74.85 years old). The method of willingness to pay, 
using three times the GDP per capita in 2010 (US$82,353), a discount rate of 3% and 
an annual increase of 1%, to calculate the economic cost. Results: In 2010, 50.3% 
deaths by lung cancer in women were LCDAS, men 83.7% , in 1983 women and men 
were 65.9% and 91.2% respectively and in 2000, 58.9% and 84.4% women and men 
respectively; percentage of all LCDAS (2010) was 73.3% (by sex and group of five). 
Total population, 2010, not by age groups 75.8%, 2000, 76.3% and1983, 82.5%. In 
2010, SAF higher in women was in the age group=45-49 (smoker=13%, SAF=0.66); 
men was in the age group of 50-54 years (SAF=0.86) (smoker= 17.5%). In women, 1% 
point decreased (1983-2010) in the prevalence of smoking representing 1.5% point of 
decreasing LCDAS; men 1% point representing 0.3% point. Lung cancer YPLL in >35 
years old represented in 2010 a total of 4,597 years [3,239 years (70.5%) were LCDAS], 
men accounted 2,383 years [2,014 (84.5%) years LCDAS] and women accounted 2,214 
years [1,225 (55.4%) years LCDAS]. In 2010 the cost (willingness to pay) associated 
for men was $166 million [$139 million (84%) LCDAS], and for women was S146 million 
[$82 million (56%) LCDAS]. The Average Years Life Lost LCDAS for men was 10.6 years 
and for women 14.2 years. Conclusion: LCDAS have been decreasing in Puerto Rico, 
as demonstrated in the reduction of SAF. LCDAS occur at an earlier age in women 
than in men. Notwithstanding , the financial cost of LCDAS is greater in men than in 
women. Total financial cost for LCDAS represented 0.3% of the Puerto Rico GDP in 2010. 
Keywords: Years of Potential Life Lost, financial cost, Trends, Mortality attributable to 
smoking
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MINI11.10 Quality of Lung Cancer Treatment in Two Neighbouring Regions 
of Germany and Denmark Hans H. Storm1, Gerda Engholm2, Ron Pritzkuleit3, Anne 
Mette T. Kejs4, Alexander Katalinic3, Jürgen Dunst5, Niels Henrik Holländer6 1Danish 
Cancer Society, Copenhagen/Denmark, 2Department of Documentation and Quality, Danish 
Cancer Society, Copenhagen/Denmark, 3Institut Für Krebsepidemiologie, Universität Zu 
Lübeck, Krebsregister Schleswig-Holstein, Lübeck/Germany, 4Department of Documentation 
& Quality, Danish Cancer Society, Copenhagen/Denmark,5Klinik Für Strahlentherapie, 
Universitätsklinikum Schleswig-Holstein, Lübeck/Germany, 6Department of Oncology, Region 
Sjaelland, Naestved Hospital, Naestved/Denmark
Background: A comparison of lung cancer incidence, mortality, prevalence and 
survival in two neighbouring regions of Germany, Schleswig-Holstein, and Denmark, 
Region Zealand, separated by the Fehmarn Belt, was planned based on data recorded 
as part of routine monitoring with a view to joint research and sharing of patients and 
treatment facilities. Methods: Altogether 14,080 lung cancer patients were recorded 
in 2004-2010 in Schleswig-Holstein and 5,009 in Region Zealand. Excluding cases of 
age 90+ years or only known from death certificates, 1- and 4-year relative survival by 
stage and sex for the periods 2004-2006 and 2007-2009 (1-year survival only) were 
calculated. Results: A very high proportion (19%) of cases in Schleswig-Holstein was 
only known from death certificates contrary to Region Zealand (0%). The incidence 
of both, age-standardised and age-specific lung cancer, was much higher in Region 
Zealand versus Schleswig-Holstein (men 73/100,000 versus 68/100,000, women 
58/100,000 versus 32/100,000), also reflected in the mortality figures. Lung cancer 
incidence was increasing among women during the observation period, more so in 
Schleswig-Holstein (3% estimated annual change) compared to Zealand (1%). Overall 
relative survival was lower in Zealand than in Schleswig-Holstein for 1-year survival 
in 2007-2009 (DK: 33% in men and 39% in women, versus G: 43% in men and 49% 
in women) and 4-year relative survival for 2004-2006 (DK: 9-13% versus G: 16-21%). 
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Medical Campus, Aurora/CO/United States of America, 7Pharmacology, University of 
Minnesota, Minneapolis/MN/United States of America, 8Pathology, University of Colorado 
Anschutz Medical Campus, Aurora/United States of America, 9Community and Behavioral 
Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 
Aurora/CO/United States of America
Background: In the context of CT screening in current and former smokers at high 
risk for lung cancer, the false positive rate is high (26% at first NLST screening; 13% 
with Lung-RADS criteria applied to NLST) and indeterminate nodules are frequently 
discovered. Noninvasive biomarkers are urgently needed to reduce false positives with 
screening CT and to improve risk stratification in those with indeterminate nodules. The 
Colorado (CO) Lung SPORE program performed a retrospective longitudinal evaluation 
(Pepe Phase 3 validation) to assess the potential of chromosomal aneusomy detected in 
sputum via fluorescence in situ hybridization (CA-FISH) as a biomarker for early detection 
in four nested case-control studies. Two of the cohorts (ACRIN/NLST and PLuSS) 
enrolled current and former smokers to investigate use of low dose CT to diagnose lung 
cancer. The other two were Colorado cohorts in which pulmonary clinic patients (mostly 
current and former smokers) were enrolled to investigate biomarkers to predict lung 
cancer. One of these cohorts (CO High Risk) was a COPD population and the other, still 
in the accrual phase, comprises patients referred for care of indeterminate lung nodules 
(CO Nodule). Methods: The cohorts were grouped into a Screening cohort (ACRIN/NLST 
(49 cases, 96 controls) and PLuSS (48 cases, 89 controls)) and a High Risk cohort (CO 
High Risk (55 cases, 59 controls) and CO Nodule (13 cases, 10 controls)). The CA-FISH 
assay was a 4-target panel including genomic sequences encompassing the EGFR and 
MYC genes, and the 5p15 and centromere 6 regions or the FGFR1 and PIK3CA genes. 
At the subject level, the assay was scored on a 4-category scale representing normal, 
probably normal, probably abnormal and abnormal. Operating characteristics (with 
95% CI) of the assay were estimated for each group of cohorts overall and separately 
for COPD patients: sensitivity, specificity, likelihood ratio+ (LR+) and likelihood ratio- 
(LR-). Results: Using the cutoff of abnormal vs. not abnormal for CA-FISH, sensitivity 
and specificity for Screening subjects are 0.20 (0.13, 0.30) and 0.84 (0.78, 0.89), 
respectively; and for High Risk subjects are 0.67 (0.55, 0.78) and 0.94 (0.85, 0.98), 
respectively. Likelihood ratios for Screening subjects are LR+: 1.36 (0.81, 2.28) and 
LR-: 0.93 (0.83, 1.05), and for High Risk subjects are LR+: 11.66 (4.44, 30.63), and 
LR-: 0.34 (0.24, 0.48). Similar results were observed when only COPD subjects were 
analyzed. Conclusion: The high LR+ of sputum CA-FISH indicates that this noninvasive 
biomarker could be a clinically useful adjunct to CT among patients in high risk settings. 
Whether this same high level of LR+ will be reproducible in patients at high risk because 
of their indeterminate nodules remains to be seen. If so, a hypothetical patient with 
indeterminate nodules and a pre-test (CA-FISH) lung cancer risk of 20% would have 
a post-test probability of lung cancer of 78% if the CA-FISH test were positive. In the 
screening setting, however, the low LR+ of CA-FISH limits its clinical utility. Prospective 
assessment of sputum CA-FISH is ongoing in the Nodule Cohort of the CO Lung SPORE. 
Keywords: Noninvasive biomarker, indeterminate nodules, positive predictive value, 
post-test probability
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MINI12.03 Comprehensive Analysis of MicroRNA Expression Patterns in Lung 
Adenocacinoma Presenting with GGNs and Non-Tumorous Tissues Yayi He, 
Caicun Zhou, Shengxiang Ren Department of Medical Oncology, Shanghai Pulmonary 
Hospital, Shanghai/China
Background: Lung cancer is the leading cause of cancer death worldwide. Non-small 
cell lung cancer (NSCLC) accounts for about 80% of primary lung cancer cases and 
approximately two thirds of them are diagnosed at an advanced stage . The poor 
prognosis of this disease is partially due to the lack of an effective means of early 
diagnosis. Discovery of an effective and reliable tool for early diagnosis of lung cancer 
would play a pivotal role in improving the prognosis of patients with lung cancer. 
Pulmonary ground-glass nodules (GGNs) are increasingly detected in clinical practice. 
GGNs are related to lung cancer, especially lung adnocacinoma . The subject of how 
to manage the pulmonary GGNs remains controversial. It is necessary to identify 
biological markers that can be used to screen high-risk patients in order to allow better 
lung adenocacinoma presenting with GGNs detection, earlier intervention and increase 
the likelihood of successful treatment. MicroRNAs are small non-coding RNAs of 18–24 
nucleotides, typically excised from 60–110 nucleotide foldback RNA precursor structures 
. MicroRNAs have drawn significant attention in cancer research after it was linked to 
oncogenesis and tumor metastasis. Abnormal expression of microRNAs has been found 
in both haematopoietic and solid tumours by various genome-wide techniques. There is no 
report about the relationship between microRNA and pulmonary GGNs. It is necessary to 
identify biological markers that can be used to screen high-risk patients presenting GGNs 
in order to allow early lung adenocacinoma detection. Our study investigated microRNA 
expression with the intention to identify a panel of microRNAs for the diagnosis of lung 
adenocarcinoma presenting with GGNs. Methods: 73 pairs of samples (tumorous and 
non-tumorous) were surgically resected from lung adnocacinoma patients presenting 
with GGNs from Shanghai Pulmonary Hospital between May 2012 and June 2014. After 
obtaining the approval of the patient consent, fresh tissues samples were taken during 
surgical resection, snap-frozen on dry ice and stored at−80αC. MicroRNA expression of 
tumor and non-tumorous tissues was investigated in 3 participants by the next generation 
sequencing. Then, we analyzed the difference expression microRNA profiles which 
were identified by second generation sequencing in 73 pairs of lung adenocacinoma 
presenting with GGNs and adjacent non-tumorous tissues using a quantitative reverse-
transcriptase polymerase chain reaction assay (qRT-PCR). Results: When we compared 
microRNA expression among lung cancer tissues versus corresponding noncancerous 
lung tissues via next-generation sequencing, 23 microRNAs had statistical differences in 
expression between groups. Five microRNAs (hsa−miR−548ar−5p, chr10_7330_star, 
to March 2015. We collected demographic information, smoking history, environmental 
exposure and clinicopathological characteristics including histology, molecular profile, 
stage, treatment and survival. The radon concentration was analysed using optical 
microscopy with radosys system 2000. EGFR, KRAS, BRAF mutation (m) were analysed 
using quantitative real-time polymerase chain reaction (PCR) and ALK and ROS1 
rearrangements by fluorescence in situ hybridization (FISH). Statistical analysis was 
performed using IBM SPSS. Results: So far now, 48 NSCLC adenocarcinoma p. have 
been enrolled although only 31 have already completed radon measurement. Median 
age 59 years (range 33- 82); 58,1% female; 77% ECOG 0; 74,4% stage IV; 90,3% living 
in Madrid. Smoking habits: non-smokers 58% (9p. EGFRm, 7p. ALKr, 2p. BRAFm), light 
smokers 6,45% (1p. EGFRm, 1p. ALKr) and heavy smokers 35,4% (6p. EGFRm, 5p. 
KRASm). Median pack-years: light smokers 2,5 (2-3), heavy smokers 44 (20-80). Non-
smoker p. reported 27,8% passive-smoking exposure and 44,4% childhood exposure. 
Radon measurement characteristics: type of building 83.9% flat; building material: 87.1% 
bricks. Median time of permanence in the same house: 25 years (2-55). Median height 
of house 3 floors (0-6). Most of measurement at bedroom (93,5%). Median of radon 
concentration: 103 Bq/m3 (42- 852); 51.6% over WHO recommendation. By molecular 
alteration: EGFRm median 91 Bq/m3 (42-164), ALKr median 128 Bq/m3 (64-852), 
BRAFm median 125 Bq/m3, KRASm median 80 Bq/m3 (44-149). ALKr demonstrated 
association with levels higher than WHO recommendation (p=0.045 Fisher’s exact 
test). Conclusion: Our preliminary results show that radon concentrations in NSCLC 
harbouring molecular alterations are higher than WHO recommendation, particularly in 
patients with ALK rearrangement. Final results will help to confirm this possible association. 
Keywords: radon, molecular, lung, cancer
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MINI12.01 A Novel Serum 4-MicroRNA Signature for Lung Cancer Detection 
Ernest Nadal1, Anna Truini2, Asuka Nakata3, Jules Lin4, Rishindra Reddy4, Andrew C. 
Chang4, Nithya Ramnath4, Noriko Gotoh3, Guoan Chen4, David Beer5 1Catalan Institute 
of Oncology, L’Hospitalet/Spain, 2, IRCCS AOU San Martino-IST, Genova/Italy, 3Institute 
of Medical Science, Tokyo/Japan, 4University of Michigan, Ann Arbor/MI/United States of 
America, 5University of Michigan, Ann Arbor/United States of America
Background: Early detection of lung cancer using low-dose CT led to a 20% reduction 
in mortality. However, this strategy has several limitations including high false-positive 
rates, potential over-diagnosis, and the potential harm associated with radiation 
exposure. The aim of this study was to identify differentially-expressed miRNAs in the 
serum of non-small cell lung cancer (NSCLC) patients that might be a clinically-useful 
tool for lung cancer early detection. Methods: We performed miRNA expression profile 
analysis using TaqMan OpenArray Human panel in a discovery set of 70 serum samples 
obtained at lung tumor resection including lung adenocarcinoma (AD) and lung squamous 
carcinoma (SCC) and 22 non-cancer subjects (NC). To construct the diagnostic 
signature, the miRNA candidates were selected based upon the following criteria: 
miRNAs significantly up-regulated (adjusted t-test p < 0.001) in the NSCLC tissue and 
serum as compared to normal lung tissue and NC serum respectively, not overexpressed 
in circulating blood cells and with Area Under the Curve (AUC) > 0.840 for discriminating 
stage I LC from NC in the receiver-operating characteristic (ROC) plots. Selected serum 
miRNAs were then validated by quantitative PCR using an independent validation set of 
serum samples from LC patients (n=84) and NC (n=23). Results: Sixty miRNAs were 
significantly up-regulated and 31 were down-regulated in the serum from NSCLC patients 
versus NC (adjusted p<0.001). Four miRNAs (miR-193b, miR-301, miR-141 and miR-200b) 
were selected for validating their diagnostic value in an independent cohort. A diagnostic 
signature was obtained by logistic regression based upon the expression values of these 
4 serum miRNAs in the discovery set. This miRNA signature generated an AUC of 0.985 
(95% CI 0.961 – 1.000, p < 0.001) for detecting NSCLC (all stages) and of 0.989 (95% 
CI 0.967 – 1.000, p < 0.001) for detecting stage I NSCLC in the discovery set. In the test 
set, the diagnostic utility of this miRNA signature was validated and exhibited an AUC of 
0.993 (95% CI 0.979 – 1.000, p < 0.001). Conclusion: We identified a serum 4-miRNA 
signature that discriminated with high accuracy lung cancer patients from NC. Further 
prospective validation of this miRNA signature is warranted using an independent cohort 
of serum samples from patients who participated in a lung cancer screening program. 
Keywords: circulating microRNAs, early diagnosis, serum biomarkers, lung cancer 
detection
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MINI12.02 Clinical Utility of Chromosomal Aneusomy in High Risk Individuals 
Anna E. Barón1, Severine Kako2, William J. Feser1, Daniel T. Merrick3, Kavita Garg4, 
Stephen Malkoski5, Shannon Pretzel2, Tim Byers6, Jill M. Siegfried7, Wilbur A. Franklin8, 
York E. Miller5, Holly J. Wolf9, Marileila Varella-Garcia2 1Biostatistics and Informatics, 
Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 
Aurora/CO/United States of America, 2Medicine, University of Colorado Anschutz Medical 
Campus, Aurora/CO/United States of America, 3Pathology, University of Colorado Anschutz 
Medical Campus, Aurora/AL/United States of America, 4Radiology, University of Colorado 
Anschutz Medical Campus, Aurora/CO/United States of America, 5Pulmonary and Critical 
Care Medicine, University of Colorado Anschutz Medical Campus, Aurora/United States of 
America, 6Epidemiology, Colorado School of Public Health, University of Colorado Anschutz 
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MINI12.06 Bioconductance Compared to 18FDG-PET in Evaluating CT-Detected 
Lung Lesions Rex Yung1, Jeff O’Driscoll2, Michael Garff3, Ming Ying Zeng4
1Pulmonology, Greater Baltimore Medical Center, Townson/MD/United States of 
America, 2Emergency Medicine, Intermountain Health Care, Salt Lake City/UT/United States 
of America, 3Prolung, Salt Lake City/UT/United States of America, 4Pulmonology, Johns 
Hopkins School of Medicine, Baltimore/MD/United States of America
Background: Lung cancer (LC) is the leading cause of cancer mortality. Computed 
tomographic (CT) screening detects LC at earlier stages but also results in fi nding 
many more smaller, benign nodules. Positron-Emission-Tomography (PET) is commonly 
used to evaluate suspicious lesions prior to invasive biopsies. However, PET accuracy 
is confounded by various factors including size, infl ammation and tumor metabolic 
activity. Another potential biomarker of cancerous tissue is a non-invasive measure of 
transcutaneous bioconductance. This study compares Electro Pulmonary Nodule (EPN), 
a tissue bioconductance scan, to 18FDG-PET in evaluating CT detected suspicious lung 
lesions. Methods: Cohort- 27 patients with suspicious nodules evaluated with both PET 
and EPN scanning (IRB approved protocol) prior to biopsy or long-term radiologic follow-
up. An EPN Scan measuring bioconductance was performed on bilateral anatomic skin 
sites and results were scored as either positive or negative dependent on a defi ned cut-off 
point. The PET results were interpreted as positive, negative or indeterminate. Results: 
There were 18 LCs (16 non-small cell LC, 2 small cell LC) and 9 benign lesions. PET 
results yielded 7 indeterminate readings. Excluding these 7, PET had 100% sensitivity 
(14/14 true positives) and 67% specifi city (4/6 true negatives). EPN Scan evaluation 
of these 20 determinate PET cases had 86% sensitivity (12/14 true positives) with 
83% specifi city (5/6 true negatives). When evaluating the entire cohort of 27, the EPN 
results improved sensitivity and specifi city to 89% (16/18 true positives) and 89%(8/9 
true negatives), respectively. Table 1 describes the 7 lesions 18FDG-PET indeterminate 
lesions compared to EPN Scanning. 
In these 7 cases, the EPN Scan correctly classifi ed all cases for 100% accuracy. Of note, 
2 of the 4 cancers classifi ed by PET as “indeterminate” were < 1 cm and were correctly 
categorized by the EPN Scan. Conclusion: While 18FDG-PET is often used as a clinical 
adjunct in the evaluation of suspicious CT detected pulmonary lesions, it has recognized 
limitations. In this feasibility study of measuring transcutaneous bioconductance as a pre-
biopsy assessment, EPN Scan performed favorably versus PET, especially in evaluating 
smaller or PET-indeterminate lesions. Keywords: Lung, Cancer, Bioconductance, PET
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MINI12.07 Exhaled Breath Analysis in Lung Cancer – One Stop Shop for 
Diagnosis, Staging and EGFR Analysis Nir Peled1, Ori Liran2, Manal Abud-Hawa3, 
Maya Ilouze1, Naomi Gai-Mor2, Dekel Shlomi2, Alon Ben-Nun4, Amir Onn5, Jair Bar5, 
Hossam Haick3 1Thoracic Cancer Unit, Davidoff Cancer Center, Petach Tiqwa/Israel, 2The 
Thoracic Cancer Research and Detection Center, Sheba Medical Center, Ramat-Gan/
Israel, 3The Department of Chemical Engineering and Russell Berrie Nanotechnology 
Institute, Technion – Israel Institute of Technology, Haifa/Israel, 4Thoracic Oncology Unit, 
Sheba Medical Center, Ramat-Gan/Israel, 5Institute of Oncology, Sheba Medical Center, 
Ramat-Gan/Israel
Background: Lung cancer (LC) is the leading cause of cancer death in the United 
States with more than 158,000 estimated deaths in 2015. Early detection of LC has 
been well established as a signifi cant key point in patients’ survival and prognosis, yet 
unfortunately, the vast majority of new LC patients are being diagnosed at advanced 
disease stages. Exhaled breath analysis can serve as a non-invasive method in early 
detection of LC. The tumor’s micro-environment releases various compounds to blood, 
some of which are then exhaled at breath as Volatile Organic Compounds (VOCs). This 
study evaluates the potential of exhaled breath analysis in LC detection and to further 
diagnose histology, EGFR mutational status and to discriminate early from advanced 
chr17_10932_star, hsa−miR−148a−3p, hsa−miR−210−3p) exhibited higher expression 
in the adnocacinoma samples than that in the non-tumorous samples, eighteen microRNAs 
(hsa−miR−548x−5p, hsa−miR−144−3p, hsa-miR-106a-5p, hsa−miR−548ay−5p, hsa−
miR−199a−3p, hsa−miR−378d, hsa−miR−4732−3p, hsa−miR−486−3p, chr7_5517, 
hsa−miR−1307−5p, chr17_10880, hsa−miR−127−3p, hsa−miR−411−5p, chr1_1402, 
chr16_10269, hsa−miR−138−5p, hsa−miR−212−3p, hsa−miR−33b−5p) demonstrated 
lower expression in adnocacinoma samples than that in the non-tumorous samples 
(P＜0.05). Further validated by qRT-PCR, six microRNAs (chr17_10932_star, hsa−
miR−148a−3p, hsa−miR−210−3p, chr1_1402, hsa−miR−378d, hsa−miR−138−5p) 
were statistically differentially expressed in tumorous compared with non-tumorous 
tissues. Conclusion: We found a microRNA panel that has considerable clinical value 
in diagnosing lung adenocacinoma presenting with GGNs. Thus, patients who would 
have otherwise missed the curative treatment window can benefi t from optimal therapy. 
Keywords: lung adenocarcinoma, microRNA, ground-glass nodules (GGNs), next-
generation sequencing
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MINI12.04 Blinded Evaluation of the LuCED test to Detect Early Stage Lung 
Cancer Michael Meyer1, Chris Presley1, David Wilbur2, Rahul Katdare1, Jon Hayenga1, 
Timothy Bell1, Jianming Liang3, Alan Nelson1 1Visiongate, Phoenix/United States of 
America, 2Massachusetts General Hospital, Boston/United States of America, 3Department 
of Biomedical Informatics, Arizona State University, Tempe/AL/United States of America
Background: A previous, non-blinded study presented at the American Society of 
Cytopathology demonstrated performance of the LuCED® test for early detection of 
lung cancer and showed a sensitivity to cancer of 93.6% with 100% specifi city based on 
94 patients. Sensitivity was consistent across tumor histology, stage, size and location. 
Here, LuCED performance is presented where the pathologist was blinded to the case 
diagnosis. Data for this evaluation was produced as part of the CLIA validation of LuCED 
for use in the VisionGate Biosignatures Laboratory. Methods: Sputum from 42 patients 
was processed by LuCED: 23 patients had biopsy-confi rmed lung cancer and 19 patients 
were normal. Sputum was collected from three spontaneous morning coughs, fi xed and 
stained with hematoxylin, and enriched for epithelial cells using fl uorescence activated 
cell sorting. Each enriched specimen was analyzed using the Cell-CT® platform that 
computes 3D digital images of single cells through tomographic reconstruction with 
isometric, sub-micron resolution. 3D morphometric biosignatures were automatically 
measured to produce a probabilistic score that identifi ed abnormal cell candidates while 
a second score identifi ed normal bronchial epithelial cells to determine specimen 
adequacy. Specimen adequacy was achieved when either abnormal cells were detected 
or 800 normal bronchial epithelial cells were enumerated by the classifi er, whichever 
came fi rst. Data was randomized by case and cell images of abnormal candidates were 
viewed using a CellGazer® workstation for blinded, cytopathologist confi rmation. Cases 
were run until one of the following conditions was met: an abnormal cell was discovered, 
the specimen was exhausted, the criterion for specimen adequacy was reached. Example 
images of positive cells are shown in Figure 1. Results: For cancer cases, lung cancer 
histology included adenocarcinoma (10 cases), squamous cancer (7), small cell lung 
cancer (3) and undifferentiated cancer (3); representing TNM stages I (5), II (10), IV (5), 
and unknown (3). Abnormal cells were found in all 23 cancer cases for 100% case 
sensitivity (lower 95% CI bound: 85.1%). Non-cancer lung diseases may produce 
reparative changes whose morphology can mimic cancer cell features. To stress test 
LuCED, patients with COPD, bronchitis, etc., were included in the normal group. 100,645 
cells were processed from the 19 normal cases with 0.47% identifi ed by the classifi er for 
review using CellGazer. No abnormal cells were found. Case specifi city is 100% (lower 
95% CI bound: 82.4%). Conclusion: This interim blinded study of LuCED performance 
demonstrates highly sensitive (100%) and specifi c (100%) early lung cancer detection 
suggesting utility as a non-invasive screening test. Keywords: Early Detection, high 
sensitivity, high specifi city, lung cancer
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and a range of psychological measurements. There is a nested qualitative study of the 
psychological effects test of results on participants. Results: In the first 14 months of 
recruitment 8 848 patients have been recruited and 9.0% of those tested have had a 
positive blood test with eight early cancers and 13 abnormalities undergoing further 
investigation detected to date in those who tested positive. Six of the eight cancers have 
been staged and four of these are early cancers. Provisional data reported to the trial 
team on those tested negative include three cancers. No data are currently available 
for the main trial comparison. From prior observational studies the test performance is 
expected to be: 40% sensitivity and 90% specificity these early data. Based on the study 
so far the current Positive Predictive Value of the test is 2.0%. Conclusion: The study 
will determine the EarlyCDT-Lung test’s clinical and cost effectiveness. It will also assess 
potential morbidity arising from the test and potential harms and benefits of a negative 
EarlyCDT-Lung test result. Early results in the test only arm of the trial are encouraging.
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MINI12.11 Screening for Lung Cancer with the Early CDT-Lung and Computed 
Tomography James R. Jett1, Debra Dyer2, Jeffrey Kern3, Donald Rollins4, Melanie 
Phillips5 1Oncology, National Jewish Health, Denver/CO/United States of America, 2Radiology, 
National Jewish Health, Denver/CO/United States of America, 3Oncology, National Jewish 
Health, Denver,Co/CO/United States of America, 4Pulmonary, National Jewish Health, Denver/
CO/United States of America, 5National Jewish Health, Denver/CO/United States of America
Background: Early CDT-Lung, a serum based biomarker consisting of a panel of seven 
autoantibodies that develop in response to tumor associated antigens, has been shown 
to detect lung cancer in all stages of disease. We hypothesized that this biomarker when 
used in combination with a low-dose CT (LDCT) in screening of a high-risk population 
would increase the detection of early stage lung cancer. Methods: A prospective study 
of 1,600 subjects at high risk for lung cancer was designed. Eligibility criteria included 
persons 50-75 years of age, current or former smokers of ≥ 20 pack years and < 10 
years since quit smoking. Those with a history of lung cancer in first degree relative(s) 
and any history of smoking were included. Exclusion criteria ware any history of cancer 
within 10 years (except skin cancer), any use of oxygen, and life expectancy of < 5 
years. A direct mail campaign was conducted with study announcements sent to the 
homes of potentially high-risk individuals, who then contacted us for consideration of 
participating in this screening study. Those fitting inclusion criteria received the Early 
CDT-Lung blood test and a LDCT. A nodule of ≥ 3mm was considered as a positive scan. 
The Early CDT-Lung test was considered positive if any one of the seven autoantibodies 
was positive. All participants are to have yearly telephone follow-up for two years. 
Results: From May 2012 through November 2014, 815 individuals were enrolled and 
814 completed the initial blood and LDCT screening tests. The cohort median age was 
59 years with 55% female and 45% male gender distribution. The mean smoking history 
was 44 pack-years. Fifty-four per cent were current smokers while 46% were former 
smokers. Forty-six per cent of the LDCTs were negative for any lung nodule while 38% 
were positive. Incidental non-lung cancer findings were identified in 15% of the study 
group. The Early CDT-Lung biomarker was positive in 60 (7%) of participants, 23 males 
and 37 females. In those with a positive LDCT (n=313), the biomarker was positive 
in 25 (8%). As of January 30, 2015, there have been six confirmed lung cancers: two 
limited stage small cell, two Stage IB adenocarcinoma (ACA), and two Stage IA (one 
ACA and one squamous cell). The Early CDT-Lung blood test was positive in two of 
the four Stage IA/B lung cancers and negative in the two small cell cancers.There are 
35 Early CDT-Lung biomarker positive individuals whose LDCT had no nodule. These 
individuals are being followed with yearly LDCT for two years. The study is continuing 
to accrue with a goal of 1,600. (NCT01700257). Conclusion: The Early CDT-Lung 
biomarker was positive in 7% of our high-risk population. The biomarker was positive in 
two of six lung cancers, specifically in two of four Stage I lung cancers. Accrual to the 
study and follow-up of 35 biomarker positive but LDCT negative participants continues. 
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MINI12.12 Validation of Blood-Based Biomarker for Classification of Patients 
with Indeterminate Pulmonary Nodules Jennifer L. Tomic1, Robert L. Lagier1, 
Harvey I. Pass2, William N. Rom3, Thomas R. Pollard4, Charlie E. Birse1 1Research and 
Development, Quest Diagnositics, Alameda/CA/United States of America, 2Department 
of Cardiothoracic Surgery, NYU Langone Medical Center, New York/NY/United States of 
America, 3Division of Pulmonary Medicine, NYU School of Medicine, New York/NY/United 
States of America, 4East Tennessee Cardiovascular Surgery Group, Knoxville/TN/United 
States of America
Background: The United States Preventive Services Task Force recommends annual 
CT-screening for lung cancer in high risk adults but also acknowledges that one 
disadvantage of CT-screening is the large number of false positive results. Circulating 
biomarkers may provide a noninvasive, cost-effective means of addressing this 
disadvantage by assisting with classification of patients with indeterminate pulmonary 
nodules. Here, we describe the development and testing of a blood-based 5-analyte 
panel to classify these patients. Methods: A 5-analyte panel was developed in a 
training study comprising stage I NSCLC patients (n=95) and healthy smoker controls 
(n=186). The ability of the biomarker to resolve patients with benign nodules from 
those with malignant lesions was investigated in two validation studies: (1) Prostate, 
Lung, Colorectal, Ovarian (PLCO), a CXR-based screening trial, cases n=56, controls 
n=56; (2) Conversant Bio (CB), cases n=22, controls n=22. Results: In the training 
study, the 5-marker classifier (TFPI, OPN, CEA, CYFRA, SCC) resolved malignant cases 
with 72% sensitivity and 90% specificity (AUC=0.90). In the PLCO validation study, the 
disease in a multinational study. Methods: Breath samples were taken from untreated 
LC patients and matching controls. Patients were enrolled in a large tertiary referral 
hospital in Israel. Analysis was performed by gold nanoparticle-based Artificial Olfactory 
System (NaNose®) and Pattern recognition methods were used to analyze the results 
obtained from the NaNose®. Histology, EGFR mutation status and staging was taken 
from patient’s files. Results: A total of 174 patients participated in this study, and 
Inter-group analysis of 80 LC patients (64 advanced stage) and 31 matched controls 
showed a significant discrimination between disease and control. Among all patients, 
83 were adenocarcinoma and 11 were squamous. EGFR mutations were detected 
in 24 patients. The comparisons resulted in: early LC versus control: p < 0.0001; 
accuracy 85.11%, advanced LC versus control: p < 0.0001; accuracy 82.11%, early 
LC versus advanced LC: p< 0.0001; accuracy 78.75%. Histology (Adenocarcinoma vs. 
Squamous cell carcinoma) and EGFR status was also significantly determined by the 
volatile signature. Conclusion: Breath analysis may support early detection of cancer 
as well as histological diagnoses, staging and mutational testing in lung cancer. This 
innovative method may pose as an important non-invasive tool for lung cancer early 
detection, thus promoting better prognosis and therapeutic possibilities for patients. 
Keywords: lung cancer, Biomarkers, Early Detection, Exhaled Breath
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MINI12.08 Validation of Autoantibody Panel for Early Detection of Lung Cancer 
in Chinese Population Shengxiang Ren1, Shucai Zhang2, Zhiyong Ma3, Hourong Cai4, 
Xiaohong Xu5, Jing Zhou6, Xiaopeng Liu6, Xuejun Hu6, Caicun Zhou1 1Shanghai Pulmonary 
Hospital, Tongji University School of Medicine, Shanghai/China, 2Beijing Chest Hospital, 
Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, 
Beijing/China, 3Henan Cancer Hospital, Zhengzhou/China, 4Nanjing Drum Tower Hospital, 
Nanjing/China, 5Zhejiang Cancer Hospital, Hangzhou/China, 6Hangzhou Cancerprobe 
Biotechnology Company, Hangzhou/China
Background: Autoantibodies is an attractive diagnostic approach for early detection of 
malignant tumors. Our previous studies found a panel of 7 TAAs(p53, GAGE7, PGP9.5, 
CAGE, MAGE A1, SOX2, GBU4-5) was associated with lung cancer. We performed this 
large-scale, multi-center clinical trial to validate their ability to aid early diagnosis of 
lung cancer in Chinese population. Autoantibodies is an attractive diagnostic approach 
for early detection of malignant tumors. Our previous studies found a panel of 7 
TAAs(p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4-5) was associated with lung 
cancer. We performed this large-scale, multi-center clinical trial to validate their ability 
to aid early diagnosis of lung cancer in Chinese population. Methods: The 7 TAAs were 
selected from 43 candidate TAAs from our previous studies, which were detected by 
ELISA in 1915 participants from 5 clinical centers in China. These samples including 
lung cancer (n = 818), benign lung diseases (n = 386), healthy volunteers (n = 415) 
and interference group (n = 296). The sensitivity and specificity from 7 TAAs and the 
traditional cancer biomarkers CEA, NSE and CYFRA21-1 were compared. Results: The 
sensitivity and specificity of autoantibody assay were 61% and 90% respectively, 
which were similar in different subgroups such as age, gender, smoker status and 
histological type. As for the enrolled patients with lung cancer, the sensitivities were 
60% for patients with stage I/II, which were significantly higher than 27% ( p < 0.01)
when using the combination of CEA, NSE and CYFRA21-1 to detect patients with 
lung cancer. While in patients with stage III/IV lung cancer, sensitivities were similar 
(63% vs. 56%, p > 0.05) and specificity was significantly improved (90% vs 71%, p 
< 0.01). The specificity was consistent in benign lung diseases and autoimmune 
diseases(interference group) and were 90% and 94% respectively and a concentration 
decrease of 7 TAAs were also observed after tumor resection. Conclusion: This 
study suggest that the 7 TAAs autoantibody panel can be used to aid diagnosis of 
lung cancer, and show a significantly improving sensitivity in patients with early stage 
lung cancer when comparing with the combination of CEA, NSE and CYFRA21-1. 
Keywords: early diagnosis, lung cancer, Antibody
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MINI12.09 Progress with an RCT of the Detection of Autoantibodies to Tumour 
Antigens in Lung Cancer Using the Early CDT-Lung Test in Scotland (ECLS) 
Frank Sullivan1, Stuart Schembri2 1Department of Family and Community Medicine, 
University of Toronto, Toronto/Canada, 2NHS Tayside, Dundee/United Kingdom
Background: Since the majority of lung cancer cases are detected at a late stage the 
prognosis remains poor at present. The National Lung Screening Trial (NLST) reported 
20% reductions in lung cancer mortality in 2011, however as a primary screening 
modality CT is expensive and may lead to significant morbidity in individuals whose 
tests are false positives. The EarlyCDT-lung test detects autoantibodies to proteins in 
the earliest stages of the disease with a specificity of 93%. Research question Does 
using the EarlyCDT-Lung test reduce the incidence of patients with late-stage lung 
cancer (3 & 4) or unclassified presentation (U) at diagnosis, compared with standard 
practice? Methods:We are conducting an RCT of 12 000 participants in areas of 
Scotland within the most deprived quintile of the population whose mortality from lung 
cancer is high by international standards. Adults aged 50 to 75 who are at 1.2% risk 
over the next 2 years are eligible to participate. They should also be healthy enough to 
undergo curative interventions. We will undertake a comparison of the EarlyCDT-lung test 
and follow-up imaging at six monthly intervals for 2 years with standard clinical practice. 
The primary outcome is the difference, after 24 months, between the rates of patients 
with stage 3, 4 or unclassified lung cancer at diagnosis. Participants who develop lung 
cancer will be followed-up via electronic record-linkage to assess both time to diagnosis 
and stage of disease at diagnosis. The secondary outcomes are cost-effectiveness, 
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tumor-non-tumor pairs. The assembled panel for this effort included n=19 tumor-non-
tumor differentiating microRNAs (miR-9, 18a, 20a, 31, 130b, 142, 146, 182, 183, 196a, 
200a, 200c, 205, 210, 212, 221, 224, 330 and 708) chosen from the literature and our 
own lung tissue-based discovery data. Small nuclear RNA U1 was a housekeeping gene 
in the study based on its universality. Qualitative and quantitative (miRNA qPCR data 
normalized to internal reference U1 small ncRNA) analyses were considered. Multivariate 
analyses considered clinical information, including age, smoking status, underlying lung 
disease (COPD or not). Results: By univariate analyses, between cases (all histologies) 
and controls, qualitative/binary data showed miR-221 (p=0.030; OR=3.11) and miR-708 
(p=0.016; OR=3.04) were significantly different. The case-adenocarcinoma subgroup 
(n=13) also differed from the controls in miR 708 frequency (p=0.034, OR=4.71). 
Examples of multivariate analyses (qualitative/binary data, case – all histologies) are 
shown in the Table: ontrols.
miRNA Odds Ratio lower bound of CI
upper bound 
of CI p-value
miR.221 3.339 0.994 12.482 0.059
age 1.084 1.026 1.158 0.008
smoking 1vs0 1.467 0.304 8.372 0.642
smoking 2vs0 2.211 0.411 14.436 0.371
Underlying lung dz (COPD vs 
no COPD) 3.400 1.184 10.349 0.026
miR.708 5.041 1.651 17.603 0.007
age 1.093 1.031 1.172 0.006
smoking former vs never 1.378 0.273 8.145 0.704
smoking current vs never 2.144 0.386 14.269 0.397
Underlying lung dz (COPD vs 
no COPD) 4.437 1.448 15.047 0.012
 
Similar multivariate models were obtained for miR 221 and miR708 in the cancer-
adenocarcinoma subgroup. No clear case-control discriminant exhaled microRNAs were 
found in the analogous quantitative data (delta CT) analyses, by univariate or multivariate 
analyses. Conclusion: From the qualitative analysis, two possible miRNA biomarkers of 
case status (miR-221 and miR-708) were obtained. Previous work had suggested miR 221 
as a discriminant microRNA in lung cancer case versus control setting. Quantitative data 
was not informative. We are working on expanding and refining the miR panel, and larger 
sample size to partition covariates such age, underlying lung disease, and other factors. 
Our goal is to test this non-invasive biomarker approach to lung cancer risk assessment. 
Keywords: microRNA, biomarker, EBC, lung cancer
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MINI13.01 Clinicopathological Profiles of ROS1 Positive Patients Screened 
by FISH Jamie Sheren, Dara L. Aisner, Daniel T. Merrick, Eamon M. Berge, Patrick 
Chesnut, Robert C. Doebele, D. R. Camidge, Marileila Varella-Garcia University of 
Colorado School of Medicine, Aurora/CO/United States of America
Background: ROS1 fusion variants represent an important subset of oncogenic driver 
mutations in approximately 0.7 – 3.4% of non-small cell lung cancers. Since the frequency 
of ROS1 positive lung cancer patients is relatively low, it is unclear whether there are 
significant clinicopathologic associations for positive cases. Thus far, ROS1 positive 
patients tend to be younger and never-smokers with tumors displaying adenocarcinoma 
histology. This study describes a further cohort of ROS1 positive lung cancer patients 
in an effort to identify clinicopathologic associations. Methods: The data represent a 
retrospective analysis of the clinicopathological profiles of primary and metastatic 
lung cancer patients tested for ROS1 gene rearrangements by break-apart (BA) FISH 
at the University of Colorado School of Medicine. Results: The cohort consisted of 
452 patients enriched for triple-negative (EGFR-, KRAS- and ALK-) non-squamous cell 
carcinomas screened for ROS1 rearrangements using the BA FISH assay. Nineteen 
cases (4.2%) were identified as positive for rearrangement, the majority (68%) of 
which were female, with a mean cohort age of 54.9 years (range 30-79); as compared 
to negative cases which included 56% female patients (P= 0.1083), and had a mean 
cohort age of 62.9 (range 21-90) (P= 0.0058). Seventeen out of the 19 ROS1 positive 
tumors were classified as adenocarcinomas, one was diagnosed as adenosquamous 
carcinoma, and the histology on one specimen was not otherwise specified (NOS). 
Among 12 individuals with information on pathologic stage at diagnosis, the majority 
(75%) were stage IV. The prevalent FISH pattern for rearrangement was a split 5’ and 
3’ signal (68%) with the remaining specimens showing primarily single 3’ signals (21%) 
or a mix of split and single 3’ signals (11%). Conclusion: The ROS1 positive tumors in 
this cohort were primarily classified as adenocarcinomas, diagnosed at an advanced 
stage, in patients significantly younger and more likely to be women, although the 
sample set was biased for non-squamous lesions thereby limiting the application of this 
information to squamous cell lung carcinoma. The higher prevalence of ROS1 positive 
cases in this cohort compared to unselected cohorts is best explained by the inclusion of 
specimens with known negative status for EGFR and KRAS mutations and ALK fusions. As 
biomarker distinguished pre-diagnostic cases with an AUC=0.65. In the CB study, a 
clinical model developed integrating nodule size, nodule location and gender, classified 
subjects with an AUC=0.79. When added to the clinical model, the biomarker significantly 
improved overall accuracy (P=0.016; AUC=0.86). Conclusion: A blood-based 
biomarker has been developed that accurately classifies patients with indeterminate 
nodules. Adding this biomarker to currently employed clinical and imaging-based 
evaluations of pulmonary nodules, may prove valuable in assessing malignant risk. 
Keywords: Early Detection, Indeterminate pulmonary nodule, Blood-based biomarker
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MINI12.13 Early Detection of Lung Cancer Using DNA Methylation in Plasma 
and Sputum Alicia Hulbert1, Alejandro Stark2, Chen Chen1, Ignacio Jusue-Torres3, 
Kristen Rodgers4, Berverly Lee4, Candace Griffin1, Andrew Yang4, Kiichi Sugimoto1, 
Zhihao Lu1, John Wrangle5, PeterB. Illei1, Richard Battafarano4, Daniela Molena4, Stephen 
Yang4, Peng Huang1, Tza-Huei Wang2, Stephen Baylin1, Robert Brown6, Malcolm Brock4, 
James G. Herman7 1Department of Oncology, Johns Hopkins University School of Medicine, 
Baltimore/MD/United States of America, 2Institute of Nanobiotechnology Johns Hopkins 
University, Baltimore/MD/United States of America, 3Department of Neurosurgery, Johns 
Hopkins University School of Medicine, Baltimore/MD/United States of America, 4Thoracic 
Surgery, Johns Hopkins University School of Medicine, Baltimore/MD/United States of 
America, 5, Medical University of South Carolina, South Carolina/SC/United States of 
America, 6Pulmonary Medicine, Johns Hopkins University School of Medicine, Baltimore/MD/
United States of America, 7Oncology, University of Pittsburgh, Pittsburgh/PA/United States 
of America
Background: Lung cancer is the worldwide leading cause of cancer-related mortality. 
Almost 85% of lung cancer cases are diagnosed at late stages with a five-year-survival 
probability at the time of diagnosis of 16.8%. The National Lung Screening Trial (NLST) 
showed a 20% reduction in lung cancer mortality using low-dose computed tomography 
(CT) screening, but there was also a 96.4% false positive rate. Lung cancer screening 
might be improved through cancer specific biomarkers detected in body fluids such as 
plasma or sputum. Previous studies using DNA methylation failed to achieve adequate 
sensitivity because of use of infrequently methylated genes and detection techniques 
unable to detect the small amounts of DNA yielded from blood and sputum. We sought to 
improve the diagnostic accuracy using gene promoter methylation in blood and sputum 
through the use of Methylation On Beads (MOB) and a highly lung-cancer specific panel of 
genes for detection of lung cancer. Methods: We conducted a prospective case-control 
study obtaining cases and controls from the Lung Cancer Spore. Cases had pathological 
confirmation of Non-Small Cell Lung Cancer (NSCLC) lesion stage IA or IB. Controls were 
defined as patients with pathological confirmation of non-cancerous lesion in the surgical 
specimens. Plasma, sputum and CT scans were obtained pre-operatively. We quantified 
methylation levels and the amplification cycle threshold from sputum and plasma 
samples by using MOB and quantitative methylation specific real-time PCR lung cancer-
related genes previously identified from The Cancer Genome Atlas (TCGA). This panel of 
genes include: CDO1, TAC1, HOXA7, HOXA9, SOX17 and ZFP42. Results: A total of 210 
subjects fulfilled inclusion criteria, including 150 patients with NSCLC and 60 patients 
with non-cancerous lesions. All six genes were methylated in significantly more people 
with cancer than without cancer in both plasma and sputum (p<0.001) with the exception 
of HOXA9 in sputum, which was methylated in more than 90% of people with cancer 
and more than 90% of people without cancer. After adjusting by age and pack·year, 
the methylated genes that were significantly associated with risk of lung cancer stage 
IA & IB from blood samples were: CDO1 (p=0.009), TAC1 (<0.001), HOXA9 (p=0.005), 
SOX17 (<0.001) & ZFP42 (p=0.003) and from sputum samples were: CDO1 (p=0.066), 
TAC1 (p=0.007), ZFP42 (p=0.009). Sensitivity and specificity for lung cancer diagnosis 
using the 3 best genes in plasma was 91% and 68% respectively and for sputum 91% and 
88%. Area under the curve for 3 best genes in plasma was 0.78 95% confidence interval 
(CI) (0.69-0.87) (p<0.001) and for the best 3 genes in sputum 0.88 95% CI (0.77-0.99) 
(p<0.001). Conclusion: This study shows that its is possible to obtain high diagnostic 
accuracy for Lung Cancer in early stages using a panel of methylated promoter genes in 
Plasma and Sputum, by using Methylation-on-beads. These epigenetic biomarkers could 
potentially be used to identify patients with high risk of lung cancer development. reducing 
unnecessary tests and increasing the chance to diagnose lung cancer at earlier stages 
Keywords: Epigenetic, Biomarkers, Gene promoter Methylation,Screening, Lung 
Cancer, Earlier Stages
BIOMARKERS AND LUNG NODULE MANAGEMENT 
MONDAY, SEPTEMBER 7, 2015 - 16:45-18:15
MINI12.14 Exhaled microRNAs as Potential Biomarkers of Lung Cancer 
Case versus Control Status Miao Shi1, Weiguo Han1, Juan Lin2, Simon D. Spivack1 
1Medicine/Pulmonary, Albert Einstein College of Medicine, Bronx/NY/United States of 
America, 2Albert Einstein College of Medicine, Bronx/AL/United States of America
Background: There is a need for non-invasive airway-based biomarkers in lung 
carcinogenesis for both risk assessment of the ex-smoker, and earlier diagnosis. 
Exhaled breath condensate (EBC) contains airway molecules, presumably in part from 
bronchial and alveolar epithelial cellular origins. Our previous study showed microRNAs 
could qualitatively be detected in EBC. Here both qualitative and quantitative multivariate 
analysis were applied to look for microRNA candidates in EBC from a new sample of 
lung cancer patients and controls. Methods: MicroRNA expression profiling using RNA-
specific RT-qPCR was performed in EBC from 41 patients and 41 contols with clinical and 
microRNA expression data. The panel of microRNAs was assembled based on literature-
derived reports of blood or lung microRNAs which segregate with case-control status, 
combined with our own lung tissue-based discovery effort using microRNA-seq on lung 
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America, 3Vanderbilt-Ingram Cancer Center, Nashville/TN/United States of America, 4Moffitt 
Cancer Center, Tampa/FL/United States of America, 5Pathology, Massachusetts General 
Hospital, Boston/MA/United States of America, 6Memorial Sloan-Kettering Cancer Center, 
New York/NY/United States of America, 7Brigham and Women’s Hospital, Boston/MA/United 
States of America, 8Emory Healthcare, Atlanta/GA/United States of America, 9Cancer Center, 
University of Colorado Denver, Aurora/CO/United States of America
Background: Activation of the MET signaling pathway can propel the growth of cancer 
cells in non-small cell lung cancer (NSCLC). Increased MET gene by amplification and/
or polysomy can cause MET protein overexpression; less common causes include 
mutations, translocations, and alternative RNA splicing. Clinical trials using MET as a 
biomarker for selection of lung cancer patients who might most benefit from targeted 
therapy have experienced variable outcomes. We aimed to characterize the relationship 
between MET protein overexpression and MET amplification or mean copy number 
alterations in patients with NSCLC. Methods: The Lung Cancer Mutation Consortium 
(LCMC) is performing an ongoing study of biomarkers with patients with NSCLC from 16 
cancer center sites across the United States. For this analysis, 403 cases had complete 
data for MET protein expression by immunohistochemistry (IHC, monoclonal antibody 
SP44, Ventana) and MET gene amplification by fluorescence in-situ hybridization (FISH, 
MET/CEP7 ratio). Pathologists evaluated MET expression using the H-score, a semi-
quantitative assessment of the percentage of tumor cells with no, faint, moderate, and/
or strong staining, ranging from 0-300. Spearman’s correlation was used to analyze 
the correlation between MET protein expression (H-scores) and FISH results (MET/CEP7 
ratio (N=403) and MET copy number (N=341). Protein overexpression using 5 different 
cut-offs was compared with amplification defined as MET/CEP7 ≥ 2.2 and high mean 
copy number defined as ≥ 5 MET gene copies per cell using the Fisher’s exact test. Cox 
Proportional Hazards models were built to examine the associations of these different 
definitions of positivity with prognosis, adjusting for stage of disease. Results: MET protein 
expression was significantly correlated with MET copy numbers (r=0.17, p=0.0025), 
but not MET/CEP7 ratio (r=-0.013, p=0.80). No significant association was observed 
between protein overexpression using a commonly used definition for MET positivity (“at 
least moderate staining in ≥ 50% tumor cells”) and MET amplification (p=0.47) or high 
mean copy number (p=0.09). A definition for MET protein overexpression as “≥ 30% 
tumor cells with strong staining” was significantly associated with both MET amplification 
(p=0.03) and high mean copy number (p=0.007), but a definition of “≥ 10% tumor 
cells with strong staining” was not significantly associated with either. Definitions of 
protein overexpression based on high H-scores (≥200 or ≥250) were associated with 
high MET mean copy numbers (p=0.03 and 0.0008, respectively), but not amplification 
(p=0.46 and 0.12, respectively). All 5 definitions of MET protein overexpression 
demonstrated a significant association with worse prognosis by survival analyses 
(p-values ranged from 0.001 to 0.03). High MET copy number (p=0.045) was associated 
with worse prognosis, but MET amplification was not (p=0.07). Conclusion: Evaluation 
of NSCLC specimens from LCMC sites confirms that MET protein expression is correlated 
with high MET copy number and protein overexpression is associated with worse 
prognosis. Definitions of MET protein overexpression as “an H-score ≥250” and “≥30% 
tumor cells with strong staining” were significantly associated with high mean MET copy 
number. It may be worth reevaluating the performance of MET as a biomarker by 
different definitions of positivity to predict response to MET-targeted therapies. 
Keywords: MET, Immunohistochemistry (IHC), Fluorescence in-situ hybridization (FISH), 
lung cancer
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MINI13.04 Characterization of Gene Mutations and Copy Number Alterations 
in Chinese Squamous Cell Lung Carcinomas Yuankai Shi, Dan Tao, Sheng Yang, 
Xiaohong Han, Di Wu, Ningning Zhang Department of Medical Oncology, Cancer Institute 
and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing/
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Background: Identification of driver mutations has led to the dramatic improvement 
in personalized therapy for lung adenocarcinoma. However, few targeted therapeutics 
are approved for treatment of squamous cell lung carcinoma. The identification of 
druggable molecular targets in SqCLC has been becoming a top research priority. 
Therefore, the aim of this study was to analyze the driver mutation profiles in a large 
cohort of Chinese squamous cell lung carcinomas to identify potential therapeutic 
targets. Methods: Approximately 2,800 COSMIC mutations from 50 oncogenes 
and tumor suppressor genes were analyzed on 159 samples by using Ion Torrent 
semiconductor-based next-generation sequencing. The gene copy numbers 
of FGFR1, EGFR, HER2, PDGFRA, CCND1, SOX2, CDKN2A, and PTEN were assessed by 
FISH on 250 samples. In addition, the status of PTEN expression was examined by 
immunohistochemistry on 250 samples. Results: Somatic mutations were detected 
in 73.6% (117/159) of patients. The most commonly mutated gene detected in this 
study was TP53 (56.0%, 89/159), followed by CDKN2A (8.8%, 14/159), PI3KCA (8.8%, 
14/159), KRAS (4.4%, 7/159), EGFR (3.1%, 5/159), FBXW7 (2.5%, 4/159), PTEN (2.5%, 
4/159), FGFR3 (1.3%, 2/159), AKT1 (1.3%, 2/159) and KIT (0.6%, 1/159). Copy number 
alterations were present in 77.6% (191/246) of patients, including FGFR1 amplification 
(13.7%, 34/248), EGFR amplification (11.4%, 28/246), HER2 amplification (8.9%, 
22/246), PDGFRA amplification (7.7%, 19/246), CCND1 amplification (11.0%, 
27/246), SOX2 amplification (35.0%, 86/246), CDKN2A deletion (18.7%, 46/246), 
and PTEN deletion (29.3%, 72/246). The loss of PTEN expression was observed in 
43.5% (108/248) of patients. TP53 mutations were significantly more common in men 
and smokers, while the frequency of EGFR mutation was significantly higher in women 
and never smokers. Amplification of FGFR1, CCND1 and SOX2 genes were significantly 
associated with smoking. The incidence of FGFR1amplification in patients without lymph 
node metastasis was significantly higher than that in patients with lymph node metastasis 
such, these data are in agreement with previous descriptions of ROS1 positive cohorts. 
Screening for ROS1 rearrangements in lung cancer patients displaying adenocarcinoma 
histology and negative for EGFR, KRAS and ALK activating events should identify a 
higher frequency of ROS1 rearranged tumors compared to unselected approaches 
and facilitate this subset of patients to be treated with targeted ROS1 inhibitors. 
Keywords: ROS 1, FISH, clinicopathology, Adenocarcinoma
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MINI13.02 Detection of ALK Rearrangement and EGFR Mutation in Primary 
Pulmonary Lymphoepithelioma-Like Carcinoma Ying Liang1, Liang Wang2, 
Yongbin Lin3, Hao Long3, Guowei Ma3, Yu Zhang4, Tiehua Rong3 1Medical Oncology, Sun 
Yat-Sen University Cancer Center, Guangzhou/China, 2Hematology, Sun Yat-Sen University 
Cancer Center, Guangzhou/China, 3Thoracic Surgery, Sun Yat-Sen University Cancer Center, 
Guangzhou/China, 4Pathology, Sun Yat-Sen University Cancer Center, Guangzhou/China
Background: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare 
histological type of large cell NSCLC. Histopathologically it is similar to nasopharyngeal 
carcinoma which is most commonly occurred in Southern China. It had close relationship 
with Epstein-Barr virus (EBV) infection. Over the past 28 years since it was first reported, 
less than 300 Primary pulmonary LELC cases have been reported in the literature. Due 
to its rarity, the treatment of advanced LELC is not only empirical, but controversial. 
Testing for EGFR mutation and ALK rearrangement are routine for NSCLC patients in 
clinical practice now. However, only few genotype studies have been done in pulmonary 
LELC, and till now no targeted therapy has been shown effective in the treatment of these 
patients. Methods: We investigated a cohort of 42 patients with primary pulmonary 
LELC and genotyped for ALK rearrangement and EGFR mutation. ALK rearrangement was 
detected by Fluorescence in situ Hybridization (FISH). EGFR mutational analysis of exons 
18 through 21 was analyzed by TaqMan real-time polymerase chain reaction 
(PCR). Results: The clinicopathologic characteristics of 42 patients with pulmonary 
LELC are presented in Table 1. Twenty-seven of 42 patients were in stage I-IIIA (64.3%), 
and only 15/42 patients (35.7%) were in stage IIIB or IV. The female to male ratio was 
about 22:20, and the median age at diagnosis was 51 years (range, 29-67 years). Only 
13 (31.0%) patients were smokers. In situ hybridization for Epstein-Barr virus-encoded 
RNA (EBERs) showed positive signals in all 42 patients. By immunohistiochemistry 
staining, all patients demonstrated positive expression of CK5/6 and P63, but almost all 
patients were negative for TTF-1(34/34, 100%) or CK7 (34/35, 97.1%). None of the 42 
patients had ALK rearrangement. Of 42 patients tested EGFR mutation, only one patient 
(2.4%) harbored L858R mutation and gefitinib was applied to this case, however no 
objective response was observed and the progression free survival PFS time was only 1 
month.
 
Conclusion: Primary pulmonary LELC is a unique histological subtype of non-
small cell lung cancer. ALK rearrangement and EGFR mutation are lack and they 
may not be the oncogenic driver gene in pulmonary LELC. Conventional cytoxic 
chemotherapy is by far still a backbone treatment in advanced stage primary 
pulmonary LELC. Future efforts should be made to explore other oncogenic driver 
gene to guide targeted therapy in this rare disease to determine the optimal treatment. 
Keywords: Epidermal growth factor receptor, Epstein-Barr virus, pulmonary 
Lymphoepithelioma-Like Carcinoma, Anaplastic Lymphoma Receptor Tyrosine Kinase
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MINI13.03 Characterization of MET Gene and MET Protein Expression in 
Lung Cancer Theresa A. Boyle1, Xian Lu2, Lynne Berry3, Kim E. Ellison1, Ashley 
A. Kowalewski1, Christopher J. Rivard1, Farah Khalil4, Mari Mino-Kenudson5, Andre 
Moreira6, Lynette Sholl7, Gabriel Sica8, Kelly Kugler9, David J. Kwiatkowski7, Marileila 
Varella-Garcia1, Paul A. Bunn, Jr.1, Fred R. Hirsch1 1Division of Medical Oncology, 
University of Colorado Denver, Aurora/CO/United States of America, 2Biostatistics and 
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specimens with two mutations, combinations involving KRAS were the most prevalent 
(70%, 14/20) followed by TP53 (50%, 10/20). Conclusion: These results demonstrate 
the wide spectrum of mutations that can be detected in adenocarcinoma specimens, 
with high prevalence rates in the EGFR and KRAS genes. Most patients had only one 
identified driver mutation. The study revealed age and geographical associations in some 
mutations. The clinical relevance of the studied mutations in relation to chemotherapy 
and the human EGFR antibody, Necitumumab, will be studied.
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MINI13.07 Kinome Targeted Deep Sequencing Identifies Novel Mutations in 
Korean Adenocarcinoma of the Lung Yoohwa Hwang1, Min Jung Kim2, Yoo Jin 
Jung3, Sae Bom Lee3, Yun Ho Kim3, Jung Sun Park4, Byung-Chul Lee4, Tae Gyun Yun4, 
Dong Yoon Park4, Hyun Joo Lee1, In Kyu Park1, Chang Hyun Kang1, Jong-Il Kim2, Young 
Tae Kim1 1Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul/
Korea, 2Biochemistry and Molecular Biology, Seoul National University, Seoul/Korea, 3Cancer 
Research Institute, Seoul National University, Seoul/Korea, 4Molecular Diagnostic R&D Team, 
SK Telecom, Seoul/Korea
Background: Various protein kinases have been discovered as drivers in cancer and 
subsequently used as therapeutic targets. Methods: To discover potential target driver 
genes, we investigated characteristics of genome wide scans of genetic lesions in 
kinases from 103 Korean lung adenocarcinoma patients, whose driver mutations were 
unknown or negative after conventional screening of EGFR and KRAS mutations as well 
as EML4-ALK fusion. We employed targeted, pair-end deep sequencing and screened the 
coding sequences of 518 protein kinase and genes that are known to be mutated with 
considerable frequencies in lung adenocarcinoma such as TP53 and EGFR. 
Results: Pathway analysis revealed that recurrent alterations were enriched 
in p53 signaling (TP53, ATM, CHEK2, CDKN2A) and ErbB signaling (EGFR, BRAF, KRAS, 
ERBB4) pathways. Mutations in TP53 and an EGFR exon 21 hotspot regions were found in 
28% (29/103) and 13% (13/103) of cases (Fig 1). TP53 mutation was significantly more 
common in older group (97%) than in younger group (3%). We identified novel somatic 
mutations of genes, including CHEK2, NEK2 (mitotic progression) and SMG1 (nonsense-
mediated mRNA decay), that have not been highlighted in lung cancer previously.
Fig 1. Discovery of recurrent mutations with identical substitutions at the same 
site Conclusion: As the inhibitors of these protein kinases can be therapeutic candidates 
to eradicate cancer cells, our results provide useful information for the development of 
effective therapeutic target agents, by which the activity of various kinases can be 
modulated, in adenocarcinoma of the lung. 
Keywords: Adenocarcinoma, kinome sequencing, mutation, target
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MINI13.08 Targetable Genomic Aberrations in Squamous Cell Lung Cancer 
(SCC): A Report from the Lung Cancer Genomics Ireland (LCGI) Study 
Shereen Rafee1, Sinead Toomey2, Yasir Elamin2, Kathy Gately1, Sinead Cuffe1, Aoife 
Carr2, Stephen Finn1, Siobhan Nicholson1, Ronan Ryan1, Vincent Young1, John Crown3, 
Patrick Morris2, Oscar Breathnach2, Elaine Kay2, Anthony O’Grady2, Bryan Hennessy2, 
Kenneth J. O’Byrne4 1St.James’s Hospital, Dublin/Ireland, 2, Beaumont Hospital, Dublin/
Ireland, 3St.Vincent’s University Hospital, Dublin/Ireland, 4Princess Alexandra Hospital, 
Brisbane/QLD/Australia
Background: The prognosis of lung  SCC continues to be poor with no molecularly 
targeted agents specifically developed for its treatment. LCGI aims to identify potential 
targetable oncogenes in lung SCC. Methods: The LCGI study is being carried out in 500 
patients with surgically resected lung SCC, treated at St James’s University Hospital and 
Beaumont University Hospital, Dublin. We used the platform of Sequenom’s MassArray to 
perform genotyping for accustomed panel of 258 somatic hotspot mutations in 49 genes 
including genes in the MAPK and PI3K pathways. We also evaluated FGFR1 amplification 
by fluorescence in situ hybridization (FISH) and MET protein expression by 
immunohistochemistry (IHC). Results: Lung SCCs from 258 patients have been tested 
by Sequenom MassArray to date. Lung SCCs from 150 patients have been evaluated for 
MET protein expression and 89 for FGFR1 amplification. 163 (63.2%) patients were male. 
The median age of the cohort was 68. The majority of patients were either current (39.5%) 
or former (58.1%) smokers at the time of diagnosis. 138 (53.5%) were stage I, 87 (33.7%) 
were stage II, and 33 (12.8%) were stage III SCCs. At least one aberrant, potentially 
targetable oncogene was identified in the SCC of 101 (39.1%) patients (see Table). The 
presence of PIK3CA or KRAS mutations, or FGFR1 amplification did not have a statistically 
(19.4% vs. 10.2%，P=0.043). The frequency of SOX2 amplification in tumors with 
moderate and poor differentiation was significantly higher than that in tumors with well 
differentiation (39.6% vs. 33.6% vs. 0%，P=0.036). The incidence of loss of PTEN protein 
expression in patients with pleural invasion was 51.2%, which was significantly higher 
than that in patients without pleural invasion (P=0.017). The loss of PTEN expression was 
significantly associated with PTEN gene deletion (P=0.001). No significant association 
was observed between the molecular abnormalities and disease-free survival and 
overall survival. Conclusion: Genetic alterations are common in squamous cell 
lung cancers. The findings of this study may facilitate the identification of molecular 
target candidates for precision medicine in patients with squamous cell lung cancers. 
Keywords: Squamous cell lung carcinoma, Driver mutation, copy number variation, 
Targeted therapy
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MINI13.06 Mutation Prevalence for Oncogenic Drivers in Lung 
Adenocarcinoma Christopher J. Rivard1, Theresa A. Boyle2, Qing Ren3, Ashley 
A. Kowalewski2, Rebecca R. Hozak4, Gu Mi4, Anamarija Kurljac-Letunic4, Symantha 
Melemed4, Raffael Kurek4, Dara L. Aisner5, Fred R. Hirsch2 1Medical Oncology, 
University of Colorado Denver, Aurora/CO/United States of America, 2Division of Medical 
Oncology, University of Colorado Anschutz Medical Campus, Aurora/CO/United States of 
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Pathology, University of Colorado Som, Aurora/CO/United States of America
Background: Identification of mutations which drive pulmonary adenocarcinomas 
(ADC) has rapidly moved from the research arena to clinical practice. The prevalence of 
these mutations has been suggested by a multitude of studies but here we describe the 
prevalence of mutations from a large study of patients with advanced ADC treated in the 
international phase III study INSPIRE (Lancet Oncology 2015) with all testing performed 
in one CLIA-certified laboratory under standardized conditions. Methods: Mutation 
testing was performed on 412 adenocarcinoma specimens using SNaPshot® 
methodology. Mutations were examined in the AKT, EGFR, KRAS, BRAF, NRAS, PIK3CA, 
TP53, PTEN, CTNNB1, and MEK1 genes. The relative frequencies of genetic alterations 
were calculated based on the total number of adequate specimens and specific consent 
for testing. Results: Of the 412 adenocarcinoma specimens tested, 372 (90.3%) 
had evaluable results from mutation testing. A single mutation was detected in 157 
(42.2%) specimens, whereas mutations in two genes were detected in an additional 
20 (5.4%). The overall prevalence of mutations for each specific gene was as follows: 
KRAS (34.2%), EGFR (12.2%), TP53 (4.9%), PTEN (2.8%), PIK3CA (2.2%), CTNNB1 (2.2%), 
NRAS (1.8%), BRAF (1.2%), MEK1 (0.3%), and AKT (0%).
 
Evaluation of smoking status identified a substantially higher percentage of KRAS mutations 
in ex-light smokers and current smokers (38.2% and 40.5%) combined compared to 
never smokers (7.6%, p<0.0001) , and a lower proportion of EGFR mutations in ex-light 
and current smokers (10.9% and 4.9%) combined compared to never smokers (39.7%, 
p<0.0001). Patients ≥70 years old had a higher proportion of both NRAS (7.1% vs. 0.7%, 
p=0.009) and TP53 mutations (12.5% vs. 3.3%, p=0.010). In addition, males had a lower 
incidence of EGFR mutation (8.6% vs. 19.0%, p=0.007) as compared to females. Patients 
from North America, Europe, and Australia/New Zealand demonstrated lower rates of 
mutation in CTNNB1 (1.4% vs. 8.6%, p=0.030) and PIK3CA (1.4% vs. 8.3%, p=0.032) 
compared to patients from Central/South America, South Africa and India. Finally, among 
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MINI13.11 Detection of Rare Clinically Actionable Mutations in NSCLC 
Metastatic to the Brain by Targeted Next Generation Sequencing Laura J. Tafe1, 
Ko K. Maung2, Shelsey J. Weinstein2, Gregory J. Tsongalis1, Konstantin H. Dragnev2 
1Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon/NH/United States 
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Background: Genotyping of non-small cell lung cancers (NSCLC) is important for 
directing patient care, particularly in adenocarcinomas (ADC) where targeted therapeutics 
are available. There is emerging evidence of efficacy of targeted therapy in the treatment 
and prevention of brain metastases. With recent adoption of next-generation sequencing 
technologies it is possible to test individual tumors simultaneously for somatic mutations 
in multiple genes. Here, we present the mutational spectrum of NSCLC brain metastases 
in our institution over a three year period. Methods: The department of pathology 
archives was searched to identify cases of NSCLC metastatic to brain that underwent 
surgical resections during 2012-2014. Clinicopathologic information was recorded 
from the pathology reports and the medical records. Molecular genotyping analysis 
was performed for EGFR/KRAS mutations using single gene analysis (prior to 2013) 
or by next generation sequencing (NGS) using the AmpliSeq Cancer Hotspot Panel v2. 
FISH was used to test for ALK rearrangements. Results: During 2012-2014, 31 NSCLC 
patients underwent surgical resection for brain metastases. Eighteen patients were 
female (58%) and 13 were male. The median age was 70 years (range 51-89). Tumor 
histology included 24 ADC and 7 squamous cell carcinomas (SCC). Twenty-three cases 
had molecular genotyping studies performed on the metastatic disease or the primary 
lung cancer. These included 3 SCC and 20 ADC. Of the ADC, 12 were tested with the 
NGS panel; 8 had been tested prior to 2013. The most frequently mutated genes were 
KRAS (8/20; 40%) and TP53 (7/12; 58%). Of the patients with KRAS mutations 7/8 
were female (p = 0.085). The NGS assay detected clinically actionable mutations that 
would have not been detected with prior single gene assays including an EGFR exon 20 
insertion, an ERBB2 exon 20 insertion, and two PIK3CA mutations. Additional mutations 
were detected in JAK3, FLT3, FBXW7, ATM, STK11, VHL and RB1. Conclusion: We found 
that 40% of the genotyped ADC metastases harbored KRAS mutations more frequently in 
females (although not significant), similar to prior reports. In addition, with NGS we were 
able to detect additional clinically significant targetable mutations. In summary, NSCLC 
genotyping can potentially help guide treatment and prevention of brain metastases. 
Keywords: brain metastases, NSCLC, Molecular genotyping
GENETIC ALTERATIONS AND TESTING 
TUESDAY, SEPTEMBER 8, 2015 - 10:45-12:15
MINI13.12 The Abundance of EGFR Mutations Could Be More Better Predictor 
for EGFR-TKI Therapy in Advanced Non-Small Cell Lung Cancer Xuefei Li1, 
Chunxia Su2, Chao Zhao1, Shengxiang Ren2, Caicun Zhou2 1Lung Cancer and Immunity 
Laboratory, Shanghai Pulmonary Hospital, Tongji University; Tongji University Medical School 
Pulmonary Cancer Institute, Shanghai/China, 2Department of Medical Oncology, Shanghai 
Pulmonary Hospital, Tongji University; Tongji University Medical School Pulmonary Cancer 
Institute, Shanghai/China
Background: Incresing data show advanced non-small cell lung cancer (NSCLC) patients 
with EGFR activating mutant have discrepant response to EGFR-TKI. The abundance of 
EGFR mutations may be a powerful explanation for the uneven clinical benefit. This study 
was designed to investigate the influence of EGFR mutant abundance on efficacy of 
EGFR-TKI by a quantitative method. Methods: 201 NSCLC patients treated with EGFR-
TKI with available tissue samples for EGFR mutation test were enrolled into the study. 
EGFR common mutations were detected by amplification refractory mutation system 
(ARMS) and percentage of mutant EGFR was tested with the method of an Allele Specific 
Quantitative PCR with Competitive Blocker (ASB-qPCR). In this assay, the copies of all 
mutations and EGFR locus were calculated by standard curve respectively. The cutoff 
values were obtained by the receiver operating characteristics (ROC) curve in training 
set. Further, the cutoff values were confirmed in validation set and the whole population. 
The relationship between the abundance of EGFR mutations and efficacy of EGFR-TKI 
was statistically analyzed. Results: Of the 201 samples, 72 harbored 19DEL mutation, 
63 carried L858R mutant, and 66 with wild-type. The cohort was randomly divided into 
training and validation sets. The cutoff values of 19DEL and L858R mutation abundance 
were 4.84% and 9.47% determined by ROC curve in training set. 9.7% of patients with 
19DEL positive were low abundance (<4.84%, LA group), while 33.3% of L858R-positive 
patients were LA (<9.47%).High abundance (HA) group, regardless of 19DEL or L858R 
positive had more longer median progression free survival (PFS) compared with LA and 
wild-type groups in either validation set or the whole population (15.0 vs 2.0 vs 1.9, 8.0 
vs 1.9 vs 1.9; 15.0 vs 4.0 vs 2.0, 12.0 vs 2.0 vs 2.0; p<0.001). COX regression analysis 
showed that EGFR mutation abundance, together with smoking status, were independent 
factors of response to EGFR-TKI. Conclusion: The abundance of EGFR mutation 
could more precisely predict EGFR-TKI efficacy. NSCLC patients with LA mutation had 
inferior clinical benefit with EGFR-TKI. The heterogeneity in EGFR mutant abundance 
partly explain the efficacy discrepancy in patients with 19DEL or L858R positive. 
Keywords: EGFR-TKI, mutant abundance, non-small cell lung cancer, EGFR mutation
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MINI13.13 Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Mutations 
(EGFR-m) and Breast Cancer (BC): A Retrospective Analysis Teresa Morán, 
Vanesa Quiroga, Enric Carcereny, Beatriz Cirauqui, Mireia Margeli, Laia Vila, Maria De 
significant impact on median overall survival or recurrence-free survival. However, the 
presence of two or more aberrations in driver oncogenes in a tumor (patients, n=19) 
was associated with a worse median overall survival compared to patients with either a 
single driver aberration (p=0.04) or no aberrations (p<.01). Table: Frequency of driver 
mutations in LCGI compared to The Cancer Genome Atlas (TCGA) study
Mutation LCGI (n=258) TCGA (n=178)
FGFR1 amp (n=89) 13 % 16.8 %
PIK3CA 15.1 % 10.1 %
KRAS 6.5 % 0.6 %
PTPN11 3.5 % 1.7 %
STK11 3.1 % 1.7 %
MYC 1.9 % 0.0 %
NRAS 1.6 % 0.0 %
BRAF 1.2 % 3.9 %
HRAS 1.6 % 1.7 %
CTNNB1 1.5 % 1.7 %
FBXW7 1.5 % 3.4 %
MET Overexpression 
(n=150) 1.3 % NA
EGFR 0.9 % 2.8 %
AKT1 0.4 % 0.6 %
CDK4 0.4 % 0.0 %
GNA11 0.4 % 0.6 %
MAP2K1 0.4 % 0.6 %
DDR2 0 % 1.1 %
 
Conclusion: 39.1% of lung SCC patients have an aberrant, potentially targetable driver 
oncogene in their tumor. The presence of two or more aberrant oncogenes is a poor 
prognostic factor in lung SCC. These findings can be used to guide clinical trials in lung SCC. 
Keywords: Squamous cell lung cancer, Targetable oncogenes 
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MINI13.09 Next-Generation Sequencing Analysis of Driver Gene Mutations in 
Pleomorphic Carcinoma of the Lung Saki Manabe1, Rika Kasajima2, Yohei Miyagi2, 
Teppei Nishii1, Tomoyuki Yokose3, Shuji Murakami1, Tetsuro Kondo1, Haruhiro Saito1, 
Masanori Hashimoto1, Hideyuki Furumoto1, Tetsuya Isaka1, Hiroyuki Ito1, Haruhiko 
Nakayama1, Takeshi Kaneko4, Kouzo Yamada1 1Department of Thoracic Oncology, 
Kanagawa Cancer Center, Yokohama/Japan, 2Molecular Pathology and Genetics Division, 
Kanagawa Cancer Center, Yokohama/Japan, 3Department of Pathology, Kanagawa Cancer 
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Background: Research into druggable driver gene mutations in non-small cell lung 
cancer has identified several molecule-targeting agents that are clinically prescribed to 
inhibit tumor growth in adenocarcinoma. However, lung cancers without targeted driver 
gene mutations show poorly differentiated histologies and unfavorable prognoses without 
medication. Pleomorphic carcinoma, a lung cancer that includes a mixed conventional 
histology and sarcomatoid components, is an extremely aggressive tumor and rarely 
responds well to anticancer treatments. However, it has recently been reported that 
lung cancer with a sarcomatoid component contains the ALK gene rearrangement. 
Therefore, we used a next-generation sequencing (NGS) analysis of the driver gene 
mutations in pleomorphic carcinoma (PC) of the lung to identify druggable target 
molecules. Methods: We selected PCs from primary lung carcinomas by reviewing 
the records of 944 patients who had undergone surgical resection between 2007 and 
2014. The Ion PGM™ NGS sequencer (Life Technology Inc., US) was used to identify 
known gene rearrangements in lung cancers by analyzing RNA with IonAmpliSeq™ 
RNA Lung FusionPanel® (Life Technology). With our original panel for targeted gene 
amplifications, the Ion PGM was also used to analyze nucleotide sequence of whole 
exons of 41 driver genes reported to be involved in lung cancers. The cases examined 
were also analyzed with ALK immunohistochemistry (ALK-IHC) using the N-Histofine® 
ALK Detection Kit (Nichirei Bioscience Inc., Tokyo, Japan) on sliced paraffin-embedded 
tumor specimens. Results: Twenty-one lung cancer specimens diagnosed as PC and 
frozen material from nine patients were available for NGS. The EML4ex6/ALKex20 fusion 
gene was detected in one case, which was also positive on ALK–IHC. No other fusion 
genes were detected. Another case, which was negative for the fusion gene, was weakly 
positivity on ALK–IHC, so an unbalanced 5¢/3¢-end ALK expression test is planned. 
Six of nine cases but not the ALK-fusion-positive cases showed driver gene mutations 
in TP53. We also found several somatic mutations in druggable genes in this study, 
which should be considered carefully to determine whether they are driver or passenger 
genes. Conclusion: Although a small number of PCs were examined in this study, the 
ALK fusion gene was detected, which indicates the frequency of ALK fusion might be 
high in PC. Other possible druggable gene mutations were also identified in PCs. Further 
cases must be investigated to understand the mutation status of driver genes in PC. 
Keywords: pleomorphic carcinoma, next-generation sequencing, druggable gene 
mutation
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MINI14.01 EGFR-Mutated PDX in NSCLC: Molecular Fidelity and Correlation 
of PDX and Patient Response to EGFR Inhibition Jonathan W. Riess1, David R. 
Gandara1, Rebekah A. Tsai1, Mingshan Cheng2, Will S. Holland1, Kaitlin D. Crawford1, 
Hongyuan Yang2, Tianhong Li1, Primo Lara Jr.1, Karen Kelly1, Susan Airhart2, Joel 
Graber2, Carol Bult2, James G. Keck2, PhilipC. Mack1 1UC Davis Comprehensive Cancer 
Center, Sacramento/CA/United States of America, 2The Jackson Laboratory, Bar Harbor/ME/
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Background: Inevitable emergence of resistance to tyrosine kinase inhibitor (TKI) therapy 
in EGFR-mutated NSCLC warrants development of pro-active therapeutic strategies 
to delay or circumvent this evolution. To model such approaches, we are employing 
a clinically and genomically annotated patient derived xenotransplant (PDX) resource 
designed to duplicate relevant known mechanisms of resistance to TKI therapy. This 
analysis examines molecular fidelity and correlates response between patient and PDX in 
EGFR-mutant NSCLC. Methods: Six EGFR-mutated NSCLC, 1 EGFR-TKI naïve and 5 after 
progressive disease on erlotinib, were implanted subcutaneously into the flank of NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice as previously described (DR Gandara, Clin Lung 
Cancer 2015). Models were considered established when PDX growth was confirmed in 
passage 1 (P1); tumor growth studies were conducted in P3-P5. The donor patient tumor 
(PT) and the resultant PDX were analyzed for driver mutations (Response Genetics Inc., 
and Illumina TSCAP), copy number variants (CNV) and global RNA expression (Affymetrix 
arrays). Informed consent was obtained from all patients. EGFR-mutant PDX treatments 
included: erlotinib, afatinib, cetuximab, and afatinib+cetuximab. Patient response was 
graded by RECIST 1.1 and measured in PDX by tumor shrinkage from pre-treatment 
baseline. In select models, pharmacodynamic studies (kinase arrays; immunoblotting) 
were also performed. Results: The EGFR mutation subtypes identified in the donor PT 
were preserved in all PDX models (4 EGFR E19del and 2 EGFR L858R). Corresponding 
putative mechanisms of resistance were identical in both PT and PDX in 3 cases: EGFR 
T790M (2 of 5) and MET amplification (1 of 5). Of 5 post-erlotinib progression PDX 
models, 3 had progressive disease (PD) and 2 had transient tumor shrinkage to erlotinib. 
The PDX derived from an erlotinib-naïve patient (EGFR E19del) demonstrated sustained 
tumor shrinkage to erlotinib. Patient-PDX treatment correlations were possible in 3 post 
erlotinib-progression models. Two of these patients received afatinib-cetuximab: 1 with 
partial response (PR) and 1 with PD. The two models corresponding to these patients, 
when treated with afatinib-cetuximab, underwent complete regression of tumor (CR) 
and PD, respectively. Pharmacodynamic assessment of the responding model at 24h 
showed near complete diminishment of pEGFR following afatinib-cetuximab, concomitant 
with decreased pHer2, pERK, pAKT and p38. Erlotinib showed transient inhibition on 
signaling in this model at 6h, returning to baseline by 24h. In contrast, the non-
responding model showed minimal effects on target inhibition and signal transduction 
following treatment with any EGFR inhibitor. Conclusion: Genomic fidelity was preserved 
in EGFR-mutant PDX, including putative mechanisms of resistance in the post-erlotinib 
progression models. The majority (3/5) of the EGFR-mutant PDXs created after 
erlotinib resistance demonstrated PD. In the other post-erlotinib progression models 
transient tumor shrinkage was noted, which may reflect PDX passaging in the absence 
of selective pressure of EGFR-inhibition or pharmacokinetic considerations. Overall, 
the PDX response to treatment reflected the corresponding patient’s clinical course. 
Pharmacodynamic studies of select models informed PDX response to treatment. 
Keywords: NSCLC, Patient Derived Xenotransplants, EGFR mutation
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MINI14.02 TAE226, a Bis-Anilino Pyrimidine Compound, Shows Anti-Tumor 
Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells including T790M 
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Tsukuda1, Katsuyuki Kiura4, Shinji Hatakeyama5, Eiji Kawahara6, Yoshio Naomoto2, 
Shinichiro Miyoshi1, Shinichi Toyooka1 1Thoracic Surgery, Okayama University Graduate 
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Surgery, Kawasaki Medical School, Okayama/Japan, 3Cell Biology, Okayama University 
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Background: TAE226, a bis-anilino pyrimidine compound, has been developed as an 
inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-
IR). These tyrosine kinases are known to be overexpressed in many malignant tumors 
including some NSCLCs and to play an oncogenic role in cancer cells. Methods: We 
investigated the effect of TAE226 on non-small-cell lung cancer (NSCLC), especially 
focusing on the EGFR mutational status. Drug sensitivity of TAE226 to various NSCLC 
cell lines was determined by MTS assay. Interaction of TAE226 and variant EGFR proteins 
was evaluated by in vitro binding assay, and kinetic interaction analysis to calculate 
Kdvalue. Finally, the effect of TAE226 on NSCLC was investigated using a xenograft 
mouse model. Results: TAE226 was more effective against cells with mutant EGFR, 
including the T790M mutant, than against cells with wild-type one. TAE226 preferentially 
inhibited phospho-EGFR and its downstream signaling mediators in the cells with 
Los Llanos Gil Medical Oncology, Catalan Institute of Oncology-Hospital Germans Trias I 
Pujol, Badalona/Spain
Background: EGFR-m in NSCLC and its responsiveness to TKI has proved beneficial in a 
subset of NSCLC patients (p) Breast cancer (BC) represents the most incident neoplasm 
among women. The co-existence of both EGFR-m-NSCLC and BC has been reported in 
p with Li-Fraumeni Syndrome. However, no systematic evaluation of the presence of 
both types of cancers has been performed in the general population. Methods: We 
sought to evaluate if EGFR-m-NSCLC associates higher rates of 2nd BC than the EGFR-
wild type (WT)p. Clinical and molecular characteristics, as well as clinical outcomes 
of female p visited at our Institution from 2008 to 2014 and harboring both types of 
tumors were registered. Results: 69/578 female p with EGFR-m were identified. Data 
on treatment and follow-up of 62p were available. 11/ 62p (17.7%) were diagnosed with 
both EGFR-m-NSCLC and BC. For EGFR-m-W-p, BC was diagnosed in 3 cases (0.52%) 
Regarding EGFR-m-NSCLC, age of diagnosis was 65y; 100% of p were Caucasian and 
never smokers. Del19, L858 and L861Q represented the 72.7%, 27.3% and 9% of 
EGFR-m. 36.3% had stage IV, 27.2% recurred after surgery and 36.3% initial stages 
never recurred. 63.6% received a TKI (42.8% erlotinib). 85.7% received TKI as 1st line. 
The overall response rate was 85.7%. 42.8% received subsequent therapies. The cause 
of death was related to lung cancer in all cases of death (54.5%). mOS was 29 months 
from the time of LC diagnosis. Regarding BC, the median age of diagnosis was 52y, 
BC was a prior diagnosis in 90.9%; the stage was 0, I, IIA and IIIA in 18.18%, 27.27%, 
45.45% and 9.09%, respectively. After surgery (100%), 36.36% received ET, 36.36% 
both chemotherapy and ET and 54.54% radiotherapy (RT). 83.33% of p treated with RT 
developed the LC in the RT field. 90.90% of p never recurred. Conclusion: Diagnosis of 
BC appears to be higher in EGFR-m-NSCLC-p than in the general population. Evaluation 
of the molecular mechanism potentially related to this association is warranted. 
Keywords: EGFR mutations, Breast Cancer
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Background: Epidermal growth factor receptor (EGFR) mutations are relatively common 
oncogenic drivers in non-small cell lung cancer (NSCLC). Interestingly a number of 
patients have more than one mutation in EGFR. In order to understand whether these 
patients respond to EGFR inhibition, we reviewed our experience treating these patients. 
Herein we describe the Mayo Clinic experience with the S768I mutation of exon 20 of the 
EGFR gene. Methods: Relevant clinical and laboratory data were abstracted for selected 
cases, including evaluation of response after treatment with TKIs using the Response 
Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Inclusion criteria were cases 
including EGFR S768I mutation performed at Mayo Clinic or elsewhere until December 
2014. EGFR testing was performed following microscopic examination by a pathologist 
to identify and select areas of tumor for macrodissection and confirm sufficient tumor 
percent. The EGFR test is a PCR based assay employing allele specific amplification 
and is used to test for mutations within exons 18-21 of the EGFR gene, most recently 
using the FDA approved platform. When testing was performed elsewhere, bidirectional 
sequencing was used. Results: 1,527 cases of NSCLC that underwent EGFR testing 
were reviewed and the S678I mutation was present in 9 patients (0.59%), 4 of which 
were female. Median age at diagnosis was 61 years (range 49-68 years), 5 patients 
were never smokers and no subjects were current smokers at the time of diagnosis. 
The stage at diagnosis was I in 2, III in 3 and IV in 4 patients, respectively. All specimens 
were adenocarcinomas with 5 of them being grade 3. Only 3 cases had an isolated 
S768I mutation, 4 cases had a concurrent G719S mutation and 2 cases had a concurrent 
L858R mutation. The tumor responses of patients with stage IV disease are shown in the 
table. One patient with a concurrent S768I and L858R mutation with stage IIIa disease 
received curative intent lobectomy after neoadjuvant treatment with erlotinib. Erlotinib 
was discontinued in one case due to fatigue. Table: Response of S768I mutations to 
erlotinib by RECIST 1.1
Mutation(s) Best response on erlotinib PFS (months)
Overall survival 
(months)
S768I alone Progressive disease 3 5
S768I + G719 Partial response 6 23
S768I + G719S Stable disease 12 33
S768I + L858R Stable disease 30 51+
 
Conclusion: S768I mutations in exon 20 of the EGFR are rare and are commonly 
seen in conjunction with common EGFR mutations. Due to its rarity and the 
variability of responses of treated cases, its exact prognostic and predictive 
role is not fully understood. Better understanding of its function and sensitivity 
to newer TKIs will allow for better management of patients with this mutation. 
Keywords: non-small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) 
mutations, S768I mutation
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NTRK3) and LC-2/Ad (CCDC6-RET) were used for the in vitro evaluation of MGCD516 
inhibitory activity against these oncogenic fusion kinases. Cell lines were assessed 
for cell viability (MTS-base proliferation assay) and downstream signaling pathways 
(immunoblot analysis) upon treatment with MGCD516. For in vivo studies, xenograft 
models of TRKA fusion tumors (CUTO-3 and KM12) and RET fusion tumors (LC-2/Ad and 
a tumor biopsy from a KIF5B-RET patient) were generated in athymic nude mice. Once 
tumors reached ~200cm3, a single daily dose of 5mg/kg, 10mg/kg or 20mg/kg of 
MGCD516 was given to mice by oral gavage. Mice in the control arm of the study were 
gavaged with vehicle at similar volume. Tumor size and weight measurement of mice 
were assessed 3 times per week. Results: MGCD516 had notable in vitro effects on the 
proliferation of cell lines with either RET fusion (LC-2/Ad), TRKA fusion (KM12 and CUTO-
3) or TRKC fusion (MO-91) with low nanomolar IC50. Western blot analyses showed specific 
loss of phosphorylated CCDC6-RET or TRKA/C fusion protein and decreased activation 
of the AKT and MAPK signaling pathways when cells were treated with MGCD516. In 
mouse xenograft studies, tumors with TRKA fusion displayed dose-dependent growth 
inhibition at 5mg/kg and 10mg/kg daily doses of MGCD516 compared to controls. 
Notably, we observed tumor regression in the mice originally assigned to the vehicle 
control arm once we enrolled the mice on a 10mg/kg or 20mg/kg daily regimen of 
MGCD516. Comparable to the TRKA fusion xenografts studies, RET fusion tumors were 
growth inhibited with a 20mg/kg daily dose of MGCD516. Conclusion: The spectrum-
selective tyrosine kinase inhibitor, MGCD516, demonstrates potent in vitro activity 
in multiple TRKA/C and RET fusion cancer cell line models and in vivo activity against 
TRKA and RET fusion kinase in murine xenograft models. A phase I clinical trial of 
MGCD516 is ongoing and the inclusion of patients with TRK and RET fusion is planned. 
Keywords: NTRK, fusion oncogene, kinase inhibitor, RET
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MINI14.06 High-Affinity α3β1 Integrin Ligand LXY30 for the Screening, 
Imaging and Targeted Drug Delivery in Non-Small Cell Lung Cancer (NSCLC) 
Wenwu Xiao1, Ruiwu Liu1, Ai-Hong Ma1, Kaili Zhou2, Alan Nguyen1, Joyce Lee2, KenY. 
Yoneda3, Kit S. Lam1, Yuanpei Li1, Tianhong Li2 1Department of Biochemistry and 
Molecular Medicine, UC Davis Comprehensive Cancer Center, Sacramento/United States of 
America, 2Internal Medicine, Div Hematology & Oncology, UC Davis Comprehensive Cancer 
Center, Sacramento/United States of America, 3Division of Pulmonary, Critical Care and 
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Background: High-affinity peptidomimetic or small-molecule ligands against cancer cell 
surface receptors have attracted wide interest as cancer-targeting agents to enhance 
cancer diagnosis and treatment. We have previously identified and characterized 
several peptide ligands specific for different integrins, such as a3b1, a4b1 and avb3, 
on livetumor cells using our invented high throughput one-bead one-compound (OBOC) 
random combinatorial libraries and “on-bead” whole-cell binding assay. The objective of 
this study was to select the best integrin ligand for the screening, imaging and targeted 
drug delivery studies in NSCLC. Methods: High-affinity integrin ligands coated on the 
surface of TentaGel resin beads were screened for the binding to a panel of NSCLC cell 
lines, malignant pleural effusion and peripheral blood mononuclear cells (PBMCs) from 
lung cancer patients using the established whole-cell binding assay. The binding affinity 
was determined in selected NSCLC tumors by flow cytometry using the biotinylated 
integrin ligands and Streptavidin-Phycoerythrin (PE). For in vivo biodistribution, mice 
bearing subcutaneous and intracranial NSCLC xenograft tumors were injected with 
LXY30-biotin-streptavidin-Cy5.5 conjugate for 6 hrs before being subjected to in 
vivo and ex vivo optical imaging. Results: Among the available integrin ligands, LXY30, 
a recently optimized cyclic peptide targeting α3β1integrin, bound to the majority of 
NSCLC cell lines tested within one hour of incubation. We further demonstrated that 
LXY30 bound to α3β1 integrin on the surface of lung cancer cells with high specificity by 
flow cytometry and entered into the cells via endocytosis by fluorescence microscopy 
imaging. Flow cytometry confirmed the high specificity binding of LXY30 to NSCLC 
cells. While sparing the PBMCs isolated from lung cancer patients, LXY30 strongly 
bound to tumor cells in the pleural effusion from several NSCLC patients and could 
capture the tumor cells spiked into PBMCs in 1: 5,000 dilution after a 2-hour incubation. 
Furthermore, several EGFR-mutant lung cancer cell lines have high level expression of 
α3β1 integrin on their surface. In nude mice bearing two representative, EGFR-mutant 
lung cancer H3255 (EGFR L858R) and H1975 (EGFR 858R/T790M) xenograft tumors, 
optical images have shown the preferential updates of LXY30-biotin-streptavidin-Cy5.5 
conjugate in the subcutaneous and intracranial xenograft tumors. Conclusion: The 
rapid, sensitive and high specificity binding of LXY30 makes it an ideal candidate for 
screening and isolating NSCLC tumor cells in the pleural effusion and whole blood. 
LXY30 can be used as a cancer-targeting agent to guide in vivo delivery of imaging 
dye and cancer drugs to the simulated extracranial and metastatic brain tumors. 
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Tiffany N. Razabdouski3, Joseph Shan2, Jeff Hutchins2, Kerstin Menander2, Scott J. 
Antonia3 1Nilogen Oncosystems, Tampa/FL/United States of America, 2Clinical, Peregrine 
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United States of America
Background: Bavituximab is a chimeric monoclonal antibody that targets the membrane 
phospholipid phosphatidylserine (PS) exposed on endothelial cells and cancer cells in solid 
mutant EGFR than in those with wild-type one. Phosphorylation of FAK and IGF-IR was 
not inhibited at the concentration at which the proliferation of EGFR-mutant cells was 
inhibited. Results of the in vitro binding assay indicated significant differences in the 
affinity for TAE226 between the wild-type and L858R (or delE746_A750) mutant, and 
the reduced affinity of ATP to the L858R (or delE746_A750) mutant resulted in good 
responsiveness of the L858R (or delE746_A750) mutant cells to TAE226. Of interest, 
the L858R/T790M or delE746_A750/T790M mutant enhanced the binding affinity 
for TAE226 compared with the L858R or delE746_A750 mutant, resulting in the 
effectiveness of TAE226 against T790M mutant cells despite the T790M mutation 
restoring the ATP affinity for the mutant EGFR close to that for the wild-type. TAE226 
also showed higher affinity of about 15-fold for the L858R/T790M mutant than for the 
wild-type one by kinetic interaction analysis. The anti-tumor effect against EGFR-mutant 
tumors including T790M mutation was confirmed in mouse models without any significant 
toxicity. Conclusion: We showed that TAE226 inhibited the activation of mutant EGFR 
and exhibited anti-proliferative activity against NSCLCs carrying EGFR mutations, 
including T790M mutation. Our results showed that the EGFR L858R/T790M (or 
delE746_A750/T790M) mutant retains the binding affinity to TAE226 comparable to 
that of the L858R (or delE746_A750) mutant, suggesting that TAE226, or its relatives, 
is promising to overcome acquired TKI resistance mediated by EGFR T790M mutation. 
Keywords: EGFR, non-small cell lung cancer, TAE226
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MINI14.03 New Monoclonal Antibody Targeting on Basic Fibroblast Growth 
Factor against Lung Cancer In Vitro and In Vivo Meng Xu1, Penghui Hu1, Fengzhi 
Zhao1, Junjian Xiang2 1Department of Oncology, The First Affiliated Hospital, Jinan University, 
Guangzhou/China, 2The Antibody Engineering Researching Center, School of Life Sciences 
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Background: basic fibroblast growth factor (bFGF) is an important molecule that involved 
with proliferation, angiogenesis, invasion and metastasis in malignant tumors. bFGF in 
lung adenocarcinoma,squamous cell carcinoma, breast cancer, colon cancer, malignant 
melanoma cells was highly expressed in the cytoplasm and cytoplasm. bFGF expression 
was closely related with tumor poor prognosis. FGF pathway activation is a potent driver 
of lung cancer. Autocrine activation of FGF signaling in NSCLC may contribute to EGFR 
inhibitor insensitivity. We have developed new monoclonal antibody targeting bFGF (anti-
bFGF mAb) which neutralizes bFGF, blocking its ability to activate FGFR1 in treating solid 
tumors. The antitumor, antiangiogenesis, antimetastatic and reversal multidrug resistance 
(MDR) activities of anti-bFGF mAb could be investigated. Methods: The effect of anti-
bFGF mAb on the proliferation of cancer cells was detected by CCK-8 method. Cellular 
apoptosis, cell cycle distribution and the expression of associated protein were analyzed 
by flow cytometry. The expressions of associated protein with apoptosis, metastasis, 
multidrug resistance, anti-bFGF mAb in suppressing cancer cells growth through the 
PI3K/AKT/mTOR pathway were examined by real-time fluorescence quantitative PCR 
and Western blotting. Preclinical pharmacokinetics of anti-bFGF mAb was measured 
in mice. Results: Anti-bFGF mAb significantly could inhibit the proliferation and induce 
apoptosis of lung cancer and show obvious inhibitory effects on the migration of cancer 
cells and the tube formation of HUVECs in vitro. Treatment of transplanted cancer with 
anti-bFGF mAb in vivo resulted in significant reduction in tumor size and prolonged survival 
time of mice. The expression of caspase-3，caspase-9, PARP, and BAX in combination 
group was higher than those from either agent alone. Anti-bFGF mAb suppressed the PI3K/
AKT/mTOR pathway. The radiotherapy sensitization enhancement ratio of the combined 
treatment group increased 2.37 times by anti-bFGF mAb. bFGF, VEGF expression and 
MVD were significantly decreased by anti-bFGF mAb. Anti-bFGF mAb could induce down-
regulated P-glycoprotein and MDR1. The main pharmacokinetic parameters of anti-bFGF 
mab were as follows: T1/2α 0.2 h，T1/2β 1.84h and T1/2γ 90.3h. Lung tissue was major 
organ for deposition of anti-bFGF mAb. Conclusion: Anti-bFGF mAbs display remarkable 
antitumor and antiangiogenic effects in vitro and in vivo. Anti-bFGF mAb is potential 
therapeutic candidates for lung cancer by effectively suppressing the tumor growth 
through inhibition of angiogenesis, proliferation, induction of apoptosis and autophagy, 
reversal of MDR. Further preclinical and systematical investigation on anti-bFGF mAb 
may help to increase efficacy and safety of molecular target treatment in lung cancer. 
Keywords: lung cancer, Monoclonal antibody, bFGF
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MINI14.04 In Vitro and in Vivo Evaluation of the Kinase Inhibitor, MGCD516, 
in TRK and RET Fusion Cancer Cells Anh T. Le1, Adriana Estrada-Bernal1, Sarah 
Nelson1, James Christensen2, Robert C. Doebele1 1Division of Medical Oncology, 
University of Colorado Som, Aurora/United States of America, 2Mirati Therapeutics, San 
Diego/United States of America
Background: The paradigm of treating oncogene-selected patients with non-small 
cell lung cancer (NSCLC) and other malignancies using targeted kinase inhibitors has 
significant improved patient outcomes, specifically for patients harboring ALK, ROS1, 
and EGFR oncogenes. Additional oncogene targets that may benefit from this therapeutic 
strategy are therefore of immense interest. NTRK1 (TRKA) and RET gene fusions are 
recently identified oncogenes in NSCLC (and other malignancies) without approved 
kinase inhibitors. MGCD516 is a spectrum-selective tyrosine kinase inhibitor with activity 
against TRKA, RET, MET, VEGFR, PDGFR, AXL, and Eph family of receptors. In this report, 
we evaluated MGCD516 in vitro activity in cell lines with an NTRK1, NTRK3, or RET gene 
rearrangements. Additionally, we used a mouse xenograft model to assess the in 
vivo effects of MGCD516 on tumors harboring TRKA and RET fusions. Methods: Gene 
fusion positive cell lines, KM12 (TPM3-NTRK1), CUTO-3 (MPRIP-NTRK1), MO-91 (ETV6-
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apoptosis. HDAC6 controls autophagosome maturation and is essential for autophagy. 
CAY10603 is a potent and selective inhibitor of HDAC6. Therefore, inhibition of HDAC6 
by CAY10603 could be a promising strategy to treat NSCLC by targeting both apoptosis 
and autophagy pathways. Methods: We evaluated the effect of CAY10603 alone or in 
combination with autophagy inhibition on cell proliferation, apoptosis and autophagy in two 
human NSCLC cell lines, A549 and H460. Pharmacological (chloroquine or bafilomycin-A1) 
or genetic (knockdown of ATG5 or Beclin1 with shRNA) approaches were utilized to block 
autophagy. Cell proliferation of untreated or drug-treated cells was measured by CCK8 
assay. Percentage of apoptotic cells was measured using PE-conjugated Annexin V with 
a flow cytometer. Autophagy was determined by conversion of LC3I to LC3II and p62 
degradation using Western blot. Results: CAY10603 inhibits NSCLC cell proliferation 
and induces apoptosis. CAY10603 also inhibits HDAC6 dependent basal autophagy and 
activates the PI3K-Akt-mTOR pathway. Meanwhile, HDAC6 independent autophagy exists 
in NSCLC cells and confers resistance to CAY10603. Cotreatment with chloroquine 
or bafilomycin-A1 promotes the autophagy inhibition, cell growth suppression and 
apoptosis induction of NSCLC cells compared to CAY10603 alone. Knockdown of ATG5 
or Beclin1 by shRNA also increased CAY10603-induced cytotoxicity in above NSCLC 
cells. Conclusion: Our results indicate that CAY10603 may be a promising agent for the 
treatment of NSCLC by modulating autophagy and apoptosis pathways. Furthermore, 
the combination of CAY10603 with classical autophagy inhibitors represents a 
promising therapeutic strategy that warrants further clinical evaluation in NSCLC. 
Keywords: HDAC6, CAY10603, Autophagy, apoptosis
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Oncology, Fondazione IRCCS, Istituto Nazionale Dei Tumori, Milan/Italy, 2Pathology and 
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Background: Studies based on cell lines were found to be poor predictors of clinical 
effects and therefore in many cases translation of the results into the clinics failed. A major 
determinant for the poor performance of cell lines is the observation that cell lines do not 
reflect the whole complexity and heterogeneity of primary tumors. A growing body of work 
suggests that Patient-Derived Xenografts (PDX) represent a more informative cancer model, 
providing a faithful representation of the patient’s original tumor. Methods: PDX were 
obtained by direct implants of small tumor fragments (30mm3) in previously anesthetized 
SCID mice, and were subsequently passaged as tissue explants. PDX metabolic in 
vivo imaging was performed using weekly [18F]FDG-PET and coronal and 3D-reconstruction 
at different days. Analysis of mutations and copy number alterations of PDX and human 
constitutive and tumoural DNA was performed by SALSA MLPA® probe mix X050-A1 Lung 
Cancer (MRC Holland). Results: Tumor samples from 95 lung cancer patients (66 AC, 16 
SCC and 13 other lung cancer histotypes (OL)) have been implanted in the flanks of SCID 
mice. Overall, 36 samples (37,9%) successfully grafted and were propagated for at least 3 
passages in immunocompromised mice. Take rate was 34,8 % (23/66) in AC, 43,8% (7/16) 
in SCC and 46.1% (6/13) in OL (2 large cell carcinomas, 1 sarcomatoid carcinoma and 3 
small cell carcinomas). A detailed immunohistochemical analysis of 27 PDX, at different 
passage in mice, confirmed that tumor histology, expression of specific markers (TTF-1, p40, 
Vimentin, Ki64 and Synaptophysin) and the amount of specific tumor cell subpopulations 
(i.e. CD133+ Cancer Initiating Cells) were generally maintained in PDX. In vivo animal PET 
imaging showed that also metabolic activity of PDX was strictly correlated with parental 
tumor’s features, especially for tumours with a SUVmax level higher than 8 (R
2=0.67, p<0.05). 
Mutation and copy number analyses, performed on 29 biological samples belonging to 
11 different engrafted models, showed that genetic changes were maintained in PDX that 
well recapitulated the frequency of the major changes involved in lung cancer development 
(66.7% TP53; 60% CDKN2A, 40% LKB1, 40% KEAP1, 38.4% KRAS, 20% SWI/SNF, 20% PTEN, 
8% ERBB2). Furthermore, we developed a freeze/thawing procedure on samples derived 
from PDXs that allows for 100% successfully thawing and established a large collection 
of more than 200 frozen PDX samples for future preclinical studies. Conclusion: The 
deep characterization of our established PDX panel confirmed that these mouse models 
recapitulate the parental primary tumors in terms of tumor histology, cellular and mutation 
pattern, metabolic activity and expression of specific markers for several passages in mice. 
All these data support the use of these “human in mouse” models for functional studies, 
highlighting the relevance of our PDX panel as a valuable platform for preclinical studies. 
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Aberrations Associated with Better Prognosis in Non-Small Cell Lung Cancer 
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tumors. Bavituximab blocks PS-mediated immune suppression and activates cytotoxic 
T lymphocyte anti-tumor responses. Methods: Tissues from consented patients with 
adenocarcinoma of the lung were extracted at the time of surgical resection and disaggregated 
to characterize expression of immune checkpoint proteins such as PD-1, CTLA-4, LAG3, 
TIM3, BTLA and adenosine A2A receptor on both CD4+ and CD8+ tumor infiltrating 
cells by flow cytometry (FACS) and stained for PD-L1, CD68, and CD163 via 
immunohistochemistry (IHC). 3D tumor microspheres were prepared and treated ex 
vivo with an IgG control, F(ab)’2 version of bavituximab, bavituximab, docetaxel, anti-PD-1 
or PD-L1 and combinations of bavituximab, anti-PD-1 or PD-L1 and docetaxel for 36 hours 
within an intact tumor microenvironment. A multiplex human cytokine assay was used to 
simultaneously analyze the differential secretion of cytokines. Additionally, a NanoString 
platform containing probes to quantitate 770 immune function genes was used to 
determine potential positive or negative associations between expression of immune 
function genes and TIL activation by treatment. In a few cases, the expanded TILs were 
tested in PDX models using the consented patient’s tumor. Results: Bavituximab induces 
activation of TILs in 3D ex vivo tumor microsphere models of lung cancer, as demonstrated 
by a significant increase in IFN-α, TNF-a, and GM-CSF secretion. FACS, IHC, and NanoString 
gene function analysis read out assays revealed that this effect was associated with low 
PD-1 expression on CD8+ cells, negative PD-L1 expression in the stating biopsy tissue, and 
a conversion of the M2 to M1 macrophage phenotype. Conclusion: These data support 
the use of bavituximab as an immunomodulatory treatment in adenocarcinoma of the 
lung by enhancing the activation of CD8+ TIL derived from patients’ tumors with negative 
PD-L1 expression; correlating with increased cytokine production by lymphoid cells and 
repolarization of myeloid cells from an immunosuppressive to an immune active state. 
Keywords: Tumor microenvironment immunomodulation, 3D tumor microspheres, 
Chimeric monoclonal antibody-targeted therapy, Cytokine and immne function genes 
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Background: Ionizing radiation (IR) therapy is an integral component of treatment 
for NSCLC, however, the majority of patients succumb to this disease as the disease 
tends to relapse and metastasize. The failure of the therapies is associated with 
hypermalignant cancer-initiating cells (CICs). CICs are radiation-resistant; therefore, 
targeting CICs represent an important therapeutic strategy for improving the outcome 
of IR treatment. Ganetespib, a novel heat shock protein 90 (HSP90) inhibitor, reduces 
expression of multiple HSP90-dependent client oncoproteins. We evaluated both the 
in vitro and in vivo antitumor effects of ganetespib, in combination with IR, in human 
lung adenocarcinoma (AC) cells. Methods: The radiosentisizing activity of ganetespib, 
HSP90 inhibitor, was evaluated in human lung AC cells established from surgical tumor 
samples. Results: Ganetespib inhibits growth of bulk AC cells, as well as lung CICs, 
growing as tumor spheres. The cytotoxic effects of ganetespib G2/M cell cycle DNA 
repair, apoptosis, and senescence. All of these antitumor effects were both concentration- 
and time-dependent. At the molecular level, ganetespib inhibited pro-survival signaling in 
adenocarcinoma cells through decreased p-AKT expression, the downregulation of RAD51 
and the upregulation of p21. Ganetespib, at low nanomolar concentrations sensitizes AC to 
IR treatment. Importantly, both pretreatment and post –radiation treatment (24h after IR) 
with ganetespib (3nM) could dramatically augment the antitumor effects of IR decreasing 
the survival rate of IR-treated cells. Our study suggests that ganetespib may impart 
radiosensitization through multiple mechanisms: such as the down regulation of the PI3K/
Akt pathway; diminished DNA repair capacity and the promotion of cellular senescence. 
In vivo, ganetespib was effective in reducing the tumor growth of primary T2821 tumor 
xenografts in mice and sensitized tumors to IR. Conclusion: The HSP90 inhibitor, 
ganetespib, potentiates the effect of IR in NSCLC and eliminates CICs. The radiosensitizing 
effect of ganetespib is mediated by the combinatorial inhibition of cell growth and 
survival pathways. Ganetespib is the most potent HSP90-mediated radiosensitizer yet 
reported in vitro, and for the first time validated in a clinically relevant in vivo model. The 
use of ganetespib as a therapeutic warrants a further investigation in the clinical setting. 
Keywords: lung adenocarcinoma radiotherapy ganetespib, molecular chaperone HSP90 
inhibitor, lung cancer stem cells apoptosis senescence
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MINI14.10 CAY10603, a Novel Inhibitor of HDAC6, Suppresses Non-Small 
Cell Lung Cancer Cell Growth via Modulating Both Autophagy and Apoptosis 
Pathways Zhihao Wang, Fang Tang, Shaoxing Sun, Chunxu Yang, Conghua Xie 
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, 
Wuhan/China
Background: Histone deacetylase 6 (HDAC6) is a key regulator of many signaling 
pathways linked to cancer. But unlike other HDACs, inhibition of HDAC6 is believed 
not to be associated with severe toxicity, making HDAC6 a possible cancer treatment 
target. Overexpression of HDAC6 has been observed in many types of cancer including 
NSCLC. Knockdown of HDAC6 sensitizes NSCLC cell lines to chemotherapy induced cell 
apoptosis. Apoptosis and autophagy are the 2 cellular processes likely to alter efficacy 
of a therapeutic agent. Autophagy confers resistance to chemotherapy by inhibiting 
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previous work, we found the activity of CD26/DPP4 of lung cancer from patients was 
four times higher than normal lung tissue from same patients (n=38). Therefore, we 
tested if pharmacological CD26/DPP4 inhibitor (Vildagliptin) inhibits lung cancer growth 
in various animal models. Methods: Mouse lung cancer cell line (Lewis Lung Carcinoma 
(LLC)) and human lung adenocarcinoma cell line, H460, were used to develop syngeneic 
(C57BL6: n=8) or xenogeneic (CD1-nude: n=20) tumor models by sc. injection. Tumor 
growth was represented by wet weight of tumor mass at harvest (4 weeks). BALB/c 
mouse strain (n=12) was used to induce lung cancer by Urethane (1g/kg) ip. Urethane 
injected mice were harvested 5 months after ip. Vildagliptin treatment was given 
in drinking water (0.2 mg/ml: 50mg/kg day) during the experimental course. Tumor 
nodules were counted macroscopically under surgical microscope. For histological 
assessment, HE, TUNEL, immunohistochemistry (IHC) of CD31, Ki67, CD3, Nkp46, and 
F4/80 were performed. The expression of surfactant protein C (SP-C) was detected by 
western blotting. Results: Vildagliptin treatment significantly reduced the size of tumor 
developed by lung cancer cell line injection (p<0.05 for both). Tumor induced by Urethane 
ip. in BALB/c mice was less incident by Vildagliptin treatment (40%: 2/5 mice) than 
control (100%: 7/7) group. The number of tumor nodule per mouse was also significantly 
reduced by Vildagliptin compared to control (p<0.05). Beside tumor weight, there was 
no difference in HE, TUNEL stain, and IHCs of CD31, Ki-67, CD3, and Nkp46. However we 
found significantly increased numbers of macrophages (F4/80) in the tumors induced by 
lung cancer cell line injection (p<0.05 for both) along with increased expression of SP-C 
in lung cancer cell lines in vitro. Conclusion: Inhibition of CD26/DPP4 by Vildagliptin 
decreased lung cancer growth in the models of mouse and human lung cancer cell 
lines and increased infiltrating macrophages within tumors. Furthermore, there was 
increased expression of SP-C by Vildagliptin treatment found in lung cancer cell lines. 
This finding suggests that surfactant production in lung cancer is induced and potentially 
activates macrophages against lung cancer by CD26/DPP4 inhibitor, Vildagliptin. 
Keywords: lung cancer, CD26/DPP4, Surfactant protein, macrophage
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MINI15.01 A Phase I/II Study Evaluating the Combination of Resminostat and 
Docetaxel for Platinum-Pretreated NSCLC Atsushi Horiike1, Toshiaki Takahashi2, 
Hiroshi Nokihara3, Noriko Yanagitani1, Hirotsugu Kenmotsu2, Yutaka Fujiwara3, Yuichi 
Tambo1, Shintaro Kanda3, Makoto Nishio1, Tomohide Tamura4 1Thoracic Medical 
Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo/
Japan, 2Shizuoka Cancer Center, Shizuoka/Japan, 3Thoracic Oncology, National Cancer 
Center Hospital, Tokyo/Japan, 4St Luke’s International Hospital, Tokyo/Japan
Background: Resminostat, an oral hydroxamate-type inhibitor of class I and II histone 
deacetylases, has shown a broad spectrum of anti-tumor activity against human cancer 
cell lines, and synergetic or additive effects in combination with docetaxel in non-small cell 
lung cancer (NSCLC) cell lines. We initiated a phase I/II study to evaluate the safety and 
efficacy of combining resminostat and docetaxel in patients (pts) with NSCLC pretreated 
with platinum-based therapy. The purpose of the phase I portion was to evaluate dose-
limiting toxicities (DLTs) in the first cycle, estimate the maximum tolerated dose (MTD) 
of resminostat when administered in combination with docetaxel, and determine the 
recommended dose (RD) for the phase II portion. Here, we report the results of the 
phase I portion. Methods: NSCLC pts with failure of a platinum-based therapy were 
eligible for the study. Patients were treated with docetaxel on day 1 and resminostat on 
days 1 to 5 every 21 days. Phase I was an open-label, 3+3 cohort, dose-escalation study. 
While the docetaxel dose was fixed at 75 mg/m2, the resminostat dose was escalated 
from 400mg (Dose Level 1: DL1) to 600 mg (DL2). DLT was defined as follows: grade 4 
thrombocytopenia, grade 4 neutropenia lasting >7 days, febrile neutropenia lasting >3 
days, and any other clinically significant grade 3/4 non-hematological toxicity. Results: A 
total of 9 pts (DL1: 3 pts, DL2: 6 pts) were enrolled in the phase I portion: male/female, 
6/3; median age, 60 yr (50-71 yr); histologically proven adenocarcinoma/squamous cell 
carcinoma, 7/2; performance status, 0/1 in 7/2 pts. No DLTs were observed at DL1 or 
DL2. The most frequent grade 3/4 adverse events in any cycle were neutropenia (8 pts, 
88.9%), leukocytopenia (8 pts, 88.9%), and febrile neutropenia (4 pts, 44.4%). These 
events were transient and resolved prior to the next cycle. No pharmacokinetic (PK) 
interaction between resminostat and docetaxel was observed. A partial response was 
observed in 1 pts (DL1) and stable disease in 3 pts (DL2).
DL1 N=3 DL2 N=6
PK parameters (Geometric Mean) Resminostat Docetaxel Resminostat Docetaxel
Cmax (ng/mL) 3,010 2,840 5,610 3,140
Tmax (h) 1.78 1.00 1.47 1.03
AUCinf(h·ng/mL) 11,800 3,030 25,500 3,280
t1/2 (h) 2.98 8.21 3.02 8.73
 
Conclusion: The combination of resminostat and docetaxel was tolerable up to DL2 
(docetaxel 75 mg/m2, resminostat 600 mg); the MTD was not reached. Dose Level 2 was 
determined as the RD for the phase II portion of this study, which is currently ongoing. 
Keywords: Phase I/II, resminostat, docetaxel, platinum-pretreated NSCLC
Toronto, Toronto/ON/Canada
Background: Patient-derived tumor xenografts (PDXs) increasingly are being used 
as preclinical models to study human cancers, test novel therapeutics, and identify 
potential biomarkers, as they more accurately model human cancers than established 
tumor cell line cultures. However, uncertainty remains as to how well the genomic 
characteristics of patient non-small cell lung cancer (NSCLC) are recapitulated in 
these PDX models. Methods: PDXs were established by implantation of surgically 
resected NSCLC patient tumors into the subcutaneous or sub-renal capsule of non-
obese diabetic severe combined immune deficient (NOD-SCID mice. Comprehensive 
genomic profiling including exome, gene copy number, DNA methylation and mRNA 
expression were conducted on 36 independent PDX models, their matched patient 
tumors and normal lung tissue. Publicly available cell line and TCGA data were used 
for comparison. Integrative analysis was performed to identify genomic alterations in 
PDXs that are associated with significant clinical outcomes in patients. Results: From 
441 resected NSCLC tumors, 127 serially transplantable and stable PDX models were 
established. Among 264 NSCLC patients with at least 3-years follow-up, patients whose 
tumor formed stable PDXs (versus those who did not) showed significantly worse disease 
free (HR=3.12, 95% CI =2.02-4.83, P<0.0001) and overall survival (HR=4.08, 95% CI 
=2.16-7.73, P<0.0001), after multivariable adjustment for clinical pathological factors. 
Genomic and transcriptomic profiling of 36 PDXs showed greater similarity in somatic 
alterations between PDX and primary tumors than with published cell line data. In addition 
to known mutations, we found at least 16 non-synonymous somatic mutations in known 
oncogenes and tumor suppressors that have never been reported. All these mutations 
had higher observed variant allele frequency in PDXs compared to their matched 
patient tumors, suggesting that these were tumor sub-clones selected or enriched 
for growth in the PDXs. Tumor models characterized by a higher number of somatic 
alterations among 865 frequently altered genes were associated with better overall 
patient survival (HR=0.15, p=0.00015) compared to patients with corresponding PDXs 
characterized by higher alteration number; this was validated in the TCGA lung cancer 
dataset patients (HR=0.28, p=0.000022). These 865 genes were enriched for those 
encoding for proteins involved in cell adhesion and interactions with the extracellular 
matrix, and a quarter of the genomic alterations would putatively form neo-antigens 
implicating a potential role of immune response in the observed improved patient 
survival. Conclusion: PDXs are close preclinical models of patient tumors. Further 
investigations of passenger mutations may clarify their clinical impact on interactions 
between tumor cells, stroma, immune microenvironment and patient prognosis. 
Keywords: Genomics, Xenograft, Prognostic, preclinical model
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MINI14.13 Small Molecule Demonstrates Potent Tumor Suppression by 
Inhibiting the PI3K/AKT Pathway in Non-Small Cell Lung Cancer Gavitt A. 
Woodard, Jane Crockard, Csaba Peto, Bhairavi Tolani, Biao He, David Jablons Thoracic 
Surgery, University of California, San Francisco/CA/United States of America
Background: The phosphoinositide 3-kinase (PI3K) / protein kinase B (AKT) / mammalian 
target of rapamycin (mTOR) pathway is frequently activated in many malignancies 
including non-small cell lung cancer (NSCLC). Dysregulation of this pathway leads drives 
oncogenic genes and imparts resistance to conventional chemotherapy. We identified 
a small molecule AKT pathway inhibitor as a potential lead compound. Methods: The 
AKT pathway inhibitor was tested in vitro on a panel of NSCLC cell lines A427, A549, 
NCI-H1703, NCI-H2170, NCI-H1650, and NCI-H1975. Cell viability was determined 
by MTS assay after 72 hours of drug treatment. Activation kinases in the PI3K/AKT/
mTOR pathway was determined by western blot analysis. Results: Treatment with 
the PI3K/AKT pathway inhibitor caused potent concentration-dependent inhibition of 
cell proliferation with a half maximal inhibitory concentration (IC50) in the nanomolar 
range. Kirsten rat sarcoma (KRAS) mutant cell lines were the most sensitivity to the 
PI3K/AKT pathway inhibitor while epidermal growth factor receptor (EGFR) mutant cell 
lines were more resistant. Western blot analysis showed inhibition of AKT and mTOR 
phosphorylation at nanomolar concentrations. Conclusion: A novel small molecule 
AKT inhibitor inhibits growth of NSCLC cells in vitro, is potent against KRAS mutants, 
and shows promise as a small molecule targeted chemotherapy drug for NSCLC. 
Keywords: phosphoinositide 3-kinase (PI3K) pathway, protein kinase B (AKT), epidermal 
growth factor receptor (EGFR) pathway, small molecule
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MINI14.14 Suppression of Lung Cancer Growth by CD26/DPP4 Inhibitor 
Jae-Hwi Jang1, Florian Janker1, Stephan Arni1, Yoshito Yamada1, Ignacio Gil-Bazo2, Ingrid 
D. Meester3, Walter Weder1, Wolfgang Jungraithmayr1 1Division of Thoracic Surgery, 
University Hospital Zurich, Zurich/Switzerland, 2Oncology, Clinica Universidad de Navarra, 
Pamplona/Spain, 3Medical Biochemistry, University of Antwerp, Antwerp/Belgium
Background: Lung cancer is the most prominent cause of death among cancers, 
accounting for 1.38 million deaths worldwide annually. In spite of improved treatment 
in surgery, chemo- and radiation therapy, the five year survival is poor, being 69% for 
stage Ia and <5% for stage IV. The cure rates of current therapies are disappointing 
and did not significantly prolong long term survival. Surfactant protein (SP) in lung 
determines not only function of the organ, but also inflammatory reaction in an 
infectious condition. Recently Nishioka et al. showed that stimulated SP production in 
the orthotopic models of human lung cancer recruits inflammatory, type I macrophages 
in the tumor which decreased the size of the tumor. Also, Stephan et al. found increased 
productions of SPs in rat by CD26/DPP4 inhibitor treatment or CD26-/- animal. In our 
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with slower tumor kinetics might benefit more from this type of epigenetic therapy. 
Keywords: decitabine, genistein, epigenetics, lung cancer
CHEMOTHERAPY DEVELOPMENTS FOR LUNG CANCER 
TUESDAY, SEPTEMBER 8, 2015 - 16:45-18:15
MINI15.04 Phase I Study of Continuous Intravenous Infusion of Rh-Endostatin 
Combined with Pemetrexed and Carboplatin in Advanced NSCLC Yan Huang1, 
Yunpeng Yang1, Hongyun Zhao1, Yuxiang Ma1, Qingfeng Zou2, Li Zhang1 1Medical 
Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/China, 2Cancer Center of 
Guangzhou Medical University, Guangzhou/China
Background: Endostar TM (rh-endostatin, 7.5mg/m2, 3-hour intravenous infusion (IV) 
daily for 14 days) was approved by Chinese FDA for treatment of advanced NSCLC 
in 2005. Considering continuous intravenous infusion (CIV) may be a more favorable 
way to deliver Endostar, we designed the phase I study to evaluate pharmacokinetics, 
tolerability and efficacy of Endostar CIV at different doses combined with pemetrexed and 
carboplatin in untreated advanced non-squamous NSCLC patients. Methods: In phase Ia, 
19 patients were assigned to 4-6 cycles (21 days/cycle) of pemetrexed (500mg/m2, day 
1), carboplatin (AUC 5, day 1), and CIV Endostar from day 2 to day 21 at doses of 7.5mg 
(8 patients), 15mg (6 patients), 30mg (5 patients) /m2/d, respectively. Serum samples 
were obtained 0h、1h、2h、4h、8h、24h、48h、72h、96h、120h、122h、124h、128h、13
2h and 144h after the Endostar infusion. In phase Ib, another 21 patients received CIV 
Endostar at doses of 7.5mg (10 patients) or 15mg (11 patients) /m2/d with pemetrexed 
+ carboplatin. Results: The AUC0-120h of Endostar 7.5mg/m
2 CIV and 7.5mg/m2 3-hour 
IV daily were comparable (12.6±7.6 vs 13.3±8.8 ug/mL × hour). Cmax (ng/ml) (7.5mg: 
152.4±83.7; 15mg: 287.2±122.6; 30mg: 398.2±52.6) and AUC0-120h (ug/mL × hour) 
(7.5mg: 12.6±7.6; 15mg: 21.2±10.8; 30mg: 33.4±8.5) were linear with dose. In phase 
Ia, the most common adverse events were anemia (78.9%, G3/4 10.5%), neutropenia 
(68.4%, G3/4 31.6%), thrombocytopenia (63.2%, G3/4 10.5%), LDH increase (47.4%), 
aminotransferase increase (42.1%), and supraventricular arrhythmia (26.3%). No grade 
3 or 4 non- hematologic adverse event was observed. The incidence of supraventricular 
arrhythmia in 30mg cohort (40%) was higher than the other two cohorts. Thus 30mg 
cohort was excluded in Ib phase. Totally, 15 patients in 7.5mg cohort and 17 patients 
in 15mg cohort were evaluable for treatment response. The DCR and ORR were 
80.0% and 60.0% in 7.5mg cohort, 94.1% and 76.5% in 15mg cohort, respectively.
Conclusion: The pharmacokinetics of Endostar CIV and daily IV were comparable. At 
doses of 7.5mg and 15mg/m2/d, Endostar CIV was well tolerated with encouraging 
anti-tumor efficacy. Increasing dose of Endostar might lead to better response. 
Keywords: pharmacokinetics, non-small cell lung cancer, endostatin, chemotherapy
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MINI15.06 Impact of Three and Further Lines in Advanced Non-Small Cell Lung 
Cancer Patients According to Molecular Profile: A Retrospective Analysis  
Enric Carcereny, Teresa Moran, Maria De Los Llanos Gil, Iris Teruel, Laia Vila, Max 
Hardy-Weber, Ana Estival Medical Oncology, Catalan Institute of Oncology-Hospital 
Germans Trias I Pujol, Badalona/Spain
Background: There is little evidence supporting the efficacy of third-line systemic 
therapy in non-small cell lung cancer (NSCLC) patients (p) with advanced (a) disease, 
except for erlotinib, and its role is unclear in unselected population. Nonetheless, further-
line chemotherapy(CT) is frequently offered in daily clinical practice. We retrospectively 
analyzed the clinical, pathological characteristics and outcomes of p with aNSCLC who 
received >3 CT regimens to identify subsets of patients more likely to benefit. The presence 
of underlying molecular alterations has also been evaluated. Methods: The study included 
data from all consecutive p diagnosed with aNSCLC in our Institution from January 2008 
to December 2013. Median overall survival (mOS) and progression free survival (PFS) 
were evaluated with Kaplan-Meier curves and groups were compared using the Log-rank 
test. Variables analyzed included p tumor and treatment characteristics. Overall response 
rate(ORR) was calculated according to the RECIST criteria. Results: A total of 486 p were 
included .175 p (36%) received >3 lines (group3+). Table 1 summarized p characteristics. 
Group 3+included more females (35.4%vs22.8%; p= 0.0041),younger p (58.9vs61.9;p 
=0.0016), more never-smoker p (26.9%vs18%;p=0.015), less lung (10.9%vs22.2%;p= 
0.0020) and heart (4%vs11.6%;p=0.0020) comorbidities, a higher proportion of 
molecular alterations (EGFR/ALK) (25.7%vs12.9%; p= 0.0005), more adenocarcinoma 
(68.6%vs55%;p=0.0045) and less brain metastasis (14.3%vs23.5%;p=0.018). ORR 
to first line was higher in group 3+ (45.8%vs 29%;p=0.0009). 82.3% non-squamous 
histology were tested for at least one molecular alteration. There were no differences 
in PFS between both groups. The mOS of p in group 3+ was longer [24.3 m vs. 7.7 
m, p<0.0001)], including p with EGFR/ALK/ROS1 wild-type or unknown [21.6 m vs. 7.4 
m, p<0.0001) ]. OS was also longer in the group 3+ harboring a molecular alteration 
[32.2 m vs 12.7m;p=0.0002]. In the univariate analysis the presence of a molecular 
alteration were related to longer PFS. In univariate analysis having received >3, 
female gender, age<65 and the presence of molecular alterations were associated 
with longer OS. In the multivariate analysis >3 therapeutic lines and the presence of 
molecular alterations were related to longer OS. Conclusion: P treated with >3 systemic 
treatments were more likely to respond better, progress later and live longer. This 
better prognosis could be related to the presence of molecular alteration. However p 
without or unknown molecular alteration could benefit from receiving subsequent lines. 
Keywords: chemotherapy, molecular alterations, beyond second line
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MINI15.02 NEJ016: Phase II Study of CBDCA and Weekly PTX plus BEV 
Followed by BEV for Highly Selected Elderly Non-Squamous NSCLC Patients 
Ou Yamaguchi1, Satoru Miura2, Makoto Maemondo3, Akira Iwashima4, Toshiyuki 
Harada5, Shunichi Sugawara6, Kunihiko Kobayashi1, Akira Inoue7, Taku Nakagawa8, Yuichi 
Takiguchi9, Hiroshi Watanabe10, Masahiro Seike11, Takashi Ishida12, Masaki Terada13, 
Akihiko Gemma11, Hirohisa Yoshizawa14 1Respiratory Medicine, Saitama Medical University 
International Medical Center, Hidaka/Japan, 2Respiratory Medicine, Niigata University Medical 
and Dental Hospital, Niigata/Japan, 3Respiratory Medicine, Miyagi Cancer Center, Natori/
Japan, 4Respiratory Medicine, Nagaoka Chuo General Hospital, Nagaoka/Japan, 5Center for 
Respiratory Disease, JCHO Hokkaido Hospital, Sapporo/Japan, 6Pulmonary Medicine, Sendai 
Kousei Hospital, Sendai/Japan, 7Respiratory Medicine, Tohoku University Hospital, Sendai/
Japan, 8Thoracic Surgery, Omagari-Kousei Medical Center, Daisen/Japan, 9Medical Oncology, 
Graduate School of Medicine, Chiba University, Chiba/Japan, 10Respiratory Medicine, Saka 
General Hospital, Shiogama/Japan, 11Pulumonary Medicine and Oncology, Nippon Medical 
School, Graduate School of Medicine, Tokyo/Japan, 12Internal Medicine, Niigata Prefectural 
Central Hospital, Joetsu/Japan, 13Respiratory Medicine, Saiseikai Niigata Daini Hospital, 
Niigata/Japan, 14Respiratory Medicine, Niigata Medical Center Hospital, Niigata/Japan
Background: It is considered that there is a population of “fit-elderly” patients, but how 
to select this population is undetermined. Two-drug regimen consisted of carboplatin 
(CBDCA) + weekly paclitaxel (PTX) in elderly patients with non-small cell lung cancer 
(NSCLC) was reported to be active but to have 4.4% of toxic deaths. When considering 
to add bevacizumab (BEV) to the two-drug regimen, meta-analysis of BEV-related 
adverse events taught that congestive heart failure (CHF) and arterial thromboembolic 
events increased in elderly patients. In this phase II study, we employed exclusion 
criteria of having both congestive heart failure (CHF) and diabetes mellitus (DM), which 
relates to arterial thromboembolism. Methods: Elderly (≥70 years old) patients with 
chemotherapy-naive, stage IIIB/IV or recurrent non-squamous NSCLC, ECOG-PS 0-1, 
measurable target lesion, and adequate organ functions were eligible for this study. 
Pts with CHF (i.e. those with brain natriuretic peptide (BNP) ≥ 100 pg/ml and ejection 
fraction (EF) ≤ 50%) and with DM (i.e. those with HbA1c ≥ 7.0%) were excluded. Treatment 
included CBDCA at AUC 5 on day 1, PTX at 90 mg/m2 on days 1 and 8, and BEV at 
15 mg/kg on day 1 of each 21-day cycle for up to 4 cycles, followed by maintenance 
BEV. Results: Thirty-six eligible patients (14 male, 22 female; median age, 75 years) 
were enrolled between February 2012 and September 2014. Fifteen and 21 patients 
had ECOG-PS of 0 and 1, respectively. The median number of CBDCA + weekly-PTX + 
BEV treatment cycles received was 4, and that of BEV maintenance dosing was 5. Grade 
3/4 non-hematological and hematological toxicities were observed in 13 (36.1%) and 
20 pts (55.6%), respectively. The most common grade 3/4 AEs included neutropenia 
(52.8%), hypertension (11%), anemia (8.3%), and infection (8.3%). No fatal AE was 
observed. The response rate, the primary endpoint of this study, was 69.4% (95% CI = 
51.9–83.7), and median progression free survival was 9 months. Conclusion: CBDCA 
+ weekly PTX + BEV followed by BEV was a feasible and effective first-line regimen 
for selected elderly non-squamous NSCLC patients. BNP, EF, and HbA1c may aid in 
selecting “bevacizumab-fit” elderly patients. Clinical information: UMIN000006622. 
Keywords: Elderly patients, bevacizumab (BEV), phase II study, non-small cell lung 
cancer (NSCLC)
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MINI15.03 Phase I & II Studies of the Decitabine–Genistein Drug Combination 
in Advanced Solid Tumours Elie Kassouf1, Mustapha Tehfe1, Marie Florescu1, 
Denis Soulieres1, Bernard Lemieux1, Jean-Pierre M. Ayoub1, Danielle Charpentier1, 
Louise Yelle1, Luc Daigneault2, Patrick Colin3, Richard L. Momparler4, Isabelle 
Plante5, Guylaine Lassonde5, Michel R. Charbonneau5, Noel J. - M. Raynal4, Normand 
Blais1 1Hematology and Medical Oncology, Hôpital Notre Dame - CHUM, Montreal/QC/
Canada, 2Scimega Research, Montreal/QC/Canada, 3Patrick Colin Consultant Inc, Montreal/
QC/Canada, 4Hôpital Sainte-Justine, Montreal/QC/Canada, 5Institut National de La Recherche 
Scientifique, Laval/QC/Canada
Background: The combination of epigenetic drug decitabine with genistein, a natural 
isoflavone, produces synergistic responses in preclinical studies with particular activity 
shown in lung cancer cell lines. Our phase I dose-escalation study of decitabine with a 
fixed dose of genistein to treat advanced solid tumor was followed by a phase II study 
in advanced lung cancer patients. Methods: In phase I, decitabine was administered 
over 10-hours at increasing doses (60, 120, 240 mg/m2) with continuous administration 
of genistein 300 mg/day orally. The MTD was 120 mg/m2 with neutropenia as DLT. 
Decitabine at 120 mg/m2 and genistein produced plasma levels of 0.62±0.06 µM 
and 8.5±5.6 µM, respectively. Results: The drug combination was well tolerated and 
produced stable disease for more than 6 months (7-14 months) in 5/10 patients. One 
gastric cancer patient had a 50% reduction in tumor burden after 6 months of therapy. 
Stable disease was also achieved in patients with desmoplastic small round cell tumor, 
oncocytic carcinoma, follicular thyroid carcinoma and bladder cancer. The phase II 
study was focused on nine patients with non-small cell lung cancer refractory to 3-4 
lines of therapy. Eight progressed within the first radiologic evaluation at week 6. One 
NSCLC patient remains on therapy with SD after 3 months of treatment. A total of 60 
adverse events were reported during the study with all patients experiencing at least 
one AE. Grade 3 & 4 treatment related toxicities were observed in 6/9 patients (66%) : 
neutropenia (4) anemia (2) febrile neutropenia (1) and hypertension (1). Conclusion: This 
combination of genistein with decitabine was well tolerated in advanced patients 
with solid tumors. The activity of the combination seen in some patients with tumors 
of more indolent biology was modest in the phase II cohort of heavily pretreated 
NSCLC patients. The efficacy profile observed in this trial suggests that tumors 
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received 4 courses of Cb plus PEM, followed by maintenance PEM, without showing 
disease progression or severe toxicities. The primary endpoint was the 1-year overall 
survival (OS) rate, and the secondary endpoints were OS, progression free survival (PFS), 
response rate (RR), and safety. Results: Thirty four patients were enrolled between 
June 2012 and May 2013. All patients had an ECOG performance status 0 or 1, and 
adenocarcinoma. The median patient age was 77 years (75-84 years). Twenty four 
patients were male and ten patients were female. Three patients harbored activating 
epidermal growth factor recepter mutation (exon19 or 21). The median observation 
time was 22.7 months. In clinical outcome, the overall RR was 41.2%, and the disease 
control rate was 85.3%. No patient showed a complete response, 14 showed partial 
responses, 15 showed stable disease, 4 showed disease progression, and 1 was not 
evaluated. The maintenance therapy rate was 58.8%. The median PFS for all patients 
was 5.7 months (95% confidence interval, 3.3–8.5 months), whereas the median OS 
was 20.5 months (95% confidence interval, 7.8–25.4 months). The 1-year OS rate was 
58.0%. In adverse events (total phase of this study), hematological adverse events 
≥grade 3 were leucopenia (in 23.5% of patients), neutropenia (55.9%), anemia (35.3%), 
and thrombocytopenia (20.6%), and major non-hematological adverse events ≥grade 
3 were febrile neutropenia (in 8.8% of patients), increased levels of aminotransferase 
(5.9%), infection (23.5%), and anorexia/fatigue (5.9%). There was 1 treatment-related 
death due to interstitial lung disease. Conclusion: The combination of Cb plus 
PEM followed by maintenance PEM was effective and reasonably well tolerated in 
chemotherapy-naïve elderly (≥75-years-old) patients with non-squamous NSCLC. This 
data was promising and valuable to conduct the phase III study compared with docetaxel 
(DOC) monotherapy in the first-line setting. Now, the phase III trial compared Cb plus 
PEM followed by maintenance PEM with DOC for chemotherapy-naïve elderly (≥75-years-
old) patients with non-squamous NSCLC (JCOG1210/WJOG7813L: UMIN000011460) 
is ongoing and the result is warranted. Clinical trial information: UMIN000004810 
Keywords: carboplatin plus pemetrexed, non-small cell lung cancer, elderly (≥75-years-
old), maintenance therapy
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MINI15.09 Bayesian Network Meta-Comparison of Maintenance Treatments 
for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Gilberto De Lima 
Lopes1, Pui S. Tan2, Sanchalika Acharyya2, Marcel Bilger2, Benjamin Haaland2 1Grupo 
Oncoclinicas Do Brasil, São Paulo/Brazil, 2Health Services and Systems Research, Duke-Nus 
Graduate Medical School, Singapore/Singapore
Background: Recent trials suggested that maintenance treatments improve outcomes 
for patients not progressing after first-line therapy for advanced NSCLC. However, 
physicians have little guidance on selecting which patients benefit the most and what 
drug or regimen is optimal. Here, we report a systematic review and network meta-
analysis (NMA) of current evidence assessing relative efficacies of maintenance options 
in unselected populations, as well as in subgroups determined by EGFR mutation, 
histology, and response to induction. Methods: PubMed and conference proceedings 
were reviewed and individual study relative efficacy measures were meta-analyzed in 
a Bayesian hierarchical model. The primary and secondary outcomes, Overall Survival 
(OS) and Progression Free Survival (PFS), respectviely, were evaluated in terms of (i) 
posterior surface under cumulative ranking curve (SUCRA), (ii) probability of being 
best treatment, (iii) probability of outperforming no maintenance, and (iv) posterior 
median hazard ratios with 95% credible intervals, in an unselected population, as well 
as by EGFR mutation status, histology, and response to induction. Secondary outcomes 
were overall survival (OS) and adverse events. Results: Twelve trials evaluating eight 
maintenance treatments in 3,850 patients were included in NMA. Selected maintenance 
treatments showed substantial PFS and OS benefits with probabilities ≥99% and ≥92% 
respectively of outperforming no maintenance. Results suggest the following strategy 
for optimal OS and PFS: (i) switch to or continue pemetrexed or switch to anti-EGFR 
TKI for nonsquamous patients, (ii) continue gemcitabine for squamous patients, (iii) 
switch to docetaxel or continue gemcitabine for responders to previous induction, and 
(iv) switch to or continue pemetrexed or switch to anti-EGFR TKI for patients with stable 
disease post-induction. Conclusion: Maintenance treatments improve PFS and OS in 
good performance status patients with stage IIIb/IV NSCLC not progressing after first-
line chemotherapy. Benefits are optimized by targeting specific maintenance treatments 
to selected patient groups guided by histology and response to previous induction. 
Keywords: maintenance, meta-analysis, bayesian
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MINI15.11 Optimal Second Line Chemotherapy after 1st Line Pemetrexed and 
Cisplatin Treatment in EGFR Mutation Negative Advanced NSCLC Patients 
Sung Yong Lee1, Kyung Ho Kang1, Jae Jeong Shim1, Jae Kyeom Sim1, Jee Youn Oh1, 
Gyu Young Hur1, Kyung Hoon Min2, Kwang Ho In2 1Korea University Medical Center, Seoul/
Korea, 2Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, 
College of Medicine, Korea University, Seoul/Korea
Background: Pemetrexed and cisplatin (P-C) has become the standard 1st line 
chemotherapy in NSCLC patients with wild-type EGFR. The recommended drugs in 
the 2nd line are docetaxel, docetaxel plus ramucirumab, gemcitabine or EGFR TKIs. 
Gemcitabine and vinorelbine have good clinical efficacies and low toxicity profiles, so 
this two drug combination therapy is challenged for their clinical efficacy as 2nd line 
treatment. The optimal 2nd line chemotherapy following failure of 1st line P-C treatment 
in advanced NSCLC patients with wild-type EGFR is not yet defined. Therefore, we 
evaluated the optimal 2nd line chemotherapy in P-C non-responders with advanced 
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MINI15.07 Prognostic Importance of Pretreatment Sodium Levels in Patients 
of NSCLC Treated with Pemetrexed-Platinum Doublet Chemotherapy Manjunath 
Nookala Krishnamurthy1, Vikram Gota1, Kartik Doshi1, Bharti Shriyan1, Amit Joshi2, 
Kumar Prabhash2, Vanita Noronha2 1Department of Clinical Pharmacology, Advanced 
Centre for Treatment, Research and Education in Cancer, Navi Mumbai/India, 2Dept of 
Medical Oncology, Tata Memorial Hospital, Mumbai/India
Background: A recent study has shown pretreatment sodium levels to be a predictive 
and prognostic marker in NSCLC patients treated with erlotinib. The objective of this study 
was to evaluate the prognostic impact of pretreatment sodium levels on progression free 
survival (PFS) and overall survival (OS) in patients of NSCLC treated with pemetrexed-
platinum doublet chemotherapy. Methods: Stage IIIB/ IV NSCLC patients aged ≥ 18 
years treated between January 2011 to November 2014 at our centre were included in 
this retrospective study. Patients received pemetrexed 500 mg/m2 with either cisplatin 
75 mg/m2 or car boplatin (AUC 5) on day 1 of a 21 day cycle for 6 cycles followed by 
maintenance pemetrexed till progression. Electronic medical record (EMR) database of 
our hospital was used to retrieve demographic data, pretreatment sodium levels, PFS 
and OS data. LSS was defined as serum sodium < 136mEq/L. Survival analysis was 
performed using Kaplan-Meier curves and compared between LSS and normal serum 
sodium (NSS) groups using Log-Rank test and proportional hazard model. Results:
 
Data was available for 256 patients (M/F = 172/84) with median age of 53 (25-79) years. 
Majority had ECOG PS of 1 (0 = 34, 1 = 172, 2 = 44, 3 = 6). Stage IIIB = 24 (9%), stage IV = 
232 (91%). Pretreatment LSS was observed in 75 (29%) patients while 181 (71%) had NSS. 
Median duration of follow-up was 17 months. Patients with NSS had significantly longer 
PFS (10.7 vs. 7.4 months; P < 0.05) and OS (17.6 vs. 13.4 months; P < 0.05) compared to 
LSS group. Cox-proportional hazard model has shown LSS was an independent prognostic 
biomarker for poor survival (P < 0.05). Conclusion: Pretreatment serum sodium level is 
an important prognostic marker in stage IIIB/ IV NSCLC patients. The simple possibility of 
testing coupled with low cost makes it an attractive marker to implement in clinical practice. 
Keywords: Hyponatremia, prognostic biomarker, NSCLC
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MINI15.08 A Phase II Study of Pemetrexed plus Carboplatin Followed by 
Maintenance Pemetrexed in Elderly Patients with Advanced Non-Squamous 
NSCLC Motohiro Tamiya1, Akihiro Tamiya2, Hiroyasu Kaneda3, Kazuhiko Nakagawa3, 
Koichi Goto4, Kiyotaka Yoh4, Hiroaki Okamoto5, Tsuneo Shimokawa5, Hiroshi 
Tanaka6, Tetsuya Abe6, Haruko Daga7, Koji Takeda7, Tomonori Hirashima1, Shinji 
Atagi8 1Department of Thoracic Malignancy, Osaka Prefectural Hospital Organization 
Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino/
Japan, 2Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest 
Medical Center, Osaka/Japan, 3Department of Medical Oncology, Kinki University Faculty 
of Medicine, Osaka-Sayama/Japan, 4Division of Thoracic Oncology, National Cancer Center 
Hospital East, Kashiwa, Chiba/Japan, 5Department of Respiratory Medicine, Yokohama 
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Background: Non-small-cell lung cancer (NSCLC) accounts for >80% of all lung 
cancers, and the risk of lung cancer clearly increases with advancing age. Because 
of the progressive aging of population, the number of elderly patients with NSCLC is 
increasing and the desease is becoming an increasing public health problem worldwide. 
We previously reported a phase I study that recommended a dose of carboplatin (Cb, 
area under the curve = 5) plus pemetrexed (PEM, 500 mg/m2) for elderly (≥75-years-
old) patients with non-squamous NSCLC. Furthermore, PEM maintenance therapy, 
following the combination therapy, was also found to be well tolerated. Therefore, 
we conducted a multicenter phase II trial to evaluated the efficacy and safety of Cb 
(area under the curve = 5) plus PEM (500 mg/m2) followed by maintenance PEM for 
elderly (≥75-years-old) patients with non-squamous NSCLC. Methods: Treated patients 
S317Copyright © 2015 by the International Association for the Study of Lung Cancer
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Background: Randomized clinical trials have demonstrated the benefits of chemotherapy 
in carefully selected NSCLC patients. How generalizable these results are to the general 
population of NSCLC patients, who often have multiple comorbidities that would have 
rendered them ineligible for licensing trials, is unresolved. Methods: The outcomes of 
unselected patients with stage IV NSCLC who did not participate in a clinical trial and who 
were treated with standard chemotherapy regimens (paclitaxel/carboplatin; gemcitabine/
carboplatin; pemetrexed/carboplatin; paclitaxel/carboplatin/bevacizumab) as first line 
therapy between 2002 and 2012 at a tertiary teaching hospital were compared to the 
reported outcomes observed in the licensing trials supporting the use of these drug 
regimens. Results: Results are summarized in Table 1 Patients treated with three-weekly 
paclitaxel plus carboplatin at recommended dosages had a median progression free 
survival of 4.9 months for patients responding to this regimen and an overall survival 
of 13.1 months for responders vs 9.2 months for non-responders. In patients’ treated 
with gemcitabine plus carboplatin on a three or four week cycle the median progression 
free survival was 4.8 months for patients responding to the regimen and overall survival 
of 13 months for responders vs 8.9 months for non-responder group of patients. For 
patients receiving pemetrexed plus carboplatin the median progression free survival was 
7.1 months for patients responding to the regimen with an overall survival of 15.5 months 
for responders vs 5.9 months for non-responders. Those patients’ treated with paclitaxel 
plus carboplatin plus bevacizumab the median progression free survival was 7.3 months 
for patients responding to treatment and overall survival was 16.7 months vs 14.6 
months for those patients who did not respond to this regimen as initial treatment. Table 











Age 70> 15.2% 31.4% 26.9% 25.0%
< 70 84.8% 68.6% 73.1% 75.0%
Gender Male 
Female 64.8% 35.2% 51.4% 48.6% 57.7% 42.3% 60.7% 39.3%
Smoker 89.2% 91.2% 84.6% 71.4%
ECOG 0 12.6% 12.1% 8.7% 23.1%
1 68.9% 63.6% 47.8% 76.9%
2 17.5% 24.2% 43.5% 0.0%
3 1.0% 0.0% 0.0% 0.0%
PFS 
(months) 4.9 4.8 7.1 7.3
OS (months) 
PR PD 13.1 9.2 13 8.9 15.5 5.9 16.7 14.6
 
Conclusion: Progression free survival in an unselected population of NSCLC patients 
was similar to that reported in clinical trials supporting the approval of these drugs and 
regimens. The present analysis provides further support for the use of combination 
chemotherapy in patients with stage IV NSCLC, including those who would have been 
ineligible for many clinical trials due to comorbidities. Further analysis is ongoing. 
Keywords: chemotherapy, outcome, NSCLC
CHEMOTHERAPY DEVELOPMENTS FOR LUNG CANCER 
TUESDAY, SEPTEMBER 8, 2015 - 16:45-18:15
MINI15.14 The Role of Breath Sampling in Monitoring Response to Treatment in 
Lung Cancer Inbar Nardi Agmon1, Manal Abud-Hawa2, Ori Liran3, Naomi Gai-Mor3, Maya 
Ilouze4, Amir Onn1, Jair Bar1, Rossie Navon1, Dekel Shlomi3, Hossam Haick5, Nir Peled6 
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Hashomer, Ramat Gan/Israel, 5, Technion-Israel Institute of Technology, Haifa/Israel, 6, Rabin 
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Background: The current available method to monitor response to treatment in lung 
cancer patient is by Computerized Tomography (CT) scans. However, time intervals 
between consecutive CT scans might be too long to allow early identification of 
treatment failure. The aim of this study is to examine the use of breath sampling as 
a tool for monitoring response to anti-cancerous treatment in patients with advanced 
lung cancer. Methods: In a prospective study, repeated exhaled breath samples were 
collected from patients with advanced lung cancer before and under systemic therapy. 
VOCs[1] profiles were determined by GC-MS[2] and nanomaterial-based array of sensors 
and correlated with response to therapy, assessed by CT scans as Complete Response 
(CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD). [1] 
Volatile Organic Compounds [2] gas-chromatography/mass-spectrometry Results: One 
hundred forty three breath samples were collected from 39 patients with stage III/IV 
lung cancer. GC-MS anaylsis identified 3 VOCs as significantly indicating PR/SD samples. 
One of them was also significantly discriminated between PR/SD and PD. Further, the 
NA-NOSE signals were able to alarm per a change in tumor response across therapy, 
i.e. indicating lack of further response to therapy, or developement of resistance to 
therapy. PR/SD was detected in a sensitivity of 93%, specificity of 85% and accuracy of 
NSCLC. Methods: We conducted a retrospective analysis of patients with stage IIIB or 
IV NSCLC who had been treated with P-C as a first line treatment from February 2010 to 
May 2014. Patients who had EGFR mutation or were on pemetrexed maintenance therapy 
were excluded. We compared the progression free survival, overall response rate and 
adverse effects of each regimen. Results: Among 110 patients, 52 were eligible for the 
study. 28 received EGFR TKI (gefitinib or erlotinib); 13 received docetaxel monotherapy; 
11 received gemcitabine-vinorelbine (G-V) combination therapy. Median age was 64.5, 
61 and 63 years, respectively. All patients showed adenocarcinoma type histology 
except two in docetaxel and G-V group with large cell type histology. Best response 
rates were 15.4% in docetaxel group, 18.1% in G-V group and 11% in EGFR TKIs group. 
Median progression free survival time was 62 days(95% CI 54-70) in EGFR TKIs group, 
63 days (95% CI 30-96) in docetaxel group, and 83 days (95% CI 55-111) in G-V group 
(P=0.17). In pairwise comparisons, p-value was 0.54 for EGFR TKI versus docetaxel 
group, 0.08 for TKI versus G-V group, and 0.23 for docetaxel versus G-V group. There 
were no difference in progression-free survival and response rate among the groups. 
There was a higher rate of grade 3/4 neutropenia in the Docetaxel group. Conclusion: 
Despite the absence of statistical significance, there was a trend that G-V combination 
therapy had longer progression-free survival outcome compared to EGFR TKI or 
Docetaxel groups. G-V as well showed better toxicity profiles compared to Docetaxel 
group. A larger study is required to confirm the efficacy of cytotoxic chemotherapy, 
especially G-V, as a second line treatment in EGFR mutation negative NSCLC patients. 
Keywords: docetaxel, non-small cell lung cancer, 2nd line treatment, Gemcitabine/
Vinorelbine
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MINI15.12 Satisfaction with Therapy and the Relation with Quality of Life in 
Patients with Advanced NSCLC Receiving Chemotherapy Sabine Visser1, Mark 
De Mol2, C Cheung3, Nico Van Walree2, Jermo Van Toor1, B. L. Den Oudsten4, Bruno 
Stricker3, Joachim G. Aerts1 1Pulmonary Diseases, Erasmus MC Cancer Centre, Rotterdam/
Netherlands, 2Pulmonary Diseases, Amphia Hospital, Breda/Netherlands, 3Epidemiology, 
Erasmus Medical Centre, Rotterdam/Netherlands, 4Medical and Clinical Psychology, Tilburg 
University, Tilburg/Netherlands
Background: In advanced non-small cell lung cancer (NSCLC) decisions regarding 
palliative treatment are based on tumor response, increasingly combined with patient 
reported outcomes, especially quality of life (QoL). However, considering treatment 
decisions in this manner ignores patients’ own opinion about (change in) QoL. A more 
patient-oriented view regarding therapy could offer valuable information in the process of 
shared decision-making about treatment initiation or continuation with chemotherapy. We 
assessed patients’ satisfaction with the received chemotherapy using the Cancer Therapy 
Satisfaction Questionnaire (CTSQ) in relation with QoL during treatment. Methods: In 
a prospective observational multi-center study, patients with stage IIIB or IV NSCLC 
receiving pemetrexed (PEM)-based chemotherapy as first or second line treatment were 
enrolled. Prior to and after four cycles of chemotherapy, patients completed the WHO 
Quality of Life-BREF (WHOQoL-BREF) and EORTC-Quality of Life Questionnaire-Core 30 
(EORTC-QLQ-C30), which both contain one item measuring overall QoL on a 1-5 and 1-7 
scale, respectively. After four cycles patients also completed the CTSQ, which consists 
of 16 items scored on a 1-5 scale and is divided in three domains, including the domain 
satisfaction with therapy (SWT). Linear transformation of the domain score results in a 
score range 0-100, with a higher score representing a better treatment satisfaction. 
Items of special interest were Question 7 (Q7) “Chemotherapy was worth taking even with 
side effects”, Question 16 (Q16) “If given the choice again, would you decide to take this 
chemotherapy treatment” and Question 2 (Q2) “Chemotherapy would cure the cancer”. 
From all patients tumor response measurements were obtained according to RECIST 
1.1. Results: Of the 88 patients receiving four cycles of PEM-based chemotherapy, 65 
patients completed the WHOQoL-BREF, EORTC-QLQ-30 and the CTSQ. The majority of 
these patients had stage IV NSCLC (87.7%) and received PEM-based therapy as first 
line treatment (92.3%). Treatment resulted in stable disease (53.8%), partial response 
(40.0%) and progressive disease (6.2%). Eighteen patients often (13.8%) or always (13.8%) 
expected chemotherapy would cure the cancer. During therapy, overall QoL measured 
by WHOQoL-BREF increased (1.3±0.6), remained stable (0±0) and decreased (-1.4±0.7) 
in respectively 15 (23.1%), 30 (46.2%) and 20 (30.8%) patients. The SWT domain score 
(77.5±12.3 vs. 83.8±13.1) and single item scores Q7 (4.1±0.9 vs. 4.4±0.8) and Q16 
(4.4±0.7 vs. 4.5±0.6) in patients with decrease vs. increase of overall QoL did not differ 
significantly between the groups (p> 0.05). Change in overall QoL measured by the EORTC-
QLQ-C30 related to SWT, Q7 and Q16 showed similar results. Conclusion: Despite a 
decrease of QoL during chemotherapy, patients still consider the treatment as worth 
taking and would decide to receive the chemotherapy again. Since the majority of 
patients understand that the treatment has no curative intentions, it is unlikely that the 
satisfaction with treatment only reflects false expectations of cancer cure. Our results 
represent a group of patients who mainly established disease stabilization, which 
could have influenced our findings. In shared decision-making on palliative treatment, 
patients’ QoL cannot be used as a single decision criterion because it does not reflect 
patients’ satisfaction with treatment. This study is funded by ZonMw, the Netherlands 
Keywords: shared decision-making, satisfaction with therapy, advanced NSCLC, quality 
of life
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MINI15.13 An Evaluation of Chemotherapy Regimens in an Unselected 
Population of NSCLC Patients Ahmed A. Badawy1, Sejong Bae2, Stefan C. Grant3 
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Birmingham/AL/United States of America, 3Medical Oncology, Wake Forest Baptist Medical 
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Background: Erlotinib, gefitinib and afatinib, tyrosine kinase inhibitors directed at EGFR 
signalling (EGFR-TKI), are currently used for the treatment of patients with advanced-
stage non-small cell lung cancer (NSCLC). A considerable progress in the field of 
molecular oncology and cancer genomics in recent years has let to identification of 
several gene alterations predicting clinical outcome of patients treated with EGFR-TKIs. 
Activating EGFR mutations are widely recognized predictors of good response to EGFR-TKI 
treatment. While the predictive role of common EGFR mutations (exon 19 deletions and 
exon 21 L858R point mutation) is well described, very little clinical evidence data exist on 
the role of rare EGFR mutation types. The aim of this study was to assess the distribution 
of common and rare EGFR mutations in patients with NSCLC and to evaluate the efficacy 
of EGFR-TKIs for patients harboring rare and common EGFR mutations. Methods: Clinical 
data of 305 patients with advanced-stage NSCLC (IIIB or IV) treated with EGFR-TKIs 
having EGFR mutation positive primary tumors at the time of diagnosis were evaluated in 
a retrospective setting. The therapy included erlotinib, gefitinib or afatinib as recorded in 
a Czech national lung cancer registry – TULUNG. The relative frequency and survival data 
(PFS and OS) were evaluated for individual EGFR mutation types. Results:The common 
activating EGFR mutations (exon 19 deletion and exon 21 L858R point mutation) were found 
in a total of 249 (81.6%) patients. Rare EGFR mutations were found in 56 (18.4%) patients, 
the most frequent of which was exon 18 - G719X mutation found in 29 patients (9.5%), 
followed by mutations in exon 20 found in 28 patients S768I in 3 patients (0.98%) and 
insertion 3 mutations in 16 patients (5.2%). Patients with exon 19 deletion had median 
median OS 11.0 months, patients with exon 21 point mutation L858R median OS 9.4 
months,respectively. Patients with rare EGFR mutations median OS 12.5 months.Comparing 
frequent and rare mutations, there were no differences in sex, age, PS, stage of disease 
and adverse effects of first line gefitinib therapy, the group of patients with rare mutations 
were more frequently smokers, duration of gefitinib therapy was shorter, response rate and 
PCR, PFS and OS were worse than in patients having frequent EGFR mutations. There were 
no significant differences in characteristics, PFS and OS between exon 19 deletion and 
exon 21 L858R point mutation tumour patients. Conclusion: While patients with frequent 
EGFR sensitive mutations have significant benefit from gefitinib therapy, patients with 
G719X mutation on exon 18 have marginal PFS and OS benefit, while pagtients with exon 20 
insertion mutations have no demonstrable benefit from targeted therapy.Next generation 
tyrosinkinase inhibitors may prolong survival in some of rare EGFR mutated tumour patients. 
Keywords: EGFR, NSCLC, EGFR-TKI, mutation
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MINI16.03 Dose Optimization of Rociletinib for EGFR Mutated NSCLC 
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Background: Rociletinib (CO-1686) is a novel, oral, irreversible mutant selective tyrosine 
kinase inhibitor for the treatment of patients with mutant epidermal growth factor receptor 
(EGFR) non-small cell lung cancer (NSCLC). Rociletinib has demonstrated efficacy against 
activating mutations (L858R and Del19) and the dominant acquired resistance mutation 
(T790M), while sparing wild-type EGFR. A maximum tolerated dose was not identified 
in Phase 1 with 1000 mg BID the highest dose studied. Here we assess the efficacy 
and safety of the three doses of rociletinib (500 mg BID, 625 mg BID and 750 mg BID) 
selected for Phase 2 study. Methods: TIGER-X (NCT01526928) is a Phase 1/2 open-label, 
safety, pharmacokinetics and preliminary efficacy study of rociletinib in patients with 
advanced EGFR mutant NSCLC progressing after ≥1 EGFR tyrosine kinase inhibitor (TKI). 
Efficacy is assessed using RECIST. Safety is evaluated using standard adverse event (AE) 
reporting. Results: As of April 2015, a total of 231 central T790M positive patients were 
evaluable for efficacy and 343 for safety (any T790M). All patients were enrolled in the 
USA (85%), Europe (9%) and Australia (6%). Baseline characteristics were similar in each 
dose group. The median number of prior therapies was 2. 85% had EGFR TKI as their 
89% and ppositive/negative predictive values (PPV; NPV) of 86% and 92% respectively. 
PD was detected with 100% specificity and 92% accuracy, but the sensitivity was only 
28%. The PPV and NPV were 100% and 91%, respectively. The achieved results indicate 
high reliability in predicting a progression of the disease and detecting patient’s lack of 
response to treatment (i.e., PD). Conclusion: Breath analysis may serve as a serogate 
marker for response to systemic therapy in lung cancer. Such a monitoring tool can 
provide the oncologist with a quick and simple method to identify patient’s response 
to anti-cancerous treatment in shorter intervals than currently available by CT scans. 
Keywords: lung cancer, biomarker, treatment monitoring, exhaled breath
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Background: Treatment of epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKIs) is the standard therapy for advanced non-small cell lung cancer (NSCLC) with 
common EGFR mutations such as exon 19 deletions or L858R mutations. However, the 
efficacy of EGFR-TKIs in patients with uncommon EGFR mutations remains 
unclear. Methods: We have retrospectively surveyed a consecutive database of NSCLC 
patients with EGFR mutations at Kinki-chuo Chest Medical Center, Osaka Prefectural 
Medical Center for Respiratory and Allergic Diseases. We analyzed the collect data of 
NSCLC patients with uncommon mutations including single or complex (uncommon plus 
uncommon mutations, or uncommon plus common mutations) mutations, treated with 
gefitinib or erlotinib between July 2007 and September 2014. Results: Forty-one patients 
who had any EGFR uncommon mutations were analyzed in this study. By the Response 
Evaluation Criteria in Solid Tumors criteria, the overall response rate (RR) was 22.0% with 
9 partial response (PR) in all patients with uncommon mutations. Among uncommon 
single mutations, RR was 12.5% with 3 PR in patients with G719X mutation and 33.3% 
with 2 PR in patients with L861Q mutation. As for complex mutations, there were no 
patients in PR with uncommon plus uncommon mutations but RR was 50.0% with 4 PR in 
patients with uncommon plus common mutations. Median progression-free survival (PFS) 
was 3.5 months in all patients with uncommon mutations. Among uncommon single 
mutations, PFS in patients with G719X (median PFS: 1.8 months) was shorter than PFS in 
patients with L861Q mutation (median PFS: 7.6 months). Furthermore, there was a 
difference in the efficacy of EGFR-TKIs among patients with each G719X mutation (median 
PFS in G719A: 8.2 months, median PFS in G719C: 1.1 months, median PFS in G719S: 1.7 
months).
 
Conclusion: First generation EGFR-TKIs are less effective in NSCLC patients with uncommon 
mutations than in those with common mutations. However, they had favorable response 
in patients with L861Q or G719A mutations, compared with G719C or G719S mutations. 
Keywords: Epidermal growth factor receptor tyrosine kinase inhibitor, non-small cell 
lung cancer, uncommon mutation
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Background: AZD9291 is an oral, potent, irreversible epidermal growth factor 
receptor tyrosine kinase inhibitor (EGFR-TKI), selective for both EGFR-TKI-sensitizing 
(EGFRm) and T790M resistance mutations. The Phase I AURA study was a dose 
escalation/expansion study in patients with EGFRm positive advanced non-small cell 
lung cancer (NSCLC) who had progressed after EGFR-TKI treatment. The 80 mg once 
daily (qd) dose was chosen for further evaluation in a Phase II extension cohort of the 
AURA study, and in an additional Phase II study (AURA2). Here we report efficacy and 
safety of AZD9291 from the AURA study Phase II extension cohort (NCT01802632) 
in patients pre-treated with EGFR-TKI and with centrally confirmed T790M positive 
advanced NSCLC. Methods: Eligible patients had measurable disease, World Health 
Organization performance status (WHO PS) 0 or 1, and acceptable organ function; stable 
brain metastases were allowed. A mandatory tumor sample was taken after disease 
progression on the most recent line of therapy, for prospective confirmation of T790M 
positive status by central laboratory testing (cobas™ EGFR Mutation Test). Patients 
received AZD9291 at 80 mg qd until disease progression. The primary endpoint was 
objective response rate (ORR) according to RECIST 1.1 (assessed by independent central 
review, ICR). Secondary objectives included disease control rate (DCR), duration of 
response (DoR), progression-free survival (PFS), investigator-assessed ORR, and safety. 
Planned enrollment was 175 patients to give an estimate of the ORR with 95% CI within 
±8%. Data cut-off was January 9, 2015 after all patients should have undergone the 
second tumor assessment. Results: 201 patients were dosed in the extension cohort 
of the study; two patients without measurable disease at baseline by ICR were excluded 
from the evaluable-for-response set. By central testing, EGFR mutation subtypes were: 
T790M, 98%; Ex19del, 71%; L858R, 25%; other, 3%. Median age was 62 years; female, 
66%; Asian, 57%; WHO PS 0/1/2, 34%/66%/1%; second/≥third-line, 30%/70%. At the 
data cut-off, median treatment exposure was 4.9 months and 168 patients remain on 
treatment. ORR by ICR was 58% (115/199; 95% CI 51, 65) and DCR was 92% (95% CI 
87, 95). ORRs were similar across lines of therapy (second-line, 59.0% [36/61] vs ≥third-
line, 57.2% [79/138]). Investigator-assessed ORR was 68% (137/201; 95% CI 61, 75). 
Median DoR and median PFS have not been reached (maturity 2% and 21%, respectively). 
The most common all-causality adverse events (AEs) were diarrhea, 41% (0.5% Gr≥3) 
and grouped rash terms 37% (0.5% Gr≥3); 42 (21%) patients experienced Gr≥3 AEs. 
Interstitial lung disease grouped terms were reported in five (2.5%) patients, one of which 
was fatal (0.5%) and considered possibly causally related to AZD9291 by the investigator. 
Eight patients (4%) discontinued treatment due to an AE. Updated results from a later 
data cut-off will be available for presentation. Conclusion: In the AURA study Phase 
II extension cohort, AZD9291 80 mg qd demonstrates clinical activity, manageable 
tolerability, and a low discontinuation rate in patients with centrally confirmed EGFR 
T790M positive advanced NSCLC that has progressed on or after EGFR-TKI treatment. 
These data provide further validation of the results from the Phase I study cohorts. 
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Background: AZD9291 is an oral, potent, irreversible epidermal growth factor receptor 
tyrosine kinase inhibitor (EGFR-TKI) selective for both EGFR-sensitizing (EGFRm) 
and T790M resistance mutations. It has shown anticancer activity and manageable 
tolerability in patients with EGFRm advanced NSCLC that had progressed after EGFR-TKI 
treatment. Methods: In this first-line expansion cohort (AURA, NCT01802632), patients 
received AZD9291 at 80 or 160 mg/day, in sequential dose groups. EGFRm status was 
determined locally and/or by central testing using the cobas EGFR Mutation Test. Other 
inclusion criteria included measurable disease, World Health Organization performance 
status (WHO PS) 0 or 1, and acceptable organ function; stable brain metastases were 
allowed. Safety, tolerability, and anticancer activity were assessed in these cohorts, to 
evaluate AZD9291 in the first-line treatment setting. The data cut-off was December 2, 
2014. Results: Sixty treatment-naïve patients were enrolled; 30 patients in each dose 
group (80 or 160 mg/day). By central testing, EGFR mutation subtypes were: L858R 
40%; exon 19 deletion, 37%; other EGFR-sensitizing mutations, 3%; and T790M, 8%. 
Baseline median age was 63.5 years; 25% of patients were male; 57%/43% had WHO 
PS 0/1, respectively; 72% were Asian and 23% Caucasian. Median treatment exposure 
at the 80 and 160 mg dose levels was 260 and 171 days, respectively. Fifty-two out of 
60 patients remained on treatment at the data cut-off. Anticancer activity of AZD9291 is 
shown in Table 1. One-third (33%) of patients experienced Grade ≥3 adverse events; two 
patients had Grade 3 diarrhea and one patient had Grade 3 skin rash. New data from a 
2015 data cut of the AURA first-line expansion will be available for presentation.
most recent prior therapy and 10% had a history of diabetes/hyperglycemia. Immature 
ORRs are 53% (500 mg BID), 52% (625 mg BID) and 43% (750 mg BID), with disease 
control rates of 89% (500 mg BID), 87% (625 mg BID) and 82% (750 mg BID). The most 
common ≥grade 3 treatment-related AE was hyperglycemia [16% (500 mg BID), 25% 
(625 mg BID) and 35% (750 mg BID)] which was managed with oral hypoglycemic agents. 
Only one patient discontinued the study for hyperglycemia. Grade 3 QTc prolongation 
was uncommon, occurring in 2% (500 mg BID), 7% (625 mg BID) and 10% (750 mg BID) 
of patients, and demonstrated a relationship to dose. There were no clinically relevant 
cutaneous toxicities with 7 cases of grade 1 rash and 4 cases of grade 1 stomatitis (no 
dose relationship) and no paronychia. Conclusion: All 3 Phase 2 doses of rociletinib are 
active and well tolerated in a Western patient population with advanced NSCLC. The lack 
of cutaneous toxicities confirms the selectivity of rociletinib for mutant forms of EGFR 
and is an important contributor to QOL and maintaining dose intensity (Lacouture et al. 
2011). Overall, the adverse event frequency appears to be related to dose, but antitumor 
activity does not, thus the risk/benefit profile may be optimal at the lowest dose studied. 
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Background: Rociletinib (CO-1686) is a novel, oral, irreversible tyrosine kinase inhibitor 
for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-
small cell lung cancer (NSCLC) with activity against the activating mutations (L858R and 
Del19) and the dominant acquired resistance mutation (T790M), while sparing wild-type 
EGFR. TIGER-X (NCT01526928) is a Phase I/II open-label, safety, pharmacokinetics and 
preliminary efficacy study of rociletinib in patients with advanced EGFR mutation-positive 
NSCLC with progressive disease after ≥1 EGFR tyrosine kinase inhibitor (TKI). An overall 
response rate of 67% has previously been reported in this trial for T790M positive patients 
treated with the 500 and 625 mg BID doses (Soria 2014). Here we provide preliminary 
data on the activity of rociletinib in the subgroup of patients with a history of CNS 
disease. Methods: Patients with a history of CNS disease were permitted if asymptomatic 
and stable, as defined by steroid requirements. The primary activity endpoint was RECIST 
overall response rate. However, patients who developed progressive disease (PD) while 
on study treatment were allowed to continue therapy with rociletinib if deemed clinically 
beneficial by the investigator. Results: As of 16 March 2015, a total of 401 patients 
received therapeutic dose levels of rociletinib (500, 625 and 750 mg BID) including 170 
(42%) patients with a history of CNS metastases. Based on this interim analysis, the RECIST 
overall response rate among these patients with a history of CNS disease is 41%. To date, 
42 patients with a history of CNS disease have continued therapy with rociletinib post-
progression. Of those who continued for at least 14 days the average treatment duration 
beyond PD was 89 days (range: 14 - 336 days). Twenty-two of the 42 patients with a history 
of CNS disease with PD also received brain radiation and continued rociletinib treatment 
for an average of 120 days (range: 22 – 336 days) after PD. Rociletinib is held on radiation 
days only. Progression-free survival data for these subgroups is not yet mature. The three 
most common adverse events in the patient population with a history of CNS disease are 
similar to those found in the general TIGER-X patient population: hyperglycemia, diarrhea 
and nausea. Conclusion: In patients with a history of CNS disease, a factor associated 
with poor prognosis, rociletinib is active with a RECIST response rate of 41%. Local CNS 
radiation has been administered safely with rociletinib held on radiation days and continued 
afterwards. Prolonged use of rociletinib post CNS radiation suggests ongoing systemic 
benefit is still experienced by these patients. The role of rociletinib in NSCLC patients with CNS 
involvement is being further explored in the ongoing TIGER clinical development program. 
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Background: Epidermal growth factor receptor (EGFR ) -mutant non-small cell lung 
cancer (NSCLC) exhibits sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such 
as erlotinib and gefitinib; however, acquired resistance eventually develops in most 
patients. The most common mechanism of TKI resistance is a second-site mutation 
in the EGFRkinase domain, T790M. AZD9291 is an oral, potent, irreversible EGFR-TKI 
with potency against both T790M resistance and sensitizing EGFR mutations. In the 
ongoing Phase I AURA study (NCT01802632), AZD9291 induced durable responses 
in patients with acquired resistance to EGFR-TKIs. We report results of paired biopsy 
cohorts of the AURA trial, reviewing modulation of key molecular biomarkers of 
AZD9291 activity in patient tumor samples. Methods: Two cohorts of patients on 
the AURA trial were consented for collection of paired tumor biopsies. These patients 
had a pre-study tumor biopsy with T790M positive tumor status confirmed by central 
laboratory EGFR testing (Cobas™ EGFR Mutation Test). Following 8 to 15 days of once 
daily AZD9291 treatment (80 or 160 mg), a post-dose tumor biopsy was obtained. 
Baseline and post-dose tumor tissue was processed for routine histology and pathologic 
evaluation. More than 100 viable tumor cells per sample were required for subsequent 
biomarker scoring. Formalin-fixed paraffin-embedded tumor biopsies were profiled 
by immunohistochemistry with a suite of key pathway and tumor-relevant markers 
(phospho[p]-EGFR, pERK, pAKT, pS6, PD-L1, CD8). Matching plasma pharmacokinetic 
samples were also obtained for PK-PD correlations. Results: As of February 2015, 58 
potential patients with an evaluable baseline biopsy were identified as candidates for 
post-dose biopsy collection. Sixteen of these patients did not proceed to an on-study 
biopsy as the identified lesions had regressed too substantially or were no longer 
considered suitable for re-biopsy, one patient was medically excluded from re-biopsy, 
and one patient’s sample was not available. In total, 40 patients supplied matched pre- 
and on-treatment biopsies. As of March 2015, paired tumor samples were available for 
QC from 26 of these 40 patients. Ten of these 26 biopsy specimens subsequently failed 
QC due to inadequate tumor content, leaving 16 paired tumor samples available for 
biomarker analyses, of which five have thus far been evaluated. AZD9291 treatment 
resulted in the inhibition of EGFR pathway components in the majority of post-treatment 
tumor biopsies. Tissue biomarker analyses are ongoing and updated data on evaluable 
biopsy pairs will be reported at the time of the congress. Conclusion: The completion 
of a paired biopsy cohort within the AURA trial was challenging due to the rapid onset 
of anti-tumor effects of AZD9291. Approximately 29% (17/58) of potentially eligible 
patients were unsuitable for the post-dose biopsy procedure due to tumor regression 
and 38% (10/26) of available post-dose biopsies were found to contain too little 
tumor for analysis. In the evaluable tumor pairs, pharmacodynamic modulation of 
the EGFR pathway was evident. Further biomarker analyses, including evidence of 
modulation of immune system markers, may help inform future combination strategies. 
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Background: Afatinib, an irreversible tyrosine kinase inhibitor (TKI), has shown clinical 
benefits and prolonged progression free survival in EGFR mutated patients. HGF, a ligand 
of c-MET, may be involved in resistance to EGFR-TKIs. Methods: A total of 66 patients 
with advanced lung adenocarcinoma (stage IIB and IV) and documented progression to 
first-line chemotherapy were enrolled to receive afatinib 40 mg/day. Mutational EGFR and 
HER-2 status were assessed by RT-PCR. HER2 amplification was evaluated by FISH. Plasma 
HGF levels were measured by ELISA before and 2 months after the start of treatment 
with afatinib. We assessed the change in plasma HGF levels and the association with 
objective response rate (ORR), progression free survival (PFS) and overall survival (OS). 
The protocol is registered in ClinicalTrials.gov (NCT01542437). Results: We identified 
2 patients carrying a HER2 mutation and both presented stable disease (SD). HER2 
amplification was not detected. HGF-positive plasma reduction status had a significant 
higher ORR (75.0% vs 44.1% p= 0.011), and was strongly associated with longer PFS 
(HR 0.40 [95% CI 0.18 - 0.87], p= 0.02) and OS (HR 0.31 [0.13 - 0.71] p=0.006). A 
stratified multivariate analysis in EGFR mutated patients showed that the HGF plasma 
levels reduction remains as a significant and independent factor associated with longer 
Table 1. Anticancer activity findings in AURA first-line expansion
Endpoint Finding
Objective response rate:
Overall 70% (95% CI 57, 81)
AZD9291 80 mg/160 mg 60%/80%
Disease control rate:
Overall 97% (95% CI 89, 100)
AZD9291 80 mg/160 mg 93%/100%
Progression-free survival:
Median Not yet reached
3-month/6-month 93%/87%
Events to date 7/60 (12% mature)
 
Conclusion: AZD9291 has a manageable tolerability profile and is associated 
with promising anticancer activity in treatment-naïve patients with EGFRm 
advanced NSCLC. A Phase III study (FLAURA, NCT02296125) has been 
initiated to assess the efficacy and safety of AZD9291 in comparison with 
a standard-of-care EGFR-TKI (gefitinib or erlotinib) in the first-line setting. 
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Background: The epidermal growth factor receptor (EGFR) T790M mutation is found in 
about half of patients who have developed resistance to EGFR-tyrosine kinase inhibitors 
(TKIs), gefitinib or erlotinib. AZD9291 is an oral, potent, irreversible EGFR-TKI selective 
for both EGFR-sensitizing (EGFRm) and T790M resistance mutations. In the Phase I 
AURA study, AZD9291 80 mg (dose selected for further evaluation) was found to be 
clinically active, with an acceptable tolerability profile. This ongoing AURA2 Phase II 
study (NCT02094261) investigates the efficacy and safety of AZD9291 80 mg once daily 
after previous EGFR-TKI treatment in patients with EGFRm and T790M positive advanced 
NSCLC. Methods: AURA2 (NCT02094261) is a global, open-label, single-arm Phase II 
study. To be eligible, all patients had a mandatory tumor sample taken after disease 
progression on the most recent line of therapy, for confirmation of T790M positive status 
by central laboratory testing using the cobas™ EGFR Mutation Test. Further inclusion 
criteria included measurable disease, World Health Organization performance status 
(WHO PS) 0 or 1, and acceptable organ function; stable brain metastases were allowed. 
Patients receive AZD9291 at 80 mg once daily until disease progression. The primary 
endpoint was objective response rate (ORR) according to RECIST 1.1 (assessed by 
independent central review, ICR). Secondary objectives included disease control rate 
(DCR), duration of response (DoR), progression-free survival (PFS), and safety. Planned 
enrollment was 175 patients to give an ORR with 95% confidence interval (CI) within 
±8%. The data cut-off was January 9, 2015. Results: Recruitment is complete and 210 
patients were enrolled; 12 patients did not have measurable disease at baseline by ICR 
and are excluded from the evaluable-for-response set. By central testing, in addition 
to T790M, patients had background EGFR mutation: Ex19del, 65%; L858R, 32%; 
other, 3%. Baseline characteristics: median age, 64 years; female, 70%; WHO PS 0/1, 
40%/60%; Asian, 63%; second-/≥third-line, 32%/68%. Median treatment exposure was 
4.0 months and 183 patients remain on treatment at the data cut-off. ORR by ICR was 
64% (127/198; 95% CI 57, 71) and DCR was 90% (95% CI 85, 94). Investigator-assessed 
ORR was 64% (135/210; 95% CI 57, 71). Median DoR and median PFS have not been 
reached (maturity 6% and 20%, respectively). The estimated proportion of patients 
who are alive and progression free is 82% and 70% at 3 and 6 months, respectively. 
The most common all-causality adverse events (AEs) were diarrhea, 34% (1% Gr≥3) 
and grouped rash terms 40% (0.5% Gr≥3); 38 (18%) patients experienced Gr≥3 AEs. 
Interstitial lung disease grouped terms were reported in four (1.9%) patients, one of 
which was fatal (0.5%) and considered possibly causally related to AZD9291 by the 
investigator. Eight patients (4%) discontinued treatment due to an AE. Updated results 
from a later data cut-off will be available for presentation. Conclusion: AZD9291 80 mg 
once daily demonstrates clinical activity and manageable tolerability in patients with 
EGFRm, T790M mutation positive advanced NSCLC that has progressed on or after 
EGFR-TKI treatment. AZD9291 is being investigated in the randomized AURA3 Phase 
III study (NCT02151981) in comparison with platinum-based doublet chemotherapy. 
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no significant differencs were observed in median PFS and OS respectively between 
the two arms, p＞0.05. Receiving erlotinib or gefitinib treatment, EGFR exon 19 mutant 
patients were superior to those with exon 21 mutations in terms of ORR (62.2% versus 
43.5%, p=0.003), median PPS (9.1 [95%CI: 7.0~11.2] versus 4.6 [95%CI: 3.4~5.8] 
months,p=0.011 ) and OS (24.8 [95%CI: 20.9~28.8] versus 17.7 [95%CI: 15.1~20.3] 
months, HR=0.66 [0.48~0.89], p=0.006) respectively, even though there was no 
significantly difference in median PFS (11.4 [95%CI: 9.6~13.2] versus 11.1 [95%CI: 
9.4~12.9] months, HR=0.80 [0.60~1.05], p=0.101). Multivariant Cox regression 
analysis showed that subsequent EGFR TKIs, combination of subsequent EGFR TKIs 
and local treatment, as well as subsequent chemotherapy were prognostic factors for 
OS, p＜0.05. Conclusion: Erlotinib was not significantly superior to gefitinib in advanced 
NSCLC with either exon 19 or 21 mutations in response and survival, with similar 
toxicities. However, EGFRexon 19 mutant patients had remarkably increased ORR, PPS 
and OS than those with exon 21 mutations after taking erlotinib or gefitinib. Subsequent 
treatments after failure to EGFR TKIs were significantly prognostic factors for OS. 
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Background: Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase 
inhibitors (TKI) develop clinical resistance, often associated with acquisition of EGFR 
T790M. Upregulation of JAK/STAT signaling is involved in resistance to EGFR TKIs and 
JAK inhibition is a proposed treatment strategy in the setting of acquired resistance by 
restoring sensitivity to erlotinib. Ruxolitinib is an FDA-approved oral JAK1/2 inhibitor given 
at 20mg twice daily for hematologic malignancies with a largely non-overlapping toxicity 
profile with erlotinib. Methods: We evaluated the toxicity and efficacy of once daily oral 
erlotinib and twice daily oral ruxolitinib in patients with EGFR-mutant lung cancers and 
acquired resistance to erlotinib therapy (NCT02155465). Using a 3+3 dose escalation, 
we assessed escalating doses of ruxolitinib (10mg BID, 15mg BID, 20mg BID) with 
erlotinib 150mg daily for 21 day cycles. Response was evaluated by RECIST 1.1. Tissue 
and peripheral blood samples were obtained; exosomes will be extracted from peripheral 
blood and molecular and proteomic analyses will be performed. Results: From May 2014 
to February 2015, 12 patients (pts) were enrolled. Median age: 60; Women: 7 (58%); 
never-smokers: 6 (50%); EGFR L858R=4 (33%) and Exon 19 deletion=8 (67%). Two of 
twelve (17%) were EGFR T790M positive at rebiopsy at the time of acquired resistance. Of 
12 pts treated, 3 received ruxolitinib 10mg BID, 3 received 15mg bid and 6 received 20mg 
BID with erlotinib 150mg daily. No dose limiting toxicities were seen. The recommended 
phase 2 dose is ruxolitinib 20mg BID with 150mg erlotinib daily. Treatment-related 
AEs were all grade 1-3. The most frequent treatment related clinical adverse events 
(all grade 1-3) were anemia (25%), diarrhea (25%), rash (25%), pain (17%), fatigue 
(8%), and pneumonitis (8%). The most frequent treatment-related laboratory adverse 
events (all grade 1-2) were anemia (33%), elevated ALT (17%), elevated AST (17%), and 
hyperbilirubinemia (8%). Of the 12 pts treated, 2 (17%) required a dose reduction of 
erlotinib for treatment emergent toxicities; both subjects were on lower doses of erlotinib 
than 150mg daily prior to study enrollment. There were no dose reductions of ruxolitinib. 
Of 12 evaluable patients, no partial responses were seen. The median-progression free 
survival is 3 months. Two patients remain on study. One patient has been on study for 10 
months with ongoing stable disease. Nine patients (75%) came off study for progression, 
1 (8%) for toxicity. One person discontinued treatment on study for grade 3 pneumonitis, 
possibly related to the combination of erlotinib and ruxolitinib. The symptoms resolved 
with discontinuation of erlotinib and ruxolitinib. Conclusion:Combination erlotinib and 
ruxolitinib is well-tolerated. The phase 2 dose of ruxolitinib is 20mg BID in combination 
with erlotinib. There were no partial responses, but durable disease control was seen in 
some patients. The phase 2 study of erlotinib and ruxolitinib in this population is ongoing. 
Keywords: Acquired resistance, JAK, EGFR
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MINI17.01 Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction 
P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR 
Mutation Chun-Ming Tsai1, Chun-Liang Lai2, Chao-Hua Chiu1, Te-Chun Hsia3, Chen-Hsin 
Chen4, Gee-Chen Chang5, Jin-Yuan Shih6, Ching-Liang Ho7, Yuh-Min Chen1, James Chih-
Hsin Yang8 1Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans 
General Hospital, Taipei/Taiwan, 2Division of Pulmonary and Critical Care, Department of 
Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi/Taiwan, 3Department of 
Respiratory Therapy & Division of Pulmonary and Critical Care Medicine, Department of 
Internal Medicine, China Medical University Hospital, Taichung/Taiwan, 4Institute of Statistical 
Science, Academia Sinica and, Graduate Institute of Epidemiology and Preventive Medicine, 
National Taiwan University, Taipei/Taiwan, 5Division of Chest Medicine, Department of 
Internal Medicine, Taichung Veterans General Hospital, Taichung/Taiwan, 6Department of 
Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan 
University, Taipei/Taiwan, 7Division of Hematology and Oncology, Triservice General Hospital, 
PFS (HR 0.34 [95% CI 0.13 - 0.89] p= 0.04) and OS (HR 0.34 [95% CI 0.13 - 0.88] p= 
0.02). Conclusion: HGF plasma levels reduction is strongly related to better outcomes 
with afatinib therapy, irrespective of EGFR mutation status. The lack of reduction might 
allow the identification of a subgroup of patients who will not expected to respond and could 
benefit with the use of drugs targeting the HGF-c-Met axis. Further studies are warranted. 
Keywords: Epidermal growth factor receptor, afatinib, Hepatocyte growth factor, non-
small cell lung cancer
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MINI16.12 Lung Adenocarcinoma Transformation into Small-Cell Lung Cancer 
after Treatment: Clinical Evidence and the Exploratory Mechanism Jie Wang, 
Jia Zhong, Jun Zhao, Hua Bai, Shuhang Wang, Xiandan Yang Peking University Cancer 
Hospital and Institute, Beijing/China
Background: The phenomenon of small cell lung cancer(SCLC) transformation in EGFR 
mutated adenocarcinoma had been previously identified as a resistant mechanism. 
However, this phenomenon was only reported in single case and a repeat biopsy patient 
cohort. Moreover, the underlying molecular mechanism remains unclear. Previous study 
found that the inactivation of TP53 and Rb1 could efficiently transform neuroendocrine 
and alveolar type 2 cells into SCLC. We inferred that TP53 and Rb1 might also play an 
important role in SCLC transformation. So we use the sh-RNA mediated depletion of RB1 
adenocarcinoma cell line, that also have TP53 inactivation in nature, to investigate the 
molecular mechanism of SCLC transformation. Methods: Both primary and metastatic 
tissue were analyzed on 3 SCLC transformation patients by whole genome sequencing 
(WGS). We knock down RB1 in TP53 inactivation cell lines, PC-9, HCC-827 and H1975. 
Western blot and immunohistochemistry (IHC) were used to confirm RB1 knock down 
and expression of neuroendocrine (NE) markers. Trans well cell invasion assay and 
softer agar clone formation test were investigated the change of invasion and migration. 
CCK8 kit was used to evaluate relative viability of cells after RB1 knock down. Cell cycle 
and apoptosis were determined by folw cytometry. And we use balb/c mice for cell line 
tumorgenesis. Results: ① Pathological analysis of the 3 patients’ primary lesion and the 
consistent EGFR mutation status confirmed the phenomenon of SCLC transformation. 
WGS showed the copy number variation of primary tumor and transformed metastasis 
was distinct. RB1 is lost in 100% of the three transformed cases but occur in one 
patient’s primary tissue in extremely low frequency(<5%). ② PC-9, HCC827 and H1975 
cell line showed up-regulation of NE markers after sh-RNA mediated RB1 depletion, which 
presented more capable of invasion and migration. Cell folw cytometry showed more 
cells was in G2 and S phase after RB1 knock down. The expression of Bik and puma 
that belong to Bcl-2 family was up-regulated after RB1 inactivation compared with the 
control group. Conclusion: The NE differentiation and changes in invasion, migration, 
apoptosis and cell cycle indicated that the loss of TP53 and RB1 promote the process 
of SCLC transformation. TP53 and RB1 deficiency may be a necessary event for SCLC 
transformation to emerge, but is still insufficient to induce SCLC transformation. 
Keywords: RB1 gene, small cell lung cancer, neuroendocrine transdifferentiation, drug 
resistance
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MINI16.13 A Randomized Controlled Trial of Erlotinib versus Gefitinib 
in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations 
(CTONG0901) Jin-Ji Yang1, Qing Zhou2, Hong -Hong Yan1, Xu-Chao Zhang3, Hua-Jun 
Chen1, Han-Yan Tu1, Zhen Wang1, Chong -Rui Xu1, Jian Su1, Yi-Sheng Huang1, Bin-Chao 
Wang1, Ben-Yuan Jiang1, Xiao-Yan Bai1, Wen-Zhao Zhong1, Xue-Ning Yang1, Yi-Long Wu1 
1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of 
Medical Sciences, Guangzhou/China, 2Guangdong Lung Cancer Institute; Guangdong General 
Hospital (GGH) & Guangdong Academy of Medical Sciences, Guangzhou/China, 3Guangdong 
Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical 
Sciences, Guangzhou/China
Background: For non-small-cell lung cancer (NSCLC) harboring epidermal growth factor 
receptor (EGFR ) mutations, preclinical data showed the superiority of exon 19 mutations 
to exon 21 mutations in both response to EGFR tyrosine kinase inhibitors (TKIs) and 
survival. Meanwhile, retrospective studies demonstrated that erlotinib was significantly 
superior to gefitinib in progression-free survival (PFS) for advanced NSCLC patients 
with EGFR mutations. However, no randomized controlled trials compared erlotinib to 
gefitinib in advanced NSCLC patients with EGFR exon 19 or 21 mutations. Methods: We 
conducted a randomized controlled trial (CTONG 0901αNCT01024413) comparing 
erlotinib to gefitinib in advanced NSCLC harboring EGFR exon 19 or 21 mutations from 
July 2009 to July 2014. Eligible patients were randomized to receive erlotinib (150 mg, 
qd) or gefitinib (250 mg, qd) at the ratio of 1:1 in any line settings. The primary endpoint 
was PFS, and the secondary endpoints included overall survival (OS), objective response 
rate (ORR), post-progression survival (PPS), and toxicities. Results: The last follow-up 
was on March 30, 2015. Totally, 256 patients (148 with exon 19 mutations and 108 
with exon 21 mutations), of whom 165, 83 and 9 were in the first, second or further-line 
settings respectively, were randomized to receive erlotinib or gefitinib. Median PFS was 
12.4 (95%CI: 10.6~14.1) months in erlotinib arm and 10.4 (95%CI: 8.8~11.9) months in 
gefitinib arm, HR=0.80 (0.61~1.05), p=0.100; ORR, median PPS and OS were 56.3% 
versus 52.3% (p=0.530), 6.9 (95%CI: 4.3~9.5) versus 6.9 (95%CI: 4.5~9.2) months 
(p=0.784), and 22.4 (95%CI: 17.9~27.0) versus 20.5 (95%CI: 17.1~23.8) months 
(HR=0.90 [0.67~1.22]; p=0.496) respectively. There were no significant differences in 
toxicities between the two arms, p＞0.05. In the four subgroups (the first-line, second 
or further-line setting, exon 19 and 21 mutations), except for median PFS being 11.4 
versus 7.9 months (HR=0.58 [0.37~0.90], p=0.015) in the second or further-line setting, 
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Conclusion: In Zubrod PS2 pts with advanced NSCLC and “good” classification by serum 
preoteomics, pharmacodynamically-separated erlotinib plus chemotherapy had better 
observed median PFS/OS versus erlotinib alone and surpassed the protocol-specified 
benchmark of PFS >= 3 months required for further study. Updated data will be 
presented.  
Keywords: proteomics, poor performance status, chemotherapy
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MINI17.03 Prognostic and Predictive Value of the VeriStrat Classifier in 
Chemo-Naive NSCLC Patients Treated with Erlotinib or Placebo (TOPICAL Trial) 
Siow-Ming Lee1, Stephen Nash2, Yenting Ngai2, Allan Hackshaw2 1Oncology, UCL Cancer 
Institute/University College London Hospitals NHS Trust, London/United Kingdom, 2Cancer 
Research UK & UCL Cancer Trials Centre, London/United Kingdom
Background: National Comprehensive Cancer Network Guidelines recommend using 
VeriStrat, a blood proteomics test to determine using erlotinib instead of chemotherapy 
as second-line treatment for patients with non-small cell lung cancer (NSCLC). 
However, VeriStrat has not been evaluated in a first-line setting within a randomized 
trial. Methods: TOPICAL was a double-blind randomised placebo-controlled trial, 
for 670 chemotherapy-naive NSCLC patients (stage IIIb/IV) considered unsuitable for 
chemotherapy, mainly due to poor performance status (ECOG ≥2) or co-morbidities. 
They were randomized to receive best supportive care plus oral placebo or erlotinib 
(150mg/day) until disease progression/toxicity. Although there was no overall survival 
(OS) benefit among all patients, patients on erlotinib who developed first-cycle rash had 
improved OS, compared to placebo: hazard ratio (HR 0.76), p=0.006; unlike those without 
rash (HR 1.30, p=0.017). Pre-treatment serum samples were available for 477 of 670 
(70%) TOPICAL patients. They were sent as anonymised aliquots to Biodesix for VeriStrat 
testing. Results: VeriStrat testing classified 52% (250/477) as having good outcomes, 
46% (221) poor outcomes, and 6 unknown. In all patients, VeriStrat classification was 
associated with OS (good vs. poor: HR=0.58, 95%CI 0.47-0.73; P<0.0001) and PFS 
(HR=0.72; 95% CI 0.53-0.97; P=0.002), after allowing for gender, histology, stage, 
treatment and first-cycle rash (unadjusted HRs were similar, as were those ignoring rash). 
In all erlotinib patients, median OS was 4.9 (good) vs. 3.1 months (poor); HR=0.63, 95% 
CI 0.47-0.85, p=0.002. The corresponding results among all placebo patients were: 5.3 
(good) vs. 2.9 months (poor), HR=0.53, 95% CI 0.39-0.73, p<0.001. Similar results were 
found for PFS: median 3.1 (good) vs. 2.2 (poor) months (HR=0.72; 95% CI 0.53-0.96, 
P=0.027) for erlotinib patients; and 2.8 vs. 2.4 months for placebo patients (HR=0.72, 
95% CI 0.53-0.97, p=0.033). Among all patients, VeriStrat was not predictive: OS HR for 
erlotinib vs. placebo was 1.02 (95% CI 0.79-1.31) in the ‘good’ group, and 0.86 (95% CI 
0.66-1.12) for ‘poor’; interaction p-value=0.38. Corresponding PFS HRs were 0.86 (95% 
CI 0.67-1.10) and 0.84 (95% CI 0.65-1.10); interaction p-value=0.92. VeriStrat was also 
not predictive when allowing for first-cycle rash (Table 1). However, among patients who 
had rash, those with ‘good’ classification had longer OS (p<0.001) and PFS (p=0.001) 
than those classified as ‘poor’.
  
Conclusion: Our large randomized trial among NSCLC patients considered unsuitable 
National Defense Medical University, Taipei/Taiwan, 8Department of Oncology, National 
Taiwan University Hospital, Graduate Institute of Oncology & Cancer Research Center, 
National Taiwan University, Taipei/Taiwan
Background: We have proposed that synergistic epidermal growth factor receptor-
tyrosine kinase inhibitor (EGFR-TKI) -chemotherapeutic interaction in lung cancer cells 
has 3 essentials: no platinum, cells not or no more sensitive to EGFR-TKI, and using a 
synergistic chemo partner, e.g., pemetrexed (P) (Tsai, et al. Lung Cancer 82:305, 2013 ). 
Methods: GENIUS study (NCT01579630) was a phase II, multicenter, randomized, open-
label prospective trial comparing maintenance G/P versus P in patients with metastatic 
lung adenocarcinoma (mLADC) harboring no sensitizing EGFR mutations (sEGFRm) 
detected by high sensitivity methods following a 4-cycle P/Platinum induction therapy 
in frontline setting. Patients with no disease progression (PD) were 1:1 randomized to 
receive P (500 mg/m2, 3-week cycle) ± G (250 mg, daily) until PD or treatment failure, 
and stratified by study site and response. The primary endpoint was progression free 
survival (PFS) by both independent radiologist review (IRR) and investigator assessment 
(IA), secondary endpoints included time to treatment failure (TTF), overall survival (OS), 
safety and toxicity profile. Results: Between 03/2011 and 11/2013, 55 patients were 
randomized, G/P 26, P 29. Baseline characteristics were balanced between arms (age 
57; female 42%; never smoker 55%; ECOG1 91%; ≥2 metastatic sites 38.2%; ALK+ 16%). 
Median follow-up was 20.4 mo. Median cycle of treatment was G/P 9.5 (range 1-32) and 
P 4 (2-21). Median PFS was substantially longer for G/P than P, both by IRR (3 deemed as 
PD at randomization were excluded; n = 25 v 27): 8.4 v 3.8 mo; HR [95% CI] 0.42 [0.23-
0.79]; p = 0.0057, and by IA: 8.7 v 2.9 mo; HR 0.38 [0.21-0.70], p = 0.0013. Response 
with induction therapy, age, and smoker had interactions with treatment for PFS. Median 
TTF: 7.0 v 2.9 mo; HR 0.46 [0.25-0.83], p = 0.0085. OS was also better for G/P than P by 
IRR (undefined v 29.3 mo; HR 0.44 [0.20-0.97]; p = 0.037) and IA (undefined v 21.7 mo; 
HR 0.46 [0.22-0.97]; p = 0.038). There were more treatment-related diarrhea, liver and 
skin toxicities on G/P v P, but generally mild. Two G/P patients were off-study due to liver 
toxicity. Conclusion: This proof of concept ph 2 study first demonstrated survival benefit 
of EGFR-TKI plus chemo in the maintenance phase of frontline treatment for patients 
with mLADC harboring no sEGFRm. This strategy deserves phase III study to confirm. 
Keywords: gefitinib, pemetrexed, maintenance therapy, combined EGFR-TKI and chemo
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MINI17.02 SWOG 0709: Randomized Phase II Trial of Erlotinib vs. Erlotinib plus 
Carboplatin/Paclitaxel in Patients (Pts) with Advanced Non-Small Cell Lung 
Cancer (NSCLC) and Impaired Performance Status (PS2) as Selected by Serum 
Proteomics Primo Lara Jr.1, James Moon2, Paul J. Hesketh3, Mary Redman2, Steve 
Williamson4, Fred R. Hirsch5, Philip C. Mack6, David R. Gandara1 1UC Davis Comprehensive 
Cancer Center, Sacramento/United States of America, 2SWOG Statistical Center, Portland/
OR/United States of America, 3Medical Oncology, Lahey Hospital and Medical Center, 
Burlington/United States of America, 4University of Kansas, Lawrence/United States of 
America, 5University of Colorado Cancer Center, Aurora/CO/United States of America, 6UC 
Davis Comprehensive Cancer Center, Sacramento/CA/United States of America
Background: Advanced NSCLC pts with Zubrod PS2 are often excluded from 
clinical trials and platinum-based therapy. In SWOG 0341, erlotinib in PS 2 pts yielded 
progression-free (PFS) and overall survival (OS) of 2.1 and 5 months respectively. In a 
trial of erlotinib versus carboplatin/paclitaxel in PS2 pts (Lilenbaum, JCO 2008), PFS 
for erlotinib and chemotherapy were 1.9 and 3.5 months, respectively. Early reports 
suggested a potential role for serum proteomics in predicting erlotinib benefit beyond 
that of EGFR mutational status. We therefore conducted a prospective trial of erlotinib +/- 
chemotherapy in NSCLC pts with PS2 enriched by serum proteomics (Veristrat assay). 
Methods: Metastatic NSCLC pts with PS2, acceptable end-organ function, and “good” 
classification by serum proteomics were randomized to either Arm A (erlotinib 150 mg 
orally QD) or Arm B (erlotinib 150 mg orally QD on days 2-16 plus carboplatin AUC 5 IV 
day 1 and paclitaxel 200 mg/m2 IV day 1 x 4 cycles, followed by erlotinib 150 mg orally 
QD). Cycle length was 3 weeks. Arm B agents were “pharmacodynamically separated” 
to mitigate potential antagonism. The arm with superior observed median PFS would 
be selected for further evaluation, but only if ≥ 3 months. A sample size of 98 pts was 
based on a variety of assumed PFS probabilities for each arm. The trial was prematurely 
closed after the FDA determined midway through accrual that an IDE application was 
required for the proteomics assay; however SWOG had limited resources available 
for such filing. Results: Of 156 pts screened, 83 (59%) were classified as “good” by 
serum proteomics. 59 of 83 pts (60%) met trial eligibility and were randomized. 
Treatment-related grade 4 adverse events were seen in 2 pts in Arm A (thrombosis, 
hypomagnesemia) and 5 pts in Arm B (neutropenia -5, febrile neutropenia-1, leukopenia 
-1), with no treatment related deaths. 
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reported in 70 patients (46.1%), including 48 grade ≥ 3 AEs in 31 patients (20.4%). 
The most frequent AEs related to erlotinib were skin rash (all grades [23,7%], grade 
≥ 3 [5,2%]) and diarrhea (all grades [11,8%], grade ≥ 3 [2.0%]); 19 serious adverse 
events (SAEs) were reported in 12 patients (7.9%), including 16 grade ≥ 3 SAEs in 10 
patients (6.6%). There were 6 SAEs leading to death (3.9% patients), but none SAE was 
related to erlotinib. Conclusion: PEPITA is the first non-interventional study assessing 
modalities of use in daily practice of patients with stade IIIb/IV squamous NSCLC 
treated in 2nd line with erlotinib. This final analysis show similar efficacy and safety 
results to those observed in clinical trials. Clinical profile may drive EGFR genotyping. 
Keywords: Erlotinib, 2nd line, squamous NSCLC
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MINI17.06 Subgroup Analysis of East Asian Patients in the Phase III REVEL Trial  
Jin-Hyoung Kang1, Keunchil Park2, Joo-Hang Kim3, Eun Kyung Cho4, Jin-Yuan Shih5, 
Annamaria H. Zimmermann6, Pablo Lee6, Ekaterine Alexandris6, Tarun Puri7, Mauro 
Orlando8 1The Catholic University of Korea, St. Mary’s Hospital, Seoul/Democratic 
People’s Republic of Korea, 2Samsung Medical Center, Sungkyunkwan University School 
of Medicine, Seoul/Democratic People’s Republic of Korea, 3Severance Hospital, Yonsei 
University Health System, Seoul/Democratic People’s Republic of Korea, 4Hematology and 
Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon/
Korea, 5Department of Internal Medicine, National Taiwan University Hospital, College of 
Medicine, National Taiwan University, Taipei/Taiwan, 6Eli Lilly & Company, Indianapolis, in/
AL/United States of America, 7Eli Lilly and Company (India) Pvt. Ltd, Gurgaon/India, 8Eli Lilly 
& Company, Buenos Aires/Argentina
Background: The REVEL trial demonstrated that second-line treatment with ramucirumab 
(RAM) plus docetaxel (DOC) significantly improved overall survival (OS) compared to 
placebo (PBO) plus DOC in the intent-to-treat (ITT) population (N=1253) of patients 
with stage IV non-small cell lung cancer. The REVEL trial also significantly improved 
progression-free survival (PFS) and objective response rates (ORRs). Results from the 
East Asia (EA) subgroup (Taiwan and Korea) analysis are presented. Methods: Subgroup 
analyses were performed in the EA ITT population, which consisted of all patients who 
were randomized in Taiwan (n=27) and Korea (n=62). Endpoints evaluated in the EA 
subgroup were OS, PFS, ORR, and safety. OS and PFS were analyzed using the Kaplan-
Meier method and Cox proportional hazard model. Response was compared using the 
Cochran-Mantel-Haenszel test. ClinicalTrials.gov number NCT01168973. Results: In the 
89 ITT EA patients, median OS was 15.44 months for the RAM plus DOC arm (n=43) and 
10.17 months for PBO plus DOC arm (n=46) (HR: 0.762, 95% CI: 0.444–1.307). Median 
PFS was 4.88 months for the RAM plus DOC arm and 2.79 months for the PBO plus DOC 
arm (HR: 0.658, 95% CI: 0.408–1.060). The ORRs were 25.6% (95% CI: 13.5–41.2) in the 
RAM plus DOC arm and 9% (95% CI: 2.4–20.8) in the PBO plus DOC arm. Approximately 
two years after the enrollment of the first patient, in May 2012, the independent data 
monitoring committee recommended a reduction in the dose of DOC from 75 mg/m2 to 
60 mg/m2 for newly enrolled EA patients, based on a higher incidence of neutropenia 
and febrile neutropenia associated with 75 mg/m2 in EA patients compared to non-EA 
patients. This amendment resulted in a reduction in the toxicity associated with the 
original treatment regimen (Table). Table: Select grade ≥3 treatment-emergent adverse 
events, regardless of causality, by treatment arm and DOC dose in EA patients
Preferred term
RAM plus DOC 
(75 mg/m2) (n 
= 32)
PBO plus DOC 
(75 mg/m2) (n 
= 33)
RAM plus DOC 
(60 mg/m2) (n 
= 11)
PBO plus DOC 
(60 mg/m2) (n 
= 13)
Any 31 (96.9) 26 (78.8) 6 (54.5) 7 (53.8)
Neutropenia* 26 (81.3) 24 (72.7) 6 (54.5) 5 (38.5)
Febrile neutro-
penia 14 (43.8) 4 (12.1) 0 1 (7.7)
 
Data are n (%). *Consolidated term. Conclusion: Although not statistically powered 
to demonstrate significant improvement, the improved OS, PFS, and ORR observed 
in the EA subgroup treated with RAM plus DOC is consistent with the treatment 
effect observed in the overall ITT population in the REVEL trial. A dose reduction 
in DOC from 75 mg/m2 to 60 mg/m2 was associated with an improved safety 
profile and a reduction in the incidence of febrile neutropenia in the EA subgroup. 
Keywords: NSCLC, febrile neutropenia, ramucirumab, docetaxel
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MINI17.07 Efficacy of Nintedanib/Docetaxel after Bevacizumab, Pemetrexed 
or Taxanes Therapy David Heigener1, Martin Reck1, Anders Mellemgaard2, Sergei 
Orlov3, Maciej Krzakowski4, Joachim Von Pawel5, Maya Gottfried6, Igor Bondarenko7, 
Silvia Novello8, Jean-Yves Douillard9, José Barrueco10, Ute Von Wangenheim11, Rolf 
Kaiser11, Jaafar Bennouna9 1Department of Thoracic Oncology, Lung Clinic Grosshansdorf, 
Airway Research Center North (ARCN), Member of the German Center for Lung Research 
(DZL), Grosshansdorf/Germany, 2Department of Oncology, Herlev University Hospital, 
Herlev/Denmark, 3Department of Thoracic Oncology, GOU VPO St. Petersburg State 
Medical University, St. Petersburg/Russian Federation, 4The Maria Sklodowska-Curie 
Institute of Oncology, Warsaw/Poland, 5Pneumology Clinic, Asklepios Fachkliniken, Gauting/
Germany, 6Lung Cancer Unit, Meir Medical Center, Kfar Saba/Israel, 7Medical Academy, 
Clinical Hospital #4, Dnepropetrovsk/Ukraine, 8Department of Oncology, University of 
Turin, Turin/Italy, 9Department of Medical Oncology, Centre René Gauducheau, Nantes/
for chemotherapy shows that VeriStrat status was prognostic for OS and PFS; but it was 
not predictive for OS nor PFS, in relation to erlotinib vs. placebo as first-line treatment. 
Keywords: VeriStrat, Erlotinib, Prognostic, Predictive
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MINI17.04 Erlotinib in 2nd Line in Advanced Squamous NSCLC: Final Results 
of the Pepita Cohort Alain Vergnenegre1, Olivier Molinier2, Isabelle Monnet3, Clarisse 
Audigier-Valette4, Nicolas Girard5, Pierre Jean Souquet6, François Blanchon7, Franck 
Bonnetain8, Hakim Saal9, Julien Néaume9, Corinne Lamour10, Marie Wislez11 
1CHU de Limoges, Limoges/France, 2CH Le Mans, Le Mans/France, 3Chi Créteil, Créteil/
France, 4Chi Toulon, Toulon/France, 5Louis Pradel Hospital, Lyon/France, 6CHU Lyon-Sud, 
Lyon/France, 7CH Meaux, Meaux/France, 8CHRU Besançon, Besançon/France, 9Roche France 
(SAS), Boulogne/France, 10CHU Poitiers, Poitiers/France, 11Tenon Hospital, Paris/France
Background: Erlotinib in 2nd line improves survival in patients with recurrent/
progressive NSCLC, is also active in squamous cell NSCLC, as reported in a BR.21 study 
subgroup. So far, no prospective non interventional study has specifically evaluated 
patients with this histological subtype treated with erlotinib. We present the final results 
of PEPITA cohort. Methods: PEPITA is a French multicenter, prospective cohort study 
assessing erlotinib modalities of use in daily practice in squamous NSCLC. The primary 
endpoint was progression-free survival (PFS); secondary endpoints included patients’ 
characteristics, overall survival (OS), safety and quality of life. EGFR mutation was tested 
in 41 patients (28.5%) reason why exploratory analyses assessing EGFR genotyping and 
smoking status were also performed. Results: Between June 2012 - May 2013, 152 
patients were included and 146 patients were analyzed for efficacy; median follow-up 








EGFR not tested* 
(n=103) p-value
Mean age (±SD), 
years Men 67.7 (±8.6) 90.4% 67.4 (±8.9) 87.8% 67.8 (±8.6) 92.2% 0.79 0.52
ECOG PS 0/1 
ECOG PS 2/3
 
17.5% / 43.8% 
33.6% / 5.1%
n=39 
20.5% / 56.4% 
23.1% / 0
n=96 
















































































































*[95% CI] In the safety population (n=152 patients), 158 adverse events (AEs) were 
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FLT). Methods: Tumor growth was evaluated using all available tumor measurements. Mixed-
effects models were used to quantify the non-linear individual relationships between time from 
randomization and tumor burden, measured as the sum of longest diameter of target lesions 
(SLD) and assessed by independent central review (RECIST 1.0). Analyses were conducted 
for the entire population of patients with ACH, T<9m and PD-FLT. Results: Estimated mean 
baseline SLD was 82.5 mm in all patients with ACH, 88.3 mm in T<9m and 98.1 mm in PD-
FLT. N+D showed a significant reduction of tumor growth over time (p<0.0001) in patients 
with ACH compared to D. Treatment difference at 6 months (SLD D group – SLD N+D group) 
for patients with ACH was 9.7 mm. This treatment difference was even more pronounced in 
the T<9m group (16.8 mm) and in patients with PD-FLT (19.7 mm). Tumor growth over time 
for N+D showed a non-linear J-shaped curve, indicating a decline in SLD at the beginning of 
treatment, which was maintained over time followed by a linear increase (see Figure for curves 
for the T<9m group). This relationship was consistently observed between populations. For 
patients treated with D, a linear increase in SLD from baseline over time in all ACH patients, 
T<9m and PD-FLT was observed.
Conclusion: In the LUME-Lung 1 study, N+D significantly decreased tumor 
burden and decelerated tumor growth over time compared to D in all 
patients with ACH and in the groups of patients with the poorest prognosis. 
Keywords: nintedanib, NSCLC, tumor burden, angiogenesis
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MINI17.10 Oligometastatic Non-Small-Cell Lung Cancer and Unresectable 
Primary Tumor: Safety and Efficacy of Radical Treatment Sara Marin1, Carmen 
Salvador Coloma2, Javier Garde-Noguera1, Óscar Juan Vidal2, Jose Garcia Sanchez1, 
Corina Escoin2, Julia Hidalgo1, Rene Arturo Albino1, Antonio Llombart Cussac1 1Medical 
Oncology, Hospital Arnau de Vilanova, Valencia/Spain, 2Medical Oncology, Hospital 
Universitari I Politècnic La Fe, Valencia/Spain
Background: Metastatic non-small cell lung cáncer (NSCLC) is associated with a poor 
prognosis, and palliative chemotherapy is the mainstay of treatment. However, long-
time survival has been observed in oligometastatic patients treated with locally ablative 
therapies to all sites of tumoral disease. Oligometastatic NSCLC with unresectable 
primary tumor at diagnosis represents a therapeutic challenge, and nowadays there is 
limited evidence about the benefit of the treatment with radical intention of both primary 
tumor and metastases. Methods: Retrospective study of patients with oligometastatic 
(3 or less lesions, in a unique location) and unresectable NSCLC treated with radical 
chemo-radiotherapy at primary tumor and with surgery or stereotactic radiation therapy 
to the metastases. We have done a systematic review of clinical histories from NSCLC 
advanced patients diagnosed between October 2011 and March 2015. The aim of our 
study is to analyze the safety and efficacy of this treatment strategy in terms of response 
rate, progression free survival (PFS) and overall survival (OS). Results: Twenty-three 
patients met inclusion criteria. Median age 57 year, eighteen male (78,3%) and ECOG 
(0-1) 95,7%. Histology: 15 adenocarcinoma (65,2%), 5 squamous carcinoma (5%), 
and 3 (13%) others. All patients had unresectable mediastinal lymph nodes infiltration. 
Location of metastases included the brain (n=12, 52.2%), lung metastases (n=6, 
26,1%), bone metastases (n= 3, 13%), adrenal (n=1, 4,3%) and lymph node (n=1, 4,3%). 
Chemotherapy: 9 CDDP-Pemetrexed (39,1%), 9 CDDP-Vinorelbina (39,1%), 3 Carboplatin-
paclitaxel, 1 CDDP-Gemcitabina (4.3%), 1 CDDP-Docetaxel (4.3%). Ten patients (43.5%) 
received sequential thoracic radiotherapy and 12 (52.2%) concomitant. Metastases 
treatment: 12 stererotactic radiation (52.2%), 7 external radiotherapy (30, 4%), 3 surgery 
(13%), 1 radiofrequency (4.3%). Toxicity: four patients (17,39%) developed G3 toxicity (2 
hematological, 1 pneumonitis, 1 esophagitis). Median follow up was 15 months, median OS 
18 m, median PFS 11 months. The 1-year OS were 73.9%, 2-year OS 21,7% and 3-year OS 
8.7%. Conclusion: Radical treatment of oligometastatic and unresectable NSCLC patients 
is a safe therapeutic strategy. Despite the limited data and the small numbers of our study, 
it could be contemplated as an effective therapeutic alternative for selected patients. 
Keywords: Oligometastases, lung cancer, unresectable primary tumor, ablative 
treatment
France, 10Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield/CT/United States of 
America, 11Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Germany
Background: Nintedanib is a triple angiokinase inhibitor of receptors for vascular 
endothelial growth factor (VEGF), platelet-derived growth factor and fibroblast growth 
factor. The randomized, placebo-controlled, Phase III LUME-Lung 1 study (NCT00805194; 
1199.13) investigating nintedanib/docetaxel was the first trial of an antiangiogenic agent 
to demonstrate significant overall survival (OS) benefit in previously treated patients 
with non-small cell lung cancer (NSCLC) of adenocarcinoma histology; nintedanib/
docetaxel is approved in the European Union for the treatment of patients with locally 
advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after 
1st-line chemotherapy. Here we report LUME-Lung 1 data from the adenocarcinoma 
population who received 1st-line chemotherapy containing bevacizumab, pemetrexed or 
taxanes. Methods: In LUME-Lung 1, 1314 patients with Stage IIIB/IV recurrent NSCLC 
received either nintedanib/docetaxel or placebo/docetaxel. Primary endpoint was 
centrally assessed progression-free survival (PFS); OS was a key secondary endpoint. 
Prior treatment with anti-VEGF agent bevacizumab was a stratification factor. Analyses of 
the adenocarcinoma population (n=658) according to prior treatment with bevacizumab 
(n=45 in either arm), pemetrexed (1st-line [n=126] or maintenance [n=27]) or taxanes 
(n=142) were performed to determine if 1st-line regimens could influence subsequent 
outcomes for nintedanib/docetaxel. Results: Patient characteristics were generally 
well-balanced across prior-treatment subgroups. For the adenocarcinoma population, 
there was no interaction between 1st-line treatment with bevacizumab, pemetrexed 
or taxanes and treatment outcome with nintedanib/docetaxel. Independent of 
pretreatment, nintedanib/docetaxel-treated adenocarcinoma patients had an OS benefit 
(Table). In the overall patient population, efficacy outcomes for these subgroups were 
also similar regardless of prior treatment. Furthermore, there was no significant effect 
on nintedanib/docetaxel outcomes for the few adenocarcinoma patients who received 
maintenance pemetrexed. The adverse event (AE) profile for nintedanib/docetaxel in 
each subgroup was consistent with that reported for the adenocarcinoma population 
in LUME-Lung 1, with diarrhea and reversible liver enzyme elevations among the more 
frequently reported AEs. Among patients who received nintedanib/docetaxel, there was 
no difference between prior-treatment subgroups in the frequency of AEs commonly 
associated with the prior treatment, such as hypertension with bevacizumab, mucositis 
with pemetrexed and peripheral neuropathy with taxanes. Conclusion: In LUME-Lung 
1, regardless of whether a patient with NSCLC of adenocarcinoma histology received 
1st-line chemotherapy containing bevacizumab, pemetrexed or taxanes, subsequent 
treatment with nintedanib/docetaxel led to improved OS.
Table: OS results in patients with NSCLC of adenocarcinoma tumor histology stratified by 
± prior 1st-line bevacizumab, pemetrexed or taxanes treatment
No BEV BEV No PEM PEM No TAX TAX
N/D Pl/D N/D Pl/D N/D Pl/D N/D Pl/D N/D Pl/D N/D Pl/D
Patients, n 298 315 24 21 261 271 61 65 245 271 77 65
Median OS, 
months 12.6 10.6 14.9 8.7 13.4 10.8 12.0 8.0 12.2 10.3 15.1 11.6
















p-value p=0.24 p=0.90 p=0.61
 
BEV, bevacizumab; CI, confidence interval; HR, hazard ratio; N/D, 
nintedanib/docetaxel; NSCLC, non-small cell lung cancer; OS, overall 
survival; PEM, pemetrexed; Pl/D, placebo/docetaxel; TAX, taxanes. 
Keywords: NSCLC, angiogenesis, VEGF, nintedanib
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MINI17.08 Tumor Growth Over Time with Nintedanib/Docetaxel or Placebo/
Docetaxel in Adenocarcinoma NSCLC: Analysis From the LUME-Lung 1 Study 
Martin Reck1, Hannes Buchner2, Maya Gottfried3, Silvia Novello4, Anders Mellemgaard5, 
Birgit Gaschler-Markefski6, Rolf Kaiser6, Jean-Yves Douillard7 1Department of Thoracic 
Oncology, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of 
the German Center for Lung Research (DZL), Grosshansdorf/Germany, 2Staburo GmbH, 
Munich/Germany, 3Lung Cancer Unit, Meir Medical Center, Kfar Saba/Israel, 4Department 
of Oncology, University of Turin, Turin/Italy,  5Department of Oncology, Herlev University 
Hospital, Herlev/Denmark, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/
Germany, 7Department of Medical Oncology, Centre René Gauducheau, Nantes/France
Background: Nintedanib (N; Vargatef®), a triple angiokinase inhibitor, is approved in the 
EU in combination with docetaxel (D) for the treatment of patients with advanced NSCLC of 
adenocarcinoma histology (ACH) after 1st-line chemotherapy. In the randomized, placebo-
controlled, Phase III LUME-Lung 1 study (NCT00805194; 1199.13), N+D significantly 
improved overall survival (OS; secondary endpoint) vs D in patients with ACH (median OS: 
12.6 vs 10.3 months (m); HR: 0.83 [95% CI: 0.70–0.99]; p=0.0359) and in patients who 
progressed either during or within 9 m of 1st-line therapy (time[T]<9m) (median OS: 10.9 
vs 7.9 m; HR: 0.75 [95% CI: 0.60–0.92]; p=0.0073). We explored the impact of on tumor 
growth over time as a treatment effect of N+D, with a specific focus on early progressors 
(T<9m) and patients who had progressive disease as best response to 1st-line therapy (PD-
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Conclusion: OS of SIM stage IV is remarkably improved compared to non SIM stage IV, 
and comparable to stage III. This data supports aggressive treatment in the subgroup of 
SIM stage IV.
Keywords: Oligometastase, Lung neoplasm, survival, Local treatment
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MINI17.13 Prognosis of Stage III NSCLC Patients Presenting with Isolated Brain 
Failure after Definitive Concurrent Chemoradiotherapy Erkan Topkan, Berna 
Akkus Yildirim, OzanC. Guler, Yurday Ozdemir Radiation Oncology, Baskent University 
Faculty of Medicine, Adana/Turkey
Background: We retrospectively investigated the survival outcomes of stage III non-
small-cell lung cancer (NSCLC) patients presenting with isolated brain failures (IBF) 
after definitive concurrent chemoradiotherapy (C-CRT) and treated with whole brain 
radiotherapy (WBRT) ± stereotactic radiosurgery (SRS) or surgery. Methods: A total 
of 162 patients with stage III NSCLC who were treated with platinum based C-CRT 
between January 2007 and December 2012 and presented with proven IBF with/without 
locoregional failures were included in this retrospective analysis. All patients received 
WBRT of 20-30 Gy (3-4 Gy/fx) ± SRS of 16-22 Gy or surgery. The primary and secondary 
end points were overall survival (OS) and identification of factors associated with longer 
survival. Results: Median follow-up was 12.7 months from the IBF diagnosis.IBF occurred 
at median 7.8 months (range: 1.7-46.4) from the commencement of C-CRT.WBRT was 
the sole local intervention in 78 patients whereas 55 and 29 patients received additional 
SRS or surgery mostly prior to WBRT. Median and 3-year survival rates were 11.7 months 
and 20.4%, respectively. In univariate analysis, controlled primary (20.3 vs. 6.4 months; 
p<0.001) and absence of extracranial metastasis development during follow-up (23.3 
vs. 10.6 months; p<0.001) were determined to be significantly associated with longer 
OS times, which also retained their independent significance in multivariate analysis. 
Addition of SRS or surgery was related with better brain control rates but not OS in overall 
population. However, in patients presenting with ≤3 brain lesions and controlled lung 
primary the addition of SRS or surgery to WBRT was associated with significantly superior 
OS times than WBRT alone (25.8 vs. 8.2 months; p<0.001). Conclusion: Present results 
demonstrated that controlled lung primary and absence of extracranial metastasis 
development during follow-up period were the factors positively associated with longer 
OS after WBRT ± SRS or surgery in stage III NSCLC patients presenting with IBF after 
platinum based C-CRT.Additionally, our results suggested superior survival with addition 
of SRS or surgery to WBRT in patients with 1-3 brain lesions and controlled lung primaries. 
Keywords: Stage III NSCLC, Definitive Concurrent Chemoradiotherapy, Isolated Brain 
Failure
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MINI17.11 Results of Radical Local Treatment of Non-Small Cell Lung Cancer 
Patients with One or Two Synchronous Metastases Margriet Kwint1, Heike Peulen1, 
Sjaak Burgers2, Koen Hartemink3, Marcel Verheij1, Jose Belderbos1 1Radiation Oncology, 
The Netherlands Cancer Institute, Amsterdam/Netherlands, 2Pulmonology, The Netherlands 
Cancer Institute, Amsterdam/Netherlands, 3Thoracic Surgery, The Netherlands Cancer 
Institute, Amsterdam/Netherlands
Background: Stage IV non-small cell lung cancer (NSCLC) patients are considered 
incurable and mainly treated with palliative intent. The overall survival (OS) and disease 
free survival (DFS) of this patient group is considered as poor. The purpose of this study 
was to investigate the OS and DFS of NSCLC patients, diagnosed with synchronous 
oligometastatic disease treated with curative intent of the intrathoracic disease as 
well as the metastases. Methods: Patients treated between 2008 and 2014 were 
included in this retrospective cohort analysis. Main inclusion criteria were: synchronous 
presentation of NSCLC and oligometastatic disease at diagnosis, and multidisciplinary 
consent on a radical treatment of both the intrathoracic disease and the metastases. 
Besides systemic treatment. The intrathoracic disease was radically irradiated (> 55 
Gy biological effective dose) or resected. Treatment of the metastases consisted of: 
radical/stereotactic radiotherapy, surgical resection or radiofrequency ablation (RFA). 
Results: A total of 56 patients, 31 men and 25 women, were included. The mean age 
was 61 years (range 36-79) and all were in good condition (WHO 0-1). Most patients had 
a solitary metastasis (brain (22), bone (17), adrenal gland (6), lymphe node (3), liver 
(2), soft tissue (1), pulmonary (1), thyroid gland (1) and breast (1)). Two patients had 2 
metastases (liver and bone / pleural and bone). The intrathoracic tumor stage,ignoring 
M-status, was IA in 3 patients, IB in 2 patients, IIA in 8 patients, IIB in 4 patients, IIIA in 
24 patients and IIIB in 15 patients. Fifty patients were treated with radiotherapy and 
4 patients had a surgical intervention for the primary tumor; 2 patients only received 
systemical treatment for the intrathoracic disease. Fifty patients received chemotherapy 
(89%), of which 5 (10%) concurrent with the radiotherapy of the intrathoracic disease 
and 45 (90%) sequential. The metastases were treated with ablative/stereotactic 
radiotherapy (45), surgical intervention (2), only systemical treatment (5), combination of 
surgical intervention and radiotherapy (3) and RFA (1). The mean follow-up was 21 months 
(range 4-69). Forty-one (73%) patients developed recurrent disease of whom 29 (52%) 
died. Only 8 (20%) recurrences occurred within the irradiated area. Most recurrences 
where brain (13) and pulmonary metastases (11). For the whole group, the median 
DFS was 14 months (range 2-69, 95% CI 11-17) and the median OS was 32 months 
(range 4-69, 95% CI 16-48). The 1- and 2-year OS was 86% and 58%, respectively. 
The 1- and 2-year DFS was 66% and 30%, respectively. Conclusion: Radical local 
treatment of a highly selected group of NSCLC patients in good condition presenting 
with synchronous oligometastatic stage IV disease (maximum 2 metastases) 
resulted in excellent local control, and also in favorable long-term DFS and OS. 
Keywords: overall survival, NSCLC, Oligometastatic disease, Radical treatment
WT EGFR, ANGIOGENESIS AND OMD 
TUESDAY, SEPTEMBER 8, 2015 - 16:45-18:15
MINI17.12 Survival Analysis of Stage IV NSCLC with Synchronous Isolated 
Metastasis in a Large Retrospective Cohort Michael Duruisseaux1, Marion 
Perrin1, Matteo Giaj Levra1, Linda Sakhri1, Pierre-Yves Brichon2, Julie Villa3, Dominique 
Hoffmann4, Pascale Guillem5, Denis Moro-Sibilot1, Anne Claire Toffart1 1Pôle Thorax et 
Vaisseaux, Unité D’Oncologie Thoracique, Service de Pneumologie, Grenoble/France, 2Pôle 
Thorax Et Vaisseaux, Service de Chirurgie Thoracique, Grenoble/France, 3Pôle D’Oncologie, 
Service de Radiothérapie, Grenoble/France, 4Pôle Tête et Cou et Chirurgie Réparatrice, 
Service de Neurochirurgie, Grenoble/France, 5Pôle Urgences et Médecine Aigüe, Centre de 
Coordination En Cancérologie, Grenoble/France
Background: Stage IV Non-Small Cell Lung Cancer (NSCLC) is considered as an 
incurable disease with median survival of 6 to 12 months. Palliative platinum based 
chemotherapy is the standard therapy. It has been suggested that patients with one 
synchronous isolated metastasis (SIM) suitable for local therapy have longer survival. 
Methods: Database of the Multidisciplinary Thoracic Oncology Group of our centre 
was retrospectively screened from 1993 to 2012. Consecutive NSCLC of any stage 
were included. Median overall survivals (OS) between stage III and stage IV (SIM and 
non SIM) were compared with log-rank test. For the multivariate analyses Cox models 
were performed. Results: 4917 patients were registered, 85 were excluded because 
of missing data. Among the study population, 1335 (27.6%) patients were stage III 
NSCLC, 1483 (31%) non SIM stage IV and 109 (2%) SIM stage IV. SIM site were mainly 
brain (n=70, 64%) and adrenal gland (n=16, 15%). Clinical and histological data differed 
substantially between each stage (Table 1). Median OS was significantly longer in SIM 
stage IV compared to non-SIM stage IV (18 [IQR, 9-33] months vs 6 [IQR, 2-13] months 
respectively, p-value<10-4) and not significantly different between SIM stage IV and 
stage III (14 months [IQR, 6-31], p-value=0.05). In multivariate analysis (Table 2), we still 
observed that median survival of SIM stage IV and stage III were not significantly different 
(p-value= 0.47).
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compare their outcomes to those of younger patients. Methods: Patients with primary 
lung cancer treated with SBRT were identified from a multi-institutional (5) database 
of 1192 cases. Details of patient factors, treatment specifics, toxicity and clinical 
outcomes were extracted from the database. All events were calculated from the end of 
radiotherapy. Estimates of local (LR), regional (RR), and distant metastases (DM) were 
calculated using the competing risk method. Cause specific (CSS) and overall survival 
(OS) were calculated using the Kaplain-Meier method. Outcomes were compared for 
those <70, 70-79, >=80. Toxicity was graded per CTCAE V3.0. The 90 day mortality 
was reported for those <70, 70-79, >=80. Univariable analysis was performed to 
determine associations with CSS in patients aged >70. Results: The median follow-up 
was 1.7years (1-10y) and median age 75 (41-94). There were 364 patients age <70 
(28%), 546 age 70-79 (42%) and 387 age ³80 (48%). 621(48%) were female, 1125(87%) 
were peripheral and 852(66%) were biopsied. There was no difference in baseline SUV 
(p=0.6), histology (p=0.4), radiation dose (p=0.1), gender (p=0.3) or biopsy rate 
(p=0.2) among the three age groups. Patients aged >=80 had significantly more T2 
tumors 21% vs 23% vs 32 % (p<0.01). There was no difference in 5 year LR (10% vs 
11.5% vs 10%, p=0.7), RR (22% vs 10% vs 9%, p=0.1), DM (17% vs 16% vs 21%, p=0.07) 
or CSS (80% vs 80% vs 75%, p=0.6). Those age ³80 had significantly lower 5 year 
OS (75% vs 44% vs 23%, p<0.01). The grade 3+ pneumonitis rate was 1.3% vs 1.6% 
vs 1.5% (p=0.9) in patients ages <70,70-79, >=80 respectively. The 90 day mortality 
rates for patients aged <70,70-79, >=80 were 1.4%, 2.7%, and 2.6% respectively. In 
patients aged >70 CSS was associated with tumor size (p<0.01; HR1.4) and baseline 
SUV max (p=0.03; HR1.04). Conclusion: SBRT is a safe treatment modality in elderly 
patients (aged >80). Despite larger tumor volumes, the tumor control outcome were 
identical to the younger patients treated with SBRT. All patients, regardless of age, 
should be considered for treatment of early stage lung cancer (T1-T2) with SBRT. 
Keywords: SBRT, elderly, NSCLC, outcomes
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MINI18.03 Immune Activation in Early Stage Non-Small Cell Lung Cancer 
(NSCLC) following Stereotactic Ablative Radiotherapy (SABR) and Surgery 
Joachim G. Aerts1, Pauline De Goeje1, Merel Schram1, Koen Bezemer1, Margaretha 
Kaijen-Lambers1, Joost Hegmans1, Joop De Langen2, Alexander Maat3, Joost Nuyttens4, 
Rudi Hendriks1, Egbert Smit5, Suresh Senan6 1Pulmonary Diseases, Erasmus Mc Cancer 
Centre, Rotterdam/Netherlands, 2VUMC, Amsterdam/Netherlands, 3Dept. of Thoracic 
Surgery, Erasmus Medical Center, Rotterdam/Netherlands, 4Dept. of Radiation Oncology, 
Erasmus Medical Center, Rotterdam/Netherlands, 5Dept. of Thoracic Oncology, Netherlands 
Cancer Institute, Amsterdam/Netherlands, 6Radiation Oncology, VU University Medical 
Center, Amsterdam/Netherlands
Background: An anatomical surgical resection is considered to be the standard of care 
in fit patients, but non-randomized comparative effectives studies suggest that survival 
outcomes may be similar following SABR. An antitumor immune microenvironment 
was found to be a prognostic factor in surgically resected early stage NSCLC. SABR 
has been reported to activate the immunesystem in malignant diseases via a number 
of mechanisms. We investigated the impact of both surgery and SABR in early stage 
NSCLC on the immunesystem, studied in peripheral blood over time. Methods: This 
is a non-randomised trial. Treatment by either surgery or SABR treatment for 
early stage (cT1-T2aN0M0) were determined by an institutional multi-disciplinary 
tumorboard, and in accordance with the patient’s preference . SABR was typically 
delivered in 3-8 fractions in 1-2 weeks, based on risk-adapted radiotherapy schemes 
that delivered a biologically effective dose of >100 Gy. Surgery generally involved a 
VATS lobectomy. Blood was collected prior to treatment, and at weeks 1, 2, 3 and 6 
after start of treatment. The peripheral blood mononuclear cell (PBMC) fraction was 
isolated and was stimulated for 4 hours with phorbol 12-myristate 13-acetate (PMA) 
and ionomycin, to activate the T cells. Subsequently, the T-cells cells were harvested 
and analyzed by flow cytometry on the expression of CD4 and/or CD8, granzyme B 
and interferon (IFN) γ. As PD-1 expression is induced in T-cells after antigen exposure 
the expression of PD-1 was determined. Changes of population proportions between 
the different time points were analyzed with the related-samples Wilcoxon signed 
rank test. Results: 23 early stage non-small cell lung cancer (NSCLC) patients were 
included in the study. Of these, 13 patients underwent surgical resection at a mean age 
(±standard deviation) of 62,9± 8,4 years, and 10 patients who underwent SABR at a 
median age of 70,0 ±10,4 years. SABR patients had more comorbidities, and a poorer 
WHO performance score, but clinical tumor stage was comparable. A significant increase 
in the proportion of IFNγ+Granzyme B+ CD8 T cells (p<.05) was observed at week 2 
in the SABR treated group, whereas no difference was found after surgical resection. 
The PD1+ fraction of CD4+ T cells was significantly increased at week 2 in the SABR 
treated group (p<.05), whereas no differences were seen at two weeks after surgical 
resection. Proportions of PD1+ CD4 T cells remained elevated in the SABR group at 
week 3 and 6. A similar trend was observed in the CD8+ T cell population, although 
this did not reach statistical significance (p<.1). Conclusion: SABR but not surgery, 
enhances T-cell activation and PD-1 upregulation. The results of our study warrant further 
investigation as to whether SABR induces an anti-tumor response in patients with early 
stage NSCLC . The upregulation of PD-1 inherently accompanied with this activation of 
the immune system potentially warrants combination treatment with PD-(L)1 blockade. 
Keywords: immune system, PD-1, SABR, Surgery
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MINI17.14 Survival Analysis following Pulmonary Metastasectomy for Non-
Small Cell Lung Cancer Hyo-Jun Jang, Sungjoon Park, Eunjue Yi, Sukki Cho, 
Sanghoon Jheon, Kwhanmien Kim Seoul National University Bundang Hospital, Seongnam-
Si/Korea
Background: The effectiveness of pulmonary metastasectomy for non-small cell lung 
cancer(NSCLC) is controversial. The aim of this study is to report the overall survival 
after pulmonary metastasectomy for NSCLC and to determine prognostic factors for 
survival. Methods: Between June 2003 and July 2007, 39 patients underwent pulmonary 
metastasectomy in single center. Data from first time of pulmonary metastasectomy 
were included and data from more than second time of pulmonary metastasectomy 
were excluded. Results: There were 24 men and 15 women, and the median age at 
pulmonary metastasectomy was 64.0 years. The median recurrence free time from 
initial pulmonary resection to pulmonary metastasectomy was 18.5 months. The 
overall 5-year survival rate was 67.2%. In univariate analysis, ager under 70 years, 
recurrence free time over 24 months, adenocarcinoma and normal CEA level were 
prognostic factors for overall survival. Gender, initial TNM stage, operation type of 
pulmonary metastasectomy, number and size of pulmonary nodule and distance from 
nodule to margin were not associated with overall survival. Conclusion: In selected 
patients, pulmonary metastasectomy for NSCLC may confer a good survival. It 
appears reasonable that such patients should be considered as surgical candidates. 
Keywords: lung cancer, pulmonary metastasectomy, intrapulmonary metastasis
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MINI18.01 Stereotactic Body Radiation vs. Observation for Early-Stage NSCLC 
in Elderly Patients Ronica H. Nanda1, Theresa W. Gillespie2, John L. Mikell1, Yuan 
Liu2, Joseph Libscomb3, Suresh S. Ramalingam4, Felix Fernandez5, Walter J. Curran1, 
Kristin A. Higgins1 1Radiation Oncology, Emory University Winship Cancer Institute, Atlanta/
United States of America, 2Biostatistics and Bioinformatics, Emory University Winship Cancer 
Institute, Atlanta/United States of America, 3School of Public Health, Emory University 
Winship Cancer Institute, Atlanta/United States of America, 4Medical Oncology, Emory 
University Winship Cancer Institute, Atlanta/United States of America, 5Thoracic Surgery, 
Emory University Winship Cancer Institute, Atlanta/United States of America
Background: Stereotactic body radiotherapy (SBRT) has demonstrated high 
rates of local control with low morbidity and has now emerged as the new standard 
of care for medically inoperable, early-stage non-small cell lung cancer (NSCLC). 
However, the impact of lung SBRT on survival in the elderly population is less clear 
given competing co-morbid conditions. An analysis of the National Cancer Data Base 
(NCDB) was undertaken to determine whether definitive SBRT in patients 70 and older 
improves survival relative to observation alone. Methods: The NCDB, a retrospective 
national database capturing up to 80% of all patients treated for cancer, was queried 
for patients ages 70 or higher with early stage (T1-T3N0M0) NSCLC from years 2003-
2006. Overall survival was compared between patients treated with stereotactic body 
radiotherapy alone and patients receiving no treatment. Extended Cox proportional 
hazards model was applied to estimate the treatment effect of SBRT. Results: A total 
of 3,147 patients met the selection criteria for this analysis. SBRT was delivered to 
258 patients (8.2%) and 2889 patients (91.8%) received no treatment. There was no 
significant difference in the distribution of Charlson/Deyo comorbidity index scores 
between the two groups (p=0.076). Multivariable analysis revealed improved overall 
survival with SBRT compared with observation for the entire cohort (HR 0.64, p<0.001), 
as well as for each age group as follows: 70-74, HR=0.72; 75-79, HR=0.66; 80-84, 
HR=0.59; 85 and above, HR=0.56. Conclusion: SBRT is associated with improved 
survival in elderly patients with early stage NSCLC with concurrent comorbid conditions 
compared to observation alone . The data support the use of SBRT for treatment of 
elderly patients with early stage NSCLC that have limiting co-morbid conditions. 
Keywords: Early-stage NSCLC, Stereotactic body radiation therapy, Elderly patients
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MINI18.02 Stereotactic Body Radiotherapy Is Safe and Effective in Octo- and 
Nonagenarians for the Treatment of Early Stage Lung Cancer Meredith Giuliani1, 
Andrew Hope2, Matthew Johnson3, Matthias Guckenberger4, Frederick Mantel5, Heike 
Peulen6, Jan-Jakob Sonke6, Jose Belderbos7, Maria Werner-Wasik8, Hong Ye9, Inga Grills9 
1Radiation Oncology, University of Toronto and Princess Margaret Cancer Center, Toronto/
ON/Canada, 2University of Toronto and Princess Margaret Cancer Center, Toronto/ON/
Canada, 3William Beaumont Hospital, Michigan/AL/United States of America, 4University 
Hospital Zurich, Zurich/Switzerland, 5University of Wuerzburg, Wuerzburg/
Germany, 6Department of Radiation Oncology, The Netherlands Cancer Institute – Antoni 
Van Leeuwenhoek Hospital, Amsterdam/Netherlands, 7Radiation Oncology, The Netherlands 
Cancer Institute, Amsterdam/Netherlands, 8Radiation Oncology, Thomas Jefferson University 
Hospital, Philadelphia/United States of America, 9William Beaumont Hospital,, Michigan/AL/
United States of America
Background: To determine the safety and efficacy of lung SBRT in older patients and to 
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CT high risk factor for local 
recurrence Sensitivity (%) Specificity (%) p-value
Any HRF 93 64 .001
enlarging opacity (≥5mm and ≥20%) 86 68 .003
sequential enlarging opacity 57 89 .002
enlarging opacity after 12 months 71 89 <.001
bulging margin 64 100 <.001
loss of linear margin 64 100 <.001
loss of air bronchograms 7 100 0.33
cranio-caudal growth (≥5mm and ≥20%) 86 82 <.001
new pleural effusion 14 93 0.59
 
Conclusion: In this matched group of biopsy proven LR and controls, cranio-caudal growth 
was the best individual predictor of LR after SBRT. Combining HRF bulging margin with either 
cranio-caudal growth or enlarging opacity after 12 months resulted in higher sensitivities 
and specificities than number of HRFs. 1)Huang et al. Radiotherapy&Oncology 2013 
Keywords: SBRT, local recurrence, CT high risk features, NSCLC
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MINI18.07 Early Results of a Quality Assurance Program in a Randomized 
Trial of Stereotactic Body Radiotherapy for Stage I Medically Inoperable Lung 
Cancer Anand Swaminath1, Marcin Wierzbicki2, Jim Wright1, Theodoros Tsakiridis1, 
Kathryn Cline3, Catherine Bucci4, Orest Ostapiak2, Sameer Parpia3, Jim Julian3, Timothy 
Whelan1 1Oncology, McMaster University, Hamilton/ON/Canada, 2Medical Physics, McMaster 
University, Hamilton/ON/Canada, 3Ontario Clinical Oncology Group, McMaster University, 
Hamilton/ON/Canada, 4Radiation Therapy, Juravinski Cancer Centre, Hamilton/ON/Canada
Background: A large Canadian multicentre randomized trial (LUSTRE) has recently 
opened to determine if stereotactic body radiotherapy (SBRT) to 48 Gy in 4 fractions 
(peripheral) or 60 Gy in 8 fractions (central) improves outcomes compared to 
conventionally hypofractionated radiotherapy (CRT) to 60 Gy in 15 fractions in early 
stage non-small cell lung cancer. Given the rapid diffusion of lung SBRT technology 
across Canada, a unique radiotherapy quality assurance (RTQA) program was devised 
to minimize variations in practice. This study describes the RTQA experience to 
date. Methods: Centres participating in LUSTRE are required to satisfy three RTQA 
requirements prior to being accredited: (a) Respond to a survey describing treatment 
equipment, planning system details and image guidance parameters in order to confirm 
that their centre is compliant with protocol guidelines; (b) Assess SBRT delivery 
accuracy using a thoracic phantom produced by IROC (Imaging and Radiation Oncology 
Core); and (c) Successfully complete four treatment plans from the developed trial 
planning guide using SBRT and CRT for one centrally and one peripherally located 
cancer. Results: Currently 13 centres are undergoing RTQA: (a) Surveys have been 
completed in 8 centres, 2 require revision, and 3 are incomplete. (b) Phantom testing 
has been completed in 9 centres, 2 are incomplete, 1 has results pending, and 1 is 
being resubmitted. Although 6/13 centres were identified as having active SBRT 
programs (>3 patients/month), only 2/6 had completed the IROC phantom prior to study 
accreditation (most having in-house end-to-end tests). (c) 8/13 centres have successfully 
submitted their test cases. All 8 submitting centres passed on SBRT/CRT distributions 
and conformality indices. However, 5/8 centres required resubmission for contouring 
revisions. In one case, the GTV/ITV was incorrectly contoured. In another case, it was 
contoured on the incorrect dataset. In the remainder, normal organs (lungs, bronchi, 
esophagus) had contouring errors, particularly the bronchial tree; contours excluded 
the major bronchi, and in 2 cases, normal lung parenchyma was included. Some centres 
did not follow standardized nomenclature for targets and normal organs, as they were 
likely new to this naming convention. Some issues were related to misinterpretation of 
the planning guide, prompting the trial group to work with centres to ensure a seamless 
future workflow. Conclusion: Preliminary results show that most well-established lung 
SBRT centres rely on their own in-house standards, while others are using LUSTRE RTQA 
to implement new SBRT programs. Our experience shows that when centres participate 
in an independent review, alterations are recommended that can improve their own 
existing QA processes, and contribute to standardized practice nationwide. Such an 
RTQA process can be a model worth considering in future radiotherapy randomized trials, 
and also when instituting new radiotherapy technologies into existing clinical programs. 
Keywords: stereotactic radiotherapy, early stage disease, quality assurance, treatment 
planning
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MINI18.08 A Systematic Review of Comparative Effectiveness Studies of 
Surgery versus SABR in Early Stage Lung Cancer: How Good Is the Data? 
Alexander V. Louie1, Chris D. Goodman2, Hanbo Chen1, George B. Rodrigues1, David 
A. Palma1, Berend Slotman3, Suresh Senan3 1Radiation Oncology, London Regional 
Cancer Program, London/Canada, 2Medicine, University of Western Ontario, London/AB/
Canada, 3Radiation Oncology, VU University Medical Center, Amsterdam/Netherlands
Background: Three prospective randomized control trials (RCTs) comparing stereotactic 
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MINI18.04 Tumor Volume Variations and Related Dosimetric Impact During 
Stereotactic Body Radiation Therapy for Lung Cancer Luigi Moretti, Younes 
Jourani, Florian Charlier, Thomas De Brouwer, Paul Van Houtte Institut Jules Bordet, 
Brussels/Belgium
Background: This study aimed to evaluate the importance of interfraction variations in 
gross tumor volume (GTV) during stereotactic body radiotherapy (SBRT) for early lung 
cancer patients and assess its impact on dosimetric GTV coverage. Methods: Forty-
seven consecutive patients undergoing SBRT were treated with 48 Gy in 4 fractions (group 
1: n=35) or 60 Gy in 8 fractions (group 2: n=12). For each patient, Cone-Beam Computed 
Tomography (CBCT) imaging obtained at each fraction and initial planning 4DC (CT) were 
analyzed. GTVs were delineated on all CBCTs, and individual treatment planning was 
recalculated on each CBCT. Statistical analyses were performed to compare differences 
between independent samples: the Mann-Whitney U test was used for non-normal 
continuous variables analyses between groups and the χ2 test for proportions within 
each SBRT group. Wilcoxon signed rank test was also used to assess changes in volume, 
dosimetric parameters, and tumor localization. All significance tests were two-tailed and 
p<0.05 was considered significant. Results: A total of 236 CBCTs were processed and 
analyzed. Median total treatment times were 8 days for group 1 and 19.5 days for group 
2. There was a significant tumor volume change between the initial CT and the 1st CBCT 
(p=0.003) in group 1. This was not found in group 2 (p=0.67). GTV was significantly 
larger at the 2nd CBCT (p=0.003 for group 1 and p=0.049 for group 2) compared 
to the 1st CBCT. Volume changes were not significantly different at the 3rd fraction 
compared to 1st CBCT. In group 1, GTV volume significantly decreases at the 4th fraction 
compared to the 2nd (p=0.047). In group 2, the significant decrease in volume occurs 
at the 6th fraction (p=0.026). There was no association between the overall treatment 
time and tumor volume variations. Taken individually (n=47) 83% of tumors have at least 
one occurrence of a greater than 15% volume change during SBRT compared to the 
1st CBCT. Variations of more than 20%, 30% and even 40% were observed in ~60%, 
40%, and 17% of treatments, respectively. No factor that would predict a significant 
volume change during SBRT for the patients analyzed could be identified. In group 1, 
tumor coverage factor (>95%) for any given fraction deviated no more than 5% from 
optimised coverage obtained in the initial treatment plan. Although sample size is smaller, 
there was a trend towards lower tumor coverage factors in group 2 compared to group 
1. Conformity index for all tumors still ranged from 3.41 to 13.35 in group 1, and 0.95 
to 10.48 in group2, without any association with tumor volume variations or treatment 
time. Conclusion: There was considerable variation in tumor volumes and more frequent 
than initially expected for patients undergoing lung SBRT. However, these volume 
changes did not significantly impact dosimetric parameters. Whether these results affect 
treatment and/or patient outcome remains to be investigated in prospective clinical trials 
Keywords: lung cancer, CBCT, SBRT, imaging
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MINI18.06 Validation of High Risk Features on CT for Detection of Local 
Recurrence After SBRT for Stage I NSCLC Heike Peulen1, Frederick Mantel2, 
Maddalena Rossi1, Barbara Stam1, Inga Grills3, Meredith Giuliani4, Maria Werner-
Wasik5, Andrew Hope4, Jose Belderbos1, Matthias Guckenberger2, Jan-Jakob 
Sonke1 1Netherlands Cancer Institute, Amsterdam/Netherlands, 2University of 
Wuerzburg, Wuerzburg/Germany, 3Beaumont Hospital, Royal Oak/AL/United States of 
America, 4University of Toronto and Princess Margaret Cancer Center, Toronto/ON/
Canada, 5Thomas Jefferson University Hospital, Philadelphia/AL/United States of America
Background: Fibrotic changes after SBRT for stage I NSCLC are difficult to distinguish 
from local recurrences (LR), hampering proper selection for salvage therapy. Huang et 
al. (1) defined CT high risk features (HRF) for detection of LR. This study attempts to 
validate these HRFs in an independent patient cohort. Methods: From a multicenter 
combined database of patients treated with SBRT for stage I NSCLC between 2006 
and 2012, 53 LR were detected of which 14 were biopsy proven. The biopsy proven LR 
(N=14) were matched 1:2 to patients without LR (n=28) based on: 1) dose 2) PTV 3) 
follow up time 4) central/peripheral location 5) lung lobe. Of the resulting 42 patients 
18 were male and 24 female with a median age of 73 years (range 56-89years). Median 
tumor size, PTV and dose were 2.3 cm (range 1.0-4.9cm), 49cc (range 9-166cc), 48 Gy 
(range 48-60Gy) in 4 fractions (range 3-8) respectively. Most tumors were peripheral 
(76%) and located in the upper lobes (55%). Median follow up (FU) was 36 months (range 
14-78months) and median time to LR was 18 months (range 12-45months). For all 
patients, planning CT scans and at least two follow up scans were available. Two blinded 
observers scored eight HRFs for each scan. Sensitivity and specificity in predicting LR 
were assessed and compared using Fisher’s exact test. Analysis for best fit was done 
using AUC. Results: Results of sensitivity and specificity are shown in Table 1. The best 
performing HRF was cranio-caudal growth: sensitivity 86%, specificity 82%. The odds of 
LR increased on average by 2.6 (95%CI1.5-4.3) for each additional HRF detected, while 
the AUC was 0.86. The presence of ≥ 3 HRFs resulted in the best cut-off with sensitivity 
79% and specificity 86%. Loss of linear margin and bulging margin were scored identical 
and therefore only the latter was included in the model. The two best combinations of 
HRFs were: 1) bulging margin & cranio-caudal growth, with a sensitivity of 93% and 
specificity of 82% or 2) bulging margin & enlarging opacity after 12 months, with a 
sensitivity of 86% and specificity of 89%. Table 1
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Conclusion: Based on 5 years of population based data, an age cutoff 
for lung-SABR is not endorsed. In our treated population, patients ≥85 
yo have similar OS as younger patients despite greater CCI scores. 
Keywords: Population analysis, Stereotactic body radiation, radiation, elderly
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MINI18.11 Does Motion Management Technique for Lung SBRT Influence Local 
Control? Gregory M.M. Videtic1, Neil Woody2, Chandana Reddy2, Kevin Stephans2 
1Radiation Oncology, Cleveland Clinic, Cleveland/United States of America, 2Cleveland Clinic, 
Cleveland/United States of America
Background: Abdominal compression (COMP) for motion management began with 
our lung stereotactic body radiotherapy (SBRT) practice. From 11/2009, breath hold 
technique by automatic breath control (ABC) device is selectively employed typically for 
fit oligometastatic patients (pts). We now compare local failure (LF) results for COMP 
versus ABC. Methods: Our IRB-approved SBRT registry was queried for pts. treated 
for either a primary lung cancer (PRIME) or an oligometastatic (OLIGO) diagnosis with 
a minimum 6 months follow up. SBRT was delivered by a stereotactic-specific LINAC 
platform with vacuum-bag based immobilization, and infrared-based X-ray positioning 
system+/- CBCT for image-guidance. With COMP, tumor excursion was limited to <1cm 
and the ITV was created one of two way dependent on treatment era: 1. Fused GTV 
excursion CTs from free breathing, fixed inhale and exhale travel or 2. by 4DCT, with PTV 
created from the MIP ITV after adding a 5mm margin. With ABC, 3 serial CT image sets 
confirmed target immobilization, with the PTV generated after 5 mm was added to the 
static GTV. SBRT was delivered either with dynamic arcs or step-and-shoot intensity–
modulated beams. SBRT dose/fractionation schedules evolved over time and reflected 
treatment era, tumor location, clinician preference, and trial-based experience. LF was 
defined as progressive and increasing CT scan abnormalities confirmed by progressive 
and incremental increases in a lesion’s SUVs on serial PET imaging, with or without 
biopsy. Results: For the interval 10/2003 to 7/2014, 873 pts with 931 lesions were 
treated. Overall pt. characteristics were: 455 (52.1%) female; 83.9% Caucasian; median 
age 73 years (range 37-97); median KPS 80 (range 40-100); median BMI 26.2 (range 
12.1-56.3). Overall tumor characteristics were: median tumor size 2.2 cm (range 0.7-
10.0); median PET SUVmax 7.5 (range 0.8-59), per RTOG 0813 definitions 234 (25.4%) 
were central lesions, with no significant tumor differences between COMP and ABC 
cohorts. 830 (89.2%) lesions were PRIME, 101 (10.8%) were OLIGO. ABC was used 
significantly more for OLIGO vs. COMP (34.4% vs.8.3%, p<0.0001). Median follow-up 
and SBRT dose were 16.4 months (0-109.5) and 50 G/5 fractions respectively. Overall 
crude rate of LF was 9.9%. Use of ABC was not associated with increased LF compared 
to COMP: hazard ratio (HR)=1.043 [95% CI 0.48-2.29; p=0.92] Three-year actuarial rates 
of LF for ABC vs. COMP were 13.8% and 16.5%, respectively. After stratifying by OLIGO/
PRIME, neither ABC nor COMP was significantly associated with LF. There is a suggestion 
that centrality may be associated with LF with ABC (HR =2.087, p=0.066)On univariate 
analysis, BMI, tumor size, PET SUVmax and central location were associated with failure, 
with size the most significant. Conclusion: Although form of motion control overall did 
not predict for LF in lung SBRT, LF for central tumors may be associated with ABC use. 
Keywords: lung SBRT, motion control, local failure
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MINI18.12 Assessment of Dose Response via Regional Lung Perfusion following 
Stereotactic Radiotherapy for Lung Cancer Ross McGurk1, Shiva K. Das2, Eric 
Schreiber3, Timothy Zagar3, Arif Sheikh3, William Mccartney3, Michael Lawrence1, 
Patricia Rivera2, Rebecca Green3, Lawrence Marks1 1North Carolina Cancer Hospital, 
Chapel Hill/NC/United States of America, 2University of North Carolina, Chapel Hill/United 
States of America, 3University of North Carolina, Chapel Hill/NC/United States of America
Background: Radiation therapy (RT) -induced lung injury is one of the major causes 
of morbidity in patients with thoracic cancer. Extensive work has been done to 
understand the predictors of lung injury in patients receiving conventionally fractionated 
RT. However, less work has been done in the setting of hypo-fractionation. Further, 
conventional methods to consider lung injury typically assess global lung function 
(e.g. symptoms, pulmonary function tests), are affected by many other (non-radiation) 
factors, and are thus non-specific. Single photon emission computed tomography 
(SPECT) perfusion imaging affords an objective quantitative manner to assess the effects 
of RT on regional lung function. We herein report the preliminary results of a prospective 
study to assess the magnitude of RT-induced reductions in regional lung perfusion 
following hypo-fractionated stereotactic RT. Methods: Four patients undergoing hypo-
fractionated stereotactic lung RT (SBRT: 12 Gy x 4 fractions or 10 Gy x 5 fractions) 
had a pre-treatment SPECT (single-photon emission computed tomography) perfusion 
scan providing a 3D map of regional lung perfusion. Scans were repeated 3-6 months 
post-treatment. Pre- and post SPECT scans were registered to the planning CT scan (and 
hence the 3D dose data). Changes in regional perfusion (counts per cc on the pre-post 
scans) were computed in regions of the lung exposed to different doses of radiation (in 
5 Gy intervals), thus defining a dose-response function. SPECT scans were internally 
normalized such that total counts in the regions receiving <5 Gy were equal between 
pre- and post-treatment scans. Results: 3 months post-RT, changes in perfusion are 
highly variable. At 6 months, there is a consistent dose-dependent reduction in regional 
perfusion. Average percent decline in regional perfusion was 10% at 15-20 Gy, 20% and 
20-25 Gy, and 30% at 25-30 Gy representing a relatively linear dose response with an 
approximate 2% reduction per Gray for doses in excess of 10 Gy. Subtle increases in 
perfusion were seen in lung receiving <10 Gy.
ablative radiotherapy (SABR) and surgery in early stage non-small cell lung cancer (ES-
NSCLC) failed to complete accrual. Numerous other comparative effectiveness studies 
have been published, but such studies may be more prone to bias, and conclusions may 
vary based on study quality. The goal of this study was to perform a systematic review 
of comparative effectiveness studies that compare both treatment modalities in this 
patient population, to assess study quality and conclusions. Methods: In accordance 
with PRISMA guidelines, a systematic review was conducted on studies reporting on 
comparative outcomes of surgery versus SABR for ES-NSCLC. Studies published in the 
English language over a 10-year period (April 2006-March 2015) were identified using 
PUBMED with an inclusive search strategy, using the National Library of Medicine’s 
medical subject headings. Eligible study designs included RCTs, population analyses, 
match pair comparisons, propensity-match score comparisons, retrospective case-
control series, decision analyses, and cost-effectiveness analyses. Letters, editorial 
and systematic reviews were excluded. Abstracts identified were independently 
reviewed by two investigators to determine eligibility, with discrepancies settled by a 
third investigator. Using a standardized data abstraction form, study, patient, tumor, 
and treatment characteristics were abstracted. As patients undergoing surgery and 
SABR often differ in their baseline characteristics, we determined the proportion of 
studies reporting statistical adjustment for baseline characteristic imbalances (e.g. 
matching in patient studies, sensitivity analyses in modeling studies). The Fisher’s exact 
test was used to determine if there was an association between the use of statistical 
adjustment and differences in overall survival (OS) findings. Results: Of the 568 
studies identified by our search strategy, 22 were eligible for analysis. Primary study 
design was retrospective (n=11), population-based (n=7), or model-based (n=4). Most 
patient studies (n=17) reported on a statistical adjustment for differences in baseline 
characteristics, with propensity score matching (n=12) being the most common 
technique employed. All studies, except for 1, reported details of the type of surgery 
performed. SABR doses employed ranged from 30 Gy in 1 fraction, to 60 Gy in 3 
fractions. The weighted average pathologic confirmation of malignancy rate for SABR 
patients was 72% (range 22-100%). Of the 20 studies reporting on overall survival, 12 
found that SABR and surgery were equal, or sensitive to variability in baseline patient, 
treatment, or tumor factors. The remaining 8 studies reported an overall survival benefit 
of surgery over SABR, however, 4 of these studies did not employ statistical adjustments 
for baseline characteristics. In the other 4 studies reporting overall survival superiority of 
surgery when controlling for various co-variates, at least one other recurrence endpoint 
(local, regional, or distant) was found to be equal between surgery and SABR. All but 2 
studies stated in their conclusion that future clinical trials are warranted to investigate 
the role of SABR in the potentially operable ES-NSCLC patient. Conclusion: A systematic 
review of the comparative effectiveness literature indicates that the results of well-
controlled studies comparing surgery and SABR argue for clinical equipoise. Results of a 
pooled analysis of two international RCTs that closed prematurely are expected shortly. 
Keywords: early stage lung cancer, stereotactic radiation, Surgery, comparative 
effectiveness
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MINI18.09 Survival of Elderly Patients after SABR for Early Lung Cancers – A 
Population Based Retrospective Comparison of Survival among Age Cohorts 
Devin Schellenberg1, Maryam Dosani2, Ruobing Yang2, Annie Houle2, Steven Thomas2, 
Chad Lund1, Hannah Carolan2 1Radiation Oncology, BC Cancer Agency, Surrey/BC/
Canada, 2Rad Onc, BC Cancer Agency, Vancouver/Canada
Background: As Stereotactic Ablative Body Radiotherapy (SABR) is increasingly used 
to treat early non-small cell lung cancer, a larger proportion of elderly patients are now 
receiving radical therapy. This review aims to assess whether age significantly influences 
overall survival (OS) in patients with early stage lung cancer treated by SABR according 
to a standard provincial protocol, and to determine if a maximum age guideline should be 
introduced. Methods: Using a population database all lung-SABR patients were divided 
into age categories <70 yo (n=45), 70-74 (n=28). 75-79 (n=39),80-84 (n=33) and 
≥85 (n=22). Patient and tumor characteristics were collected including: sex, Charlson 
comorbidity index (CCI), ECOG performance status, tumor diameter, maximum tumor 
SUV (SUVmax), forced expiratory volume in 1 second (FEV1), and whether a pathologic 
diagnosis was obtained. For each cohort, OS from date of SABR was calculated. Variability 
among tumor characteristics between cohorts was evaluated by Chi-squared test and 
OS was calculated by Kaplan-Meier. Results: 185 patients were treated from 2009 to 
2013. Median age was 76 (range 49-94). The percentage of patients with pathologic 
diagnoses and the percentage of males was similar among age categories. FEV1 values, 
ECOG status, SUVmax values and tumor length were not significantly different among the 
age categories. Older patients had significantly greater CCI scores (see table p=0.001). 
Median OS for all patients was 36 months and was not reduced in the oldest cohorts 
(<70: 34 months, 70-74: 24 months: 75-80: 39 months, 80-84:36 months, ≥85: 36 
months).
Age Categories (years old)
<70 70-74 75-79 80-84 85+
CCI
0-1 5 (%) 0 0 0 0
2-4 59 (%) 39 35 15 10
5-7 34 (%) 54 57 76 60
8 or more 2 (%) 7 8 9 30
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of this study was to examine patient characteristics and radiological factors associated 
with increased risk of radiation pneumonitis in individuals with lung cancer receiving 
curative radiotherapy. Methods: Individuals with lung cancer treated with curative 
radiotherapy between January and June 2009 were identified from our departmental 
database. Data were extracted on patient sex, age and smoking status, lobe affected 
by cancer, pathology, T and N stage, radiation dose delivered, the use of concurrent 
chemotherapy, and the grade of fibrosis present on the diagnostic CT scan. The CT 
scans were reviewed and the fibrosis scored by two pulmonary radiologists. CTCAEv3.0 
toxicity scores were used to grade the pneumonitis. Mann-Whitney, chi-squared and 
Fisher exact tests were used to determine the impact of the various factors on the risk 
of developing pneumonitis. Results: 84 patients were identified who underwent curative 
radiotherapy for lung cancer between January and June 2009. The minimum follow-
up for the cohort was 5 years. One year and 3 year survival were 61.9% and 29.8% 
respectively. 8/84 patients (9.5%) developed significant pneumonitis (CTCAEv3 grade 
3 - 5). 6/22 (27.3%) patients with fibrosis on their diagnostic CT developed grade 3 - 5 
pneumonitis compared with 2/58 (3.4%) of patients with no fibrosis on the diagnostic 
CT (Fisher exact test, p=0.0042). Low grade pneumonitis had no impact on survival 
(grade 0, median survival 80 weeks, grade 1 - 2, median survival 78 weeks) whereas 
median survival was reduced to 16 weeks in those with grade 3 - 5 pneumonitis. 
One out of 8 patients in this group survived one year. Only the presence of fibrosis 
on the diagnostic CT scan and continued tobacco use affected the risk of developing 
pneumonitis with fibrosis increasing the risk of developing pneumonitis (relative risk 7.9, 
p < 0.04) and continued tobacco use reducing the risk (relative risk 0.3, p < 0.02). There 
appeared to be a trend between the fibrosis score on the baseline scan and the risk of 
developing pneumonitis which did not achieve statistical significance. Conclusion: The 
data from this small study suggest radiation pneumonitis affects approximately 1 in 10 
individuals receiving curative radiotherapy for lung cancer. The presence of pulmonary 
fibrosis on the diagnostic CT scan increased the risk of developing pneumonitis. 
Consideration should be given to alternative treatment options for these patients. 
Keywords: Radiation pneumonitis, fibrosis
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MINI19.01 Benefits of Surgical Treatment and Complementary Utility of 
Metabolic Tumor Volume in Selecting Therapy for Stage III NSCLC Lingyun 
Xiong1, Kristen Wroblewski2, Yulei Jiang1, Ravi Salgia3, Heber Macmahon1, Mark 
Ferguson4, Yonglin Pu1 1Radiology, The University of Chicago, Chicago/IL/United States 
of America, 2Public Health Sciences, The University of Chicago, Chicago, Chicago/IL/
United States of America, 3Oncology, University of Chicago, Chicago/IL/United States of 
America, 4Surgery, The University of Chicago, Chicago/IL/United States of America
Background: Stage III NSCLC has large variations in primary and nodal metastatic tumor 
burden and its treatment is controversial.We determined the benefit to overall survival 
(OS) of these patients from surgery, and potentially complementary role of FDG-PET/
CT-based metabolic tumor volume of primary tumor (MTVT), nodal metastasis (MTVN), 
and whole-body (MTVWB) in selecting patients for surgery. Methods: With IRB approval, 
we retrospectively reviewed 239 stage III NSCLC cases with pre-therapy FDG-PET/CT 
scans treated 2004 – 2013 (141 IIIA and 98 IIIB, 115 men and 124 women, median age 
67.2 years), and measured MTVT,MTVN, and MTVWB. Kaplan-Meier curves and log-rank 
test were used for determining survival differences between surgically and non-surgically 
treated patients. Multivariate Cox regression analyses were conducted. Logistic 
regression analysis was used to evaluate whether each covariate was associated with 
receiving surgery(including surgery alone and surgery in combination with chemo or 
radiation). Wilcoxon rank-sum tests were performed for determining differences of 
primary, nodal, and whole-body MTV between the groups. Results: 30% (42/141) of IIIA 
patients and 10% (10/98) of IIIB patients had surgical treatment (p<0.001, Chi-square 
test). OS was different between surgically and non-surgically treated patients (p<0.001) 
at 1 year(86% vs. 54%), 2 years(64% vs. 32%), 3 years(52% vs. 21%), and 5 years(39% 
vs. 14%), with median survival of 37.3 months vs.13.6 months, respectively. Covariates 
associated with OS were: surgery (0.43 ≤ HR ≤ 0.46, p≤0.001), log10MTVT (HR=1.54, 
p<0.001), log10MTVN (HR=1.63, p<0.001), and log10MTVWB (HR=2.06, p<0.001) (Figure 
1). Log10MTVT, Log10MTVN, and Log10MTVWB were inversely associated with receiving 
surgery, with odds ratio of 0.53(p=0.01), 0.55(p=0.036), and 0.38 (p=0.002), 
respectively. MTVT, MTVN, and MTVWB were smaller in surgically treated patients, with 
median of surgically vs. non-surgically treated patients of 17.8 vs. 55.0, 5.3 vs. 15.1, and 
27.8 vs. 92.0 cc, respectively (p≤0.004). Additionally, those with stage IIIB disease were 
significantly less likely to receive surgery after controlling for age, gender, and MTV. No 
statistically significant interactions were found between surgery and stage or between 
surgery and log10MTVT, log10 MTVN, or log10MTVWB.
  
 
Conclusion: Hypo-fractionated stereotactic RT appears to cause a dose-
dependent reduction in regional lung perfusion. There appears to be a threshold 
effect with no apparent perfusion loss at doses <10 Gy, in both normalized and 
unnormalized dose-response curves. Additional data is needed from a larger 
number of patients to better assess this issue. This sort of data can be used 
to assist optimizing RT treatment plans that minimize the risk of lung injury. 
Keywords: functional imaging, stereotactic body radiotherapy, dose response
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MINI18.13 Can Stereotactic Ablative Radiotherapy (SABR) Improve Patient 
Selection for Lung Cancer Surgery and Reduce Perioperative Mortality? 
Nicholas Serrano1, Bret Adams2, Szabolcs Szentpetery3, C. Leland Rogers4, Michael 
Chang4, Drew Moghanaki4 1Radiation Oncology, Virginia Commonwealth University, 
Richmond/VA/United States of America, 2Radiation Oncology, University of Miami, Miami/
FL/United States of America, 3Thoracic Surgery, Hunter Holmes Mcguire Veterans Affairs 
Medical Center, Richmond/VA/United States of America, 4Radiation Oncology, Hunter 
Holmes Mcguire Veterans Affairs Medical Center, Richmond/VA/United States of America
Background: Comparative effectiveness research has demonstrated similar rates of 
disease control and overall survival (OS) for patients with stage I non-small cell lung 
carcinoma (NSCLC) who are treated with either surgery or SABR. It was therefore 
hypothesized that the introduction of SABR might improve patient selection for surgery, 
lead to the referral of high operable risk patients for SABR, and consequently reduce 
the lung cancer surgery perioperative mortality rate. Methods: Cancer registry data 
identified all patients with stage I NSCLC who underwent surgery or SABR between 
1993-2014 at a Veterans Affairs medical center. Mortality rates from the pre-SABR 
and post-SABR (after 2007) eras were compared. Clinical records in the Computerized 
Patient Record System were queried to analyze rates of disease control and overall 
survival (OS). Results: A total of 284 patients underwent surgery for stage I NSCLC 
in the pre-SABR (n=171) and post-SABR (n=113) eras. The majority of patients were 
male (96.6%) and the median follow-up was 4.1 years. Operative procedures included 
a pneumonectomy (n=10), lobectomy (n=206), or wedge resection (n=68). The 90-
day mortality rate was 3.2%, whereas the 6-month mortality rate was 7.0%. Comparing 
mortality rates in the pre-SABR to post-SABR eras, there were no declines at 90-days 
(3.5% vs. 2.7%, p=0.47), or 6-months (7.0% vs. 7.1%, p=0.36). Patients referred for 
SABR have included 27 medically inoperable patients and 0 operable patients. The 
mortality rate after SABR was 0% at both 90-days and 6 months. Comparing SABR and 
surgery, the rate of disease progression was similar (p=0.47); found in 18.5% after SABR 
(1 distant, 4 regional), 23.4% after lobectomy (9 regional, 2 regional and distant, 11 
distant), 33.3% after wedge (3 local, 3 distant), and 0% after pneumonectomy. Two-
year OS was numerically superior with SABR (69.4% vs. 63.1%), although this was 
not statistically significant (p=0.52). Conclusion: The introduction of SABR neither 
influenced patient selection for surgery, nor reduced the perioperative mortality 
rate for patients with stage I NSCLC. These data suggest comparative effectiveness 
research alone may be insufficient to improve outcomes for this disease. Efforts to 
complete a prospective randomized trial of surgery vs. SABR should not be abandoned. 
Keywords: SABR, NSCLC, stereotactic
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MINI18.14 Pre-Existing Pulmonary Fibrosis Increases the Risk of Radiation 
Pneumonitis Sorcha Campbell1, Gill Kerr1, John Murchison2, Gillian Ritchie2, Sara 
Erridge1, Tamasin Evans1, Felicity Little1, Melanie Mckean1, Allan Price1 
1Edinburgh Cancer Centre, Western General Hospital, Edinburgh/United Kingdom, 2Radiology, 
Royal Infirmary, Edinburgh/United Kingdom
Background: Radiation pneumonitis is a potentially life-threatening complication of 
curative radiotherapy in individuals with lung cancer. Predicting which patients are at 
higher risk of pneumonitis is constrained by limited understanding of its causes. The aim 
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MINI19.03 Subcarinal Lymph Node Dissection Is Also Necessary in Upper 
Lobectomies for Lung Cancer Jens Eckardt, Erik Jakobsen, Peter B. Licht 
Cardiothoracic Surgery, Odense University Hospital, Odense/Denmark
Background: Mediastinal lymph node evaluation in Non Small-Cell Lung Cancers 
(NSCLC) is of paramount importance for optimum planning of treatment. Recently, 
it was claimed that subcarinal lymph node dissection could be spared in upper lobe 
NSCLC resections because of the low incidence of metastatic disease. These data, 
however, were single institution reports. We used complete national data to investigate 
patterns of unsuspected mediastinal lymph node involvement in patients operated for 
NSCLC. Methods: A national registry was used to identify every single patient operated 
for NSCLC during an 11-year period (2003-2013). Unsuspected mediastinal lymph node 
involvement was investigated by comparison of clinical and final pathological nodal 
stage, and patients with clinical mediastinal lymph node metastases were excluded. For 
every patient we extracted information about tumor location, histopathology, clinical 
and pathological TNM-stage. All preoperative imaging and staging investigations were 
recorded. Results: An unsuspected mediastinal lymph node metastasis was found 
in 426 patients (9.8%) of 3953 patients and 167 (4.4%) had unsuspected subcarinal 
metastases, which were significantly more frequent in patients with lower lobe or middle 
lobe cancers compared with upper lobe cancers 7 % (101/1440) versus 1.8% (42/2258), 
(p<0.01). Preoperative invasive mediastinal staging was used in 57% (n=2253) of all 
patients and significantly more frequent in upper lobe cancers (62% (n=1400), p<0.01), 
in patients who had unsuspected mediastinal lymph node metastasis (75% (n=320), p< 
0.01) and in patients with subcarinal metastases (74% (n=124), p< 0.01).
Location of the 
tumor All patients
Patients with N2 
disease
Metastasis in station 
7
RUL 1254 121 28 (2.2 %)
LUL 1004 116 14 (1.4 %)
RLL 672 78 52 (7.7 %)
LLL 585 62 36 (6.2 %)
Middle lobe 183 16 13 (7.1 %)
Bilobectomy 255 33 24 (9.4 %)
Total 3953 426 167
 
Conclusion: A substantial number of patients undergoing surgery for NSCLC have 
unsuspected subcarinal mediastinal lymph node involvement despite 74% had preoperative 
invasive mediastinal staging. Unsuspected subcarinal metastases were most common in 
lower and middle lobe cancers but were also frequent in upper lobe NSCLC. Subcarinal 
lymph node dissection should therefore be a routine part of surgery for NSCLC - 
regardless of tumor location to avoid undiagnosed subcarinal lymph node metastasis. 
Keywords: lymph node metastases, mediastinal lymph node dissection, NSCLC, 
Thoracic Surgery
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MINI19.04 Relationship Between Adequacy of Intra-Operative Lymph Node 
Sampling During Surgical Resection of NSCLC and Survival Matthew Evison, 
Stuart Britton, Haider Al-Najjar, Rajesh Shah, Philip Crosbie, Richard Booton 
Manchester Thoracic Oncology Centre, University Hospital of South Manchester, 
Manchester/United Kingdom
Background: Intra-operative lymph node sampling during lung cancer resection is a key 
surgical performance measure. It informs prognosis, treatment selection for adjuvant 
chemotherapy and surveillance programs following treatment. This study aimed to 
analyse the relationship between adequacy of intra-operative lymph node sampling 
and survival at a large thoracic oncology centre in the United Kingdom. Methods: A 
retrospective review of pathological reports for all patients undergoing lung cancer 
resections at the University Hospital South Manchester from 01/01/2011 to 31/12/2013 
was undertaken. Intra-operative lymph node sampling was assessed for adequacy against 
standards set out by the IASLC Staging Manual in Thoracic Oncology. Survival data was 
obtained through national death registry data and provided a minimum of twelve months 
follow-up for all patients at the time of analysis in January 2015. Results: A total of 
987 patients underwent surgical resection for NSCLC in the study period. Overall, there 
was no significant difference in survival between patients with adequate intra-operative 
lymph nodal sampling and those with inadequate sampling (log rank p=0.66). Median 
survival times were not estimable for pN0 and pN1 patients as only a small proportion 
died. However there was a significant difference in the median survival time of pN2 
patients according to whether the intra-operative lymph node sampling was adequate 
or inadequate (Figure 1). 
Conclusion: Surgery and smaller MTV are associated with better OS of stage-III NSCLC 
patients. Smaller MTV and stage IIIA (vs. IIIB) are associated with receiving surgery. FDG 
PET/CT-based metabolic tumor volume can potentially inform surgical treatment 
decisions to further improve survival outcome. 
Keywords: Metabolic tumor volume, non-small cell lung cancer, FDG PET/CT, survival 
analysis
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MINI19.02 Mediastinal Nodal Involvement in Patients with Clinical Stage I 
Non–Small-Cell Lung Cancer -Possibility of Rational Lymph Node Dissection- 
Tomohiro Haruki1, Keiju Aokage2, Tomohiro Miyoshi2, Tomoyuki Hishida2, Genichio Ishii3, 
Junji Yoshida2, Masahiro Tsuboi2, Hiroshige Nakamura1, Kanji Nagai2 1Department of 
Surgery, Division of General Thoracic Surgery, Tottori University, Faculty of Medicine, Tottori/
Japan, 2Division of Thoracic Surgery, Department of Thoracic Oncology, National Cancer 
Center Hospital East, Kashiwa/Japan, 3Pathology, Resarch Center of Innovative Oncology, 
National Cancer Center Hospital East, Kashiwa, Chiba/Japan
Background: Recent developments of radiological examinations have been able to 
bring more accurate information about the biological malignancy of primary tumors in 
non-small cell lung cancer (NSCLC). The aim of this study is to elucidate the optimal 
candidate of lobe-specific selective lymph node dissection (LND) that reduces the extent 
of mediastinal LND according to clinical information including radiological evaluation 
of primary tumor on thin-section computed tomography (TSCT) and tumor location in 
clinical(c) -stage I NSCLC patients. Methods: Eight hundred and seventy-six patients 
with c-stage I NSCLC (adenocarcinoma and squamous cell carcinoma), who underwent 
complete surgical resection between January 2003 and December 2009 were included 
in this study. For all tumors, we obtained the maximum dimension of the tumor (tumor) 
and solid component (consolidation) using a lung window level setting from the TSCT 
scan images, and estimated the consolidation-to-tumor ratio (C/T ratio) for each tumor. 
We elucidated the lymph node metastatic incidence and distribution according to the 
primary tumor lobe location and extracted the associated clinicopathological factors 
with mediastinal lymph node involvement. Results: The patients included 490 men 
and 386 women, with a median age of 66 years old. The radiological findings were 
ground glass opacity (GGO)-predominant (C/T ratio ≤ 0.5) in 134 patients and solid-
predominant (C/T ratio > 0.5) in 742 patients. There were 744 adenocarcinoma cases 
and 132 squamous cell carcinoma cases, and the incidences of mediastinal lymph 
node metastasis were 9.9% in adenocarcinoma cases and 4.5% in squamous cell 
carcinoma cases, respectively. There were no cases with hilar and mediastinal lymph 
node metastasis in GGO-predominant tumors. There was no significant association 
of clinical factors with subcarinal lymph node metastasis in right upper-lobe and left 
upper-division lung adenocarcinoma. In 257 bilateral lower-lobe lung adenocarcinomas, 
a total of 32 cases (12.5%) were positive for mediastinal lymph node metastasis, 
and seven cases (2.7%) were negative for subcarinal lymph node metastasis but 
positive for upper mediastinal lymph node metastasis (mediastinal skip metastasis). 
An elevated preoperative serum carcinoembryonic antigen (CEA) level (p < 0.001) 
showed only a significant association with upper mediastinal lymph node metastasis 
in the patients with bilateral lower-lobe primary lung adenocarcinoma. Conclusion: It 
would be acceptable to perform selective LND in patients with c-stage I NSCLC 
with GGO-predominant tumor. Elevated serum CEA was associated with upper 
mediastinal lymph node involvement in lower-lobe primary lung adenocarcinoma with 
radiologically solid-predominant tumor. We should be careful when applying selective 
LND to patients with solid-predominant tumor, especially located in the lower lobe. 
Keywords: consolidation tumor ratio, Mediastinal lymph node metastasis, lobe-specific 
lymph node dissection, lung cancer
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and R 3.1.2 respectively. Results: From April 2007 to February 2015 a total of 1442 
patients underwent surgery for primary lung cancer at our institution. We excluded 118 
patients with carcinoid tumours (not in the original Chinese development set) and 86 
patients without complete lymph node assessment leaving 1238 patients for validation. 
For all patients from stage IA to IIB the mean (SD) score was 9.95 (4.2). The ROC score 
comparing patients who died versus those that remained alive was 0.62 (95% CI 0.58 
to 0.67). This was lower than the 0.71 reported by the Chinese group when split into 1,3 
and 5 year survival. When divided into prognostic score tertiles, survival discrimination 
remained evident for the entire cohort, as well as those for stage IA and IB alone. The P 
value comparing survival between the middle and highest score with baseline (low score) 
was P=0.031 and P=0.034 respectively. Figure 1. Survival discrimination within Stage I
  
Conclusion: Our results of external validation suggested lower 
survival discrimination than reported by the original group, however 
discrimination between survival remained evident for stage I. 
Keywords: non small cell lung cancer, External Validation, Nomogram, Stage I Survival
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MINI19.07 ICG Fluorescence Localization of Small Sized Pulmonary Nodules 
for VATS Takashi Anayama1, Kentaro Hirohashi1, Ryohei Miyazaki1, Hironobu Okada1, 
Motohiko Kume1, Nobutaka Kawamoto1, Takayuki Sato2, Kazumasa Orihashi1 1Thoracic 
Surgery, Kochi Medical School, Kochi University, Kochi/Japan, 2Department of Cardio-
Vascular Control, Kochi Medical School, Kochi University, Kochi/Japan
Background: Video-assisted thoracoscopic wedge resection of multiple small, 
non-visible, and nonpalpable pulmonary nodules is a clinical challenge. We propose 
an indocyanine green (ICG) injection and intraoperative fluorescence detection 
with a near-infrared (NIR) fluorescence for localization of small sized pulmonary 
nodules. Methods:Fluorescence properties of ICG topically injected into the lung 
parenchyma were determined using a resected porcine lung and previously reported 
by the authors. In clinical study, 15 cases of VATS pulmonary resection for small 
sized pulmonary nodules were enrolled in the study. The ICG mixed with iopamidol 
was injected into the pulmonary nodules by CT-guided percutaneous injection. ICG 
fluorescence was visualized by a near-infrared (NIR) thoracoscope, then the target 
nodule was excised by VATS procedure. Results: Topically injected ICG / iopamidol 
mixture spot remained at the injected point of the lung parenchyma for more than 
6 hours in each case, and each ICG fluorescence was identified at the pulmonary 
nodule with the NIR thoracoscope. Each target nodule was successfully removed with 
negative surgical margin. Conclusion: CT guided ICG injection and intraoperative NIR 
thoracoscopic detection is a feasible method to localize small sized pulmonary nodules. 
Keywords: minimally invasive thoracic surgery, localization of small-sized pulmonary 
nodule, infra-red fluorescence
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MINI19.08 Validation of a Surgical Predictive Score for 90 Day Mortality 
in Lung Cancer and Comparison with Thoracoscore Emma L. O’Dowd1, Tricia 
Mckeever1, David R. Baldwin2, Helen A. Powell1, Richard B. Hubbard1 1Epidemiology and 
Public Health, University of Nottingham, Nottingham/United Kingdom, 2Respiratory Medicine, 
Nottingham University Hospitals, Nottingham/United Kingdom
Background: Current British Thoracic Society (BTS) guidelines advocate the use of a 
global risk prediction score such as Thoracoscore to estimate the risk of death prior 
to radical surgical management in those with non-small cell lung cancer (NSCLC). A 
Conclusion: Few patients have died in the pN0 and pN1 categories limiting interpretation. 
As the data matures we expect to see a survival difference according to adequacy of 
intra-operative nodal sampling that is supported by the differential median survival data 
of pN2 patients according to nodal adequacy. The data supports that the survival 
difference is due to inaccurate staging, inadequate resection (R1) and inappropriate 
omission of adjuvant. Keywords: NSCLC surgery, NSCLC nodal staging, NSCLC survival
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MINI19.06 External Validation of a Chinese Developed Survival Score in a 
Western Cohort Undergoing Surgery for Non-Small Cell Lung Cancer  
Ulas Kumbasar, Hilgardt Raubenheimer, May Al Sahaf, Nizar Asadi, Maria Elena Cufari, 
Chiara Proli, Periklis Perikleous, Leire Azcarate, Zakiyah Niwaz, Emma Beddow, Vladimir 
Anikin, Niall Mcgonigle, Simon Jordan, George Ladas, Michael Dusmet, Eric Lim 
Department of Thoracic Surgery, Royal Brompton and Harefield NHS Trust, London/United 
Kingdom
Background: Currently adjuvant chemotherapy is not recommended for patients with 
completely resected stage I lung cancer. The ability to sub-stratify survival within stage I 
is an important consideration as it is assumed that survival is heterogeneous within this 
sub-group. Liang et al recently published a Chinese multi-institutional logistic regression 
derived model to predict post-operative survival in over 5000 patients undergoing lung 
cancer surgery for all stages. The aim of our study is external validation of their published 
nomogram in a British cohort focusing on stages IA and IB to determine applicability 
in selection of adjuvant chemotherapy within stage I. Methods: We retrospectively 
analysed data from a prospectively collected database from our institutions. Patient 
variables were extracted and the score individually calculated. Receiver operative 
characteristics curve (ROC) was calculated and compared with the original derivation 
cohort and the discriminatory ability was further quantified using survival plots by 
splitting our (external) validation cohort into three tertiles and Kaplan Meier plots were 
constructed and individual curves tested using Cox regression analysis on Stata 13 
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Results: In our initial experience with 10 cases, CBCT acquisition, reconstruction and 
3D-overlay was successful in all cases. This procedure enabled confirmation of biopsy 
tool position within the target lesion in all cases. In one case, the new information 
obtained successfully discriminated a diaphragm implant from what previously had been 
interpreted as a basilar parenchymal nodule. In a second case, CBCT reconstruction 
enabled biopsy of a 15mm lesion thought to be a solitary metastasis. The biopsy 
was interpreted as normal, albeit in clinical circumstances which were suspicious for 
malignancy. The patient elected non-surgical treatment of an esophageal primary, 
precluding definitive pathologic confirmation. A third case provided a biopsy interpreted 
as normal in a patient who ultimately proceeded to resection for growth of the nodule. 
While frozen section suggested a benign entity, final pathology demonstrated scattered 
elements of malignancy. In the remaining cases, CBCT and 3D overlay assisted in 
successful and accurate biopsy of nodules <20mm. Conclusion: Intraoperative 
CBCT and real time 3D overlay onto fluoroscopic images to confirm appropriate 
positioning of the biopsy tools in the lesion during ENB is technically feasible. It 
effectively combines the advantage of real time CT imaging with the advantages of 
ENB biopsy. This has the potential to increase the diagnostic accuracy of ENB aided 
tissue diagnosis of small pulmonary nodules. This novel technique will facilitate early 
accurate diagnosis of lung cancer in small nodules with a minimally invasive approach. 
Keywords: Cone beam CT, Elctromagnetic Navigational Bronchoscopy, Small Pulmonary 
Nodule
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MINI19.11 Use of Electromagnetic Navigational Bronchoscopy to Localize 
Pulmonary Nodules Prior to Minimally Invasive Sublobar Resection 
Sandeep Sachidananda1, Jonathan E. Hasson2, Gregoire Avignon3, Cristobal G. 
Alvarado4 1Department of Surgery, Waterbury Hospital, Waterbury/United States of 
America, 2Department of Vascular & Endovascular Surgery, Hartford Healthcare Medical 
Group, Meriden/CT/United States of America, 3Interventional Radiology, GE Health Care, 
Buc/France, 4Department of Thoracic Surgery, Hartford Healthcare Medical Group, Meriden/
CT/United States of America
Background: Sublobar resection of small pulmonary nodules by minimally invasive 
techniques can be a challenge, as this approach reduces the haptic feedback often 
required to reliably localize small lesions. Use of Electromagnetic Navigational 
Bronchoscopy (ENB) is a relatively new technique that has potential to assist in real time 
operative localization of such lesions, as ENB can deliver visual cues for their location 
in the form of either a dye marking or a radio-opaque clip, or both. There is limited data 
available on the feasibility of this approach. We want to describe our experience with this 
technique. Methods: A retrospective review of cases in which ENB was used to localize 
small pulmonary nodules was done from August 1, 2013 to February 1, 2015. We start by 
using ENB to navigate to the target lesion. In our initial experience, methylene blue was 
injected into the parenchyma around the mass, and dye migration to the pleural edge was 
used as a visual cue for location. We then amended our protocol to include placement of 
both methylene blue dye and a radio-opaque clip in the parenchyma immediately adjacent 
to the target lesion. Fluoroscopy was then used to triangulate the location of the clip, 
and by extension the mass, via markings on the chest wall with the lung deflated prior to 
incision. The visual cue of the dye marking as well as the fluoroscopic localization of the 
clip served to confirm each other. This was followed by minimally invasive resection of 
the lesion using these cues to assist in port placement. 
recent publication by Powell et al(1) used the National Lung Cancer Audit (NLCA) linked to 
Hospital Episode Statistics (HES) to produce a score to predict 90 day mortality. The aim 
of this study is to validate this score, henceforth called the NLCA score, and compare its 
performance with Thoracoscore. Methods: We identified data on all patients in the NLCA 
who received curative surgery for NSCLC between 2010 and 2012. We calculated the 
proportion that died in hospital and within 90 days of surgery. Each person was given a 
score based on the coefficients and constants in the NLCA score and Thoracoscore. The 
discriminatory power of both scores was assessed by a receiver operating characteristic 
(ROC) and an area under the curve (AUC) calculation. Results: We identified 2858 patients 
for whom we had complete data to form our validation cohort. The 90 day mortality 
was 5%. We generated ROC curves to assess the discrimination of the NLCA score in 
predicting 90 day mortality and to test the ability of Thoracoscore to predict in-hospital 
mortality. Area under the ROC curve was 0.68 and 0.60 respectively. We performed 
a post hoc analysis using data from the NLCA on all 15554 patients who underwent 
curative surgery for NSCLC between 2004 and 2012 to derive summary tables for 
90 day mortality, stratified by procedure type, age and performance status (table 1). 
Conclusion: These results suggest that although the NLCA score performs slightly 
better than Thoracoscore neither performs well enough to be advocated for routine 
use to risk stratify patients prior to lung cancer surgery. It may be that the addition of 
physiological parameters to demographic and procedural data or use of physiological 
measurements alone would better predict mortality; however this would form the basis of 
a further project. In the interim we advocate the use of our summary tables that serve to 
provide clinicians and patients the real-life range of mortality according to performance 
status and age for both lobectomy and pneumonectomy. 1. Powell HA, Tata LJ, Baldwin 
DR, Stanley RA, Khakwani A, Hubbard RB. Early mortality after surgical resection for lung 
cancer: an analysis of the English National Lung cancer audit. Thorax. 2013;68(9):826-
34.
  
Keywords: surgical mortality, non-small cell lung cancer, surgical risk prediction
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MINI19.09 Adjunct Intraop Cone Bean CT (CBCT) with Real Time 3D Overlay 
Improves Diagnostic Accuracy of Electromagnetic Navigational Bronchoscopy 
(ENB) Sandeep Sachidananda1, Jonathan E. Hasson2, Gregoire Avignon3, Cristobal 
G. Alvarado4 1Department of Surgery, Waterbury Hospital, Waterbury/United States of 
America, 2Department of Vascular & Endovascular Surgery, Hartford Healthcare Medical 
Group, Meriden/CT/United States of America, 3Interventional Radiology, GE Health Care, 
Buc/France, 4Department of Thoracic Surgery, Hartford Healthcare Medical Group, Meriden/
CT/United States of America
Background: ENB is limited by diagnostic accuracy of 60-80% [1]. We hypothesize 
that using intraoperative CBCT with real time 3D overlay onto fluoroscopic images to 
confirm placement of biopsy tools in the lesion will increase the diagnostic accuracy 
of ENB biopsies. 1 Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-Analysis of Guided 
Bronchoscopy for the Evaluation of the Pulmonary Nodule. Chest. 2012;142(2):385-
393. doi:10.1378/chest.11-1764 Methods: Patients with undiagnosed small pulmonary 
nodules (<20 mm) underwent biopsy where an initial CBCT of the chest under breath 
hold was performed, followed by a 3D model reconstruction of the lesions while the 
surgeon started the ENB. At the end of the bronchoscope navigation, the 3D model of 
the lesion was fused and automatically registered in real time over the 2D fluoroscopy, 
allowing an evaluation of the biopsy tool positioning in 3-dimensions. Multiple samples 
were collected after confirmation of the tool position using various oblique views.
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with mediastinal lymph node dissection at our institution from 2013 to 2015. CT or PET 
scan was used to determine clinical stage. The DiPasquale Quality Index (DQI) defines a 
complete lymph node dissection (LND) as sampling LN 4R, 7, and 9 for right-sided tumors. 
Our institutional policy for the initial two years of our RATS program was to limit such to 
right-sided tumors. Results: Robotic anatomic lung resection was performed in 70 patients 
with right-sided clinical stage I NSCLC. The majority were of the upper lobe (41; 58.6%). The 
most frequent lymph node stations sampled robotically were LN 4R, 7, 9, 10, and 11 (60.6%, 
90.1%, 66.2%, 49.3%, and 64.8%, respectively). According to the DQI, 31 (44.3%) tumors 
underwent complete LND. Pathologic nodal upstaging occurred in 5 patients (7.1% [pN1 4, 
5.7%; pN2 1, 1.4%]). Hilar (pN1) upstaging occurred in 2.8%, 0%, and 20.0%, respectively, 
for cT1a, cT1b, and cT2a tumors. Comparatively, historic hilar upstage rates of video-assisted 
thoracoscopic surgery (VATS) versus thoracotomy versus recent robotic data for cT1a, cT1b, 
and cT2a were 5.2%, 7.1%, and 5.7%, versus 7.4%, 8.8%, and 11.5%, versus 3.5%, 8.6%, 
and 10.8%, respectively. The 1-year overall survival was 97% and the disease-free survival 
was 98% at 1 year. Conclusion: When patients are appropriately selected and proper 
lymph node sampling is performed, the rate of upstaging with RATS is comparable to VATS 
and lower than thoracotomy. The rate of hilar upstaging with robotic resection, however, 
increases with increasing clinical T stage and appears superior to both VATS and thoracotomy 
for cT2a tumors. This also has implications for patients who may be considered for therapies 
like stereotactic radiation therapy. Larger studies comparing matched open, VATS, and 
robotic approaches are necessary to quantify long term survival and local failure rates. 
Keywords: robotic-assisted thoracic surgery, nodal staging, Lymph node dissection, non-
small cell lung cancer
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MINI19.14 Survival After Sub-Lobar Resection for Early Stage Lung Cancer: 
Methodological Obstacles in Comparing the Efficacy to Lobectomy Emanuela 
Taioli1, Rowena Yip2, Ingram Olkin3, Andrea Wolf4, Daniel Nicastri4, ClaudiaI. Henschke2, 
Harvey I. Pass5, Raja Flores4 1Department of Population Health, Hofstra-North Shore LIJ 
School of Medicine, Great Neck/NY/United States of America, 2Radiology, Icahn School of 
Medicine at Mount Sinai, New York/United States of America, 3Stanford University, Stanford/
United States of America, 4Thoracic Surgery, Icahn School of Medicine at Mount Sinai, 
New York/United States of America, 5Department of Cardiothoracic Surgery, NYU Langone 
Medical Center, New York/NY/United States of America
Background: Surgery is the treatment of choice for early stage lung cancer (LC). While 
lobectomy (L) is the historic standard, whether long term outcomes of sub-lobar resection 
(SL) are comparable is still under debate. The only randomized trial was conducted 20 
years ago; 5 subsequent meta-analyses showed inconclusive or conflicting results. We 
present a comprehensive review of the literature on 5 year-survival after SL compared to 
L for early stage LC. Methods: A priori inclusion criteria were: 1) observational studies, 2) 
L compared to SL for early stage LC, 3) at least CT staging, 4) 5-year survival reported. 
A Medline search through January 2015 resulted in 32 studies, representing 24 distinct 
datasets. The absolute difference in 5-year survival was calculated and plotted for each 
study. Results: There were 4,702 cases treated with L, 2,323 treated with SL. Of 20 
studies reporting the reason for SL, 11 indicated that SL was performed because of 
comorbidities, or impaired cardiopulmonary function. Among all 24 studies, 4 showed 
no difference in 5-year survival, 13 favored L, and 7 favored SL (Figure 1). Of the two 
studies using propensity scores, one favored L and the other SL. No meta-estimate could 
be calculated due to high statistical heterogeneity. Of 21 studies reporting recurrence 
rate (Figure 2), 11 favored L and 10 favored SL.
Results: A total of 28 cases were identified. ENB was successful in navigating to the 
lesion in all cases. ENB dye localization alone was successful in 5 of 6 cases. After the 
first unsuccessful dye localization, our amended protocol of dye marking and clip 
placement led to successful localization in 22 consecutive cases. Conclusion: Use of 
electromagnetic navigational bronchoscopy to localize small pulmonary nodules is a 
feasible approach and is technically straightforward. As we see broader implementation 
of lung cancer screening protocols, thoracic surgeons can expect to encounter many 
more small pulmonary nodules requiring resection. There is accumulating data that 
sublobar resection is equivalent to lobar resection for small, peripherally located lung 
cancer. Use of the algorithm – ‘Navigate, Triangulate and Resect’ will enable thoracic 
surgeons to more successfully perform sublobar resections of small pulmonary nodules 
by minimally invasive techniques.
 Keywords: Electromagnetic Navigational Bronchoscopy, peripheral lung cancer, Small 
Pulmonary Nodule
SURGICAL TOPICS IN LOCALIZED NSCLC 
TUESDAY, SEPTEMBER 8, 2015 - 16:45-18:15
MINI19.12 The Value of Video-Assisted Mediastinoscopic Lymphadenectomy 
in Clinical Stage I Non-Small Cell Lung Cancers Akif Turna1, Hasan V. Kara1, Kamil 
Kaynak2 1Department of Thoracic Surgery, Istanbul University, Cerrahpasa Medical Faculty, 
Istanbul/Turkey, 2Department of Medical Oncology, Istanbul University Cerrahpasa Medical 
School, Istanbul/Turkey
Background: The rate of mediastinal lymph node metastasis is controversial for patients 
with clinical N0 non-small cell lung cancer. The primary advantage of video-assisted 
mediastinoscopic lymphadenectomy(VAMLA) over conventional mediastinoscopy 
or videomediastinoscopy is to reduce the false-negative rate. We aimed to analyze 
to evaluate the value of routine VAMLA for patients with clinical T1a-T2aN0 patients 
prospectively. Methods: From March 2010-January 2015, 41 patients with non-small cell 
lung cancer with clinical stage T1-T2aN0 by postireon emission tomography/computed 
tomography underwent routine VAMLA before planned resectional surgery. Routinely, 
stations #2L, 2R, #4R, #4L, 7 were nearly completely resected. In some patients, #10R 
and #8 lymph nodes were biopsied. The prevalence of mediastinal lymph node metastases 
at VAMLA and lung resection was recorded. Results: There were 5 females (12.2%) and 
36 (87.8%) males. The mean age was 62.5 . years. A total of 5 patients were had cT1a-
bN0, whereas 36 patients had T2aN0. Eleven patients (26.8%) had occult mediastinal 
lymph node metastasis. A total of 26 patients underwent lung resectional surgery; only 
one patient (3.8%) were upstaged to pN2, whereas 3 patients (11.5%) were upstaged to 
pN1. Conclusion: VAMLA seems to disclose considerable number of mediastinal lymph 
node metastasis in these patients with T1 and T2 clinically staged N0 by positron emission 
tomography/computed tomography. Routine use of VAMLA is recommended with 
limited use of mediastinal lymph node evaluation in patients during resectional surgery. 
Keywords: mediastinoscopy, lung cancer, staging, N2
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MINI19.13 Nodal Staging via Robotic-Assisted Thoracic Surgery for Clinical 
Stage I Non-Small Cell Lung Cancer Vanessa M. Dipasquale1, Ryan T. Hughes1, 
StefanC. Grant2, Brian E. Lally3, William J. Petty2, Alfred Proto4, Leonard J. Wudel4 
1Wake Forest School of Medicine, Winston-Salem/NC/United States of America, 2Medical 
Oncology, Wake Forest Baptist Medical Center, Winston-Salem/NC/United States of 
America, 3Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem/NC/
United States of America, 4Cardiothoracic Surgery, Wake Forest Baptist Medical Center, 
Winston-Salem/NC/United States of America
Background: One measure of the quality of thoracic surgery for non-small cell lung cancer 
(NSCLC) is the adequacy of nodal evaluation; the rate of pathological nodal upstaging can 
introduce bias in patient selection for surgical therapy. Robotic-assisted thoracic surgery 
(RATS) offers the ability to sample nodal stations not easily assessed with conventional 
open surgical methods. We sought to determine the rate of nodal upstaging as a function 
of the frequency of various lymph node stations sampled in clinical stage I NSCLC patients 
undergoing RATS. Methods: We retrospectively reviewed the charts of patients with 
right-sided clinical stage I NSCLC who underwent robotic-assisted pulmonary resection 
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41.9 [High], p<.001), have adenocarcinoma (62.4%[Low] vs. 58.1%[High], p<.001), stage 
IA disease (41.6%[Low] vs. 39.6%[High], p<.001) and receive sub-lobectomy (11.7%[Low] 
vs. 9.9%[High], p<.001). Low-outlier facilities were more likely to be teaching/research or 
NCI-designated programs (54.8% [Low] vs. 18.5% [High], p<.001) and in the highest quartile 
of total cancer surgical volume (90.4% [Low] vs. 34.5% [High], p<.001) and lung cancer 
surgery volume (42.5% [Low] vs. 29.2% [High], p<.001) (Table 1). They also had smaller 
proportions of uninsured/Medicaid patients (45.2% [Low] vs. 36.2% [High], p=.006). The 
5-year unadjusted OS estimates were: 0.62 (low-outliers), 0.58 (non-outliers), 0.57 (high-









Northeast 18(15.9) 154(20.4) 19(26.0) 0.03
Midwest 39(34.5) 223(29.5) 15(20.6)
South 37(32.7) 257(34.0) 35(48.0)
West 19(16.8) 121(16.0) 4(5.5)
Facility_type
Community_Cancer_





Teaching/Research 17(15.0) 128(17.0) 28(38.4)
NCI_program 4(3.5) 17(2.3) 12(16.4)
Other 7(6.2) 27(3.6) 5(6.9)
Proportion_of_Medic-
aid/uninsure_patients
Q1(low) 25(22.1) 206(27.3) 13(17.8) 0.006
Q2 16(14.2) 204(27.0) 20(27.4)
Q3 41(36.3) 174(23.1) 21(28.8)




Q1(low) 8(7.1) 73(9.7) 0(0.0) <0.001
Q2 37(32.7) 224(29.7) 9(12.3)
Q3 35(31.0) 226(29.9) 33(45.2)
Q4(high) 33(29.2) 232(30.7) 31(42.5)
Total_cancer_sur-
gery_volume
Q1(low) 12(10.6) 98(13.0) 0(0.0) <0.001
Q2 32(28.3) 193(25.6) 0(0.0)
Q3 30(26.6) 253(33.5) 7(9.6)
Q4(high) 39(34.5) 211(28.0) 66(90.4)
 
Conclusion: Facility performance in lung cancer surgery can be captured by using the RAMP 
rate. Low-outlier facilities delivered superior OS than high-outliers. RAMP metrics could allow 
facilities to understand their performance and serve as a quality improvement benchmark. 
Keywords: NSCLC, NCDB, Quality Metric, Margin
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MINI20.03 The Survival Impact of Missed Lymph Node Metastasis in Surgically 
Resected Non-Small Cell Lung Cancer (NSCLC) Nicholas Faris1, Matthew P. 
Smeltzer2, Courtney Adair3, Allen Berry4, Xinhua Yu2, Laura Mchugh1, Raymond U. 
Osarogiagbon1 1Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology 
Program, Baptist Cancer Center, Memphis/TN/United States of America, 2Epidemiology and 
Biostatistics, University of Memphis School of Public Health, Memphis/TN/United States of 
America, 3Duckworth Pathology Group, Memphis/TN/United States of America, 4St. Francis 
Hospital Pathology, Memphis/TN/United States of America
Background: Lymph node (LN) metastasis is an important prognostic factor for patients 
with surgically resected NSCLC. We have previously described the extent of missed N1 
LN metastasis in a cohort of patients treated at metropolitan institutions. With long-term 
Conclusion: Studies comparing 5-year survival rates of SL to L are heterogeneous, and 
traditional meta-analytic summary estimates of survival and recurrence could not be 
calculated. SL survival is often similar to L survival, despite the fact that SL is performed 
in patients with comorbidities or impaired cardiopulmonary function. New approaches to 
comparing L to SL survival are needed.
Keywords: meta-analysis, epidemiology, Surgery
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MINI20.01 Do Secondary Lung Cancers Have the Same Disease-Specific 
Survival and Overall Survival as Primary Lung Cancers? Cameron Stock1, John 
M. Varlotto1, Suhail Ali2, John Flickinger3, Malcolm Decamp4, Deborah Maddox1, Karl 
Uy1, Jonathan Glanzman1, James Liebmann1, Syed Quadri1, Fei Gu1, Geoffrey Graeber1, 
Vijay Kasturi1, William Walsh1, Aaron Yao5 1University of Massachusetts, Worcester/MA/
United States of America, 2Penn State Hershey Medical Center, Hershey/United States of 
America, 3University of Pittsburgh, Pittsburgh/PA/United States of America, 4Northwestern 
University, Chicago/IL/United States of America, 5Virginia Commonwealth University, 
Richmond/VA/United States of America
Background: The risk of recurrent lung cancer decreases markedly after 4 years. It is 
unknown whether frequent surveillance after this time period would be beneficial in order 
to diagnose and treat secondary lung cancers. The purpose of investigation is to assess 
whether there is an increasing frequency of second lung cancers and whether the first 
primary reduces Overall Survival(OS)/Lung Cancer Specific Survival(LCSS) as compared 
to similar patients presenting with their first lung cancer (new primary, NP). Methods: The 
SEER databases were used to investigate incidence (1973-2010) and OS/LCSS (1998-
2010) of secondary lung cancer. Incidence was examined by frequency and trend analyses. 
A SP population was chosen who was originally treated for Stage I-III NSCLC and developed 
a new primary at least four years after diagnosis of their original primary lung cancer 
(N=1,699). The OS/LCSS of their SP NSCLC were compared to patients presenting 
with a new primary (NP) NSCLC. OS/LCSS in NP and SP were analyzed by Kaplan-Meier 
estimation, multivariate proportional hazards modeling and log-rank tests in the overall 
group and in a favorable sub-group (stage I, < 4cm). Results: The annual incidence rates 
per 100,000 persons for SP NSCLC has increased almost 5 fold in last three decades (2.5 
in 1973; 12 in 2010; p<0.001), more so in male patients. OS and LCSS in SP were higher 
than NP in the log rank tests (p<0.001). In the subgroup of NP and SP who had favorable 
tumor characteristics, OS/LCSS was significantly different between NP and SP (P=0.0032; 
P=0.0015), but did not remain so after accounting for treatment, tumor factors, and 
patient characteristics (HR=0.983, p=0.8493; HR=1.154, p=0.1770). Rates of OS and 
LCSS improved significantly with increasingly aggressive treatment in the SP group. Patient 
and tumor characteristics of the first primary NSCLC were not signantly linked to mortality. 
Conclusion: Patients presenting with a second primary lung cancer had a similar or better 
OS/LCSS as compared to patients presenting with a new primary lung cancer. The SP 
population also benefitted from increasingly aggressive treatment. Continued surveillance 
for new primary lung cancers after 4 years may be beneficial to lung cancer survivors. 
Keywords: lung cancer, second primaries, surveillance
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MINI20.02 Risk-Adjusted Margin Positivity (RAMP) Rate as a Surgical 
Quality Metric for Non-Small-Cell Lung Cancer in the US National Cancer 
Data Base (NCDB) Chun Chieh Lin1, Matthew P. Smeltzer2, Xinhua Yu2, Raymond U. 
Osarogiagbon3, Ahmedin Jemal1 1Surveillance and Health Service Research, American 
Cancer Society, Atlanta/GA/United States of America, 2School of Public Health, University 
of Memphis, Memphis/TN/United States of America, 3Thoracic Oncology Research Group, 
Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis/TN/United 
States of America
Background: Surgical resection is the most important curative treatment modality for 
early-stage non-small-cell lung cancer (NSCLC). However, incomplete (margin-positive) 
resection is associated with inferior survival. We sought to develop a valid facility-based 
quality metric to measure surgical quality, adjusting related patient demographic and 
clinical characteristics. Methods: We identified facilities that performed cancer-directed 
surgery for patients diagnosed with AJCC stage I-IIIA NSCLC in the NCDB between 2004 
and 2011. We used a multivariate logistic regression model, adjusting for patient risk-mix 
in each facility, to predict the expected number of risk-adjusted margin positivity (RAMP) 
cases for each facility. We divided the number of observed margin positivity (OMP) cases by 
the expected number of RAMP cases to obtain an observed: expected (O/E) ratio for each 
facility. We categorized facility performance as low outlier (O/E ratio<1 and p<.05), high 
outlier (O/E ratio>1 and p<.05), or non-outlier. Facility characteristics across performance 
categories were compared by chi-square test. Five-year unadjusted overall survival (OS) 
rates were estimated by Kaplan-Meier analyses and compared across categories with the 
log-rank test. Results: A total of 96,596 NSCLC stage I-IIIA patients underwent surgery 
in 941 facilities. The overall OMP rate was 4.6%. We identified 73 facilities as low outliers 
(mean O/E ratio=0.41), 755 as non-outliers (mean O/E ratio=1.28) and 113 as high 
outliers (mean O/E ratio=2.78). Compared to patients treated at high-outlier facilities, 
patients treated at low-outliers were more likely to be privately insured (34.7%[Low] vs. 
32.9%[High]), reside in high-income neighborhoods, have no comorbidity (51.7% [Low] vs. 
S335Copyright © 2015 by the International Association for the Study of Lung Cancer
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Conclusion: The presence of metastasis in inadvertently discarded LNs in NSCLC 
resection specimens has signifi cant implications for patients’ post-operative clinical 
course. Additional LN metastasis found on re-dissection was associated with 
reduced survival. A more rigorous protocol for gross dissection of lung resection 
specimens is needed, and should prove benefi cial to patients’ long-term survival. 
Keywords: lymph node retrieval, lymph node metastasis, survival impact, missed lymph 
nodes
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MINI20.04 Right-Sided vs. Left-Sided Pneumonectomy after Induction Therapy 
for Non-Small Cell Lung Cancer Chi-Fu J. Yang, Derek Y. Chan, Brian C. Gulack, 
David N. Ranney, Betty C. Tong, Mark W. Onaitis, David Harpole, Thomas A. D’Amico, 
Matthew G. Hartwig, Mark F. Berry Surgery, Duke University, Durham/NC/United States of 
America
Background: A right-sided pneumonectomy after induction therapy for non-small cell 
lung cancer (NSCLC) has been shown to be associated with signifi cant perioperative risk. 
We examined the impact of laterality on long-term survival using the National Cancer Data 
Base (NCDB). Methods: Perioperative and long-term outcomes of patients who underwent 
pneumonectomy following induction chemotherapy ± radiation from 2003-2011 in the 
NCDB were evaluated using Kaplan-Meier method, multivariable logistic regression 
analysis and multivariable Cox proportional hazards modeling. Results: During the study 
period, 1,652 patients met inclusion criteria, of whom 740 (45%) underwent right-sided 
pneumonectomies. Right-sided patients were more likely to have adenocarcinomas, cN2 
disease and lower co-morbidity scores (Table). The 30-day mortality rate was higher 
for right-sided procedures in univariable (11% [84/740] vs 4% [39/912], p<0.001) and 
multivariable (OR 9.1 [1.8-50.0], p<0.01) analysis. However, 5-year overall survival 
between right and left pneumonectomy were not signifi cantly different (fi gure) after 
a median follow up of 30.2 months. Right-sided procedure also did not impact overall 
survival in multivariable analysis (hazard ratio (HR), 1.41 [95% CI: 0.87-2.27], p=0.16), 
while increasing age (HR, 1.02 [95% CI: 1.01-1.03]), Charlson co-morbidity Score of 2 
(HR, 1.42 [95% CI: 1.04-1.93]), adenosquamous histology (HR, 1.72 [95% CI: 1.18-2.51]), 
cN1 status (HR, 1.27 [95% CI: 1.02-1.58]), cN2 status (HR, 1.38 [95% CI: 1.14-1.66]), 
cN3 status (HR, 1.84 [95% CI: 1.19-2.83]), cM1 status (HR, 2.04 [95% CI: 1.42-2.92]) and 
incomplete resection (HR, 1.45 [95% CI: 1.14-1.84]) all predicted worse survival.
follow up, we now quantify the survival impact of missed LN metastasis. Methods: We 
conducted a prospective cohort study to retrieve intrapulmonary LNs from discarded 
NSCLC resection specimens after completion of routine pathology examination. 
Retrieved materials were histologically examined and classifi ed as LNs with and without 
metastasis. Survival information was retrieved from institutional tumor registries. 
Survival distributions were plotted using the Kaplan-Meier method and evaluated with 
proportional hazards models controlling for gender, race, pathologic N-category, tumor 
size, margin status, and Charlson score. Results: We evaluated 111 patients who were 
47% male with a median age of 66 years. Clinical characteristics are summarized in 
Table 1. Discarded LNs with metastasis were found after re-dissection in 25 (23%) 
patients. Patients with discarded LN metastasis had an increased risk of death (Figure 
1) with an unadjusted hazard ratio (HR) of 2.0 (p-value=0.06) and an adjusted HR of 1.8 
(p-value=0.23) compared to those with no discarded LNs with metastasis. When >2 
discarded LNs with metastasis were found, patients had 4.8 (p-value=0.0002) times 
the hazard of death compared to those with no discarded LNs with metastasis (adjusted 
HR=4.4, p-value=0.0032).
N(%) No LN Metastasis LN Metastasis Total
Bi-lobectomy 8 2 10
9% 8%
Lobectomy 75 16 91
87% 64%
Pneumonectomy 3 7 10
3% 28%
N0 71 6 77
83% 24%
N1 6 12 18
7% 48%
N2 9 7 16
10% 28%
T1 45 3 48
52% 12%
T2 29 11 40
34% 44%
T3 10 8 18
12% 32%
T4 2 2 4
2% 8%
Margin Negative 83 22 105
97% 88%
Margin Positive 3 3 6
3% 12%
Mean(SD)
Charlson Score 1.8 1.8 1.8
1.6 1.7 1.6
Tumor Size(cm) 3.2 5.0 3.6
1.8 2.1 2.0
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Center, Los Angeles/United States of America, 5Surgery, David Geffen School of Medicine at 
UCLA, Los Angeles/CA/United States of America
Background: Biopsy of APW (levels 5/6) lymph nodes can be important for lung 
cancer staging, but the APW is not accessible by routine mediastinoscopy or EBUS. 
Although some consider ECM potentially dangerous, we reviewed our ECM experience to 
determine safety and accuracy and to define/validate parameters for patient selection. 
Methods: With IRB approval we reviewed two institutions’ databases for patients 
undergoing ECM between 3/1/97 and 12/31/11. Physical parameters (PP) that were 
thought to impact on the difficulty and safety of ECM, ie., clavicular head (CH), thoracic 
inlet (TI), and anterior mediastinal (AM) dimensions, were measured using 55 CT scans 
available from the first 100 pts. Results: Of 190 patients, 128 (67.3%) were male and 
ages ranged 28-91 yrs. Indication for surgery was either cancer (>95% with lung cancer 
>80%) or adenopathy (<5%). All procedures were performed by a single surgeon during 
routine mediastinoscopy. There were no intraoperative complications and blood loss was 
<25 cc in all cases. Morbidity occurred in 15 (7.9%) with 1 (0.55%) major complication 
and no mortality. A pathologic diagnosis was obtained in 189 (99.5%). Postop pain was 
easily controlled with bupivicaine. PP were compared to those in an additional 12 control 
patients with failed procedures (Table). Although each PP alone was not useful, the APWI 
(TI X AM product) did predict degree of difficulty (p=0.015) and divided patients into 3 
groups predictive of the degree of difficulty: Straightforward (APWI>17), Intermediate 
(APWI=6-17), and Prohibitive (APWI<6) (Figure). The APWI was then prospectively 
validated with excellent accuracy in the next 90 patients. The APWI can be helpful in the 
selection of patients for thoracic surgeons, particularly those learning ECM. A short video 
demonstrating the technique of ECM will be presented.
Table: Physical Parameter Measurements (values were obtained from CT scans avail-
able on 55/100 initial patients comparing with a separate group of 12 patients with 
unsuccessful ECM
Parameter Successful ECM (cms)
UnSuccessful ECM 
(cms)
Clavicular Head (CH) 2.3+0.36 2.28+0.36
Thoracic Inlet (TI) 6.32+1.07 5.99+0.62
Anterior Mediastinum (AM) 2.53+0.82 1.89+0.82
APWI (TI X AM) 16.2+6.77 11.1+4.4*
*p=0.015
Conclusion: ECM is straightforward, safe, and accurate in mediastinal staging. Our 
novel APWI helps to safely select patients for any thoracic surgeon’s skill and comfort 
level.  
Keywords: Staging, mediastinum, AP Window, Mediastinoscopy
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MINI20.08 Survival in Unexpected Multi-Station pN2 Following Surgical 
Resection of NSCLC Matthew Evison, Stuart Britton, Haider Al-Najjar, Rajesh Shah, 
Philip Crosbie, Richard Booton Manchester Thoracic Oncology Centre, University Hospital 
of South Manchester, Manchester/United Kingdom
Background: In our cancer network, single station N2 NSCLC may be managed with 
surgical resection followed by adjuvant chemotherapy as meaningful survival has been 
shown in such circumstances. Multi-station N2 disease diagnosed pre-operatively is not 
considered a surgical entity. However, sometimes occult multi-station pN2 may only be 
identified during intra-operative nodal sampling. This study aimed to analyse the survival 
of such patients at a large thoracic surgical centre in the United Kingdom. Methods: A 
retrospective review of all pathological reports from NSCLC resections at the University 
Hospital South Manchester from 01/01/2011 to 31/12/2013. Based on the histological 
results from intra-operative nodal sampling, patients were stratified into nodal categories 
pN0, pN1, pN2 single station and pN2 multi-station. Survival data was obtained through 
national death registry data allowing a minimum of twelve months follow-up for all patients 
Table: Baseline characteristics.
Variable Right-sided (n=740) Left-sided (n=912) p
Induction chemoradiation 461 (62%) 584 (64%) 0.47
Age (median, IQR) 59 (52-66) 60 (52-67) 0.07
Charlson/Deyo Comorbidity Score 0.02
0 518 (70%) 610 (66%)
1 190 (26%) 243 (27%)
2 32 (4%) 68 (7%)
Histology 0.02
Adenocarcinoma 227 (37%) 243 (32%)
Squamous 310 (50%) 450 (59%)
Large cell 28 (5%) 19 (2%)
Adenosquamous 20 (3%) 21 (3%)
Neuroendocrine/carcinoid 4 (1%) 7 (1%)
BAC 28 (5%) 23 (3%)
Clinical N < 0.01
0 190 (27%) 269 (31%)
1 134 (19%) 187 (21%)
2 368 (52%) 381 (44%)
3 16 (2%) 34 (4%)
 
There were no significant differences between the groups with regards to sex, 
race, facility type, and clinical T and M status. Conclusion: In this population 
analysis, right-sided pneumonectomy after induction therapy was associated with 
a significantly higher perioperative but not worse long-term mortality compared 
to a left-sided procedure. These findings can be used in the risk/benefit analysis 
when considering patients for pneumonectomy following induction therapy. 
Keywords: lung cancer, pneumonectomy, induction therapy
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MINI20.06 The Importance of Sleeve Lobectomy after Induction Therapy for 
Patients with Stage IIIA-N2 Lung Cancer: The Avoidance of Pneumonectomy  
Jong Ho Cho1, Yong Soo Choi1, Jhingook Kim1, Hong Kwan Kim1, Jae Ill Zo1, Young Mog 
Shim1, Kwhanmien Kim2 1Thoracic & Cardiovascular Surgery, Samsung Medical Center, 
Seoul/Korea, 2Department of Thoracic and Cardiovascular Surgery, Seoul National University 
Bundang Hospital,Seoul National University College of Medicine, Seoul/Korea
Background: Outcomes of pneumonectomy after neoadjuvant chemoradiastion therapy 
(CCRT) for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) have been 
well-known as grave. Whenever possible, we have tried sleeve resection in patients 
to avoid pneumonectomy(PN). We evaluated whether the sleeve resection (SL) could 
have avoided the postoperative mortality/morbidity and achieved comparable long-
term outcomes with pneumonectomy. Methods: We retrospectively reviewed medical 
records of 574 consecutive patients with clinical stage IIIA-N2 non-small cell lung 
cancer who underwent surgery after neoadjuvant CCRT from 1997 to 2013. Clinical 
outcomes were analyzed and compared in 98 consecutive patients who had either SL 
(n = 25) or PN (n = 73) after neoadjuvant CCRT in a single institution. Results: Thirty-
day postoperative mortality were 0% (0/25) in SL group, and 5.5% (4/73) in PN group 
(p=0.120). Ninety-day postoperative mortality were 12.0% (3/25) in SL group, and 17.8% 
(13/73) in PN group (p=0.498). The most common cause of ninety-day mortality was 
acute respiratory distress syndrome (n=11). Morbidity rate was 48.0 % (12/25) in SL, 
and 49.3% (36/73) in PN. The 5-year survival was lower in the PN group (PN, 24.7 % 
versus SL, 45.1%, p=0.086). The recurrence pattern (locoregional versus distant) did 
not differ between two groups (p=0.726). When recurrences occurred (n = 50), the 
site of first recurrence was local (stump site) in 0 % (0/25) of patients with SL and in 
4.1% (3/73) of patients with PN. Conclusion: Following neoadjuvant CCRT for patients 
with stage IIIA-N2 NSCLC, SL showed a comparable or even better early and long term 
clinical outcomes with PN. Therefore, SL should be considered, whenever possible. 
Keywords: Surgery
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MINI20.07 Extended Cervical Mediastinoscopy (ECM) for Biopsy of 
AortoPulmonary Window (APW) Lymph Nodes and an APW Index (APWI) Useful 
in Patient Selection Robert B. Cameron1, Shahriyour Andaz2, Graciela Hoal3, Lien Hua-
Feng1, Mollie Doyle4, John Benfield5 1Surgery, David Geffen School of Medicine at UCLA and 
West Los Angeles VA Medical Center, Los Angeles/United States of America, 2South Nassau 
Hospital, Lynbrook/NY/United States of America, 3Surgery, West Los Angeles VA Medical 
Center, Los Angeles/CA/United States of America, 4Surgery, West Los Angeles VA Medical 
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MINI20.11 Lymph Node Impact on Conversion of VATs Lobectomy to 
Open Thoractomy Yun Li Department of Thoracic Surgery, People’s Hospital of Peking 
University, Beijing/China
Background: Conversion to open thoracotomy occurs when thoracoscopic manipulation 
becomes difficult as a result of particular situations during complete thoracoscopic 
lobectomy after the surgeon starts to dissect blood vessels Based on special intra-
operative situations, conversion to open thoracotomy can be divided into active and 
passive conversion. Active conversion to open thoracotomy implies that the surgeon 
gives up the thoracoscopic manipulation voluntarily and performs open surgery under 
direct vision as a result of the difficulty of thoracoscopic manipulation when encountering 
problems, such as adhesions of lymph nodes and difficulty of exposing huge tumors, 
which may result in massive bleeding, tumor rupture, and undue extension of the operative 
time. Passive conversion to open thoracotomy implies that the surgeon has to discontinue 
thoracoscopic manipulation and perform open surgery under direct vision because of 
urgent or serious intra-operative complications, including blood vessel breakage and 
bronchial membrane rupture, which are difficult to treat thoracoscopically. Lymph 
nodes are an important etiology affecting the conversion of complete thoracoscopic 
lobectomy to open thoracotomy.Five hundred consecutive patients with non-small 
cell lung cancer underwent complete thoracoscopic lobectomy at the Department of 
Thoracic Surgery of Peking University People’s Hospital, and the conversion to open 
thoracotomy was performed in 47 cases (9.4%). Lymph node interference means that 
a lymph node cannot be separated easily, and was the reason for conversion to open 
surgery in 31 cases (65.9% of 47 cases).The effect of lymph node interference on 
surgery has not been thoroughly addressed to date. We studied the data of patients 
who underwent complete thoracoscopic lobectomy in our hospital, and analyzed the 
effect of lymph nodes on the conversion to open thoracotomy and corresponding 
factors. Methods: Between September 2006 to April 2013, 1006 patients （545 
men, 461women, median age 60 years, range from 13 to 86 years)received completly 
thoracoscopic lobectomy, including segmectomy(n=13), simple lobectomy(n=846), 
compound lobectomy(n=131), pneumonectomy (n=8), sleeve lobectomy(n=8). The 
main procedure was completely video-assisted anatomical lobectomy with mediastinal 
lymphadenectomy as we have reported. Results:All procedures were carried out 
smoothly without serious complication. 83 cases converted to thoracotomy(8.2%), 
including 70 cases of initiative conversion and 13 cases of passive conversion in which 
59 cases was interference by doornail lymph nodes. Pathological result show 821 
cases of malignant disease and 185 cases of benign disease. All patients recovered 
well.the average operative time in the conversion thoracotomy group was significantly 
longer (272.7 ± 67.2min versus186.9 ± 58.1min, P = 0.001)compared with completely 
endoscopic surgery group, the average blood loss was significantly increased(564.2 
± 507.7ml versus 158.0 ± 121.0ml, P = 0.001), the drainage time was significantly 
longer(8.9 ± 5.0d versus 6.6 ± 3.5d, P = 0.001) and the postoperative hospital stay was 
significantly longer(12.5 ± 7.7d versus 9.2 ± 5.8d, P = 0.001). Conclusion: Interference 
of lymph doeds was the main reason for conversion to thoracotomy on VATs 
lobectomy. It may prolonged the operative time, increase the blood loss in operation 
and delay the postoperative recovery of the patients. Select the proper indication of 
conversion thoracotomy may reduce the negative effects of conversion thoracotomy. 
Keywords: lymph nodes, Complete video-assisted thoracoscopy, conversion 
thoracotomy, lobectomy
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MINI20.12 Advancements in Bronchoplasty as Treatments for Lung Cancer: 
Single Institutional Review of 213 Patients Takeshi Nagayasu, Naoya Yamasaki, 
Tomoshi Tsuchiya, Keitaro Matsumoto, Takuro Miyazaki Department of Surgical Oncology, 
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki/Japan
Background: Bronchoplasty has become widely accepted as a reliable and safe lung-
saving procedure for lung cancer. The purpose of this study was to evaluate the factors 
contributing to the outcomes of bronchoplasty for lung cancer by analyzing a single 
institution’s data for a 30-year period. Methods: In the 2416 patients who underwent 
lung resections for lung cancer at Nagasaki University Hospital from 1980 to 2010, 
there were 222 bronchoplastic procedures. After excluding patients who underwent 
carinoplasty, 213 patients (161 bronchoplasty and 52 broncho-angioplasty) were 
included. The patients were divided into two groups by the date of surgery: the 1st period 
was 1980 to 1995, and the 2nd period was 1996 to 2010. Results: Bronchoplasty 
and broncho-angioplasty were performed in 100 (75.8%) and 32 (24.2%) patients, 
respectively, in the first period and 61 (75.3%) and 20 (24.7%) patients, respectively, 
in the second period. Overall 90-day operative morbidity and mortality rates were 
25.8 and 9.8%, respectively, in the first period and 45.7 and 2.5%, respectively, in the 
second period. Thirty-day mortality rates were 6.8% in the first period and 0% in the 
second period. Five-year survival was 41.1% (n = 132) in the first period and 61.5% 
(n = 81) in the second period (P = 0.0003). Comparing bronchoplasty and broncho-
angioplasty, the 5-year survival was 45.6 and 26.5%, respectively, in the first period 
(P = 0.0048) and 60.9 and 62.1%, respectively, in the second period (P = 0. 8131). 
Using multivariate analysis to identify potential prognostic factors, the type of operation 
(broncho-angioplasty), postoperative complications and histology (non-squamous cell 
carcinoma) were significant factors affecting survival in the first period, but none of the 
factors significantly affected survival in the second period. When the rates of pN2 or N3 
histological type disease were compared in each period, the rate of pN2 or N3 disease 
in non-squamous cell carcinoma was 51.4% in the first period and 45.5% in the second 
period; both were significantly higher than in squamous cell carcinoma (31.6 and 16.9%, 
respectively; P = 0. 0365 and 0.0073). 
at the time of analysis in January 2015. Results: 987 surgical resections for NSCLC were 
performed during the study period 2011 to 2013 at UHSM. A total of 132 patients had 
pN2 disease; 85 with single station pN2 and 47 with multi-station N2. The median survival 
time for those patients with multi-station pN2 was 798 days (95% CI 405-1191 days) and 
762 days (95% CI 616-908 days) for those with single station pN2. Median survival times 
were not estimable for patients with pN0 and pN1 as only a small proportion of patients 
died. For pairwise comparisons between N categories, a Bonferroni adjustment for 
multiple comparisons used a critical value of 0.008 for significance. Patients with single 
station pN2 and multi station pN2 had significantly lower survival times than patients with 
N0, but there was no statistically significant difference in survival between patients with 
pN1, single station pN2 and multi-station pN2 (Figure 1).
 
Conclusion: Interestingly, patients with multi-station pN2 had a similar survival 
to those with single station pN2. This cohort of multistation pN2 patients is likely 
to represent those with microscopic nodal metastases and does not represent 
all multistation N2 disease. Although the numbers are small it does raise 
interesting questions about the exclusion of patients with radiologically-occult 
multi-station N2 disease, detected during the pre-operative systematic sampling 
of small mediastinal nodes through endoscopic or surgical techniques, being 
excluded from surgery as part of their multi-modality treatment in our network. 
Keywords: NSCLC surgery, Multi-station N2, NSCLC survival
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MINI20.10 Prognostic Impact of Lymph Node Ratio in Patients with Pathologic 
Stage N1 Non-Small Cell Lung Cancer Sumin Shin1, Hong Kwan Kim1, Yong Soo 
Choi1, Kwhanmien Kim2, Jhingook Kim1, Jae Ill Zo1, Young Mog Shim1 1Thoracic & 
Cardiovascular Surgery, Samsung Medical Center, Seoul/Korea, 2Department of Thoracic 
and Cardiovascular Surgery, Seoul National University Bundang Hospital,Seoul National 
University College of Medicine, Seongnam-Si/Korea
Background: Current nodal staging for non-small cell lung cancer (NSCLC) only take into 
account the anatomic location of lymph node (LN). Although among patients with same 
pathologic N1 NSCLC, they are known to have heterogeneous prognosis and prognostic 
significance of extent of LN involvement is still uncertain. The objective of current study 
was to evaluate whether LN ratio (LNR) is a marker of prognostic factor for survival in 
patients with pathologic stage II/ N1 NSCLC after complete resection. Methods: A total 
of 4,089 consecutive patients underwent curative surgical resection for NSCLC between 
2004 and 2012. Of these, 413 patients who found to have pathologic stage II/N1 NSCLC 
after complete resection were retrospectively analyzed. For LNR, the optimal cutoff value 
was determined using chi square score, which were calculated using the Cox proportional 
hazards regression model. The prognostic value of the LNR was calculated by Cox 
regression hazard model analysis. Results: The study included 337 males and 76 females 
with a mean age of 62 years. The mean numbers of metastatic and dissected LN were 1.84 
and 26 respectively and the mean LNR was 0.082. The number of the metastatic LN was 
significantly correlated to the LNR (r=721; p<0.0001). Based on the maximum chi square 
score and minimum p value approach, the optimal cutoff value of LNR was 0.1 and patients 
were classified into two groups according to LNR. Both 5-year overall survival rate and the 
lung cancer-specific survival rate in the high LNR group (LNR ≥0.1) were significantly lower 
than those in the low-LNR group (overall survival: 55.4.% vs 69.8%, p=0.003; lung cancer 
specific survival rate: 58.4% vs. 77.0%, p<0.0001) Also, disease free survival (DFS) rates 
according to LNR were 56.8% in low-LNR group (LNR<0.1) and 35.0% in high-LNR group 
(LNR≥0.1). DFS rate in the low-LNR group was significantly higher than that in the high-LNR 
group (p<0.001). LNR is an independently related prognostic factor with overall survival 
(OR=2.288; 95% CI=1.513~3.459; p<0.0001), lung cancer-specific survival (OR=2.740; 
95% CI=1.709~4.395; p<0.0001) and DFS (OR=2.191; 95% CI=1.543~3.110; p<0.0001) 
after adjustments of clinical variables including sex, age, stage, surgical extent, 
histology and adjuvant treatment. Conclusion: LNR is an independent prognostic 
factor of survival in patients with pathologic N1 NSLC after complete surgical resection. 
Keywords: non-small cell lung cancer, Surgery, lymph node, Staging
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Conclusion: Our findings demonstrate clinically significant discrepancy between two 
modalities frequently used to stage mediastinal disease extent in NSCLC patients being 
considered for radiotherapy. PET-based radiotherapy planning alone may not be 
appropriate given the risk of excessively large, or insufficiently large, radiation fields 
where planning is not based on invasive LN sampling. These results suggest minimally 
invasive comprehensive/systematic mediastinal staging should be considered for all 
patients prior to radiotherapy to accurately assess pathologic stage and extent of 
disease, and to ensure treatment fields most accurately encompass all sites of disease. 
Keywords: Staging, endobronchial ultrasound, radical radiotherapy
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MINI21.01 Purinergic Signaling in NSCLC - First in Vivo Data and Potential 
Therapeutic Targets Severin Schmid1, Korcan Ayata2, Zsofia Lazar2, Markus Kübler1, 
Mirjam Elze1, Benedikt Haager1, Bernward Passlick1, Marco Idzko2 1Thoracic Surgery, 
University Hospital Freiburg, Freiburg/Germany, 2Pneumology, University Hospital Freiburg, 
Freiburg/Germany
Background: Purines are well known as intracellular sources for energy but also act as 
extracellular signaling molecules. In the last decade there has been a growing interest 
in the therapeutic potential of purinergic signaling for cancer treatment. The effects 
carried out depend on the concentration, expressed pattern of purinergic receptors 
and general dynamics of synthesis and degradation. In this study we analyze different 
purines and purinergic receptors in bronchoalveolar lavage (BAL) of patients with non-
small-cell lung cancer (NSCLC) to provide further insight on their relevance in the tumor 
microenvironment. Methods: In this prospective clinical trial we enrolled 27 patients 
with NSCLC and 16 patients with chronic obstructive pulmonary disease (COPD) 
without signs of malignancy. The study was approved by our local ethics committee 
and registered as a clinical trial in the German Registry for Clinical Trials (DRKS-ID: 
DRKS00005415). BAL was performed using flexible bronchoscopes. The bronchoscope 
was wedged into a subsegment were the tumor was present and a total of 300 ml 
sterile saline was instilled. The BAL-fluid (BALF) was recovered by gentle aspiration. 
Purines (ATP, ADP, AMP, Adenosine and Inosine) were analyzed using fluorescence/
luminescence based assays. Expression of purinergic receptors and Ectonucleotidases 
in NSCLC (P2X1, P2X4, P2X7, P2Y1, P2Y2, P2Y4, P2Y6, P2Y12, P2Y13, P2Y14, CD39, 
CD73) were analyzed using qPCR. Results: Patients with NSCLC have significantly 
lower ATP and ADP concentrations in BALF than patients with COPD without signs of 
malignancy (p=0.006 and p=0.009). Inosine concentrations however are higher in 
patients with malignant disease (p=0.01). In the subgroup-analysis of metastasized 
versus non-metastasized tumors receptor-analysis revealed a higher expression of P2X4 
(p=0.07), P2X7 (p=0.0008) and P2Y1 (p=0.009) as well as of the ectonucleotidase 
CD39 (p=0.007). Analysis of the purine metabolites in the respective groups showed 
no statistically significant differences. Furthermore there is a positive correlation of the 
proportion of macrophages in differential cell count in BAL with the expression of P2X7 
(r=0.53, p=0.02). Conclusion: Previous data suggests pro-inflammatory, zytotoxic and 
thus anti-neoplastic effects of Adenosine-Triphosphate (ATP) and ADP. Also it has been 
shown that low ATP concentrations in the tumor microenvironment can lead to enhanced 
proliferation of tumor cells. In this first in vivo study on purinergic signaling in lung cancer 
we find lower concentrations of ATP and ADP in samples from NSCLC patients compared 
to COPD without signs of malignancy in accordance with these findings. Furthermore in 
aggressive, metastasized NSCLC we find a higher expression of the ectonucleotidase 
CD39. This enzyme degrades ATP and ADP to Adenosin and has previously been shown 
to hence induce immune escape in malignant disease. Furthermore we demonstrate 
elevated expression of P2X4, P2X7 and P2Y1 in the tumor microenvironment of 
metastasized NSCLC compared to non-metastasized tumors. This suggests a role of 
these receptors in tumor metastasis, however the exact mechanisms remain unclear. To 
further illustrate these interactions we are currently initiating a study to identify purinergic 
receptors in NSCLC tumor cells from pathologic specimen. With this knowledge future 
translational studies can be conducted to potentially provide new therapeutic targets. 
Keywords: lung cancer, purinergic signaling, tumor microenvironment
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MINI21.02 CCT68127 Is a next Generation CDK2/9 Inhibitor with Potent 
Antineoplastic Activity Against Lung Cancer Cells Masanori Kawakami1, LisaM. 
Mustachio2, Xi Liu1, Shanhu Hu2, Yun Lu2, David Sekula1, Sarah Freemantle2, Ethan 
Dmitrovsky1 1Thoracic/Head & Neck Medical Oncology, The University of Texas MD 
Anderson Cancer Center, Houston/TX/United States of America, 2Pharmacology and 
Toxicology, Geisel School of Medicine at Dartmouth, Hanover/NH/United States of America
Background: Lung cancer growth was significantly repressed by the first generation 
CDK2/9/7 inhibitor seliciclib (R-roscovitine, CYC202, Cyclacel Ltd). This induced 
anaphase catastrophe and apoptosis to occur. Anaphase catastrophe happens when 
supernumerary centrosomes attempt mitosis by clustering extra centrosomes. If this 
clustering is inhibited, cells segregate chromosomes inappropriately and anaphase 
catastrophe occurs and leads to death of daughter cells. This study explored antineoplastic 
effects of a next generation CDK2/9 inhibitor: CCT68127 (Cyclacel) against lung cancer 
cells. CCT68127 inhibits CDK2/9 more potently and selectively than seliciclib (IC50s 
Conclusion: The present study suggests that progress in the preoperative staging 
system and perioperative medical management, as well as surgery, has contributed to 
current improvements in patients undergoing bronchoplasty and broncho-angioplasty. 
However, since nodal status in non-squamous cell carcinoma is not precisely evaluated 
before the operation, the indication for bronchoplasty should be considered carefully. 
Keywords: bronchoplasty, Broncho-angioplasty, lung cancer, complications
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MINI20.13 A Prospective Comparison of FDG-PET & EBUS for Determining the 
Extent of Mediastinal Lymph Node Involvement in NSCLC Daniel P. Steinfort1, 
Shankar Siva2, Tracy Leong3, Morgan Rose1, Dishan Gunawardana4, Phillip Antippa5, 
David Ball2, LouisB. Irving1 1Respiratory Medicine, Royal Melbourne Hospital, RMH/
VIC/Australia, 2Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne/
VIC/Australia, 3University of Melbourne, Parville/VIC/Australia, 4Nuclear Medicine, Royal 
Melbourne Hospital, RMH/VIC/Australia, 5Cardiothoracic Surgery, Royal Melbourne Hospital, 
Melbourne/VIC/Australia
Background: Non-small cell lung cancer (NSCLC) may be treated with curative intent 
using radiotherapy, either as single modality or in combination with systemic 
chemotherapy. Most commonly, radiation treatment is planned based on findings at 
18-Fluorodeoxyglucose Positron Emission Tomography (PET), following pathologic 
confirmation of involvement at a single mediastinal site. We hypothesized that systematic 
mediastinal evaluation with EBUS-TBNA in NSCLC patients considered for radical 
radiation therapy may identify disease extent discrepant with that indicated by PET-
CT. Methods: This prospective ethics board-approved multi-centre cohort study in three 
Austrailan tertiary centres consented patients prior to mediastinal evaluation with 
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) for 
NSCLC,where non-invasive imaging indicated the likely treatment modality would include 
radical radiotherapy. EBUS evaluation was performed systematically with sampling of 
any lymph node (LN) exceeding 6mm diameter. Results: Thirty eligible patients with 
NSCLC form the basis of this report. No procedural complications occurred during 
performance of EBUS-TBNA. LN sampling was performed from a mean 2.5 lymph node 
stations per patient (median 3,range 1–5). Adequate samples were obtained from all 
sites examined by EBUS-TBNA. Mean long-axis size of sampled LN was 16+7.8mm 
(median 13mm,range 5–36mm). 24% of sampled LN were 10mm or less. Discordant 
findings were observed in 10 of 30 patients (33%) (Figure 1) EBUS-TBNA identified a 
greater extent of mediastinal involvement than PET in four patients, with invasive 
sampling resulting in upstaging in three patients. In one further patient, extent of disease 
was greater than noted on PET due to more proximal involvement of LN disease not 
resulting in stage advancement. Median size of LN upstaged by EBUS was 7.5mm (range 
7–9). In eleven mediastinal LN in six patients, EBUS identified a lesser extent of 
mediastinal disease than PET, including two patients down-staged from N3 à N2. Median 
size of LN down-staged by EBUS was 12mm (range 6–21). FIGURE 1. Flowchart of 
patients 
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regulated. Moreover, when HS3ST3B1 was knockdown by siRNA in mesenchymal 
phenotype NSCLC cell lines, cells were reversed to epithelial phenotype morphologically. 
With Targetscan, we found that HS3ST3B1 was one potential targets of miR-218 and dual 
luciferase report system demonstrated that HS3ST3B1 was direct target of miR-218 in 




Conclusion: HS3ST3B1 may regulate EMT and it can be regulated by miR-218 in NSCLC. 
Keywords: HS3ST3B1, EMT, NSCLC, TGF-beta
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MINI21.06 Role of the Focal Adhesion Protein Paxillin in Lung Cancer — From 
Genetic Alterations to Novel Mitochondrial Functionality Rifat Hasina1, Alex 
Rodriguez1, Sravya Tumuluru1, Frances Lennon1, Yi-Hung Carol Tan1, Ichiro Kawada2, 
Rajani Kanteti1, Ravi Salgia1 1Medicine, Section of Hematology/Oncology, University of 
Chicago, Chicago/IL/United States of America, 2Internal Medicine, Tokyo Saiseikai Central 
Hospital, Tokyo/Japan
Background: Cytoskeletal and focal adhesion abnormalities are observed in several 
types of cancer including lung cancer, which is attributed to a greater number of deaths 
than prostate, breast and colorectal cancers combined. Paxillin is a 68 kDa protein that is 
an integral part of the focal adhesion and acts as an adaptor molecule. We initially cloned 
the gene for paxillin, and localized it to chromosome 12q24. We have previously reported 
that paxillin can be mutated (approximately 8%), amplified (5-7%), and/or overexpressed 
in almost 80% of lung cancer patient samples. Paxillin protein is upregulated in more 
advanced stages of lung cancer compared with earlier stages and is a prognostic 
factor for non-small cell lung cancer (NSCLC). Paxillin gene is amplified in some pre-
neoplastic lung lesions as well as neoplastic lesions. We identified 22 different variants 
of paxillin mutation in our initial investigation especially between the LD and the LIM 
domains (Jagadeeswaran et al. 2008). There are mutations that have been validated 
in the TCGA set. We selected six mutants to perform further studies ((P52L, A127T, 
P233L, T255I, D399N, and P487L as well as wild-type as control). Our investigations 
focused on an effort to understand the contribution of molecular abnormalities found 
for CDK2 and CDK9 are 30nM and 110nM, respectively). Methods: Antineoplastic 
CCT68127 effects in murine (transgenic mouse-derived) and human lung cancer cells 
were compared to seliciclib using luminescent cell viability assays. Cell cycle arrest and 
apoptosis induction by CCT68127 were detected using fluorescence-based cell imaging 
after staining with propidium iodide (PI) and double-staining with Annexin V and PI. 
Multipolar anaphase cells were scored after a tubulin and DNA staining. RPPA (Reverse 
Phase Protein Assay) analyses were performed in CCT68127 and vehicle-treated lung 
cancer cells to uncover mechanisms engaged by CDK2/9 antagonism. Expression 
levels of nearly 200 key growth-regulatory proteins were examined before and after 
6, 24, and 48 hours of CCT68127 versus vehicle treatments of murine: ED1 (wild-type 
KRAS) and LKR13 (mutant KRAS) and human lung cancer cells: H522 (wild-type KRAS) 
and Hop62 (mutant KRAS). Results: IC50s of CCT68127 in murine lung cancer cells 
(ED1, LKR13, and 393P) were <1µM while IC50 of seliciclib was >25µM. KRAS mutant 
murine lung cancer cells (LKR13 and 393P) were more sensitive to CCT68127 than 
the KRAS wild-type line (ED1). In contrast, growth inhibition in C10 immortalized 
murine pulmonary epithelial cells was negligible. IC50s in human lung cancer cell lines 
(Hop62, A549, H2122, H522, and H1703) were comparable to murine lung cancer cell 
lines. KRAS mutant lung cancer cells (Hop62, A549, and H2122) were more sensitive than 
KRAS wild-type lung cancer cell lines (H522 and H1703). Immortalized human bronchial 
epithelial cells (BEAS-2B) were resistant to CCT68127 treatment. CCT68127 triggered 
apoptosis in a dose-dependent manner in murine lung cancer cell lines and at much lower 
concentrations than seliciclib. CCT68127 caused G1 arrest. Its growth inhibition was 
partially reversed in washout experiments. CCT68127 also induced apoptosis in human 
lung cancer cells (Hop62, A549, H522, and H1703). A mechanism responsible for these 
effects was found. Anaphase catastrophe was triggered by CCT68127 treatment of 
murine and human lung cancer cell lines and was independent of KRAS mutation status. 
RPPA analyses uncovered distinct protein profiles after CCT68127 treatment. These 
included DNA repair, Hippo and Rab GTPase pathway members that were each markedly 
down-regulated. Conclusion: CCT68127 is a next generation CDK2/9 inhibitor that has 
more potent antineoplastic activity against KRAS mutant and wild-type lung cancer cells 
than the prior inhibitor, seliciclib. This occurred via induced anaphase catastrophe and 
was linked to changes in expressed growth regulatory proteins. Taken together, these 
findings implicate use of a next generation CDK2/9 inhibitor for human lung cancer cases. 
Keywords: reverse phase protein array, CDK2, anaphase catastrophe
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MINI21.03 CACNA2D1 Is a Novel Biomarker for Tumor Initiating Cells and Has 
Therapeutic Effect in Non-Small Cell Lung Cancer Yuanyuan Ma Peking University 
Cancer Hospital, Beijing/China
Background: Tumor initiating cells (TICs) are a small subpopulation within cancer that 
is thought to be resistant to conventional therapies and capable of reinitiating tumors. 
However, only a few biomarkers of TICs have been well elucidated. Methods: By the 
methods of QPCR, FACS, western blot, colony formation and statistic analysis, we 
have investigated whether CACNA2D1 (α2δ1) to enrich TICs of non-small cell lung 
cancer (NSCLC) and and tharget therapy of its antibody. Results: In comparison to 
α2δ1-, α2δ1+ cells demonstrated greater TICs properties with higher potential of self-
renewal, differentiation and reconstituting tumors. Following treatment, these cells were 
enriched in clinical samples. We verified a monoclonal antibody of α2δ1 mAb which 
targets to α2δ1 had therapeutic treatment to TICs of NSCLC and further α2δ1 mAb 
combined with the common anti-cancer drug of carboplatin was obtained to suppress 
the established xenograft tumors. Importantly, the disease free survival and overall 
survival of NSCLC patients with increased α2δ1 expression was significantly shorter 
than that of patients with decreased expression. Mechanically, our results showed that 
a role of α2δ1 in up-regulating stemness of NSCLC cells was associated with NOTCH 
signaling. Conclusion: Collectively, our data indicate that α2δ1 could be used as a marker for 
identifying TICs of NSCLC and targeting these cells might provide a way to treat this disease. 
Keywords: lung cancer, tumor initiating cells, CACNA2D1, NOTCH
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MINI21.04 HS3ST3B1 Is a Novel Regulator of TGF-Beta Mediated EMT and 
Regulated by miR-218 in Lung Cancer Liyun Miao, Yongsheng Wang Nanjing Drum 
Tower Hospital, Nanjing/China
Background: Heparan sulfate D-glucosamine 3-O-sulfotransferase 3B1 (HS3ST3B1) 
participates in the biosynthetic steps of heparan sulfate (HS) and found to target VEGF in 
acute myeloid leukemia(AML) cells thus contributing the angiogenesis and proliferation of 
AML cells . However, the role of HS3ST3B1 in NSCLC has never been reported. In this 
study, we aim to investigate the role of HS3ST3B1 in NSCLC epithelial-to-mesenchymal 
transition. Methods: Expression of HS3ST3B1 was investigated by qRT-PCR in specimens 
of tumor and matched normal tissues of NSCLC patients and also in epithelial and 
mesenchymal NSCLC cell lines. A549 and HCC827 cell lines was induced to mesenchymal 
phenotype by TGF-β, and expression of HS3ST3B1, CDH1, and VIM were studied by PCR. 
HS3ST3B1 was knockdown by siRNA to analyze the effect of HS3ST3B1 on EMT. 
Computational predicting software was used to predict potential regulators of HS3ST3B1 
and dual luciferase report system demonstrated that miR-218 may target HS3ST3B1 in 
cells. MiR-218 was tranfected into cells to analyze the association of miR-218 and 
HS3ST3B1 in cells. Results: HS3ST3B1 was significantly up-regulated in tumors 
compared with matched normal tissues(P=0.002). Its expression was also up-regulated 
in mesenchymal phenotype NSCLC cells lines compared with epithelial 
phenotype(P＜0.05). When epithelial phenotype NSCLC cells transformed to 
mesenchymal phenotype induced by TGF-β, HS3ST3B1 was also significantly up-
S340 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
NOVEL TARGETS 
TUESDAY, SEPTEMBER 8, 2015 - 16:45-18:15
MINI21.08 Bombesin Receptor Subtype-3: An Underappreciated Growth Factor 
in Lung Cancer Paola Moreno1, TerryW. Moody2, Suk H. Lee1, Samuel A. Mantey1, 
Robert T. Jensen1 1NIDDK, National Institutes of Health (NIH), Bethesda/MD/United States 
of America, 2NCI, National Institutes of Health (NIH), Bethesda/MD/United States of America
Background: Human bombesin receptors (BnR) are one of the most frequently over-
expressed receptor families by human lung-cancers. It is known the activation of 
the classical members of the BnR family (GRPR, NMBR), causes a marked effect on 
cell-signaling and growth, often autocrine in nature, on lung-cancer cells. In addition, 
it has been discovered that the orphan receptor related to the BnR family, BRS-3, is 
widely distributed in central/peripheral normal tissues, and numerous tumors include 
lung-cancer cells. However, in contrast to the classical BnRs (GRPR, NMBR), BRS-3 has 
received little attention in lung-cancer in large part due to the fact its natural ligand is still 
unknown, and also because, until recently, the lack of specific pharmacological tools to 
study it. To address this, in this study, we examined the frequency of hBRS-3 expression 
in lung-cancer cells, and the effects of specific hBRS-3 activation on cell-signaling and 
cell-function (growth) in different lung-cancer cell lines. Methods: 17 human lung-cancer 
(LC) cell lines were studied (9 NSCLC, 8 SCLC), as well as hBRS3 transfected H1299 and 
Balb 3T3 cells. The BRS-3 selective agonist, MK-5046 and selective BRS-3 antagonist, 
Bantag-1 were used. BnR expression was assessed by PCR using specific primers for 
hBRS3, hGRPR or hNMBR. Receptor activation was determined by assessing PLC and 
MAPK cascade activation using Western Blotting, and cytosolic Ca2+ release. Proliferation 
was studied by clonogenic and [3H]-Thymidine assays, and EGFR transactivation was 
assessed using Western blotting. Results: Of the 17 LC cell lines, 9 (53%) express 
hBRS3 [H358, H460, H520, H720, H727, H69, H82, N417, H510], 14 (82%) express 
hGRPR [H28, H157, H358, H520, A549, H838, H1299, SK-LU-1, H720, H727, H69, H82, 
H345, H510] and 13 (77%) express hNMBR [H28, H157, H358, A549, H838, H1299, SK-
LU-1, H720, H727, H82, H345, N417, H510]. MK-5046 stimulated PLC activation in 6/9 
cells which express hBRS3 (H358, H720, H727, H69, H82, N417), and MAPK activation 
in all 9 hBRS3 cell lines. Cytosolic Ca2+ increased with MK-5046 addition in all hBRS-
3-containing cells, included Balb and H1299 transfected cells, except in H358 cells. 
Similarly, MK-5046 increased 3H-Thymidine uptake in 5/9 cells (H460, H520, H720, H727, 
H82, H510), as well as in Balb and H1299 hBRS-3 transfected cells, and this increase was 
in a dose-response manner in H727, H69 and N417 cells. MK-5046 stimulated the clonal 
growth of N417 and H727 cells. MK-5046 addition to H358, H460, H727 (NSCLC) and 
H69, N417, H510 (SCLC) caused Tyr1068 phosphorylation of the EGFR. Conclusion: These 
results show the orphan human BnR, hBRS-3 is present in more than one-half of human 
lung cancer cells. Furthermore, these receptors are functional with their activation 
effecting cell signaling (MAPK, PLC, Ca2+) and cell growth. Transactivation of EGFR is 
likely an important transduction cascade. These results suggest this orphan BnR, similar 
to classical BNRs, will be important to assess for growth effects and expression in human 
lung tumors, and its pharmacological inhibition may be a useful therapeutic approach. 
Keywords: growth factor, lung cancer, Bombesin receptor subtype-3, cell signaling
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MINI21.10 The TORK/DNA-PK Inhibitor CC-115 Shows Combination Anti-
Proliferative Effects with Erlotinib in NSCLC Cells Resistant to EGFR Inhibition 
Simon Ekman1, Dan Chan1, MurryW. Wynes1, Zhiyong Zhang1, Kristen Hege2, Ellen 
Filvaroff2, Heather Raymon3, Raffit Hassan1, Leslie Rozeboom1, Fred R. Hirsch1 1School 
of Medicine University of Colorado Anschutz Medical Campus, Division of Medical Oncology, 
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Background: In non-small cell lung cancer (NSCLC), activation of the phosphoinositide-
3-kinase (PI3K)/mTOR pathway is common in tumors resistant to Epidermal Growth 
Factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). CC-115 (Celgene Corporation), 
an mTOR kinase inhibitor that targets both mTORC1 and mTORC2 as well as DNA-
dependent protein kinase (DNA-PK), is currently under early clinical development. 
We evaluated CC-115 in combination with Erlotinib to overcome resistance to EGFR 
tyrosine kinase inhibition in non-small cell lung cancer (NSCLC) cell lines and xenografts 
in nude mice. Methods: In the present study we investigated whether CC-115 is able 
to increase the therapeutic effect of the EGFR TKI Erlotinib in several different NSCLC 
cell lines which exhibit intermediate or high resistance to EGFR TKIs: A549, H1975, 
H1650, HCC95, H2122 and H23. Mechanisms of inhibition were analyzed with assays for 
proliferation, apoptosis, and cell cycle progression. Cell signaling activity was analyzed 
using phospho-specific antibodies in Western blotting. Xenograft mice studies were 
performed to confirm the results in vivo. Results: CC-115 demonstrated anti-proliferative 
activity in NSCLC cell lines with various degrees of sensitivity as reflected in different 
IC50 values, ranging from 0.07 up to 6.9 mM. The anti-proliferative efficacy of Erlotinib 
was increased in the NSCLC cells synergistically by combination treatment with CC-115 
with combination indices down to 0.04-0.2, indicating strong synergy. The synergistic, 
anti-proliferative effect of the combination treatment could be explained by increased 
cell cycle arrest and inhibition of signaling components in the mTOR pathway, especially 
4E-BP1. In vivo studies in mice xenografts demonstrated a strong synergistic effect of 
the combination treatment of Erlotinib and CC-115. Conclusion: We demonstrate that 
the therapeutic effect of the EGFR tyrosine kinase inhibitor Erlotinib can be increased by 
simultaneous treatment with the mTOR kinase/DNA-PK inhibitor CC-115, justifying further 
clinical studies in lung cancer patients with primary or acquired resistance to EGFR TKIs. 
Keywords: non-small cell lung cancer, mTOR, erlotinib, CC-115
in paxillin and their relationship to mitochondrial functionality. Methods: HEK293 cells 
as well as a paxillin null NSCLC cell line H522 was used to overexpress the above 
paxillin mutants and wild-type paxillin. Live cell confocal microscopy was performed to 
evaluate cell motility, immunoprecipitation to determine interaction with other proteins, 
and gene expression analysis was performed to evaluate effects on gene expression. 
Results: Among the mutations we investigated, we found that the most common 
paxillin mutant A127T in lung cancer cells enhanced cell proliferation, focal adhesion 
formation and co-localized with the anti-apoptotic protein B cell CLL/Lymphoma 2 (BCL-
2), which among other sites also localizes to the mitochondria. We further found that 
when these variant clones of activating mutations were expressed in HEK293 cells, they 
conferred phenotypic changes resembling neoplastic cells. In gene chip microarrays 
assay investigating gene expression modulation conferred by these mutations in these 
same HEK293 cells, we found that P52L, A127T, T255I, P233L and D399N mutations, 
compared to wild-type paxillin, indeed modulated the expression of a significant number 
of genes. In particular, there were a number of mitochondrial signature proteins that 
were altered in the various mutants. Analyzing mitochondrial functions by measuring the 
interaction of these mutants with mitochondrial proteins MFN2, and DRP1, we identified 
that they alter mitochondrial dynamics, with significant fission rather than fusion. 
Paxillin also translocated from the focal adhesion to the mitochondrial membrane. In 
relationship to cisplatin responsiveness, PXN and mutant overexpression lead to cisplatin 
resistance. Conclusion: These data suggest that wild-type and mutant paxillin variants 
play a prominent role in neoplastic changes with direct implications in lung cancer 
progression and hence, its potential as a therapeutic target needs to be explored further. 
Keywords: SIGNAL TRASNDUCTION, Paxillin, mitochondria, FOCAL ADHESION
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Background: The methyltransferase enhancer of zeste homolog 2 (EZH2) belongs to 
the polycomb repressive 2 complex (PRC2). EZH2 is upregulated in several malignancies 
including prostate, breast and lung cancer. The EZH2 protein forms one of the critical 
protein complexes of PRC2 by partnering with EED (embryonic ectoderm development) 
protein. This EED/EZH2 complex has been shown to interact with histone deacytelase 
(HDAC). This interaction is highly specific and HDAC does not interact with any other 
PRC2 protein complexes. In the present study, we investigated the link between EZH2 
and HDAC in lung cancer cell lines and in human tumor tissue microarrays (TMAs). We also 
further investigated EZH2 as a marker for response to HDAC inhibitors. Methods: We 
analyzed EZH2 and HDAC1 mRNA expression in two lung adenocarcinoma datasets 
(MDACC n=152, and TCGA n=308), and correlated the gene expression with tumors’ 
clinico-pathological characteristics and patients’ outcome. To study the association of 
EZH2 and HDAC1 expression with response to the HDAC1 inhibitor suberanilohydroxamic 
acid (SAHA), we examined mRNA and protein expression by RT-PCR and Western 
blot, respectively, in twelve lung adenocarcinoma (LUAD) cell lines at baseline and 
after overexpression or knock-down of EZH2 or HDAC1 gene expression using siRNA. 
Response to (SAHA) in cell lines was measured by MTT assay and correlated with protein 
and mRNA expression levels of EZH2 and HDAC1. Results: Direct and positive correlation 
was found between EZH2 and HDAC1 expression NSCLC cell lines (P <0.0001). This 
correlation was confirmed in NSCLC specimens from MDACC (Spearman’s correlation 
r=0.416; p < 0.0001) and TCGA datasets (r=0.221; p <0.0001).Patients with high 
EZH2 and high HDAC1 expression in stage I NSCLC specimens of MDACC and TCGA 
datasets had lowest survival compared to the patients who had either or both low 
expressions. Overall survival in the univariate analysis (MDACC dataset; Hazard Ratio 
(HR)=2.97; p=0.031 and TCGA dataset; HR=2.6 and p=0.041) and multivariate 
analysis (MDACC; HR=2.92 and p=0.034 and TCGA; HR=3.17 p=0.016). When EZH2 
expression was knock down, there was a significant reduction in HDAC1 expression; 
conversely, when HDAC1 was knocked down EZH2 expression was also decreased. 
These concordant change in expression was seen both at the protein and mRNA 
level. Importantly, while all 8 cell lines with high EZH2 protein expression responded 
to SAHA treatment with average inhibition rate reaching 73.1%, three out of four cell 
lines with low EZH2 expression had a significantly lower response rate to SAHA inhibition 
with average inhibition rate 43.2% (P<0.0001). Additionally, altering the expression of 
EZH2 concordantly altered the sensitivity to SAHA i. e. forced increased expression of 
EZH2 increased the response to SAHA and vice versa. Conclusion: Our data suggest 
that EZH2 and HDAC expression are correlated in LUAD cell lines in human tissue 
microarrays and overexpression of both is a negative prognostic indicator. Additionally 
we show that increased EZH2 expression predicts for response to HDAC inhibitors 
and thus could serve as a biomarker for selecting LUAD patients with HDAC inhibitors. 
Keywords: EZH2, HDAC, SAHA, lung cancer
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to Twist1 protein degradation and tumor growth inhibition in our KrasG12D/Twist1 murine 
model of lung adenocarcinoma. We are currently testing and designing structure 
analogs of the initial candidate agents to develop more specific and potent inhibitors of 
TWIST1. Conclusion: We have identified a novel TWIST1 inhibitor harmine that induces 
degradation of TWIST1 and its binding partners, E12/E47 and inhibits the growth of KRAS 
mutant NSCLC both in vitro and in vivo. Therefore, we believe that targeting the TWIST1-
E2A pathway would be an effective therapeutic strategy. Since TWIST1 is essential 
not only for KRAS mutant NSCLC but more broadly for oncogene driven NSCLC, the 
development of this novel class of TWIST1 inhibitors could have a significant clinical impact. 
Keywords: EMT, KRAS, TWIST1 inhibitor
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MINI22.01 Detecting ALK, ROS1 and RET Fusion Genes in Advanced Non-Small 
Cell Lung Cancer (NSCLC) Using a Novel Multiplexed NCounter-Based Assay 
Noemi Reguart1, Ana Gimenez-Capitan2, Miguel Angel Molina2, Patricia Galvan3, Laia 
Pare3, Santiago Viteri4, Cristina Teixidó2, Sonia Rodriguez2, Josep Castellví2, Erika 
Aldeguer2, Nuria Viñolas1, Rafael Rosell5, Aleix Prat1 1Medical Oncology, Hospital Clinic, 
Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut D’Investigacions 
Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona/Spain, 2Pangaea Biotech, Quirón 
Dexeus University Institute, Barcelona/Spain, 3Translational Genomics and Targeted 
Therapeutics in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi I Sunyer 
(IDIBAPS), Hospital Clinic Barcelona, Barcelona/Spain, 4Dr Rosell Oncology Institute, Quirón 
Dexeus University Institute, Barcelona/Spain, 5Hospital Germans Trias I Pujol, Catalan 
Institute of Oncology, Barcelona/Spain
Background: Gene fusions of anaplastic lymphoma kinase (ALK), ROS1, and RET are 
targetable oncogenes present in approximately 9% of advanced NSCLC. Current assays 
for detecting gene fusions are based on FISH (FDA-approved companion diagnostic test 
for ALK), immunohistochemistry (IHQ) and qRT-PCR. These tests, however, are complex 
and have disadvantages in terms of turnaround, sensitivity, cost and throughput. The 
nCounter platform allows joint detection, in a single tube, without any enzymatic reaction 
and in 72 hours, of multiple fusion genes by transcript-based method from formalin-
fixed paraffin-embedded (FFPE) samples. Methods: A custom set consisting of 5´and 
3´ probes and/or fusion-specific probes to detect ALK, ROS1 and RET fusion transcripts 
was evaluated. A panel of ALK-ROS-RET positive cell lines (H2228, H3122 [EML4-ALK], 
SU-DHL-1 [NPM-ALK], HCC78 [SLC34A2-ROS], BaF3 pBABE [CD74-ROS], LC2/ad [RET]) 
and control fusion negative cell lines (PC9, H1975 [EGFR mut], H460, H23 [KRAS mut]) 
were used for nCounter validation. To determine the minimum of tumor surface area 
for detection, ALK translocated cell line H2228 was tested in FFPE at increasing cell 
numbers (2500, 5000, 10.000, 25000, 50000) corresponding to a surface area of 0.27, 
0.55, 1.1, 2.75 and 5.5 mm2, respectively, in the FFPE block. A total of 38 FFPE samples 
positive by FISH, IHC and/or qRT-PCR for ALK (n=30), ROS (n=7) and RET (n=1) were 
also analyzed. Total RNA was isolated from cell lines and FFPE and < 225 ng were used 
for hybridization. Raw counts were normalized using positive controls, negative controls 
and 4 house-keeping genes (GAPDH, GUSB, OAZ1 and POLR2A) as described in Lira et al. 
J Mol Diagn 2013. Positive and negative ALK fusion translocation was defined by a 3’/5’ 
ratio score of > 2.0 and ≤ 2.0 respectively. Response to crizotinib by RECIST criteria 
was retrospectively collected in patients with ALK-positive NSCLC. Results: nCounter 
sensitivity to predict fusion transcripts ALK, ROS and RET in cell lines by using both 
methods (3’/5’ and direct reporter probes) was 100%. Results indicate that samples 
containing as few as 10% positive tumor cells and a 2.75 mm2 tumor surface area 
were sufficient for adequate gene fusion detection. The accuracy of prediction (AUC) 
of ALK 3’-5’ ratio score in 45 independent samples was 82.6% (95% CI 69.3-95.6) with 
a kappa coefficient score of 0.637. Among 28 samples ALK-FISH-positive, ALK 3’-5’ 
scoring was positive in 27 samples (96%). One sample was non-evaluable by ALK 3’-
5’ scoring. Among the 17 samples ALK-FISH-negative, ALK 3’-5’ score was negative 
and positive in 10 (59%) and 7 (41%) samples, respectively. All patients with ALK-
FISH-negative samples but ALK 3’-5’ score positive (n=7) were positive for ALK IHC 
and 5 of them were treated with crizotinib. Response assessment was available in 3 
of these patients and response rate was 100%. One patient non-evaluable by FISH 
but positive 3’-5’ scoring also responded to crizotinib. Conclusion: The ALK/ROS1/
RET nCounter-based assay is a highly sensitive screening modality that might identify 
FISH-negative/non-evaluable NSCLC patients who could benefit from ALK inhibitors. 
Keywords: NSCLC, gene fusions, nCounter
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MINI22.02 Clinically Adoption of MSK-IMPACT, a Hybridization Capture-
Based next Generation Sequencing Assay, for the Assessment of Lung 
Adenocarcinomas Maria E. Arcila1, Ahmet Zehir1, Helena Yu2, Alexander Drilon2, Bob 
T. Li2, Gregory J. Riely2, Natasha Rekhtman1, Oscar Lin1, David Hyman2, Michael Berger1, 
Charles M. Rudin2, Mark G. Kris3, Marc Ladanyi1 1Department of Pathology, Memorial Sloan 
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Background: Mutation analysis plays a central role in the management of lung 
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MINI21.11 A Novel Cell Line Model of EGFR Exon 20 Insertion Mutations Adriana 
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Camidge1, Robert C. Doebele1 1Medical Oncology, University of Colorado-Amc, Aurora/CO/
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Background: In-frame insertions in exon 20 of EGFR are infrequent activating mutations 
in the tyrosine kinase domain that have decreased sensitivity to EGFR inhibitors and 
currently have no available targeted therapies. In vitro studies ectopically expressing 
some of the common insertions (3 to 21 bp between codons 762 and 770) show 
reduced sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Non-small cell lung cancer 
(NSCLC) patients whose tumors harbor these mutations do not respond to EGFR kinase 
inhibitors. To date, there are no known patient-derived cell lines that harbor the EGFR 
exon 20 insertions that recapitulate patient insensitivity to EGFR TKIs. Here we report the 
isolation and characterization of a patient derived cell line with an EGFR exon20 insertion. 
Methods: The CUTO-14 cell line was derived from a malignant pleural effusion of a lung 
adenocarcinoma patient harboring the EGFR exon 20 insertion p.A767_V767dupASV 
after obtaining IRB-approved informed consent. PCR amplification of EGFR exon 20 and 
subsequent Sanger sequencing was performed on genomic DNA isolated from CUTO-14. 
H3255 (L858R) and HCC827 (exon 19 del) cell lines were used as controls because 
they harbor sensitizing EGFR mutations. Cell viability was evaluated by MTS proliferation 
assay. Phosphorylation status and signaling was analyzed by western blot and an EGFR 
phosphorylation array. For tumor xenograft studies, nude mice were injected with 
1.5 x 106 cells in matrigel and evaluated weekly for tumor growth. Results: Genomic 
sequencing of CUTO-14 demonstrated that the cell line maintains the pA767_
V767dupASV EGFR exon 20 insertion. CUTO-14 showed relative resistance to gefitinib 
inhibition compared to HCC827 and H3255 in ERK1/2 phosphorylation assays. 
CUTO-14 also demonstrated reduced sensitivity to gefitinib compared to HCC827 
and H3255 in cell proliferation assays. Tumor formation was observed in mice after 
injection in nude mice. Conclusion: CUTO-14 cells represent a novel model for 
the investigation of therapeutic strategies for EGRF exon 20 insertions mutations. 
The cell line has the ability to develop tumors in vivo and importantly shows reduced 
sensitivity to EGFR TKIs mimicking the lack of response in patients with these mutations. 
Keywords: EGFR Exon 20 Insertion, Cell Line, EGFR Inhibitor, EGFR mutation
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Background: Although a large fraction of non-small cell lung cancers (NSCLC) are 
dependent on defined oncogenic driver mutations, little progress has been made in the 
treatment of patients with the most common driver mutation, mutant KRAS. We previously 
demonstrated that the basic helix-loop-helix transcription factor, Twist1 cooperates 
with mutant Kras to induce lung adenocarcinoma in mouse models, and that inhibition 
of Twist1 in murine models and KRAS mutant NSCLC cell lines led to oncogene-induced 
senescence (OIS) and in some cases, apoptosis. Therefore, targeting the TWIST1 pathway 
represents an exciting and novel therapeutic strategy which may have a significant 
clinical impact. Methods: We used gene expression profiles from KRAS mutant human 
NSCLC cell lines following shRNA-mediated TWIST1 knockdown to perform connectivity 
map (CMAP) analysis to identify pharmacologic inhibitors of TWIST1. Growth inhibition 
was determined through the colony formation and MTS assays. Apoptosis (cl-PARP, 
active anti-C3) and OIS (SA-β-Gal) was assessed. Genetic (shRNA) and pharmacologic 
inhibition of the TWIST1-E2A pathway was performed. Lung tumor burden as well as 
levels of TWIST1 protein, apoptosis and proliferation were measured after treatment 
with harmine in the CCSP-rtTA/tetO-KrasG12D/Twist1-tetO7-luc(CRT) mice. Results: We 
found that several of our CMAP compounds had significant growth inhibitory effects 
in NSCLC cell lines. Interestingly, a family of related harmala alkaloids including 
harmine ranked highly in our CMAP analysis. We observed that harmine could inhibit 
growth in KRAS mutant NSCLC cell lines through the induction of OIS or apoptosis and 
phenocopied genetic inhibition of TWIST1. Remarkably, harmine treatment led to TWIST1 
protein degradation as well as degradation of its binding partners, the E2A proteins, 
E12/E47. Furthermore, the growth inhibitory effects of the harmala alkaloids correlated 
with the ability to degrade TWIST1 and were independent of its ability to inhibit the DYRK 
kinases. In addition, we demonstrated that heterodimer formation of TWIST1/E12/
E47 resulted in a reciprocal stabilization of each binding partner and that E12/E47 are 
required for TWIST1 mediated suppression of OIS and apoptosis. Importantly, we found 
that harmine preferential targets the TWIST1-E12 heterodimer for degradation and the 
growth inhibitory effects of harmine are in due in at least part to the ability to inhibit 
the TWIST1/E12/E47 heterodimer as overexpression of the E2A proteins can suppress 
harmine induced cytotoxicity. Finally, we have demonstrated that harmine treatment lead 
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IHC, to demonstrate genetic mutations that make patients eligible for molecularly targeted 
agents. This new quadriplex IHC offers the capability with a single 4 micron section 
to accurately diagnose primary lung adenocarcinoma, squamous cell carcinoma or 
adenosquamous carcinoma and while conserving tissue for additional molecular testing. 
Keywords: Non Small Cell Lung Carcinoma, Multiplex (Quadruple) IHC
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Background: Next generation sequencing (NGS) has exceptional sensitivity, but at the 
expense of false positives. This can result in a less than optimal positive predictive value 
and eventually the futile treatment of patients. We have developed a unique set of quality 
control filters for both Ion Torrent and Illumina that minimize false positives, but have 
little negative impact on sensitivity. To address this paradoxical association of sensitivity 
and false positives, we developed a dual platform methodology of NGS using both the 
Ion Torrent and Illumina to solve this classical dilemma. Methods: A series of filters 
were developed to determine quality cutoffs for variant calls to minimize false positives 
that included the minimum quality score threshold (QUALT), minimum percent variant 
reads (MPVR), minimum variant reads (MVR), minimum variant reads threshold (MVRT), 
minimum variant allelic frequency threshold (MVAF), minimum variant reads positive 
predictive value (MVR-PPV), and systematic errors (SE). A parallel system of using the 
MiSeq and PGM to sequence all specimens within an IT systems control and a Classify 
Callsmatrix solution for mutational analysis was designed. Unique cohorts of patients 
with prior exome sequencing as part of TCGA were used as gold standard controls with 
matching fresh frozen and FFPE samples. Results: Table 1 provides the results of filters 
developed to maximize sensitivity versus PPV. Using our targeted sequencing panel the 
PGM consistently outperformed the MiSeq for the standard performance characteristics 
of sensitivity and PPV for both frozen and FFPE samples. Both platforms have systematic 




















PGM FF 0.2% None None None 100% 93-100% 88% 70-96%
PGM FF 0.2% >99 >=20 >.035 99% 93-100% 95% 78-100%
PGM FFPE 0.2% None None None 99% 93-100% 58% 2-94%
PGM FFPE 0.2% >99 >=21 >.018 97% 63-100% 92% 40-100%
MiSeq FF 1% None None None 97% 79-100% 49% 31-66%
MiSeq FF 1% >99 >=5 >.017 95% 66-100% 82% 66-95%
MiSeq FFPE 1% None None None 94% 43-100% 10% 2-37%
MiSeq FFPE 1% >99 >=10 >.028 92% 39-100% 62% 6-100%
 
Table 2 provides the results for dual platform sequencing which show a marked reduction 
in false positives while maintaining sensitivity.
Table 2 FF FF FF FF FFPE FFPE FFPE FFPE
SNV(s) SNV(s) Indels Indels SNV(s) SNV(s) Indels Indels
Per-
cent VAF Percent VAF Percent VAF Percent VAF
Assay Sensitivity 99.8% 2.87% 100.0% 2.90% 98.3% 3.56% 100.0% 3.60%
Assay PPV 97.5% 2.87% 91.0% 2.90% 96.7% 3.56% 91.0% 3.60%
 
Conclusion: Single platform NGS is plagued by false positives. Dual platform sequencing 
is a reliable method of diminishing false positives with minimal to no impact on sensitivity. 
Keywords: NGS, clinical testing, Quality Control, False Positives
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Background: Molecular testing has become important in managing advanced non-small 
cell lung cancer (NSCLC), both in clinical practice, as well as in clinical trials. For the 
latter, tissue samples often have to be analysed in a central laboratory. We evaluated 
the turnaround time and possible delay in start of therapy in this process. Methods: 
We reviewed our prospective database on all molecular testing cases for clinical trial 
adenocarcinomas (LUAD). The use of multiple single gene or mutation specific assays, 
broadly adopted in many laboratories to detect clinically relevant genomic alterations, 
often leads to delays if sequentially performed, tissue exhaustion, incomplete 
assessment and additional biopsy procedures. Comprehensive assays using massively 
parallel “next-generation” sequencing (NGS) offer a distinct advantage when addressing 
the increased testing needs of genotype-based therapeutic approaches. Here we 
describe our experience with a 410 gene, clinically validated, hybrid-capture-based 
NGS assay applied to testing of LUAD. Methods: Consecutive LUAD cases submitted 
for routine mutation analysis within a 1 year period were reviewed. Unstained slides 
of formalin fixed, paraffin embedded tissue were received for each case (range 15-
20 slides/case). Corresponding H&E stained slides were reviewed and cell counts 
were performed in a subset of cases with limited material to establish minimal tissue 
requirements. Testing was performed by a laboratory-developed custom hybridization-
capture based assay (MSK-IMPACT) targeting all exons and selected introns of 410 
key cancer genes (J Mol Diagn 17:251-264, 2015). Barcoded libraries from tumor / 
normal pairs were captured and sequenced on an Illumina HiSeq 2500 and analyzed 
with a custom analysis pipeline. Results: A total of 469 specimens were received for 
comprehensive testing (98 cytology samples, 239 needle biopsies, 132 large biopsies/
resections) of which 93% (436/469) were successfully tested. Thirty four cases (7%, 
34/469) failed due to very low tumor content or low DNA yield. Cell counts for failed 
samples averaged 239 cells / slide (range 10-270) while all successfully tested had over 
1,000 cells / slide each. Failure rate was similar for cytologies and biopsies. An average 
of 10 genomic alterations were detected per patient (range 1-96). The most frequently 
mutated genes were TP53, EGFR, KRAS, KEAP1 and STK11. Copy number gains of NKX2-
1 and EGFR genes and CDKN2A loss were most common. EGFR mutations and ALK 
fusions were detected in 28% and 4% of cases, respectively. Among the 299 EGFR / 
ALK WT cases, MSK-IMPACT uncovered targetable genomic alterations that would have 
remained undetected through focused EGFR/ALK testing alone. These included fusions 
in RET (10) and ROS1 (13), mutations in ERBB2 (11) and BRAF (19) and amplifications in 
MET (12, unrelated to EGFR), MDM2 (26) and CDK4 (20) among others. The higher than 
expected rates of RET and ROS1 fusions are related to enrichment of previously tested 
cases known to be negative for other driver alterations. Conclusion: Comprehensive 
hybrid-capture based NGS assays such as MSK-IMPACT are an efficient testing 
strategy for LUAD across sample types. This upfront broad approach enables 
more optimal patient stratification for treatment by targeted therapeutics. 
Keywords: Targeted therapeutics, lung adenocarcinoma, molecular profiling, next 
generation sequencing
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Background: Lung cancer is the most common cancer worldwide and has the highest 
mortality rate. Carcinomas comprise 95% of all lung cancers, the vast majority of 
which are non-small cell lung carcinomas (NSCC). It is critical to further distinguish 
adenocarcinomas from squamous carcinomas in order to optimize the efficiency of the 
precision medicine analysis for the detection of active molecular targets for therapies. 
Currently Thyroid Transcription Factor-1 (TTF-1) and Napsin-A are the most commonly 
used immunohistochemical (IHC) stains to identify primary lung adenocarcinoma, and 
p40 and cytokeratin 5/6 (CK5/6) are used for squamous cell carcinoma. IHC stains for 
these markers, are performed either individually (IHC brown staining) or in combination 
as dual immunostains (i.e. TTF-1 + Napsin-A and p40 + CK5/6, utilizing brown and red 
chromogens). Here we present a novel, truly multiplex immunohistochemical approach 
that combines staining with the above four antibodies on a single tissue section utilizing 
four different chromogens to accurately diagnose primary lung adenocarcinomas, 
squamous cell carcinomas, and combined adenosquamous carcinomas of the 
lung. Methods: Developmental reagents from Ventana Medical Systems, Inc. were 
leveraged for this study. Detection of CK 5/6 and p40 [BC28] was used to identify 
squamous cell carcinoma cells. Detection of Napsin A and TTF-1 was used to identify 
adenocarcinoma cells. Detection was accomplished using secondary antibody:enzyme 
conjugates and orthogonal chromogenic detection chemistries to simultaneously detect 
all 4 biomarkers. Fully automated multiplexed detection was performed on a Benchmark 
XT with 4 microns thick sections from formalin fixed paraffin embedded, non-small cell 
lung cancer specimens obtained from both the Ventana Medical Systems, Inc. tissue 
bank and from the Thomas Jefferson University’s Department of Pathology, Anatomy 
and Cell Biology laboratories. Detection of each marker in multiplex was compared to 
individual detections using diaminobenzidine deposition according to established Ventana 
Medical Systems, Inc. protocols. All detections were reviewed by a board certified 
pathologist. Results: Adenocarcinomas (7 of 7) and the adenocarcinoma components of 
the adenosquamous carcinomas (6 of 6) stained positive for TTF-1 (yellow nuclear stain) 
and Napsin-A (pink cytoplasmic granular stain). Squamous cell carcinomas (5 of 5) and the 
squamous cell carcinoma components of the adenosquamous carcinomas (6 of 6) stained 
positive for p40 (blue nuclear stain) and CK5/6 (brown cytoplasmic stain). The colors 
were clear, distinct, easily differentiated and recognizable. There was no discrepancy 
between the expression of the individual antibodies and the expression of the same 
antibodies in the multiplex setting. Conclusion: Increasingly, the diagnosis of lung cancer 
is established by examination of small tissue specimens obtained by minimally invasive 
techniques. It is critical to employ these tissues at maximum efficiency in order to render 
an accurate pathologic diagnosis and to perform theranostic studies, either genomic or 
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Background: Next-generation sequencing (NGS) can be used to interrogate multiple 
areas of the tumor genome. Several hot-spot panels have been developed to identify 
variants amenable to targeted therapies and enrollment into clinical trials. Variants of 
unknown significance (VUS) in the vicinity of hot-spots are routinely discovered. To better 
understand these obscure VUS, we built a Protein Viewer that displays the relationship of 
known actionable variant(s) to the VUS. Methods: We developed a web-based protein 
viewer that can be deployed across multiple browsers. The tool supports the visual 
representation of 23 genes which are interrogated by our NGS platform. We used the 
longest mRNA transcript (hg19) to define the protein domains. All actionable variants as 
reported by an knowledge database were included, with the selected VUS differentially 
highlighted. VUS is defined as a non-actionable variant that is not reported in 
dbSNP. Results: Approximately 50% of all stage III and IV lung cancer patients tested by 
our NGS platform have one or more VUS. After the variant information is loaded in the 
Protein Viewer, a two-dimensional image of the full length protein with actionable variants 
and VUS is displayed (Figure 1). The Viewer is utilized at RPCI to present cases at our 
molecular tumor board for quick visualization and discussion.
Figure 1: Protein Viewer with a PIK3CA VUS harboring a Q546H (pink) in a lung 
adenocarcinoma. Top panel with PIK3CA exons 2-21 boundaries (vertical lines) with 
protein domains (blue rectangles along axis). Bottom panel with the zoom feature which 
allows more discreet visualization of the VUS, a neighboring Q546K actionable variant 
(green), and additional actionable variants for ovarian cancer (green 
rectangles). Conclusion: Understanding the relationship of VUS to protein domains and 
proximity to previously known actionable sites is a potentially powerful way to evaluate 
and determine whether a patient might be a candidate for targeted therapy. Because the 
exact effect of the VUS on the function of the protein is still impossible to discern (tyrosine 
kinase inhibitor sensitivity/ resistance/no effect), the next generation of protein viewers 
should incorporate 3D and protein folding/domain interaction prediction capabilities. 
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Background: Genomic profiling is a powerful method for identifying mutations that 
drive tumors and matching patients to targeted therapies. However, this may only be 
a transient solution and resistance commonly emerges as the mechanism of targeted 
inhibition is overcome. Proteomic profiling of the tumor provides a dynamic tool to 
survey altered protein expression and deregulated pathways, which in turn may implicate 
specific treatments or identify novel therapeutic targets. Mass spectrometry offers 
highly multiplexed proteomic measurements, but extensive sample pre-processing and 
low sample throughput can lead to extended analysis times of weeks or months. Thus 
a need exists for a high throughput, sensitive and quantitative platform for proteomic 
analysis. Methods: We used the SOMAscan proteomic platform, which measures 1129 
proteins with a median limit of detection of 40 fM and 5% CV, to analyze protein lysates 
from 63 lung tumor samples. The assay does not require sample pre-fractionation, and 
this study (which generated over 142,000 protein measurements) represents less than 
one day of SOMAscan throughput. The study consisted of matched tumor/non-tumor 
protein lysates prepared from 18 squamous cell carcinoma and 45 adenocarcinoma fresh-
frozen resected specimens, 86% of which were Stage I/II. The paired log2 tumor/non-
tumor ratio was calculated and hierarchical clustering heat maps and dendrograms were 
constructed to identify related protein regions and tumor phenotypes. Results: Common 
suitability in patients with advanced NSCLC between March 1, 2011 (start) and October 
31, 2014. The following time points were considered: T1 (request for tissue sections 
from the pathology lab); T2 (receipt of sections and shipment); T3 (arrival of sections in 
central lab (CL)); T4 (receipt of biomarker result from CL). Results: 251 patients were 
considered for biomarker-driven trials. Twenty-three cases did not have further analysis, 
as the request for central molecular testing was cancelled: insufficient tissue (n=11); 
exclusion criterion (n=10); patient refusal (n=2). Results for the remaining 228 patients 
were: failure of central biomarker analysis due to insufficient quantity of tissue (n=18), 
or quality of tissue (n=3, i.e. decalcification or poor fixation). Valuable results were 
obtained for 207 patients. In 91 of 228 (39.9%) samples sent, a biomarker of interest 
was documented. This led to 34 clinical trial inclusions. Other patients were no longer 
eligible due to loss of performance status (n=20), loss of contact (n=14), no trial slot 
available at the appropriate time (n=18), or exclusion criteria (n=5). The mean waiting 
time between signing informed consent (T1) and receiving results of the biomarker 
analysis (T4) was 25.1 calendar (SD 17.3) days (Table). The preparation of the unstained 
slides by the pathology lab took about 9.1 (SD 6.8) days, the time of the biomarker 
testing itself accounted for 12.8 (SD 7.3) days. For 18 of 228 (7.9%) patients, repeated 
sample shipments were needed because of insufficient tumor cells, their mean waiting 
time between informed consent and receiving the biomarker result was 62.2 (SD 38.4) 
days. Table: Waiting times (t) in molecular testing for 228 patients.
Time interval Mean StDev Median Range
Pathology lab (T2-T1) 9.1 6.8 7.0 1 - 70
Shipment (T3-T2) 1.8 1.6 1.0 0 - 17
Analysis (T4-T3) 12.8 7.3 12.0 2 - 58
Request to result (T4-T1) 25.1 17.3 22.0 7 - 184
 
Conclusion: While molecular testing is important in many NSCLC trials, our results show 
that waiting times for central laboratory analysis can cause an important delay in treatment 
initiation, and even ineligibility for the trial(s) under consideration. Start of therapy 
based on properly validated local testing, with a posteriori central biomarker testing to 
guarantee the integrity of the trial, would be more rewarding for quite some patients. 
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Background: Lung cancer is the leading cause of cancer mortality worldwide, and 
metastatic spread of cancer to distant organs is the main reason for lung cancer deaths. 
They spread to different distant organs, exhibit an outstandingly different situation 
of clinical characteristics and will be medically and surgically incurable. Thus, there 
is a clear need for a reliable and efficient in vitro culture model to enable transition 
to invasion and journey to distant organs of these critical steps in cancer metastatic 
progression. Methods: Here we report a biomimetic multi-organ microfluidic chip 
system more closely reconstituting the structural tissue arrangements, functional 
complexity and dynamic mechanical microenvironments and reproducing survival, 
growth, transition to invasion and journey to distant multi organs in lung cancer 
metastasis. To reconstitute the actual growth conditions of lung cancer in vivo, we 
created a thin, porous, flexible membrane, integrated microfluidic chip emulating the 
in vivo tissue structure and enabling heterotypic cell interactions, while maintaining 
cell compart-mentalization. The human bronchial epithelial cells and stromal cells were 
cultured on opposite sides of the membrane. Once the cells were grown to confluence, 
air was introduced into the epithelial compartment to create an air-liquid interface 
and more precisely mimic the lining of the lung air space. Then lung cancer cells were 
cultured on the human epithelial compartment to mimic lung cancer formation and the 
multi organ chambers were linked with side channels that supply lung cancer cells to 
the brain, bone or liver cells chamber to mimic lung cancer metastasis. In addition, the 
system provided analyzing cell physiology and visualizing complex cell behaviors in a 
more physiologically relevant context. Results: A biomimetic multi-organ microfluidic 
chip system was created. The quick formation of lung cancer cells that grow away from 
their natural margins and then attack adjacent components and spread to other organs 
were observed at all times and the cells characterizations were also detected accurately 
and effectively. In this multi-organ pathogenesis system, it might be possible to provide 
an ultrahigh level of reproducibility, authenticity and sensitivity. Conclusion: This 
microdevice provides a proof of principlefor this novel biomimetic strategy that is 
inspired by the integrated chemical, biological, and mechanical structures and functions 
of the living multi organs. This versatile system enables direct visualization and 
quantitative analysis of diverse biological processes of the intact lung cancer metastasis 
in ways that have not been possible in traditional cell culture or animal models. 
Keywords: lung cancer metastasis, in vitro, microfluidic chip, biomimetic multi-organ 
chip
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CellSave vacutainers for up to 96 hours after blood collection. Methods: To evaluate the 
suitability of using CellSave preserved samples for circulating free DNA (cfDNA) analysis, 
we undertook a 20 healthy normal volunteers (HNV) study and 45 patient sample study, 
with parallel EDTA and CellSave bloods collected. For each sample cfDNA was isolated 
between 4 hours and 96 hours post-draw and cfDNA yields determined. A potential 
issue with using CellSave blood was that the CellSave preservative could act as a DNA 
damaging agent and effectively increase background sequencing errors. To test this, the 
EDTA and CellSave cfDNA samples were subjected to next generation sequencing (NGS) 
to estimate the overall mutation burden. In addition, the utility of CellSave ctDNA for 
targeted NGS was also determined. Finally, SCLC-specific copy number aberrations (CNA) 
were analysed in ctDNA and CTCs isolated from the same CellSave blood sample from 
individual SCLC patients. Results: We demonstrate that yields of cfDNA obtained from 96-
hour whole blood CellSave samples are equivalent to those obtained from conventional 
EDTA plasma processed within 4 hours of blood draw. Targeted and genome-wide NGS 
revealed comparable DNA quality and resultant sequence information from cfDNA within 
CellSave and EDTA samples, thereby validating CellSave blood as a viable source of 
ctDNA. We also demonstrate that CTCs and ctDNA can be isolated from the same patient 
blood sample, and give the same patterns of CNA allowing direct comparison of the 
genetic status of patients’ tumours. Conclusion:In summary, we have demonstrated the 
suitability of whole blood CellSave samples for both CTC and ctDNA molecular analysis 
in SCLC. The ability to generate informative molecular profiles of both CTCs and ctDNA 
from a simple whole blood sample, up to 4 days post-draw represents a significant 
methodological improvement for clinical benefit. We posit that as minimally invasive, 
liquid biopsies become increasingly employed for cancer patient management, the ability 
to routinely and simply draw blood and ship samples to accredited biomarker assessment 
laboratories will greatly facilitate the delivery of personalised cancer medicines. 
Keywords: CTC, ctDNA, SCLC, NGS
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MINI23.01 Risk of Lung Cancer in Female Non-Smokers Requires Extended 
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Background: The National Lung Screening Trial (NLST) established a 20% reduction in 
lung cancer-specific mortality with low-dose computed tomography (LDCT) in 30 pack 
year smokers. However, approximately 25% of all lung cancers occur in non-smokers, 
and screening guidelines are needed for this large cohort. Pre-test probability of lung 
cancer can be estimated in this group using a validated risk prediction model [Liverpool 
Lung Project, LLP]. The LLP compares risk in 579 lung cancer cases with 1157 age and 
sex matched controls. Methods: We used the LLP model to illustrate risk profiles for non-
smoking females compared to 30 pack year smokers [the NLST target population]. This 
tool revealed the individual and cumulative effect of risk factors in non-smoking females. 
The LLP estimates the probability of developing lung cancer within 5 years based on 
age, sex, smoking history, family history of lung cancer, infectious and occupational 
exposures, and prior diagnosis of a malignant tumor other than lung cancer. This tool 
has been validated in a Caucasian population including never and ever smokers up 
to 79 years of age (cross validation of tool: AUC=0.70). Results: We generated risk 
profiles for female non-smokers between 65-79 years old and no other co-morbidity, 
and compared the risk against those for women in the same age bracket with 30-pack 
year smoking history or additional non-tobacco risk factors (i.e. previous pneumonia, 
asbestos exposure, having a relative with lung cancer < 60years, and the combination 
of all factors listed). Significant risk with increasing age was predicted by the LLP model 
for women with 30 pack year smoking history (peak risk at age 75 years 2.2% over 
next 5 years). This is less than the risk of 6.7% over the next 5 years (at age 75 years) 
for non-smoking women with the combination of all mentioned risk factors. Relative 
risk of lung cancer of non-smoking women with all noted risk factors was 3.5 compared 
to women with no other risk factors other than 30 pack-years smoking history. Relative 
risk of smoking women compared to non-smoking without other risk factors was 4, while 
relative risk of non-smoking women with cumulative risk factors was 14 compared to 
non-smoking women with no other risk factors.
proteomic changes and unique tumor phenotypic groups were identified by unbiased 
clustering algorithms. Large, consistent tumor/non-tumor differences of at least 4-fold 
were observed for 35 proteins in at least 20 (32%) of the tumors. Some of these proteins 
were more than 100-fold higher in individual tumors. The two most commonly elevated 
proteins were thrombospondin 2 and MMP12, which were increased in 81% and 61% of 
the tumors, respectively. We have previously reported higher levels of MMP12 in the 
serum of lung cancer patients, and the current data supports a tumor-associated origin 
for circulated MMP12. A second analysis identified sub-phenotypes of tumors clustered 
by common protein alterations independent of histological classification or mutation 
status. Many of these tumor subsets had increased expression of known oncology 
drug targets. Conclusion: Broad, unbiased high-throughput proteomic profiling of 
tumor tissue may reveal individual phenotypes that hold the potential to respond to 
targeted therapies and to monitor therapeutic efficacy throughout treatment. Measuring 
proteins complements mutation analysis by enabling therapeutic selection beyond driver 
mutation targets, including immune modulator therapies, repurposing existing drugs and 
enriching clinical trials with likely responders. While genomics is a fixed snapshot, blood- 
and tissue-based serial proteomic measurements respond to change and can lead to 
the personalized adaptation of treatment and identification of novel therapeutic targets. 
Keywords: Tumor phenotype, Proteomic analysis, SOMAmer
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Background: There is a clinical need to establish whether those pathways activated in 
vitro and in animal models, are also activated in human lung cancer. We established 
a window-of-opportunity clinical trial platform in lung cancer where novel agents 
are administered in the preoperative period. Intratumoral drug concentrations are 
correlated with molecular marker changes. Our four completed window-of-opportunity 
clinical trials established that optimal intratumoral drug concentrations are needed 
for the desired pharmacodynamic effects, providing direction for optimal dose and 
schedule. To further evaluate the value of this window-of-opportunity platform, we 
investigate the impact on standard postoperative outcome measures. Methods: 39 
consecutive patients enrolled under the window-of-opportunity platform were matched 
to 39 contemporary patients undergoing the same operation by the same surgeon. Co-
morbidities and stage of lung cancer and postoperative complications were compared 
using univariate and multivariate analysis. Wilcoxon Scores (Rank Sums) for variable 
data elements and Fisher’s Exact Test was used for analysis. Results: When comparing 
window-of-opportunity patients to control patients, there was no difference in age, pack 
years of smoking, or incidence of comorbidities including diabetes, coronary artery 
disease, hypertension, chronic obstructive pulmonary disease, and previous cancer. 
There was no difference in the stage distribution, (stage I: 28 vs. 22, stage II: 5 vs. 
3, stage III: 5 vs. 2 stage IV: 1 vs. 1, p=0.1642). There was also no difference in the 
incidence of postoperative pneumonia (4 vs. 9, p=0.2235), other infection (2 vs. 3, 
p=0.8208), atelectasis (2 vs. 4, p=0.6748), myocardial infarction (0 vs. 0, p=1.000), 
reoperation for bleeding (1 vs. 1, p=1.000), pulmonary embolism (1 vs. 2, p=1.000) 
or number patients experiencing any complication (14 vs. 8, p=0.131118). There was 
no difference in the distribution of survival at 2 years (27 vs. 30) or 5 years (10 vs. 
15), p=0.2266. Conclusion: The window of opportunity platform does not increase the 
perioperative risk of complications in early stage NSCLC patients undergoing surgery. By 
evaluating drug effect and the potential toxicities, window-of-opportunity trials validate 
mechanisms established in the laboratory and facilitate bi-directional translation research. 
Keywords: lung cancer, chemotherapy, Surgery, pharmacodynamics
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DNA and Circulating Tumour Cells Isolated from the Same Whole Blood Sample 
Dominic G. Rothwell1, Nigel Smith1, Daniel Morris1, Hui Sun Leong2, Yaoyong Li3, 
Louise Carter1, Fiona Blackhall4, Crispin Miller2, Caroline Dive1, Ged Brady1 1CEP, CR-UK 
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Background: Small Cell Lung Cancer (SCLC) is an aggressive, highly metastatic disease 
with dismal prognosis. Response rates to first line chemotherapy are generally high, but 
progression free survival is short due to development of chemotherapy resistance via 
mechanisms not well understood. Due to the difficulty in collecting tissue biopsies in 
SCLC, blood, which can be sampled simply and routinely, provides a means of inferring 
the current genetic status of a patients tumour via analysis of circulating tumour cells 
(CTCs) or circulating tumour DNA (ctDNA). These offer a minimally invasive opportunity to 
study drug resistance mechanisms, evaluate tumour heterogeneity and potentially reveal 
new drug targets in this disease. However, accurate assessment of both CTCs and ctDNA 
requires all blood cells be maintained intact until samples are processed, particularly 
when analytes present are at very low concentrations. Here we describe and validate a 
blood collection protocol that does not require on-site processing, and which is amenable 
for analysis of both CTCs and ctDNA following storage at ambient temperature in 
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Conclusion: In a large prospective study of unselected high risk smokers with and 
without COPD, we report a strong linear association between increasing severity of COPD 
and increasing lung cancer risk (incidence). This suggests that the risk of lung cancer is 
greatest in those with the most severe COPD and 3-4 fold greater than those with normal 
lung function. We also report that lung cancers of more aggressive histology were more 
common in those with COPD. Funding This study was funded by a grant from Johnson 
and Johnson and grants U01-CA-80098 and U01-CA-79778 to the American College of 
Radiology Imaging Network Keywords: Lung Cancer, COPD, risk, incidence
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Background: Chronic obstructive pulmonary disease (COPD) is a major intermediate 
phenotype for Lung cancer (LC); the presence of COPD conferring a three- to 10-fold 
increased risk of LC when compared with smokers without COPD. Variability in lung 
function and risk for COPD in people with similar cigarette smoking histories, together 
with studies of familial aggregation, support an important role for genetic factors in 
COPD. Therefore, we employed a targeted sequencing approach to identify variants 
associated with susceptibility to COPD. We focused on 107 common susceptibility 
loci identifi ed in recent genome-wide association studies (GWAS) catalog in LC, COPD, 
lung function and smoking behavior. Methods: We employed an extreme phenotype 
approach in two carefully phenotyped extreme categories of smokers from the 
COPDGene study: 1) Long-term smokers with normal lung function defi ned as post-
bronchodilator FEV1 ≥ 80% predicted, FEV1/FVC ≥ 0.7, with smoking histories of 15+ 
pack-years, considered as resistant to the effects of smoking, n = 318.; 2) Susceptible 
smokers with severe COPD defi ned as GOLD Stages 3-4 (post-bronchodilator FEV1 < 
50% predicted and FEV1/FVC < 0.7), with smoking histories of 10+ pack-years, n = 
309. We performed exome sequencing and analyzed rare (minor allele frequency [MAF] 
< 0.01 in reference exome databases) substitution and indel variants predicted to be 
functional in susceptibility loci previously identifi ed by GWAS. Results: Our analysis 
revealed eight potentially causative non-synonymous substitution variants, occurring 
in 3+ susceptible smokers with COPD, and with none in resistant smokers. The two 
most intriguing associations wereTGM5 Thr42Asn and ZBTB9 Leu43Val, that presented 
in six and four susceptible smokers with severe COPD, respectively. Moreover, we 
found an additional TGM5 compound heterozygous mutation, Val202Ile, carried by two 
severe COPD patients with none in the resistant smokers. TGM5 is located on 15q15.2, 
a susceptibility locus only reported in LC GWAS, and the p.Thr42Asn in exon 2 is only 
1563bp away from the LC GWAS hit (rs504417) in intron 1. ZBTB9 is located on 6p21.31, 
a locus common to LC, lung function and smoking behavior. Table 1. List of top candidate 
deleterious mutations in susceptible smokers
Marker Gene Protein # Mutat-ed COPD
# Mutated 
Control MAF in KG
rs148913728 TGM5 Thr42Asn 6 0 0.0012
rs144575810 TGM5 Val202Ile 2 0 0.0002
rs41267651 ZBTB9 Leu43Val 4 0 0.0008
rs147018937 NID2 Lys1296Arg 3 0 0.0004
rs147278493 SLC6A18 Gly496Arg 3 0 0.0002
rs116926108 IFIT3 Leu390Arg 3 0 0.0002
rs142934543 LAMA1 Lys2086Thr 3 0 0.0002
rs41316996 DBH Gly482Arg 3 0 0.0004
rs41298243 MYOF Phe1400Leu 3 0 0.0002
LC, lung cancer; COPD, chronic obstructive pulmonary disease; SM, smoking behavior; PF, 
pulmonary function; MAF, minor allele frequency; KG, thousand genome. Conclusion: Our 
targeted exome sequencing results demonstrate highly disruptive COPD risk-
conferring TGM5 and ZBTB9 rare mutations that are associated with susceptibility to lung 
cancer in smokers, and strengthen the concept of a shared genetic link between COPD and LC. 
Keywords: Targeted Exome Sequencing, Chronic obstructive pulmonary disease, lung 
cancer, rare mutation
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MINI23.04 Familial Clustering of Lung Cancer (LC) Cases in a South European 
Population (sEp) Iosune Baraibar1, Eduardo Castanon1, Jos M. Lopez-Picazo1, Alfonso 
Gurpide1, Jose L. Perez-Gracia1, Juan P. Fusco1, Patricia Martin1, Leire Zubiri1, Lucía 
Ceniceros1, Jairo Legaspi1, Isabel Gil-Aldea2, Javier Zulueta3, Christian Rolfo4, Ignacio 
Gil-Bazo1 1Oncology, Clinica Universidad de Navarra, Pamplona/Spain, 2Biobank, Fundacion 
Miguel Servet-Navarrabiomed, Pamplona/Spain, 3Pulmonology, Clinica Universidad de 
Conclusion: Therefore, the development of lung cancer risk prediction models is a key 
advance in the assessment of patients at risk. Individual risk assessment can be judged 
using the LLP model and could encourage refi nement of screening recommendations. 
Keywords: Non-smokers, Screening, lung cancer, Females
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MINI23.02 COPD Severity by GOLD Status and Lung Cancer Risk: Results from 
a Large Prospective Screening Study (NLST-ACRIN Cohort Analysis, N=18, 
714) 
Raewyn J. Hopkins1, Robert Young1, Fenghai Duan2, Caroline Chiles3, Greg D. Gamble1, 
Denise R. Aberle4 1University of Auckland, Auckland/New Zealand, 2Department of 
Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, 
Providence, Rhode Island, Providence/United States of America, 3Wake Forest University 
Baptist Medical Center, Winston-Salem/AL/United States of America, 4Department of 
Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles/CA/United 
States of America
Background: Epidemiological studies consistently show that chronic obstructive 
pulmonary disease (COPD) is associated with an increased risk of lung cancer among 
smokers. However, debate exists as to whether there is a linear relationship between 
the severity of COPD and risk of lung cancer. The National Lung Screening Study (NLST) 
and it’s sub-study by the American College of Radiology and Imaging Network (ACRIN), 
provides the means to re-examine these fi ndings. We examined the effect of spirometry-
defi ned COPD (according to GOLD status at baseline), on the risk of lung cancer in the 
NLST-ACRIN cohort (according to lung cancer incidence), in a large prospective lung 
cancer screening study of high risk smokers. Methods: In the NLST-ACRIN cohort of 
18,475 screening participants eligible for the NLST, 6,436 screening participants had 
COPD (35%) according to baseline pre-bronchodilator spirometry and were followed for 
a mean of 6.4 years. From this group, 401 lung cancer cases were identifi ed. The 6,436 
screening participants with COPD were sub-grouped according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stages 1 (N=1607), 2 (N=3528), 3 (N=1083) 
and 4 (211). Lung cancer incidence at the end of follow-up was compared between the 
GOLD subgroups and those with normal spirometry (N=12,039). Results: Compared 
to those with normal spirometry, where the lung cancer incident rate was 4.63/1000 
person years, the lung cancer incident rate was 7.58/1000 person years for GOLD 
1, 9.43/1000 person years for GOLD 2, 12.7/1000 person years for GOLD 3 and 
15.55/1000 person years for GOLD 4 (all P<0.0001). The lung cancer histology was 
signifi cantly different, with more squamous and non-small cell cancers in those with 
COPD but more adenocarcinoma and Bronchoalveolar carcinoma in those with normal 
lung function (P<0.004).
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workplace, family history of lung cancer and other cancer for all subjects, and clinical 
characteristics (cell type, EGFR mutation status, staging and treatment etc.) for lung 
cancer patients were administered to cases and controls. Using SNPstats package, 
logistic regression analysis adjusted for age and gender was performed to evaluate the 
association between the studied SNPs and lung cancer development. Results: From 
September 2006 to February 2015, a total of 614 lung cancer patients regardless of 
histological type and smoking status were recruited. Out of which, 267 never-smoking 
lung adenocarcinoma patients (72% females, mean age 61.6+/-12.6 years) were regarded 
as cases in the study. From July 2013 to August 2014, a total of 453 healthy controls 
(40% females, mean age 53.8+/- 8.3 years) were recruited. Most cases (69%) were 
at advanced stage with chemotherapy treatment (67.8%). Higher proportion of cases 
(41.7% at home; 35.4% at workplace) than controls (24.9% at home; 26.9% at workplace) 
had been exposed to second-hand smoke. Genetic analysis was restricted to 184 pairs 
of age and gender well-matched cases and controls. Two of the 51 SNPs showed a 
significant association with lung adenocarcinoma, which were rs2069840 of IL-6 gene 
in inflammatory pathway (OR: 5.80; 96%CI: 1.60-20.99) and rs1106087 of XPC gene 
in DNA repair pathway (OR: 3.72; 95%CI: 1.40-9.83). Conclusion: Our results suggest 
that IL-6 rs2069840 and XPC rs1106087 are susceptibility genes for development 
of EGFR-driven lung adenocarcinoma in never-smoking Hong Kong population. 
Keywords: Adenocarcinoma, EGFR mutation, genetic risk, never smokers
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MINI23.07 The Airway Field of Injury Reflects Metabolic Changes Associated 
with the Presence of Lung Squamous Premalignant Lesions Sarah Mazzilli1, 
Gang Lui2, Stephen Lam3, Marc Lenburg1, Avrum Spira2, Jennifer Beane2 1Computational 
Biomedicine, Boston University, Boston/MA/United States of America, 2Boston University, 
Boston/MA/United States of America, 3BC Cancer Agency, Vancouver/Canada
Background: Lung SCC arises in the epithelial layer of the bronchial airways and is 
preceded by the development of premalignant lesions (PMLs). The molecular events 
involved in the progression of PMLs to lung SCC are not clearly understood as not all 
PMLs that develop go on to form carcinoma. Our group is using high-throughput genomic 
techniques to characterize the process of premalignant progression by examining 
PMLs and non-lesion areas of individuals with PMLs (“field of injury”) to identify events 
that lead to the development of SCC. Pathway analysis revealed enrichment oxidative 
phosphorylation (OXPHOS) /respiratory electron transport among genes up-regulated 
in the airways of subjects with PMLs. OXPHOS is the most efficient metabolic pathway 
that generates energy in the form of ATP by utilizing the structures and enzymes of the 
mitochondria. OXPHOS is often elevated during epithelial tissue repair and is superseded 
by glycolysis in the development of cancer. Methods: mRNA-Seq was conducted on 
cytologically normal airway epithelium collected from indviduals with (n=50) and 
without (n=25) PMLs. Linear modeling strategies were used to identify genes altered 
between subjects with and without PMLs (n=206 out of 13,900, genes at FDR<0.001). 
Pathway analysis by GSEA revealed enrichment (FDR<0.05) of oxidative phosphorylation 
(OXPHOS)/respiratory electron transport genes among genes up-regulated in subjects 
with PMLs. To validate these findings, we examined oxygen consumption rates (OCR) 
and extracellular acidification rates (ECAR) in primary airway epithelial cells cultures 
from PMLs and non-lesion areas and cancer cell lines that have high OXPHOS/ moderate 
glycolytic (H1299), moderate OXPHOS/ high glycolytic (HCC4006) or low OXPHOS/ low 
glycolytic (H2085) gene expression. In addition, protein expression of genes elevated 
in the field of injury including, translocase of the outer mitochondrial membrane (TOMM 
22) and cytochrome C oxidase (COX-IV) were measured in FFPE sections of human 
PMLs and PMLs from the N-nitroso-tris-chloroethylurea (NTCU) mouse model of lung 
SCC. Results: OCR and ECAR values in the lung cancer cell lines were consistent with 
gene expression patterns. Perturbations of OXPHOS resulted in 3 fold (H1299) and 2 fold 
(HCC4006) higher OCR vales than those in H2085 cells (p<0.05) reflecting higher OXPHOS 
activity. Whereas the ECAR values were 2.5 fold (HCC4006) and 1.5 fold (H1299) higher 
than those in H2085 cells (p<0.05), reflecting higher glycolytic metabolism. The OCR and 
ECAR patterns in the primary premalignant cultures also supported the computational 
findings in the field of injury of PMLs. The baseline OCR/ECAR values were 1.5 fold higher 
in the cultures from PMLs compared to non-lesions controls (p<0.001). Additionally the 
OCR and ECAR values were elevated in response to perturbations in OXPHOS in the PMLs 
compared to controls. Protein levels of TOMM 22, and COX-IV were found to be elevated 
in dysplastic lesions compared to controls. Conclusion:Together these data suggest 
that metabolism-associated gene expression is correlated with cellular metabolism and 
there is an increase in OXPHOS associated with the development of PMLs. Furthermore, 
there is potential that therapeutically increasing or maintaining OXPHOS in premalignant 
lesions or the field of injury may be a mechanism of prevention for lung cancer. 
Keywords: OXPHOS, Premalignant lesions, Lung Squamous cell carcinoma
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MINI23.08 Comparison of in Vivo Raman and NIR Spectroscopy and EBUS as 
Confirmatory Method for Ideal Biopsy Area during Bronchoscopic Navigation 
Jiri Votruba Pulmonary, Charles University Hospital, Praha/Czech Republic
Background: Recently, SPNs have become more frequently encountered in 
bronchology. Therefore, an efficient and reliable method for detecting SPNs based on 
their morphological characteristics is needed The aim of this study was to compare 
the diagnostic value of near infrared (NIR) spectroscopy, in vivo Raman spectroscopy 
and radial endobronchial ultrasound (EBUS) for solitary pulmonary nodule (SPN). 
Fluoroscopic guidance with transbronchial biopsy and needle biopsy was performed 
in all patients. Methods: Between February 2014 and February 2015 we examined 22 
Navarra, Pamplona/Spain, 4Department of Medical Oncology, Phase I-Early Clinical Trials 
Unit, Edegem/Belgium
Background: The National Lung Cancer Screening Trial found, after 6.5 years, a 20% 
reduction in LC mortality in high-risk patients (pts) screened with low-dose computed 
tomography compared to chest x-ray. However, LC screening programs (SP) result 
controversial due to potential cost-effectiveness issues. Familial LC aggregation (fLCa) 
has been described previously. The estimated relative risk of LC is ∼1.8 for offspring 
of parents with LC. Linkage analysis has mapped a dominant locus to chromosome 
6 in LC pedigrees. Therefore, in this high-risk subpopulation, SP may have clear 
advantages. This is the first study to investigate the incidence of fLCa conducted in a 
sEp. Methods:Overall, 509 cancer pts of Spanish (n = 473) or Portuguese (n = 36) origin 
were included in the analysis. A cohort of 236 consecutive pts (cases) diagnosed with LC 
was studied for family history (FH) of any type of cancer including LC. Another cohort of 
273 pts (controls) with similar demographic characteristics diagnosed with cancer types 
other than LC was also studied for FH of cancer. We investigated whether LC pts show 
a higher incidence of fLCa than subjects with other solid tumors. Results: Among LC 
pts with a positive FH for LC, 36.7% showed one of their parents as the only LC relative, 
26.5% showed one or more siblings, 18.4% one or more either uncle or aunt, 6.1% their 
grandfather/grandmother and 12.2% other combinations. Regarding the number of 
relatives affected, in our LC cohort one relative was the most frequent finding with 42/49 
pts (85.7%), 2 in 3 cases (6.2%) and > 3 relatives in 4 subjects (8.1%). We studied the 
overall incidence of any type of family cancer among cases and controls. No differences 
were found between groups (72.9% vs 67.4%; p = 0.18). However, in our cohort of LC 
cases, 49/236 pts (20.8%) had a FH of LC in first or second degree whereas among 
cancer controls only 29/273 pts (10.6%) showed a LC FH (p = 0.002). Conclusion: This 
is the first estimation of LC FH in a non-selected sEp with LC. 20.8% of LC cases showed 
a positive FH for LC, being significantly higher (twofold) compared to other cancer pts. 
Therefore, the usefulness of directed SP for subjects with positive FH of LC should be 
prospectively evaluated and potential genomic drivers studied.
Table 1. Comparison of incidence of any type of familial cancer and fLCa between a 
cohort of LC patients and a cohort of subjects with other solid tumors
LC patients Other solid tumor patients p value
N= 236 N=273
Familial cancer (any type) (n (%))
Yes 172 (72.9) 184 (67.4) 0.18
No 64 (27.1) 89 (32.6)
Familial Lung Cancer (n (%))
Yes 49 (20.8) 29 (10.6) 0.002*
No 187 (79.2) 244 (89.4)
*Statistically significance at p < 0.05
fLCa: familial lung cancer; LC: lung cancer
 
Keywords: Familial clustering, lung cancer, Screening, European population
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MINI23.05 A Case-Control Study on the Genetic Risks for Development of Lung 
Adenocarcinoma in Never-Smoking Hong Kong Population Li Han1, Cheuk-Kwong 
Lee2, James Chung Man Ho1 1Department of Medicine, The University of Hong Kong, Hong 
Kong/Hong Kong, 2Blood Transfusion Service, Hong Kong Red Cross, Hong Kong/Hong Kong
Background: Lung cancer with different molecular profile behaves in different ways in 
terms of etiology, clinical characteristics, and prognosis. It implies that fighting against 
lung cancer should be moving forward in the direction of modifying the screening 
strategies on genetically-defined high risk groups, initiating early chemoprevention 
trials on selected high-risk subjects, and developing personalized cancer treatments. 
Lung adenocarcinoma in never-smokers, more often harboring epidermal growth factor 
receptor (EGFR) mutations especially in Asians, has a remarkable therapeutic response 
to specific tyrosine kinase inhibitors. Most single nucleotide polymorphisms (SNPs) 
identified by candidate gene and genome-wide association studies are of genes involved 
in carcinogen metabolic pathway, DNA repair pathway, inflammatory pathway and tumor 
suppressor pathway. Conflicting results are likely due to heterogeneity of the study 
population and lack of focus on specific molecular subgroups (e.g. EGFR-mutants). We 
therefore embark on the current study to identify susceptibility genes in a molecularly-
defined (EGFR-mutated) subgroup of never-smoking lung adenocarcinoma in Hong Kong 
population. Methods: Eligible patients with confirmed primary lung adenocarcinoma 
were recruited from Queen Mary Hospital, Hong Kong. Voluntary healthy controls were 
recruited from blood donors in Hong Kong Red Cross. 10mL venous blood samples were 
taken from both cases and controls for DNA extraction and SNP assays. 51 SNPs of 14 
genes involved in four different pathways were tested using MassARRAY. A structured 
questionnaire including the information of environmental exposures at home and 
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such as endobronchial specimens, is a basic obstacle to perform sensitive and accurate 
detection of SCAs. Methods: We used: 1) a lung cancer cell line (NCI-H1395) and its 
matched lymphoblastoid (NCI-BL1395) cell line; 2) frozen lung tissues containing different 
percentage of invasive cancer cells surgically resected from a patient; and 3) biopsies and 
brushings obtained at the visually concerning areas during bronchoscopy. The histology 
of the clinical samples were graded by the study pathologist. Genomic DNA was isolated 
from each sample, quantified, and labeled for Illumina SNP array (HumanOmni 2.5-Quad 
BeadChip). Data analysis and visualizations were performed using Partek Genomic Suite 
6.6 software. Results: Our study focused on the detection of SCAs by the comparison of 
genomic DNAs from cancer/premalignant cells (subject) to blood/normal cells (reference) 
from the same individual. We tested a B allele frequency metric, the subtraction of allelic 
fractions (delta-θ), on a standardized mixture of genomic DNAs from a lung cancer cell 
line and its matched lymphoblastoid cell line. Delta-θ proved to be a sensitive parameter 
to clearly delineate SCAs present in the tumor cell line even with a large proportion 
of normal cells (up to 90%). To explore the utility of using delta-θ for heterogeneous 
samples, we used clinical lung cancer specimens with known cancer cell content. In 
comparison to the other publicly available analytical metrics/algorithms (conventional 
Log R Ratio plot, mirrored B Allele Frequency plot, and GAP algorithm), delta-θ performed 
as well or better (with lower computational power needed), and enabled the detection 
of SCAs even in highly heterogeneous clinical samples (<30% tumor cell content). In 
addition, we completed a study using a number of bronchial biopsies and brushings with 
histologic grade ranging from normal to squamous cell carcinoma. SCAs were rarely 
detected in those of low to mild dysplasia, while they were detected in approximately 
25% of moderate or severe dysplasia, and in all carcinoma in situ (CIS) and squamous 
cell carcinoma specimens. Longitudinal, repeated samplings from a high risk patient who 
persistently showed high grade dysplasia across the bronchus, revealed that delta-θ 
could identify SCAs continuously across the whole genome. The fact this individual 
had highly overlapping SCAs between different bronchial locations indicates genomic 
field cancerization may occur, along with the histological field effect in premalignant 
epithelium. Conclusion: In SNP microarray studies, delta-θ is a highly sensitive metric for 
detecting SCAs even in heterogeneous dysplastic bronchial specimens. SNP array may 
be a powerful tool to understand premalignant genetic alterations and field cancerization. 
Keywords: SNP array, bronchial dysplasia, chromosomal alteration, chemoprevention
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MINI23.12 HAases and HAS in Lung/Bronchial Pre-Neoplastic Lesions: Impact 
on Prognosis Vanessa K. De Sá1, Tabatha Prieto1, Eloisa R. Olivieri2, Dirce M. Carraro2, 
Fernando A. Soares2, Lina Carvalho3, Andrew G. Nicholson4, Vera L. Capelozzi1 
1Pathology, Faculdade de Medicina Da USP, São Paulo/Brazil, 2Pathology, AC Camargo 
Cancer Center, São Paulo/Brazil, 3Pathology, Faculdade de Medicina Da Universidade de 
Coimbra, Coimbra/Portugal, 4Pathology, Royal Brompton and Harefield NHS Foundation Trust 
and National Heart and Lung Institute, London/United Kingdom
Background: Lung cancer is the result of a multi-step accumulation of genetic and/or 
epigenetic alterations; therefore, a better understanding of the molecular mechanism, by 
which these alterations affect lung cancer pathogenesis, would provide new diagnostic 
procedures and prognostic factors for early detection of recurrence. In this regard, many 
have studied molecular or other markers in pre-neoplastic and neoplastic lesions to 
discover what might relate to tumor recurrence and shortened survival.  Methods: A series 
of 136 lung/bronchial and lung parenchyma tissue samples from 136 patients consisting 
of basal cell hyperplasia, squamous metaplasia, moderate dysplasia, adenomatous 
hyperplasia, severe dysplasia, squamous cell carcinoma and adenocarcinoma were 
analyzed for the distribution of hyaluronidase 1 (HYAL1) and 3 (HYAL3), and hyaluronan 
synthases 1 (HAS1), 2 (HAS2) and 3 (HAS3) by immunohistochemistry. Results: HYAL 
1 was significantly more expressed in basal cell hyperplasia compared to moderate 
dysplasia (p=0.01), atypical adenomatous hyperplasia (p=0.0001) and severe 
dysplasia (p=0.03). A lower expression of HYAL 3 was found in atypical adenomatous 
hyperplasia compared to basal cell hyperplasia (p=0.01) and moderate dysplasia 
(p=0.02). HAS 2 was significantly higher in severe dysplasia compared to basal cell 
hyperplasia (p=0.002), and equally higher in squamous metaplasia compared to basal 
cell hyperplasia (p=0.04). HAS 3 was significantly expressed in basal cell hyperplasia 
compared to atypical adenomatous hyperplasia (p=0.05) and severe dysplasia (p=0.02). 
A lower expression of HAS 3 was found in severe dysplasia compared to squamous 
metaplasia (p=0.01) and moderate dysplasia (p=0.01). Epithelial HYAL 1 and 3 and HAS 
1, 2 and 3 expressions were significantly increased in pre neoplastic lesions compared 
to neoplastic lesions. Comparative Cox multivariate analysis controlled by N stage and 
histologic types of tumors showed a significant association between poor survival 
and high pre neoplastic cell associated to HAS3 (HR=1.19; p=0.04). Conclusion: We 
concluded that localization of HYALs and HASs in lung/bronchial pre-neoplastic and 
neoplastic lesions was inversely related to malignancy, these factors emerging as 
potentially important diagnostic markers in patients with suspicion of lung cancer. 
Keywords: Hyaluronan synthases, lung cancer, Hyaluronidades, Extracellular matrix
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MINI23.13 Extracellular Sulfatase SULF2: A Potential Biomarker for the 
Early Detection of Lung Cancer Yi-Wei Yang, Natalie Lui, Wasima Mayer, David 
Jablons, Hassan Lemjabbar-Alaoui Surgery, Thoracic Oncology Program, University of 
California San Francisco, San Francisco/CA/United States of America
Background: The extracellular sulfatases (SULF1 and SULF2) are overexpressed in 
a wide assortment of human cancers. SULF2, in particular, has been shown to drive 
carcinogenesis in non-small cell lung cancer (NSCLC), malignant astrocytoma, and 
male and 29 female patients having a median age of 68 years with positron emission 
tomography-computed tomography findings of metabolically active SPN between 1, 
5 to 3 cm in diameter. We used tree types of point monitoring systems. Fluoroscopic 
guidance (with guide- sheath) was combined with a radial EBUS. In the case radial EBUS 
conclusively showed catheter position in the centre of SPN (41 cases) than in-vivo Raman 
Spectroscopy and NIR spectroscopy probes were placed into the guide sheath in order 
to gather tissue information. Mean measurement time was less than five minutes after 
establishing ideal position of guide -sheath. Results of in spectroscopy measurements 
from both Raman spectroscopy and NIR spectroscopy were obtained as differences 
between spectral characteristics of normal tissue (same side, different lobe) to SPN 
tissue. Results: The results are expressed as sensitivity of RAMAN spectroscopy and 
NIR spectroscopy towards EBUS navigated biopsies. Statistical analysis of the results 
showed comparable very high sensitivities for NIR spectroscopy and Raman spectroscopy 
in confirmation of SPN tissue. From 41 EBUS positive visualisations of SPN there were 
38 conclusive histological findings. Both Raman spectroscopy (positive differences 
in 38 cases) and NIR spectroscopy (positive differences in 36 cases) showed good 
performance in tissue discrimination. Conclusion: Every confirmatory method brings 
different information about tissue. EBUS describes volume of the SPN and gives valuable 
information about the position of catheter in the SPN. Raman spectroscopy and NIR 
spectroscopy bring information about biochemical/ optical characteristics of the tissues. 
Keywords: NIR spectroscopy, SPN, radial EBUS, Raman spectroscopy
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MINI23.09 Clinical Application of Computer Assistant Diagnostic System in 
Probe-Based Confocal Laser Endomicroscopy (pCLE) for Pulmonary Diseases 
Dawei Yang1, Maosong Ye1, Yu Zhu2, Xia Yin1, Yafei Chen1, Min Fu1, Hongjie Xu1, 
Chunxue Bai1, Jie Hu1 1Zhongshan Hospital Fudan University, Shanghai/China, 2Department 
of Electronic and Communication Engineering, East China University of Science and 
Technology, Shanghai/China
Background: Probe-based confocal laser endomicroscopy (pCLE) allows for real-
time noninvasive histological imaging via bronchoscopy. Interpreting pCLE images 
and correlating with pulmonary disease remains challenging. We performed an in vivo 
study to evaluate the correlation between pathological diagnosis and pCLE imaging of 
pulmonary disease. Methods: We sequentially enrolled the patients with undiagnosed 
lung lesion, and randomly grouped into control group (TBLB and peripheral EBUS) and 
pCLE group (TBLB + pCLE and peripheral EBUS + pCLE). pCLE was performed with 
Cellvizio system (Mauna Kea Technologies, Paris, France). All patients were consent to 
the procedure. Pathologists and pulmonologists reviewed the images by the Columbus 
Classification (CC). Questionnaires were applied post the procedure to collect patients’ 
condition. We developed a computer assistant diagnostic (CAD) system to calculate 
alveolar diameter, vessel diameter and optical density percentage and compare the 
CAD diagnostic accuracy with CC standard. The CAD system involved image processing 
methods to calculate the diameters in pixel domain and then transformed them into the 
real value. Pseudo-color processing was used to show the density percentage of different 
tissues. And the histogram was also calculated to figure out the distribution alone gray 
scale. Results: 258 patients enrolled in the study, 98 under pCLE examination, while 
160 under control group. Among them 128 lesions were diagnosed as malignant tumor 
by pathological diagnosis, 87 cases were diagnosed as benign disease. Primary features 
were observed in the samples using pCLE in the lesion of cancer: The normal alveolar in 
malignant nodules is smaller than benign nodules. While, the vessel in the malignant nodules 
is thicker than the benign ones. The cellular structure and vessel domination in various 
subtypes of lung cancer is different. There was no significance on procedure time between 
control and pCLE group, as well as patients’ secretion, tolerance and willing for repeat 
examination. Conclusion: pCLE can identify lung carcinoma in in vivo procedure with well 
tolerance and with limit procedure time. As a non-invasive method, pCLE could improve 
accuracy and avoid unnecessary biopsy. The Computer Assist Diagnosis system could help 
pulmonologists to better acquire the right image and to differentiate diseases on the site. 
Keywords: bronchoscopy, computer assistant diagnostic, lung nodule, Probe-based 
confocal laser endomicroscopy
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MINI23.10 Subtraction of Allelic Fractions (Delta-θ): A Sensitive Metric to 
Detect Chromosomal Alterations in Heterogeneous Premalignant Specimens 
Ichiro Nakachi1, Robert S. Stearman2, Michael Edwards2, Wilbur A. Franklin3, Jessica L. 
Rice2, Aik-Choon Tan4, Jihye Kim4, Minjae Yoo4, Akihiro Fujisawa5, Tomoko Betsuyaku6, 
Kenzo Soejima6, York E. Miller7, Mark W. Geraci2 1Department of Pulmonary Medicine, 
Saiseikai Utsunomiya Hospital, Utsunomiya/Japan, 2Department of Medicine, University of 
Colorado Denver, Aurora/CO/United States of America, 3Department of Medicine, University 
of Colorado Denver, Aurora/United States of America, 4Medicine, University of Colorado 
Denver-AMC, Aurora/United States of America, 5Dermatology, Kyoto University, Kyoto/
Japan, 6Pulmonary Medicine, Keio University School of Medicine, Tokyo/Japan, 7Pulmonary 
and Critical Care Medicine, University of Colorado Anschutz Medical Campus & Denver 
Veterans Affairs Medical Center, Aurora/CO/United States of America
Background: Lung squamous carcinoma is believed to arise from premalignant bronchial 
epithelial dysplasia, which demonstrates progressive histologic changes leading up to 
invasive cancer. However, only a small subset of these lesions progress to carcinoma. 
Recent studies have shown that somatic chromosomal alterations (SCAs) status is a 
better biomarker than premalignant histology alone. Single-nucleotide polymorphism 
microarray (SNP array) has been frequently used to delineate these genomic alterations 
across the whole genome. However, the cellular heterogeneity, from clinical samples 
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pleura and more rarely the peritoneum. Occupational exposure to asbestos is the most 
common cause, but domestic exposure through cohabitation with an asbestos worker 
and environmental exposure by living in proximity to an asbestos emitting industry are 
acknowledged risk factors. The Region of North Jutland in Denmark hosted two large 
shipyards and the only Danish asbestos cement factory in the period 1928-1986, 
using mainly chrysotile asbestos and resulting in high MM incidence (5/100,000 in 
2011). In our patient cohort the proportion of MM cases in peritoneum (MAM) is larger 
for females than males, also noted by others. We examined whether this could be 
related to the source of asbestos exposure. Methods: A retrospective investigation 
of medical records (Departments of Pathology and Medicine, Aalborg University 
Hospital) was performed, concerning females diagnosed with pleural MM (MPM) and 
MAM between January 1992 and February 2015. We focused on the correlation between 
the source of asbestos exposure and the development of either pleural or peritoneal 
disease. The asbestos exposure source was divided in two categories; primary, 
representing occupational asbestos exposure and secondary, including domestic 
and environmental exposure. Patients with unknown asbestos exposure or habitation 
history were excluded. We hypothesized that the site of MM development, pleura or 
peritoneum, is independent from primary or secondary asbestos exposure. Fischer´s 
exact test was applied to test the hypothesis. Results: Out of 67 women with MM, 27 
were excluded due to insufficient information about asbestos exposure or habitation 
(data not shown). Of the remaining 40 females, 33 were diagnosed with MPM (83%) 
and 7 with MAM (17%). The median age for MAM and MPM diagnosis was 60 and 72 
years respectively. Among the 40 MM patients, 25% (n=10) had a history of occupational 
asbestos exposure, 57.5% (n=23) had domestic and 17.5% (n=7) had environmental 
exposure. Importantly, secondary asbestos exposure was documented for 85% of the 
MPM patients (n=28) while primary in only 15% of them (n=5). On the contrary for the 
MAM patients, secondary asbestos exposure was reported for 29% (n=2) and 71% of 
them had primary exposure (n=5). The correlation between the source of asbestos 
exposure and the MM site was significant (p= 0.006, OR= 0.078). Conclusion: The 
majority of female MM patients have a non-occupational asbestos exposure, with a 
considerable rate of environmental exposure. Furthermore, the source of asbestos 
exposure seems to play an important role in determining the site of MM development. 
Primary asbestos exposure, inferring more intense exposure through occupation, may 
predispose to peritoneal while secondary, lighter asbestos exposure to pleural disease. 
This may also be indicated by younger age at MAM diagnosis and is in line with previous 
reports. Anatomical, biological or other genetical differences related to the site of MM 
cannot be excluded, as some studies indicate that asbestos exposed women develop 
MAM more often than men. Our study of large Danish population cohorts is in progress 
and aims to elucidate these questions (updates will be presented at the conference). 
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MINI24.02 Mesothelioma Risk in Turkey Muzaffer Metintas Lung and Pleural Cancers 
Research and Clinical Center, Eskisehir Osmangazi University, Eskisehir/Turkey
Background: Turkish Mesothelioma Working Group; Drs. Abdurrahman Abakay, Sedat 
Altın, Güntülü Ak, αule Akçay, Hasan Bayram, Mehmet Bayram, Hasan Fevzi Batırel, 
Serdar Berk, Mehmet Bilgin, Nilgün Yılmaz Demirci, Figen Deveci, Levent Elbeyli, Ahmet 
Erbaycu, Dilek Ernam, Sebahat Genç, Murat Gültekin, Ezgi Hacikamiloαlu, Hüseyin αlter, 
Selahattin Kadir, Hasan Kahraman, Mehmet Karadaα, Özkan Kaan Karadaα, Talat Kılıç, 
Gamze Kırkıl, Berna Kömürcüoαlu, Muzaffer Metintaα, Selma Metintaα, Arzu Mirici, Tevfik 
Pınar, Ömer Özbudak, Sibel Özkurt, Önder Öztürk, Mutafa Taαdemir, Dursun Tatar, Engin 
Tutkun, Umran Toru, Toros Selçuk, Zehra Seyfikli, Nazan αen, Abdurrahman αenyiαit, 
Gaye Ulubay, Ülkü Yılmaz, Adil Zamani. In this study, we aimed to detect the current and 
future mesothelioma risk for Turkey to guide the studies for the elimination of asbestos 
exposure in the rural areas. Methods: Thirty-eight faculty members who were members 
of the Turkish Mesothelioma Working Group and and 4 foreign consultants took part in 
this study. In hospitals of 30 provinces where mesothelioma cases were most diagnosed, 
the patients diagnosed with “mesothelioma” under the code of C45 between 2008 and 
2012 (for five years) were identified. The cases were checked one by one according to 
their identity, name, age, birth place, register and address information with their national 
identification numbers from the Central Register System (MERNIS). The deceased cases 
were identified; their dates of death and age were determined and these were also 
verified by the national registers. Following the identification of all deceased cases, the 
median survival was determined according to their diagnoses dates. After obtaining the 
final records of the cases with mesothelioma, the cases born in villages/rural areas were 
determined. Finally, “population exposed to asbestos in rural areas for a risky period of 
time” was determined. The number of mesothelioma to develop in the risky populations 
for the next 20 years was estimated based on those findings. Results: 7,789 cases 
with C45 code between 2008 and 2012 in Turkey was collected and the demographic 
information was collected from 5,617 mesothelioma cases whose data were reliable. 
Out of these cases, 3,718 were born/lived in villages. 3,495 of the 5,617 mesothelioma 
cases had died until July 2014. The median survival was 8 months. 1,879 cases were 
not born and/or lived in a village with known asbestos exposure. These cases were most 
possibly related with occupational exposure. Between 2013 and 2033, it was projected 
that 15,450 mesothelioma will emerge in the population exposed to asbestos in the 
above mentioned rural areas. Moreover, it was projected that 2,511 new mesothelioma 
cases will emerge in the population who are still being exposed to environmental 
asbestos after 2013. Conclusion: We determined that mesothelioma caused by 
environmental and occupational asbestos exposure in Turkey is a more serious problem 
than previously anticipated. This is a unique epidemiological study that has determined 
the magnitude of an environmental/occupational carcinogen induced cancer problem 
through data collection from patients. Country wide measures are being implemented 
by the Public Health Institute of Turkey and Turkish Mesothelioma Working Group. 
Keywords: Mesothelioma, asbestos exposure, environment
hepatocellular carcinoma. As extracellular enzymes that are both tethered to the cell 
membrane and secreted, the SULFs and their heparan sulfate proteoglycan (HSPG) 
substrates are present in the extracellular environment. We hypothesize that the blood 
levels of SULF2 can serve as biomarkers for the early detection of NSCLC and malignant 
astrocytoma. The primary goal of this study is to evaluate the patient tumor and blood 
samples for the presence of the SULF2 in order to develop novel biomarkers for the early 
detection of NSCLC. Methods: We identified patients who underwent lung resection for 
adenocarcinoma (ADC) (41 patients) or squamous cell carcinoma (SCC) (51 patients) at 
our institution from 2000 to 2006. We excluded patients with recurrent lung cancer, or 
less than 3 mm of invasive tumor on H&E slide. A section from each paraffin-embedded 
tissue specimen was stained with a monoclonal antibody to SULF2. A pathologist 
determined the percentage (0-100%) and intensity (0-3) of tumor cells staining. Survival 
analysis was performed using a multivariate Cox proportional hazards model. We 
developed an ELISA to detect SULF2 in human blood. After testing a number of different 
strategies including using different combinations of our anti-SULF2 mAbs, we determined 
that a sandwich ELISA with capture mAb 5C12 followed by detection with biotinylated 
mAb 8G1 was best for the most sensitive detection of SULF2. Results: SULF2 staining 
(either tumor or stroma) was positive for 82% of the samples The SCC samples had a 
higher mean percentage of tumor staining compared to the ADC samples (100% vs. 
60%; p<0.0005). However, after adjusting for age, sex, race, histologic type, stage, 
and neoadjuvant therapy, there was no significant association between percentage of 
SULF2 tumor staining and overall survival. Nonetheless, these initial findings are very 
encouraging, because the vast majority of ADC samples, including early stage disease, 
and all of the SCC tumor samples have some degree of staining for SULF2 protein. Using 
our SULF2 ELISA assay, we analyzed plasma samples from 54 healthy donors and 85 
patients with newly diagnosed early stage NSCLC before surgical resection. The level 
of SULF2 protein is significantly higher in patients with NSCLC compared with healthy 
controls (738.4 ± 55.17, vs. 439.4 ± 40.88 pg/mL; p<0.0001). Conclusion: SULF2 
protein was detected in the vast majority of tumor and blood samples of patients with lung 
cancer. Although additional studies are required, these data provide the first indication 
that SULF2 blood level may be a useful biomarker for the early detection of lung cancer. 
Keywords: SULFs, Biomarkers, NSCLC, Early Detection
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MINI23.14 Circulating Long Non-Coding RNA GAS5 Is a Novel Biomarkers for 
the Diagnosis of Non-Small Cell Lung Cancer Wen J. Liang1, Xue F. Shi1, Hong B. 
Liu2, Tang F. Lv1, Yong Song1 1Department of Respiratory Medicine, Jinling Hospital, Nanjing 
University School of Medicine, Nanjing/China, 2Department of Dermatology, Aurora/USA, 
University of Colorado Anschutz Medical Campus, Denver/CO/United States of America
Background: Long non-coding RNAs (lncRNAs) are new-founding RNAs which could 
regulate many biological processes. Our previous study shown that lncRNA-GAS5 was 
decreased in lung cancer tissue, which contributed to the proliferation and apoptosis 
of non-small lung cancer (NSCLC). GAS5 was also associated with the prognosis of 
lung cancer patients. However, the plasma samples were more easily available than 
the tissue sample in the clinic. And the expression of GAS5 in the plasma of NSCLC 
patients was unknown. Methods: 90 patients with NSCLC and 33 health controls 
were included in our study. Blood samples were collected before surgery and therapy. 
We extracted the free RNA in the plasma and analyzed the expression of GAS5 with 
quantitative reverse transcription polymerase chain reaction (qRT-PCR). Suitable 
statistics methods were used to compare the plasma GAS5 levels between the NSCLC 
patients and health controls, preoperative and postoperative plasma samples. Receiver 
operating characteristic (ROC) analysis was used to evaluate the diagnostic sensitivity 
and specificity of plasma GAS5 in NSCLC. Results: The 2-αCT of GAS5 in the plasma of 
NSCLC patients and health controls are 1.053774 and 3.019817, respectively. GAS5 
in NSCLC plasma was down-regulated compared with health controls (P=0.001), which 
was significantly correlated with TMN stage (P=0.024). Furthermore, plasma GAS5 
increased markedly on day 7 after surgery compared with preoperative levels in NSCLC 
patients (P=0.003). The CT values of preoperative and postoperative are 2.225909 and 
1.050455, respectively. The area under the ROC curve of GAS5 was up to 0.832. The 
combination of the GAS5 and CEA could produce 0.909 area under the ROC curve in 
distinguishing NSCLC patients from control subjects (95% CI 0.857–0.962,p=0.000).
These results indicated that lncRNA GAS5 may be a more precise biomarker in 
NSCLC. Conclusion: We have demonstrated that GAS5 was decreased in NSCLC plasma 
expression and the plasma samples were more easily available than the tissue sample 
in the clinic. So GAS5 could be ideal biomarkers for the early diagnosis of NSCLC. 
Keywords: non small cell lung cancer, Long noncoding RNA, GAS5, diagnostic
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MINI24.01 Pleural and Peritoneal Malignant Mesothelioma in Women 
Correlated to Occupational, Domestic and Environmental Asbestos Exposure 
Vasiliki Panou1, Øyvind Omland2, Christos Meristoudis3, Leif Hoffmann2, Oluf D. Røe4 
1Department of Respiratory Diseases, Aalborg University Hospital, Aalborg/
Denmark, 2Department of Occupational Medicine, Aalborg University Hospital, 
Aalborg/Denmark, 3Department of Pathology, Aalborg University Hospital, Aalborg/
Denmark, 4Department of Medical Oncology, Aalborg University Hospital, Aalborg/Denmark
Background: Malignant Mesothelioma (MM) is an aggressive neoplasm affecting the 
S349Copyright © 2015 by the International Association for the Study of Lung Cancer
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combined spatial clusters in the Greater New Orleans area suggested that exposure to 
asbestos was likely a combination of occupational and environmental exposure. Spatial 
analysis of MM incidence is an effective approach for investigating geographic areas 
with elevated rates of the disease, especially where exposure to asbestos has not been 
investigated. Further research is needed to evaluate occupational and environmental 
exposure sources in these populations by gathering detailed asbestos exposure 
measurements, demographic and health data among cases by gender and age group. 
Keywords: malignant mesothelioma, Cluster analysis
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MINI24.06 Mesothelioma in Finland: 10 Year Population-Based Cohort Between 
2000-2009 Ilkka Ilonen, Sanna Laaksonen, Jarmo A. Salo Department of General 
Thoracic Surgery, Heart and Lung Center, Helsinki University Central Hospital, Helsinki/
Finland
Background: Malignant pleural mesothelioma (MPM) is associated with high morbidity 
and poor prognosis. We evaluated in population-based analysis the impact of enhanced 
diagnostics like positrone emission tomography (PET) and thoracoscopy. Also 
introduction of new medical therapy, Pemetrexed in 2004 could also benefit overall 
survival. Methods: Complete national data on 763 patients from the Finnish Cancer 
Registry sampled from 2000 to 2009 are presented. Survival for 1 year and 2 years and 
median survival were calculated. Survival data was acquired in February 
2013. Results: During study period the incidence of MPM has been significantly and 
steadily increasing. The incidence was highest among men in all time periods (fig 1). 
Median age at the diagnosis was 68 years (range: 25-94 years). Reported histology was 
epitheloid in 211 (27.7%), sarcomatoid in 79 (10.4%), biphasic 33 (4.3%) and non-
specified in 437 patients (57.3%). Median survival was 10 months (range 0 - 150 months), 
Fig 2. Between two 5-year cohorts (2000-2004 and 2005-2009) no significant difference 
in overallsurvival was observed (0.537). One year survival was 43.1% and two year 
18.7%, with no differences were noted in the 5-year cohorts (0.826 and 0.402 
respectively). Primary diagnosis was made in autopsy in 50 (6.6%) patients. A total of 27 
patients (3.7% of deceaced) died for other reasons than MPM. 34 patients (4.5%) lived 
over 5 years and 16 (2.1%) of these are still alive.
Conclusion: Despite significantly increased availability of new diagnostic tools like 
thoracoscopy, PET, and pemetrexed therapy during this cohort, no significant difference 
in overall survival was noted in this population based analysis. In order to facilitate better 
outcomes nationaly, new means are needed to coordinate both diagnostic and therapy of MPM. 
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MINI24.03 Asbestos Knowledge and Awareness Level Selma Metintas1, Guntulu 
Ak2, Filiz Bogar3, Muzaffer Metintas2 1Lung and Pleural Cancers Research and Clinical 
Center; Medical Faculty Department of Public Health, Esogu, Eskisehir/Turkey, 2Chest 
Diseases, Esogu Lung and Pleural Cancers Research and Clinical Center, Eskisehir/
Turkey, 3Esogu Lung and Pleural Cancers Research and Clinical Center, Eskisehir/Turkey
Background: Asbestos is an important carcinogen and people can be exposed to 
asbestos either occupationally or environmentally. There is naturally occurring asbestos 
in some regions of Turkey. The soil including asbestos was commonly used for plastering, 
whitewashing and roofing to build village house in these regions. The aim of this study 
is to determine knowledge and awareness level of people about asbestos in a region of 
Turkey where asbestos related diseases is endemic due to environmental exposure to 
asbestos in the rural area. Methods: The study is a questionnaire-based cross-sectional 
study included patients and their relatives admitted to a tertiary hospital in Eskisehir 
located central part of Turkey, in 2015. The questionnaire was applied by face-to-face 
interview after verbal consent from each participant. The questionnaire included 19 
questions. The data was determined by percent and confidence interval. Chi-square test 
was used to compare the groups and multiple logistic regression analysis was used to 
determinate variables affecting knowledge level of asbestos. Results: A total number 
of 505 participants were included in this study. The mean age of them was 52.6±15.2 
years (15-89) and 51.9% of them were male. About 41.2% of participants were born 
in the rural area and 14.5% of them still live in the villages. The educational status: 
8.3% never, 55.7% elementary school; 19.0% secondary school; 17% university. About 
4.4% of the participants were unemployed, 13.5% official, 20.8% worker, 2.8% farmer, 
34.5% housewife and 24.2% others including retired, barber etc. About 76.4% of the 
participants who live in the villages had history of asbestos-contaminated soil in their 
villages. Only 20.5% of the group knew that white soil included asbestos. About 3.5% 
of the group mentioned that asbestos was useful, 44.1% harmful, 3.5% ineffective 
and the rest of them had no idea. Regarding the knowledge about asbestos related 
diseases among them, 34.9% stated that asbestos can cause lung cancer, 18.3% 
benign pleural or lung diseases and 23.1% mesothelioma. Most of the participants 
who never live in the village or moved to the city (62.9%) stated that asbestos was 
harmful and 30.9% had no idea. About 53.1% of them mentioned that asbestos can 
cause lung cancer, 26.9% benign pleural or lung diseases and 33.5% mesothelioma. 
In this group, the rate of true answers regarding usage of asbestos at workplace was 
12.9% (8%-20%). Their knowledge about environmental usage of asbestos was low 
(16.6%) in this group. More than half of the participants (53.5%) pointed out that it is 
necessary to avoid from asbestos. The factors affecting knowledge level of asbestos 
were found to be young (p=0.016), live in the city (p=0.016) and high education level 
(p<0.001) by multiple logistic regression analysis. Conclusion: Although approximately 
30 years passed after the first scientific report about hazards of environmental asbestos 
exposure on the respiratory system in this region, knowledge and awareness level 
of asbestos was quite low by sampling of this population. Health and environment 
authorities should inform the people as quickly and intensely about asbestos. 
Keywords: Asbestos; Exposure; Questionnaire; Awareness
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MINI24.04 Cluster Analysis of Malignant Mesothelioma Incidence in Louisiana  
Elizabeth G. Levitzky, Edward Trapido Epidemiology, LSU Health Sciences Center - New 
Orleans, New Orleans/LA/United States of America
Background: Exposure to asbestos fibers is the predominant causal factor in 
malignant mesothelioma (MM). The higher than expected incidence of MM in Louisiana, 
particularly among males, has been attributed to occupational exposure at facilities 
engaged in the shipping, ship construction and manufacturing industries that utilized 
substantial quantities of materials containing asbestos fibers. The primary aim of this 
study was to investigate the locations and demographic characteristics of spatial 
clusters of malignant mesothelioma (MM) cases reported in Louisiana between 1992 
and 2011. Methods: Incident case data reported to the SEER Louisiana Tumor Registry 
(LTR) were geocoded by census tract and stratified into four categories based on gender 
and age at diagnosis - Males under 60 years, Males 60 years and over, Females under 
60 years and Females 60 years and over. Investigation of probable spatial clusters for 
each gender/age group combination was conducted using a Poisson-based model for 
the LTR incidence data. The ratio of male to female cases in the probable clusters was 
utilized to assess environmental versus occupational exposure. Locations of possible 
spatial clusters and locations of facilities processing, manufacturing and utilizing 
asbestos materials were illustrated graphically using geographic information system 
software. Results:The most likely clusters of MM for each age/gender group were 
located in the Greater New Orleans area and were statistically significant. There was 
substantial overlap of the boundaries for the four clusters located in Jefferson Parish 
with 15 census tracts included in all four clusters. The overall ratio of male to female 
cases in the most likely clusters was 1.35:1. A statistically significant secondary cluster 
was identified for males under 60 years of age northwest of Baton Rouge, LA. A pair of 
spatial clusters was identified for Males under 60 years and Females 60 years and older 
south of Lafayette. Conclusion: Our results of a most likely cluster of MM for males 60 
years and older in Jefferson Parish was expected given the presence of large business 
enterprises known to have processed, manufactured and used asbestos materials since 
the 1930s. The presence of probable spatial clusters of MM cases of females in both age 
groups and males under 60 years of age was unexpected. The spatial clusters reported 
for Males under 60 years and Females 60 years and older near Lafayette and no cluster 
for Males 60 years and older in the area also suggested possible environmental exposure 
in the area. These results, along with the ratio of male to female cases among the four 
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(Lamote et al., 2014). We investigated if asbestos induces VOCs and how breath VOCs 
could help discriminating MPM patients from occupational asbestos-exposed and non-
exposed controls. Methods: Twenty-three MPM patients, ten healthy asbestos-exposed 
(AEx) individuals and twelve healthy non-exposed (HC) persons were included. After a 
fasting period of 2 hours before the breath sampling, participants breathed tidally for 
3 minutes through a mouthpiece connected to a bacteria filter. Subsequently, ten ml 
alveolar air was sampled via a CO2-controlled ultrasonic sensor and analyzed using the 
BioScout Multicapillary Column/Ion Mobility Spectrometer (MCC/IMS, B&S Analytik, 
Dortmund, Germany). Per subject a background sample was taken. VOCs were visually 
selected and their intensity (V) was calculated via on-board VisualNow 3.7 software. 
After calculating the alveolar gradient, we performed a lasso regression in R to search 
for peaks that have the most discriminative power to distinguish MPM patients from 
controls. Predictions were made by leave-one-out cross-validation. The use of breath 
VOCs on the diagnostic performance was investigated by ROC-analysis. Results: Eighty-
nine VOCs were selected in breath and background samples. The VOCs P25, P8 and 
P7 were able to discriminate HC from AEx controls with 91% accuracy (AUCROC=0.95), 
yielding a sensitivity, specificity and positive (PPV) and negative predictive value (NPV) of 
respectively 90%, 92%, 90% and 92%. MPM patients were discriminated from AEx by the 
VOCs P5, P3, P30, P1 and P54 with 82% accuracy (AUCROC=0.73), yielding a sensitivity, 
specificity and PPV and NPV of respectively 91%, 60%, 84% and 75%. When discriminating 
MPM patients from pooled HC and AEx controls, the VOCs P5, P3 and P1 were found to 
be important, yielding 73% accuracy (AUCROC=0.71) and a sensitivity, specificity and PPV 
and NPV of respectively 70%, 77%, 76% and 71%. Conclusion: Breath analysis can 
discriminate MPM patients from healthy asbestos-exposed persons with 82% accuracy 
and from combined asbestos-exposed and non-exposed controls with 73% accuracy 
while healthy asbestos-exposed persons can be discriminated from non-exposed 
persons with 91% accuracy. The VOCs P25, P8 and P7 seem markers for asbestos-
exposure while VOCs P5, P1 and P3 seem linked to MPM pathogenesis after exposure. 
For screening and to rule out diagnosis, a high sensitivity and NPV are mandatory and to 
rule in diagnosis, a high specificity and PPV are mandatory, which can enrich a population 
at risk for follow-up with (annual) CT scans or chest radiography. Hence, our results 
hold promise to use the breath test for screening of asbestos-exposed healthy seniors. 
Keywords: Mesothelioma, breath analysis, volatile organic compounds, Biomarkers
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MINI24.09 Cell-Free MicroRNA miR-625-3p Is Elevated in the Blood of Patients 
with Thoracic Malignancies Michaela B. Kirschner1, Marissa Williams1, Sjaak 
Burgers2, Mir A. Hoda3, Catharina M. Korse4, Daan Van Den Broek4, Thomas Klikovits3, 
Balazs Hegedus3, Balazs Dome3, Michael Grusch5, Walter Klepetko3, Nico Van Zandwijk1, 
Glen Reid1 1Asbestos Diseases Research Institute, Sydney/NSW/Australia, 2Pulmonology, 
The Netherlands Cancer Institute, Amsterdam/Netherlands, 3Division of Thoracic Surgery, 
Medical University Vienna, Vienna/Austria, 4The Netherlands Cancer Institute, Amsterdam/
Netherlands, 5Institute of Cancer Research, Medical University Vienna, Vienna/Austria
Background: In most instances definitive diagnosis of malignant pleural mesothelioma 
(MPM) requires a tissue biopsy of sufficient size. As a biopsy is not always feasible, 
the identification of an accurate biomarker easily measured in blood would represent 
an important step forward. A recent study indicated that microRNA miR-625-3p was 
present in elevated concentration in plasma or serum of MPM patients compared to 
healthy controls and asbestosis patients. (Kirschner et al, JTO; 7:1184). In this study, 
we have further investigated the diagnostic potential of miR-625-3p. Methods: MiR-
625-3p and other microRNAs were measured by RT-qPCR in two independent series 
of MPM patients and controls. After exclusion of haemolysed samples and those 
yielding RNA of insufficient quality, series 1 consisted of serum samples from 73 
MPM patients, 69 healthy volunteers and 64 patients with non-small cell lung cancer 
(NSCLC) collected at the Netherlands Cancer Institute (NKI) between 1994 and 2013. 
The second series consisted of plasma samples from 29 MPM patients and 35 healthy 
volunteers collected in Vienna and Hungary (V/H) between 2011 and 2013. Additionally 
levels of soluble mesothelin-related protein (SMRP) were assessed (ELISA) in the NKI 
series. Results: Analyses of samples from patients and controls in the NKI series 
revealed that serum miR-625-3p concentrations were on average 5.35-fold higher 
(p=0.0054) in MPM, and 3.47-fold (p=0.003) in NSCLC than in control samples. Levels 
in MPM patients were 1.54-fold higher than in NSCLC patients but this did not reach 
statistical significance (p=0.273). Compared to healthy controls, the areas under the 
ROC curve (AUC) were 0.82 (95% CI: 0.75-0.89) for MPM and 0.75 (95% CI: 0.67-0.84) 
for NSCLC. In the samples of the V/H series, plasma miR-625-3p concentrations were 
on average 1.98-fold (p<0.001) higher in MPM patients than in healthy volunteers, with 
an AUC of 0.80 (95% CI: 0.69-0.91). Assessment of SMRP in the NKI series revealed 
AUCs of 0.69 (95% CI: 0.59-0.78) differentiating MPM from healthy individuals and 
0.65 (95% CI: 0.54-0.75) separating MPM from NSCLC, comparable to AUC values 
reported earlier. Conclusion: Data from two independent validation series confirms the 
previously observed increased abundance of miR-625-3p in blood from MPM patients. 
However, the miR-625-3p levels observed in NSCLC patients show that elevation of the 
level of this microRNA in plasma/serum is not restricted to MPM. Further studies into 
combinations of microRNAs and SMRP (diagnostic signature) in MPM are warranted. 
Keywords: MicroRNAs, biomarker, diagnosis, Mesothelioma
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MINI24.07 Infrared Spectroscopy as a Novel Approach in Differential Diagnosis 
of Malignant Pleural Mesothelioma from Lung Cancer Using Pleural Fluid Sherif 
Abbas1, Nihal S. Ozek1, Deniz Koksal2, Mete Severcan3, Salih A. Emri4, Feride Severcan1 
1Biological Sciences, Middle East Technical University, Ankara/Turkey, 2Chest Disases, 
Hacettepe University, Mesothelioma and Medical Geology Research and Application Center, 
Ankara/Turkey, 3Electrical and Electronics Engineering, Middle East Technical University, 
Ankara/Turkey, 4Hacettepe University, Mesothelioma and Medical Geology Research and 
Application Center, Ankara/Turkey
Background: Malignant pleural mesothelioma (MPM) is an aggressive and rare form 
of cancer which arises from mesothelial cells lining pleural cavity. Since it is difficult to 
differentiate the benign pleural thickenings from carcinomas, MPM can only be diagnosed 
in the advanced stage. To decrease the mortality rate of this disease highly sensitive and 
specific diagnostic methods are required. In the current study we propose Attenuated 
Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectroscopy coupled with 
chemometrics as a novel approach in diagnosis of MPM from pleural fluids with better 
sensitivity and specificity values than the other biomarker analysis methods that are 
currently used. Methods: The pleural fluid samples from MPM (n=24), lung cancer 
(LC, n=20) and benign transudate (BT, n=20) patients were collected to perform FTIR 
spectroscopic experiments. Recording and analysis of the spectral data were performed 
by using Spectrum One software. Unsupervised chemometric analysis methods 
including hierarchical cluster (HCA) and principal component analysis (PCA) were applied 
to discriminate MPM from BT and LC groups. To develop a diagnostic method, SIMCA, 
a supervised chemometric method was also performed. Results: Quantitative spectral 
analysis indicated that lipid, triglyceride, cholesterol ester, protein and nucleic acid 
contents of MPM group differ from BT and LC groups. The score plots obtained from PCA 
analysis of pleural fluid at whole (4000-650 cm-1), lipid (3000-2800 cm-1) and fingerprint 
(1800-650 cm-1) spectral regions showed that BT, LC and MPM groups are successfully 
discriminated from each other (fig 1.).
 
Figure 1. PCA scatter plots for all BT, LC and MPM pleural fluid samples in the 4000–650 
cm-1 spectral region. Moreover, the loading plots obtained from these spectral regions 
supported the differences in molecular content of all three groups. SIMCA results 
performed at whole and fingerprint regions also revealed high accuracy values for 
the diagnosis of MPM and LC. Conclusion: The results demonstrated that ATR-FTIR 
spectroscopy together with chemometric tools can be used for successful and rapid 
differential diagnosis of MPM from LC and BT groups . *This work was supported by the 
Scientific and Technical Research Council of Turkey (TUBITAK), SBAG-113S294 Research Fund. 
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MINI24.08 Breath Analysis by Ion Mobility Spectrometry Allows Discrimination 
of Pleural Mesothelioma Patients From Controls Kevin Lamote1, Matthijs Vynck2, 
Joris Van Cleemput3, Olivier Thas2, Kristiaan Nackaerts4, Jan P. Van Meerbeeck5 
1Internal Medicine, Ghent University, Gent/Belgium, 2Mathematical Modelling, Statistics and 
Bioinformatics, Ghent University, Ghent/Belgium, 3Occupational Health Service, Eternit Nv, 
Kapelle-Op-Den-Bos/Belgium, 4Respiratory Oncology, University Hospital KU Leuven, Leuven/
Belgium, 5Thoracic Oncology, Antwerp University Hospital, Edegem/Belgium
Background: Despite the use of asbestos has been banned in many countries, 125 
million people worldwide are still exposed to asbestos and at risk for developing 
malignant pleural mesothelioma (MPM). Since MPM is a lethal tumor, with diagnosis 
mainly at advanced stage due to non-specific symptoms and investigations, it is thought 
that only an early diagnosis will improve patient’s outcome (van Meerbeeck et al., 2011). 
Breathomics has emerged as a new research field, allowing to detect volatile organic 
compounds (VOCs) in breath which can be used as non-invasive markers for disease 
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MINI24.13 Molecular and Pathological Features of Different Malignant 
Pleural Mesothelioma (MPM) Histologic Subtypes Giulia Pasello1, Loredana 
Urso2, Manlio Mencoboni3, Federica Grosso4, Giovanni L. Ceresoli5, Francesca 
Lunardi6, Roberta Bertorelle7, Vincenzo Ciminale2, Federico Rea6, AdolfoG. Favaretto1, 
Pierfranco Conte2, Fiorella Calabrese6 1Medical Oncology 2, Istituto Oncologico Veneto, 
Padova/Italy, 2Department of Surgery, Oncology and Gastroenterology, University of 
Padova, Padova/Italy, 3Oncology Unit, Villa Scassi Hospital, ASL 3 Genovese, Genova/
Italy, 4Mesothelioma Unit, Oncology, SS Antonio E Biagio General Hospital Alessandria, 
Alessandria/Italy, 5Oncology, Cliniche Humanitas Gavazzeni, Bergamo/Italy, 6Department of 
Cardio-Thoracic and Vascular Sciences, University of Padova, Padova/Italy, 7Immunology and 
Molecular Oncology Unit, Istituto Oncologico Veneto IRCCS, Padova/Italy
Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor 
prognosis and limited treatment options. Sarcomatoid/biphasic mesotheliomas are 
characterized by more aggressive behaviour, characterized by a higher resistance to 
systemic treatments, more frequent distant spread and a poorer prognosis compared 
with the epithelioid subtype. To date prognostic and tailored therapeutic biomarkers 
are lacking. Methods: The present study analyzed the expression levels of MDM2 and 
HIF1alpha and the presence of inflammation, necrosis and proliferation in different 
histologic subtypes from chemonaive MPM patients. Diagnostic biopsies of MPM 
patients from four Italian cancer centers were centrally collected and analyzed. MDM2, 
and HIF1alpha expression levels were investigated through immunohistochemistry and 
RT-qPCR. A pathological assessment of necrosis, inflammation and proliferation index 
(through Ki67 immunostaining) was also performed. Molecular markers, pathological 
features and clinical characteristics were related to overall (OS) and progression free 
survival (PFS). Results: Sixty MPM patients were included in the study (32 epithelioid 
and 28 non-epithelioid). Higher levels of MDM2 (p<0.001), HIFalpha (p=0.013), 
necrosis (p=0.013) and proliferation index (p<0.001) were significantly associated 
with sarcomatoid/biphasic subtypes, while higher levels of inflammation were 
significantly associated with epithelioid subtype (p=0.044). MDM2 expression levels 
were correlated with HIF1alpha (p=0.0001), necrosis (p=0.008) and Ki67 (p=0.009). 
Univariate analysis showed a significant correlation of non-epithelioid histology 
(p=0.04), high levels of necrosis (p=0.037) and proliferation index (p=0.0002) 
with shorter PFS. This finding, however, was not confirmed by the multivariate 
analysis. Conclusion: Sarcomatoid/biphasic and epithelioid mesotheliomas show 
different MDM2 and HIF1alpha expression levels and are characterized by different 
levels of necrosis, proliferation and inflammation. Further studies are warranted 
in order to confirm a prognostic and predictive role of such markers and features. 
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MINI24.14 Use of Next Generation Sequencing to Improve Lung Tumor 
Immunotherapy Bruce W. S. Robinson1, Shaokang Ma1, Sophie Sneddon1, Michelle R. 
Tourigny1, Ian Dick1, Justine S. Leon1, Andrea Khong1, Scott A. Fisher1, Richard A. Lake1, 
Willem Joost Lesterhuis1, Anna K. Nowak2, Shay Leary3, Mark W. Watson3, Jenette 
Creaney1 1School of Medicine and Pharmacology, University of Western Australia, Perth/WA/
Australia, 2Medical Oncology, Sir Charles Gairdner Hospital, Perth/WA/Australia, 3Institute for 
Immunology & Infectious Diseases, Murdoch University, Perth/WA/Australia
Background: Immunotherapy of pulmonary tumors is now a clinical reality, however 
most patients do not respond. To convert non-responders into responders one potential 
approach is to identify the tumor‐specific ‘neo‐antigens’ that arise from DNA mutations 
in order to follow tumor-specific responses and to design therapeutic vaccines to try to 
‘enforce’ a response against these resistant tumors. Methods: First, in order to identify 
tumor neo-antigens we performed RNAseq and exome analysis to identify single nucleotide 
variants (SNV) in murine pulmonary tumors. An average of 485 SNVs was found. We focused 
on AB1 and AB1-HA (asbestos-induced mesotheliomas, which mimic human mesothelioma) 
and Line 1 (lung cancer). We used the NetMHCpan 2.8 algorithm to identify candidate 
mutation‐carrying peptides and screened them in an interferon‐γ ELISPOT assay. 
Second, to determine if more neo-antigens could be ‘unmasked’ by therapy, we tested 
three candidate therapies in our murine model then reanalyzed neo-antigen responses 
a) Treg depletion using Foxp3-DTR mice, b) gemcitabine, an immunogenic cytotoxic 
chemotherapy commonly used for pulmonary malignancies, and c) antiCTLA4 (a checkpoint 
blockade therapy). Results: We identified 20 candidate mutation‐carrying peptides in 
the ELISPOT assay. A strong spontaneous endogenous pre-treatment immune response 
was demonstrated to DUqcrc2, a component of the respiratory chain protein ubiquinol 
cytochrome complex. It was found to stimulate a strong response at a similar magnitude 
to the model neo-antigen viral haemagglutinin (HA). The DUqcrc2 peptide sequence (amino 
acid 405-413) is predicted to bind the H-2Kd, and the mutant has a proline to alanine 
substitution mutation at position 408. Treg depletion unmasked a second neo-antigen, 
DGANAB. GANAB is an alpha glucosidase which cleaves the 2 innermost alpha-1,3-linked 
glucose residues from the Glc-2-Man-9-GlcNAc-2 oligosaccharide precursor of immature 
glycoproteins. There is an arginine to glutamine substitution mutation at position 969 of 
DGANAB (965-972) sequence. This observation supports the theory that removing Treg 
cells may broaden the immune response to a greater number of neo-antigens, a response 
presumably otherwise restrained by Treg suppression. Gemcitabine and antiCTLA4 
checkpoint blockade did not unmask any additional neo-antigens. Conclusion: Thus, 
removing some immune restraints may expose a greater number of neo-antigens as 
potential clinical targets. The results from these approaches suggest novel ways to improve 
the immunotherapy of lung tumor and are the basis for planning current clinical trials. 
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MINI24.11 Expression of PD-1 and Its Ligands in Human Malignant Pleural 
Mesothelioma Elly Marcq1, Jorrit De Waele1, Jonas Van Audenaerde1, Karen 
Zwaenepoel2, Paul Baas3, Patrick Pauwels2, Evelien L. J. Smits1, Jan P. Van Meerbeeck4 
1Center for Oncological Research (CORE), Antwerp University, Wilrijk/Belgium, 2Molecular 
Pathology Unit & Core, Antwerp University Hospital & Antwerp University, Edegem/
Belgium, 3Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam/
Netherlands, 4Thoracic Oncology, Multidisciplinary Oncology Centre Antwerp, University 
Hospital Antwerp, Edegem/Belgium
Background: The discovery of immune checkpoint receptors as cytotoxic T lymphocyte 
antigen-4 (CTLA-4) and more recently programmed death-1 (PD-1) introduced a new 
era in cancer immunotherapy. Immune checkpoints are responsible for controlling 
and inactivating the immune system in order to avoid autoimmunity and prevent tissue 
damage. PD-1 is expressed primarily on activated effector T lymphocytes. Its natural 
ligands are programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2). 
Expression of PD-L1/PD-L2 on tumor cells or in stroma impairs effector T lymphocyte 
activity within the tumor microenvironment. Trials with antibodies that block the ligand-
immune checkpoint interaction have shown promising results in several cancer types.
Data on few mesothelioma patients suggest that blocking immune checkpoints could offer 
new opportunities for treatment of this very aggressive tumor.. We investigated PD-1, PD-
L1 and PD-L2 expression in MPM. Furthermore the effect of interferon-gamma (IFNg), an 
important cytokine for immune-mediated tumor control, on their expression pattern was 
analyzed. Methods: Flow cytometry and immunohistochemistry (IHC) were used for the 
expression of PD-1, PD-L1 and PD-L2 on human primary MPM and T cells and on MPM 
cell lines that cover the three major histological subtypes of of MPM, i.e. epitheloid (M28, 
H2795, H2818), sarcomatoid (VAMT-1, H2731, H-Meso-1) and mixed (NKI04, MSTO-211H) 
mesothelioma cells. The effect of stimulation with IFNg on expression of PD-1 and its 
ligands was measured. Results: PD-1 surface expression was found on T cells and not 
on MPM tumor cells, corresponding to literature showing that PD-1 is only expressed 
on T cells, B cells and macrophages. Different expression patterns were observed 
regarding PD-L1 and PD-L2. Flow cytometry showed significant PD-L1 expression on all 
the epitheloid and sarcomatoid mesothelioma cell lines. Two out of three cell lines tested 
positive for PD-L2, both for the epitheloid and the sarcomatoid subtype. The mixed cell 
lines were negative for PD-1 and its ligands. Following IFNg stimulation, PD-L1 and PD-
L2 expression was induced or upregulated on all cell lines. Primary MPM cells showed 
variable expression of PD-L1. IHC data for PD-1 and PD-L1 expression correspond to 
the flow cytometry results. Conclusion: Taken together, these data on PD-1, PD-L1 
and PD-L2 expression on human MPM cells and T cells support further investigation of 
the expression profile of the immune checkpoint PD-1 and its ligands in MPM patients 
samples. We are currently performing this using multicolor flow cytometry and IHC. 
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MINI24.12 Assessment of PD-L1, TGF-β Expression and Tumor-Infiltrating CD8+ 
T Cells in Advanced Thymic Epithelial Tumors Jie Wang, Han Chen, Hua Bai, Jun 
Zhao, Shuhang Wang Peking University Cancer Hospital and Institute, Beijing/China
Background: “Avoiding immune destruction” is one of the emerging hallmarks of 
cancer, as proposed by Weinburg and Hanahan. High expressions of immunosuppresive 
proteins strongly links to prognosis and cancer treatment. This study aimed to 
exam the expressions of immunosuppressors programmed death receptor ligand-1 
(PD-L1) and transforming growth factor –β (TGF-β), and CD8+ tumor-infiltrating 
lymphocytes (TILs) in pre-treatment specimens from patients with advanced thymic 
epithelial tumors (TETs) including advanced thymic carcinoma and advanced invasive 
thymoma. To our knowledge, this is the first report to demonstrate the expression 
of PD-L1, TGF-β and CD8 and their clinical relevance in advanced TETs in Chinese 
population. Methods: Retrospective analysis was performed using tumor specimens 
from 20 patients with stage IV thymic carcinoma and 13 patients with stage III/IV 
invasive thymoma. Tissue biopsies were obtained before the first-line chemotherapy with 
(or without radiotherapy). The expression level of PD-L1, TGF-β and the prevalence of 
CD8+ TILs were assessed using immunohistochemistry (IHC). Their prognostic value 
for predicting overall survival (OS) and progression-free survival (PFS) were statistically 
analyzed using the SPSS software. Results: Higher expression levels of PD-L1 and TGF-β 
were detected in advanced thymic carcinoma than in advanced invasive thymoma (65.0% 
vs. 46.2%, 65.0% vs. 15.4%, respectively). Low level of CD8+ TILs was presented in 
45.0% cases with advanced thymic carcinoma. In advanced thymic carcinoma, higher 
TGF-β expression was strongly associated with worse OS, with a p-value almost 
reaching statistical significance (p = 0.052). Median OS of patients with TGF-β high 
and low expression was 29.5 ms (95%CI: 18.6-40.4) and 62.9 ms (95%CI: 15.6-110.1), 
respectively. Higher PD-L1 expressions significantly predicted worse PFS after firs-line 
chemotherapy with (or without) radiotherapy (p =0.043). Median PFS was not estimable 
in PD-L1 low expression group. Mean PFS of patients with PD-L1 high and low expression 
was 13.3ms (95%CI: 8.0-18.6) and 23.5ms (95%CI: 13.9-33.2), respectively. An 
additional radiation treatment was particularly needed for CD8 low expression patients, 
in which first-line treatment with “chemotherapy + radiotherapy” significantly prolonged 
PFS compared to “chemotherapy-alone” (median PFS = 6.8ms, 95%CI: 0.0-2.7 vs. 3.5ms, 
95%CI: NE, p = 0.015). Conclusion: Our results documented the clinical relevance of 
PD-L1, TGF-β, and CD8 in advanced TETs, with the prognostic value of predicting OS and 
PFS, as well as a potential association of immune conditions with therapeutic benefits. 
Keywords: Thymic epithelial tumor;, thymic carcinoma;, PD-L1;, thymoma;
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MINI25.03 Potent Anti-Mesothelioma Activity by the Novel Naftopidil Analogue 
HUHS1015; Preclinical Evidence for Treatment Kozo Kuribayashi1, Ryuji Ieki1, 
Taiichiro Otsuki1, Akinobu Gotoh2, Akito Tanaka3, Tomoyuki Nishizaki4, Takashi Nakano1 
1Division of Respiratory Medicine,Department of Internal Medicine, Hyogo College of 
Medcine, Nishinomiya, Hyogo/Japan, 2Laboratory of Cell and Gene Therapy, Institute 
for Advanced Medical Science, Hyogo College of Medcine, Nishinomiya, Hyogo/
Japan, 3Laboratory of Chemical Biology, Advanced Medical Research Center, Hyogo 
University of Health Science, Kobe, Hyogo/Japan, 4Department of Physiology, Hyogo College 
of Medicine, Nishinomiya, Hyogo/Japan
Background: Malignant pleural mesothelioma (MPM) is usually a fatal neoplasm, 
and current therapeutic interventions are far from satisfactory. Naftopidil, an α1-
adrenoceptor antagonist, is used clinically for the treatment of benign prostate 
hypertrophy, and has been found to reduce the incidence of prostate cancer and to inhibit 
prostate cancer cell proliferation via G1 cell cycle arrest. Recently, naftopidil has been 
demonstrated to induce apoptosis in mesothelioma cells by activating caspase-8 and 
the effector caspase-3 independently of α1-adrenoceptor suppression. Hence, a more 
potent naftopidil analogue, HUHS1015, was synthesized. The current study evaluates the 
inhibitory effect of HUHS1015 on malignant mesothelioma cell proliferation in preclinical 
models and assesses whether HUHS1015 can be the basis for new drug for the 
treatment of MPM. Methods: We treated the human MPM cell lines MSTO-211H, NCI-H28, 
NCI-H2052 and NCI-H2452 with HUHS1015, and evaluated cell viability using the MTT 
method. Additionally, NCI-H2052 tumor xenograft models in BALB/c-nu/nu mice were 
utilized to investigate anti-mesothelioma activity in vivo. Results: HUHS1015 reduced 
the viability of MPM cells more potently than cisplatin or paclitaxel at concentrations 
higher than 30 µM, and the drug induced both necrosis and apoptosis of MSTO-211H and 
NCI-H2052 cells. The effect of HUHS1015 on the expression of Bcl-2 family mRNAs in 
MSTO-211H and NCI-H2052 cells was tested using real-time RT-PCR. Puma, Hrk, and Noxa 
mRNAs were up-regulated in both cell lines. In the NCI-H2052 mouse xenograft models, 
HUHS1015 strongly suppressed tumor growth. Conclusion: These results indicate that 
HUHS1015 may be an effective anticancer drug candidate for the treatment of MPM. 
HUHS1015 induces apoptosis of MPM cells through modulation of a mitochondrial 
pathway, and future clinical investigations with this drug are warranted for mesothelioma. 
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MINI25.04 Utilizing Molecular Profiling to Identify Potential Therapies in 
Sarcomatoid Lung Cancer Jue Wang1, David Arguello2, Zoran Gatalica2, Sandeep 
Reddy2, Panagiotis Fidias3 1University of Arizona Cancer Center/St. Joseph’s Hospital and 
Medical Center, Phoenix/AZ/United States of America, 2Caris Life Sciences, Irving/United 
States of America, 3Thoracic Oncology, University of Arizona Cancer Center, Phoenix/AL/
United States of America
Background: Sarcomatoid lung cancer (SLC) is an aggressive subset of poorly 
differentiated non-small cell lung carcinoma (NSCLC), comprising just one percent of 
all NSCLC. Further elucidation of this unique histological entity has been hampered by a 
lack of large-scale clinical trial evidence. The National Comprehensive Cancer Network 
(NCCN) contains no clear direction regarding optimal management. The purpose of 
this study, therefore, is to identify potential therapeutic options for this disease using 
a multiplatform, biomarker-directed approach. Methods: In total, 48 SLC specimens 
analyzed via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) 
consisting of gene sequencing (Sanger or next generation sequencing [NGS]), protein 
expression (immunohistochemistry [IHC]) and gene amplification (CISH or FISH) were 
retrospectively evaluated. Results: High rates of PD-L1 (83.3%, 5/6) and PD-1 (80.0%, 
4/5) protein expression by IHC imply benefit to recently-approved compounds. EGFR 
amplification by ISH (18.8%, 3/16) and MET amplification (9.5%, 2/21) were independent 
of EGFR mutation in this group. No ALK, HER2 or ROS1 ISH abnormalities were detected. 
Mutational analysis shows the highest mutation rates in TP53 (50.0%, 7/14), KRAS 
(44.4%, 16/36), cKIT (5.3%, 1/19), EGFR (5.1%, 2/39) and BRAF (4.8%, 1/21). The two 
EGFR mutations detected were L858R and exon 20 insertion. Conclusion: Multiplatform 
profiling identified multiple potential actionable targets with various approved therapies. 
PD-1 and PD-L1 overexpression rate was comparable to that published in sarcomatoid 
renal cell carcinoma. Therefore, new immunotherapies should be prospectively tested 
in sarcomatoid disease specific trials based on high PD-1/PD-L1 overexpression. 
Our finding of low EGFR mutational frequency is consistent with previous, published 
findings in this disease. Lower rates of ALK, ROS1, and EGFR are not surprising 
given SLC’s association with smoking. Clinical trials evaluating the benefit of imatinib 
and vemurafenib in subgroups with cKIT or BRAF mutations may be worthwhile. 
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MINI25.06 Appropriate Time of Adjuvant Adiotherapy for Thymoma with MG 
After Thymectomy Lei Yu1, Shan Ma2 1Department of Thoracic Surgery, Beijing Tongren 
Hospital, Capital Medical University, Beijing City/China, 2Beijing Tongren Hospital, Capital 
Medical University, Beijing City/China
Background: Controversy over adjuvant radiation of thymoma has raged on among 
experts for decades. 20-30% thymoma patients present with myasthenia gravis (MG). 
The co-existence of MG and thymoma makes the surgical treatment and adjuvant 
radiation more complicated. The aim of this article is to investigate whether patients with 
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MINI25.01 A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural 
Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial Scott A. 
Laurie1, Desiree Hao2, Natasha Leighl3, John Goffin4, Abderrahim Khomani5, Marc 
Filion6, Gregory R. Pond6, Mark N. Levine6 1Medical Oncology, The Ottawa Hospital Cancer 
Centre, University of Ottawa, Ottawa/ON/Canada, 2Medical Oncology, Tom Baker Cancer 
Centre, Calgary/Canada, 3, Princess Margaret Cancer Centre, Toronto/ON/Canada, 4Medical 
Oncology, Juravinski Cancer Centre, Hamilton/ON/Canada, 5Medical Oncology, Health 
Sciences North, Northeast Cancer Centre, Sudbury/ON/Canada, 6Ontario Clinical Oncology 
Group, McMaster University, Hamilton/ON/Canada
Background: Following failure of a platinum-antifolate combination regimen, there 
is no standard therapy for advanced malignant pleural mesothelioma (MPM). The 
fibroblast growth factor receptor (FGFR) signaling pathways may be a relevant target in 
MPM. Dovitinib inhibits multiple tyrosine receptor kinases, predominantly the vascular 
endothelial growth factor receptors (VEGFR), but also FGFR. Methods: This open-label 
multicentre phase II trial enrolled consenting adult patients with advanced, histologically-
confirmed MPM who had previously received platinum-antifolate combination 
chemotherapy and up to one additional line of systemic therapy. Patients were ECOG 
PS < 2 and had adequate end-organ function. Dovitinib was administered orally at 500 
mg/day for 5 days on, 2 days off; cycle length was 28 days. Two dose reductions (to 300 
mg) for toxicity were permitted. Response was assessed every 2 cycles using RECIST 1.1 
criteria modified for MPM. Correlative studies included FGFR-1 amplification on archival 
tumour and serum samples for circulating angiogenesis factors. Pre- and cycle 1 day 15 
on-treatment diffusion-weighted pleural MRI was evaluated for its potential as an early 
marker of drug effect. The primary end-point was the proportion of patients progression-
free at 3 months (PF3). A two-stage design was used: H0: 3-month PFS=40% versus 
HA: 3-month PFS=65% (roughly corresponding to a median PFS of 4.5 months), with 
α=0.05, β=0.20. If 6 of 12 PF3 in stage I, an additional 14 patients would be enrolled, 
with dovitinib of interest if > 15 of 26 PF3. Results: 12 patients (10 males, median 
age 67) were enrolled. The median number of cycles administered was 2.5 (range 1-8). 
Commonly observed and / or grade 3 at least possibly related adverse events (any grade 
/ grade 3, %): diarrhea (67 / 0%) vomiting (50 / 0%) fatigue (42 / 8 %), nausea (42 / 8 %), 
rash (0 / 17 %), syncope / generalized muscle weakness / elevated ALT (0 / 8 % each). 
No hyperphosphatemia was observed. 7 patients had at least one dose interruption (5 
in cycle 1) and 5 had a dose reduction (1 to 300 mg); median dose intensity during 
cycles 1 and 2 was 80 %. 3 patients discontinued due to clinical progression by day 1 
cycle 2. Best response: 1 unconfirmed PR, 4 SD, 2 PD and 4 inevaluable (3 with clinical 
PD; 1 intercurrent illness). The median PFS was 2.6 months and the median OS was 4 
months. PF3 was 50%; although the criterion for proceeding to stage II accrual was 
met, the trial was halted due to a combination of minimal activity with several early 
progression events and poor tolerability in this patient population. Conclusion: Dovitinib 
has minimal activity and a toxicity profile comparable to other VEGFR inhibitors in 
previously-treated MPM; it is not clear if FGFR is effectively targeted. Correlative studies 
are ongoing and may help to clarify the role of the FGFR in MPM. [NCT01769547]. 
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MINI25.02 A Clinical Study on Intra-Thoracic Chemotherapy of Recombinant 
Human Endostatin Combined with Cisplatin for Malignant Pleural Effusion 
Xingsheng Hu, Yuankai Shi, Hongyu Wang, Changgong Zhang, Peng Liu, Yan Wang, 
Junling Li Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical 
Sciences and Peking Union Medical College, Beijing/China
Background: To observe the efficacy and safety of intra-thoracic chemotherapy of 
recombinant human endostatin (Endostar) combined with cisplatin in the treatment 
of malignant pleural effusion. Methods: A total of 84 patients with malignant pleural 
effusion were randomly divided into intra-thoracic chemotherapy of Endostar combined 
with cisplatin group (combination group) and single cisplatin group (single group). Before 
treatment, pleural effusion was completely resolved. Combination group was treated 
with intra-thoracic injection of 40～50 mg cisplatin and 60 mg Endostar twice a week, 
and 4 times were as a cycle at most. Single group was only treated with cisplatin, and 
other operations were the same as the combination group. RECIST1.0 hydrothorax 
evaluation criteria and NCI-CTC AE 3.0 version classification criteria were applied to 
evaluate the efficacy and adverse reactions, respectively. Results: The response rates 
of initially-treated patients in combination group and single group were 63.6% and 
40.6%, respectively, and significant difference was presented (X2＝2.737, P＝0.022). 
The response rates of all patients in combination group and single group were 58.1% 
and 36.6%, respectively, and the difference was significant (X2＝4.877, P＝0.019). The 
progression-free survival (PFS) in combination group was dramatically longer than in 
single group (95 d vs. 53 d; X2＝3.872, P＝0.039). No adverse reactions at degree Ⅳ 
were observed in all groups. Incidences of adverse reactions including neutropenia, 
anemia, fatigue and increase of blood pressure in combination group were all higher than 
in control group, but there was no statistical significance (P＞0.05). Conclusion: Intra-
thoracic injection of cisplatin alone is effective for treating patients with malignant pleural 
effusion, and its efficacy is better in combination with Endostar. Cisplatin combined with 
Endostar has a synergistic effect and better safety, being worthy of further popularization 
in clinic.
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patients (T) received 5, 15 and 20mg respectively. Patients had received a median 
of 2 previous anti-cancer treatments [range: 0-6]. Median duration of treatment with 
lucitanib was 7 cycles [range 2-44]. All patients were evaluable for anti-tumour activity 
according to RECIST v1.1. Two patients had confirmed partial response (1T / 1TC) lasting 
at least 7 months (TC patient is still ongoing) and 10 patients had a stable disease with 
6 of them lasting at least 6 months. To date, 4 patients are still ongoing and receiving 
benefit from lucitanib independently of the number of previous regimens. The most 
common adverse events related to lucitanib in this population (all grades, all doses) were 
hypertension (80%), hypothyroidism (53%), proteinuria (53%) and diarrhoea (40%). There 
was no major bleeding event reported. These findings were in line with the overall safety 
profile of lucitanib already described. Conclusion: The results of this tumour cohort 
analysis suggest that lucitanib has signs of clinical activity in patients with advanced 
thymic epithelial tumours, and should be further investigated in dedicated studies. 
Keywords: tyrosine kinase inhibitor, lucitanib, Thymic malignancies
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MINI25.08 Systemic Treatment in Advanced Thymic Epithelial Tumors. Insights 
From a Prospective Cohort of 888 Patients Enrolled in RYTHMIC Nicolas Girard1, 
Eric Dansin2, Hervé Léna3, Eric Pichon4, Pascal-Alexandre Thomas5, Julien Mazières6, 
Luc Thiberville7, Virginie Westeel8, Gérard Zalcman9, Christelle Clément-Duchêne10, 
Gilbert Massard11, Xavier Quantin12, Jaafar Bennouna13, Pierre Fournel14, Thierry Molina15, 
Benjamin Besse16 1Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon/France, 2Centre 
Oscar Lambret, Lille/France, 3Centre Hospitalier Universitaire, Rennes/France, 4Hôpital 
Bretonneau, Centre Hospitalier Universitaire, Tours/France, 5Assistance Publique Hôpitaux 
de Marseille, Marseille/France, 6Hôpital Larrey, Centre Hospitalier Universitaire, Toulouse/
France, 7Centre Hospitalier Universitaire, Rouen/France, 8Centre Hospitalier Universitaire, 
Besançon/France, 9Centre Hospitalier Universitaire, Caen/France, 10Centre Hospitalier 
Universitaire, Vandoeuvre-Les-Nancy/France, 11Hôpitaux Universitaires, Strasbourg/
France, 12Centre Hospitalier Universitaire, Montpellier/France, 13Institut de Cancérologie 
de L’Ouest, Saint Herblain/France, 14Institut de Cancérologie Lucien Neuwirth, Saint-Priest 
En Jarez/France, 15Assistance Publique-Hôpitaux de Paris, Paris/France, 16Gustave Roussy 
Cancer Campus, Villejuif/France
Background: RYTHMIC (Réseau tumeurs THYMiques et Cancer) is the French nationwide 
network for thymic malignancies. Starting 2012, all patients diagnosed with thymic 
tumor had to be enrolled, as recommended by the French National Cancer Institute, 
part of good clinical practice. Methods: RYTHMIC prospective database is hosted by 
the French Thoracic Cancer Intergroup (IFCT), and collects clinical, imaging, treatment, 
and follow-up data of patients discussed at the reference national multidisciplinary tumor 
board (MTB). Data cutoff was April 1st, 2015 for this analysis. Results:  1089 questions 
were raised at the MTB about the management of 888 patients with thymic epithelial 
tumor. Among assessable cases, Masaoka-Koga stage III-IV tumors accounted for 42% 
of cases; histology was thymoma in 82% of cases, and thymic carcinoma in 18% of 
cases. First-line treatment of locally advanced disease, and management (diagnosis 
and treatment) of recurrent disease led to raise 227 (21%), and 234 (21%) questions 
at the MTB, respectively, 312 (68%) of which were about the modalities of systemic 
treatment. Figure 2 shows the proposed regimens for primary (A) and exclusive (B) 
chemotherapy in treatment-naïve patients, and chemotherapy (C) and targeted agents 
(D) for recurrent tumors. Combination of cisplatin, adriamycin, and cyclophosphamide 
and carboplatine, paclitaxel were the most frequently proposed regimens as first- and 
second-line treatment, respectively. 
MG and thymoma should receive mediastinal radiation therapy and when after extended 
thymectomy. Methods: Between 2002 and 2012, 159 patients with MG and thymoma 
underwent extended thymectomy. These patients were subdivided into 3 groups: Group 
1 (n=89), patients having mediastinal radiotherapy within one month after surgery; 
Group 2, having mediastinal radiotherapy over three month after surgery (n = 49); and 
Group 3, without adjuvant radiation (n = 21). Results: 152 patients underwent extended 
thymectomy by VATS, and 7 undergoing the trans-sternal approach due to thymoma 
invading great vessels. The resection was extended to the pericardium in 23 patients, 
the lung in 17 patients, and the innominate vein in 11 patients. There were no inoperable 
cases. The proportions of type A, AB, B1, B2, B3, and thymic carcinoma in this data were 
0.6%, 19.5%, 25.8%, 32.7%,21.4%, and 0%, respectively. 146 patients were followed for 
15 months to 12 years: 82 in Group 1, 45 in Group 2, and 19 in Group 3. Postoperative 
myasthenic crisis occurred in 38 cases: 16 cases in Group 1, 14 in Group 2, and 8 in 
Group 3. There was a significant difference in occurrence of postoperative myasthenic 
crisis between Group 1 and Group 3 (P=0.045). The rates of reaching CSR were 31.7% 
in Group 1, 22.2% in Group 2, and 21.1% in Group 3, respectively. The overall survival of 
Group 1, Group 2, and Group 3 were 90.2%, 86.7%, and 78.9%, respectively. 6 patients 
in Group 1 recurred, while 4 patients in Group 2 and 4 in Group 3 recurred. There was no 
lymph node metastasis detected. Kaplan-Meier survival curves demonstrate that there 
is no significant difference in overall survival among 3 groups. However, Cox regression 
analysis made by entering some factors including sex, age, and adjuvant radiation, 
revealed that adjuvant radiation might have significant influence in prognosis in thymoma 
patients ( P = 0.047). 
Conclusion: Adjuvant radiation within one month after extended thymectomy may help 
decrease possibility of postoperative myasthenic crisis, raise the cumulative probabilities 
of reaching CSR, and might have significant influence in prognosis in thymoma patients 
with MG. In recurrence cases, no lymph node metastasis was detected 
Keywords: adjuvant radiotherapy, Thymoma, MG, thymectomy
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MINI25.07 Clinical Activity of Lucitanib in Advanced Thymic Epithelial Tumours 
Benjamin Besse1, Nicolas Girard2, Anas Gazzah3, Cinta Hierro4, Josep Tabernero4, 
Filippo Debraud5, Gabriella Camboni6, Frederic Dubois7, Catherine Leger7, François 
Legrand7, Renata Robert7, Patrick Therasse7, Jean-Charles Soria8 1Gustave Roussy 
Cancer Campus, Villejuif/France, 2Respiratory Medicine, Thoracic Oncology, Louis Pradel 
Hospital, Hospices Civils de Lyon, Lyon/France, 3Gustave Roussy, Villejuif/France, 4Vall 
D’Hebron Institute of Oncology, Barcelona/Spain, 5European Institute of Oncology, Milano/
Italy, 6Areslifesciences, London/United Kingdom, 7Institut de Recherche International Servier, 
Suresnes/France, 8Gustave Roussy Cancer Campus and University Paris-Sud, Paris/France
Background: Thymic epithelial tumours are rare malignancies for which there is 
no standard treatment for patients with advanced disease progressing on or after 
chemotherapy. Despite the lack of identified targets in thymic malignancies, several 
studies demonstrated that VEGFR and KIT pathways are the most relevant targets for 
therapeutic intervention. Lucitanib is an oral, potent, selective inhibitor of the tyrosine 
kinase activity of FGFR1-3, VEGFR1-3, and PDGFR α/β, all key targets involved in pro-
angiogenic and proliferative pathways leading to tumour progression. Therefore, lucitanib 
could be a potential therapeutic alternative for patients with recurrent or refractory 
disease. Methods: This first in human study is currently evaluating oral lucitanib as 
monotherapy in various solid tumours. The escalation phase used a 3+3 design in 
patients with advanced solid tumours to establish the recommended phase II dose. 
Safety and efficacy were further evaluated in patients whose tumours were determined 
to be FGF aberrant (FGFR1 and/or 11q amplification) or in patients with tumours known 
to be anti-angiogenesis-sensitive such as thymic epithelial tumours. In addition, different 
doses and administration schedules were investigated. Results: Of the 134 patients 
treated in the study, 3 had B-type Thymoma (T) and 12 had Thymic Carcinoma (TC). 
Among these patients, median age was 54 years [range 37-72], 7 were males and 8 
females. Twelve patients (80%) were treated at 12.5mg on daily basis. The other 3 
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MINI25.11 Optimization of Gross Tumour Volume Definition in Lung-Sparing 
Volumetric Modulated Arc Therapy for Pleural Mesothelioma Angela Botticella1, 
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Nafteux5, Stéphanie Peeters6, Dirk De Ruysscher6 1Department of Oncology, Laboratory 
of Experimental Radiotherapy, KU Leuven, Leuven/Belgium, 2Dept of Respiratory Diseases, 
Respiratory Oncology Unit, KU Leuven-University of Leuven, University Hospitals Leuven, 
Leuven/Belgium, 3Department Imaging and Pathology, Nuclear Medicine and Molecular 
Imaging, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven/
Belgium, 4Department of Radiology, University Hospitals Leuven, Leuven/Belgium, 5Thoracic 
Surgery, University Hospitals Leuven, Leuven/Belgium, 6Department of Radiation Oncology, 
KU Leuven - University of Leuven, University Hospitals Leuven, Leuven/Belgium
Background: High dose lung-sparing pleural radiotherapy for malignant pleural 
mesothelioma (MPM) is difficult. Given the steep dose gradient with volumetric modulated 
arc therapy (VMAT), accurate target delineation is critical. The optimal imaging modality 
to define radiotherapy target volumes has not been studied in depth. This is the aim 
of the present study. Methods: Twelve consecutive patients with a histopathological 
diagnosis of stage I-IV MPM (6 left-sided and 6 right-sided) were included. CT scans with 
intravenous (IV) contrast, 18F-FDG PET/CT scans, MRI scans (post-contrast T1-weighted 
and T2-weighted) and diffusion-weighted images (DWI) were obtained and downloaded 
from the institutional database onto a standalone image fusion workstation (MIM 
Software Inc., Cleveland, OH, USA) for image registration and contouring. CT scans were 
rigidly co-registered with 18FDG-CT-PET, with MRI scans and with DWI scans. Four sets of 
pleural GTVs were defined: 1) a CT-based GTV (GTVCT); 2) a PET/CT-based GTV (GTVCT+PET/
CT); 3) a T1/T2-weighted MRI-based GTV (GTVCT+MRI); 4) a DWI-based GTV (GTVCT+DWI). Only 
the pleural tumor was contoured; mediastinal nodes were excluded. In each of the 4 
co-registrations, a “quantitative” and a “qualitative” (visual) evaluation of the volumes 
were performed. “Quantitative” evaluation was carried out through the coefficient of 
variation (COV; the ratio between the standard deviation [SD] and the mean: a measure 
of the dispersion of a distribution) and the Jaccard index (the ratio between the union and 
the intersection between two volumes: a measure of overlap). “Qualitative” evaluation 
consisted of a visual identification of any additional tumor site in each of the 4 obtained 
co-registrations. Results: Compared to CT-based GTV definition, PET/CT identified 
additional tumour sites in 12/16 patients. Compared to either CT or PET/CT, MRI and 
DWI identified additional tumour sites in 15/16 patients. Additional tumour sites were 
mainly the parietal pleura, the diaphragm and the chest wall. Mean GTVCT, GTVCT+PET/CT, 
GTVCT+MRI and GTVCT+DWI (+SD) were respectively 630.1 mL (+302.81), 640.23 (+302.83), 
660.8 (+290.8) and 655.2 mL (+290.7). Mean Jaccard index was lower in MRI-based 
contours versus all the others. Conclusion: To the best of our knowledge, this is the 
first study showing that the integration of the MRI (T1/T2-weighted) and DWI into the 
target volume definition in lung-sparing hemi-thoracic VMAT in MPM may allow to improve 
the accuracy of target delineation and reduce the likelihood of geographical misses. 
Keywords: target volume definition, lung-sparing IMRT, malignant pleural mesothelioma, 
non-surgical treatments
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MINI25.12 Hospital Resource Utilization and Outcomes of Pleurectomy 
Compared to Extrapleural Pneumonectomy for Mesothelioma Robert B. 
Cameron1, Olga Olevsky2, Michael Selch3, Michael Fishbein4, Fereidoun Abtin5, W. Dean 
Wallace6, Robert Suh5 1Surgery, David Geffen School of Medicine at UCLA and West Los 
Angeles VA Medical Center, Los Angeles/United States of America, 2Medical Oncology, David 
Geffen School of Medicine, Los Angeles/United States of America, 3Radiation Oncology, 
David Geffen School of Medicine, Los Angeles/United States of America, 4Pathology, David 
Geffen School of Medicine at UCLA, Los Angeles/CA/United States of America, 5Radiological 
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Background: Although extrapleural pneumonectomy (EPP) and pleurectomy/
decortication (P/D) provide similar survival in malignant pleural mesothelioma (MPM), 
we sought to compare the two procedures in terms of another important outcome” 
hospital resource utilization (RU). Methods: With IRB approval, we retrospectively 
reviewed our prospective database to determine RU (ICU and hospital stay, mechanical 
ventilation, and central line use, etc) and Kaplan-Meier median survival (MS) for patient 
undergoing P/D. Our results are compared with similar findings for EPP reported in the 
literature. Results: We identified 121 pts on an “intent to treat” basis from 1997-2011. 
94 (77.7%) were male. Mean age was 65.9 yrs (range 27-84). Comorbidities included 
hypertension 45.5%, coronary artery disease 11.6%, diabetes 10.7%, and vascular 
disease 6.2%. Mean surgical time was 7 hrs 57 mins (range 3 hrs 15 min–14 hrs 21 min). 
R1 resection was achieved in 116 (95.9%). Microscopic “margins” were assessed in 63 
with 40 (63.5%) positive. Pathologic T- and N-staging is shown in Table 1. Morbidity was 
mostly limited to air leaks >10 days 41 (33.9%) and atrial arrhythmias 38 (31.4%). Three 
patients (2.5%) died. Relevant RU data included: intraoperative CVP lines 3 (2.5%), OR 
extubation 113 (93.4%), no ICU stay 99 (81.7%), and mean hospital stay 10 (range 5-103) 
days. RU data with P/D + RTx is compared to EPP as reported by others (figure 1). MS 
was 13.8 mos for all patients and 17.8 mos for epithelioid histology, which was better 
than biphasic (10.3 mos) and sarcomatoid (2.1 mos) subtypes (p<0.01). MS for 85/121 
patients (70.2%) who completed P/D + RTx was 19.7 mos. MS for similar groups of EPP 
patients is reportedly 16.8-19 mos (eg, Thorac Cardiovasc Surg 1999;117(1):54-65 and 
J Clin Oncol 2009;27(18):3007-13).
 
Conclusion:  RYTHMIC is an exhaustive registry of thymic malignancies, which provides 
unique insights in the management of advanced and recurrent tumors with systemic agents. 
Meanwhile, limited data have been made available in the literature so far, as clinical trials 
were conducted in small numbers of patients, and existing databases enrolled a majority 
of surgically resected, early-stage tumors. Through the use of targeted agents, RYTHMIC 
allows the rapid implementation of new results in clinical practice, while ensuring patients 
an equal access to therapeutic innovation. Supported by Institut National du Cancer 
Keywords: Thymoma, Thymic carcinoma, chemotherapy, Reccurence
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MINI25.09 Percutaneous Cryoablation for Recurrent Mesothelioma following 
Lung Sparing Pleurectomy and Decortication: Safety and Efficacy Fereidoun 
Abtin1, Robert B. Cameron2, William Hsu1, Mathew Quirk1, Robert Suh1, Hyun. J. Kim1 
1Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles/CA/United 
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Background: Percutaneous cryoablation (PC) is an ablative technique, being used for 
local treatment of recurrent mesothelioma in patients following surgical lung sparing 
decortication and pleurectomy, and occasionally for palliative control of tumor extension 
to vital structures or pain control. The purpose of this study was to evaluate the safety 
and efficacy of PC in local control of recurrent mesothelioma. Methods: With IRB 
approval, patients with recurrent mesothelioma following lung sparing pleurectomy 
and decortication with at least one PC were identified from a database containing 
ablation information. Intra procedural and immediate post procedural hospital 
information was assessed for complications and follow up imaging was used to asses 
for late complications and recurrence. Patients were followed with CT and and PET/
CT scans for 6 and some up to 12 months. Local recurrence determined by increased 
regional metabolic activity or increased size of post ablation zone at 6 months. A 
stepwise multiple logistic regression model was used to assess predictors of local 
recurrence after ablation, considering clinical variables including: stage at diagnosis, 
chemotherapy, radiation, recurrence time lag following surgery, and number of lesions 
at time of recurrence presentation, And PC variables including: size of the lesion, edge 
of ice ball beyond the tumor, number of probes, size of probes, number of cryo cycles, 
maximum and total freeze and thaw time. Results: From the database, 25 patients 
were identified who underwent a total of 117 outpatient cryoablations (range of 1-25). 
4 ablations in 3 patients were performed for palliative and pain control indications. 
Lesions measured a mean of 32.5 mm (range 9-113) by 18.0 mm (range 6-60) in 
diameter. At 6 months 110/117 (94.0%) of ablations showed no recurrence. No major, 
but minor complications including hematoma, small pneumothorax and hemoptysis in 
one patient each and erythema in 3 chest wall subcutaneous lesions (5/117 =4.2%). 
Late complications in 4/117 (3.4%) ablations. Considering the clinical and cryoablation 
variables no recurrence was seen in patients having the edge of iceball more than 7 
mm beyond the tumor. Conclusion: PCT can be used for management of recurrent 
mesothelioma following surgery with low recurrence rate of 6%, and limited procedural 
complications 4.2% and late complications of 3.4%. When performing PCT, at least 7 mm 
of the of iceball is needed to extend beyond the edge of tumor to limit local recurrence. 
Keywords: Percutaneous Cryoablation, Mesotheliom, cryoablation, Pleurectomy
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Conclusion: Our prediction model using a nomogram and regression trees can be easily 
employable for calculating survival benefits. Nomogram and RPA are complementary to 
each other. RPA displays comprehensive grouping of patients who have similar prognosis, 
while nomogram is useful for predicting hazard ratio of individual patient. In this study, 
our combined model constitutes a useful tool for predicting prognosis of patients who 
undergo repeated metastasectomy for osteosarcoma. Keywords: Nomogram, 
Prognosis, regression tree, metastasectomy
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MINI25.14 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia 
(DIPNECH): Descriptive Analysis and Overall Survival Mukesh Kumar1, Chao 
Zhang2, Zhengjia Chen2, Marquita Nelson2, Vinicius Ernani3, Gerald Staton2, Srihari 
Veeraraghavan3, Anthony Gal2, Gabriel Sica2, Taofeek K. Owonikoko1 1Hematology/
Oncology, Emory University, Atlanta/GA/United States of America, 2Emory University, 
Atlanta/GA/United States of America, 3Hematology and Medical Oncology, Emory University, 
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Background: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) 
is a rare disorder characterized by proliferation of neuroendocrine cells in the bronchial 
wall and considered to be pre-invasive lesion for lung carcinoid tumors [1]. There is 
increasing rate of diagnosis of this condition due to widespread availability and use of 
cross sectional imaging. DIPNECH is reported as an incidental finding in approximately 
5.4% of patients undergoing resection for lung neoplasms [2]. The optimal management 
of this condition is currently not well-established. The limited data regarding the 
clinicopathologic characteristics and long term outcome for patients with DIPNECH 
provided a strong rationale for this study. Methods: We employed medical records 
to obtain demographic, clinical characteristics and survival for patients diagnosed 
with DIPNECH at our institution between January 1990 to December 2014. A review of 
archival diagnostic material was conducted by expert pulmonary pathologists to confirm 
the original diagnosis. Differences in clinical characteristics and survival was assessed 
between patient groups defined by race, gender, age, smoking status, body habitus 
and treatment received. Survival was computed using the Kaplan–Meier method while 
univariate and multivariate models were employed to assess for significant association 
between patient survival and variables of interest. Results: A total of 27 patients were 
included in this analysis. The majority of patients were females (89%) and predominantly 
of Caucasian (66.7%) or Black (14.8%) race. The median age at diagnoses was 63 years 
(range: 20-77) and 61.5% of patients were non-smoker. Approximately 52% underwent 
surgical resection. The median overall survival (OS) was 151 months (95%CI: 39-165) 
while 1-year and 5-year survival rates were 95.2% and 73.2% respectively. Nineteen 
patients (71%) remain alive at the time of this analysis. Male patients (HR: 4.58, 
95%CI: 0.76-27.67, p=0.098) and smokers (HR: 23.79; 95%CI: 0.98-579.54; p<0.052) 
appeared to have an inferior survival. No statistically significant difference in survival 
was recorded in patient subgroups defined by age, race, surgical intervention or body 
weight. Conclusion: DIPNECH is a rare condition with increasing rate of diagnosis. The 
overall prognosis is good in comparison to other lung neoplasms but up to a quarter of the 
patients do not survive beyond five years post diagnosis. Male gender and associated use 
of tobacco products may be associated with poor outcome. References: 1. Chassagnon, 
G., et al., DIPNECH: when to suggest this diagnosis on CT. Clin Radiol, 2015. 70(3): p. 
317-25. 2. Ruffini, E., et al., The significance of associated pre-invasive lesions in patients 
resected for primary lung neoplasms. Eur J Cardiothorac Surg, 2004. 26(1): p. 165-72. 
Keywords: Diffuse Idipathic Neuroendocrine Carcinoma, Carcinoid Tumors
Conclusions: P/D +RTx provide essentially the same outcomes as EPP with less use of 
hospital resources






Conclusion: P/D provides essentially the same outcomes as EPP with less use of 
hospital resources.  
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MINI25.13 Survival Prediction Model of Repeated Pulmonary Metastasectomy 
for Osteosarcoma: A Nomogram and Regression Trees Haewon Lee1, Junhye 
Kwon2, Moonchul Kang1, Cheol Hyeon Kim3, Hee Jong Baek1 1Thoracic Surgery, Korea 
Cancer Center Hospital, Seoul/Korea, 2Translational Research, Korea Cancer Center Hospital, 
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Background: Surgical resection for pulmonary metstasis of osteosarcoma has been 
considered as the treatment of choice, however, it was not feasible to predict the benefit 
of metastasectomy for patients with multiple poor prognostic parameters. Survival 
prediction model can be very helpful for this purpose, so we made a nomogram based 
on parametric survival model(PSM) and regression trees from recursive partitioning 
analysis(RPA). Methods: We reviewed the clinical variables of patients who underwent 
single or multiple surgical resection for pulmonary metastasis of osteosarcoma between 
1994 and 2012. Prognostic parameters were incorporated into PSM and RPA to build 
a nomogram and regression trees for the prediction of survival after single or multiple 
metastasectomy. The ‘rms’ and ‘rpart’ package of R(version 3.2.0) were used for this 
procedure. PSM was validated with C-index calculated by bootstrap method and then the 
parameters of PSM were used for RPA. Results: We analyzed 186 patients who received 
294 metastasectomies. The number of second, third, and forth metastasectomy cases 
were 62, 28, and 11 respectively. Overall 5-year survival rate after first metastasectomy 
was 47%. Age, gender, number of metastatic nodules, frequency of metastasectomy, 
disease free interval before metastasectomy, size, subtype and resection margin of 
primary tumor were affecting overall survival. Nomogram and regression trees were 
displayed in figures. C-index of PSM was 0.71. 
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Conclusion: We for the first time showed that cfDNA concentration and mutational 
burden might influence the efficacy and prognosis of patients receiving EGFR-TKIs. These 
findings call for the need for the multiplex genetic analysis of patients’ cfDNA to tailor 
their treatment. Keywords: Non-small-cell lung carcinoma, next-generation sequencing, 
EGFR-TKIs
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MINI26.03 Detecting C-MET Amplification in Blood and Tumor Tissue of 
Non-Small Cell Lung Cancer Meiyu Fang1, Chunwei Xu2 1Zhejiang Cancer Hospital, 
Hangzhou/China, 2Affiliated Hospital of Academy of Military Medical Sciences, Beijing/China
Background: To detect the consistency of the c-MET gene amplification in peripheral 
blood and tumor tissue of patients with non small cell lung cancer and discuss the 
clinical application value of c-MET gene amplification in peripheral blood. Methods: Real-
time fluorescent quantitative PCR was used to test the tissues in 257 patients of non 
small cell lung cancers and the peripheral blood samples in 318 patients of non small 
cell lung cancer, of which 185 cases of peripheral blood specimens could match the 
tissue samples, and detected the c-MET gene amplification in them by comparison of 
amplifications consistency in blood and tissue samples, and analysed the correlation 
between c-MET gene amplification and clinical characteristics of patients. Results: The 
c-MET gene amplification rate was 9.75% in peripheral blood of 31 patients with non small 
cell lung cancer，and was 8.95% in 23 cancer tissues, the amplification consistency was 
81.25% in peripheral blood-tumor tissue matched samples. The difference was statistically 
significant (P<0.05). Conclusion: The consistency of the c-MET gene amplification in 
peripheral blood and tissue is high. c-MET gene amplification of peripheral blood could be 
used for clinical diagnosis and treatment in cases when tissue specimen is hard to get． 
Keywords: Cancer; Non small cell lung; c-MET gene;
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MINI26.05 Immunophenotyping of Circulating T Cells and TILs with 
Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer Frank 
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MINI26.02 Deep Sequencing Reveals the Significance of Plasma DNA 
Concentration and Mutational Burden in Advanced Non-Small-Cell Lung 
Cancer Patients Li Zhang1, Shaodong Hong1, Yan Wang2, Wenfeng Fang1, Yan Huang1, 
Hongyun Zhao1, Yuanyuan Zhao1, Cong Xue1, Yunpeng Yang1 1Sun Yat-Sen University 
Cancer Center, Guangzhou/China, 2Questgenomics (Nanjing) Biotechnology Ltd., Nanjing/
China
Background: Plasma cell-free DNA (cfDNA) contains genetic information from primary 
and metastatic cancer foci. We utilized multiplex deep sequencing technology to 
investigate the clinical significance of cfDNA concentration and mutational burden 
in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase 
inhibitors (TKIs). Methods: Between January 2012 and February 2014, seventy-one 
eligible patients from Sun Yat-sen University Cancer Center were enrolled. All the patients 
provided written informed consent and donated 2 ml plasma before taking EGFR-TKIs. 
Plasma DNA was isolated and purified using QIAamp Circulating Nucleic Acid Kit. CfDNA 
concentration was determined by Qubit Fluorometer. A set of 234 primer pairs were 
designed to amplify sequences covering hotspots of 35 genes. The amplicon libraries 
were prepared and entered into deep sequencing on Ion Torrent PGM chip. Variants were 
called by established bioinformatics methods. Circulating DNA mutational burden was 
defined as the number of somatic variants other than EGFR mutations. Objective response 
rate (ORR) and disease control rate (DCR) between different groups were compared 
using Fisher’s exact test while progression-free survival (PFS) and overall survival (OS) 
between different groups were compared by Kaplan-Meier curves and log-rank tests. 
Multivariate stepwise Cox regression analyses were performed to identify independent 
prognostic factors. Results: Forty-nine out of 71 patients were observed to harbor at 
least one variant and at most 7 variants, involving 10 genes (totally 124 variants). Higher 
cfDNA concentration was associated with impaired DCR (18.6% vs 81.4%; p=0.008), 
PFS (median PFS, 3.5 vs 15.2 months; HR=3.03; p=0.001) and OS (median OS, 27.3 vs 
not-reached; HR=2.38; p=0.042) compared with low cfDNA concentration group. Higher 
mutational burden was associated with unfavorable ORR (31.6% vs 73.7%; p=0.004) and 
PFS (median PFS; 8.6 vs 17.8 months; HR=1.61; p=0.050) compared with low mutational 
burden group. EGFR mutation conferred better ORR, DCR and PFS compared with EGFR 
wild-type (Figure 1). Multivariate analyses revealed that apart from EGFR mutation status, 
cfDNA concentration and mutational burden were also associated with the efficacy and/
or the prognosis of EGFR-TKIs.
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Background: Precision therapy with tyrosine kinase inhibitor (TKI) crizotinib and 
ceritinib against EML4-ALK (ALK+) non-small cell lung cancer (NSCLC) has advanced 
rapidly in recent years as a new paradigm in personalized cancer therapy. However, 
acquired drug resistance despite initial response still remains the rule, necessitating 
further investigations into mechanisms of resistance and novel therapies to overcome 
progressive resistant disease. Liquid-biopsy using peripheral blood circulating tumor 
cells (CTCs) as a minimally-invasive tool to determine patient’s disease status, tumor 
cells molecular-genomic make-up and evolution during therapies, is highly desirable. 
There is still an unmet need to develop affordable and robust technology platforms to 
empower such liquid-biopsy assay of CTC. There are relative advantages and pitfalls 
with various CTC platforms and a method to capture CTC in an unbiased fashion 
without pre-definition would be beneficial. Methods: We conducted pilot studies with 
adoption of two different CTC detection and enrichment platforms. First, we used the 
CellSearch® “positive-selection” platform through EpCAM immunomagnetic separation 
to profile 11 pts with ALK(+) NSCLC who were treated with crizotinib prospectively. 
Blood samples were collected (i) pretreatment, (ii) on TKI with CR/PR/SD, and (iii) at 
disease progression. Second, we evaluated a novel “negative-selection” CTCs capture-
isolation platform, based on unbiased immunomagnetic removal of pan-leukocyte marker 
CD45+ cells coupled with RBC lysis, to enable CTC isolation without predefined CTC 
criteria. Pilot studies utilizing ALK+ H3122 cell line and ALK+ patients’ blood samples 
were performed for assay optimization and comparison. Whole genome sequencing 
using Illumina HiSeq x TEN was performed after whole genome amplification of the CTC 
tumor gDNA with paired-normal germline DNA for genomic interrogation. Results: Using 
ALK+ NSCLC patients’ peripheral blood samples, we demonstrated the presence of 
the EML4-ALK fusion (variant 1) in QPCR assay from the enriched CTC isolated using 
the CellSearch® platform. Also, CellSearch® enumeration in our pilot ALK+ cohort 
revealed a trend of correlation between the CTC numbers and disease status. The 
spike-in experiment in “negative selection” CTC platform enriched the spiked H3122 
cells by 10,000 fold from the nucleated blood cells. Applying our “negative-selection” 
CTC assay to a patient with known EML4-ALK variant 1 (EML4-ex13/ALK-ex20) fusion 
lung cancer during disease progression on crizotinib, we detected the specific EML4-
ALK variant 1 fusion in QPCR assay from the CTC enriched “eluate” fraction, but not in 
the “feed” fraction, whether the CellSearch® platform revealed any CTCs or not. In our 
index case of ALK-rearrangement NSCLC, we successfully performed whole genome 
sequencing analysis on the pretreatment negative-selection CTCs in comparison with 
the germline DNA and pretreatment lymph node tumor biopsied tissue tumor DNA. 
Our preliminary WGS results revealed similar genomic landscapes between the CTC 
and the biopsied tumor tissues. Conclusion: Taken together, our pilot CTC study 
results support the high sensitivity of the unbiased “negative selection” enrichment 
platform and its potential to empower molecular and genomic determinations in lung 
cancer. We also demonstrated the feasibility of the negative-selection CTC liquid-
biopsy platform to achieve whole genome sequencing analysis of the captured CTCs. 
Keywords: Circulating tumor cells, liquid biopsy, ALK rearranged lung cancer, whole 
genome sequencing
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Zhou1, Ying Liang1, Hai-Ying Wu1 1Sun Yat-Sen University Cancer Center, Guangzhou/
China, 2Dongguan People’s Hospital, Dong-Guan/China, 3Panyu Hospital of Chinese Medicine, 
Guangzhou/China
Background: The addition of bevacizumab, a monoclonal antibody against vascular 
endothelial growth factor, to a standard, first-line platin-based, two-agent chemotherapy 
regimen conferred a significant improvement in overall survival, progression-free survival, 
and response rate in patients with advanced non-squamous NSCLC (ns-NSCLC). The 
feasibility of the combination of bevacizumab and chemotherapy as the second-line or 
more therapy for ns-NSCLC is currently explored as well. However, no effective biomarker 
is validated to predict the response or clinical benefit of bevacizumab. This study aims 
to investigate the correlation between biomarkers and overall response to bevacizumab 
plus chemotherapy for patients with advanced ns-NSCLC. Methods: Patients with 
locally advanced or metastatic ns-NSCLC who were assigned to 7.5mg/kg 3-weekly 
doses of bevacizumab plus chemotherapy were eligible. Aaccording to investigators’ 
decision, chemotherapy regimens were pemetrexed (500mg/m2) with or without 
platinum (75mg/m2). Peripheral blood samples were collected at baseline and after 
2nd cycle of therapy for the analysis of granulocyte colony-stimulating factor（G-CSF), 
vascular endothelial growth factor A（VEGF-A) and VEGF receptor-2 (VEGFR-2). Plasma 
samples concomitantly with the radiological evaluation of disease progression were 
collected as possible. Correlation between biomarkers and overall response rate 
(ORR) were assessed by using a logistic regression model. Results: Baseline blood 
Background: Ipilimumab (Ipi) is a humanized CTLA-4 antibody that blocks binding of 
CTLA-4 with its cognate ligands, permitting T cell activation through CD28 binding. There 
is evidence that phased in Ipi added to chemotherapy (C) may enhance efficacy in non-
small cell lung cancer NSCLC. This trial was undertaken to gain a better understanding 
of the changes that occur in T cells, regulatory T cells (Tregs), and myeloid-derived 
suppressor (MDSC) in both the blood and tumor micro-environment with CTLA-4 
blockade. Methods: Patients with stage T > 4 cm and/or N1, N2 NSCLC were offered 
neoadjuvant carboplatin AUC6 plus paclitaxel 200 mg/m2 every 21 days 3 cycles with 
ipilimumab 10 mg/kg day 1 cycles 2 and 3. Blood for immune profiling of circulating T 
cells was collected prior to cycle 1, after cycle 1 chemotherapy alone, and after cycle 
3 chemotherapy plus Ipi. If patients underwent tumor resection and excess tumor was 
available, viable tumor infiltrating lymphocytes (TILS) were disaggregated and stored for 
later analysis. Phenotypic and functional polychromatic flow cytometry (PFC) analyses 
were performed on peripheral blood mononuclear cells (PBMC). Results: Blood was 
successfully collected at all 3 time points for the first 17/18 patients who initiated 
trial therapy. Excess tumor (0.96-5 gms) was collected on 5 patients and ample viable 
CD45+ TIL cells (9.4-26x106) were isolated and viably cryopreserved. Phenotypic 
analyses revealed that both CD4+ and CD8+ cells from all 17 patients were highly 
activated following two cycles of ipilimumab (cycle 3) as evidenced by greatly increased 
frequencies of CD28, HLA-DR, PD-1, and intracellular CTLA-4 expressing cells. The 
frequencies of Tregs, defined by CD4+CD25+FoxP3+ expression, were highly variable 
among the 17 participants, with 8 showing increased Tregs, 7 showing decreased 
frequencies, and 2 remaining unchanged over the course of therapy. Seven of the 17 
participants had levels of MDSC cells at or above 5%, with two patients achieving MDSC 
levels of 13% and 26.7%. Tumor associated antigen (TAA) -specific CD4+ or CD8+ 
cells were detected at baseline on 4 patients (24%), but their relative frequencies were 
unaltered by Ipi therapy. The most commonly recognized TAA was Survivin, followed 
by MAGEA3 and PRAME. No patients developed detectable de novo TAA reactivities 
while on Ipi therapy. We will report the phenotypic and functional parameters of TILs 
isolated from 5 tumors of the patients enrolled on the current trial at the time of 
presentation. Conclusion: TAA-specific CD4+ or CD8+ cells were unexpectedly detected 
in the blood at baseline in a subset of patients. We were able to determine what common 
NSCLC antigens the circulating CD4+ or CD8+ T cells were activated against, and this 
has the potential to be a blood based biomarker for trials studying immunotherapy 
such as vaccines. Neoadjuvant ipilimumab therapy neither facilitated the development 
of anti-TAA reactivities nor enhanced the frequencies of existing TAA-reactive T cells 
in PBMC. Neoadjuvant ipilimumab therapy effectively enhanced the frequencies 
of highly activated T cells, but had no consistent effect of the frequencies of Tregs. 
Keywords: ipilimumab, immunophenotype, non-small cell lung cancer, neoadjuvant
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Background: During the past decade, circulating tumor cells (CTCs) have been accepted 
as new prognostic and predictive factors for some type of cancers. In non small lung 
cancer cells (NSCLC) their detection and characterization is especially important to 
identify treatment resistances that some patients develop. Here, we report the value of 
characterization of CTCs and established cytological criteria to assess a good response 
for EGFR- tyrosine-Kinase inhibitors. Methods: From Feb 2012 to October 2014, 39 
patients (median age 63 years) with metastatic lung cancer were included in this study. 
NSCL (26 Adenocarcinomas and 13 Squamous cell carcinoma) EGFR wild-type patients 
were being treated with second or higher lines therapies with erlotinib. 10 ml of blood 
were collected from each patient into a CellSave TM Preservatives Tubes (Veridex, LLC, 
Johnson & Johnson Company) blood collection tube, maintained at room temperature 
and processed within a maximum of 72 hr after collection according to the protocol 
established by our group .For CTCs enrichment from PBMCs we used “Carcinoma Cell 
Enrichment and Detection kit: MACS technology (Miltenyi Biotechnology), using magnetic 
beads labeled with a multi-CK-specific. After isolation of CTCs, samples containing CTCs 
CK+ were stained for EGFR in double immunofluorescence (IF) experiments, following 
our standard protocol.The assessment of treatment was evaluated by histological 
criteria (CyCaR: Cytological Criteria of assessment Response).This way, as favorable 
response was defined when the number of CTCS was reduced more than 50% at 6 or 
12 weeks of starting erlotinib treatment. Results: Before treatment 18/39 patients 
(46%) were identified as positive for CTCCK+ with an average number of 3.5 cell (range 
1-11); 9 of which were presented persistence of CTCs after treatment. 7/ 18 patients 
positive for the presence of CTCCK + were positive to presence EGFR marker (CTCCK+ 
/EGFR +).. More important was, that we found A positive correlation between CTCs 
and survival: patients with CTC(CK+ /EGFR-) presented a shorter OS (34 vs 53 weeks) 
and PFS (13 vs 17 weeks) compared with those patients with CTC(CK+ /EGFR +) which 
responded favorably to erlotinib. Patients without cytological response criteria had a 
worse survival OS (28 vs 53 weeks, p=0.057) and PFS (11,5 vs 21,3 weeks, p=0.06). 
Conclusion: Our study suggests that the characterization of CTC based in the EGFR 
expression might be useful as a marker for the therapeutic selection and monitoring 
of lung cancer patients sensitive to treatment with inhibitors of tyrosin-kinase. 
Keywords: lung cancer, Erlotinib, Circulating tumor cells, cytological criteria
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At multivariate analysis, SUVmax of T was the only variable independently associat ed 
with cfDNA (p=0.036). No correlations were highlighted between CTCs and all PET-
derived parameters. A trend towards significance between high HTERT and the presence 
of metabolically active bone lesions was observed (p=0.058). Conclusion: Our data 
demonstrate that the expression of cfDNA is correlated with the metabolic activity of 
the primary tumor lesion. Since SIMaxSUV was not correlated with HTERT, it appears 
that the expression of cfDNA depends from tumor metabolism rather than its burden. 
Further analyses on 18FDG-PET/TC-derived metabolic tumor volume are ongoing. 
Keywords: Circulating tumor cells, circulating-free DNA, PET, non-small cell lung cancer
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Background: Detection of epidermal growth factor receptor (EGFR) mutation in non-
small cell lung cancer (NSCLC) patients is mainly based on tissue biopsy, which is 
invasive and time consuming. Furthermore, there is still a need for serial monitoring of 
EGFR mutations and detection of EGFR tyrosine kinase inhibitors (TKIs) resistance. We 
hypothesized that plasma-based EGFR mutation analysis may be feasible for monitoring 
response to EGFR TKIs and could be used to predict the resistance. Methods: From 
January 2012 to October 2014, 200 EGFR mutant NSCLC patients were enrolled and 
treated with EGFR TKIs (141 patients for gefitinib, 46 patients for erlotinib, and 13 
patients for afatinib). Plasma samples were prospectively obtained every 2 months 
from baseline until disease progression. The longitudinally collected plasma samples 
(n = 368) from 81 patients who progressed were analyzed using droplet digital PCR 
(ddPCR). We identified an association between serial EGFR mutant titers in plasma cell-
free DNA (cfDNA) samples and the patient’s clinical response to EGFR TKIs. Results: Of 
a total 58 baseline cfDNA samples available for ddPCR, 43 (74%) samples demonstrated 
same mutation in the matched tumors (i.e. sensitivity: 70.8% (17/24) for L858R vs 76.5% 
(26/34) for exon 19 deletions). The concordance rate of plasma with tissue results of 
EGFR mutation was 88% for L858R and 86% for exon 19 deletion, respectively. Of the 
54 patients with both before and after treatment plasma samples, 40 patients showed 
a dramatic decrease of mutant copies (greater than 50%) in blood in the first 2 months 
after treatment. We also found the secondary mutation (T790M) emerged in 28 patients 
around 3~13 months after treatment and in 4 patients before the treatment. Elevated 
circulating mutations (L858R/ex19/T790M) can be detected in 5 patients before disease 
progression as determined by CT scan. Conclusion: These results suggest that ddPCR 
is an appropriate method for determining plasma-based EGFR mutation status and may 
aid in monitoring response to EGFR TKIs and early detection of EGFR TKIs resistance. 
Keywords: non-small cell lung cancer, EGFR mutation, plasma, droplet digital PCR
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Background: Analysis of circulating tumor DNA (ctDNA) in plasma offers an opportunity 
to noninvasively monitor tumor burden and identify alternative drivers of disease 
progression in real-time. However, cancer progression during targeted therapy, such 
as EGFR-targeted therapies in non-small cell lung cancer (NSCLC), is driven by clonal 
evolution, and how this impacts the levels of targeted mutations in circulating tumor 
DNA (ctDNA) for monitoring disease burden is unclear. Methods: We collected serial 
plasma samples from 47 NSCLC patients receiving EGFR-targeted therapy (gefitinib) and 
hydroxychloroquine, and analysed mutations in EGFR, TP53, PTEN and PIK3CA in plasma 
by digital PCR and tagged-amplicon deep sequencing (TAm-Seq) of ctDNA. Results: We 
identified the same EGFR mutations in tumor and plasma samples in over 97% of 
patients, and found that patients with high pre-treatment levels of ctDNA are associated 
with worse progression-free survival and overall survival. Serial plasma analysis of 32 
patients reveals clonal dynamics in ctDNA in response to treatment. In >72% of patients 
(23/32), EGFR mutations levels increased preceding clinical progression, with the 
resistant mutation T790M detected in around 50% of these patients (13/23) a median 
of 6 months before progression became clinically evident. In the remaining 9 of the 
32 patients, EGFR-mutant ctDNA levels became uninformative during treatment, and 
in two patients we identified alternative driver mutations in ctDNA that correlated with 
progression. In one patient we also showed that the analysis of relative representations 
samples were available from 45 patients (100%, 19 patients were therapy naive, 26 
patients failed of prior therapies), while samples after 2nd cycle were obtained from 
37 patients (82.22%). For the primary analysis, there was no significant association 
between baseline plasma biomarkers and best overall response to the treatment. But, 
patients with low baseline plasma G-CSF level showed a trend toward improving ORR 
versus patients with high G-CSF level (odds ratio [OR], 3.846; 95%CI, 0.868 to 17.044
，p＝0.076). Patients with high baseline plasma VEGF-A level showed a trend toward 
higher ORR versus patients with low VEGF-A levels (OR, 3.477; 95%CI, 0.857 to 14.113
，p＝0.081). No significant correlations were observed between plasma biomarkers and 
progression-free survival (PFS). In comparison to baseline, plasma VEGF-A level increased 
significantly at 2nd cycle or radiological disease progression (p＜0.001). However, the 
magnitude of the difference did not correlate with ORR or PFS. Conclusion: Baseline 
or dynamic changes in plasma G-CSF, VEGF-A and VEGFR-2 did not correlate 
significantly with response of bevacizumab plus chemotherapy treatment for ns-NSCLC 
patients, while low baseline plasma G-CSF and high VEGF-A are possible candidate 
biomarkers for predicting response of bevacizumab plus chemotherapy for ns-NSCLC. 
Keywords: non-small-cell lung cancer; bevacizumab; chemotherapy; biomarker.
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Background: Circulating tumor cells (CTCs) and plasma circulating-free DNA (cfDNA) 
are promising candidates as non-invasive prognostic markers in malignant diseases. 
18-fluorodeoxyglucose positron emission tomography integrated with computed 
tomography (18FDG-PET/TC) has a well-recognized diagnostic and prognostic value in 
non-small cell lung cancer (NSCLC). Very little is known about the mutual relationship 
between circulating biomarkers (CTCs and cfDNA) and 18FDG-PET/CT indicators in 
NSCLC. Methods: Peripheral blood samples from 28 patients affected by advanced/
metastatic NSCLC were collected before starting first-line chemotherapy. CTCs were 
isolated by size using a filtration-based device (ScreenCell) and then identified and 
enumerated; cfDNA was isolated from plasma (QIAamp DNA Blood Mini Kit, Qiagen) 
and quantified by qPCR method using human telomerase reverse transcriptase (hTERT). 
All patients underwent 18FDG-PET/TC (Biograph 16 Siemens) at baseline. Maximum 
diameter (dmax) of the primary lesion (T), dmax of the greater lymph nodal (N), and 
metastatic (M) lesions were measured. Similarly, maximum and mean standardized 
uptake value (SUVmax, SUVmean) and size-incorporated SUVmax (SIMaxSUV) were 
computed for T, N and M, respectively; SIMaxSUV was calculated with the following 
formula for T, N, and M: SIMaxSUV= SUVMax*dmax. Presence (B+) and absence (B-) of 
metabolically active bone lesions (bone mets) were recorded. The association among 
CTCs, cfDNA and 18FDG-PET/CT-derived parameters was evaluated through multivariate 
analysis. T-test was performed to evaluate the difference in CTCs and cfDNA in B+ and B- 
groups, respectively. Results: Twenty-eight patients were evaluated; median age was 66 
years (range: 51-80); male/female ratio was 18/10; 15 patients were current smokers, 
while 11 were former-smokers and 2 were never-smokers. Histo-types were grouped as 
it follows: adenocarcinoma= 22; squamous cell carcinoma= 5; not otherwise specified 
NSCLC= 1. Nine patients out of 28 had metabolically active bone lesions. Median CTC 
count was 7 CTCs/3ml (range: 0-47 CTCs/3ml), while median HTERT copy number was 
109.0 (range: 16.7-1405-5).
18FDG-PET/CT PARAMETERS MEAN STANDARD DEVIATION P
T
Size 44.93 20.25 0.175
SUV max 10.16 4.48 0.036
SUV mean 10.6 3.4 0.994
SIMaxSuv 487.7 333.5 0.472
N
Size 22.2 10.9 0.313
SUV max 7.4 4.0 0.318
SUV mean 5.8 3.0 0.294
SIMaxSuv 172.8 158.1 0.231
M
Size 23.9 15.0 0.083
SUV max 7.5 4.1 0.318
SUV mean 7.4 1.2 0.307
SIMaxSuv 216.4 206.5 0.463
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during EGFR-TKI treatment and higher L858R mutation abundance on EGFR-TKI resistance 
is correlated with longer PFS.
Keywords: quantity of EGFR L858R, lung cancer, serial assessment, ctDNA
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Background: EGFR-T790M mutation, which is the valuable target for the next generation 
of EGFR-TKI, accounts for about half of the acquired resistance to current EGFR-TKI 
therapy in the EGFR sensitive mutation positive NSCLC patients. Due to clinical challenge 
in obtaining re-biopsy tumor tissues, noninvasive detection of EGFR-T790M in plasma 
circulating free DNA (cfDNA) has been proved to be feasible. Yet a highly sensitive assay 
needs to be developed to avoid false-negative detection. We here explored whether 
droplet digital PCR (ddPCR) of cfDNA can an alternative assay to identify the EGFR-TKI 
resistance mediated by EGFR-T790M in the clinical practice. Methods: The digital PCR 
method was recently developed for EGFR sensitive mutations, and its high sensitivity 
and specificity were validated in plasma cfDNA from EGFR-TKI-naïve NSCLC patients. 
In this study, we applied this method to detect EGFR-T790M in plasma cfDNA from 
metastatic NSCLC patients who initially responded but acquired resistance to current 
EGFR-TKI treatment. For the concordance analysis, the paired re-biopsy or pleural 
effusion cytology samples after failed EGFR-TKI were also collected for EGFR-T790M 
testing. Results: 25 consecutive NSCLC patients were enrolled and analyzed in this 
study according to these criteria: 1. Metastatic NSCLC patients with acquired EGFR-TKI 
resistance. 2. The re-biopsy tissue or cytology samples and paired plasma samples 
were available after disease progression on EGFR-TKI. Among these 25 patients, 13 were 
positive and 9 were negative for EGFR-T790M mutation in both tumor tissue and plasma 
samples. 3 patients positive for EGFR-T790M mutation in tumor tissue were detected 
negative in their plasma. The overall concordance rate between plasma and tumor tissue 
testing was 88.00% (22/25) (Kappa=0.757, 95%CI: 0.4996-1.0). The sensitivity and 
specificity for plasma testing of EGFR-T790M mutation by ddPCR were 81.25% (13/16) 
(95%CI: 54.35%-96.00%) and 100.00% (9/9) (95%CI: 66.37%-100%), respectively.
 
Conclusion: Detection of EGFR-T790M in plasma cfDNA by ddPCR is highly sensitive 
and specific when compared to the pairedre-biopsy tissue or cytology samples. This 
noninvasive method could complement current invasive biopsy approach or provide 
an alternative method to identify specific mutation mediated resistance in clinic. 
Keywords: EGFR, lung cancer, ddPCR, cfDNA
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of resistant and sensitizing mutations may provide insight to the response to sequential 
treatment. Conclusion: Our results demonstrate the potential of ctDNA for noninvasive 
stratification and monitoring disease progression in NSCLC patients, and highlight that 
targeted therapy may drive the selection of alterative mutations. This may impact the 
representation of the targeted mutations in plasma for assessing disease burden. We 
therefore propose that effective ctDNA-based monitoring of targeted therapies in oncogene-
addicted cancers requires tracking of multiple mutations beyond the targeted genes. 
Keywords: Circulating Tumor DNA, non-small cell lung cancer, liquid biopsy, TAm-Seq
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Background: Plasma circulating tumor DNA (ctDNA) has been widely accepted as a form 
of liquid biopsy to detect EGFR mutations in NSCLC for its high concordance rate with 
tumor tissues. There are some retrospective studies about the ctDNA quantitative 
changes of EGFR mutations in EGFR-TKI treatment, but there is no report about serial 
ctDNA assessment of response and resistance to EGFR-TKI by detecting the dynamic 
changes of EGFR mutations during the whole course of EGFR-TKI treatment based on 
prospective clinical trial. Methods: Based on a randomized trial initiated to compare 
erlotinib with gefitinib in advanced NSCLC harboring EGFR exon 21 L858R mutation in 
tumor tissues (CTONG0901, NCT01024413), we prospectively collected serial plasma 
samples as preplanned schedule (baseline, one week after treatment, one month after 
treatment and then every 8 weeks until disease progression) and quantitatively 
detected EGFR L858R mutation in ctDNA by using fluorescence quantitative polymerase 
chain reaction. We made a serial ctDNA assessment of response and resistance to EGFR-
TKI and its correlation with survival outcomes. Four patients’ serial plasma samples were 
selected to undergo next generation sequencing (NGS). Results: From 108 patients 
enrolled in the trial, serial plasma of 80 patients were collected as schedule and tested 
the quantity of L858R. As a whole, the quantity of L858R decreased to the lowest level 
when patients achieved best response to EGFR-TKI and increased to the highest level 
when disease progressed. Further analysis by Ward’s Hierarchical Clustering Method 
showed that the dynamic changes of quantity of L858R could be categorized into two 
groups, Ascend Group and Stable Group (Figure 1A). Median progression-free survival 
(PFS) was 11.1 months (95%CI=6.6-15.6) and 7.5 months (95%CI=1.4-13.6) in two 
groups, respectively (HR=0.57, 95%CI=0.34-0.97, P=0.035) (Figure 1B). Median overall 
survival was 20.1 months (95%CI=15.7~24.5) vs. 16.4 months (95%CI=13.3~19.6) 
(HR=0.73, 95% CI =0.38~1.38, P=0.322). In multivariate Cox proportional hazards 
regression analysis, changing group was independent predictive factor for PFS. In plasma 
samples of 4 patients underwent NGS, similar dynamic changing characteristics were 
confirmed and more genetic mutations were found. Detailed data will be presented on 
site.
Conclusion: This is the first report about serial ctDNA assessment of response and 
resistance to EGFR-TKI by detecting the dynamic changes of EGFR mutation based on a 
prospective clinical trial. The quantity of plasma L858R has different changing patterns 
S360 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
BIOLOGY AND OTHER ISSUES IN SCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 16:45-18:15
MINI27.03 PD-L1 Expression in Small Cell Lung Carcinoma: An 
Immunohistochemical Analysis of 26 Cases Using Two Anti-PD-L1 Antibodies 
Peter B. Illei1, Patrick Forde2, Christine Hann2, Stephen Yang3, Ronan Kelly2 
1Pathology, Johns Hopkins University School of Medicine, Baltimore/MD/United States of 
America, 2Oncology - Lung Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive 
Cancer Center, Baltimore/MD/United States of America, 3Thoracic Surgery, Johns Hopkins 
University School of Medicine, Baltimore, MD, Baltimore/MD/United States of America
Background: Small cell lung carcinoma (SCLC) represents 15% of lung cancers and 
is treated using chemotherapy +/- radiation but despite initial responses most recur 
within a few months and become resistant to therapy. Novel immune checkpoint 
inhibition of programmed death-1 (PD1) targeted therapy has shown promise in other 
solid tumors including non-small-cell lung cancer (NSCLC) and malignant melanoma. In 
some tumor types correlation with response and significant expression of programmed 
death- ligand 1 (PD-L1), the lead candidate biomarker of anti-PD-1 therapy, has been 
described but no data is available regarding expression levels in SCLC. Here we report 
the rate of PD-L1 expression in SCLC and in associated tumor infiltrating immune cells 
lymphocytes and macrophages. Methods: Immunohistochemistry (IHC) for PD-L1 using 
two monoclonal antibodies (clone 5H1 and clone SP142) and for CD3 (clone PS1) was 
performed on standard formalin fixed paraffin embedded tissue sections of 21 resected 
SCLC specimens (median age: 67) and three additional tumors with pre- and post-therapy 
biopsies. Since there is no generally accepted scoring system for PD-L1 expression we 
chose to evaluate staining in tumor cells and immune cells infiltrating the tumor nests and 
in adjacent stroma using a 4 tier semi quantitative scoring system (score 0 -no or <1%, 
1+ 1-<5%, 2+ 5-25% and 3+ >25% of cells staining). Both cytoplasmic and membranous 
staining was accepted as positive. The number of tumor infiltrating lymphocytes (TIL) 
were estimated utilizing a CD3 stain while macrophages were identified on corresponding 
H&E stains. Results: PD-L1 staining of tumor cells and Immune Cells (TIL & Macrophage) 
are shown in the table below. Membranous PD-L1 staining was only seen in two tumors 
and in variable number of immune cells with 2+ or 3+ PD-L1 scores. The majority of 
positive staining was cytoplasmic with both antibodies. The staining intensity was stroger 
with the 5H1 antibody. The paired pre- and post-therapy samples were all negative for 
PD-L1.
Clone/score PD-L1 staining in
5H1 Tumor IC in tumor IC in stroma
0 (<1%) 19/21 (90%) 7/21 (33%) 5/21 (24%)
1+ (1-<5%) 1/21 (5%)* 11/21 (53%) 6/21 (29%)
2+ (5-25%) 1/21 (5%)* 3/21 (14%) 7/21 (33%)
3+ (>25%) 3/21 (14%)
SP142 Tumor IC in tumor IC in stroma
0 (<1%) 20/21 (95%) 8/21 (38%) 10/21 (48%)
1+ (1-<5%) 1/21 (5%)* 11/21 (52%) 7/21 (33%)
2+ (5-25%) 2/21 (10%) 4/21 (19%)
3+ (>25%)
 
* Tumors with membranous staining; IC: immune cells Conclusion: Most SCLC are 
tumor membrane PD-L1 negative by IHC. A subset of SCLC contain PD-L1 positive 
TILs and/or macrophages in the tumor and the stroma. No up regulation of PD-L1 
expression was seen in a small pilot sample of matched pre- and post-therapy biopsies. 
It is unclear whether PD-L1 expression assessed by IHC will be a predictive marker for 
PD-1 targeted therapy in SCLC. Preliminary data indicates single agent and combined 
checkpoint inhibitors (PD1 plus CTLA-4 inhibitors) are active in previously treated 
SCLC indicating additional research is required to understand their mechanism of 
action in a tumor type that has seen no therapeutic advances in the last two decades. 
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MINI27.04 PD-L1 and C-MET Expression and Survival in Patients with Small 
Cell Lung Cancer Lulu Miao1, Yun Fan1, Yunyun Lu2, Yanjun Xu1, Zhiyu Huang2, Lei 
Gong2 1Zhejiang Cancer Hospital, Key Laboratory Diagnosis and Treatment Technology on 
Thoracic Oncology, Hangzhou/China, 2Chemotherapy, Zhejiang Cancer Hospital, Hangzhou/
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Background: Blocking the interaction between the programmed cell death (PD) -1 
protein and one of its ligands, PD-L1, has been reported to have impressive antitumor 
responses. PD-L1 interaction is a major pathway often hijacked by tumors to suppress 
immune control. Studies on the roles of PD-L1 in non-small cell lung cancer (NSCLC) are 
controversial, but its roles in small cell lung cancer (SCLC) are rare and unclear. Moreover, 
MET/HGF axis seems to be the other one of the most aberrant signaling pathways in 
SCLC. The aim of our study was to investigate the expression and prognostic roles of PD-
L1 and cellular-mesenchymal to epithelial transition factor(c-MET) in SCLC. Methods: The 
expression of PD-L1 and c-MET were evaluated by immunohistochemical analysis in 83 
specimens of SCLC, including 47 limited disease (LD) and 36 extensive disease(ED). 
Tumors with PD-L1 staining in over 5% of tumor cells were scored as positive for PD-L1 
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with an average 
of 20,000 new cases per year and 16,000 deaths per year. SCLC accounts for about 
10-15% of newly diagnosed lung cancers. Even in the face of extensive research, the 
standard of care- platinum-based combination chemotherapy- has not changed in 
decades. Yet even with modern chemotherapy formulations, the two year survival rate 
for advanced disease stages is less than 5%. Complicating treatment is that often at 
the time of diagnosis, SCLC as already metastasized to the patient’s surrounding lymph 
nodes. Therefore, a novel therapeutic strategy will have address three disease aspects: 
(1) reduce primary tumor growth and eliminate metastatic spread; (2) avoid resistance 
mechanisms used by SCLC to escape radio- and chemotherapies; (3) synergize with 
or supersede current therapeutic strategies. Chimeric antigen receptor T cells, little 
explored in SCLC, is well suited to address these aspects. Methods: Human SCLC cell 
lines were analyzed using a 90 gene signature to establish immunological targets. Western 
blot analysis confirmed the expression of CD56 and other targets on SCLC cell lines. For 
CAR T cell generation, PBMC were electroporated with the Sleeping Beauty transposase 
and a transposon containing a CD56R chimeric antigen receptor. CD56R-CAR transduced 
T cells were cultured for 4 weeks in the presence of K562 cells expressing CD56 and 
the cytokines IL-2/IL-21 to expand CD56R-CAR T cells. CAR T cells were tested in vitro for 
killing ability in the presence of three SCLC cell lines using a chromium release assay. 
CAR T cells were also analysed via FACS to assess CAR expression, T cell phenotype, 
and memory status. Results: An analysis of immune markers in SCLC cell lines revealed 
that, compared to NSCLC lines, there is a reduction in the expression of suppressive 
ligands and co-stimulatory ligands, antigen presentation, and natural killer ligands. 
SCLC cell lines, however, express high levels of CD56. When two CD56-positive and 
one CD56-negative cell line was tested, CD56-CAR T cells could kill efficiency CD56 
expressing cell lines, however there was little killing of the CD56-negative cell line. An 
analysis of PBMCs cultured after electroporation revealed that a large percentage of 
CD3+ T cells expressed the CD56 CAR and even after 4 weeks in culture, the CAR T cells 
displayed a memory phenotype. Conclusion: An interrogation of SCLC cell lines versus 
NSCLC cell lines revealed that SCLC cell lines had reduced expression of checkpoint 
ligands, NK cell killing ligands, antigen presentation, but consistent with their origin, high 
expression of CD56. Our conclusion from this analysis is that expansion of SCLC-specific 
immune responses in vivo or elicitation of de novo responses in vivo will be hindered. 
Therefore, immunotherapies centered around adoptive transfer of T cell that can kill 
in an HLA-independent manner maybe better suited for SCLC. In that vein, CD56R-CAR 
T cells effectively targeted CD56-positive SCLC in vitro, but was unable to kill CD56-
negative cells- which indicates a possible escape variant. Our lab is now moving toward 
testing CD56R-CAR T cell in vivo in both xenograph models and spontaneous ones. 
Keywords: SCLC, CD56, CAR T cell, Immunotherapy
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MINI27.02 RPS25 Is Essential for the Translation of the Seneca Valley Virus 
Genome and Proliferative Capacity of Small Cell Lung Cancer Cell Lines 
Linde A. Miles1, Tyler Hitchman2, John Poirier3, Charles M. Rudin3 1Department of 
Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore/MD/United 
States of America, 2Chemistry & Biomolecular Science, Clarkson University, Potsdam/NY/
United States of America, 3Memorial Sloan Kettering Cancer Center, New York/NY/United 
States of America
Background: Small cell lung cancer (SCLC) is an extremely aggressive and lethal 
disease for which there is a desperate need for novel and more effective treatments. 
A recently discovered oncolytic picornavirus, Seneca Valley Virus (SVV), infects tumors 
with neuroendocrine features, including SCLC with high selectivity. SVV is highly effective 
in the eradication of solid tumors in multiple in vivo models; however the mechanism 
of selective tropism for SVV is unknown. Because of the strong selectivity of the virus 
for SCLC, we hypothesize the host determinants of SVV permissivity could constitute 
future druggable targets for the treatment of SCLC. Methods: A retroviral gene trap 
mutagenesis screen was utilized in HAP1, a haploid human cell line permissive to SVV, 
HAP1. Once mutagenized, resistant cells, or cells with retroviral insertion in a gene 
essential to the viral life cycle, were selected for by incubation of the pool with SVV 
at a high multiplicity of infection (MOI). Hits from this screen were deconvoluted using 
an insertion mapping approach. Illumina sequencing provided quantitative counts of 
each insertion site in each gene. Hits from the screen were validated using various 
mechanistic approaches. Results: Our screen identified multiple unique insertion sites 
in the gene RPS25 on Chromosome 11. The RPS25 protein is a ribosomal protein that 
is a component of the 40S subunit of the ribosome. RPS25 has been previously shown 
to be important for IRES-dependent translation of multiple viral genomes as well as 
cellular mRNAs containing IRES elements. Using the CRISPR-Cas9 approach, we knocked 
out the RPS25 gene in the SVV-permissive SCLC cell line, NCI-H446. Upon total knock-
down of RPS25, H446 cells become completely resistant to cell killing by SVV at high 
MOI. Surprisingly, these cells also show a severely marked decrease in doubling time 
and robustness in culture. In contrast, RPS25 CRISPR knock-down in HEK293T cells 
has been previously shown to have no distinguishable phenotype other than defects 
in IRES-dependent translation. Further studies to fully characterize the interaction of 
RPS25 with the SVV genome as well as the importance of RPS25 in other SCLC cell 
lines are ongoing. Conclusion: We have identified a host protein that is essential for 
SVV replication and infection using a genome wide mutagenesis screen. SCLC cells 
completely defective in RPS25 are resistant to SVV-dependent cell killing. RPS25 appears 
to not only be important for the life cycle of SVV but may be important in proliferative 
capacity in SCLC. As SVV is highly selective for SCLC, we hypothesize that the host 
determinants of SVV tropism may be very specific to SCLC cells. Proteins important 
in the SVV life cycle may be novel “druggable” targets for the treatment of SCLC. 
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was measured by the side-population CSC assay in vitro and in limiting dilution tumor 
initiation assay in vivo. Results: VS-5584 inhibited SCLC growth in vitro at sub-µM 
IC50, and was synergistic with cisplatin and etoposide in reducing the viability of 
SCLC cells. In vivo, single agent VS-5584 (20 mg/kg, 3 days per week dosing, MWF) 
demonstrated robust anti-CSC activity in the NCI-H841 SCLC model by reducing tumor 
initiating potential 70-fold (p=5x10-6). In tandem, VS-5584 partially reduced tumor 
growth of the NCI-H841 xenograft tumors. Furthermore, a VS-5584 dose dependency 
was evident, both for tumor initiating potential and tumor growth reduction. When 
VS-5584 was combined with cisplatin and etoposide, the standard of care agents 
for SCLC, an increased tumor growth inhibition was observed whether VS-5584 was 
concurrently administered or added sequentially following the dual chemotherapy. In the 
SCLC PDX model, combination treatment also suppressed the regrowth of the tumor 
following cessation of chemotherapy for extended duration. VS-5584 was found to 
preferentially induce apoptosis in CSCs in multiple cell lines, indicating that these cells 
are eliminated through cell death-related mechanism. Importantly, we demonstrated 
that for eradication of CSCs it is necessary to inhibit simultaneously multiple PI3K 
isoforms and mTOR pathways. Conclusion: The VS-5584 pre-clinical findings support 
the preferential targeting of CSCs in SCLC models and provide an important rationale 
for advancing clinical development of the compound. A phase 1 dose finding clinical 
trial is on-going to establish a Phase 2 dose of VS-5584 and explore target inhibition. 
VS-5584 alone or in combination with standard of care chemotherapy may lengthen 
the time to relapse and improve outcome for patients with small cell lung cancer. 
Keywords: mTOR, PI3K, Cancer Stem Cells, small cell lung cancer
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MINI27.08 NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer 
(SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3) 
Anne Chiang1, Joseph Mclaughlin1, M. Catherine Pietanza2, Alexander Spira3, Robert 
Jotte4, Shirish Gadgeel5, Alain Mita6, Larry Gluck7, Stephen Liu8, Ann Kapoun9, Dawn 
Hill9, Roy Herbst10, Lei Zhou9, Jakob Dupont9, David R. Spigel11 1Yale University School 
of Medicine, New Haven/CT/United States of America, 2Memorial Sloan Kettering Cancer 
Center, New York/NY/United States of America, 3Virginia Cancer Specialists, Fairfax/VA/
United States of America, 4Rocky Mountain Cancer Centers, Denver/CO/United States 
of America, 5Thoracic Oncology, Barbara Ann Karmanos Cancer Institute, Detroit/MI/
United States of America, 6Cedars Sinai Medical Center, Los Angeles/CA/United States of 
America, 7Greenville Health System, Greenville/SC/United States of America, 8Georgetown 
University Medical Center, Washington Dc/DC/United States of America, 9Oncomed 
Pharmaceuticals, Inc, Redwood City/CA/United States of America, 10Yale University, New 
Haven/United States of America, 11Sarah Cannon Research Institute/Tennessee Oncology, 
PLLC, Nashville/TN/United States of America
Background: NOTCH expression is associated with cancer cell survival via effects 
on cancer stem/progenitor cells. Targeting NOTCH2 and 3 decreases growth and 
survival of SCLC patient-derived human tumor xenografts (PDX). Phase1b/2 trials 
testing Tarextumab (TRXT) anti-NOTCH2/3 therapy are underway (NCT01647828 and 
NCT01859741) and show promising anti-tumor activity. Here, we studied NOTCH3 protein 
expression using immunohistochemistry (IHC) in SCLC human tissues and correlated with 
survival. Also, we studied NOTCH3 gene expression in phase 1b patients (pts) treated 
with TRXT. Methods: For NOTCH IHC staining, murine monoclonal antibodies were 
generated by immunizing mice with a NOTCH3 extracellular domain (ECD) protein, then 
creating hybridomas. Clones were screened by FACS and western blots for specificity 
to NOTCH3.ECD. A lead clone was selected for NOTCH3 protein measurement in 47 
SCLC samples represented in a tissue microarray from Yale Pathology Tissue Services 
(YPTS). NOTCH3 signal was determined in tumors using H-scores generated by Leica 
Aperio Scanscope IHC membrane image analysis. For survival analysis, NOTCH3 signal 
was binarized with cutoffs defined by X-tile software. For the phase 1b clinical trial, a 
standard 3+3 dose escalation design was employed with cohorts of 3 to 6 pts treated 
at each dose level. TRXT was given IV on Day 1 of each 21 day cycle with etoposide 100 
mg/m2 (Days 1-3) and cisplatin 80 mg/m2 or carboplatin at AUC 5 (Day 1) for 6 cycles, 
followed by TRXT alone every 21 days until progression of disease or unacceptable 
toxicities. Then, the MTD TRXT plus etoposide and carboplatin was confirmed in a cohort 
of 6 subjects. All pts are required to submit tissues for Notch 3 gene expression and 
IHC staining. Results: A single hybridoma clone demonstrating specific reproducible 
membranous staining with a dynamic range for NOTCH3.ECD in control and PDX tissues 
was chosen for IHC analysis in SCLC human FFPE tissues (n=47). Forty cases (85.1%) 
demonstrated NOTCH3 signal, with eighteen (38.3%) having none to very low signal. Of 
the 31 cases with adequate follow-up, there was a strong trend with worse outcome 
and high NOTCH3 expression in the extensive stage (p=0.063), but not in limited stage 
(p=0.857). The level of significance was a function of the experimental cut-point and can 
only be considered exploratory. Finally, 27 pts were treated with TRXT in the phase 1b 
trial, with an overall response rate of 84%. The median duration of treatment was 128 
days (6 cycles) with mPFS and mOS of 124 and 228 days, respectively. The median 
follow-up for PFS and OS was 86 and 107 days, respectively. Twenty-five pts have tissues 
evaluable for NOTCH3 gene expression and the analysis is underway. Conclusion: 
NOTCH3 IHC staining showed expression in most SCLC cases, with high NOTCH3 trending 
towards worse survival in extensive stage. This supports the rationale of targeting 
NOTCH3 by TXRT in SCLC pts. Further evaluation of the prognostic and predictive value 
of TRXT for anti-Notch therapies in SCLC is underway in an ongoing Phase 2 clinical trial. 
Keywords: NOTCH 2 and NOTCH 3, tarextumab, anti-cancer stem cell terapy, SCLC
expression. Tumors with c-MET strong staining in at least 10% or weak to moderate 
staining in at least 40% of tumor cells were scored as positive for c-MET expression. 
Survival analysis was performed using the Kaplan-Meier method. Results: The positive 
rate of PD-L1 and c-MET in SCLC specimens were 51.8% and 25.3% respectively. The 
higher expression level of PD-L1 in tumor specimens was significantly correlated with 
a limited disease (LD) stage (p=0.004), a normal serum LDH level (p=0.031), and a 
normal NSE level (p=0.005). No association was found between the expression level of 
c-MET and PD-L1 , or c-MET expression with the other clinical characteristics of SCLC 
patients. SCLC patients with PD-L1-positive tumors showed significantly longer overall 
survival (OS) than those with PD-L1-negative (median OS, 17.0 vs 9.0, p=0.018). SCLC 
patients with positive c-MET expression showed a trend of shorter overall survival (12.0 
vs 15.0, p=0.186). But sub-analysis of Limited disease (LD) -stage patients showed 
that the c-MET negative group had a longer OS (25.0 vs 14.0; p=0.011). Multivariate 
analyses revealed that LD stage, good performance status but except for PD-L1 or c-MET 
immunoreactivity were independently predictive of better OS. Conclusion: In patients 
with SCLC, expression of PD-L1 was positively correlated with a LD stage and better 
OS, but was not an independently predictive factor of outcome. High expression level 
of c-MET revealed a trend of worse outcome. It was associated with poor prognosis 
especially in LD-Stage patients.
BIOLOGY AND OTHER ISSUES IN SCLC 
WEDNESDAY, SEPTEMBER 9, 2015 - 16:45-18:15
MINI27.06 Acquired Resistance Mechanisms in Small Cell Lung Cancer 
Mediated by the Cancer Stem Cell Marker Calcium Channel α2δ1 Subunit 
Jie Wang, Jiangyong Yu, Yanhua Tian, Hua Bai, Zhijie Wang, Sifan Yu Peking University 
Cancer Hospital and Institute, Beijing/China
Background: As a subtype of lung cancer, small cell lung cancer (SCLC) remains a 
severe threat to human health. Although it is initially a chemosensitive disease, 
development of acquired resistance is a major problem. Studies in recent years revealed 
that cancer stem cell (CSC) could play a role in this process. However, the CSC specific 
marker and the detailed signal pathway associated with acquired resistance in SCLC 
is unknown yet. It was recently reported that the voltage-dependent calcium channel 
α2δ1 subunit positive cells is a CSC marker in hepatic cell cancer and that 1B50-1 is 
the specific monoclonal antibody of the α2δ1 subunit. In present study, we attempted to 
disclose that α2δ1 could play a role in acquired resistance of SCLC. Also we investigated 
possible molecular mechanism of α2δ1 mediated resistance in SCLC and finally provided 
the potential strategies overcoming the resistance. Methods: We screened for positive 
expression of 1B50-1and CD133 in SCLC cell lines and in patient-derived xenograft (PDX) 
models, and we used flow cytometry to verify the properties of CSCs. We recorded the 
expression of 1B50-1 before and after chemotherapy in PDXs in chemosensitive and 
resistant models to determine if α2δ1 subunit-positive cells were related to acquired 
resistance. We used exome and transcriptome sequencing to explore the expression 
of genes related to stem cell properties and drug resistance. We used Western blotting 
to verify the key molecules and pathways in the process of drug resistance. On the 
basis of these results, we explored the mechanisms of acquired drug resistance that 
are mediated by the α2δ1 subunit. Results: We observed a difference in the positive 
expression levels of 1B50-1 and CD133 in SCLC cell lines (H1048, H69, and H209) 
and PDX models. Both 1B50-1-positive and CD133-positive cells exhibited stem cell-
like properties such as the capacity to self-renew in vitro, tumorigenesis in vivo, the 
potential for differentiation, and high expression levels of genes related to CSCs and drug 
resistance. Chemotherapy could induce the enrichment of 1B50-1-positive cells but not 
CD133-positive cells in PDXs. Also, high rates of 1B50-1-positive cells corresponded to 
high levels of resistance. Together, these findings indicated that the expression of 1B50-1 
is related to chemoresistance. Exome and transcriptome sequencing revealed that the 
expressions of multiple pathway related genes in pathways, including MAPK, CAMs, TGFβ, 
and Notch, were increased in 1B50-1-positive H1048 cells. Western blotting revealed the 
activation of the Erk protein in the MAPK pathway and the over-expression of the Erk 
protein in 1B50-1-positive H1048 cells. The specific α2δ1 antibody 1B50-1 improved 
response to chemotherapy and delayed relapse when combined with chemotherapy 
or used y as maintenance therapy. Conclusion: The α2δ1 subunit positive SCLC cells 
(1B50-1+) displayed CSC properties, and were associated with acquired resistance. The 
Erk protein in the MAPK pathway was highly expressed in the 1B50-1-positive H1048 cell 
line, and might be the key molecule involved in resistance mediated by the α2δ1 subunit. 
The α2δ1 subunit-specific antibody 1B50-1 could improve response to chemotherapy and 
delay relapse when combined with chemotherapy or when used as sequential therapy. 
Keywords: cancer stem-like cell,, chemotherapy resistance and relapse, Small cell lung 
cancer,
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MINI27.07 Targeting Cancer Stem Cells in Small Cell Lung Cancer Vihren Kolev, 
Yan Wang, Mahesh Padval, Jonathan Pachter, David Weaver Verastem, Boston/MA/United 
States of America
Background: Small cell lung cancer (SCLC) is an extremely aggressive cancer with 
limited treatment options and poor outcome. The majority of SCLC patients respond to 
frontline chemotherapy, but experience rapid recurrence with metastasis, that may be 
attributed to the prevalence of cancer stem cells (CSCs). We previously demonstrated 
that PI3K/mTOR signaling is key for CSCs in cell culture and solid tumor models. As 
shown with a dual PI3K/mTOR inhibitor, VS-5584, inhibition of multiple PI3K isoforms 
and mTOR is necessary to achieve preferential targeting of CSCs. Methods: Antitumor 
activity of VS-5584 was assessed by in vitro proliferation assay as well as in multiple 
xenograft models in vivo, including patient-derived xenograft models. Anti-CSC activity 
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samples contained smoking associated G-to-T transversions (see Table). Inactivation 
of RB1 and TP53occurred in 75% and 50% of the samples, respectively. Only patient 4 
had platinum-refractory disease. The median survival of these patients was 20.7 months 
(range, 17 to 25).
Sample Gene altered Alteration Present Protein Alteration Base Pair Alteration
Patient 1 PHOX2B Missense Mutation P82L G-to-A
NOTCH1 Frame-Shift Insertion P2485fs
RB1 Splice Site R500_splice G-to-A
TP53 Frame-Shift Deletion V218fs
TP53 Frame-Shift Deletion V73fs
TERT Amplification
Patient 2 CBL Missense Mutation C401S G-to-C
GNAS Missense Mutation M102V A-to-G
MYCL Amplification
Patient 3 TP53 Nonsense Mutation R342 G-to-A
RB1 Frame-Shift Insertion T197fs
CDKN2C Amplification
MYCL Amplification
Patient 4 RB1 Nonsense Mutation C666
ETV1 Amplification
Conclusion: Using a targeted NGS assay, we have shown that the molecular 
characteristics differ between never-smokers and smokers, while the majority of the 
tumors demonstrate RB loss. Whole exome sequencing of the tumors from these 
never-smokers is underway. Ongoing comprehensive, multiplexed genotyping is 
needed to fully characterize the molecular diversity of SCLC in this unique population. 
Keywords: SCLC, never-smoker, mutations, next generation sequencing
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MINI27.12 Using a Cell Surface Antibody Screen to Identify Biomarkers of 
Drug Resistance in Small Cell Lung Cancer (SCLC) Daniel Meyers1, Armando 
Poeppl2, Vasudeva Bhat3, Cheryl Peltier2, Afshin Raouf3, Shantanu Banerji2 1Queen’s 
University, Kingston/ON/Canada, 2CancerCare Manitoba, Winnipeg/MB/Canada, 3University 
of Manitoba, Winnipeg/MB/Canada
Background: SCLC is an aggressive malignancy that shows dramatic clinical responses 
in 70% of cases to platinum-based chemotherapy in the first line setting, while the 
remainder have de novo treatment resistance. Of initial treatment responders, almost 
all will relapse with drug-resistant disease within months of initial therapy. From a clinical 
perspective, the emergence of drug resistance remains one of the most important 
barriers to improving SCLC patient outcomes. Better models of in vitro and in vivo drug 
resistance are therefore required. Cell surface markers are proteins expressed on the 
outer surface of cells that can identify specific cell types and biologic states. Surface 
markers represent an attractive class of biomarkers in SCLC: 1) they are independent 
of cellular transport mechanisms that are known to play a role in SCLC drug resistance; 
and 2) they can be readily accessed for diagnostic and therapeutic purposes using 
commercial antibodies. Methods: NCI-H69 is a classic SCLC cell line derived from 
a patient prior to systemic treatment, and is chemotherapy sensitive. H69AR is an 
anthracycline-resistant derivative cell line generated through serial culture of NCI-H69 
in increasing concentrations of Adriamycin. H69AR is also cross-resistant to other 
cytotoxic drugs commonly used to treat SCLC. We performed a pilot screen in both 
cell lines in duplicate using a human cell surface marker panel containing Alexa Fluor 
647-conjugated antibodies against 242 unique cell surface proteins. High-throughput
multiplexed flow-cytometry was performed to generate cell surface expression profiles
for each antibody in each cell line. Results: A total of 53 markers were expressed in at
least 20% of cells in either cell line, with 22 positive markers shared by both cell lines
including CD44. NCI-H69 was uniquely positive for 24 markers including CD56, a neural
progenitor marker used commonly to diagnose SCLC. Seven markers were uniquely
positive in H69AR including CD9 and some of its known interactors. The percentage
H69AR cells positive for each of the 7 markers ranged from 25% to 88%. CD9 is a
member of the transmembrane 4 superfamily involved in many cellular processes
including differentiation, adhesion, and signal transduction. Eighty-eight percent
of H69AR cells were positive for CD9 compared to only 5.4% of H69 cells. CD9 has
previously been implicated in a cell adhesion-mediated drug resistance mechanism in
unrelated SCLC chemotherapy-resistant cell lines (S. Kohmo et al. Cancer Research
2010). Conclusion: Our pilot data provides a proof-of-concept for our surface biomarker
screen-based approach to further understand mechanisms of chemotherapy-resistance
in SCLC. We have expanded this screen to additional drug-sensitive and drug-resistant
SCLC cell line pairs. Results of the expanded screen will be presented at the meeting.
Keywords: drug-resistance, biomarker, SCLC
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MINI27.09 A DLL3-Targeted ADC Effectively Targets Pulmonary 
Neuroendocrine Tumor-Initiating Cells to Result in Sustained Tumor 
Regressions Laura R. Saunders1, Alex J. Bankovich1, Wade A. Anderson1, Monette 
Aujay1, Sheila Bheddah1, Kristen A. Black1, Radhika Desai1, Paul Escarpe1, Johannes 
Hampl1, Albert Park1, Amy Laysang1, David Liu1, Javier Lopez-Molina1, Milly Milton1, 
Marybeth Pysz1, Hui Shao1, Michael Torgov1, Samuel Williams1, Orit Foord1, Phil Howard2, 
J T. Poirier3, M Catherine Pietanza3, Pierre P. Massion4, Charles M. Rudin3, Robert A. 
Stull1, Brian S. Slingerland1, Scott J. Dylla1 1Stemcentrx, Inc., South San Francisco/
CA/United States of America, 2Spirogen, A Member of the Astrazeneca Group, London/
United Kingdom, 3Memorial Sloan Kettering Cancer Center, New York/NY/United States 
of America, 4Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram 
Cancer Center, Nashville/TN/United States of America
Background: Pulmonary neuroendocrine tumors such as small cell lung cancer 
(SCLC) and large cell neuroendocrine cancer (LCNEC) remain among the most deadly 
malignancies and are increasing in incidence. Patient-derived xenograft (PDX) tumors 
provide excellent models to study tumor biology and discover tumor-initiating cell (TIC) 
populations. Novel therapies that target and eradicate TIC represent a promising strategy 
to improve survival. An effectively targeted antibody-drug conjugate (ADC) carrying a 
cell-cycle independent toxin should result in significant anti-tumor activity and eliminate 
TIC. Methods: Whole transcriptome sequencing was performed using TIC isolated by 
fluorescence-activated cell sorting from SCLC and LCNEC PDX tumors. Quantitative RT-
PCR, microarray analysis of PDX tumors and cell lines, and mining of publically available 
transcriptome and proteome datasets were executed to validate that prospective targets, 
such as Delta-like protein 3 (DLL3), were highly expressed in neuroendocrine tumors, but 
limited in their expression in normal tissues. DLL3-specific monoclonal antibodies were 
generated and used to determine protein expression by immunohistochemistry, flow 
cytometry and ELISA. Select DLL3-specific antibodies were conjugated to a cell-cycle 
independent pyrrolobenzodiazepine (PBD) dimer toxin and evaluated for their ability to 
internalize and mediate cell killing. Finally, established SCLC and LCNEC PDX tumors were 
treated in vivo with a lead anti-DLL3 ADC (i.e. SC16LD6.5). Limiting dilution assay (LDA) 
serial transplantation experiments were executed to assess the impact of SC16LD6.5 
on TIC. Results: Elevated expression of DLL3 mRNA was discovered in TIC of SCLC and 
LCNEC PDX tumors and confirmed in additional distinct primary SCLC and LCNEC tumor 
samples and PDX tumors. In contrast, little to no mRNA expression was detected in vital 
organs and other normal tissues outside of the brain. DLL3-specific antibodies confirmed 
protein expression on the cell surface in both primary SCLC and LCNEC tumors and in PDX 
tumors initiated from patients with these diseases, whereas protein was scarce in normal 
tissues. SC16LD6.5 rapidly internalizes and localizes to late endosomes, and treatment 
of 10 SCLC and 2 LCNEC PDX tumor models resulted in significant and durable tumor 
regression with a median time to progression benefit of 75 days versus 16 days with 
standard-of-care (SOC: SCLC, cisplatin/etoposide; LCNEC, cisplatin). During the course 
of these in vivo studies, many mice were cured as tumors often did not recur despite 
being followed for 120+ days post-randomization and treatment. LDA experiments 
executed using tumors actively responding to SC16LD6.5 provided further functional 
evidence that the common lack of tumor recurrence following treatment resulted from 
effective targeting of DLL3-expressing TIC. In vivo efficacy strongly correlated with 
DLL3 protein expression, and responses were observed in PDX tumor models initiated 
from patients with both limited and extensive stage disease and independent of their 
sensitivity to SOC. Conclusion: The DLL3-targeted ADC, SC16LD6.5, effectively targets 
and eradicates TIC in SCLC and LCNEC PDX tumors. SC16LD6.5 (i.e. rovalpituzumab 
teserine) is currently concluding Phase 1b trials and is a promising first-in-class 
therapeutic for the treatment of high grade pulmonary neuroendocrine tumors. 
Keywords: SCLC, tumor-initiating cell, Patient-derived xenograft, Antibody-drug 
conjugate
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MINI27.11 Comprehensive Mutation Analysis of Never-Smokers with Small 
Cell Lung Cancer (SCLC) M. Catherine Pietanza, Helen Won, LeeM. Krug, Anna M. 
Varghese, Gregory J. Riely, Natasha Rekhtman, Lu Wang, William D. Travis, Maureen 
Zakowski, Marc Ladanyi, Michael Berger, Mark G. Kris, Charles M. Rudin Memorial Sloan 
Kettering Cancer Center, New York/NY/United States of America
Background: Although most patients with SCLC are current or former smokers, this 
disease has been reported in never-smokers. In our prospective genomic profiling of 
SCLC patients, we have identified four never-smokers. Here, we report next generation 
sequencing (NGS) results for these four SCLC patients and describe how they differ 
from those of smokers. Methods: We are evaluating pathologically confirmed SCLC 
tumors in patients undergoing treatment. Formalin-fixed, paraffin-embedded surgical 
resections, core biopsies, and fine needle aspirates are being evaluated using a targeted, 
hybrid capture-based, NGS assay, MSK-IMPACT, which identifies single nucleotide 
variants, indels, and copy number alterations in 341 cancer-associated genes. We 
determined never-smoking status prospectively: all smoked <100 cigarettes in their 
lifetime. Clinical data on stage [extensive (ES), limited (LS)], treatment, and response 
were collected. Results: Four never-smokers have been identified within the 50 patient 
samples that have undergone NGS evaluation thus far. The median age at diagnosis 
of the four never-smokers is 58 (range, 47-75); 50% are male; and one presented with 
LS-SCLC. None of these four patients developed SCLC as acquired resistance to EGFR 
tyrosine kinase inhibitors after treatment for EGFR-mutant lung cancers. The tumors from 
the four never-smokers displayed a median of 3 non-synonymous somatic mutations, 
while those from moderate (<20 pack years) and heavy (20+ pack years) smokers 
contained 4.5 and 8 mutations, respectively (P<0.05). None of the four never-smoker 
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> 12.9 vs < 12.9. The odds of being sensitive is 11 (95% CI, 1.2, 103) time higher
for cell lines with cMYC gene expression > 12.9 compared to cell lines with cMYC gene
expression < 12.9. Sensitive cell lines were enriched in a published MYC-signature of
gene expression (p = 0.042). AZD1152 (prodrug) caused significant growth delay in
vivo in two of these lines. The doses of AZD1152-HQPA used in this study are within
the range reported to be clinically achievable. Conclusion: Aurora kinase inhibitors
have promise in SCLC therapy. Questions that currently need answering in translating
aurora kinase inhibitors in the clinical setting are: (1) the dosing schedule to avoid
myelosupression, (2) should aurora kinase inhibitors be used in maintenance therapy and
(3) should the aurora kinase inhibitors be evaluating in combination with chemotherapy.
Keywords: SCLC AURKB myc amplification
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MINI28.01 The Impact of Physical Activity on Fatigue and Quality of Life in 
Lung Cancer Patients: A Randomized Controlled Trial (RCT) Janette Vardy1, 
MelanieL. Bell2, Hidde P. Van Der Ploeg3, Jane Turner4, Michael Kabourakis4, Lissa 
Spencer5, Craig Lewis6, Rina Hui7, Prunella Blinman8, Stephen Clarke9, Michael 
Boyer10, Haryana Dhillon11 1Concord Cancer Centre, University of Sydney, Sydney/NSW/
Australia, 2University of Arizona, Tuscon/AL/United States of America, 3VU University Medical 
Center, Amsterdam/Netherlands, 4University of Sydney, Sydney/NSW/Australia, 5Royal 
Prince Alfred Hospital, Camperdown/NSW/Australia, 6University of New South Wales, Prince 
of Wales Hospital, Randwick/NSW/Australia, 7Department of Medical Oncology, Westmead 
Hospital, Sydney/Australia, 8Concord Cancer Centre, Concord/NSW/Australia, 9Medical 
Oncology, Northern Cancer Institute, St Leonards/NSW/Australia, 10Medical Oncology, Chris 
O’Brien Lifehouse, Camperdown/NSW/Australia, 11University of Sydney, Sydney/Australia
Background: Physical activity (PA) has been shown to improve fatigue and quality 
of life (QOL) in a range of cancer populations. Little research has been done in the 
advanced lung cancer setting. This RCT evaluated a 2-month PA intervention in patients 
with unresectable lung cancer. Methods: Participants were stratified (disease stage, 
performance status [PS] 0-1 vs 2, centre) and randomized (1:1) to usual care (UC) (general 
nutrition and PA education materials) or UC plus 2-month program of supervised weekly 
PA and behaviour change sessions and home-based PA. Assessments were completed 
at baseline, 2, 4 and 6 months. The primary endpoint was fatigue (FACT-F subscale) 
at 2-months. Secondary endpoints included: QOL, functional abilities, physical fitness, 
activity (accelerometers), mood, dyspnea, survival and blood results. Intention-to-treat 
analysis using linear mixed models was done. Results: 111 patients were randomized: 
male 55%, median age 62 (35-80); 95% NSCLC, 5% SCLC; 95% Stage IV. At baseline 77% 
were on active treatment. Baseline characteristics, including PA levels, comorbidities 
and Glasgow Prognostic Score (GPS) were well balanced between groups. Attrition 
was 22, 36 and 50% at 2, 4 and 6 months respectively; no difference between groups. 
Adherence to intervention sessions: behavioral 77%, PA 69%. There were no significant 
differences in fatigue, QOL, symptoms, mood, distress, sleep, dyspnea, activities of 
daily living, GPS between the groups at 2, 4 or 6 months. Patients over report PA levels 
compared to accelerometer data. Using accelerometer data, PA only increased in the PA 
group from 0 – 2 months, but the difference in PA between groups was not significant. 
Median survival (months): PA 13.7 vs UC 12.6 (p= 0.76): 38 participants remain alive.
PA n=55 UC n=56 p-value
FACT-F Fatigue: 0 2 4 6 38.4 37.5 39.6 36.6 36.3 36.3 35.4 34.5 0.61 0.10 0.44
EORTC Global QOL 0 2 4 6 63.8 63.2 64.2 60.8
58.9 64.3 60.2 
54.2 0.81 0.45 0.26
Performance Status 0 2 4 6 0.8 0.8 0.8 0.7 0.9 1.0 1.0 1.2 0.30 0.16 0.01
Conclusion: Adherence to the 8-week intervention was good but did 
not increase PA levels compared to education materials alone. No 
difference was seen in fatigue, QOL, symptom control or functional status. 
Keywords: advanced lung cancer, fatigue, quality of life, physical activity
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MINI28.02 Utilization of Survivorship Care Plans and Analysis of Patient 
Reported Outcomes in Multinational Lung Cancer Patients Abigail T. Berman1, 
Christina Decesaris2, Charles B. Simone2, Carolyn Vachani2, Margaret Hampsire1, 
James M. Metz1, Christine Hill-Kayser2 1Radiation Oncology, University of Pennsylvania, 
Philadelphia/PA/United States of America, 2Radiation Oncology, University of Pennsylvania, 
Philadelphia/United States of America
Background: Lung cancer is the leading cause of cancer death in the United States 
and is also a significant source of morbidity. Patient-reported outcomes (PROs) are 
prognostic for survival. Herein we report our analysis of emerging patterns of longitudinal 
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MINI27.13 Progastrin-Releasing Peptide (ProGRP) as a Biomarker for Clinical 
Response in Small-Cell Lung Carcinoma (SCLC) Thomas Muley1, Xiaotong 
Zhang2, Stefan Holdenrieder3, Catharina M. Korse4, Xiu-Yi Zhi5, Rafael Molina6, 
Zhongjuan Liu2, Gunther Hartmann3, Michel Van Den Heuvel4, Kun Qian5, Ramon 
Marrades6, Christine Engel7, Birgit Wehnl7, Farshid Dayyani8, Felix Herth1 1Translational 
Research Unit, Thoraxklinik at University of Heidelberg and Translational Lung Research 
Center (TLRC), Heidelberg/Germany, 2Peking Union Medical College Hospital (PUMCH), 
Beijing/China, 3University Hospital Bonn, Bonn/Germany, 4The Netherlands Cancer 
Institute, Amsterdam/Netherlands, 5Capital Medical University, Xuanwu Hospital, Beijing/
China, 6Hospital Clinic, University of Barcelona, Barcelona/Spain, 7Roche Diagnostics GmbH, 
Penzberg/Germany, 8Roche Diagnostics International Ltd, Rotkreuz/Switzerland
Background: Most cases of small-cell lung cancer (SCLC) are detected at extensive 
stage, where current guidelines recommend 4-6 cycles of chemotherapy. Although 
upfront progression to doublet platinum based chemotherapy in SCLC is <20%, current 
clinical practice often includes treatment monitoring with imaging, mainly with computed 
tomography, every two cycles. Since the purpose of imaging during treatment is 
identification of progression (to avoid further exposure to an ineffective but still potentially 
toxic regimen), we sought to evaluate whether monitoring SCLC patients during treatment 
with a blood-based biomarker (ProGRP) would correlate with response. Methods:Patients 
with SCLC treated with mainly standard chemotherapy at six centers worldwide (Europe 
and China) were included. ProGRP levels from serum or plasma were measured with a fully 
automated ProGRP assay in a prospective fashion prior to treatment start and repeatedly 
during treatment. Imaging was done and interpreted according to local guidelines at each 
institution. Percent change of ProGRP from baseline to the time of maximum response 
(‘best response’) was correlated with imaging findings, and patients were divided into 
two groups: Responders (= stable disease [SD] or better) vs. Non-Responders (= 
progression on scan). The ability of ProGRP to discriminate between Responders and 
Non-Responders was assessed by sensitivity and specificity. Results: 215 patients 
with available CT result were included, of whom 145 had received first-line treatment 
(131 received platinum+VP-16 doublet). Clinical characteristics were as follows: 60.5% 
male, median age was 62 years, 72.1% were (ex)smokers, 93.5% with Stage IIIB or IV 
SCLC, and the majority of patients were either Caucasian (59.6%) or Asian (32.6%). 
Across all lines of treatment, 186/215 (86.5%) had SD or better as best response to 
treatment. There was a positive trend for higher ProGRP levels with clinical stage at 
presentation, and in general higher pre-treatment levels in 1st line compared to later 
lines of treatment. A decline in ProGRP levels was strongly correlated with response, 
whereby higher baseline levels were associated with subsequent higher relative declines 
of ProGRP during treatment. Using different cut-off levels for ProGRP decline during 
treatment (-50%, -70%, or -90%), we detected patients with no response to treatment 
based on ProGRP levels alone, with a sensitivity of 82.8%, 89.7% and 96.6%, and a 
specificity of 65.6%, 55.4%, and 39.8%, respectively. Specificity was increased by 
approximately 10% when only patients with baseline ProGRP levels exceeding 100 pg/
ml were included. Conclusion: To our knowledge, this is the largest SCLC cohort to 
date with available ProGRP data for therapy monitoring. The data showed that ProGRP 
levels at baseline were positively correlated with advanced disease stage, and decline 
in ProGRP levels during treatment was associated with tumor control in SCLC. The 
ProGRP assay used in this study is currently not cleared or approved for use in the USA. 
Keywords: treatment monitoring, SCLC, ProGRP, assay
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MINI27.14 The Aurora Kinase B Inhibitor AZD1152-HQPA Inhibitor in Small Cell 
Lung Cancer (SCLC) Barbara Helfrich1, Jihye Kim2, Dexiang Gao3, Dan Chan2, Aik-
Choon Tan2, Paul A. Bunn, Jr2 1Medicine, University of Colorado Denver-AMC, Auorora/CO/
United States of America, 2Medicine, University of Colorado Denver-AMC, Aurora/CO/United 
States of America, 3Biostatistics & Informatics, University of Colorado Denver-AMC, Aurora/
CO/United States of America
Background: Aurora kinase expression has been associated with a poor prognosis in 
non-small cell lung cancer (NSCLC) and aurora kinase inhibitors have activity in preclinical 
lung models. Aurora kinases are required for mitosis and cell division. Small cell lung 
cancer cells have rapid proliferation and higher rates of MYC family amplification, 
which makes aurora kinase inhibition a natural target. Methods: 23-SCLC lines with 
known MYC family amplification and MYC family gene expression were exposed to 
varying concentrations of the specific aurora kinase B inhibitor AZD1152-HQPA. The 
percentage growth inhibition compared to control was determined in MTS assays at 120 
hours. Cell lines were classified as “sensitive” if the GI50 concentration was < 50 nM 
and with ≥ 80% growth inhibition at 100 nM. Fisher’s exact test was used to determine 
the correlation between amplification of MYC family members and sensitivity of the 
cell lines to growth inhibition by AZD1152-HQPA. A two-group t-test (gene expression 
as a continuous variable) and an odds ratio estimate (dichotomized gene expression 
level) were used to determine a correlation between MYC family gene expression and 
growth inhibition by AZD1152-HQPA. To determine whether growth inhibition correlated 
with the published MYC-signature gene expression, we used Fisher’s exact test. In vivo 
growth inhibition by AZD1152 (prodrug) was evaluated on SCLC xenografts in nude 
mice. Results: Nine (39%) of the 23 cell lines were sensitive to AZD1152-HQPA with 
IC50 values < 50 nM. There was a significant association between sensitivity to growth 
inhibition by AZD1152-HQPA and cMYC amplification (p = 0.018). The odds of being 
sensitive is 16 (95% CI, 1.4, 183) times higher for cMYC amplified compared to non -
cMYC amplified cell lines. By a two-group t-test, the mean cMYC gene expression of 10.9 
(std 4) in sensitive lines compared to 7.2 (std 3.3) in resistant lines was also significant 
(p = 0.026). Cell lines were separated into two groups based on cMYC gene expression 
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of Hope National Medical Center, Duarte/CA/United States of America, 3Division of Nursing 
Research & Education, Department of Population Sciences, City of Hope, Duarte/CA/United 
States of America
Background: Survivorship care has emerged as an important topic in lung cancer 
due to advances in screening and treatment that have led to prolonged survival. 
These survivors may have pre-existing comorbidities or health impairments from their 
treatments that impact quality of life. A better understanding of the healthcare needs of 
lung cancer survivors will assist in the development of patient-centered, comprehensive 
survivorship care. We used a population dataset to assess the most common reasons 
for hospital admission and causes of death among long term (5-year) survivors of lung 
cancer. Methods: Using linked data from the California Cancer Registry and Office of 
Statewide Health Planning and Development database, we identified all in-state lung 
cancer patients diagnosed from 2000-2009. Patients of all stages were included. 
We used ICD-9 codes to identify causes of death and primary admission diagnoses in 
survivors after 5 years of lung cancer diagnosis. Annual proportional distribution of 
reasons for admission and causes of death for survivors were calculated over time. 
Results: Among 157,236 lung cancer patients, 80.6% (n=126,775) died within 5 years of 
diagnosis. Although lung cancer accounted for the majority of hospital admissions in the 
initial years post-diagnosis, nonmalignant pulmonary disease, (n=7,102, 23.3%) replaced 
lung cancer progression (n=2,047, 6.7%) as the most common principal diagnosis in 
30,461 admissions among 9,166 survivors who were admitted after 5 years from initial 
lung cancer diagnosis (Figure 1A). Cardiovascular (n=5,712, 18.8%), gastrointestinal 
(n=2,901, 9.5%), and infectious diseases (n=2,819, 9.3%) also surpassed lung cancer 
progression as reasons for admission after 5 years of survival. However, lung cancer 
progression remained the leading cause of death in long-term lung cancer survivors 
(Figure 1B). Among 5-year survivors, 46.2% (n= 2,855) eventually died from lung cancer 
progression. The next most common causes of death were cardiovascular disease 
(n=947, 15.3%), nonmalignant pulmonary disease (n=776, 12.6%), and secondary 
malignancy (n=605, 9.8%).
Conclusion: Most lung cancer patients died within 5 years of diagnosis. Among remaining 
survivors, cardiovascular, pulmonary, and gastrointestinal diseases rather than lung 
cancer were the primary reasons for hospital admission 5 years after diagnosis. However, 
lung cancer progression remained the dominant cause of patient death even beyond 
5 years of survival. Cardiopulmonary disease and other malignancies were secondary 
competitors for mortality. Active control of chronic cardiopulmonary disease in addition 
to lung cancer surveillance should be priorities in long-term lung cancer survivors. 
Keywords: lung cancer, survivorship, cause of death, reasons for admission
PROs collected in the development of survivorship care plans (SCPs) using an anonymous 
web-based program. Methods: OncoLife and the LIVESTRONG Care Plan are web-based 
programs that generate unique SCPs and are accessed via OncoLink (www.oncolink.
org), the world’s first cancer website. We selected all consecutive patients identifying as 
primary lung cancer survivors creating SCPs. Patient-reported demographics, treatment 
and toxicity were examined. For toxicity data, questions with > 10 “yes” responses were 
included, and were categorized into: cardiovascular; genitourinary; neurocognitive; 
endocrine; speaking, breathing, swallowing (SBS); thoracic; and musculoskeletal/
dermatologic symptoms. Research was conducted under an IRB-approved protocol. 
Results: Overall, 689 plans were created for users self-identifying as primary lung 
cancer survivors. Average time from diagnosis to reporting was 1.68 years (0-24). 
Most were Caucasian (85.9%), well-educated (67.3% > “some college”), and lived in a 
suburban area (45.6%) and the United States (91%). Table 1 shows treatment modalities 
. Neurocognitive symptoms (e.g. fatigue and cognitive changes) were most common 
(48.8%), followed by musculoskeletal/dermatologic (14.1%), and thoracic (13.5%). Figure 
1 shows symptoms analyzed by treatment. Only 11.2% were initially offered a SCP, and 
of those, 54.5% were offered by their healthcare provider, most often at a non-university-
based cancer center (66.2%).
TREATMENT N (689 total) %
Any Surgery 375 54.4
Any Chemotherapy 522 75.8
Any Radiation 377 54.7
Surgery Alone 98 14.2
Surgery + Chemotherapy 119 17.3
Surgery + Radiation 15 2.2
Surgery + Chemotherapy + Radiation 143 20.8
Chemotherapy Alone 70 10.2
Chemotherapy + Radiation 190 27.9
Radiation Alone 29 4.2
Not Specified 25 3.6
Conclusion: For lung cancer patients worldwide, it is feasible to obtain PROs and create 
SCPs through a web-based program. As lung cancer survivors live longer, further attention 
should be paid to PROs, and our data indicates that, surprisingly, the most common symptoms 
to address are neurocognitive. As very few patients were offered SCPs, increased effort 
should be made to provide SCPs, particularly in urban and university cancer center settings. 
This study was funded in part by the LIVESTRONG Foundation.
Keywords: survivorship care plan, lung cancer treatment, toxicity, patient reported 
outcomes
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MINI28.03 Causes of Death and Hospitalization in Long-Term Lung Cancer 
Survivors: A Population-Based Appraisal Geena X. Wu1, Philip H. G. Ituarte2, Betty 
Ferrell3, Virginia Sun3, Dan J. Raz1, Jae Y. Kim1 1Division of Thoracic Surgery, Department 
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MINI28.06 Patterns of Palliative and Psychosocial Care in Stage IV NSCLC 
in South Western Sydney Kirsten J. Duggan1, Jennifer Wiltshire2, Rebecca Strutt2, 
Miriam Boxer3, Angela Berthelsen1, Joseph Descallar4, Shalini K. Vinod3 1SWS & SLHD 
Clinical Cancer Registry, Liverpool Hospital, Liverpool/NSW/Australia, 2Dept. of Palliative 
Care, Liverpool Hospital, Liverpool/NSW/Australia, 3Cancer Therapy Centre, Liverpool 
Hospital, Liverpool/NSW/Australia, 4Ingham Institute for Applied Medical Research, 
Liverpool/NSW/Australia
Background: South West Sydney (SWS) is a region of greater ethnic diversity and 
poorer socioeconomic status than the Australian average. Over half of all patients 
with Non-Small Cell Lung Cancer (NSCLC) in SWS present with metastatic disease. 
The primary goals of management are palliation of symptoms and maintenance of 
quality of life. Patients need adequate access to specialist palliative care (PC) and 
psychosocial care (PSC) in order to achieve these goals. The aims of this study were 
to evaluate referrals to PC and PSC services in SWS residents with Stage IV NSCLC 
and identify factors associated with utilisation of these services. Methods: SWS 
residents diagnosed with Stage IV NSCLC between January 2006 and December 
2012 were identified from the SWS Local Health District Clinical Cancer Registry. 
Supplementary information was sourced from oncology and hospital electronic medical 
records and palliative care databases. Modified Poisson regression was used to analyse 
significant factors associated with referrals to PC and PSC. Cox regression was used 
for multivariate survival analysis. Results: A total of 923 patients were identified. 
The median age was 69 years, 63% were male and 54% were born overseas. Active 
treatment was received by 65% of patients with 34% receiving chemotherapy and 65% 
receiving radiotherapy. Eighty-three percent of patients were referred to PC, with 67% 
occurring within 8 weeks of diagnosis. Eighty-two percent of patients were referred to 
PSC, with referrals to social workers being most frequent (76%) followed by specialist 
nursing (26%) and psychology/psychiatry (16%). On multivariate analysis, radiotherapy 
treatment, M1b disease and residential location were associated with PC referrals, 
and radiotherapy treatment, PC referral and residential location were associated with 
PSC referrals. Age, language spoken, country of birth, socioeconomic status, year of 
diagnosis and multidisciplinary team discussion were not significant factors in referral 
to either service. The median overall survival was 4.3 months and one year survival was 
19%. On multivariate analysis, factors associated with improved survival were active 
treatment, chemotherapy and multidisciplinary team discussion. Conclusion: Rates 
of referral to PC and PSC services were high in this cohort suggesting good access 
to care. Greater referrals were particularly associated with patients undergoing 
radiotherapy. There were no sociodemographic barriers to referral. Some geographic 
differences were noted in referrals to both services. Further investigation into referral 
gaps will guide service delivery to improve quality of life and care for future patients. 
Keywords: non-small cell lung cancer, patterns of care, palliative care, psychosocial 
care
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Background: Palliative care is focused on supporting the best possible quality of life 
(QOL) for patients and family caregivers (FCGs) coping with serious and complex illnesses 
such as lung cancer. Although the accepted definition of palliative care encompasses the 
entire trajectory of the cancer continuum from diagnosis to the end of life, the majority of 
published palliative care trials focused primarily on patients with metastatic disease. The 
purpose of this National Cancer Institute-supported Program Project (P01) was to test 
the effect of a concurrent, interdisciplinary palliative care intervention in patients with 
Stage I-IV non-small cell lung cancer (NSCLC) and FCGs in an ambulatory care setting, 
comparing the usual care and intervention groups. Methods: Patients undergoing 
treatments for NSCLC and their FCGs were enrolled in a prospective, sequential 
design whereby the usual care group was accrued first followed by the intervention 
group. Patients and FCGs in the intervention group completed a comprehensive QOL 
assessment at baseline, and were presented by nurses at weekly interdisciplinary 
care meetings. They also received four educational sessions that addressed physical, 
psychological, social, and spiritual well-being needs. Patients and FCGs in the usual care 
group received disease-focused therapies and procedures and were referred by their 
treating oncologist to palliative care services as needed per standard of care. Patients’ 
QOL, symptoms, and psychological distress were assessed at baseline and 12 weeks 
using validated measures which included the FACT-L, FACIT-Sp-12, LCS, and the Distress 
Thermometer. FCG outcomes included QOL, psychological distress, perceived burden, 
and caregiving preparedness, with validated measures that included the COH-QOL-FCG, 
Distress Thermometer, Caregiver Burden Scale, and Caregiver Skills Preparedness 
Tool. Outcomes were tested using factorial ANOVAs controlling for baseline scores, 
with disease stage as a blocking variable and group (usual care versus intervention) as 
the factor. Results: A total of 491 patients (219 = usual care; 272 = intervention) and 
354 FCGs (157 = usual care; 197 = intervention) who completed baseline assessments 
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MINI28.05 Depression and Anxiety in Lung Cancer Patients: The Unmet Need 
for Recognition and Early Detection Tomi Kovacevic, Bojan Zaric, Jelena Stanic, 
Branislav Perin, Darijo Bokan Clinic for Thoracic Oncology, Institute for Pulmonary Diseases 
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Background: Anxiety and depression are present in significant number of patients with 
lung cancer. Aims of this trial were to examine the frequency of depression and anxiety 
in lung cancer (LC) patients and to investigate relations between clinico-pathological 
characteristics (CPC) and depression and anxiety disorders. Methods: This prospective 
observational trial was conducted at Institute for Pulmonary Diseases of Vojvodina, 
Serbia. Two hundred and eight LC patients at various stages of disease and treatment 
rated themselves on the Hospital Anxiety and Depression Scale (HADS). Investigated 
CPC among other were Eastern Cooperative Oncology Group Performance Status 
(ECOG PS), tumor type and tobacco abuse. In order to correlate the data univariate 
and multivariate analysis was performed. Results: Of total 208 enrolled patients 76% 
(158) were males and 24% (50) females. Majority of patients were with ECOG PS 1 75%
(156), smokers (58.7%), in stage III and IV (42.3% each) LC. Most frequent LC type was
adenocarcinoma 46.6% (97) while squamous, small-cell and other types were confirmed 
in 38% (79), 13.5% (28) and 1.9% (4) respectively. Patients with brain metastasis and
known depression and/or anxiety disorder before LC diagnosis were excluded from the
trial. HADS-defined depression and/or anxiety were identified in 39.5% (82) patients.
Frequency of anxiety was 22.6% (47) and of depression 36.1% (75). Both depression and 
anxiety severity were ranged from mild to severe. Combined depression with anxiety was 
identified in 19.2% (40) patients. We identified significant relation (p=0.003) between
ECOG PS and anxiety. There is positive correlation between depression and ECOG PS
(p=0.007). When depression and anxiety are present as combined disorders severity of
each anxiety and depression are significantly higher (p<0.0001).
MALE FEMALE
N (%) 158(76%) 50(24%)




SMOKING Never 16(10.1%) 11(22%)
Ex smoker 46(29.1%) 13(26%)
Smoker 96(60.8%) 26(52%)
PCKY Ex smoker 50,7 37,7
(mean) Smoker 40,9 37,2
TUMOR TYPE Adenocarcinoma 68(43%) 29(58%)
Squamouse carcinoma 65(41.1%) 14(28%)
Small-cell carcinoma 22(13.9%) 6(12%)
Other 3(1.9%) 1(2%)






SEVERITY OF DEPRESSION Mild 34(21.5%) 8(16%)
Moderate 20(12.7%) 8(16%)
Severe 5(3.2%) -
SEVERITY OF ANXIETY Mild 22(13.9%) 5(10%)
Moderate 10(6.3%) 3(6%)
Severe 5(3.2%) 2(4%)
Conclusion: Anxiety and depression are diagnosed in significant number of lung cancer 
patients. Presence of these disorders can significantly influence quality of life of lung cancer 
patients. The results of this trial suggest that screening on depression and anxiety should 
be performed at any stage of disease course. Early recognition, detection and therapy can 
help in better control of depression and anxiety with aim to increase patients quality of life. 
Keywords: depression, lung cancer, Anxiety
S366 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Conclusion: This is the only large randomised trial evaluating the utility of WBRT 
in this disease. Although the results include the pre-specified non-inferiority 
margin, the estimate of the difference in QALYs suggests WBRT provides no 
additional clinically significant benefit for this group of patients. Additionally 
there were no significant differences in overall survival or quality of life. . 
Keywords: supportive care, brain metastases, Whole Brain Radiotherapy, quality of life
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MINI28.10 C-Type Natriuretic Peptide Attenuates Bleomycin-Induced Fibrosis 
and Inflammation in Murine Lung Toru Kimura1, Takashi Nojiri1, Hiroshi Hosoda2, 
Yasushi Shintani1, Masayoshi Inoue1, Mikiya Miyazato2, Meinoshin Okumura1, Kenji 
Kangawa2 1Department of General Thoracic Surgery, Osaka University Graduate School of 
Medicine, Suita/Japan, 2Department of Biochemistry, National Cerebral and Cardiovascular 
Center Research Institute, Suita/Japan
Background: Interstitial lung diseases (ILDs) are sometimes seen in patients with 
primary lung cancer. Therapeutic interventions for lung cancer patients with ILDs 
occasionally induce acute exacerbation (AE), which is a potentially fatal complication. 
However, no prophylactic treatments have been established. Although the etiology of 
ILD-related AE is unknown, management of the ILD disease process, including fibrotic 
changes and inflammatory reactions, is thought to lead to the prophylaxis of AE. C-type 
natriuretic peptide (CNP) is a member of the natriuretic peptide family, which includes 
atrial and brain natriuretic peptides. CNP has cardioprotective effects, such as anti-
fibrotic and anti-inflammatory effects, in animal models of myocarditis and myocardial 
infarction. The objective of the present study was to investigate the anti-fibrotic and anti-
inflammatory effects of CNP on bleomycin (BLM)-induced lung injury. Methods: C57BL/6 
mice were divided into two groups, vehicle- and CNP-treated groups, for evaluation of 
pulmonary fibrosis and inflammation induced by BLM. CNP (2.5 µg/kg/min) or vehicle 
were subcutaneously infused using an osmotic mini-pump from 24 h before BLM 
administration until the mice were euthanized. On 14 days after intratracheal 
administration of BLM (1 mg/kg), histological changes, collagen content, and mRNA 
expression of inflammatory cytokines in lungs and bronchoalveolar lavage fluid (BALF) 
were assessed. Results: Continuous infusion of CNP attenuated BLM-induced fibrotic 
changes. Quantitative histological analysis showed that BLM-induced fibrotic lesions 
were significantly smaller in CNP treated mice compared to vehicle mice. The collagen 
content, determined with the hydroxyproline assay, increased in BLM-administered lung 
and CNP treatment reduced BLM-induced collagen production. CNP treatment tended to 
improve body weight loss after BLM administration. In BALF, BLM administration 
augmented the number of inflammatory cells in the vehicle group, which was significantly 
lower in CNP treated mice. The expression of IL-1β, IL-6, and bFGF mRNA were significantly 
elevated by BLM administration, and CNP treatment significantly attenuated these 
increases.
Conclusion: These results indicate that CNP attenuates fibrotic changes, namely the 
accumulation of inflammatory cells, and the increased expression of inflammatory 
cytokines in BLM-induced pulmonary fibrosis. CNP may have therapeutic potential in 
patients with ILD and lead to prophylaxis for AE. 
Keywords: C-type natriuretic peptide, pulmonary fibrosis, bleomycin, inflammation
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MINI28.11 Randomised Study of Acupuncture, Morphine and Combination in 
NSCLC/Mesothelioma Mary E.R. O’Brien1, Anna R. Minchom1, Ravi Punwani1, Jaishree 
Bhosle1, Kofi Nimako1, Ranga Gunapala1, Sanjay Popat2, Jacqueline Filshie3 1Lung Unit, 
Royal Marsden Hospital NHS Foundation Trust, Sutton/United Kingdom, 2Royal Marsden 
Hospital, London/United Kingdom, 3Royal Marsden Hospital NHS Foundation Trust, Sutton/
United Kingdom
were included in the primary analysis. Patients who received the intervention had 
significantly better scores for QOL (109.1 vs. 101.4; p<.001), symptoms (25.8 vs. 
23.9; p<.001) spiritual well-being (38.1 vs. 36.2; p=.001), lower psychological distress 
(2.2 vs. 3.3; p<.001), and more advance care planning (44% versus 9%; p<.001) at 12 
weeks compared to patients in the usual care group. FCGs in the intervention group 
had significantly better scores for social well-being (5.84 vs. 6.86; p<.001) and lower 
psychological distress (4.61 vs. 4.20; p=.010) at 12 weeks compared to FCGs in the 
usual care group. Survival analysis for stage IV patients using the Kaplan-Meier approach 
did not achieve statistical significance but showed a 6 month difference in favor of the 
intervention group. t included the COH-QOL-FCG, Distress Thermometer, Caregiver 
Burden Scale, and Caregiver Skills Preparedness Tool. Outcomes were tested using 
factorial ANOVAs controlling for baseline scores, with disease stage as a blocking variable 
and group (usual care versus intervention) as the factor. Conclusion: Interdisciplinary 
palliative care in the ambulatory care setting resulted in significant improvements 
in QOL, symptoms, and psychological distress for NSCLC patients and FCGs. 
Keywords: symptoms, family caregivers, palliative care, quality of life
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MINI28.09 Can WBRT Be Omitted in NSCLC Patients with Inoperable Brain 
Metastases? Results from the UK MRC QUARTZ Randomised Clinical Trial 
Paula Mulvenna1, Matthew Nankivell2, Corinne Faivre-Finn3, Rachael Barton4, Paula 
Wilson5, David Ardron2, Elaine Mccoll6, Barbara Moore7, Iona Brisbane8, Ben Sydes2, 
Richard Stephens2, Mahesh Parmar2, Ruth Langley2 1Freeman Hospital, Newcastle/United 
Kingdom, 2MRC Clinical Trials Unit at UCL, London/United Kingdom, 3Univ. of Manchester, 
Manchester/United Kingdom, 4Castle Hill Hospital, Hull/United Kingdom, 5University 
Hospitals Bristol, Bristol/United Kingdom, 6Newcastle Clinical Trials Unit, Newcastle/United 
Kingdom, 7NISCHR, Cardiff/United Kingdom, 8Beatson West of Scotland Cancer Centre, 
Glasgow/United Kingdom
Background: Brain metastases affect up to 40% of patients with non-small cell lung 
cancer (NSCLC), and for patients not suitable for surgical resection or stereotactic 
radiosurgery, whole brain radiotherapy (WBRT) and dexamethasone is standard treatment. 
However there are no randomised clinical trials showing whether WBRT improves either 
quality of life (QoL) or survival. Methods: A phase III randomised non-inferiority trial 
with a primary outcome measure of quality adjusted life years (QALYs). Patients with 
brain metastases from NSCLC who were not suitable for resection or stereotactic 
radiotherapy, irrespective of any other clinical characteristics, were randomly allocated 
to either optimal supportive care, including dexamethasone, plus WBRT 20 Gy/5f 
(OSC+WBRT) or OSC alone. QALYs were generated from overall survival and patients’ 
weekly completion of the EQ-5D questionnaire. OSC alone was considered non-inferior 
if not greater than 7 QALY days worse than OSC+WBRT (80% power and a one sided 
significance level of 5% requiring 534 patients). Secondary outcome measures include 
sub-group analyses to identify/validate predictive classifications. Results: From 2007-
2014 538 patients were recruited from 69 UK and 3 Australian centres. Summary trial 
information is presented in table 1, with baseline characteristics well balanced between 
trial arms. Median survival was 65 days (OSC+WBRT) vs 57 days (OSC), hazard ratio 
1.05 (95% CI 0.89 – 1.26). The mean QALY was 43.3 days (OSC+WBRT) vs 41.4 days 
(OSC), difference -1.9 days (90% CI -9.1 – +6.6). More OSC patients received additional 
anti-cancer treatment (39% vs 25%, p-value=0.0004), particularly radiotherapy (22% 
vs 13%, p-value=0.0067), with palliative thoracic irradiation in the two weeks following 
randomisation accounting for most of the difference. At 4 weeks post-randomisation, 
36% of patients in each arm were alive with maintained or improved QoL compared to 
baseline. This fell to 17% in each arm at 8 weeks. The most commonly reported problems 
at 4 weeks concerned mobility (73% WBRT vs 79% OSC) and the ability to perform usual 
activities (68% vs 67%). Table 1. Summary of main trial data
OSC+WBRT (N=269) OSC (N=269)
Sex Male 157 (58%) 157 (58%)
Age Median 66 67
IQR 60 – 72 62 – 72
Range 38 – 84 45 – 85
KPS <70 101 (38%) 102 (38%)
≥70 168 (62%) 167 (62%)
Extra-cranial mets No 122 (45%) 124 (46%)
Number of brain 
mets Solitary 80 (30%) 82 (30%)
Time since brain 
mets diagnosis <= 4 weeks 165 (61%) 153 (57%)
> 4 weeks 104 (39%) 116 (43%)
Median (days) 23 26
Range (days) 2 – 235 0 – 196
Survival (weeks) Deaths 260 262
One-year (95% CI) 2.6% (1.1%, 5.1%) 2.7% (1.2%, 5.3%)
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1.36 and 1.52, respectively. The highest RRs of all-grade and high-grade hyponatraemia 
were associated with brivanib (6.5 and 5.2, respectively). Grouping by drug category, 
the RR of high-grade hyponatraemia with angiogenesis inhibitors was 2.69 compared 
to anti-Epidermal Growth Factor Receptors Tirosine Kinase Inhibitors or monoclonal 
Antibodies (1.12). Conclusion: Treatment with biological therapy in cancer patients is 
associated with a significant increased risk of hyponatraemia, therefore frequent clinical 
monitoring should be emphasized when managing these and newer targeted agents. 
Keywords: Hyponatraemia, Cancer, meta-analysis, Targeted Therapies
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MINI29.01 Squamous Cell Carcinoma of Lung in the United States: Analysis 
of the National Cancer Database (NCDB) Madhusmita Behera1, Taofeek K. 
Owonikoko2, Yuan Liu3, Theresa W. Gillespie2, Michael Yuan4, Rathi N. Pillai5, Conor 
Steuer6, Kristin A. Higgins7, Suchita Pakkala6, Chandra P. Belani8, Fadlo Khuri9, Suresh S. 
Ramalingam9 1Hematology/Medical Oncology, Winship Cancer Institute of Emory University, 
Atlanta/United States of America, 2Winship Cancer Institute of Emory University, Atlanta/
United States of America, 3Biostatistics and Bioinformatics, Emory University Winship 
Cancer Institute, Atlanta/United States of America, 4Winship Cancer Institute of Emory 
University, Atlanta/GA/United States of America, 5Winship Cancer Institute, Emory University, 
Atlanta/GA/United States of America, 6Emory, Atlanta/United States of America, 7Radiation 
Oncology, Emory University Winship Cancer Institute, Atlanta/United States of America, 8Penn 
State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute, Hershey/PA/
United States of America, 9Medical Oncology, Emory University Winship Cancer Institute, 
Atlanta/United States of America
Background: Lung squamous cell carcinoma (SCC) is the second most common 
histological sub type of lung cancer and accounts for about 30% of all non-small cell lung 
cancers (NSCLC). We analyzed the NCDB, an oncology outcomes database administered 
by the American College of Surgeons and the American Cancer Society, to study 
the epidemiology, patterns of care, outcomes and temporal changes in incidence of 
SCC. Methods: The NCDB was queried from 1998 to 2011 for SCC using ICD-O-3 codes. 
Temporal changes in incidence were estimated in intervals (1998-1999, 2000-2003, 
2004-2007, 2008-2011). The univariate association with covariates between SCC and 
other subtypes of NSCLC was assessed using Chi-square test or ANOVA. The univariate 
(UV) and multivariable analysis (MV) with OS were conducted by Cox proportional hazards 
model and log-rank tests. All statistical analyses were conducted using SAS Version 
9.3. Results: A total of 435,358 pts with SCC were included in the analysis and accounted 
for 28% of all NSCLC pts in NCDB. Pt characteristics: median age 70 (18-90 yrs); males 
64%; whites 87%; academic centers 27%; metro locations 78%; government insured 
72%; Charlson/Deyo comorbidity score (CDS) 0 in 55% and ≥2 in 15%, and stage III/
IV- 34/31%. Chemotherapy was used in 39% of pts, radiation in 46% and surgery in 32%. 
Approximately 19% of the pts did not receive any of the three treatments. Incidence of
SCC decreased over time (35%, 28%, 26%, 27%) vs. increasing trend in non-SCC (65%,
72%, 75%, 72%); p<0.001). The trend was similar across all races and sex. SCC was
associated with a higher co-comorbidity burden than non-SCC across all stages (CDS 0: 
55% vs. 62%; CDS 1: 31% vs. 27%; CDS ≥2: 15% vs. 11%; p<0.001). SCC was associated
with inferior 5 yr survival vs. non-SCC in all stages (stage I- 30% vs. 41%, stage II- 16%
vs. 21%, stage III- 8.5% vs.10%, stage IV- 1.9% vs. 2.5% respectively; p<0.0001). The 1
yr survival in stage IV SCC is 19.6% vs. 22.2% in non-SCC (p<0.0001). Males had worse
survival (HR 1.11 (1.09-1.13; p<0.001). Pts at community centers had worse survival vs. 
academic centers (HR 1.27 (1.23-1.30; p<0.001). An increasing trend in chemotherapy
use was observed (31% in 1998 to 43% in 2011) vs. a decreasing trend in use of radiation 
(52% in 1998 to 46% in 2011) and surgery (32% in 1998 to 27% in 2011). Chemotherapy 
was received by 48% of patients with stage IV SCC. Chemotherapy use across other
stages: 0/I- 18%, II- 46%, III- 60%. Males were more likely to receive any treatment
(OR 1.12 (1.08-1.15); p<0.001). Pts that received any treatment had significantly
better 5 year survival than those who did not receive any (20.3% vs. 3.3%, p<0.0001)
Conclusion: SCC accounted for 28% of all cases of NSCLC in the United States, was
associated with higher comorbidities and a significantly worse survival compared to
non-SCC of the lung. Chemotherapy was used in only 48% of pts with stage IV SCC.
Keywords: lung squamous, NCDB analysis
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MINI29.02 Effect of Statins and Metformin on Survival in Patients with Non-
Small Cell Lung Cancer Narjust Duma1, Mohleen Kang2, Khaleb Abu-Ihweij3, Moaz 
Choudhary2, Arpita Gandhi3, Martin Gutierrez4 1Internal Medicine, Rutgers-New Jersey 
Medical School, Newark/NJ/United States of America, 2Rutgers-New Jersey Medical School, 
Newark/NJ/United States of America, 3Rutgers-New Jersey Medical School, Newark/United 
States of America, 4Hackensack University Medical Center, Hackensack/AL/United States of 
America
Background: Lung cancer is the number one cause of cancer-related death worldwide; 
with the incidence of non-small cell lung cancer (NSCLC) risen dramatically, the 
importance of understanding the influence of comorbidities and their treatments takes 
a great importance. The aim of this study was to investigate the effect of statins and 
metformin on survival in patients with NSCLC. Methods: We reviewed the records of 
Background: Dyspnoea is a common symptom of lung cancer. Morphine is widely used 
to control dyspnoea. Methods: We randomised 173 patients with advanced non-small 
cell lung cancer or mesothelioma with a dyspnoea score ≥ 4 on visual analogue scale 
(VAS) to one of three arms (acupuncture [A], morphine [M] or combination [AM]). A was 
delivered to upper sternal, paravertebral, hand and trapezius trigger points. Patients on 
arm A were given rescue morphine if needed. We recorded VAS dyspnoea and relaxation, 
lung function tests, respiratory rate, and EORTC QLQ-30/ QLQ-LC13 questionnaires at 
baseline, 30mins, 90mins, 4 hours, day 2, 7 and 14. Primary endpoint was proportion of 
patients achieving ≥1.5 improvement in VAS dyspnoea at 4 hours. Results: The median 
age of the study population was 73. 53% were performance status 2-3. The baseline 
median VAS dyspnoea score was 6.5. All patients scored >7 on HAD depression score. 
44.3% scored >10 on HAD anxiety. Dyspnoea improved by ≥1.5 points on the VAS in 
74% of patients in arm A, 60% in arm M and 66% in arm AM (A versus M p-value 0.12, 
AM versus M p-value 0.50). On VAS scales there was improved anxiety, relaxation and 
tiredness of A over M. Analysis of EORTC questionnaire data showed a mean change from 
baseline global health % score for arm A of 7.08 compared to -2.08 for arm M (p-value 
= 0.009). There was a mean change from baseline in dyspnoea % score for arm A of 
-7.89 compared to -1.05 for arm M (p=0.029, not significant at 1% level). There was no
improvement in lung function or respiratory rate. 21% of patients in arm A, 87% in arm
M and 87% in arm AM took one of more doses of morphine (p<0.001). 123 patients had
toxicity data. All toxicities were CTCAE grade 1/2 and in line with morphine’s toxicity
profile, with 8% of patients in arm A, 35% in arm M and 39% of patients in arm AM
reporting toxicities. Two patients stopped morphine because of side effects. There were 
two cases of skin irritation attributable to acupuncture site dressings.
Score Changes from Baseline
A M AM
Mean VAS relaxation (SD) -1.06 (±2.60) 0.19 (±2.43) -1.48 (±2.05) p<0.001
Day 7 median LAR relaxation 
(range) -1 (-6.7–4.5) 0 (-3.5–4.4) -0.9 (-5.6–4) p=0.006
Day 7 median LAR anxiety 
(range) 1.5 (-2.5–8) 0 (-4–6.2) 1.2 (-5.4–6.3) p=0.003
Mean LAR tiredness (SD) -0.82 (±2.61) 0.02 (±2.20) -0.94 (±2.37) p=0.002
Mean EORTC global health 
% (SD) 7.08 (±25.54) -2.08 (±17.70) 2.72 (±16.96) p=0.009














Conclusion: This study population was of poor performance status. A is as effective 
as M in the treatment of dyspnoea and has additive value for anxiety, relaxation and 
global health. Acupuncture is morphine sparing. Acupuncture should be a treatment 
available to lung cancer patients with dyspnoea and as a morphine adjunct. 
Keywords: supportive care, morphine, dyspnoea, acupuncture
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MINI28.12 A Meta-Analysis of Clinical Trials on the Risk of Hyponatraemia 
in Cancer Patients Treated with Targeted Therapies Rossana Berardi1, Silvia 
Rinaldi1, Matteo Santoni1, Emilia Nunzi2, Alessia Smerilli3, Miriam Caramanti1, Francesca 
Morgese1, Mariangela Torniai1, Azzurra Onofri1, Mirco Pistelli1, Augusto Taccaliti3, 
Stefano Cascinu1 1Clinica Di Oncologia Medica, Università Politecnica Delle Marche, 
Ancona/Italy, 2Università Degli Studi Di Perugia, Perugia/Italy, 3Endocrinology, Università 
Politecnica Delle Marche, Ancona/Italy
Background: The incidence of hyponatremia in non-small cell lung cancer (NSCLC) 
varies from 1% to 50%. Early recognition and a prompt treatment of this electrolytic 
imbalance could prevent clinical complications and improve survival. Hyponatraemia has 
recently been reported with targeted therapies in cancer patients. Aim of the study was 
to perform an up-to-date meta-analysis in order to determine the incidence and relative 
risk (RR) in cancer patients treated with these agents. Methods: The published scientific 
literature regarding hyponatremia in peer-review journals was extensively reviewed using 
the MEDLINE and Pubmed databases till January 2015. Eligible studies were selected 
according to PRISMA statement. Summary incidence, RR, and 95% Confidence Intervals 
were calculated using random-effects or fixed-effects models based on the heterogeneity 
of selected studies. Results: A total of 4803 potentially relevant trials were identified: 
of them, 13 randomized phase III studies were included in this meta-analysis. A total 
number of 6670 patients treated with 8 distinct targeted agents were available for 
this analysis: 648 patients had NSCLC and were treated with afatinib or gefitinib (vs. 
placebo) and vorinostat + chemotherapy (vs. placebo + chemotherapy). The highest 
incidences of all-grade hyponatraemia were observed with the combination of brivanib 
and cetuximab (63.4) and pazopanib (31.7), while the lowest incidence was reported 
by afatinib (1.7). The highest incidence of high-grade hyponatraemia was reported by 
cetuximab (34.8), whilst the lowest incidences were reported by gefitinib (1.0). Summary 
RR of developing all-grade and high-grade hyponatraemia with targeted agents was 
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IL.17A 49.4 102 16 5.82 3.65 0.004862
IL.4 66.1 104 14 6.02 2.96 0.000917
IL.8.4 3.0 25 93 12.8 4.8 0.008985
 
Conclusion: Imbalances in the glucose metabolism pathway and increased levels of 
pro-inflammatory circulating markers were uncommon but consistently associated 
with a poor prognosis in stage IV NSCLC patients early in their treatment cycle. 
Alterations in these systems have been associated with cancer cachexia and may 
be targets for intervention in improving prognosis for select patients with NSCLC. 
Keywords: proteomics, inflammation, glucose metabolism, non-small cell lung cancer
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MINI29.04 The Use of Metformin and Proper Glycemic Control Are Associated 
with Improved Survival in Non-Small Cell Lung Cancer Patients Oscar 
Arrieta Rodriguez1, Edgar Varela-Santoyo1, Enrique Soto-Pérez-De-Celis2, Roberto 
Sánchez-Reyes1, Martha De La Torre-Vallejo1, Andrés F. Cardona3 1Instituto Nacional 
de Cancerología, Mexico City/Mexico, 2Instituto Nacional de Ciencias Médicas Y Nutrición 
Salvador Zubirán, Mexico City/Mexico, 3Foundation for Clinical and Applied Cancer Research, 
Bogota/Colombia
Background: Previous population-based studies have shown an association between 
metformin use and improved survival among diabetic patients with lung cancer. 
We sought to analyze the effect of diabetes and its treatment in terms of survival in 
Mexican patients with lung cancer treated at a single institution. Methods: 1106 
patients were included. Outcomes were compared between patients with (n=186) 
and without diabetes (n=920). Characteristics associated with antidiabetic treatment 
and with proper glycemic control (defined as mean plasma glucose <130mg/dL) were 
examined. Overall survival (OS) among the different patient populations was analyzed 
using Kaplan-Meier curves and multivariate analysis was used to determine the influence 
of patient and tumor characteristics on survival. Results: OS for the entire population 
was 18.3 months (95% CI 16.1-20.4). There was no difference in OS between diabetic 
and non-diabetic patients (18.5 vs 16.4 months, p = 0.62). Diabetic patients taking 
metformin had a superior OS than those taking other antidiabetic treatment (25.6 vs 
13.2 months, p = 0.001), and those with proper glycemic control had a better OS than 
those without proper glycemic control (40.5 vs 13.2 months, p<0.001). Both the use 
of metformin (HR 0.57 p = 0.017) and proper glycemic control (HR 0.40, p =0.002) 
were significant protective factors in the diabetic patient population. Conclusion: Proper 
glycemic control and metformin use have a beneficial effect on the survival of 
patients with diabetes and lung cancer. Studies using metformin in lung cancer 
should include measures of proper glycemic control as fundamental variables. 
Keywords: Diabetes Mellitus, non-small cell lung cancer, metformin
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MINI29.06 Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real 
World Population of Advanced Lung Cancer Patients? Khalid Al-Baimani1, Hannah 
Jonker2, Tinghua Zhang3, Glenwood Goss2, Scott A. Laurie2, Garth Nicholas1, Paul 
Wheatley-Price4 1Medical Oncology, The Ottawa Hospital Cancer Centre, University 
of Ottawa, Ottawa/Canada, 2Medical Oncology, The Ottawa Hospital Cancer Centre, 
University of Ottawa, Ottawa/ON/Canada, 3Ottawa Hospital Research Institute, Ottawa/
Canada, 4Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa/ON/
Canada
Background: Modern systemic treatment options for advanced NSCLC have largely 
been established from clinical trials (CTs). It is estimated that less than 10% of cancer 
patients enter a CT, but this subgroup drives oncology practice and impacts treatment 
decisions for other cancer patients. The advantage of CTs comes from solid internal 
validity and stringent methodology. Nonetheless, the generalizability of CTs could be 
questioned due to the high selectivity of eligibility criteria. We investigated clinical 
trial eligibility in an unselected NSCLC population. Methods: With ethics approval, a 
retrospective chart review was performed of patients with de novo advanced NSCLC 
assessed by medical oncologists at a large academic cancer centre, serving a mixed 
urban and rural population, between September 2009 and September 2012. Data 
collected included patient demographics, stage, performance status, histology, 
treatment details and outcome. Two sets (A and B) of arbitrary eligibility criteria were 
created using common criteria from phase 3 CTs. These criteria were applied to this 
cohort to identify the proportions of patient who would hypothetically qualify for CT 
enrollment. Criteria A required: ECOG 0 or 1, absence of brain metastases, Creatinine 
< 120 and the absence of second malignancy. Criteria B, allowing broader inclusion, 
only required ECOG 0-2 and Creatinine < 120. We investigated survival among eligible/
ineligible and treated/untreated patients. Results: 528 patients were included: 55% 
male; 50% ECOG 0-1; 58% adenocarcinoma, 22% squamous cell; 7% stage IIIB and 93% 
stage IV. Using the strict CT criteria (A), only 144 (27%) patients were considered eligible. 
Of those, 79% actually received systemic therapy. From 384 patients who would have 
been ineligible for the CT, 178 patients (46%) still received systemic therapy. There was a 
trend to longer median overall survival (mOS) in the eligible treated compared to eligible 
non-treated patients (11.6 vs 8.1 months p=0.12). mOS was significantly longer in the 
non-treated eligible cohort compared to the non-treated ineligible cohort (8.1 vs 3.8 
months p=0.003). The eligible treated and non-eligible treated had similar mOS ( 11.6 vs 
10.2 months, p= 0.10). When less strict eligibility criteria (B) were applied, 343 patients 
(65%) would have been eligible, of whom 240 patients (70%) actually received systemic 
all patients diagnosed with NSCLC at our institution from 2011 to 2013. Demographics, 
tumor characteristics, comorbidities, statin/ metformin use and survival were analyzed. 
Cox regression was used for multivariate analysis. Results: A total 205 patients were 
studied. Median age at diagnosis was 65 years (40-91), there were more males than 
females (56% vs. 44%, p<0.01. 74% (152) were current or former smokers with average 
40 pack years (5-60). The Median BMI was 26.5kg/m2 (18-44), ECOG status was 1 
(0-4) and serum creatinine of 1.0 (0.4-3.5). Regarding comorbidities: 48% (98) had 
hypertension, 45% (93) hyperlipidemia, 22% (44) COPD and 19% (39) diabetes mellitus. 
At diagnosis, 66% (136) of the patients had stage III/IV disease vs. 25% (69) with stage I/
II, p<0.0001. Adenocarcinoma was the most common histologic subtype (61%), followed 
by squamous cell carcinoma (27%). 42% received surgery, 80% systemic chemotherapy 
and 32% radiation. Median survival was 1520 days (95% CI: 1310-1765). 42% (87) of 
the patients were taking statins and 13% (27) metformin. About the statin use, 58% 
of the patients were using statins for 25-48 months, 12% for >48 months, 11% for 
13-24 months and 18% for less than 12 months. Female gender (OR: 1.98, p<0.001), 
age<65 years (OR: 0.89, p<0.01) and statin use (OR: 0.78, p<0.02) were independent 
predictors of survival by multivariate analysis. Metformin use was not a predictor of 
survival by univariate or multivariate analysis in this group of patients. Conclusion: In our 
cohort, we observed that almost half of the patients had hypertension and hyperlipidemia 
with statin use been a significant predictor of survival. Statins are one of the mostly 
widely prescribed drugs in the US; their proven anti-inflammatory effects may play a 
role in inhibiting cancer growth. However, the exact mechanisms by which statins 
inhibit cancer proliferation remains unclear. While other observational studies have 
looked at statins and risk of developing cancer, we specifically looked at the effect of 
statins on survival in patients on statin therapy prior to cancer diagnosis. More studies 
are needed to enhance our understanding of the effect of statins on lung cancer. 
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MINI29.03 Prognostic Value of Biomarkers Associated with Glucose 
Metabolism and Systemic Inflammation in Advanced On-Small Cell Lung 
Cancer (NSCLC) Mary J. Fidler1, GabrielaC. Lobato2, Samantha Kerns3, Sanjib Basu3, 
Cristina L. Fhied4, Ravi Pithadia5, Imad Tarhoni4, Marta Batus1, Philip Bonomi6, Jeffrey A. 
Borgia4 1Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago/
AL/United States of America, 2Department of Biochemistry, Rush University Medical Center, 
Chicago/IL/United States of America, 3Hematology, Oncology and Cell Therapy, Rush 
University Medical Center, Chicago/United States of America, 4Pathology, Rush University 
Medical Center, Chicago/United States of America, 5Pathology, Rush University Medical 
Center, Chicago/IL/United States of America, 6Rush University Medical Center, Chicago/IL/
United States of America
Background: Alterations in glucose metabolism and appetite stimulating hormones 
have been correlated with inflammation but there is little information on frequency and 
prognosis in newly diagnosed stage IV non-small cell lung cancer (NSCLC) This study 
objective was to identify associations of circulating biomarkers of glucose metabolism 
and inflammation with prognosis in pre-treatment sera from stage IV NSCLC patients 
selected for platinum doublet based chemotherapy. Methods: Pretreatment serum 
from 118 Pts with frontline stage IV NSCLC were evaluated with the Bio-Plex Pro Human 
Diabetes Assay panel (adiponectin, adipsin, c-peptide, ghrelin, gastrin inhibitory peptide 
(GIP), glucagon-like peptide-1 (GLP-1), glucagon, IL-6, insulin, leptin, Plasminogen 
activator inhibitor-1, resistin, TNFα, vistatin) and HSTCMAG-28SK | MILLIPLEX MAP 
Human High Sensitivity T Cell Panel - Immunology Multiplex Assay (Fractalkin, GM-
CSF, IFNγ, IL-1 β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-21, IL-23, 
ITAC, macrophage inflammatory protein (MIP) -1α, MIP-1β, MIP-3α, TNFα) on a FlexMAP 
3D system (Luminex Corp.). Pts were treated with standard platinum doublets based 
chemotherapy. Associations of biomarkers with progression free and overall survival 
(PFS,OS) outcomes were assessed using multivariate Cox PH analyses. Results: Most 
patients had metabolic levels below the prognostic threshold. However, high levels of 
insulin, GIP, glucagon, visfatin, ghrelin, GLP-1 were significantly associated (p<0.05) with 
shorter PFS. Low levels of adipisin (deficiency of which is associated with obesity) was 
associated with shorter PFS (p=.0185). High levels of pro-inflammatory markers: ITAC, 
GM-CSF, Fratalkine, INF-α, IL-12p70, IL-13, IL17A, IL-4, IL-23, IL8.4, MIP-α, MIP-1 were also 
associated with poor PFS (p<0.05) (See Table I for more details on select biomarkers) 
High levels of these endocrine markers (except insulin and GIP) were associated 
with shorter OS as were ITAC, GMCSF, IL12p70, IL-13, IL4, IL23, IL5 (p<0.05). Table 
I.Biomarker correlation with progression free survival
Marker Cutoff-pg/mL N < N > Median PFS < Median PFS> Logrank p
Insulin 1004.9 82 36 6.08 4.04 0.026161
Glucagon 361.2 110 8 5.46 1.71 0.010219
Visfatin 8298.3 109 9 5.65 1.45 8.77E-06
Ghrelin 2897.2 104 14 6.02 2.12 0.009423
GLP.1 268.8 109 9 5.65 1.97 0.000618
ITAC 104.7 99 19 5.82 2.96 0.012529
Fractalkine 271.7 97 21 6.08 3.16 0.0067
IL.12.p70. 17.0 109 9 5.65 3.16 0.010631
IL.13 14.9 105 13 5.82 2.76 0.001533
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by two researchers for accuracy. Results: The search strategy identified 2051 articles 
that were reviewed for eligibility. Of these, 245 were eligible for inclusion. 198 (80.8%) 
studied 1L, 45 (18.4%) 2L+, and 2 investigated both lines. Of all articles, 51 (20.8%) 
found significant improvement in survival (Figure 1). Of these, 45 (88.2%) were 1L (41 
studies). 14/41 (34.1%) were terminated early or had major protocol changes during 
study enrollment, and 5/41 (12.2%) reported inconsistent outcomes. In significant 1L 
studies, the median OS improvement ranged from 0.3-7.0m and HRs ranged from 0.35 
to 0.87. The 4 2L+ positive studies, OS improvement ranged from 1.4-2.8m and HRs 
from 0.70-0.86. Of all 198 1L publications, 12 studies met the significant HR <0.80 
bar and an additional 12 studies reported statistically significant gains of ≥2.5m OS. 
Figure 1. Publications reporting significant improvement in survival
Conclusion: There is a need to improve survival outcomes for patients in NSCLC. In 1L, 
few studies would have met the ASCO target. Only four 2L+ trials were identified with 
significant improvements in NSCLC. The results of this systematic literature review inform 
the interpretation of research and the new bar recommended for meaningful outcomes. 
Keywords: non-small cell lung cancer, survival, meaningful outcomes, innovation
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MINI29.09 Recommendations for Standardized Efficacy Data Specifications 
in Lung Cancer Sean Khozin1, Gideon Blumenthal1, Alisa Khomyanina2, Boris 
Brodsky3, Ronald Fitzmartin3, Patricia Keegan1, Richard Pazdur1 1Office of Hematology 
and Oncology Products, US Food and Drug Administration, Silver Spring/MD/United States 
of America, 2International Business Machines Corporation, Armonk/NY/United States of 
America, 3Office of Strategic Programs, US Food and Drug Administration, Silver Spring/MD/
United States of America
Background: There are general standards for common clinical trial data elements 
submitted to US Food and Drug Administration (FDA) in a new drug application (NDA) 
or biologic license agreement (BLA). There is, however, considerable heterogeneity in 
the structure of data elements that are unique to a particular therapeutic area. As part 
of an effort organized by Coalition for Accelerating Standards and Therapies (CFAST), 
we developed specifications for efficacy data standardization in lung cancer. Methods: 
Using FDA guidance documents, NDA and BLA reviews, sample case report forms, and 
clinical trial datasets, we identified data elements in lung cancer clinical trials that are 
essential in evaluating the efficacy of new drugs and biologics. We constructed a concept 
map outlining the data elements and specifying their relational structure. Results: Data 
elements were captured under two main categories: efficacy endpoints (Figure 1) and 
covariates (Figure 2). Efficacy endpoints consist of overall survival, progression-free 
survival, objective response rate, duration of response, and disease-free survival. All 
lesions are assigned an organ-specific code. Data on tumor kinetics are captured as 
continuous variables supporting precise estimation of response while capturing all the 
requirements of Response Evaluation Criteria in Solid Tumors, version 1.1. Covariates 
were divided into disease and patient characteristics. Disease characteristics include 
specifications on molecular, immunohistochemical, and histological classification 
of tumors and detailed staging variables. Molecular definitions follow established 
nomenclature and include information on mutation subtypes as indicated. Patient 
characteristics include information on prior therapy, race and ethnicity.
therapy. From the remaining ineligible 185 patients, only 51 (28%) received treatment. 
The mOS was similar in the treated patient whether eligible or ineligible (10.9 vs 10.1 
months, p=0.57). As seen in criteria A, significantly longer mOS was observed in the 
eligible untreated compared to the ineligible untreated ( 4.9 vs 3.5 months p<0.001). 
Conclusion: While clinical trial criteria restrict study entry to the fittest patients, these 
results suggest that they do not reflect the broader patient population, as many ‘ineligible’ 
patients received therapy. Extrapolation of treatment paradigms to non-trial eligible 
populations is common, and may be reasonable based on these results. We observed 
similar survival among treated patients, whether trial eligible or not. This suggests 
that clinical judgement is more important than trial eligibility. In order to broaden trial 
participation, we could hypothesize that trial eligibility criteria could be relaxed. 
Keywords: eligibility, advanced, NSCLC, trial
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MINI29.07 CNS Disease Enrollment Criteria for NSCLC Drug Trials Eamon 
M. Berge1, Caroline E. McCoach1, Xian Lu2, Anna E. Barón2, D. R. Camidge1 1Medical 
Oncology, University of Colorado, Denver/CO/United States of America, 2Biostatistics and
Informatics, University of Colorado School of Public Health, Denver/CO/United States of 
America
Background: CNS metastases are common in NSCLC, yet clinical trials of new 
drugs in NSCLC have widely varying inclusion and exclusion criteria in relation to CNS 
disease. CNS disease that has received local therapy may be dormant, confounding any 
subsequent drug benefit, whereas untreated CNS disease may reduce PFS if CNS and 
systemic drug exposure differs. Recently, RANO guidelines propose explicitly explored 
activity in CNS disease within solid tumor drug trials. The true extent of variation in 
CNS related enrollment criteria in NSCLC clinical trials has not been documented 
before. Methods: ClinicalTrials.gov was interrogated on September 11, 2014 looking 
for interventional drug trials including advanced NSCLC. The following characteristics 
were extracted: 1) trial phase; 2) experimental arm therapy (chemotherapy, targeted 
therapy, immunotherapy, anti-angiogenic); 3) location (US, International only, US + 
International); 4) sponsor (Industry, University/IIT, Cooperative Group, NCI); 5) CNS 
disease allowance (strict exclusion, allowed after local treatment (surgery/radiation), 
unrestricted/untreated disease allowed). Industry sponsorship was divided into ‘large 
pharmaceutical’, (top decile by number of sponsored trials) and ‘small pharmaceutical’ 
(lower 9 deciles). Exclusion of CNS metastasis was treated as a binary variable and 
grouped as ‘strict exclusion’ vs. ‘allowed CNS metastasis’ (‘allowed with treatment’ and 
‘allowed untreated’). Univariable and multivariable logistic regression models were fit 
to test the association between exclusion of CNS metastasis and trial characteristics. 
Statistical significance was set at 0.05 with no adjustment for multiple testing. Results: Of 
735 trials involving NSCLC, 325 (44%) were excluded from analysis mostly because of 
allowance of early stage NSCLC (50%, n=164), or no active therapy inclusion (45%, 
n=146). In the remaining 406 trials, patients with CNS metastases were excluded in 58 
(14%), allowed after local treatment in 165 (41%), and allowed with no prior treatment 
in 104 (26%). CNS criteria were not referenced in the available information in 79 (19%) 
trials which were excluded from further analysis. On univariable analysis, the odds of CNS 
metastasis exclusion on trial were significantly lower in trials with vs. without targeted 
therapy (OR 0.44, 95% CI: 0.25-0.78, p=0.005) and significantly higher in trials with 
vs. without immunotherapy (OR 2.13, 95% CI: 1.06-4.28, p=0.04). No other univariable 
associations were significant. In multivariable analysis, after adjustment for all other 
factors, only trials located at international only vs. US only sites had greater odds of 
exclusion of CNS metastasis (OR 1.64, 95% CI 0.84-3.22; p=0.03). Conclusion: Although 
univariable analysis suggests class of agent may influence trial design, in multivariable 
analysis trial location was the only variable associated with strict exclusion of CNS 
metastases. This raises the possibility of exclusion based on historical/cultural 
rather than scientific factors. With 18% of trials (58/327) excluding all CNS disease 
and 50% (165/327) only allowing CNS disease if previously treated, less than a third 
of NSCLC trials permit unequivocal assessment of CNS activity (104/327). Given 
the high frequency of CNS disease in NSCLC, sponsors should consider consciously 
tailoring trial designs to more explicitly explore efficacy in this patient population. 
Keywords: clinical trials, NSCLC, CNS Metastasis
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MINI29.08 Innovation in Non-Small Cell Lung Cancer (NSCLC): Where Are the 
Clinically Meaningful Outcomes? Lisa M. Hess1, Steven L. Able1, Gebra C. Carter1, 
Joseph A. Treat2 1Eli Lilly and Company, Indianapolis/United States of America, 2Eli Lilly 
and Company, Global Med Affairs & Late Phase Prod Dev, Indianapolis/IN/United States of 
America
Background: The American Society of Clinical Oncology (ASCO) recently developed a 
set of recommended targets for clinically meaningful outcomes to encourage patients, 
advocates and investigators to expect more of clinical trials in the future and to 
encourage investigators to design trials and select agents that have the most promise. 
A systematic literature review was conducted to identify where and how research 
has successfully met the bar for meaningful improvements in NSCLC patient survival. 
Methods: A systematic search strategy was implemented in MedLine and EMBASE 
to identify randomized phase III trials reporting overall survival (OS) outcomes from 
1974-present. Eligible studies were those that reported OS data in terms of a hazard 
ratio (HR) or median OS. Patients in the eligible randomized trials were NSCLC patients 
treated in the first (1L) or post-first line (2L+) setting. Data were extracted related to study 
population, histology, interventions, and survival from trials of patients with advanced 
or metastatic disease. All eligibility determinations and extracted data were reviewed 
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to study enrolment than those considering trials with these requirements (83% vs. 55%, 
p<0.0001). Those considering trials permitting use of archival tissue were more likely to 
begin study treatment than those considering trials mandating fresh research biopsies 
(59% vs. 38%, p=0.0007). For trials requiring current tumour samples, 127 research 
biopsies were performed. Participants proceeded to study treatment in 51% of these 
encounters. Study treatment was not offered for the remaining encounters due to lack of 
the pre-specified biomarker (28%), insufficient biopsy tissue (6%) or non-biopsy related 
exclusion criteria (15%). Among all 549 trial encounters, the most common barriers to 
trial enrollment included lack of the pre-specified biomarker (35%), withdrawal of consent 
(20%), other study exclusion criteria (16%), insufficient biopsy tissue (10%), deteriorating 
clinical status (10%) and death (5%). Of 391 encounters for the molecular profiling trial, 72% 
successfully completed molecular profiling. Twenty-two percent had insufficient tissue 
for analysis and 3% died prior to completion of molecular profiling. Conclusion: With the 
evolution of personalized medicine, a growing number of NSCLC trials require tumour 
tissue for treatment eligibility. This has emerged as a significant barrier to clinical trial 
enrollment. Potential solutions include routine tissue banking at diagnosis, facilitating 
use of available diagnostic samples (e.g. fine needle aspirates) for trials, development 
of circulating DNA assays for trials, and more resources for timely tissue acquisition. 
Keywords: research biopsy, NSCLC, access to care
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MINI29.13 Safety and Clinical Implications of Repeat Tumor Biopsy (RTB) 
in Patients with Advanced Lung Cancer: A Retrospective Institutional Study 
Eberechi S. Agwa1, Francisco Almeida2, Abdo Haddad1, Bruno R. Bastos1, Roy Lee3, 
Xuefei Jia1, Vamsidhar Velcheti1, Patrick C. Ma4 1Taussig Cancer Institute, Cleveland Clinic, 
Cleveland/OH/United States of America, 2Respiratory Institute, Cleveland Clinic, Cleveland/
OH/United States of America, 3Pathology and Laboratory Medicine Institute, Cleveland Clinic, 
Cleveland/OH/United States of America, 4Mary Babb Randolph Cancer Center., West Virginia 
University, Morgantown/WV/United States of America
Background: Clinical management of lung cancer and personalized cancer therapy have 
undergone major advances and paradigm shifts in recent years. Repeat tumor biopsy 
(RTB) at disease progression is not only used for diagnostic confirmation in lung cancer 
but also has recently been increasingly adopted to profile tumor biomarkers and identify 
drug resistance mechanisms. However, information on safety and clinical consensus 
on the use of RTB remain lacking. Methods: The aim of this study is to review RTB 
patterns and safety in advanced lung cancer patients at Cleveland Clinic and its impact 
on treatment (Rx) decisions. Patients who were diagnosed and underwent RTB for 
suspected progressive disease between 2007-2013 were included in this retrospective 
study. Statistical analysis is primarily descriptive. Results: The study involved a total 
of 184 (56% male) patients. Median age at diagnosis was 65Y (21-87). 100 (54%) were 
treated initially with single modality (Surgery = 41; Chemo = 33; Radiation = 17; targeted 
therapy = 9) and 83 (45%) with multimodality Rx (2-modality = 57, 3-modality = 26), 1 
(1%) unknown. Number of RTB per patient: 1 in 66.3% (n=122), 2 in 20.1% (n=37), 3 in 
11.4% (n=21), and 4 in 2.2% (n = 4). The most common procedure employed at 1st RTB 
was bronchoscopy (44.6%, n = 82), followed by CT-guided biopsy (bx) (20.7 %, n=38), 
surgery (10.3%, n=19), excision bx (8.2%, n=15), fine needle aspiration of skin & lymph 
node (LN) (7.6%, n=14), ultrasound guided bx (5.9%, n=11) & others (2.7%, n=5). Lung 
was the most commonly rebiopsied site (46%) followed by LN (15%). Procedure-related 
complications were reported in 13 of 181 (7.2%) pts at 1st RTB (data missing in 3 pts), 
3 of 61 (4.9%) at 2nd RTB, 1 of 25(4%) at 3rd RTB, and 0 of 4 (0%) at 4th RTB. The 17 
(6.2%) complications are shown in the table below. Histologic change was seen in 13 
cases, including adeno-to-squamous carcinoma (at erlotinib resistance) and vice-versa, 
and non-small cell to small cell histology. The T790M-EGFR mutation was noted in 6 
cases, the PIK3CA mutation in 1, and a change in ALK translocation status in 3. Medical 
decision-making was impacted in 16% of cases. Further molecular and genomic analysis 
of selected cases is in progress.
RTB Complications
Complications N=17 (%)
Bleeding without hemodynamic compromise 6 (35)
Bleeding requiring transfusion 1 (6)
Pneumothorax 5 (29)
Hemodynamic instability after premedication 1 (6)
Cerebral salt wasting 1 (6)
Tracheaoesophageal fistula 1 (6)
Severe cough 1 (6)
Incomplete procedure 1 (6)
Deaths 0 (0)
Conclusion: Our study results show that RTB can be safely performed in lung cancer patients 
using standard techniques and can impact lung cancer diagnosis and Rx decision-making. 
Keywords: clinical utility, Tumor rebiopsy, non-small cell lung cancer, Procedure safety
Conclusion: The data elements we have identified (Figures 1 and 2) include concepts not 
adequately captured in current data standards and highlight important regulatory needs 
for the efficacy evaluation of new drugs and biologics in lung cancer. These specifications 
will be integrated with CFAST’s efforts to promote the development of lung cancer-
specific data standards. Keywords: lung cancer, FDA, data standards, health information 
technology
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MINI29.11 Assessing Patient-Reported Symptoms in Non-Small Cell Lung 
Cancer Clinical Trials Alicyn K. Campbell1, Mona Martin2, Juliane Lungershausen3, 
Jean Marie Arduino4, Thomas M. Atkinson5, J. Kelley Mccarrier2, Stephen J. Coons6, 
Astra Liepa7 1Genentech, South San Francisco/CA/United States of America, 2Health 
Research Associates, Inc, Seattle/United States of America, 3Boehringer Ingelheim 
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America,6Patient-Reported Outcome Consortium, Critical Path Institute, Tucson/AZ/United 
States of America, 7Eli Lilly and Company, Indianapolis/IN/United States of America
Background: In collaboration with the FDA, the Patient-Reported Outcome (PRO) 
Consortium’s Non-Small Cell Lung Cancer (NSCLC) Working Group (WG) has completed 
the initial development of a new PRO measure to assess symptom-related treatment 
benefit in clinical trials of advanced NSCLC to support labeling claims. Methods: 
Symptoms relevant to NSCLC patients were identified from the literature. This was 
followed by concept elicitation interviews conducted with patients at six US sites. 
Interview transcripts were coded using Atlas.ti software and concepts were grouped by 
similar content and subsequently reviewed by the NSCLC WG members and an expert 
panel in order to identify the symptoms most relevant for assessing treatment benefit. 
Preliminary items were generated and combined into a draft measure for cognitive 
testing with NSCLC patients for both item refinement and for assessing measurement 
equivalence between the original paper format and an electronic PRO (ePRO) data 
collection format (i.e., tablet). Results: For concept elicitation, the 51 patients interviewed 
had a mean age of 64.9 years [range 46-86], 51% were female, and 75% were white 
(non-Hispanic). Current NSCLC staging was: Stage I (12%), III (37%), and IV (51%). A total 
of 19 (37%) were treatment-naïve, 18 (35%) had received first-line treatment only, and 
14 (27%) had received second- or third-line treatment. The most commonly expressed 
symptom was fatigue, described by patients as tiredness, lack of energy, tiring easily, 
and weakness. Other symptom concepts expressed included general pain, chest pain, 
cough, shortness of breath, difficulty breathing, appetite change, and coughing up blood. 
Items were drafted to assess either symptom frequency or severity for nine distinct 
symptoms using a 7-day recall period. Cognitive interviews were conducted in 3 waves 
to support iterative refinement. 20 additional NSCLC patients participated [mean age 
65.2 years (range 44-83); 40% female; 75% white (non-Hispanic); 50% Stage III and 
50% Stage IV]. During cognitive interviews, an 11-point numeric rating scale (NRS) and 
a 5-point verbal rating scale (VRS) were tested. Results indicated the 5-point VRS was 
better understood than the 11-point NRS. Further item refinement resulted in a 7-item 
measure covering pain (2 items: pain in chest, pain elsewhere), cough, shortness 
of breath, fatigue (2 items: energy, tiredness), and appetite. Patients reported no 
differences between tablet and paper data collection formats in regard to how they 
would interpret and respond to the items. Conclusion: NSCLC symptoms elicited 
from patients, across varied disease stages and treatments, were concordant with the 
pathophysiology of NSCLC. A new symptom-based PRO measure is being developed in 
accordance with the FDA’s PRO Guidance. The content is supported by existing literature, 
patient-reported experiences, and expert opinion. The draft measure (i.e., Non-Small Cell 
Lung Cancer Symptom Assessment Questionnaire [NSCLC-SAQ]) has been programmed 
onto an ePRO tablet for quantitative testing. Once complete, the NSCLC-SAQ and 
supporting evidence will be submitted to the FDA for its qualification as an efficacy 
endpoint measure to quantify treatment benefit for product evaluation and labeling. 
Keywords: NSCLC, PRO, Clinical Trials, Symptoms
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MINI29.12 Patients with Advanced Non-Small Cell Lung Cancer: Are Research 
Biopsies a Barrier to Participation in Clinical Trials? Charles Lim, Mike Sung, 
Nazanin Nouriany, Magdalena Sawczak, Tuhina Paul, Nicole Perera-Low, Andrea Foster, 
Dianne Zawisza, Ronald Feld, Geoffrey Liu, Frances Shepherd, Natasha Leighl Princess 
Margaret Cancer Centre, Toronto/ON/Canada
Background: The evolution of targeted therapy in non-small cell lung cancer (NSCLC) 
has led to growing complexity of clinical research and a heightened expectation of 
clinical benefit for participants. Clinical trials in NSCLC increasingly require mandatory 
tumour samples or research biopsies, both potential barriers for trial participation. We 
assessed the impact of performing research biopsies in advanced NSCLC on clinical 
trial enrollment. Methods: We conducted a retrospective chart review of patients with 
advanced NSCLC evaluated for systemic therapy clinical trials at the Princess Margaret 
Cancer Center from January 2007 to March 2015. Results: Of 55 clinical trials reviewed, 
38 required tumor samples for enrolment. Six mandated fresh tumor biopsies, whereas 
archival samples were permitted for 32 trials. All studies were linked to investigational 
therapy except one trial of molecular profiling not linked to an investigational treatment. 
Confirmation of a pre-specified biomarker was required in 23 trials in order to receive 
investigational treatment. Trial participation was offered to 640 patients at 940 unique 
study encounters, with some patients enrolling in multiple trials. Of 549 encounters 
where study treatment was offered, 60% proceeded to receive study treatment. Those 
considering trials without mandatory tissue requirements were more likely to proceed 
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CLIA certified testing. Adjuvant chemotherapy, or erlotinib/gefitinib for pts with EGFR 
mutant tumors was permitted. Results: Thirty-seven patients were enrolled. Molecular 
tumor demographics included 20 pts with Kras mutations; 10 with EGFR amplification 
alone; 3 patients with EGFR mutations and four patients with BRAF V600E mutations. 
Overall, 258 cycles (median 4, range 1-47) were administered. Initial doses used were C 
AUC 6 on day 1, and P 200 mg/m2,on day 1 of each 21-day cycle. Due to unacceptable 
toxicities (grade 3 diarrhea and febrile neutropenia [1 each]) in the first two patients, 
doses were reduced to P 175 mg/m-m2 and C AUC 5.. Common toxicities considered 
at least possibly related to the therapy included fatigue (30 pts); diarrhea (21 pts); 
nausea (19 pts); arthralgia-myalgia (15 pts); and anorexia (9 pts). Grade 3-4 adverse 
events included neutropenia (7 Gr3, 1 Gr4), anemia (2 Gr3), fatigue (9 Gr3), diarrhea 
(3 Gr3), nausea/vomiting (3 Gr3) and a single case of sepsis. Response evaluation 
showed 11 PR (5 Kras mutant), 20 SD, 4 PD and 2 NE patients by RECIST (ORR: 31%, 
90% one-sided lower CI: 21%). Four of the SD patients had >40% PET SUV reductions 
after two cycles. Three patients opted to switch to pemetrexed maintenance after 4 
cycles without disease progression or moderate/severe toxicity. Median PFS, OS and 
12 month overall survival rates were: 4 months (95% CI: 2.9-6.1), 13.1 months (95% 
CI: 9.2-21.6) and 57% (95% CI: 39-72%), respectively. Seven patients are alive after 
a median follow up of 34.2 months (range: 26.9-71.5), including two patients with no 
evidence of disease progression to date (50 and 37 months). Conclusion: Oncolytic 
reovirus administration in combination with paclitaxel and carboplatin was well 
tolerated. The RECIST response rate (11/35 [31%]; 28% of Kras mutants)(15/35; 43% 
if PET is considered) is not conclusive, nor excludes additional benefit of the reovirus 
to chemotherapy. However, the number of patients surviving longer than 2 years (11; 
30%) is substantial, suggesting either effect of second/third line post paclitaxel/
carboplatin/reolysin treatment or perhaps the triggering of an immune response 
following tumor reovirus infiltration. The latter concept merits further investigation. 
Keywords: reovirus, Kras activation, BRAF, long term survival
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Background: KRAS mutations, which occur in approximately 30% of lung 
adenocarcinoma cases, represent a major unmet clinical need in thoracic oncology. 
Preclinical studies have demonstrated that KRAS mutant NSCLC cell lines and xenografts 
with additional alterations in either p53 or INK4a/Arf (CDKN2A) are sensitive to FAK 
inhibition. Defactinib (VS-6063) is a selective oral inhibitor of FAK. This trial examined 
the effect of FAK inhibition in patients with KRAS mutant NSCLC and various permutations 
of p53 and CDKN2A alterations. Methods: This multi-center, non-randomized, open-
label, multi-cohort trial enrolled patients with advanced KRAS mutant NSCLC who had 
received at least one prior (platinum-based chemotherapy doublet) line of therapy. 
The primary endpoint was progression-free survival (PFS) at 12 weeks. Patients were 
enrolled into one of four cohorts defined by INK4a/Arf and p53 status. In all cohorts, 
patients received defactinib 400 mg orally BID until disease progression. Results: 
Fifty-three patients withKRAS mutant NSCLC were enrolled across 9 US sites as of the 
data cut-off date (13-Mar-2015). Forty-seven patients were enrolled to one of the four 
molecularly defined cohorts. The median age was 62 years (range 33-80); 48% were 
female. The median number of prior lines of therapy was 3 (range 1-8) 15 (28%) pts 
met the 12 week PFS endpoint, with one patient achieving a PR. Median PFS was 46 
days (range 12-205 days). Eight patients remained on study as of the data cut-off date. 
Clinical efficacy did not correlate with secondary mutation status across this KRAS 
mutant population. Adverse events considered at least possibly related to defactinib 
were experienced by 35 pts (76%). The majority of these were grade 1 or 2. 11 patients 
(24%) experienced at least possibly related grade 3-5 events, including 2 grade 5 
respiratory failure events. Underlying disease was a confounding factor in many pts. The 
most commonly reported treatment emergent adverse events of any grade were fatigue 
(24%) and increased bilirubin (24%). Conclusion: In pretreated pts with KRAS mutant 
NSCLC defactinib demonstrates promising clinical activity with disease control rates 
comparable to other molecularly targeted agents for this pt population. Defactinib was 
generally well tolerated. Further development is warranted. Clinical trial: NCT01778803. 
Keywords: Cancer Stem Cells, FAK Inhibitor, NSCLC
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Background: The National Lung Matrix Trial is a flagship trial in the United Kingdom being 
the first to combine the development of a technology platform that screens for multiple 
genetic aberrations in tumours with testing of multiple novel genetic-marker-directed 
drugs. The trial is focused on patients with advanced non-small cell lung cancer and 
currently includes 8 different drugs and 23 different drug-biomarker combinations. The 
aim of statistical analysis is to determine whether there is sufficient signal of activity in 
any drug-biomarker combination to warrant further investigation and this paper evaluates 
the novel statistical design that has been implemented. Methods: The primary outcome 
measure representing signal of activity is best objective response rate (ORR) in most 
cases and progression-free survival (PFS) in others. Each drug-biomarker combination 
could be considered as a single arm phase II trial and could have been designed 
using standard statistical approaches such as Simon’s two stage design. However, a 
Bayesian adaptive design was chosen because it gives a more realistic approach to 
decision-making in this complex setting. It has flexibility to make conclusions without 
fixing the exact sample size which will be important with the uncertainty around the 
prevalence of each biomarker. The design allows early stopping of recruitment to any 
drug-biomarker combinations that do not show sufficient promise at an interim analysis 
to warrant continuation. It also allows, when appropriate, for information about the 
primary outcome measure to be shared across different biomarker cohorts within any 
single drug to aid decision-making. Decision-making is based on the posterior probability 
distribution for the primary outcome measure, given the observed data and any prior 
knowledge, calculated using bayesian conjugate analysis. For ORR, the critical threshold 
which defines a signal of activity is 30% for single drugs and 40% for combinations and 
for PFS the critical threshold is median 3 months. The interim and final sample sizes were 
selected to ensure the design achieved pre-defined desirable operating characteristics. 
Results: For both ORR and PFS as primary outcomes, sample sizes of 15 and 30 patients 
per drug-biomarker cohort for interim and final analyses respectively were selected as 
giving the required operating characteristics. Simulations of trials for single drugs with 
ORR as the primary outcome showed that this would ensure a high probability (82%) of 
correctly stopping early when the true ORR was only 10% and a high probability (90%) 
of correctly recommending further investigation when the true ORR was as high as 
40%. Operating characteristics for the combination drug arms were similar. Operating 
characteristics for trial arms with PFS as the primary outcome are dependent on the 
recruitment rate and give high probabilities (>95%) of stopping early when the true median 
PFS is only 1 month and high probabilities (>80%) of recommending further investigation 
when the true median PFS is as high as 4 months. Conclusion: The Bayesian adaptive 
design with 15 and 30 patients per drug-biomarker cohort for interim and final analyses 
respectively gives a flexible, efficient design with good operating characteristics 
to investigate multiple genetic-marker-directed drugs within a single phase II trial. 
Keywords: bayesian, adaptive, phase II, trial design
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NSCLC Patients with Ras Activated Malignancies, Long Term Results 
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Background: Reovirus is a naturally occurring virus which preferentially infects and 
causes oncolysis in tumor cells with a Ras-activated pathway. Cells that express high 
levels of EGFR are also susceptible to reovirus infection. In preclinical studies, reovirus 
induces host immunity and cell cycle arrest, acting synergistically with standard 
cytotoxic agents. Its adverse effects are mild to moderate flu-like symptoms. We have 
hypothesized those patients with EGFR-mutated, EGFR-amplified, or Kras-mutated 
NSCLC through a common downstream activated Ras pathway should be susceptible 
to treatment with reovirus. Methods: We designed a Fleming, single-arm, phase II study 
to evaluate the objective response rate (CR + PR RECIST, or >40% PET SUV decrease) 
of reovirus in combination with paclitaxel-carboplatin as first-line therapy in patients 
with metastatic NSCLC. Secondary endpoints included progression free and overall 
survival. Eligible patients had ECOG PS 0-2, adequate organ function, no prior systemic 
chemotherapy for metastatic disease, and tumors with the specified genotype, as per 
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Background: Cabozantinib (C) is a small molecule inhibitor of multiple receptor tyrosine 
kinases, including MET, VEGFR2 & RET. MET is involved in tumor differentiation & 
VEGFR2 is a mediator of angiogenesis. Erlotinib (E) is FDA approved for the treatment 
of NSCLC. Methods: The primary objective of this randomized phase 2 study was to 
compare progression-free survival (PFS) of pts treated with E vs. C, & E vs E+C; each 
comparison had 91% power to detect a PFS hazard ratio (HR) of 0.5 with a 1-sided 
0.10-level test stratifi ed on prior number of therapies & ECOG PS. Secondary objectives 
included overall survival (OS), RECIST 1.1 response & CTCAE v4 toxicity. Pts were 
selected with previously treated (1-2 regimens) metastatic non-squamous EGFR wt 
NSCLC. Submission of archival tissue for central MET IHC testing was required. Oral 
daily dosing was: E-150 mg; C-60 mg; E+C-150 mg E, 40 mg C. Imaging was performed 
every 8 weeks. Pts optionally crossed over to E+C following progression on E or C. 
Results: 125 pts were enrolled, of which 115 were eligible & treated (E, n=39; C, 
n=39; E+C, n=37). Pt characteristics were balanced between arms except for lower 
rate of brain mets history on E (p=0.02). Median follow up is 8.5 m. Compared with 
E (median 1.9 m), PFS was signifi cantly improved on C (3.9 m, HR 0.33, p=0.0002, 
80% CI 0.22-0.49) & E+C (4.1 m, HR 0.31, p=0.0002, 80% CI 0.21-0.46). Similarly, 
compared with E (median 4.0 m), OS was signifi cantly improved on C (HR 0.52, p=0.02) 
& E+C arm HR 0.50, p=0.02). Grade 3-4 treatment-related hypertension & mucositis 
were higher on C and grade 3-4 diarrhea was higher on E+C. Overall worst grade 
toxicities were also signifi cantly higher on C and E+C. MET IHC results were available 
on 88 patients from the primary analysis & 85% were positive (1-3+ membrane or 
cytoplasm staining with MET4 antibody). There was no correlation between MET status 
and PFS. Conclusion: C & C+E signifi cantly improved PFS over E alone in pts with EGFR 
wt NSCLC. Cabozantinib-based regimens are promising for further investigation in this 
patient population. Funded by ECOG-ACRIN and NCI Contract No. HHSN261200800001E. 
Keywords: MET, cabozantinib, Erlotinib, wild type NSCLC
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Background: EGFR exon 20 insertions (ins20) represent a rare subtype (4%) of EGFR 
mutations and are refractory to EGFR-specifi c tyrosine kinase inhibitors (TKIs). No effective 
targeted therapies exist for patients (pts) with ins20; median PFS on the irreversible 
EGFR TKI Afatinib is 2.8 months (mos). Based on a durable RECIST partial response (PR) 
to AUY922, a Heat Shock Protein 90 (Hsp90) inhibitor, observed in an EGFR ins20 patient 
in a previous study (NCT01124864), we designed a phase II investigator-initiated trial 
to assess the activity of AUY922 in NSCLC pts with EGFR ins20. Since pts with these 
mutations are rare, we identifi ed other international investigators who have treated ins20 
patients with AUY922. Here, we present the results of a pooled international experience 
of 21 patients with EGFR ins20 treated with AUY922 in the United States, Taiwan and the 
Netherlands. Methods: A total of 21 patients with EGFR in20 are included in this analysis. 
14 were treated on a single-arm, multi-center, open-label study of AUY922 in advanced 
NSCLC pts with EGFR ins20 mutations in the US (NCT01854034). Five were treated on 
a multicenter Taiwanese trial of AUY922 across a variety of molecular NSCLC subtypes 
(NCT01922583) and two were treated on a compassionate-use basis in the Netherlands. 
The starting dose of AUY922 was 70mg/m2 IV weekly for all patients. Results: 21 pts, 
including 14 females and 7 males, average age 55 (range, 27-75) were included in this 
analysis. The median number of prior therapies was 2 (range, 1-6.) 6 pts received a 
prior EGFR TKI; none responded to TKI monotherapy. The most common AUY922-related 
toxicities were grade 1-2 visual changes (18/21; 86%) diarrhea (18/21; 86%) and fatigue 
(15/21; 71%). The only treatment-related grade 3 toxicities was hypertension (2/21; 1%) 
and AST elevation (1/21; 0.5%). There was one death on study, related to pre-existing 
comorbidity/unrelated to AUY922. Among the 21 patients treated, 5 achieved a partial 
response by RECIST 1.1 (ORR 24%) (Figure 1.) The median PFS estimate is 3.9 mos 
(95% CI, 2.9 to 10.7.) 6 patients remain on treatment at the time of abstract submission. 
Updated results and correlation with specifi c ins20 mutations will be presented.
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Background: Tobacco-related non-small cell lung cancer (NSCLC) is associated with 
reduced survival and greater genomic instability. Veliparib (V) is a PARP inhibitor that 
augments platinum-induced DNA damage in preclinical studies, and a recent Phase 2 trial 
of advanced NSCLC trended to improved survival (HR 0.80; CI 0.54–1.18) when V was 
added to carboplatin (C) and paclitaxel (P). Here we report outcomes based on smoking 
status from this randomized Phase 2 study of CP with either V or placebo in advanced 
NSCLC. Methods: Patients with previously untreated advanced/metastatic NSCLC were 
randomized 2:1 to CP with either V at 120mg BID or placebo (randomization stratifi ed by 
histology and smoking history). Cotinine was measured in patients’ plasma samples as 
an index of recent tobacco use. Results: Of 158 patients, 68% were male, and 49% had 
squamous NSCLC. At study entry, 60% pts were self-reported current smokers, 27% 
former smokers, and 13% never smoked. There were no signifi cant differences in 
veliparib pharmacokinetic parameters between cotinine-high and low. Grade 3/4 AEs 
were elevated in current-smokers treated with VCP vs CP (66% vs. 40%, p=0.026); all-
grade AEs and SAEs were similar between the two groups. The most common AEs in 
current-smokers were neutropenia (41% VCP; 27% CP), alopecia (36%; 33%), and anemia 
(31%; 40%). 
A sensitivity analysis of heavy vs light-smokers (≥ vs <39 pack-years, current or former 
smokers) showed advantage of veliparib in heavy-smokers: median PFS [HR(95% 
CI)] for VCP/CP was 7.0 vs 3.5 [0.43(0.20–0.94)] for heavy-smokers and 4.4 vs 4.2 
[0.97(0.49–1.92)] for light-smokers; median OS was 12.6 vs 8.8 [0.52 (0.27–1.02)] for 
heavy-smokers and 9.9 vs 8.8 [0.92(0.53–1.61)] for light-smokers. A cotinine sensitivity 
analysis found that outcomes in cotinine-high were similar to current-smokers: PFS, 
cotinine-high HR was 0.38 (0.19–0.73) and cotinine-low was 0.97 (0.51–1.87); OS, 
cotinine-high HR was 0.52 (0.29–0.92) and cotinine-low was 1.07 (0.63–1.81). In 
univariate analyses assessing the infl uence of baseline characteristics and treatment 
on outcomes, smoking status and treatment had a signifi cant interaction (p=0.0301 
PFS, p=0.0118 OS). Additionally, multivariate analysis including all factors also identifi ed 
current smoking as predictive of improved outcomes with VCP. Conclusion: Smoking 
status was a strong predictor of effi cacy for veliparib-chemotherapy combination 
in advanced NSCLC. No differences in pharmacokinetics of V were seen based on 
plasma cotinine; toxicity of VCP was acceptable regardless of smoking history. 
A Phase 3 study has been initiated in patients with smoking history (M14-359). 
Keywords: carboplatin, veliparib, phase 2 clinical trial, smoking
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Background: Non-small cell lung cancer (NSCLC) patients with ROS1 chromosomal 
rearrangement benefit from treatment with the ROS1 inhibitor crizotinib with remarkable 
response rates and durable disease control. Similar to ALK and EGFR mutant NSCLC 
treated with targeted kinase inhibitors, disease progression inevitably occurs due to 
acquired resistance either by mutation within the kinase domain of ROS1 or via bypass 
signaling. However, limited data exists on the spectrum of resistance mechanisms 
in ROS1+ NSCLC. Here report on a novel bypass mechanism for ROS1 resistance 
discovered in a ROS1+ tumor sample from patient with acquired resistance to crizotinib 
in which an activating mutation in the KIT receptor (p.D816G) desensitize ROS1 cells 
to crizotinib inhibition. Methods: Patients with ROS1+ NSCLC treated with crizotinib 
who developed acquired resistance underwent biopsy of a progressing tumor. 
Tumor samples were analyzed for potential resistance mechanisms. Assessment of 
mutations within theROS1 kinase domain was accomplished by direct sequencing 
of exons 35 thru exon 42 of ROS1 from genomic DNA isolated from FFPE tissue. The 
SNaPshot® Multiplex System was used to profile additional tumor related genes for 
mutations. The ROS1 rearranged cell lines, HCC78 and CUTO-2, were transduced 
with lentivirus to generate ectopic expression of the KITD816G cDNA. Cell proliferation 
was assessed by an MTS assay and cellular signaling was measured by western blot 
analysis. Results: Sequencing of the patient’s post crizotinib sample showed no 
mutation in the ROS1 kinase domain. Additional mutational profiling by SNaPshot® 
revealed the acquisition of a KITD816Gmutation in the post-crizotinib sample that was 
not present in the pre-crizotinib tumor sample. HCC78 and CUTO-2 ROS1+ cell lines 
expressing the KITD816G mutation were refractory to crizotinib by both cell proliferation 
assays and analysis of downstream signaling pathways. Both ROS1 and KIT activity had 
to be inhibited in order to suppress downstream signaling and proliferation in these 
cells. Conclusion: Activation of KIT by a gain-of-function mutation is a novel mechanism of 
resistance to crizotinib in ROS1 rearranged NSCLC. This bypass-signaling pathway serves 
as a ROS1 independent mechanism of progression, similarly to previously identified 
EGFR or RAS signaling pathways, and can potentially be targeted by KIT inhibitors. 
Keywords: KIT, lung adenocarcinoma, crizotinib, ros1
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Background: Chromosomal rearrangements involving neurotrophic tyrosine kinase 
1 (NTRK1) occur in less than 1% of NSCLCs. Cell-based assays have demonstrated 
that NTRK1 rearrangement leads to expression of an oncogenic TrkA fusion protein. 
While inhibition of TrkA in preclinical models reduces TrkA auto-phosphorylation and cell 
proliferation, the clinical activity of TrkA inhibitors in NSCLCs harboring an NTRK1 fusion 
is not known. Entrectinib (RXDX-101) is an orally available tyrosine kinase inhibitor of TrkA, 
TrkB, TrkC, ROS1, and ALK, with IC50 values for kinase inhibition ≤ 2 nM. Methods: We 
used an anchored multiplex polymerase chain reaction (AMP) assay to screen 
for NTRK1 rearrangements (Zheng et al., Nature Medicine 2014). Among over 663 NSCLC 
cases screened, we identified one positive case in which the 3’ end of SQSTM1 exon 6 was 
fused to the 5’ end of NTRK1 exon 10, leading to an SQSTM1-NTRK1 fusion transcript. We 
enrolled the patient onto the Phase 1 dose escalation study of entrectinib in adult 
patients with locally advanced or metastatic tumors (NCT02097810). The dose of 
entrectinib was 400 mg/m2 (750 mg) once daily. We assessed safety of entrectinib and 
response to treatment using RECIST 1.1. Results: The patient is a 46 yo male with a 30 
pack year smoking history who was first diagnosed with metastatic NSCLC in November 
2013. Prior therapies included carboplatin/pemetrexed, pembrolizumab, docetaxel, and 
vinorelbine. At the time of study enrollment, the patient had an ECOG performance status 
of 2 and required supplemental oxygen at a rate of 3 liters per minute by nasal cannula. 
He reported significant pain and dyspnea due to widely metastatic disease, including 
a large left hilar mass narrowing the left upper lobe bronchus and obstructing the left 
lower lobe bronchus, extensive and palpable neck and chest lymphadenopathy, and a 
palpable expansile left chest wall mass. Staging head CT also revealed numerous (15 to 
20) asymptomatic brain metastases measuring up to 1.7 cm that had not been previously 
treated. The patient was started on entrectinib and tolerated the study medication
well, with one adverse event of grade 1 dysgeusia, which resolved after two weeks.
Within three weeks of starting treatment, the patient reported resolution of dyspnea
and pain, and improvement in energy and appetite. He no longer required supplemental
oxygen and all sites of palpable disease had improved or resolved. At four weeks of
treatment, restaging CT scans demonstrated a partial response by RECIST of -47%,
with significant regression or resolution of lymphadenopathy, reduction in size of the
chest wall mass, and marked reexpansion of the left lung. Restaging of the CNS by head 
CT demonstrated near complete resolution of previously visualized brain metastases.
Conclusion: In a heavily pre-treated patient with NSCLC harboring an NTRK1 gene
fusion, entrectinib therapy resulted in rapid clinical improvement and a radiologic
partial response at 4 weeks with minimal toxicity. This preliminary report suggests that
entrectinib may be an effective therapy for patients with NTRK1-rearranged NSCLC.
Conclusion:This international experience suggests that AUY922 may be an active 
therapy for advanced NSCLC pts with EGFR ins20 mutations with an ORR 24% and median 
PFS 3.9 mo. AUY922 is generally well-tolerated, though reversible low-grade ocular 
toxicity is common. Further study of AUY922 in this population is warranted. 
Keywords: NSCLC, AUY922, EGFR, metastatic
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MINI30.07 Crizotinib in Patients with ROS1 NSCLC. Preliminary Results of 
the AcSé Trial Denis Moro-Sibilot1, Laura Faivre2, Gérard Zalcman3, Maurice Perol4, 
Julien Mazières5, Fabrice Barlesi6, Josiane Otto7, Isabelle Monnet8, Alexis Cortot9, 
Marie Wislez10, Hervé Léna11, Pierre Jean Souquet12, Sylvie Lantuejoul13, Isabelle 
Rouquette14, Anne Mcleer-Florin13, Gilbert Ferretti13, Natalie Hoog-Labouret15, Fréférique 
Nowak15, Marta Jimenez16, Gilles Vassal2 1Michallon Hospital - University Hospital, 
Grenoble/France, 2Gustave Roussy, Villejuif/France, 3Côte de Nacre Hospital - University 
Hospital, Caen/France, 4Léon Bérard Cancer Center, Lyon/France, 5Larrey Hospital - 
University Hospital, Toulouse/France, 6Nord Hospital - University Hospital, Marseille/
France, 7Antoine Lacassagne Center, Nice/France, 8Intercommunal Hospital, Créteil/
France, 9Calmette Hospital - University Hospital, Lille/France, 10Tenon Hospital - AP-HP, Paris/
France, 11Pontchaillou Hospital - University Hospital, Rennes/France, 12Lyon Sud Hospital - 
Civils Hospices, Lyon/France, 13University Hospital, Grenoble/France, 14Oncopôle - University 
Hospital, Toulouse/France, 15French National Cancer Institute Inca, Boulogne Billancourt/
France, 16Unicancer, Paris/France
Background: To avoid uncontrolled off-label use and allow for a nationwide safe access 
to crizotinib (crz) for patients (pts) with an ALK, MET or ROS1 positive (+) tumor, the 
French National Cancer Institute (INCa) launched the AcSé program, funding both access 
to tumor molecular diagnosis and an exploratory multi-tumor 2-stage design phase II 
trial. We report the preliminary results of the ROS1+ NSCLC cohort. Methods: ROS1 
status was assessed in 28 regional INCa molecular genetic centers by break-apart FISH 
assays in tumor samples showing an IHC score of ≥1+. Pts with ROS1 rearrangements, 
progressing after at least one standard treatment (including a platinum-based 
doublet, unless pts were considered as unfit for chemotherapy) were proposed to 
receive crz 250 mg BID. Responses were centrally assessed using RECIST v1.1. The 
objective response rate (ORR) and disease control rate (DCR) were assessed every 8 
weeks. Results: From Aug. 5, 2013 to Mar. 1, 2015, 39 pts with ROS1+ NSCLC were 
enrolled. 37 pts had received crz, leading to 37 pts with clinical information. Median 
age: 62 years (range 33–81), 70% females, 95% non-squamous histology, and 94% 
metastatic disease at study entry. Median number of prior treatments: 2 (range 1 
–7). Twenty four pts were still on treatment at the cut-off date, 13 have stopped crz
(8 PD, 3 adverse events (AEs), 2 deaths). Among the 27 pts evaluable for response
at 8 weeks, we observed 16 PR, 7 SD and 4 PD, leading to ORR=59% [95% CI:39-78],
and DCR=85% [66-96]. DCR at 6 months was 57% (disease control was achieved in
12/21 evaluable pts). Crz was well tolerated with only 4 grade ≥3 (1 AE + 3 SAEs) and
9 grade 1-2 SAEs. Most common AEs, mainly grade 1, were visual disorders (54% of
pts), peripheral edema (51%), diarrhea (48%), nausea (46%), and elevated transaminases 
(43%). Conclusion: Crz was well tolerated and achieved a robust treatment response
rate in ROS1+ NSCLC. These results underline the interest of integrating ROS1 in
biomarkers routine screening. Survival data and duration of response will be presented.
Keywords: NSCLC, Crizotinib, ROS1 translocation, biomarkers.
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MINI30.08 ROS1 Resistance to Crizotinib Is Mediated by an Activating Mutation 
in c-KIT Rafal Dziadziuszko1, Anh T. Le2, Dara L. Aisner3, Anna Wrona1, Robert C. 
Doebele2 1Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk/
Poland, 2Division of Medical Oncology, University of Colorado SOM, Aurora/CO/United States 
of America, 3Department of Pathology, University of Colorado SOM, Aurora/United States of 
America
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(placebo arm). In the pictilisib arm, common grade ≥3 adverse events (AEs) included 
neutropenia (23%), rash (20%), thrombocytopenia (8%), febrile neutropenia (5%), and 
hyperglycemia (5%). AEs led to higher rates of discontinuation in the pictilisib arm (26% 
versus 16% in the placebo arm), particularly during the first 4 cycles. However, the 
proportion of AE-related deaths was higher in the placebo arm (9 [12%] versus 5 [6%] in the 
pictilisib arm). Conclusion: This phase II trial of first-line pictilisib plus chemotherapy and 
bevacizumab in patients with non-squamous NSCLC showed a modest trend for improved 
PFS, with additional toxicity and no OS benefit. The safety profile was consistent with other 
pictilisib trials. PTEN null/low expression was not a predictive biomarker, although its 
prognostic value cannot be excluded. A trend for improved PFS, but not OS, was observed 
in the KRAS -wildtype subgroup, especially during the maintenance phase of treatment. 
Keywords: pictilisib, PI3KCA, lung cancer, NON SQUAMOUS
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MINI30.13 A Phase II Trial of Pictilisib with Chemotherapy in First-Line 
Squamous NSCLC David Spigel1, Alexander Luft2, Ihor Vynnychenko3, Natalia 
Fadeeva4, Zsuzsanna Mark5, Santiago Ponce6, Marina Matrosova7, Jerome 
Goldschmidt8, Barna Szima9, Mansoor Saleh10, Mark Lackner11, Steve Gendreau11, Katia 
Bassett11, Jill Spoerke11, Hartmut Koeppen11, Houston Gilbert11, Huan Jin11, Geetha 
Shankar11, Wei Lin11, Fabrice Denis12 1Sarah Cannon Research Institute, Nashville/TN/
United States of America, 2Leningrad Regional Clinical Hospital, St Petersburg/Russian 
Federation, 3Sumy State University, Sumy/Ukraine, 4Chelyabinsk Regional Clinical Oncology 
Dispensary, Chelyabinsk/Russian Federation, 5Tüdőgyógyintézet Törökbálint, Törökbálint/
Hungary, 6Hospital Universitario 12 de Octubre, Madrid/Spain, 7N. Novgorod Regional 
Oncology Dispensary, Novgorod/Russian Federation, 8US Oncology Network, Marion/VA/
United States of America, 9Markusovszky Hospital, Szombathely/Hungary, 10Georgia Cancer 
Specialists, Marietta/GA/United States of America, 11Genentech Inc., South San Francisco/
CA/United States of America, 12Jean Bernard Center/Victor Hugo Clinic, Le Mans/France
Background: In squamous non-small cell lung cancer (NSCLC), the PI3-kinase (PI3K) 
pathway may be activated via several mechanisms including PIK3CA amplification and 
downregulation of phosphatase and tensin homolog (PTEN) expression; activation of this 
pathway can promote cell survival and enhance chemotherapy resistance. Pictilisib, a 
pan-PI3K inhibitor, potentiates the activity of taxanes and platinum agents in preclinical 
NSCLC models. This phase II, hypothesis-generating study (NCT01493843) evaluated 
the safety and efficacy of pictilisib in combination with carboplatin and paclitaxel in 
patients with advanced or recurrent squamous NSCLC. Methods: Overall, 160 patients 
were randomized to receive carboplatin (target area under the curve [AUC] = 6 mg/
ml/min) and paclitaxel (200 mg/m2) every 3 weeks with 340 mg oral pictilisib (n=81) 
or placebo (n=79) daily in the first 2 weeks of each cycle for a total of 4 cycles. 
Pictilisib or placebo was continued daily until disease progression or intolerable toxicity. 
Stratification factors included Eastern Cooperative Oncology Group performance status 
and smoking status. The primary endpoint was progression-free survival (PFS) in the 
intention-to-treat (ITT) population and in patients with PIK3CA amplification (assessed 
by chromogenic in situ hybridization [CISH]). Overall survival (OS), objective response 
rate (ORR), safety, and PFS in the PTEN null/low subgroup were secondary endpoints. 
Tumor assessment was based on RECIST v1.1. Safety analyses were performed on 
patients who received at least one dose of study drug. Results: Median PFS in the ITT 
population was 5.6 months in the pictilisib arm and 5.5 months in the placebo arm (HR 
0.82; 90% CI 0.60–1.12). Median OS was 11.7 months in the pictilisib arm and 12.2 
months in the placebo arm (HR 1.10; 90% CI 0.77–1.57). PFS and OS analyses in patients 
with PIK3CA amplification will be presented. Median PFS for the PTEN null/low subgroup 
was 6.7 months in the pictilisib arm and 5.5 months in the placebo arm (HR 0.69; 90% 
CI 0.42–1.13). ORR in the ITT population was 28% in the pictilisib arm and 34% in the 
placebo arm. Common grade ≥3 adverse events (AEs) included neutropenia (18%), rash 
(8%), and thrombocytopenia (7%). AEs led to higher proportion of discontinuations (22% 
in the pictilisib arm vs. 15% in the placebo arm) and AE-related deaths in the pictilisib 
arm (12 [14%] vs. 2 [3%] in the placebo arm). Deaths were due to disease progression or 
AEs typically reported in lung cancer. No unexpected safety signals were identified for 
pictilisib. Conclusion: In this first phase II trial of a PI3K inhibitor in first-line squamous 
NSCLC, the combination of pictilisib with chemotherapy introduced additional toxicity 
with a minimal PFS improvement and no OS benefit in the ITT population. The safety 
profile was consistent with other pictilisib trials. PTEN null/low expression did not 
identify a subgroup with significantly improved efficacy, although the prognostic value 
of PTEN as a biomarker in squamous NSCLC cannot be excluded. Efficacy analysis in 
the PIK3CAamplification subgroup is ongoing and will be presented at the conference. 
Keywords: squamous, metastatic, P13K, Placebo-controlled
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MINI30.14 Evaluation of the MET/AXL Receptor Tyrosine Kinase (RTK) Inhibitor 
MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) 
Harboring AXL Amplification Khanh T. Do1, Laura Macconaill2, Adrian Dubuc2, Isan 
Chen3, Richard Chao3, Vanessa Tassell3, James Christensen3, Geoffrey I. Shapiro1, 
Lynette M. Sholl2 1Early Drug Development Center, Department of Medical Oncology, Dana-
Farber Cancer Institute, Boston/MA/United States of America, 2Department of Pathology, 
Brigham and Women’S Hospital, Boston/MA/United States of America, 3Mirati Therapeutics, 
Inc., San Diego/CA/United States of America
This abstract was under embargo until the Conference and published in a Late 
Publication Supplement at the Conference. Please see the Late Publication 
Section starting page S791 in this book for the abstract.
Keywords: Neurotrophic tyrosine kinase 1 (NTRK1), Targeted therapy, entrectinib (RXDX-
101), non-small cell lung cancer
NEW KINASE TARGETS 
WEDNESDAY, SEPTEMBER 9, 2015 - 18:30-20:00
MINI30.11 Efficacy and Safety of Dovitinib in Advanced Squamous Cell Lung 
Cancer with FGFR1 Amplification: A Single-Arm, Phase II Study Sung Hee Lim1, 
Hye Ryun Kim2, Mikyong Kwak1, Mijung Han1, Se-Hoon Lee1, Jong-Mu Sun1, Byoung Chul 
Cho3, Jin Seok Ahn1, Keunchil Park1, Joo-Hang Kim2, Myung-Ju Ahn1 1Samsung Medical 
Center, Seoul/Korea, 2Yonsei Cancer Center, Seoul/Korea, 3Medical Oncology, Yonsei Cancer 
Center, Seoul/Korea
Background: FGFR1 amplification is one of the most common potential driving 
oncogenes in squamous cell carcinoma (SCC), which accounts for 20% of non-small cell 
lung cancer (NSCLC) squamous cell carcinoma. This phase II study evaluated the efficacy 
and toxicity profile of dovitinib, an orally active FGFR (fibroblast growth factor receptor) 
inhibitor, in advanced SCC patients. Methods: Patients with histological confirmed 
advanced squamous cell NSCLC and previously treated with at least one cytotoxic 
chemotherapy were enrolled from April 2013 to December 2014. All patients had FGFR1 
gene amplification more than 5 copies by fluorescent in situ hybridization (FISH). Each 
7-day treatment cycle consisted of dovitinib 500mg orally administration on days 1 to
5 and 2 days off. Primary endpoint was overall response rate and secondary endpoints
included PFS, OS and toxicity. Results: All 26 patients were male with the median age
of 68 years (range, 52 – 80). Most patients were ever smokers (96%) and had good
ECOG (0-1) performance status (85%). The median number of dovitinib treatment cycles 
administered was 2.5 (range, 1-12). The overall response rate (ORR) was 11.5% (95%
CI, 0.8 – 23.8) and disease control rate (DCR) was 50% (95% CI, 30.8 – 69.2). There
were three partial responses (PR) and ten stable diseases (SD). Duration of response in
3 patients who achieved PR was 4.5+, 5.1+ and 6.1months. After the median follow-up
duration of 15.7 months (range, 5.8 – 25.6 ), the median overall survival (OS) was 5.0
months (95% Confidential Interval, 3.61 – 6.39) and progression-free survival (PFS) was
2.9 months (95% CI, 1.54 – 4.26). Grade 1/2 fatigue (69%) and anorexia (85%) were
most commonly reported adverse events and 12 patients (46%) required dose reduction 
of dovitinib. Conclusion: Dovitinib treatment a showed modest efficacy in advanced
squamous cell lung cancer patients with FGFR1 amplification. Further studies to evaluate 
other biomarkers correlated with the efficacy of dovitinib in SCC should be warranted.
Keywords: Squamous cell lung cancer, Dovitinib, fibroblast growth factor receptor
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MINI30.12 A Phase II Trial of Pictilisib with Chemotherapy in First-Line Non-
Squamous NSCLC Benjamin Besse1, Alexander V. Luft2, Natalia Fadeeva3, Jörg 
Mezger4, Thaddeus Beck5, Paolo Bidoli6, Fabrice Denis7, Eugene Paschold8, Giles 
Robinet9, Harry Groen10, Joachim Von Pawel11, Mark Lackner12, Steve Gendreau12, Jill 
Spoerke12, Katia Bassett12, Hartmut Koeppen12, Houston Gilbert12, Huan Jin12, Geetha 
Shankar12, Wei Lin12, Enriqueta Felip13 1Institute Gustave Roussy, Paris/France, 2Leningrad 
Regional Clinical Hospital, St. Petersburg/Russian Federation, 3Chelyabinsk Regional Clinical 
Oncology Dispensary, Chelyabinsk/Russian Federation, 4St Vincentius Kliniken, Karlsruhe/
Germany, 5Highlands Oncology Group, Fayetteville/AR/United States of America, 6Azienda 
Ospedaliera San Gerardo Di Monza U.O. Oncologia Medica, Monza/Italy, 7Jean Bernard 
Center/Victor Hugo Clinic, Le Mans/France, 8Novant Health Oncology Specialists, Winston-
Salem/NC/United States of America, 9CHU Morvan, Brest/France, 10University Hospital 
Groningen, Groningen/Netherlands, 11Asklepios-Fachkliniken Mönchen-Gauting, Gauting/
Germany, 12Genentech Inc., South San Francisco/CA/United States of America, 13Val 
D’Hebron University Hospital, Barcelona/Spain
Background: In non-squamous non-small cell lung cancer (NSCLC), PI3-kinase (PI3K) 
pathway activation, including downregulation of phosphatase and tensin homolog 
(PTEN) expression, may promote cell survival and enhance chemotherapy resistance. 
Additionally, mutations in KRAS have been shown preclinically to confer resistance to PI3K 
inhibition. The pan-PI3K inhibitor pictilisib potentiates the activity of taxanes, platinum 
agents, and antivascular endothelial growth factor therapy in preclinical models of 
NSCLC. This phase II hypothesis-generating study (NCT01493843) evaluated the safety 
and efficacy of pictilisib in combination with carboplatin, paclitaxel, and bevacizumab in 
patients not treated for advanced or recurrent non-squamous NSCLC. Methods: Overall, 
158 patients were randomized to receive carboplatin (area under the curve [AUC] = 6 
mg/ml/min), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) every 3 weeks (q3w) 
with 340 mg oral pictilisib (n=79) or placebo (n=79) daily in the first 2 weeks of each cycle 
for a total of 4 cycles. Bevacizumab q3w with daily pictilisib or placebo was continued 
until disease progression or unacceptable toxicity. Stratification factors included Eastern 
Cooperative Oncology Group performance status and smoking status. The primary 
endpoint was progression-free survival (PFS) in the intention-to-treat (ITT) population and 
in patients with PTEN null/low expression (assessed by immunohistochemistry). Overall 
survival (OS), objective response rate (ORR), and safety were secondary endpoints. Pre-
planned exploratory analyses included efficacy in the KRAS -wildtype subgroup. Tumor 
assessment was based on RECIST v1.1. Safety analyses were performed on patients 
who received at least one dose of study drug. Results: Median PFS in the ITT population 
was 6.9 months in the pictilisib arm and 5.9 months in the placebo arm (HR 0.82; 90% 
CI 0.59–1.13), while median OS was 13.6 months (pictilisib arm) versus 16.1 months 
(placebo arm) (HR 1.12; 90% CI 0.79–1.59). In patients with PTEN null/low expression, 
median PFS was 5.9 months (pictilisib arm) and 5.7 months (placebo arm) (HR 0.74; 90% 
CI 0.41–1.32). In the KRAS -wildtype subgroup, median PFS was 9.7 months (pictilisib 
arm) versus 5.7 months (placebo arm) (HR 0.70; 90% CI 0.45–1.09); median OS was 
14.5 months in both arms. ORR in the ITT population was 37% (pictilisib arm) versus 29% 
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MINI31.02 Real-World Characteristics and Outcomes for ALK+ NSCLC in Korea 
Sung Hee Lim1, Kyung Ah Yoh2, Jong-Seok Lee2, Myung-Ju Ahn1, Yu Jung Kim2, Se Hyun 
Kim2, Jie Zhang3, Dony Patel4, Elyse Swallow5, Andrew Kageleiry5, Hwabok Yi6, Karen 
Stein3, Ravi Degun4, Keunchil Park7 1Samsung Medical Center Sungkyunkwan University 
School of Medicine, Seoul/Korea, 2Seoul National University Bundang Hospital, Seongnam-
Si/Korea, 3Novartis Pharmaceuticals Corporation, East Hanover/NJ/United States of 
America, 4Navigant Consulting, Inc., London/United Kingdom, 5Analysis Group, Inc., Boston/
United States of America, 6Novartis Korea Ltd., Seoul/Korea, 7Innovative Cancer Medicine 
Institute, Seoul/Korea
Background: Clinical trials have shown superior efficacy of ALK inhibitors compared with 
chemotherapies for patients diagnosed with ALK+ non-small cell lung cancer (NSCLC). 
In Korea, crizotinib was approved for ALK+ NSCLC in 2011 but is not yet reimbursed. 
The objective of this study was to describe real-world patient characteristics, ALKtesting 
and treatment patterns, and survival among Korean patients diagnosed with locally-
advanced or metastatic ALK+ NSCLC. Methods: A retrospective patient chart review 
was conducted in two major cancer centers in Korea. Participating physicians (N=4) 
reviewed patient charts and reported patient characteristics, ALK testing and treatment 
patterns, and survival of patients diagnosed with ALK+ locally-advanced or metastatic 
NSCLC. ALK inhibitor treatment duration and overall survival (OS) were estimated using 
Kaplan-Meier analyses. Results: In late 2014, 55 ALK+ NSCLC patients were identified for 
this study. The median follow-up time among these patients was 24.8 months. The median 
age at locally advanced or metastatic NSCLC diagnosis was 60 years (interquartile 
range: 52 - 67); 53% of patients were female, 51% were never-smokers, 2% were former 
smokers, 33% were current smokers, 15% had unknown smoking status, and 98% were 
diagnosed with adenocarcinoma. At primary diagnosis, 67% of patients had metastatic 
disease. ALK rearrangement was confirmed by fluorescent in situ hybridization (78%) or 
immunohistochemistry (22%). 27% of patients had their ALK rearrangement detected 
more than three months after their locally-advanced or metastatic diagnosis. The majority 
of patients received initial systemic chemotherapy; only 13% received anALK inhibitor in 
the first-line, and 62% received an ALK inhibitor by the end of follow-up. Out of 30 patients 
who received crizotinib, 83% discontinued (median duration of 6.3 months) and 13% 
died while still on crizotinib. Of those who discontinued, 32% switched to chemotherapy, 
16% switched to a different ALK inhibitor, and 52% received no further antineoplastic 
therapy. After discontinuing crizotinib, the median OS was 4.3 months. Conclusion: In 
this study of locally-advanced or metastatic ALK+ NSCLC patients in Korea, OS was 
poor following discontinuation of crizotinib with a median survival of 4.3 months. 
Additionally, many patients had delays in receiving ALK testing. Among patients who 
failed crizotinib treatment, over half received no further antineoplastic therapy. These 
findings suggest the need to provide timely access to ALK testing and effective 
treatments following crizotinib discontinuation for ALK+ NSCLC patients in Korea. 
Keywords: Locally-advanced or metastatic ALK+ NSCLC, overall survival, crizotinib, 
Korea
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MINI31.03 Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with 
Brain Metastases Keith L. Davis1, James A. Kaye2, Shrividya Iyer3 1RTI Health Solutions, 
Research Triangle Park/NC/United States of America, 2RTI Health Solutions, Waltham/MA/
United States of America, 3Pfizer Oncology, New York/NY/United States of America
Background: Crizotinib is an oral small-molecule tyrosine kinase inhibitor, which was 
approved in the United States (US) in August of 2011 for the treatment of anaplastic 
lymphoma kinase (ALK) -positive advanced non-small cell lung cancer (NSCLC). There 
are currently limited data on crizotinib treatment and related outcomes in ALK-positive 
advanced NSCLC patients with brain metastases at diagnosis in real world settings. 
The main objective of the current analyses was to assess and report the response 
rates in the ALK-positive advanced lung cancer patients with brain metastases treated 
with crizotinib in regular clinical practice. Methods: Physicians in the US (N=107) and 
Canada (N=40) were recruited from cancer centers or teaching hospitals (48%) or free 
standing oncology clinics (47%) to abstract data retrospectively from medical records 
of adult (≥18 years) patients diagnosed with ALK-positive advanced NSCLC and treated 
with crizotinib as first- or later-line therapy from 8/1/2011-3/31/2013 (for the US) or 
4/12012-3/31/2013 (for Canada) in non-clinical trial settings. IRB approval was obtained. 
A secure web-based form was used by physicians to abstract data and all patient data 
were de-identified and anonymous. Descriptive analyses were conducted to summarize 
objective response rate (ORR) in the subgroup with brain metastases. One-year survival 
rates from initiation of crizotinib were descriptively analyzed for the subgroup with brain 
metastases using the Kaplan-Meier method. Results: Data were extracted from 212 
patient records in US (N=147) and Canada (N=65), which included 33 ALK-positive 
advanced NSCLC patients with brain metastases present prior to crizotinib initiation. 
The mean (SD) patient age at diagnosis for these 33 patients was 57.4 (12.0) years and 
a majority were male (58%), Caucasian (76%), current or former smokers (67%), ECOG 
status 0 or 1 (55%), adenocarcinoma histology (85%) and initially diagnosed at the locally 
advanced or metastatic stage (70%). The majority (71%) of these patients had been 
treated with either whole brain radiotherapy (16 patients) or stereotactic radiosurgery 
(8 patients) prior to initiation of crizotinib treatment. Of these 33 patients, 21 received 
crizotinib as 1st line therapy for advanced ALK-positive NSCLC. Approximately 61% were 
alive at time of medical record data abstraction. The ORR was estimated to be 61% 
and 60% for these patients with brain metastases who received crizotinib as 1st and 
SESSION MINI 31: 
ALK 
WEDNESDAY, SEPTEMBER 9, 2015
ALK WEDNESDAY, SEPTEMBER 9, 2015 - 18:30-20:00
MINI31.01 Diverse Characteristics of ALK+ NSCLC Patients in the United States 
Edmond Bendaly1, Medha Sasane2, Jie Zhang2, Elyse Swallow3, Alexander R. Macalalad3, 
Dony Patel4, Andrew Kageleiry3, Philip Galebach3, Jacquelyn Kercheval3, Karen Stein2, 
Annie Guerin5 1Marion General Hospital, Marion/IN/United States of America, 2Novartis 
Pharmaceuticals Corporation, East Hanover/United States of America, 3Analysis Group, 
Inc., Boston/United States of America, 4Navigant Consulting, Inc., London/United 
Kingdom, 5Analysis Group, Inc., Montreal/QC/Canada
Background: ALK rearrangements in non-small cell lung cancer (NSCLC) have been 
associated with younger age of onset, East Asian ethnicity, non- or light-smoking 
history, and adenocarcinoma histology. The objective of this study was to evaluate 
data from two retrospective multicenter chart review studies conducted in 2013 
and 2014 to assess characteristics of ALK+ NSCLC patients and further understand 
the epidemiology of ALK rearrangements in NSCLC patients. Methods: This analysis 
included data from two chart review studies of patients diagnosed with locally-advanced 
or metastatic ALK+ NSCLC conducted among two separate panels of US oncologists. In 
the first study conducted in September and October 2013, 27 oncologists contributed 
data on 273 patients; in the second study conducted between July and November 2014, 
49 oncologists contributed data on 153 patients. In both studies, collected information 
included the age at diagnosis of NSCLC, sex, ethnicity, smoking history at primary 
NSCLC diagnosis, and tumor histology. Data from these studies were analyzed to 
assess ALK+ NSCLC patient characteristics. Results: Patients from the 2014 cohort 
tended to be younger than patients from the 2013 cohort at diagnosis of locally-advanced 
or metastatic NSCLC (Table). In both cohorts, a little over half of the patients were male. 
Racial composition was diverse in both patient groups. Patients had varied smoking 
histories in both studies, with approximately one third of patients reported as never-
smokers, one third as light smokers, and one third as moderate/heavy smokers. Tumor 
histology was heterogeneous in both cohorts. However, a particularly large proportion of 
patients in the 2014 cohort had squamous cell histology (14%).
Table. Characteristics of ALK+ NSCLC Patients from the 2013 and 2014 Studies
2013 Study1 N=273 2014 Study N=153
Age (years), median (IQR) 67 (58-72) 59 (52-67)
Male (%) 52% 57%
Race/Ethnicity (%)
Caucasian 59% 63%
Black/African American 18% 14%
Asian 13% 14%
Hispanic/Latino 8% 2%









Squamous cell carcinoma 3% 14%
Large cell carcinoma 5% 8%
Mixed 11% 9%
Unknown 0% 4%
Notes: IQR = inter-quartile range [1] Wakelee HA, Sasane M, Zhang J, et al. Description 
of ALK+ NSCLC patient characteristics and ALK testing patterns. J Clin Oncol 32:5s, 
2014 (suppl; abstr 8062). [2] Reported at primary NSCLC diagnosis. [3] Includes 
patients with unreported smoking history as well as 16 former smokers in the 
2014 study with unknown smoking histories. Conclusion: Assessment of patient 
characteristics in the two chart reviews suggests that ALK+ NSCLC patients may have 
diverse characteristics with varied racial composition, smoking histories, and tumor 
histology to an extent not previously detected. These results suggest that physicians 
may be testing NSCLC patients more frequently, yielding more diverse histology 
than expected among ALK+ tumors. Molecular testing could be informative for all 
newly diagnosed NSCLC patients, including patients with squamous cell histology. 
Keywords: Locally-advanced or metastatic ALK+ NSCLC, Patient characteristics, Tumor 
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a systematic review of respiratory-related events in the four largest clinical trials with 
crizotinib. Methods: An independent three-person panel composed of a pulmonologist, 
radiologist, and oncologist, none of whom were associated with any of the clinical studies, 
was convened to analyze respiratory AEs of grade ≥3 and any-grade AEs reported by 
the investigator as pneumonitis, ILD, or radiation pneumonitis in four crizotinib studies 
(PROFILE 1001, 1005, 1007, and 1014). After review by each panel member individually 
followed by consensus review, the events were classified either as disease progression 
or true respiratory AEs. Respiratory AEs were then further sub-classified as due to: 1) 
de novo ILD, 2) exacerbation or recurrence of pre-existing ILD, 3) concurrent illness 
(recurrence or progression of pre-existing condition), or 4) other toxicity not thought 
to be related to ILD (e.g. bacterial pneumonia). Results: There were a total of 1,669 
patients in the four studies, among whom 446 events in 368 patients met the criteria for 
further analysis. Of these 446 events, 77 were attributed to progressive disease, 310 to 
other toxicity not thought related to ILD, 20 to de-novo ILD, 9 to concurrent illness, and 
3 to exacerbation of underlying ILD. 27 cases (25 patients) were felt to have insufficient 
data to draw firm conclusions. Overall, the incidence of crizotinib-associated ILD was 
1.2% (20/1,644) across the four studies, with no difference in incidence seen between 
Asian and Caucasian populations. The mean onset of ILD was 82 days. The mortality rate 
for patients identified with crizotinib-associated ILD was 50% (10/20). There was a trend 
towards improved survival if crizotinib was stopped rather than continued on presentation 
(64% [9/14] vs. 17% [1/6], P=0.065). Early administration of systemic corticosteroids did 
not seem to affect survival. Conclusion: This report represents the largest systematic 
review of TKI-associated ILD that has been performed by an independent multidisciplinary 
review panel. Crizotinib-associated ILD occurred in approximately 1.2% of patients who 
were administered crizotinib and displayed a characteristic pattern of delayed but rapidly 
progressive dyspnea and hypoxemia with a mortality of 50% (10/20). This pattern is 
similar to that seen with the EGFR TKIs, but appears to have a more delayed onset and 
a higher mortality rate. In contrast to EGFR TKI-associated ILD, which has a markedly 
higher incidence in the Asian population, there appears to be no such predilection 
for crizotinib-induced ILD. Immediate cessation of crizotinib may improve survival. 
Keywords: independent review, crizotinib, ILD, pneumonitis
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MINI31.07 Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged 
Non-Small Cell Lung  Cancer Yan Zhang, Yan Wang, Junling Li, Xuezhi Hao, Di Ma 
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical 
Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on 
Anticancer Molecular Targeted Drugs, Beijing/China
Background: Crizotinib (XALKORI TM, Pfizer) , a tyrosine kinase inhibitor targeting ALK, 
ROS1 and MET, is used for the therapy of advanced anaplastic lymphoma kinase (ALK) -
rearranged non-small cell lung cancer (NSCLC). Cardiac toxicity is one of its adverse 
events which may interrupt the administration of crizotinib. Elevation of CK-MB has been 
reported but it remains to be determined whether the level of CK-MB can reflect cardiac 
toxicity of crizotinib therapy. We investigated the clinical manifestations and relevant 
frequency of heart-related side effects in 94 advanced ALK-rearranged NSCLC patients 
with treatment of crizotinib to share experiences of management of cardiac toxicity of 
crizotinib. Methods: A retrospective analysis was conducted to demonstrate the clinical 
manifestations as well as the corresponding frequency of cardiac toxicity in advanced ALK-
rearranged NSCLC patients with treatment of crizotinib enrolled in our hospital in the past 
4 years. Results: In the past 4 years, 95 advanced ALK-rearranged NSCLC patients were 
treated with crizotinib in our hospital, among which one patient dropped the treatment 
in 3 days due to grade 4 vomiting. In 94 eligible patients who continue the therapy more 
than one month, the heart-related side effects include QT interval prolongation (2/94), 
bradycardia (12/94), hypotension (3/94), aggravation of atrial fibrillation (1/94) and 
elevation of creatine kinase-MB(CK-MB) (59/94). Consequently, one of 2 patients with QT 
interval prolongation reduced dosage from 250 mg to 200mg twice daily for QT interval 
>500 ms on two electrocardiograms and then well tolerated. 12 patients with bradycardia 
presented asymptomatic and one patient with profound sinus bradycardia (heart rate
[HR]≦45) continued crizotinib without dose reduction as she was asymptomatic and
benefiting from continuous crizotinib treatment against the deadly disease. Patients with 
hypotension and aggravation of atrial fibrillation are tolerated and under close follow-up
without dose reduction. Remarkably, we observed that majority of our patients (62.77%) 
experienced elevation of CK-MB and no correlation between age and CK-MB elevation
(Pearson Correlation =-0.153，p=0.137). Conclusion: Cardiac toxicity is common
during crizotinib treatment so that heart-related examinations, such as ECG as well as
CK-MB, should be performed regularly especially for those with prior heart disease.
Keywords: Cardiac toxicity, crizotinib, NSCLC, CK-MB elevation
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MINI31.08 Real-World Persistence and Adherence to Crizotinib in over 3800 
US Patients Igor Rudychev, Marc Chioda, Greg Veneziano, Bryan Murray, Ruslan 
Horblyuk Pfizer Inc, New York/NY/United States of America
Background: Crizotinib is an oral tyrosine kinase inhibitor that has been studied in 
patients with advanced ALK-positive non-small cell lung cancer and has demonstrated 
median therapy durations ranging from 23 weeks to 10.9 months. In the real-world 
setting, persistence and adherence to oral therapies may be suboptimal compared with 
physician-administered treatments. Little is known about crizotinib treatment experiences 
outside of clinical trials. The objective of this analysis was to evaluate persistence on 
and adherence to crizotinib using US pharmacy records. Methods: De-identified records 
from five closed-distribution US specialty pharmacies supplying crizotinib in the 50 
later line treatment, respectively. The Kaplan-Meier estimates of 1-year survival from 
crizotinib initiation were 81% and 77% in patients with brain metastases, who received 
crizotinib as 1st line and later line treatment, respectively. Conclusion: In ALK-positive 
advanced NSCLC patients with brain metastases, complete or partial response was 
reported in majority of patients during treatment with crizotinib in real world settings. 
Keywords: crizotinib, lung cancer, brain metastases, response rates or outcomes
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MINI31.04 Intracranial Efficacy of First-Line Crizotinib vs. Chemotherapy 
in ALK-Positive NSCLC Benjamin J. Solomon1, Federico Cappuzzo2, Enriqueta 
Felip3, Fiona Blackhall4, Daniel B. Costa5, Dong-Wan Kim6, Kazuhiko Nakagawa7, 
Yi-Long Wu8, Tarek Mekhail9, Jolanda Paolini10, Jennifer Tursi10, Tiziana Usari10, Keith 
D. Wilner11, Paulina Selaru11, Tony Mok12 1Peter MacCallum Cancer Centre, Melbourne/
Australia, 2Istituto Toscano Tumori, Livorno/Italy, 3Vall D’Hebron University Hospital and 
Vall D’Hebron Institute of Oncology (VHIO), Barcelona/Spain, 4Manchester University and
the Christie NHS Foundation Trust, Manchester/United Kingdom, 5Division of Hematology/
Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston/MA/
United States of America, 6Seoul National University Hospital, Seoul/Korea, 7Kinki University
School of Medicine, Osaka/Japan, 8Guangdong Lung Cancer Institute, Guangdong General
Hospital, Guangzhou/China, 9Florida Hospital Cancer Insititute, Orlando/FL/United States 
of America, 10Pfizer Oncology, Milan/Italy, 11Pfizer Oncology, La Jolla/CA/United States of 
America, 12State Key Laboratory of South China, Hong Kong Cancer Institute, the Chinese 
University of Hong Kong, Shatin/China
Background: The ongoing multicenter, randomized, open-label phase III study PROFILE 
1014 recently demonstrated superior efficacy of crizotinib compared with chemotherapy 
in patients with previously untreated advanced ALK-positive NSCLC (Solomon et al, N 
Engl J Med 2014). Intracranial efficacy of crizotinib vs. chemotherapy was compared 
prospectively in this trial. Methods: Patients with previously untreated advanced non-
squamous ALK-positive NSCLC (N=343) were randomized 1:1 to receive crizotinib 250 
mg orally BID (n=172) or intravenous chemotherapy (pemetrexed 500 mg/m2 + cisplatin 
75 mg/m2 or carboplatin at AUC 5–6; all q3w for ≤6 cycles; n=171). Patients with 
treated brain metastases that were stable for ≥2 weeks with no ongoing requirement 
for corticosteroids were eligible. Treatment was continued until PD. Continuation of, or 
crossover to, crizotinib after PD (per independent radiology review [IRR]) was allowed 
for patients randomized to crizotinib or chemotherapy, respectively. Brain scanning 
was performed every 6 weeks in patients with baseline brain metastases and every 
12 weeks in those without baseline brain metastases. Protocol-specified efficacy 
endpoints included PFS (primary endpoint), ORR, OS, and 12- and 18-month OS, as well 
as intracranial TTP. Intracranial DCR at 12 and 24 weeks was also evaluated. Efficacy was 
evaluated in the ITT population and in two subgroups of patients: those with and without 
baseline brain metastases. Results: Of 343 patients in the ITT population, 79 had brain 
metastases at baseline identified by IRR (23%) and 263 did not (77%; data not reported 
for one patient). Baseline characteristics of patients randomized to receive crizotinib 
or chemotherapy were generally well balanced within these two patient subgroups. 
Among the patients with baseline brain metastases, a significantly higher proportion 
achieved intracranial disease control with crizotinib than with chemotherapy at 12 
weeks (33/39 [85%] vs. 18/40 [45%], respectively; P=0.0003) and at 24 weeks (22/39 
[56%] vs. 10/40 [25%]; P=0.006). There was a numerical improvement in prospectively 
measured intracranial TTP with crizotinib in the ITT population (HR 0.60, P=0.069), as 
well as in patients either with baseline brain metastases (HR 0.45, P=0.063) or without 
baseline brain metastases (HR 0.69, P=0.323). The frequency of progression in the 
brain was low in the ITT population (15%) and in patients with and without baseline 
brain metastases (27% and 11%, respectively). Overall PFS was significantly longer 
with crizotinib than with chemotherapy in both subgroups (brain metastases present: 
HR 0.40, P=0.0007, median 9.0 vs. 4.0 months; brain metastases absent: HR 0.51, 
P≤0.0001, median 11.1 vs. 7.2 months), as it was in the ITT population (HR 0.45, 
P<0.0001, median 10.9 vs. 7.0 months). Twenty-five patients in the crizotinib arm of 
the study experienced intracranial PD; 22 of these patients received crizotinib for ≥3 
weeks beyond PD and 19 also received intracranial radiotherapy. Conclusion: In this 
prospective assessment of intracranial efficacy, crizotinib demonstrated significantly 
greater intracranial disease control and overall efficacy compared with chemotherapy in 
patients with baseline brain metastases. These findings provide further confirmation of 
crizotinib as the standard of care for patients with previously untreated advanced ALK-
positive NSCLC, including those patients with brain metastases at baseline. 
Keywords: brain metastases, intracranial, crizotinib, ALK-positive NSCLC
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MINI31.06 Crizotinib and Interstitial Lung Disease: Systematic Review of 
Four Clinical Trials Ken Y. Yoneda1, Judith R. Scranton2, Keith D. Wilner3, Nicholas 
Stollenwerk1 1Division of Pulmonary, Critical Care and Sleep Medicine, University of 
California, Davis, Sacramento/CA/United States of America, 2Pfizer Oncology, Groton/CT/
United States of America, 3Pfizer Oncology, La Jolla/CA/United States of America
Background: Tyrosine kinase inhibitors (TKIs) have been associated with the 
development of a rare but serious and potentially fatal lung injury syndrome referred to 
as drug-induced interstitial lung disease (ILD). This has been best characterized for the 
epidermal growth factor receptor (EGFR) TKIs, with a typical presentation of delayed 
but rapidly progressive dyspnea leading to respiratory failure and death in up to one 
third of cases. While case reports of crizotinib-associated ILD have been published, little 
is known regarding the incidence, clinical characteristics, and mortality of crizotinib-
associated ILD. In an effort to better understand this adverse event (AE), we performed 
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on the patients enrolled in cohort A. Results: A total of 78 patients at 17 institutions were 
enrolled. In cohort A (n = 47), AEs which occurred in more than 40% of patients during 
8 weeks were ALT increased (75.0%), visual disorder (47.2%), anorexia (45.5%), nausea 
(45.5%), and AST increased (43.2%). In both cohorts (n = 75), 26 clinically significant 
AEs (n = 25) were observed: Gr ≥ 3 elevated transaminase level (14.7%), ILD (4.0%), Gr 
4 neutropenia (4.0%), Gr 3 thromboembolic event (4.0%), Gr 3 esophagitis (2.6%), and 
Gr 3 QTc prolongation (2.6%). There was one treatment-related death (1.3%) due to ILD. 
Clinically significant AEs tended to occur more frequently in females than males, albeit 
without significance (38.4% vs. 19.2%, respectively; p = 0.09). Blood samples for trough 
concentrations of crizotinib at steady state were collected from 63 patients. The geometric 
mean of trough concentrations were 396 (95% CI, 325-483) ng/ml in male and 395 (95% 
CI, 329-474) ng/ml in female, respectively (p=0.569, Mann-Whitney U test). No clinical 
factors including gender, weight, body surface area, and age which influenced trough 
concentrations or AEs of crizotinib were identified. Moreover, the trough concentration 
of crizotinib was not significantly different between patient with clinically significant and 
without (429 [95% CI, 361-509] ng/ml vs. 378 [95% CI, 313-456] ng/ml, respectively 
[p=0.365]). Conclusion: In this multicenter study, we observed crizotinib AEs as 
previously reported. Clinically significant AEs tended to occur more frequently in females 
than males, albeit without significance. Furthermore, we will present the association 
of clinically significant AEs and trough concentration with ABCB1 polymorphism. 
Keywords: crizotinib, toxicity, ABCB1, pharmacokinetics
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MINI31.11 Comparison of Different ALK Tests in Non-Small Cell Lung Cancer 
(NSCLC) Patients before and after Crizotinib and Their Clinical Outcome 
Anthonie Van Der Wekken1, Nils T Hart2, Thijo Hiltermann1, Wim Timens1, Harrie Groen1, 
Ed Schuuring1 1Pulmonary Oncology, University Medical Centre Groningen, Groningen/
Netherlands, 2Pathology, University Medical Centre Goningen, Groningen/Netherlands
Background: The screening algorithm for detection of ALK-rearranged NSCLC is still 
under investigation. The Break-Apart ALK FISH is the standard diagnostic test for the 
treatment with crizotinib. However, immunohistochemistry (IHC) with different antibodies 
shows excellent results when compared to ALK FISH. The efficacy of crizotinib is studied 
in relation to ALK FISH. We compared IHC outcome and the number of ALK breaks 
estimated by FISH with clinical outcome and retested at disease progression on crizotinib 
treatment. Methods: Patients treated with crizotinib who had biopsies with sufficient 
tumor tissue were selected. Tumor response was assessed by CT using RECIST v1.1. 
Fluorescence in situ hybridization (FISH) was performed with Vysis LSI ALK Break Apart 
FISH Probe KIT (Abbott Molecular Inc., Des Plaines, IL) and immunohistochemistry with 
Ventana (Ventana Medical Systems Inc, Tucson, AZ) ALK IHC Kit using D5F3 antibody. 
The same tests were performed on re-biopsy material after progression on crizotinib. 
Results: Twenty-nine patients with ALK positive advanced NSCLC were treated with 
crizotinib. Median (range) age was 54 yrs (21-75); 26 had an adenocarcinoma, 3 had 
large-cell carcinoma. We confirmed the presence of EML4-ALK fusions in all samples 
either by FISH or IHC. Median percentage of ALK breaks was 47% (2-76). Tumor responses 
occurred in 9 pts having a median of 51 (6-76) breaks per tumor sample. The 20 non-
responders had a median of 27 (15-64) breaks per tumor sample with 64 being an outlyer. 
In IHC positive pts 9/11 had a response to crizotinib treatment. In those who were IHC 
negative no pts (0/14) had a response (12 PD; 2 SD). Median PFS for positive IHC is 7.9 
mo (95% CI., 5.5 – 10.3) and for negative IHC 1.6 mo (1.3 – 1.8), n=17, p<0.0001. Overall 
survival is 6.5 mo (95% CI., 0 – 17.8) and 18.3 mo (95% CI., 11.1 – 25.6) respectively, 
n=29, p=0.05. In 8 pts with progressive disease re-biopsies were performed. Only in 
one pt FISH ALK became negative. In the other pts IHC and FISH remained both positive. 
In pts who progressed on crizotinib, 4 pts had extra red in the FISH, which may be 
treatment related. Conclusion: All IHC positive advanced NSCLC patients responded to 
crizotinib. Extra red in the FISH test may cause progression to treatment with crizotinib. 
Keywords: FISH, ALK,, NSCLC, IHC
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MINI31.12 Quality of Life for Crizotinib vs. Chemotherapy in Asian ALK-Positive 
NSCLC Patients Fiona Blackhall1, Tony Mok2, Makoto Nishio3, Dong-Wan Kim4, 
Keith D. Wilner5, Arlene Reisman6, Shrividya Iyer6, Benjamin J. Solomon7 1Manchester 
University and the Christie NHS Foundation Trust, Manchester/United Kingdom, 2Princess 
of Wales Hospital, The Chinese University of Hong Kong, Hong Kong/Hong Kong, 3Thoracic 
Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 
Tokyo/Japan, 4Seoul National University Hospital, Seoul/Korea, 5Pfizer Oncology, La Jolla/
CA/United States of America, 6Pfizer Inc, New York/NY/United States of America, 7Peter 
MacCallum Cancer Centre, Melbourne/VIC/Australia
Background: PROFILE 1014 compared the efficacy and safety of the ALK inhibitor 
crizotinib with platinum based chemotherapy in previously untreated advanced 
ALK-positive advanced NSCLC (Pfizer; NCT01154140). The primary endpoint was 
progression-free survival. The main objective of this post-hoc analysis was to compare 
patient-reported symptom and global quality of life (QOL) between crizotinib and 
chemotherapy in the subgroup of patients of Asian ethnicity in the ongoing study 
PROFILE 1014. Methods: Patients in the ongoing PROFILE 1014 study were randomized 
to crizotinib (250 mg PO bid; n= 172) or chemotherapy (pemetrexed 500 mg/m2 + 
either cisplatin 75 mg/m2 or carboplatin AUC 5–6; all IV q3w for ≤6 cycles; n= 171). 
Patient-reported outcomes were assessed at baseline, day 7 and day 15 of cycle 1, 
day 1 of subsequent 3-week cycles and end of treatment using the validated cancer 
specific questionnaire EORTC QLQ-C30 and its lung cancer module QLQ-LC13. Validated 
translations of the questionnaires in Asian languages (Japanese, Chinese, Korean etc) 
states and US territories were analyzed. Patients with at least one record of a shipped 
crizotinib prescription between 8/30/2011 and 8/1/2014 were eligible. Persistence − 
the duration of time from initiation to discontinuation of therapy − was defined as the 
total number of days between the first and last prescription shipment dates plus the 
days’ supply of the last prescription. Adherence − the extent to which a patient acts in 
accordance with the prescribed regimen − was evaluated using a medication possession 
ratio (MPR): the ratio of the total days’ supply over the entire duration of therapy for 
patients with at least two crizotinib prescriptions. A grace period of 60 days between 
prescriptions was allowed. Sensitivity analyses of persistence and adherence were 
performed assuming grace periods between prescriptions of 30 and 90 days. Results: A 
total of 3845 crizotinib patients were identified and included in the analysis. Most were 
commercially insured (69%), <65 years of age (61%), and female (56%). The cohort was 
well balanced geographically. Most prescriptions (89%) were for doses of 250 mg BID. 
Average duration of therapy was 11.4 months (95% CI: 11.2−11.6), with a median of 7.5 
months. 51% and 34% of patients remained on therapy at 6 and 12 months, respectively. 
16% of patients remained on crizotinib >24 months (Figure 1)
.  
 
An average MPR of 95% was observed in the sub-cohort of 3072 patients with two or 
more prescriptions of crizotinib. Sensitivity analyses revealed that persistence (11.2−11.6 
months) and adherence (93−96%) estimates were not impacted by the alternative grace-
period definitions applied. Conclusion: In the real-world setting, the duration of crizotinib 
therapy was similar to that reported in clinical trials. Adherence to crizotinib was high 
and may be indicative of its acceptable tolerability. Further research is warranted to 
evaluate experiences associated with crizotinib using other real-world data sources. 
Keywords: crizotinib, Real-world, treatment duration, pharmacy data
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MINI31.09 Association of Crizotinib Toxicity with Pharmacokinetics and 
Pharmacogenomics in Non-Small Cell Lung Cancer Harboring ALK Fusion Gene 
Yuichi Tambo1, Kazuhiko Yamada2, Shigeki Umemura3, Sho Saeki4, Yukiko Nakamura5, 
Takehito Shukuya6, Yoshiko Urata7, Yusuke Okuma8, Tomoya Fukui9, Yoshihito Kogure10, 
Haruko Daga11, Yoshinori Hasegawa12, Yukari Tsubata13, Tatsuya Yoshida14, Satoshi 
Oizumi15, Yosuke Tamura16, Hidenori Mizugaki15, Yutaka Fujiwara17, Akinobu Hamada18, 
Yuichiro Ohe17 1Thoracic Oncology Center, Cancer Institute Hospital, Tokyo/Japan, 2Division 
of Respirology, Department of Internal Medicine, Kurume University School of Medicine, 
Kurume/Japan, 3Division of Thoracic Oncology, National Cancer Center Hospital East, 
Kashiwa/Japan, 4Respiratory Medicine, Kumamoto University, Kumamoto/Japan, 5Respiratory 
Medicine, Yokohama Municipal Citizen’s Hospital, Yokohama/Japan, 6Respiratory Medicine, 
Juntendo University, Tokyo/Japan, 7Thoracic Oncology, Hyogo Cancer Center, Akashi/
Japan, 8Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitian Cancer and 
Infectious Diseases Center Komagome Hospital, Tokyo/Japan, 9Respiratory Medicine, 
Kitasato University School of Medicine, Sagamihara/Japan, 10Respiratory Medicine, Nagoya 
Medical Center, Nagoya/Japan, 11Medical Oncology, Osaka City General Hosp, Osaka/
Japan, 12Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya/
Japan, 13Medical Oncology, Shimane University School of Medicine, Izumo/Japan, 14Thoracic 
Oncology, Aichi Cancer Center Hospital, Nagoya/Japan, 151St Dept of Medicine, Hokkaido 
University School of Medicine, Sapporo/Japan, 16Division of Internal Medicine, Osaka Medical 
College Hospital, Takatsuki/Japan, 17Thoracic Oncology, National Cancer Center Hospital, 
Tokyo/Japan, 18Department of Clinical Pharmacology, Center for Translational Research 
Core, National Cancer Center Hospital, Tokyo/Japan
Background: Crizotinib, a standard care for advanced ALK-positive NSCLC, is a substrate 
for ABCB1-encoded P-glycoprotein, and is primarily metabolized by CYP3A4/5. The 
most common adverse events (AEs) are visual disorder, gastrointestinal disorders, and 
elevated transaminase levels. Serious AEs such as grade (Gr) ≥ 3 elevated transaminase 
levels and interstitial lung disease (ILD) occasionally develop. Methods: ALK-positive 
NSCLC patients were enrolled in cohort A (enrollment before starting crizotinib therapy) 
or cohort B (enrollment during crizotinib therapy). Trough concentrations of crizotinib at 
steady state were measured using LC/MS/MS and ABCB1 polymorphisms were analyzed. 
We evaluated clinically significant AEs, defined as Gr 4 hematological toxicity, Gr ≥ 3 non-
hematological toxicity, or any ILD. AEs during 8 weeks were also evaluated prospectively 
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Conclusion: In patients with ALKi-pretreated ALK+ NSCLC who received 
prior chemotherapy and ceritinib, clinical effi cacy was demonstrated and 
cancer symptoms were mostly improved, with health-related quality of life 
generally maintained regardless of presence or absence of baseline BrM. 
Keywords: ALK Inhibitor, brain metastases, Patient-reported outcomes, Ceritinib
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MINI31.14 PROs with Ceritinib in ALKi-Naive ALK+ NSCLC Patients with and 
without Brain Metastases Keunchil Park1, Enriqueta Felip2, Sergey Orlov3, Chong-Jen 
Yu4, Chun-Ming Tsai5, Makoto Nishio6, Manuel Cobo Dols7, Mark Mckeage8, Wu-Chou 
Su9, Tony Mok10, Giorgio V.V. Scagliotti11, David R. Spigel12, Jie Zhang13, Fabrice Branle14, 
Chetachi Emeremni14, Santosh Sutradhar13, Massimiliano Quadrigli14, Alice Shaw15
1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/
Korea, 2Vall D’Hebron University Hospital, Barcelona/Spain, 3Dept of Thoracic Oncology, 
St. Petersburg State Medical University, St. Petersburg/Russian Federation, 4National 
Taiwan University, Taipei/Taiwan, 5Taipei Veterans General Hospital, Taipei/Taiwan, 6Cancer 
Institute Hospital, Japanese Foundation for Cancer Research, Tokyo/Japan, 7Medical 
Oncology Section, Hospital Regional Universitario Carlos Haya, Málaga/Spain, 8Auckland 
City Hospital and University of Auckland, Auckland/New Zealand, 9National Cheng Kung 
University Hospital, Tainan/Taiwan, 10The Chinese University of Hong Kong, Hong Kong/
China, 11University of Torino, Torino/Italy, 12Sarah Cannon Research Institute/Tennessee 
Oncology, PLLC, Nashville/TN/United States of America, 13Novartis Pharmaceuticals 
Corporation, East Hanover/NJ/United States of America, 14Novartis Pharma AG, Basel/
Switzerland, 15Massachusetts General Hospital, Boston/MA/United States of America
Background: In the pivotal ASCEND-1 study, ceritinib, an anaplastic lymphoma kinase 
inhibitor (ALKi), demonstrated sustained clinical activity in ALKi-naive patients with ALK-
rearranged (ALK+) non-small cell lung cancer (NSCLC), including in patients with brain 
metastases (BrM). ASCEND-3 (NCT01685138) evaluated patient-reported outcomes 
(PROs) as well as clinical outcomes with ceritinib, in ALKi-naive ALK+ NSCLC patients 
with and without baseline BrM. Methods: Adult patients with ALK+ NSCLC previously 
treated with up to 3 lines of cytotoxic therapy received oral ceritinib 750 mg daily. PROs 
were assessed using Lung Cancer Symptom Scale (LCSS) and EORTC (QLQ-C30, QLQ-
LC13) quality of life and lung cancer surveys at baseline and Day 1 of treatment cycles 2, 
3, and every two cycles thereafter (1 cycle=28 days). Data were analyzed by presence/
absence of baseline BrM. Data beyond cycle 9 are not reported due to small sample 
sizes. Results: Of 124 enrolled patients (median age [range] 56 [27–82] years; 40.3% 
male), 50 (40.3%) had BrM at baseline. At data cutoff (27 June 2014), median follow-up 
was 8.3 months. Up to cycle 9, PRO questionnaire compliance was at least 97.0%. In the 
overall patient population, investigator-assessed disease control rate (DCR) was 89.5% 
and median duration of response (DOR) 9.3 months. Investigator-assessed whole-body 
DCR [95% confi dence interval (CI)] in patients with and without baseline BrM was 86.0% 
[73.3, 94.2] and 91.9% [83.2, 97.0], respectively, while DOR [95% CI] was 9.1 [7.5, Not 
Estimable] and 10.8 [9.3, 10.8] months, respectively. Mean change from baseline in 
patients’ total LCSS score ranged from -3.4 to -11.4 while receiving ceritinib, with 82.1% 
of patients experiencing symptom improvement; symptoms improved in patients with 
and without baseline BrM (Figure). QLQ-LC13 outcomes were broadly consistent with 
those of LCSS in the full patient population and in the subgroups of patients with and 
without baseline BrM. In general, mean global quality of life (QLQ-C30) was maintained on 
treatment for all patients. Patients reported diarrhea and nausea and vomiting symptoms 
were worse than baseline, however, nausea and vomiting symptoms did reduce over 
time.
were made available. Higher scores (range 0−100) indicated higher symptom severity or 
better functioning/QOL. A positive change from baseline score indicates improvement 
for global QOL/functioning and deterioration in symptoms. Repeated measures mixed-
effects analyses were performed to compare change from baseline scores between 
the treatment arms, with no adjustments made for multiple comparisons. Results: Of 
343 patients randomized, 46% were of Asian ethnicity (crizotinib, n=77; chemotherapy, 
n=80). Completion rates at baseline were ≥95% in each group and scores were balanced. 
A statistically signifi cantly greater overall improvement from baseline was observed 
with crizotinib compared with chemotherapy for global QOL (5.6 vs -7.7; p<0.001), 
emotional functioning (9.5 vs 2.7;p<0.05), physical functioning (5.0 vs - 2.7 p<0.001) 
and role functioning (3.7 vs. -7.2;p<0.001). A statistically signifi cantly greater overall 
improvement was observed with crizotinib compared with chemotherapy for cough (-17.3 
vs. -11.2; p<0.05), dyspnea (-9.5 vs.-1.1; p<0.001), pain in arm or shoulder (-11.4 vs.-2.2; 
p<0.001), pain in chest (-7.3 vs.3.3; p<0.001), pain in other parts (-11.2 vs. -0.4;p<0.001), 
fatigue (-9.9 vs. 3.9; p<0.001), insomnia (-10.3vs. -2.0; p<0.05), pain (-12.2 vs.-1.2; 
p<0.001) and appetite loss (-5.3 vs. 5.7; p<0.001). A statistically signifi cantly greater 
overall deterioration was observed in the crizotinib arm for diarrhea (12.6 vs. 2.4; 
p<0.001) compared with chemotherapy. No statistically signifi cant differences were 
observed for social functioning, sore mouth, dysphagia, nausea & vomiting, constipation 
and alopecia between crizotinib and chemotherapy.Conclusion: Consistent with 
previously reported results in the overall study population, treatment with crizotinib 
showed statistically signifi cantly greater overall improvement in patient-reported lung 
cancer symptoms and global QOL compared with chemotherapy in the subgroup of 
patients of Asian ethnicity with previously untreated advanced ALK-positive NSCLC. 
Keywords: crizotinib, patient-reported, symptoms, quality of life
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MINI31.13 Symptoms and QOL with Ceritinib in ALK+ NSCLC Patients with/
without Brain Metastases Lucio Crinò1, Myung-Ju Ahn2, Filippo De Marinis3, H. J. M. 
Groen4, Heather A. Wakelee5, Toyoaki Hida6, Tony Mok7, Alice Shaw8, Enriqueta Felip9, 
Makoto Nishio10, Giorgio V. V. Scagliotti11, Fabrice Branle12, Chetachi Emeremni13, 
Santosh Sutradhar14, Massimiliano Quadrigli12, Jie Zhang14, David Spigel15 1Perugia 
Hospital, Perugia/Italy, 2Samsung Medical Center Sungkyunkwan University School of 
Medicine, Seoul/Korea, 3Thoracic Oncology Division, European Institute of Oncology, 
Milan/Italy, 4University of Groningen and University Medical Center Groningen, Groningen/
Netherlands, 5Department of Medicine, Division of Oncology, Stanford University, Stanford/
CA/United States of America, 6Dept of Thoracic Oncology, Aichi Cancer Center, Nagoya/
Japan, 7The Chinese University of Hong Kong, Shatin/China, 8Massachusetts General 
Hospital, Boston/MA/United States of America, 9Vall D’Hebron University Hospital, 
Barcelona/Spain, 10Japanese Foundation for Cancer Research, Tokyo/Japan, 11University 
of Torino, Torino/Italy, 12Novartis Pharma AG, Basel/Switzerland, 13Novartis Pharma AG, 
East Hanover/NJ/United States of America, 14Novartis Pharmaceuticals Corporation, East 
Hanover/NJ/United States of America, 15Sarah Cannon Research Institute/Tennessee 
Oncology, Nashville/TN/United States of America
Background: In the pivotal ASCEND-1 study, ceritinib, an anaplastic lymphoma kinase 
inhibitor (ALKi), showed clinical activity in patients with ALK-rearranged (ALK+) non-
small cell lung cancer (NSCLC), including in patients with brain metastases (BrM). 
Here, patient-reported outcomes (PROs) from the recently reported ASCEND-2 study 
(NCT01685060) are described for chemotherapy- and ALKi-pretreated patients with 
ALK+ NSCLC with and without baseline BrM. Methods: In ASCEND-2, adult patients with 
ALK+ NSCLC previously treated with chemotherapy and an ALKi (crizotinib) received oral 
ceritinib 750 mg daily. PROs were assessed at baseline and Day 1 of treatment cycles 2, 
3, and every two cycles thereafter (1 cycle=28 days), using the Lung Cancer Symptom 
Scale (LCSS) and EORTC quality of life and lung cancer surveys (QLQ-C30 and QLQ-LC13, 
respectively). Data were analyzed by presence/absence of baseline BrM. Data beyond 
cycle 9 are not reported due to small sample sizes. Results: All 140 patients enrolled 
(median age [range] 51 [29–80] years; 50.0% male), had received ≥2 antineoplastic 
regimens and 100 (71.4%) had BrM at baseline. At data cutoff (13 August 2014), median 
follow-up was 11.3 months. PRO questionnaire compliance was at least 91.2% up to cycle 
9. In the overall patient population, investigator-assessed disease control rate (DCR)
was 77.1% and median duration of response (DOR) 9.7 months. Investigator-assessed
whole-body DCR [95% confi dence interval (CI)] in patients with and without baseline
BrM was 74.0% [64.3, 82.3] and 85.0% [70.2, 94.3], respectively, while DOR [95% CI]
was 9.2 [5.5, 11.1] and 10.3 [7.4, 16.6] months, respectively. Analysis of PROs data
demonstrated that treatment with ceritinib improved lung cancer symptoms in patients
with and without baseline BrM (Figure). QLQ-LC13 outcomes were broadly consistent
with those of LCSS. In general, mean global quality of life (QLQ-C30) was maintained on
treatment for both patient subgroups, with mean change from baseline in QLQ-C30 global
health status ranging from -3.06 to +7.25 in patients without baseline BrM and -2.83 to
+3.55 in those with baseline BrM.
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Inc., New York/NY/United States of America
Background: Lung cancer has been the leading cause of cancer related mortality for 
the past decades worldwide and in China. Non-small cell lung cancer (NSCLC) accounts 
for the majority of lung cancer cases. For patients with early stage NSCLC, surgical 
resection is the mainstay of the treatment. This study aimed to better understand 
characteristics of NSCLC patients who underwent curative-intent lung surgical resections 
in China. Methods: Data were obtained from the NSCLC surgical outcome registry, 
which included 3,464 NSCLC patients who underwent curative-intent surgical resections 
from 13 tertiary hospitals in 11 provinces in 2013 and 2014. The registry documented 
detailed information on demographics as well as perioperative parameters. Results: The 
median age at the time of surgery was 60 (range 14 to 92) years, and 64.0% of the 
patients were male. Approximately 49.1% had a smoking history and 12.6% had a family 
history of cancer. About 45.7% patients had at least one comorbidity. The most prevalent 
comorbidities were cardiovascular disease, metabolic disease, respiratory disease, and 
other tumor, which affected 45.2%, 15.5%, 13.3% and 9.7% of the patients, respectively. 
The pulmonary function test showed a mean FEV1 of 2.33 (SD=0.63, range 0.32 to 4.81) 
L and FEV1/FVC of 79.3% (SD=12.6%, range 0.5% to 100.0%). The types of resection 
were lobectomies (lobectomies, bi-lobectomies and sleeve lobectomies) 79.3%, sublobar 
resections (segmentectomies and wedge resection) 8.5%, pneumonectomies 7.0%, and 
others 4.3%. 44.5% resections were performed by video-assisted thoracoscopic surgery 
(VATS). Adenocarcinoma and squamous cell carcinoma were the most common types of 
NSCLC, accounting for 60.2% and 31.4% of the patients, respectively. The most common 
tumor locations were right upper lobe (26.9%), left upper lobe (22.8%), right lower lobe 
(19.4%), left lower lobe (16.5%), and right middle lobe (6.5%). Pathologic staging showed 
48.5% patients had stage I tumor; stage II, III, and IV accounted for 23.0%, 25.3% and 
3.3%. Conclusion: The NSCLC patients who underwent curative-intent lung resection 
surgeries in China were relatively young and had good lung function. Adenocarcinoma and 
squamous cell carcinoma were the most common types. Nearly half of the procedures 
were performed by VATS and almost one out of two patients had pathologic stage I disease. 
Keywords: NSCLC registry, Patient characteristics, Surgical resection
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MINI32.03 Accuracy of Respiratory Dynamic Computed Tomography for the 
Detection of Pleural Adhesions Junko Tokuno, Tsuyoshi Shoji, Ryota Sumitomo, Keiji 
Yamanashi, Cheng-Long Huang Kitano Hospital, Osaka/Japan
Background: Video-assisted thoracic surgery (VATS) plays an important role in thoracic 
surgery especially for early stage lung cancer because it is less invasive. However, 
the existence of severe pleural adhesions may make VATS diffi cult and complicated. 
So, preoperative detection of pleural adhesions can be very useful for the assessment 
of surgical approach. The aim of this study was to assess the accuracy of inspiration 
and expiration computed tomography (respiratory dynamic CT: RD-CT) in evaluation of 
pleural adhesions prior to thoracic surgery. Video-assisted thoracic surgery (VATS) plays 
an important role in thoracic surgery especially for early stage lung cancer because it 
is less invasive. However, the existence of severe pleural adhesions may make VATS 
diffi cult and complicated. So, preoperative detection of pleural adhesions can be very 
useful for the assessment of surgical approach. The aim of this study was to assess 
the accuracy of inspiration and expiration computed tomography (respiratory dynamic 
CT: RD-CT) in evaluation of pleural adhesions prior to thoracic surgery. Methods: From 
January to December 2014, RD-CT was performed on 107 patients undergoing 
thoracotomies (both VATS and open surgery, except for pneumothorax). We assessed 
synchronous motion during respiration on RD-CT using a three-dimensional CT image 
software, as Sliding Score. Regarding intraoperative fi ndings, we categorized the 
severity of pleural adhesions into 4 groups as Adhesion Grade. Then, comparing 
Sliding Score and Adhesion Grade, we assessed the utility of preoperative evaluation. 
In addition, to confi rm these patients could expire enough in expiration phase, we 
assumed lung volume in expiration phase/ inspiration phase as CT- Respiratory Ratio 
in each case. Results: Operations were performed mainly for lung cancer (78 cases; 
72.9%), others are metastatic lung tumor, mediastinal tumor, lung abcess and so 
on. A negative correlation between Sliding Score and Adhesion Grade was revealed. 
Sliding Score in adhesion positive patients was signifi cantly higher than that in adhesion 
negative patients (P < 0.0001). The sensitivity of RD-CT was 63.6%, specifi city was 
74.1%, and accuracy was 72%. Among 62 patients with a CT-Respiration Ratio of less 
than 0.65, the sensitivity of RD-CT was 77.8%, specifi city was 86.8%, and accuracy was 
85.5%. Regarding severe adhesions, RD-CT demonstrated a sensitivity of 100% in all 
107 patients. No signifi cant correlation was revealed between CT- Respiratory Ratio and 
respiratory function or Adhesion Grade. Conclusion: RD-CT may be useful for detecting 
the presence of pleural adhesions, especially to rule out the severest adhesions. It can 
be adopted as one of the criteria for deciding the surgical approach, VATS or open 
surgery. And it may enable an operation to be performed more safely and systematically. 
Keywords: Surgical treatment, preoperative evaluation, pleural adhesions, VATS (video-
assisted thoracic surgery)
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MINI32.04 Clinico-Pathological Correlations and the Role of Brain MRI in 
Combined Clinical Staging for Resectable Lung Cancer Jordyn Vernon, Nicole 
Andruszkiewicz, Laura Schneider, Colin Schieman, Christian J. Finley, Yaron Shargall, 
Christine Fahim, Forough Farrokhyar, Wael C. Hanna Surgery, McMaster University, 
Hamilton/ON/Canada
Conclusion: In ALKi-naive patients with ALK+ NSCLC, treatment with ceritinib 
demonstrated clinical effi cacy and improved cancer symptoms, with health-related 
quality of life generally maintained regardless of baseline BrM status. Improvements 
were greatest for the lung-related symptoms, cough and pain. 
Keywords: ALK Inhibitor, brain metastases, Ceritinib, Patient-reported outcomes
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MINI32.01 Computed Tomography Lymphography by Transbronchial Injection 
of Iopamidol for Preoperative Non-Small Cell Lung Cancer Patients Hiromitsu 
Takizawa1, Kazuya Kondo2, Mitsuhiro Tsuboi1, Koichiro Kajiura1, Tamaki Otani2, Hiroaki 
Toba1, Yukikiyo Kawakami1, Shoji Sakiyama1, Akira Tangoku1 1Department of Thoracic, 
Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University 
Graduate School, Tokushima City/Japan, 2Department of Oncological Medical Services, 
Tokushima University, Tokushima/Japan
Background: Sentinel node (SN) is defi ned as the fi rst node draining a tumor, and should be 
the fi rst site affected in lymphatic dissemination. Recently, with the increased incidence of 
small sized non-small cell lung cancer (NSCLC), segmentectomy is again under evaluation 
for clinical T1a N0 NSCLC patients. In the ongoing trial regarding segmentectomy 
(JCOG0802), the eligibility criteria for segmentectomy include a prerequisite of no lymph 
node metastasis by intraoperative fi ndings because node-positive cases have a chance 
to be locoregionaly controlled and to be correctly staged by converting to lobectomy. 
Therefore, intraoperative sampling and frozen sectioning of true SNs is important in 
ensuring the radicality of segmentectomy. The objective of this study was to assess the 
safety and the feasibility of computed tomography (CT) lymphography by transbronchial 
injection of a water-soluble extracellular CT contrast agent which was developed as a 
new method for identifying SNs in patient with NSCLC. Methods: Between April, 2010 
and January, 2015, clinical stage I NSCLC patients who were candidates for lobectomy 
or segmentectomy were enrolled in this study. An ultrathin bronchoscope was inserted to 
the target bronchus under the guidance of virtual bronchoscopic navigation images. CT 
images of the chest were obtained 30 seconds after 2 or 3ml of iopamidol was injected 
through a microcatheter. SNs were identifi ed when the maximum CT attenuation value 
of the lymph nodes in postcontrast CT images increased by 30 Hounsfi eld units or more 
compared to precontrast images. Patients underwent video-assisted thoracic surgery 
lobectomy with standard lymph node dissection. SNs were harvested according to 
fi ndings of CTLG and to intraoperative fi ndings of near-infrared fl uorescence imaging with 
indocyanine green. All lymph nodes, including SNs, were histopathologically examined 
by standard hematoxylin and eosin staining. Results: The ultrathin bronchoscope could 
access targeted bronchus, and iopamidol was delivered into the peritumoral area in all 
41 patients without any complications. SNs were identifi ed in 38 of 41 patients (92.7%), 
and the average number of SNs was 1.4 (range: 1-4). Lymph node metastases were 
found in 6 cases, including one false-negative case. Enlargement of lymphatic vessel 
was seen in 3 out of 6 (50%) cases with lymph node metastases, whereas it was seen in 
6 out of 35 cases (17%) without lymph node metastases. Conclusion: CT lymphography 
by transbronchial injection of iopamidol was a safe and feasible method to identify 
SNs in clinical stage I NSCLC patients. Lymphatic remodeling including peritumoral 
lymphangiogenesis and enlargement of lymphatic vessel has been reported to one of 
the crucial step of lymph node metastasis of cancer. Enlargement of lymphatic vessel 
seen in CT lymphography may be a risk factor for lymph node metastasis of NSCLC. 
Keywords: sentinel node, CT lymphography, NSCLC
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MINI32.02 Characteristics of Non-Small Cell Lung Cancer (NSCLC) Patients 
Who Underwent Curative-Intent Surgical Resections in China Jian Zhou1, Simeng 
Han2, Fan Yang1, Eric Q. Wu3, Jipan Xie4, Xun Wang1, Xiaoyu Wang2, Hao Li1, Jun Wang1
1Thoracic Surgery, Peking University People’s Hospital, Beijing/China, 2Analysis Group, Inc., 
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was quantified by calculating maximum standard uptake values (SUVmax) and tumor 
muscle ratios (TMR). Results: The uptake of 18F-FAZA were in positive proportion to that 
of 62Cu-ATSM (P < 0.05). Neutrophil lymphocyte ratio and tumor size were significantly 
correlated with uptake both in 18F-FAZA (P < 0.01) and 62Cu-ATSM (P < 0.05 in 18F-FAZA 
and 62Cu-ATSM). Pathologically, the case with vascular or pleural invasion, which indicate 
tumor malignancy, had higher uptake of 18F-FAZA (P < 0.05). Those accumulations 
increased according to advanced TNM staging (P < 0.05). The patient with higher uptake 
of these tracers significantly had a poorer overall survival (P < 0.01 in 18F-FAZA and P < 
0.05 in 62Cu-ATSM), and progression-free survival (P < 0.01 in 18F-FAZA and P < 0.05 
in 62Cu-ATSM). Conclusion: 18F-FAZA and 62Cu-ATSM can provide useful information on 
tumor malignancy and prognosis, and might contribute toward guiding individualization 
of treatment of localized NSCLC.
Keywords: 18F- FAZA, 62Cu- ATSM, PET imaging, resected NSCLC
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MINI32.07 A Phase I Feasibility Study of Kilovoltage Intrafraction Monitoring 
for Lung Cancer Fiona Hegi-Johnson1, Jeff Barber2, Katrina West2, Val Gebski3, 
Shamira Cross2, Sean White2, Roland Yegiaian-Alvandi4, Paull Keall5 1The University of 
Newcastle, Newcastle/NSW/Australia, 2Nepean Cancer Care Centre, Sydney/NSW/Australia,  
3NHMRC Clinical Trials Centre, University of Sydney, Sydney/NSW/Australia, 4Crown Princess 
Mary Cancer Care Centre, Sydney/NSW/Australia, 5Radiation Physics Laboratory, University 
of Sydney, Sydney/NSW/Australia
Background: In our model of Combined Clinical Staging (CCS) for lung cancer, patients 
with a Computerized Tomography (CT) scan of the chest that does not show distant 
metastases will then routinely undergo whole body Positron Emission Tomography 
(PET/CT) and Magnetic Resonance Imaging (MRI) of the brain prior to any therapeutic 
decision. We aim to determine the accuracy of CCS and the value of brain MRI in 
this population. Methods: A prospective database was queried for all patients who 
underwent resection of lung cancer from 01/2012 to 06/2014. Demographics, wait 
times, clinical and pathological stage (7th edition AJCC/UICC), and costs of staging 
were collected. Krippendorff’s alpha was used to determine correlation between clinical 
and pathological stage. Results: Of 315 patients with primary lung cancer, 55.6% were 
female and the median age was 70 (27-87, Table 1). The mean time from initial CT scan 
to surgical treatment was 9.12 +/- 6.0 weeks. Krippendorff’s alpha between CCS and 
pathological stage was 0.193 (0.125 to 0.260, Table 2). When correlation was analyzed 
without consideration for sub-stages A and B, 49.8% (157/315) of patients were staged 
accurately, 39.7% (125/315) were over-staged, and 10.5% (33/315) were under-staged. 
Only 4.7% (15/315) of patients underwent surgery without appropriate neo-adjuvant 
systemic treatment. Preoperative brain MRI detected asymptomatic metastases in 
4/315 patients (1.3%). At a median postoperative follow-up of 16 months (1-40), 7 
additional patients developed symptomatic brain metastases, all of which had normal 
brain MRI preoperatively. The total cost of CCS was $416,924 over the study period, with 
$131,824 (31.6%) going towards brain MRI.
Table 1: Baseline descriptive data, N=315
Age Mean (SD) 69.80 (9.62) (Min: 27.34, Max: 86.61)
Gender
Female (%) 175 (55.6%)
Male (%) 140 (44.4%)
Weeks First Visit to Consent Mean (SD) 5.49 (8.15) (Min: 0, Max: 63)
Weeks Consent to Surgery Mean (SD) 2.24 (2.07) (Min: 0, Max: 11)
Weeks Initial CT to Surgery Mean (SD) 9.12 (6.01) (Min: 0, Max: 53)
Weeks First Visit to Surgery Mean (SD) 8.00 (8.25) (Min: 0, Max: 64)
Brain Metastases at Baseline (%) 4 (1.3%)
Brain Metastases at Follow Up (%) 11 (3.5%)







Same Staging by Both (True 
Positives)
0 1 (0.3%) - -
Stage IA 89 (28.3%) 103 (32.7%) 55
Stage IB 39 (12.4%) 82 (26.0) 19
Stage IIA 42 (13.3%) 47 (14.9%) 7
Stage IIB 32 (10.2%) 42 (13.3%) 12
Stage IIIA 78 (24.8%) 39 (12.4%) 16
Stage IIIB 21 (6.7%) 0 (0.0%) 0
Stage IV 13 (4.1%) 2 (0.6%) 2
Krippendorff’s Alpha for level of agreement = 0.193 (0.125 to .260)
Conclusion: CCS is effective for patients with resectable lung cancer, with less 
than 5% of patients being under-staged in a way that denied them appropriate 
systemic treatment before surgery. Brain MRI is a low yield and high cost 
intervention in this population, and its routine use should be questioned. 
Keywords: MRI Brain, lung cancer, Staging
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MINI32.06 Clinical Impacts of Tumor Hypoxia Imaging with FAZA and ATSM 
PET in NSCLC Tomonari Kinoshita1, Hirofumi Fujii2, Masaki Anraku3, Yuichiro 
Hayashi4, Hisao Asamura1 1General Thoracic Surgery, Keio University School of Medicine, 
Tokyo/Japan, 2Functional Imaging Division, National Cancer Center Hospital East, Chiba/
Japan, 3General Thoracic Surgery, Tokyo University, Tokyo/Japan, 4Pathology, Keio University 
School of Medicine, Tokyo/Japan
Background: The noninvasive dynamic characterization of hypoxia using molecular 
imaging approaches is supportive for evaluation of malignant tumor. In this study, 
we evaluated the clinicopathological impact of newly developed tumor hypoxia 
PET tests for localized non-small cell lung cancer (NSCLC). Methods: Forty-nine 
patients with localized NSCLC were enrolled[F1] [木下智成2] . They underwent chest 
hypoxia PET tests, namely 18F-fluoroazomycin arabinoside (FAZA) and/or 62Cu-
diacetyl-bis (N4) -methylsemithiocarbazone (ATSM) PET in addition to routine whole-
body 18F-fluorodeoxyglucose (FDG) PET before treatment. Uptake of hypoxic tracers 
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most likely to benefit from metformin therapy, and furthermore, identifies mechanistic 
avenues by which metformin treatment may benefit early stage lung cancer patients. 
Keywords: metagene, metformin, early stage, recurrence
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MINI32.09 The Combination of Serum Biomarkers CYFRA 21-1 and CEA in the 
Prognostication of Early Stage Non-Small Cell Lung Cancer (NSCLC) Thomas 
Muley1, Ying He2, Vincent Rolny2, Julia Riedlinger2, Birgit Wehnl2, Farshid Dayyani3, 
Marc A. Schneider1, Christa Stolp1, Hendrik Dienemann4, Michael Meister1, Felix Herth5 
1Translational Research Unit, Thoraxklinik at University of Heidelberg and Translational 
Lung Research Center (TLRC), Heidelberg/Germany, 2Roche Diagnostics GmbH, Penzberg/
Germany, 3Roche Diagnostics International Ltd, Rotkreuz/Switzerland, 4Department 
of Thoracic Surgery, Thoraxklinik at University of Heidelberg and TLRC, Heidelberg/
Germany, 5Department of Pneumology and Critical Care Medicine, Thoraxklinik at University 
of Heidelberg and TLRC, Heidelberg/Germany
Background: Serum based biomarkers are routinely used for prognosis and monitoring 
of some solid tumors (e.g. colorectal, pancreatic, and ovarian carcinomas) but have 
not yet been widely adopted in NSCLC management. We prospectively evaluated the 
prognostic role of serum biomarkers in the management of early stage NSCLC treated 
at a single specialized center. Methods: Prospective collection of blood samples from 
patients (pts) with resectable NSCLC was done before surgery and thereafter during 
routine follow up visits. A panel of serum biomarkers was measured, including CYFRA 
21-1 (Cytokeratin fragment 19) and CEA (carcinoembryonic antigen). Several risk models 
were established and prediction accuracy was assessed by C-Index (generalized AUC), 
Hazard Ratio (HR) at median split and Net Reclassification Index (NRI). Results: 275 pts 
were enrolled (n= 180 men). Histology was adenocarcinoma (AC) in 133 pts (48.4%), 
squamous cell carcinoma in 103 pts (37.5%), and other in 39 (14.1%). Stages were based 
on IASLC 6th edition and included IA (n= 39), IB (n= 120), IIA (n= 7), IIB (n= 66), and IIIA 
(n= 43). 92 pts (33.5%) recurred after a median of 11.9 months follow-up. Occurrence 
of first relapse showed two main peaks, at 6-12 months and 21-27 months, respectively, 
indicating a high-risk group for early relapse. In multivariate analyses, clinical prognostic 
factors included: TNM stage, age, gender, histology, and smoking history. Addition of 
the baseline CYFRA 21-1 and CEA biomarkers significantly increased the number of pts 
allocated to the correct prognostic group in the model by 13.2% compared to clinical 
variables only (HR for first relapse from 2.14 to 3.02; NRI 0.132). Conclusion: In this 
largest cohort of NSCLC pts with prospective serum biomarker sample collection 
to date, time to first relapse in localized NSCLC showed subgroups of early and late 
relapse pts. Baseline levels of the CYFRA 21-1 and CEA biomarkers identified a higher 
number of pts who were likely to recur within the first year and might benefit from closer 
surveillance. The CYFRA 21-1 assay is currently not cleared or approved for use in the USA. 
Keywords: CEA, recurrence prediction, NSCLC, CYFRA 21-1
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MINI32.11 10 Years of National Lung Cancer Audit in the UK Michael D. Peake, 
Paul Beckett, Ian Woolhouse Clinical Effectiveness and Evaluation Unit, Royal College of 
Physicians of London, London/United Kingdom
Background: The UK National Lung Cancer Audit has been collecting, analysing and 
reporting data on the management of lung cancer patients for 10 years. This abstract 
summarises the progress made in this period. Methods: Hospitals working within the 
UK National Health Service are invited to submit data to a web portal on all incident 
cases of lung cancer (and mesothelioma). The dataset covers demographics, referral, 
investigation, diagnosis, treatment and outcome. Results: Clinical and organisational 
engagement in the audit increased rapidly over the first 5 years such that currently 
all hospitals submit data on 100% of the expected incident cases, with 93% of cases 
having stage and performance status recorded. Measures of good practice have shown 
incremental improvements (e.g. histological confimation rate 68% to 75%, proportion 
with subtyped NSCLC 64% to 87%, proportion of patients seen by a specilaist nurse 51% 
to 84%, proportion receiving anti-cancer treatment 45% to 60%. The surgical resection 
rate in histologically-confirmed NSCLC has risen from 14% to 23% in keeping with other 
data sources, reinforcing the suggestion that these improvements reflect real changes 
in practice rather than just better data. Survival has improved in patients with early stage 
disease and good PS as previously published utilising the audit data (Khakwani et al 
2013). Moreover, overall survival in the whole cohort appears to be improving when 
clinical features (age, sex, stage PS) are taken into acocunt as shown in Table 1.








Despite these overall improvements in process and outcome, there remains a variatin in 
ractice across organisations that perists after adjustment for case-mix (example Figure 1)
Background: New technologies in radiotherapy of lung tumours aim to reduce toxicity 
and increase tumour control by increasing the dose delivered, and reducing the size of 
radiotherapy margins. Kilovoltage intrafraction monitoring (KIM) is a novel image guidance 
technology, which permits visualisation of fiducials implanted into the tumour whilst the 
radiotherapy beam is on. KIM has been used in both prostate1 and liver tumours2, and has 
been shown to increase the accuracy of radiotherapy delivery. In this Phase I study we 
aim to establish whether it is feasible to use KIM to monitor the motion of lung tumours 
during radiotherapy delivery. 1. Ng J et al. IJROBP 2012:84(5):e656 2.Poulsen P et al. 
Radiotherapy and Oncology 2014:111(3):424. Methods: Patients receiving curative 
radiotherapy for lung cancer will have between 3-5 fiducials inserted into their tumour 
during endobronchial ultrasound (EBUS). Radiotherapy will be planned and delivered as 
per standard departmental protocols for lung cancer patients. 4D-cone beam CT (CBCT) 
will be performed , in conjunction with acquisition of KIM images and respiratory motion 
signal acquisition on the 1st, 6th, 11th, 16th, 21st, 26th, and 30th fractions before 
treatment to assess the accuracy of patient and tumour position. Results: Initial studies 
in a respiratory motion phantom have indicated that 0.4mm diameter Gold Anchor 
fiducials are visible during radiotherapy treatment. Ethical approval has been obtained 
with patient recruitment to the study to commence shortly. The primary endpoint of 
this study is the successful visualisation by the KIM technique of fiducials inserted into 
the tumour. Each patient will have a minimum of 3 fiducials (markers) inserted. As the 
implanted fiducials may be migrated or lost, the definition of technical success will vary 
according to the number of fiducials present.
• In the case of 1 to 3 markers being present, segmentation of at least 1 marker will
be required for the image acquisition to be deemed successful.
• In the case of 4 or more fiducials being present, segmentation by the KIM technique
of at least 2 markers for each image will be required for the image acquisition to be 
deemed successful.
Secondary endpoints include assessment of the stability of implanted markers, and 
the rate of marker migration, quantitative assessment of tumour motion, assessing the 
impact of tumour motion on dosimetry and an assessment of toxicity associated with 
marker insertion. Conclusion: Lung tumours move during radiotherapy treatment, both 
between radiotherapy fractions and whilst the radiotherapy dose is being delivered3. 
Establishing the feasibility of KIM will enable the visualization of tumour motion whilst 
the radiotherapy treatment is being delivered. This is currently impossible on a standard 
linac, limiting the ability of the clinician to implement changes in margin size, which could 
potentially reduce the severity of side-effects for patients. Assessing intra-fraction 
motion of lung tumours is a key step in this process – by identifying the uncertainty in 
treatment, we will in the future be able to implement gating and tracking of tumours, thus 
resulting in safer and more effective treatment. 3. Sonke J. et al. IJROBP 2008:70(2):590 
Keywords: Radiotherapy, imaging, lung cancer
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MINI32.08 Identification of a Meta-Gene Network Associated with Metformin 
Sensitivity and Recurrence in Stage I Non-Small Cell Lung Cancer 
Casey A. Frankenberger1, Christopher W. Seder2, Nicholas Lund2, Robert A. Medairos3, 
Michael J. Liptay2, Philip Bonomi4, Jeffrey A. Borgia1 1Pathology, Rush University Medical 
Center, Chicago/United States of America, 2Thoracic Surgery, Rush University Medical 
Center, Chicago/IL/United States of America, 3Rush University Medical Center, Chicago/
United States of America, 4Medical Oncology, Rush University Medical Center, Chicago/IL/
United States of America
Background: We recently reported an association between progression-free survival 
and metformin exposure in patients with early stage non-small cell lung cancer (NSCLC). 
Local recurrence in stage I disease is estimated to be as high as 50% in US populations. 
Therefore, a method to identify NSCLC patients who are most likely to benefit from 
metformin treatment has potential clinical relevance. Methods: Three previously 
published, publically available gene expression array data sets documenting the effects 
of metformin treatment on transcriptional activity in human cell lines were used for 
the initial stages of the present study. These data sets were evaluated individually 
for enrichment of differentially expressed genes with a gene set analysis related to 
biological processes also performed. Differentially expressed genes common to all 
three studies were then used to form a metformin meta-gene. This combined meta-gene 
was evaluated topologically using a protein-protein interaction database to determine if 
any gene products had previously observed direct interactions. The metformin meta-
gene network was then examined in expression array data sets from stage I NSCLC 
patients (n=293) assembled from multiple published studies. Results: We identified 
several biological themes resulting from metformin treatment, including: immune cell 
differentiation, response to hypoxia, steroid receptor signaling, alternate splicing, 
and changes in cellular metabolism. Intersecting the differentially expressed genes 
from each data set, we identified 105 genes consistently up-regulated and 30 genes 
consistently down-regulated by metformin treatment, forming a tissue-independent 
meta-gene for metformin effects. Two networks of interacting genes were identified in 
this analysis; the first network consisting of 27 genes (22 up-regulated and 5 down-
regulated) and the second consisting of three up-regulated genes.This meta-gene was 
then examined in two independent cohorts of stage I adenocarcinoma. In the first cohort 
(n=125), patients clustered into two groups when k-means analysis was performed 
with respect to the 30 genes in the metformin meta-gene network. These patients had 
a significantly (p=0.014) different incidence of recurrence between the two clusters. 
This result was independently validated in the second data set (n=168) where patients 
clustered into two groups and also demonstrated significant stratification of recurrence 
(HR=1.21; p=0.001). Conclusion: We have identified a meta-gene of interacting proteins 
associated with both metformin therapy and recurrence-free survival in early stage 
lung cancer patients. This suggests a potential method for identifying NSCLC patients 
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MINI32.13 Racial/Ethnic and Gender Differences in Treatment and Survival of 
Early-Stage Non-Small Cell Lung Cancer in an Integrated Health Care System 
Lori C. Sakoda1, Kanti M. Uppal2, Kathleen B. Albers1, Michael Oehrli1, Laurel A. Habel1, 
Charles P. Quesenberry Jr.1 1Division of Research, Kaiser Permanente Northern California, 
Oakland/United States of America, 2Thoracic Surgery, Kaiser Permanente Northern 
California, Vallejo/CA/United States of America
Background: In the U.S., racial/ethnic and gender differences in treatment and survival 
of early stage non-small cell lung cancer (NSCLC) have been reported. These fi ndings 
come largely from analyses of SEER-Medicare data, which inherently exclude younger 
and managed care patients, up through 2005. Whether such differences exist in an 
integrated health care system, other than the U.S. Military Health System and Veterans 
Health Administration, has not been comprehensively examined. Methods: Using 
electronic health record and cancer registry data from Kaiser Permanente Northern 
California, a fully integrated health care system, we identifi ed a cohort of 1,566 
patients of non-Hispanic White, Asian/Pacifi c Islander, Black, or Hispanic race/ethnicity 
diagnosed with incident stage I/II NSCLC at ages 21 to 80 years from 2004 to 2011. 
Patients were followed from NSCLC diagnosis to health plan termination, death, or study 
end (through 2013), whichever occurred earliest. We examined whether the following 
prognostic factors (at NSCLC diagnosis, unless otherwise specifi ed), in addition to 
3-year overall survival, differed statistically (p<0.05) by race/ethnicity or gender: age; 
marital status; smoking history; comorbidity score; tumor stage, size, and histology; 
and receipt, modality, and timing of initial treatment. Using multivariable Cox regression, 
we further examined the extent to which race/ethnicity and gender were associated 
with overall survival after accounting for other prognostic factors. Results: Our cohort 
included 1137 non-Hispanic Whites (482 men, 655 women); 232 Asian/Pacifi c Islanders 
(95 men, 127 women); 126 Blacks (52 men, 74 women); and 71 Hispanics (36 men, 35 
women). The median age at diagnosis was 68 years. Overall, 92% were treated (89% 
of those treated by surgery), within 1.8 months post-diagnosis on average, and 41% 
died during 69,894 person-years of follow-up (median=3.3 years). Comparing across 
the race/ethnicity groups, non-Hispanic Whites were generally older at diagnosis, 
while Asian/Pacifi c Islanders were more likely to be married, never or former smokers, 
have a lower comorbidity score, and diagnosed with adenocarcinoma. The group 
most commonly treated with surgery was Asians/Pacifi c Islanders (87.5%), followed 
by Hispanics (81.7%), non-Hispanic Whites (79.9%), and Blacks (65.1%), with 3-year 
overall survival probabilities of 77%, 73%, 69%, and 63%, respectively. Compared to 
women, men were more likely to be married, former or current smokers, have a higher 
comorbidity score, and have a tumor of higher stage, greater size, and squamous cell 
histology, although both their receipt of surgery (women: 82%, men: 78%) and 3-year 
overall survival probabilities (women: 71%, men: 69%) were similar. After accounting 
for age, marital status, smoking history, comorbidity score, tumor characteristics, and 
receipt, modality, and timing of initial treatment, overall survival was similar for Asian/
Pacifi c Islanders (hazard ratio (HR): 0.90; 95% confi dence interval (CI): 0.69-1.17), 
Hispanics (HR: 0.96; 95% CI: 0.66-1.42), and Blacks (HR: 0.99; 95% CI: 0.75-1.31) 
compared to non-Hispanic Whites, and for men (HR: 0.95; 95% CI: 0.80-1.13) compared 
to women. Conclusion: Among early stage NSCLC patients in our integrated health care 
system, we found racial/ethnic differences in treatment, but no racial/ethnic or gender 
differences in overall survival after accounting for treatment and other prognostic factors. 
Keywords: health disparities, integrated health care system, overall survival, early stage 
NSCLC
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MINI32.14 Primary Early-Stage Lung Cancer Following Head and Neck Cancer: 
A Population Based Study of Treatment and Survival in the Netherlands 
AlexanderV. Louie1, Ronald Damhuis2, Cornelis Haasbeek3, Andrew Warner1, Danielle 
Rodin4, Berend Slotman3, C. R. Leemans5, Suresh Senan3 1Radiation Oncology, London 
Regional Cancer Program, London/Canada, 2Comprehensive Cancer Center the Netherlands, 
Rotterdam/Netherlands, 3Radiation Oncology, VU University Medical Center, Amsterdam/
Netherlands, 4Radiation Oncology, Princess Margaret Cancer Centre, Toronto/ON/
Canada, 5VU University Medical Center, Amsterdam/Netherlands
Background: Second primary lung cancer (SPLC) is an important cause of death in 
survivors of head and neck squamous cell cancer (HNSCC). The goal of this Dutch 
population study was to compare treatment patterns and outcomes in early-stage SPLC 
after HNSCC. Methods: Details on all patients in a population of 16 million diagnosed 
with lung cancer between 1997 and 2011 were obtained from the Netherlands Cancer 
Registry. After excluding patients with a history of other malignancies, patients were 
dichotomized with a primary lung cancer or a SPLC after HNSCC. The latter included oral 
cavity, oropharynx, larynx, and hypopharynx sub-sites. Baseline characteristics of early-
stage primary and SPLC were compared using the chi-square, fi sher’s exact, or t-test, 
where appropriate. After stratifying patients into fi ve consecutive 3-year time periods, 
the Chi-Square Trend test was used to determine trends in treatment patterns over time. 
Overall survival was calculated using the Kaplan-Meier method, and the log-rank test 
used to assess differences in survival. 30- and 90-day treatment related mortality were 
calculated. To assess for stage migration due to routine availability of PET-staging, as well 
as the availability of stereotactic ablative radiotherapy (SABR), outcomes were analyzed 
before and after 2005. All statistical tests were two-sided and considered signifi cant 
when p<0.05. Results: Of the 153,330 lung cancer patients, 19,501 with a history of a 
non-HNSCC primary cancer were excluded from the analysis. Of the 133,829 remaining 
patients, 2,556 (2%) represented a SPLC following HNSCC. SPLC patients were more 
likely to present in stage I (27% versus 16%, p<0.01) rather than stage IV (34% versus 
44%, p<0.01). For early-stage SPLC, initial HNSCC anatomical subsites were most 
 
Conclusion: The NLCA has been instrumental in driving improvements in 
lung cancer care in the UK. Future comparative audit projects spanning 
national and international boundaries hold the promise of further insights 
into variations in care and improvement in outcomes for our patients. 
Keywords: lung cancer, epidemiology, audit, survival
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MINI32.12 Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small 
Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
Kaican Cai1, Siyang Feng1, Yuanyuan Wang2, Hua Wu1, Gang Xiong1, Haofei Wang1, 
Ziliang Zhang1 1Department of Thoracic Surgery, Nanfang Hospital, Southern Medical 
University, Guangzhou/China, 2Department of Oncology, Nanfang Hospital, Southern Medical 
University, Guangzhou/China
Background: Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of 
Asian patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC 
patients with EGFR-tyrosine kinase inhibitors (EGFR-TKI) confers a signifi cant survival 
benefi t. This study assessed the effi cacy and safety of chemotherapy with or without 
icotinib in patients undergoing resection of stage IB to IIIA EGFR-mutated 
NSCLC. Methods: Patients with surgically resected stage IB (with high risk factors) to IIIA 
EGFR-mutated NSCLC were randomly assigned (1:1) to one of two treatment plans. One 
group received four cycles of platinum-based doublet chemotherapy every three weeks, 
and the other received platinum-based chemotherapy supplemented by a consolidation 
therapy of orally administered icotinib (125 mg thrice daily) two weeks after chemotherapy 
for four to eight months, or until the occurrence of disease relapse, metastasis or 
unacceptable icotinib or chemotherapy toxicity. The primary endpoint was disease free 
survival (DFS). Results: 39 patients were enrolled between February 2011 and December 
2012. 21 patients were assigned to the combined chemotherapy plus icotinib treatment 
group, while 18 patients received chemotherapy only. DFS at 12 months was 100% for 
icotinib-treated patients and 88.9% for chemotherapy-only patients (p = 0. 122). At 18 
months DFS for icotinib-treated vs. chemotherapy-only patients was 95.2% vs. 83.3% (p 
= 0. 225), respectively, and at 24 months DFS was 90.5% vs. 66.7% (p = 0. 066). In the 
Cox proportional hazards model, the treatment groups and pTNM stage showed a 
statistically signifi cant, the HR was 0.136 (95%CI: 0.022-0.829, p = 0.030) and 5.498 
(95%CI: 1.333-22.673, p = 0.018) respectively. Adverse chemotherapy effects 
predominantly presented as gastrointestinal reactions and marrow suppression, and 
there was no signifi cant difference between the two treatment groups. Patients in the 
chemotherapy plus icotinib treatment group showed favorable tolerance to oral icotinib.
Conclusion: The results suggest that, fi rstly, chemotherapy plus orally icotinib displayed 
a longer DFS compared with chemotherapy only, and secondly, patients receiving extra 
orally icotinib showed favorable tolerance without severe side effects. Nonetheless, our 
results are promising and future trials with larger sample sizes could confi rm our current 
data. 
Keywords: chemotherapy, consolidation therapy, NSCLC, EGFR-TKI
S384 Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
Abstracts Journal of Thoracic Oncology  •  Volume 10, Number 9, Supplement 2, September 2015
87.8% (95% CI:80.7-94.9) and 67.1% (95% CI:56.3-78.0) respectively. Here we investigate 
associations between OS and dose-distributions delivered to heart, left ventricle (LV), lung 
minus gross tumour volume (lung-GTV) and oesophagus. Methods: For 80 of 82 IDEAL-
CRT patients, heart, LV, lung-GTV and oesophagus differential dose volume histograms 
(DVHs) were extracted from planning data using CERR. Since prescribed doses-per-fraction 
varied, physical DVHs were converted to EQD2s using the linear-quadratic equation with an 
α/β of 3Gy for heart, LV and lung-GTV, and 1.7Gy for oesophagus. Patient-to-patient DVH 
variability was efficiently represented using a small number of Varimax-rotated principal 
components (PCs) which explained 95% of the total variance: four for oesophagus, five 
each for heart and LV, and fourteen for lung-GTV. OS was modelled from the start of 
treatment using Cox regression. Results: On univariate analysis there is evidence that 
larger planning target volumes (PTVs) and greater Heart-PC3 and LV-PC4 coefficients are 
associated with worse OS (see table). Heart-PC3 represented heart volumes receiving 
doses of 65-75Gy, and LV-PC4 represented LV volumes receiving 1-5Gy. No lung-GTV or 
oesophageal dosimetric parameters were significantly associated with OS (p-values>0.1). 
Although OS improved with increasing prescribed dose, this trend did not reach statistical 
significance. The estimates of these effects did not change markedly after adjusting for 
other covariates in the multivariate analysis, and the relationship between greater Heart-
PC3 and worse OS remained highly significant.
Results (n=80)
Mean values
Parameters Mean Minimum Maximum
EQD2 lung-GTV dose 12.1Gy 6.2Gy 18.5Gy
PTV 448.6cm3 138.7cm3 1262.2cm3
Heart volume receiving >5Gy (V5) 33.9% 0% 99.9%
Heart volume receiving >30Gy (V30) 11.3% 0% 47%
Univariate Cox model for OS
Covariate Hazard Ratio 95% Confidence Interval p-value
EQD2 prescribed dose 0.951 0.883-1.024 0.185
PTV 1.002 1.000–1.003 0.026
Heart-PC3 1.257 1.070-1.478 0.005
LV-PC4 1.257 0.998–1.584 0.052
Multivariate Cox model for OS
Covariate Hazard Ratio 95% Confidence Interval p-value
EQD2 prescribed dose 0.977 0.900-1.060 0.570
PTV 1.001 0.999-1.003 0.179
Heart-PC3 1.228 1.039-1.452 0.016
LV-PC4 1.203 0.943-1.536 0.137
Conclusion: We found strong evidence of an association between lower OS in IDEAL-
CRT patients and heart volumes receiving 65-75Gy. There was some evidence of a 
negative association between OS and LV volumes receiving 1-5Gy. RTOG0617 has 
reported a negative relationship between OS and heart volumes receiving greater 
than 5Gy. Thus OS gains potentially achievable through tumour dose-escalation 
may be offset by associated heart dose increases. Further studies are required to 
improve understanding of radiation effects on heart substructures, aiming to identify 
avoidance structures for possible cardiac-sparing dose-escalated NSCLC treatments. 
Keywords: non small cell lung cancer, Radiotherapy, dose escalation, normal tissue 
toxicity
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MINI33.03 Heart Dose Is Associated with Shorter Overall Survival for Patients 
Treated with Chemo-Radiation for Locally Advanced NSCLC Erik Van Der Bijl, 
Maddalena M. G. Rossi, Heike Peulen, Jose Belderbos, Jan-Jakob Sonke Department of 
Radiation Oncology, The Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, 
Amsterdam/Netherlands
Background: Traditionally, sparing the heart in chemo-radiotherapy of locally advanced 
lung cancer has a low priority compared to the lungs and esophagus. Recently, however, 
the randomized phase III trial RTOG 0617 showed that the volume of the heart receiving a 
dose of at least 5Gy (V5) was associated with a lower overall survival (OS). The aim of the 
current study is to validate this in an independent database. Methods: Patients treated 
with IMRT (24x2.75Gy with daily low-dose cisplatin) at our hospital between 2006 and 
2014 were retrospectively selected. For the heart both mean dose and Vx denoting the 
volume receiving x Gy or more (x in range 5-50Gy with 5Gy increments) were calculated. 
Associations of these parameters with OS were evaluated using univariate and multivariate 
proportional hazards analysis. In multivariate analysis we separately paired the total GTV 
(primary tumor plus involved lymph nodes) to Vx and mean dose. Results: 375 pts were 
available for analysis. Median follow up was 16 months and median OS was 26 months. Using 
univariate proportional hazard modeling mean dose and all Vx for x<40Gy were significantly 
associated (p<0.05) with OS. For V5, which was most significant in the analyzed set, the 
hazard ratio (HR) was 1.008. When pts are split at the median V5 = 37.0%, the median 
OS was 29 ± 2.5 months versus 19 ± 2.4 months for pts below and above the median 
respectively (p=0.03, Log Rank). Similarly, the figure illustrates significant separation in 
Kaplan-Meier plots of OS with the pts divided in V5 quartiles. In the multivariate analysis 
the correlation between GTV (median volume 109 cc) and mean dose or Vx was less than 
0.15, indicating that a higher heart dose is not the effect of larger tumor volumes and 
hence a worse survival due to more advanced decease. Both GTV (p<0.001, HR=1.001) 
and V5 (p=.003, HR=1.007) were significant in multivariate analysis as was the case 
with GTV (p<0.001, HR=1.001) and mean dose (p=0.033, HR=1.018). Conclusion: For 
commonly larynx (53%) and oral cavity (24%). Treatment for early-stage SPLC included 
surgery (53%), radiotherapy (RT, 33%), or best supportive care (14%). The proportion 
of RT patients undergoing SABR was unknown. When compared to surgery, early-stage 
SPLC patients receiving any-form of RT tended to be older, with more advanced T-stage 
disease, poorly differentiated histology, and lower rates of pathologic diagnosis (all 
p<0.01). The proportion of all early-stage lung cancer patients receiving surgery over 
time remained stable in the primary setting (range: 59-63%, p=0.69), but decreased 
for early-stage SPLC patients (range: 68-42%, p<0.01). The use of RT increased over 
time for both primary (range: 21-30%, p<0.01) and early-stage SPLC patients (range: 
23-43%, p<0.01). 30- and 90-day treatment related mortality rates were higher
in surgical versus RT patients in both pre-2005 (3.8%, 8.6% versus 4.0%, 8.0%) and
post-2005 (2.3%, 4.0% versus and 0%, 3.2%) eras. Overall, early-stage SPLC surgical
patients had improved survival when compared to RT patients (p<0.01). In the post 2005 
era, however, survival was similar for these two modalities (p=0.13). Conclusion: In
survivors of HNSCC who develop early-stage SPLC, RT deserves attention as an
alternative gold standard to surgery. Previous studies indicated that a majority of RT
delivered for early-stage NSCLC after 2006 was SABR [Palma D, 2010]. Despite negative
selection of poorer baseline characteristics, use of RT resulted in comparable survival
and lower post-treatment mortality when compared to surgery in the modern era.
Keywords: stereotactic radiation, early stage lung cancer, Surgery, comparative
effectiveness
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MINI33.01 Prospective Phase II Trial of SBRT for Centrally-Located Lung 
Cancer Jeffrey D. Bradley1, Feng Gao2, Parag J. Parikh3, Michael Roach4, Sana 
Rehman4, Rojano Kashani3, Jehan Ganachaud3, Todd Dewees3, Clifford G. Robinson3 
1Radiation Oncology, Washington University School of Medicine, Chesterfield/MO/United 
States of America, 2Biostatistics, Washington University School of Medicine, St. Louis/MO/
United States of America, 3Radiation Oncology, Washington University School of Medicine, 
St. Louis/MO/United States of America, 4Radiation Oncology, Washington University School 
of Medicine, St. Louis/United States of America
Background: We report safety and efficacy results for an institutional prospective phase 
II trial for medically-inoperable patients with centrally-located early-stage non-small cell 
lung cancers receiving dose escalated SBRT. The Phase II objectives were to determine 
the overall survival and patterns of local failure. Methods: Eligible patients with biopsy-
proven NSCLC within 2cm of the proximal bronchial tree (RTOG definition) were enrolled 
on an IRB-approved institutional clinical trial between 2006-2015. All patients were 
medically inoperable. The Phase I portion consisted of 4 radiation dose levels using 5 
fraction regimens. Dose levels were 9, 10, 11, and 12 Gy/fraction. Phase I was previously 
reported (ASTRO 2011). Based on an early analysis of efficacy, the Phase II radiation dose 
was 11 Gy x 5 fractions. Results: 64 patients were enrolled to the trial; 23 to Phase I 
and 41 to Phase II. The median follow up for phase II patients alive is 6.2 months (range 
1.3-46.3 months). 41 patients are eligible for toxicity analysis and 37 with at least 1 post-
treatment visits are eligible for efficacy. Regarding treatment-related toxicity, 1 patient 
experienced acute Grade 3 hypoxia (2.4%; 95% CI 0.1-12.8%), 3 patients developed late 
Grade 3, 2 had late grade 4, and 1 had late grade 5 events. The grade 4 events were 
lung atelectasis resulting in hospitalization and dyspnea, respectively. The grade 5 event 
was fatal hemoptysis in a patient with tumor involving the pulmonary artery. The one-year 
local lobar recurrence rate using 11 Gy x 5 fractions is 4.6% (95% CI 0.7-13.6%). The one-
year OS is 81.2% (60.0-91.8%).The predominant causes of death were distant metastasis 
(N=6), intercurrent illness without recurrence (N=6), and secondary lung cancer (N=2). 
One patient is alive with gastric cancer. Two patients developed nodal recurrence 
and two developed local failures. Conclusion: SBRT for central tumors using 11 Gy 
x 5 fractions was tolerable, but can contribute to severe toxicity as shown by others 
where tumor involves the pulmonary vasculature. The lobar tumor control was excellent 
using 11 Gy x 5 fractions. The results of RTOG 0813, which was methodologically 
based on this trial, may help to clarify the preferred dose for central lesions. 
Keywords: central, SBRT, stereotactic, lung cancer
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MINI33.02 Dose-Escalated Radiotherapy for NSCLC: Heart Doses versus 
Survival in IDEAL-CRT Sindu Vivekanandan1, Nicholas Counsell2, Emma Parsons3, 
Yenting Ngai2, Laura Hughes2, Maria Hawkins1, David B. Landau4, John D. Fenwick1 
1Oncology, University of Oxford, Oxford/United Kingdom, 2Cancer Institute, Cancer Research 
Uk and University College London Cancer Trials Centre, London/United Kingdom, 3RTTQA, 
NCRI Radiotherapy Trials Quality Assurance Group, Northwood/United Kingdom, 4Radiation 
Oncology, 1. Guy’s & St. Thomas’ NHS Trust, King’s College London, London/United Kingdom
Background: Radiotherapy dose-escalation trials have achieved inconsistent levels of 
overall survival (OS) for non-small cell lung cancer (NSCLC). For stage III NSCLC, RTOG-
0617 reported poorer OS for 74Gy than for 60Gy delivered in 2Gy fractions with concurrent 
chemotherapy (median OS 20·3 vs 28·7 months). The phase I/II IDEAL-CRT CRUK funded 
trial (Sponsor: University College London (C13530/A10424)) of isotoxic dose-escalation 
delivered mean and maximum doses of 67.5 and 73Gy in 30 fractions over 40 days, 
equivalent to 69 and 75.6Gy in 2Gy fractions (EQD2), and reported 1- and 2-year OS rates 
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radiation therapy (IMRT) in 61%, stereotactic radiotherapy (SBRT) in 32%, and 3D 
conformal radiotherapy in 7%. Mean pretreatment FEV1 was 2.06L (78.9% of the standard), 
mean FCV was 3.17L (94.9%), mean TLCO was 16.5 (64.7%) and mean TLNO was 72.7 
(60.3%). FEV1 and FCV were stable during and after radiotherapy. However, mean TLCO 
decreased by 4.4% (P=0.01) between first and fourth PFT, mean DLNO decreased by 4% 
(P=0.001) between first and second PFT, mean VC (capillary lung volume) decreased by 
6.24% between first and fourth PFT (P=0.011), and DM (membrane diffusing capacity) 
decreased by 3.6% between first and second PFT (P=0.001). Conclusion: CONORT 
is the first study evaluating the potential impact of thoracic radiotherapy on double 
measurement of lung diffusing capacity. These preliminary results showed that thoracic 
radiotherapy has little impact on lung volumes. However, lung diffusion decreases, 
initially by membrane alteration and then by capillary alteration. Results at 6 months 
showed that this alteration is fully recovered. Updated data will be presented at meeting. 
Keywords: Radiotherapy, lung cancer, Pulmonary function tests, CO and NO diffusion
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MINI33.07 A Restrospective Study of Shrinking Field Radiation Therapy in 
Chemoradiothrapy for Stage III Non-Small Cell Lung Cancer Han Shuiyun1, 
Gang Lin1, Xiaojiang Sun1, Yaping Xu1, Wei-Min Mao2 1Department of Radiation Oncology, 
Zhejiang Cancer Hospital, Hangzhou/China, 2Department of Thoracic Surgery, Zhejiang 
Cancer Hospital, Hangzhou/China
Background: The study aimed at investigating the feasibility of shrinking field after 
complete or partial response during Chemoradiothrapy without surgery for stage III 
non-small cell lung cancer (NSCLC). Methods: This retrospective study was carried 
on 97 consecutive patients with stage III non-small cell lung cancer (NSCLC), who 
were good responders to cheomoradiation without surgery between September 2009 
and November 2014. Computed tomography scans were performed after 40-50 Gy to 
evaluate the curative effect. Fifty three-dimensional-conformal treatment or intensity-
modulated radiation therapy were redelineated to shrink the radiation volume once or 
twice during conventionally fractionated radiotherapy, leading to a boost of 6-20Gy 
delieverd to the shrunk PTV. The gross tumor volume (GTV) and planned target volume 
(PTV) were messured. The acute symptomatic irradiation-induced pneumonia(ASIP) as 
well as first progression patterns and overall survival were investigated through follow-
up. Results:Among 97 patients who obtained complete or partial response with median 
total dose of 60.0 Gy (range, 46.0-70.0 Gy), 50 patients received shrinking field radiation 
therapy with a median 184.24 cm3 (range, 28.1- 449.7cm3) reduction of PTV between 
the first and last plan. The primary GTV and PTV in shrinking field group was greater than 
that in non-shrinking field group, as well as the 59Gy-greater radiation dose rate(GTV, 
116.8 cm3 vs 102.9 cm3 ; PTV, 493.0 cm3 vs 458.0 cm3; 59Gy-greater dose rate, 70 
% vs 61.7 %). The incidence of ASIP was 20.6%(20/97) for all the population, shrinking 
field group of 18%(9/50) and non-shrinking field group of 23.4%(11/47). Fifteen patients 
progressed locoregionlly, 12 distantly and 3 in both patterns in shrinking field group, 
while 22 locoregionlly, 16 distantly and 3 in both patterns in non-shrinking field group. 
Four regional-progression located out of PTV in both groups. The locoregion-progression 
rate and out-PTV rate were not significant difference(60% vs 61%, P=0.934; 63.3% 
vs 56.1%, p=0.54). As compared with non-shrinking field group, shrinking field had a 
similar overall survival(median OS, 29 mouths vs 30 mouths, P=0.546), an improved 
median progression free survival (median PFS, 19 mouths vs 14 mouths, P=0.945) and a 
lower incidence of acute irradiation-induced pneumonia, but they were all not statistically 
significant. Conclusion: Shrinking field and dose escalation for good responders during 
chemoradiotherapy seem safe with acceptable toxicity and outPTV relapse, especially for the 
lung cancer with a bulky mass. More prospective trials are needed to validate these results. 
Keywords: Stage III NSCLC, shrinking field radiation therapy, response
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MINI33.08 Feasibility & Efficacy of Hypofractionated Radiotherapy in LA-
NSCLC: A Phase II Study Sushmita Pathy1, Soumyajit Roy1, Rakesh Kumar2, Bidhu K. 
Mohanti1, Vinod Raina3, Anand Jaiswal4 1Radiation Oncology, All India Institute of Medical 
Sciences, New Delhi/India, 2Nuclear Medicine, All India Institute of Medical Sciences, 
New Delhi/India, 3Medical Oncology, All India Institute of Medical Sciences, New Delhi/
India, 4Pulmonary Medicine, LRS Institute of TB and Respiratory Diseases, New Delhi/India
Background: Accelerated repopulation of tumour cells causes inferior local control 
in locally advanced NSCLC (non-small cell lung cancer). Hypofractionated radiation 
schedule with a shorter overall treatment time may address this issue. The current 
study was aimed at evaluating the feasibility and efficacy of using hypofractionated 
radiotherapy with concurrent chemotherapy after neoadjuvant chemotherapy in locally 
advanced NSCLC. Methods: Thirty patients of locally advanced NSCLC were enrolled 
in this randomized controlled study and were allocated to one of the two treatment arms 
between October 2011 and July 2013. Arm A (n=15) received neoadjuvant chemotherapy 
(NACT) (paclitaxel 200mg/m2 and carboplatin AUC 5) followed by external radiotherapy 
(EBRT) (60Gy/30fractions/6weeks). Arm B (n=15) received the same NACT followed 
by EBRT (48Gy/20fractions/4weeks) with concomitant chemotherapy (cisplatin 30mg/
m2 weekly). Quality of life analysis was done using EORTC (European organization for 
Research and Treatment in Cancer) QLQ C30 and LC13. Toxicity scoring was done using 
CTCAE (Common Terminology Criteria for Adverse Events) version 3.0. The treatment 
response between two arms was computed using Fisher’s exact test. The difference in 
QOL parameters were compared by Wilcoxon signed rank test and Mann-Whitney U test 
for paired and unpaired samples. Survival time was estimated by Kaplan–Meier survival 
analysis. Survival pattern was compared using the log-rank test. Factors which had p 
value <0.25 in univariate analysis were subjected to multivariate analysis using Cox 
pts treated with chemoradiation the dose received by the heart is strongly associated 
with overall survival. Our results are in accordance with the results of RTOG 0617 [1] for 
the V5 with similar HR despite the different fractionation scheme and chemo regimen. 
This indicates that cardial toxicity might be more important in lung cancer patients 
treated with chemoradiation than previously anticipated. Consequently, better sparing 
of the heart potentially improves outcome. [1] Bradley et.al. J Clin Oncol 31, 15 pp. 7501 
Keywords: heart, toxicity, Radiotherapy
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MINI33.04 Acute Radiation Pneumonitis in Lung Cancer Treated with 
Volumetric Modulated Arc Therapy Kan Wu, Bing Xia, Ruping Zhao, Xiao Xu, Bing 
Wang, Lixia Xu, Jiahao Wang, Xiadong Li, Zhibing Wu, Ke Zhang, Xiaodong Liang, 
Qinghua Deng, Shenglin Ma Hangzhou First People’s Hospital,Hangzhou Cancer Hospital, 
Hangzhou/China
Background: Thoracic radiotherapy plays an important role in the treatment of lung 
cancer. However, the safety of thoracic radiotherapy delivery is restricted to the risk of 
radiation pneumonitis(RP), which is the major dose limiting toxicity for patients undergoing 
thoracic radiotherapy. Few studies to date have assessed risk factors associated with 
the development of RP in lung cancer patients treated with volumetric modulated arc 
therapy (VMAT). This study aimed to report the RP incidence and clinical and dosimetric 
risk factors associated with RP in lung cancer patients treated with VMAT at a single 
institution. Methods: In this retrospective study, lung cancer patients treated with 
VMAT from 2013 through 2015 were reviewed. RP was graded according to Common 
Terminology Criteria for Adverse Events (CTCAE) version.4.0. Clinical factors and 
dosimetric parameters were evaluated using logistic multivariate regression for estimating 
the correlation with RP. The results were considered statistically significant when the 
p-value was<0.05. Results: Thoracic radiotherapy with VMAT was administered in 77 
lung cancer patients. Of these patients, 58 were men and 19 were women, with a median 
age of 60 years (range 22-84 years); 25 patients received concurrent chemoradiotherapy, 
and the median radiation dose was 60Gy (range 45-64Gy). VMAT plans were performed 
with single arc in 9 patients, double in 55 patients, triple in 4 patients, and the mean 
(±SD) delivery time was 189.1s±42.0s. VMAT allowed us to respect most planning 
objectives on target volumes and organs at risk, for PTV V95% = 96.8 ± 6.1%; for lung 
V5 = 41.3 ± 8.7%, V10 = 29.9 ± 7.1%, V20 = 20.9 ± 5.7%, mean dose=1150.9±277.6Gy. 
With regard to acute RP after thoracic radiotherapy, 10.4% were grade 1 (G1), 16.9% 
G2, 9.1% G3, 2.6% G5. The overall incidence rate of symptomatic RP (grade ≥ 2 
by CTCAE) was 28.6% in the entire cohort. Based on the clinical data and dosimetric 
parameters analysis, factors predictive of symptomatic RP were lung volume receiving 
≥10Gy (V10) [OR: 1.39, 95% CI 1.07–1.80, p=0.014], PS score[OR:5.44, 95% CI 1.29–
23.08, p=0.021], concurrent chemotherapy[OR:3.85, 95% CI 1.07–13.86, p=0.039]
and CRP changing level[OR:1.06, 95% CI 1.01–1.12, p=0.014]. Conclusion: VMAT, a 
novel technique, provides a viable option for the thoracic radiotherapy of lung cancer 
with acceptable toxicities. However, for patients with higher V10, poorer PS score, greater 
increasing level of CRP and undergoing concurrent chemotherapy, VAMT technique 
should be administrated with cautions. Several molecular biomarkers have been reported 
that correlated with the development of RP, which will be tested in our further analysis. 
Keywords: lung cancer, volumetric modulated arc therapy, Radiation pneumonitis
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MINI33.06 Prospective Monitoring of Lung Function Test with CO and NO 
Diffusion during Thoracic Radiotherapy: Preliminary Results of the CONORT 
Study Clara Fontaine-Delaruelle1, Imad Selmaji2, Yassine Hamou3, Nicolas Girard4, 
Virginie Zarza4, Célia Prevost2, Genevieve Letanche5, Chantal Viart-Ferber1, Pierre-Jean 
Souquet1, Sébastien Couraud1, Francoise Mornex2 1Service de Pneumologie, Centre 
Hospitaliser Lyon Sud, Pierre Bénite/France, 2Service de Radiothérapie, Centre Hospitaliser 
Lyon Sud, Pierre Bénite/France, 3Service de Pneumologie, Clinique Mutualiste de Lyon, 
Lyon/France, 4Service de Pneumologie, Hopital Louis Pradel, Bron/France, 5Service de 
Pneumologie, Groupe Hospitalier Mutualiste Les Portes Du Sud, Vénissieux/France
Background: Thoracic radiotherapy is a usual treatment for lung cancer; either at early-
stages (stereotactic mode) or at locally advanced stages (conventional radiotherapy 
mode). Thoracic irradiation appears to have little impact on lung volume such as forced 
expiratory volume in one second (FEV1) or forced vital capacity (FCV). By contrast, 
carbon monoxide diffusing capacity (TLCO) may be altered under thoracic radiotherapy. 
Pulmonary diffusion may be also evaluated by the NO (azote monoxide) diffusion 
capacity (TLNO). Moreover, double assessment of NO and CO diffusing capacities 
open the way to understand if alteration of lung diffusion is due to alveolar membrane 
and/or a pulmonary capillary alteration. CONORT aims at measuring pulmonary 
function tests (PFTs), in particular the CO and NO diffusing capacity, during thoracic 
radiotherapy. Methods: Prospective multicenter study. CONORT study was approved by 
the Lyon Sud-Est IV ethics committee and the database was declared to the national 
information registry authority as required by French laws. Overall 112 patients must be 
included to estimate a difference of 15% in diffusing capacity test, with a 90% power and 
a 5% alpha risk. All consecutive patients treated by thoracic radiotherapy in Lyon Sud 
Hospital were included regardless of histology and radiotherapy technique. PFTs including 
double diffusion are performed by the same operator and using the same technic, before-, 
during-, at the end-, six weeks after- and six months after- thoracic irradiation. All included 
patients gave their consent. Results at PFTs were expressed in % of theoretical value 
(%th), and were compared using Student t test. Results: Between 1st February 2014 
and 14 April 2015, 88 patients were included and 62 have been analyzed. Patients were 
male in 73%, mean age was 67.4 years. Radiotherapy technique was intensity-modulated 
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into group 3 were candidates to best support care. Clinical, GA and follow-up data were 
prospectively collected. Overall survival (OS) was calculated using Kaplan-Meier method 
and the median follow-up time was 13.5 months. Results: From July 2008 to November 
2014, 54 elderly p with stage III NSCLC were identified. The median age was 80 years (74-
87) and most p (93%) were males. The most common histological subtype was squamous 
cell carcinoma (54%), followed by adenocarcinoma (28%) and NOS (18%). MGA classified 
20 p (37%) as fit, 23 p (43%) as vulnerable and 11 p (20%) as dependent. Median number 
of comorbidities: 4 (0-11); median number of drugs: 6 (0-12); median Karnofsky: 80%
(60-100); median Barthel: 95 (80-100); Lawton-Brody Scale (<4/≥4): 18%/82%; Pfeiffer
(<4/≥4): 89%/11%; Yesavage test (0/≥1): 54%/46%; 1 (0-10); median GS: 1 (1-3); VES-13
(<3/≥3): 50%/50%. Risk groups 1 and 2 had significantly better median OS (20 and 17.5
months, respectively) as compared with group 3 (7.7 months, p=0.004). The number of
p treated with concurrent CRT was higher among fit patients (14; 70%) as compared with 
group 2 (8; 35%) and 3 (0; 0%). Some fit and vulnerable p did not receive concurrent CRT
due to patient and physician decision, tumor not amenable for radiotherapy or comorbid
conditions. P treated with concurrent CRT received conventional 3D thoracic radiotherapy 
(2 Gy/fraction) in combination with carboplatin AUC 2.5 and vinorelbine 15 mg/m2 on days 
1, 8, 21 and 29. Overall response rate was 68%. Median OS was 22 months (95% CI 10.6 
– 33.6). There were no differences in OS when comparing risk groups 1 and 2 (p=0.446). 
Adverse events (G3-4): neutropenia, 2p (9%); anemia, 1p (4.5%); thrombocytopenia 1p
(3%); febrile neutropenia, 1p (3%); pneumonia, 1p (3%); tracheo-bronchial infection, 3p
(14%); asthenia 2p (9%); anorexia 1p (4.5%); diarrhea, 1p (4.5%); radiation pneumonitis, 3p 
(14%) and oesophagitis 0p (0%). Three p (14%) died due to radiation pneumonitis and 1 p 
(3%) due to a respiratory infection. Conclusion: MGA may help in the selection of elderly p
for concurrent CRT and appeared to be a valuable tool to avoid undertreatment of those p. 
Keywords: concurrent chemoradiotherapy, Stage III NSCLC, Elderly patients, Geriatric
assessment
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MINI33.12 Analysis of Acute Radiation-Induced Esophagitis in NSCLC Pts 
Using Lyman NTCP Model Jian Zhu, Baosheng Li Laboratory of Image Science and 
Technology, Southeast University, Nanjing/China
Background: To analyze acute esophagitis (AE) in a Chinese population receiving 3D 
conformal radiotherapy (3DCRT) for non-small cell lung cancer (NSCLC), combined 
or not with chemotherapy (CT), using the Lyman-Kutcher-Burman (LKB) normal tissue 
complication probability (NTCP) model. Methods: 157 Chinese patients (pts) presented 
with NSCLC received 3DCRT: alone (34 pts) or combined with sequential CT (59 pts) 
(group 1) or with concomitant CT (64 pts) (group 2). Parameters (TD50, n, and m) 
of the LKB NTCP model predicting for > grade 2 AE (RTOG grading) were identified 
using maximum likelihood analysis. Univariate and multivariate analysis using a binary 
regression logistic model were performed to identify patient, tumor and dosimetric 
predictors of AE. Results: Grade 2 or 3 AE occurred in 24% and 52% of pts in group 1 
and 2, respectively (p<0.001). For the 93 group 1 pts, the fitted LKB model parameters 
were: m=0.15, n=0.29 and TD50=46Gy. For the 64 group 2 pts, the parameters were: 
m=0.42, n=0.09 and TD50=36Gy. In multivariate analysis, the only significant predictors 
of AE were: NTCP (p<0.001) and V50, as continuous variable (RR=1.03, p =0.03) or being 
more than a threshold value of 11% (RR=3.6, p =0.009). Conclusion: A LKB NTCP model 
has been established to predict AE in a Chinese population, receiving thoracic RT, alone or 
combined with CT. The parameters of the models appear slightly different than the previous 
one described in Western countries, with a lower volume effect for Chinese patients. 
Keywords: non-small cell lung cancer, normal tissue complication probability, acute 
radiation-induced esophagitis, radiation toxicity
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MINI33.13 Locally Advanced NSCLC: Patient Preferences Regarding 
Prophylactic Cranial Irradiation - A Discrete Choice Experiment Margot 
Lehman1, Peter Gorayski2, Redzo Mujcic3, Susanne Watson4, Desiree Edeling4, James 
Jackson5, Jennifer Whitty3 1Princess Alexandra Hospital, Brisbane/QLD/Australia, 2Radiation 
Oncology Queensland, Toowoomba/QLD/Australia, 3University of Queensland, Brisbane/
QLD/Australia, 4Princess Alexandra Hospital, Brisbane/QLD/Australia, 5Radiation Oncology 
Queensland, Gold Coast/QLD/Australia
Background: Brain metastases (BM) develop in 22-55% of patients with locally advanced 
Non-small cell lung cancer (LA-NSCLC) treated with curative intent. Prophylactic cranial 
irradiation (PCI) reduces the incidence of BM by40- 60% but is not part of standard practice 
due to a lack of proven survival benefit and concerns regarding toxicity. This study aimed 
to determine patient preferences with respect to the survival gain or reduction in BM 
PCI would need to provide and the amount of toxicity considered acceptable for them to 
accept PCI. Methods: A Discrete Choice Experiment (DCE) was used. Patients undergoing 
definitive chemoradiation therapy for LA-NSCLC were asked to make 15 hypothetical 
choices between two alternative PCI treatments at each of two time points (i.e. pre- and 
post their own treatment). Each alternative PCI treatment was described by four attributes: 
amount of life gained, ability to care for oneself, loss of memory and the chance of BM. 
Participants were also given the option of no PCI treatment. The choice data were analysed 
using multinomial and mixed logit regression models, to indicate the relative importance 
of improvements in each attribute for treatment preference. Results: There were 54 and 
46 surveys completed pre- and post-treatment respectively. Participants had a mean age 
of 63.6 (range 39-82) years, 74% were male. Participants chose to accept PCI versus no 
PCI in approximately one third of the choices (34.8% pre- and 33.3% post - treatment). 
Overall, participants preferred a treatment alternative if it was associated with a longer 
survival, better ability to take care of oneself, lower loss of memory, and lower chance 
regression analysis. Statistical analysis was carried out using Stata software version 
12.0. Results: The overall response rate at the time of first follow-up for arm A was 
54.55% as compared to 85.71 %( p=0.08) in arm B. At median follow-up duration of 
12 months the ORR was numerically superior in arm B (47% vs 33%) though not 
statistically significant (p=0.31). The median PFS in arm A and B were 9.2 and 17.23 
months respectively [hazard ratio 2.92 (95% C.I: 1.02-9.11); p=0.05]. No significant 
difference was discernible in OS between two arms. Social functioning showed a trend 
towards improvement while alopecia showed a trend towards worsening in arm B. The 
most common grade 3/4 hematological and non-hematological toxicity were neutropenia, 
peripheral neuropathy and dysphagia (arm A: 3; arm B: 1). Conclusion: Hypofractionated 
radiotherapy with concomitant chemotherapy after NACT is feasible for locally advanced 
NSCLC of lung. Such management approach can expedite treatment with an acceptable 
morbidity, patient compliance and quality of life and thus reduces the waiting time, machine 
load, socio-economic burden in patients which is significant in a developing nation. 
Keywords: Hypofractionated radiotherapy; locally advanced NSCLC; feasibility
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MINI33.09 Impact of Tumor Regression and Need for Re-Plan during Radiation 
Therapy for Stage IIIB Lung Cancer: Dosimetric Comparison between IMRT and 
IMPT Heerim Nam1, Yong Chan Ahn2, Sang Gyu Ju2, Chae-Seon Hong2, Su Yeon Park2, 
Dongryul Oh2, Jae Myoung Noh2, Jeong Il Yu2, Hyebin Lee1, Hongryull Pyo2 
1Radiation Oncology, Kangbuk Samsung Hospital, Seoul/Korea, 2Radiation Oncology, 
Samsung Cancer Center, Seoul/Korea
Background: Radiation pneumonitis (RP) is the most worrying complication following 
high dose radiation therapy (RT) for loco-regionally advanced lung cancer. Intensity 
modulated radiation therapy (IMRT) and intensity modulated proton therapy (IMPT) are 
expected to reduce RP compared with conventional RT technique. Adaptive re-plan 
is usually indicated to accommodate tumor shrinkage and position changes during 
fractionated RT course. This study is to comparatively evaluate dosimetric differences 
between RT techniques and interval changes of these parameters assuming that initial 
IMRT and IMPT plans are continued throughout RT course without adaptive re-plan. 
Methods: Ten patients who were given concurrent chemo-radiotherapy by IMRT (66 
Gy/33 fractions, weekly Docetaxel/CDDP #6) for having N3(+) stage IIIB lung cancer 
were selected. Surrogate rival IMPT plan on each patient was generated to compare 
with initial IMRT plan. Beam numbers used in IMRT and IMPT were 6-7 and 3. Second CT 
obtained during 3rd-4th week for adaptive IMRT plan was used to generate second sets 
of IMRT and IMPT plans, assuming that adaptive plan had not been done. Differences 
between initial RT techniques and changes in dosimetric parameters including conformity 
index (CI), homogeneity index (HI) and dose-volume histogram (DVH) of target and normal 
organs, which could have occurred by 2 RT techniques, were compared. Results: When 
comparing initial IMRT and IMPT plans, IMPT showed advantageous features over IMRT 
with respects to median HI (1.08 vs. 1.02), mean doses (Dmean) to lung, esophagus, and 
heart, lung volumes receiving 5 Gy (V5), 10 Gy (V10), 20 Gy (V20), 30 Gy (V30), and 40 
Gy (V40) and maximum dose (Dmax) to spinal cord (all p<0.05), respectively. Mean gross 
tumor volumes (GTV) on initial and second CT’s were 90.9 (48.1~163.7) cm3 and 52.2 
(23.1~89.7) cm3 and median GTV reduction was 42.2% (51.3%-84.4%). More dosimetric 
parameters could have changed significantly by IMPT (CI, HI, V5, V10, V20, V30, Dmean to lung 
and heart, and Dmax to spinal cord) than IMRT (CI, HI, V20, Dmax to spinal cord and heart), 
respectively. Absolute increase in Dmax to spinal cord was estimated as 0.53 Gy by IMRT 
and 4.79 Gy by IMPT (p=0.003). Conclusion: Impact of GTV regression during RT course 
and need for adaptive re-plan seem evident. More uncertainties on dosimetric parameters 
and higher doses to spinal cord are expected by IMPT than by IMRT if re-plan is not applied. 
Optimal timing and frequency of adaptive plans, however, need to be further evaluated. 
Keywords: lung cancer, intensity modulated radation therapy, intensity modulated proton 
therapy, tumor regression
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MINI33.11 Locally Advanced NSCLC Elderly Patients Assessed by 
Multidimensional Geriatric Assessment and Treated with Concurrent 
Chemoradiation Ernest Nadal1, Joana Saldaña1, Jennifer Linares1, Ramón Palmero1, 
Arturo Navarro2, María Dolores Arnaiz2, Maria Plana1, Jesús González3, Francesc 
Formiga4, Isabel Brao1, Núria Codorniu1, José Ruffinelli1, Susana Padrones5, Valentí 
Navarro6, Felipe Cardenal1, Maite Antonio1 1Medical Oncology, Catalan Institute of 
Oncology, L’Hospitalet/Spain, 2Radiation Oncology, Catalan Institute of Oncology, L’Hospitalet/
Spain, 3Palliative Care Unit, Catalan Institute of Oncology, L’Hospitalet/Spain, 4Geriatric 
Unit, Hospital Universitari de Bellvitge, L’Hospitalet/Spain, 5Respiratory Medicine, Hospital 
Universitari de Bellvitge, L’Hospitalet/Spain, 6Clinical Research Unit, Catalan Institute of 
Oncology, L’Hospitalet/Spain
Background: Despite the increasing number of elderly patients (p) with unresectable 
stage III NSCLC p presenting to our clinic, there is no consensus on the therapeutic 
approach to these p. The comprehensive geriatric assessment (CGA) and the comorbidity 
measurement are relevant tools to identify p who may benefit from tolerable combinations 
of concurrent chemoradiation (CRT). Methods: Elderly p (≥75 years) with stage III NSCLC 
underwent multidimensional geriatric assessment (MGA) that incorporated validated 
instruments to assess comorbidity, polypharmacy, functional status, geriatric syndromes 
(GS), mood, cognition and vulnerability. P were classified according to the MGA results 
into 3 risk groups: (1) fit p: independent in all ADL and IADL, no comorbidities and 
absence of GS; (2) vulnerable p: <3 comorbidities and/or <3 IADL but no ADL disability 
and absence of GS; (3) dependent p: ≥3 disabilities or presence of GS. P classified into 
group 1 and 2 were considered candidates for antitumoral treatment, whereas patients 
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of BM. Before treatment, an increase in survival of more than 6 months was the most 
important benefit (relative importance weight 61.2), followed by avoiding severe problems 
with memory (39.4), avoiding severe problems with self-care (30.3), and a 15% reduction 
in risk of BM (15.0). After treatment, the rank order of importance remained similar but a 
reduction in the risk of BM became more important, relative to gains in the other attributes. 
Preliminary analysis suggests if PCI is able to reduce BM risk by 15% and increase survival 
by >6months, participants have a probability of uptaking PCI of 0.66 pre- and 0.55 post-
treatment, even if they are left with severe problems caring for themselves and severe 
memory loss. Conclusion: The majority of patients would accept PCI for an increase in 
survival >6months, with a reduction in BM by 15%, , even if severe memory/self-care 
problems occurred. Patients would avoid PCI if it caused severe problems with memory/ 
self-care versus mild-moderate problems with memory/self-care, when survival gain is less 
than 6 months. Patients care more about avoiding BM following the completion of therapy. 
Keywords: Patient Preferences, Survival Gain, Reduction in Brain Metastases, toxicity, 
prophylactic cranial irradiation
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MINI34.01 MicroRNA Profiling of a Familial Primary Pulmonary Enteric 
Adenocarcinoma Ingrid Garajová1, Niccola Funel2, Michelangelo Fiorentino3, 
Valentina Agostini3, Manuela Ferracin4, Massimo Negrini4, Giovanni Luca Frassineti5, 
Christian Rolfo6, Guido Biasco1, Elisa Giovannetti7 1Department of Experimental, 
Diagnostic and Speciality Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, 
Bologna/Italy, 2Division of General and Transplant Surgery, Pisa University Hospital, Pisa/
Italy, 3Department of Pathology, S.Orsola Malpighi Hospital, University of Bologna, Bologna/
Italy, 4Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 
Ferrara/Italy, 5Department of Oncology, Istituto Scientifico Romagnolo Per Lo Studio E La 
Cura Dei Tumori (IRST) IRCCS, Meldola/Italy, 6Phase I-Early Clinical Trials Unit, Department 
of Medical Oncology, Antwerp University Hospital, Edegem/Belgium, 7Cancer Pharmacology 
Lab, Start-Up Unit, University of Pisa, Pisa/Italy
Background: Primary pulmonary enteric adenocarcinoma (PEAC) is defined as a 
pulmonary adenocarcinoma with a predominant component (>50%) of intestinal 
differentiation and tumor cells positive for at least one intestinal marker. Due to its 
peculiarity and rarity, the optimal clinical management of PEAC patients remains unclear. 
A total of thirty cases have been described in literature to date, though familial aggregation 
has never been reported before. This is the first study describing the histological and 
molecular characterization of the PEAC from a patient with a family member affected by 
the same tumor. Methods: We evaluated the molecular characteristics of proband’s PEAC 
applying a previously validated 47-miRNA signature and applying the predictive method to 
estimate tissue-of-origin probabilities. Immunohistochemical (IHC) staining (TTF-1, Napsin 
A, CDX2, cytokeratonins, mucins) and mutational analyses (EGFR, K-RAS, ALK) were 
performed on formalin-fixed, paraffin-embedded tissue of a patient affected by PEAC. 
Results: The familial aggregation of PEAC was associated with similar clinicopathological 
features (age at diagnosis, smoking-habit, tumor localization, multiple colon polyps), 
histologic findings (IHC staining negative for TTF-1 and positive for CDX2) and genetic 
findings (K-RAS(Gly12Asp) mutation, but no EGFR/ALK aberrations). MiRNA profiling 
revealed main similarities with NSCLC (75.98%), and partial overlap with pancreatic 
cancer (PDAC, 23.34%), but not with colorectal cancer (less than 0.5%). Notably, this 
PEAC shares with PDAC key miRNAs associated with tumor aggressiveness (mir-31/-126/-
506/-508-3p/-514).
(See next page for figure.)
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found to depend on MALAT-1 lncRNA expression. Gene expression analysis of A549 
adenocarcinoma cells with differential MALAT-1 lncRNA expression demonstrated 
an influence on the expression of Bcl-2 and its interacting proteins. Conclusion: Bcl-
2 expression was specifically associated with superior prognosis in localized 
NSCLC. An interaction of Bcl-2 with MALAT-1 lncRNA expression was revealed, 
which merits further investigation for risk prediction in resectable NSCLC patients. 
Keywords: NSCLC, apoptosis, MALAT-1, overall survival
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MINI34.03 Novel microRNA Prognostic Signature in Malignant Pleural 
Mesothelioma Francesco Grossi1, Carlo Genova1, Anna Truini1, Simona Coco1, Ernest 
Nadal2, Maria Giovanna Dal Bello1, Irene Vanni1, Angela Alama1, Erika Rijavec1, Giulia 
Barletta1, Federica Biello1, David Beer3 1Lung Cancer Unit, IRCCS AOU San Martino - IST, 
Genova/Italy, 2Medical Oncology, Catalan Institute of Oncology, L’Hospitalet, Barcelona/
Spain, 3University of Michigan, Ann Arbor/United States of America
Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor mainly 
associated with asbestos exposure. MPM patients have a poor outcome (median overall 
survival (mOS) <1 year), therefore novel therapeutic approaches are needed. MiRNA 
have been demonstrated to have a role in tumorigenesis and progression in MPM. This 
Conclusion: In conclusion, we described, for the first time, PEACs in two members of the 
same family, associated with clinicopathological features. Moreover, miRNA profiling 
resembled mostly NSCLC, with a partial overlap with PDAC’s pattern that could explain 
the aggressive behavior compared to most NSCLC and guide future tailored-therapy 
approaches.  
Keywords: microRNA profiling, pulmonary adenocarcinoma, enteric, intestinal
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MINI34.02 Prognostic Impact of Bcl-2 Depends on Tumor Histology and 
Expression of MALAT-1 lncRNA in NSCLC Lars Henning Schmidt1, Dennis Goerlich2, 
Christian Rohde3, Martin Schuler4, Andreas Huge5, Reinhard Voss5, Andreas Faldum6, 
Carsten Mueller-Tidow3, Wolfgang E. Berdel1, Rainer Wiewrodt1 1Muenster University 
Hospital, Muenster/Germany, 2Muenster University Hostital, Muenster/Germany, 3Halle 
University Hospital, Halle/Germany, 4Essen University Hospital, Essen/Germany, 5Integrated 
Functional Genomics, Muenster University Hospital, Muenster/Germany, 6Institute of 
Biostatistics, Muenster University Hospital, Muenster/Germany
Background: Apoptosis is a crucial pathway in tumor growth and metastatic 
development. Apoptotic proteins regulate the underlying molecular cascades and are 
thought to modulate the tumor response to chemotherapy and radiation. However, 
the prognostic value of the expression of apoptosis regulators in localized non-
small-cell lung cancer (NSCLC) is still unclear. Methods: We investigated the protein 
expression of apoptosis regulators Bcl-2, Bcl-xl, Mcl-1, and pp32/PHAPI, and the 
expression of the lncRNA MALAT-1 in tumor samples from 383 NSCLC patients (median 
age: 65.6 years; 77.5% male; paraffin embedded tissue microarrays) For statistical 
analysis correlation tests, Log rank tests and Cox proportional hazard models were 
applied. Results: Tumor histology was significantly associated with the expression of 
Bcl-2, Bcl-xl and Mcl-1 (all p<0.001). Among the tested apoptotic markers only Bcl-2 
demonstrated prognostic impact (HR=0.64, p=0.012). For NSCLC patients with non-
adenocarcinoma histology, Bcl-2 expression was associated with increased overall 
survival (p=0.036). Besides tumor histology, prognostic impact of Bcl-2 was also 
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Erlotinib. Methods: Lung cancer cell lines with EGFR mutation CRL-2868 and CRL 2871 
were treated with 5 nM of erlotinib for 24hours and 72 hours. The erlotinib resistant cells 
were then harvested and then microRNA profiling was done by real time PCR. HTB177 
cell line without EGFR mutation was used as control. Results: We observed an increased 
expression of mir 10b, mir27a and mir27b in CRL-2871 compared to control HTB 177 
cells. Mir 27b is upregulated in both cell lines. The increase expression of mir 10b and mir 
27a were higher in CRL-2871 than the control cells 9 fold and 8 folds respectively. The mir 
27b was increased 300 folds in the CRL 2868 compared with control. Conclusion: We 
observed upregulation of mir 10b, 27a and 27b in lung cancer cells lines with EGFR 
mutation that were resistant to Erlotinib treatment. This suggests an epigenetic 
mechanism of resistance other than the T790M mutation. Further research in patients 
with EGFR mutation resistance to EGFR TKI should be done to confirm this finding. 
Keywords: micro RNA, EGFR TKI resistance, lung cancer
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MINI34.07 A Novel microRNA Signature Associated with Cisplatin Resistance 
in NSCLC Lauren MacDonagh1, Steven G. Gray1, Vincent Young2, Ronan Ryan2, 
Siobhan Nicholson3, Niamh Leonard3, Kenneth J. O’Byrne4, Stephen P. Finn5, Sinead 
Cuffe6, Martin P. Barr1 1Thoracic Oncology Research Group, Trinity College Dublin/St. 
James’s Hospital, Dublin/Ireland, 2Department of Cardiothoracic Surgery, St. James’s 
Hospital, Dublin/Ireland, 3Department of Histopathology, St. James’s Hospital, Dublin/
Ireland, 4Institute of Health and Biomedical Innovation, Queensland University of Technology, 
Brisbane/Australia, 5Department of Pathology, University of Dublin, Trinity College and St. 
James’s Hospital, Dublin/Ireland, 6Hope Department, St.James’s Hospital, Dublin/Ireland
Background: MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs 
that range in size from 19 to 25 nucleotides. Alteration in miRNA expression can cause 
them to act as either tumour suppressor or oncogenes. They have also been shown 
to regulate a number of processes involved in tumour biology such as metastasis, 
invasion and angiogenesis. More recently, miRNAs have been linked to chemo- and radio-
resistance in many solid tumours, including lung cancer. Methods: An isogenic model of 
cisplatin resistance was established by chronically exposing a panel of NSCLC cell lines 
(MOR, H460, A549, SKMES-1, H1299) to cisplatin for 12 months, generating cisplatin 
resistant (CisR) sublines from their corresponding age-matched parental (PT) cells. 
MicroRNA expression profiling was carried out using 7th generation miRCURY LNA™ 
microRNA arrays consisting of 1,919 miRNAs (Exiqon). MicroRNAs that were significantly 
increased in CisR sublines were inhibited using antagomirs (Exiqon), while those that 
were significantly decreased were over-expressed using pre-miRs (Ambion). Functional 
studies examining clonogenic survival ability, proliferation (BrdU) and apoptosis 
(Annexin V/PI) were subsequently carried out in the presence or absence of cisplatin. 
To examine the translational relevance of these microRNAs, their expression was further 
examined in a cohort of pre-treatment matched normal and tumour lung tissues from 
NSCLC patients of different histological subtypes. Validation of this miRNA signature 
is currently being investigated in serum samples from this same cohort of patients and 
normal controls. Results: MicroRNA profiling analysis identified ten miRNAs which were 
significantly altered between parental and corresponding cisplatin resistant lung cancer 
cell lines. Validation of these miRNAs by real-time PCR (qPCR) identified a specific 5-miR 
signature that was significantly altered in CisR cells relative to their parental counterparts. 
Modification of these microRNAs altered the response of resistant cells to the cytotoxic 
effects of cisplatin and decreased the clonogenic survival of CisR cells when treated with 
increasing doses of cisplatin (0.1µM-10µM). Significant differential expression was found 
between normal and tumour tissues across each histological subtype, highlighting the 
potential use of these microRNAs as markers of response to cisplatin therapy in NSCLC 
patients. Three miRNAs (miR-A, B, C) belonging to the same family were significantly 
altered in tumour lung tissue of adenocarcinoma and squamous cell histology compared 
to matched normal lung tissue. MicroRNA-D expression was significantly altered in 
squamous cell carcinomas while miR-E was differentially expressed in adenocarcinomas 
only. Data relating to the expression of this novel signature in the circulation of our NSCLC 
patient cohort and normal controls will be presented at WCLC 2015. Conclusion: We 
have identified and validated a novel miRNA signature associated with cisplatin 
resistance in a panel of cisplatin resistant cell lines and in patient lung tumours. Genetic 
manipulation of these specific miRNAs in vitro altered the cisplatin resistant cell response 
to the cytotoxic effects of cisplatin chemotherapy. The data obtained from this study 
may provide a basis for the potential development of a companion diagnostic for lung 
cancer patients who are most likely to benefit, or not, from cisplatin chemotherapy. 
Keywords: MicroRNAs, Cisplatin resistance, NSCLC
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MINI34.08 MiR-33B Inhibit EMT Through Wnt/β-Catenin/ZEB1 Pathway in 
Lung Adenocarcinoma Jing J. Qu, Min Li, Tian L. Cheng, Jian An, Li M. Cao, Hua P. 
Yang, Cheng P. Hu Department of Respiratory Medicine, Xiangya Hospital, Central South 
University, Changsha/China
Background: Lung adenocarcinoma is one of the main pathological tissue types 
of lung small cell lung cancer (NSCLC). Tumor metastases are responsible for 
approximately 90% of lung adenocarcinoma-related death. The epithelial–mesenchymal 
transition (EMT) is regarded as a critical event during tumor metastasis. From our 
previous study, we found miR-33b might be involved in the EMT process of lung 
adenocarcinoma. However, the specific mechanism of miR-33b regulating EMT has not 
been established. Methods: Quantitative real time-PCR (qRT-PCR), in situ hybridization 
and immunohistochemistry were used to investigate expression of miR-33b and ZEB1 in 
paired lung adenocarcinoma tissues. MiR-33b target gene ZEB1 was investigated using 
study aimed to identify a miRNA signature associated with poor prognosis. Methods: We 
identified 26 un-resected MPM patients split as follows: 11 long survivors (LS) OS>3 
years and 15 short survivors (SS) OS<1 year. MiRNA expression in 26 FFPE biopsy and 
3 normal pleura (NP) was evaluated using Agilent Human miRNA Microarray platform 
including 2006 miRNA. Expression data were normalized by GeneSpring software 
(v.12.6). Class-comparison analysis between MPM/NP and SS/LS was performed 
using a t-test adjusted for multiple comparisons using Benjamini-Hochberg. OS curves 
were estimated using the Kaplan-Meier method and compared with the log-rank test. In 
silicovalidation was performed using miRseq data from TCGA portal based upon 16 
patients (LS: 8; SS: 8). Candidate miRNA were assessed by univariate analysis using 
Kaplan-Meier method and median as cutoff. Results: Patients’ characteristics: median 
age 67 years (53-77); 81% males, 19% females; 73% epithelioid histotype, 12% 
sarcomatoid, 12% biphasic and 1 unspecified MPM. No differences in age, gender and 
histotype were observed between LS and SS. By class-comparison analysis, 30 miRNAs 
were significantly up-regulated and 11 down-regulated in MPM vs NP (adjusted p-value 
<0.05). Fourteen miRNAs were significantly associated with outcome, in the univariate 
survival analysis and differentially expressed in MPM. A miRNA signature, based on the 
top 6 prognostic miRNAs (unfavorable, miR-1224; favorable, miR-99a, miR-125b, let-7b, 
let-7c and let-7i) classified patients into low- or high-risk. High-risk patients showed a 
significantly shorter median OS (4.1 months, 95% CI 2.2-5.9) as compared with low-risk 
patients (median not reached, Log-rank p<0.001). In silico validation analysis confirmed 
that low expression of mir-99a, miR-125b and let-7c was associated with shorter OS. 
Relevant pathways, such as PI3K/AKT, WNT were associated with these top miRNAs by 
pathway analysis. Conclusion: A prognostic miRNA signature was identified by profiling 
a cohort of un-resected MPM, underlying the clinical potential of miRNA as predictors 
of survival. An additional validation in a larger independent cohort of MPM is ongoing. 
Keywords: malignant pleural mesothelioma, miRNA, Prognosis
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MINI34.04 Serum MicroRNA-139-5p Is a Biomarker of Bone Metastasis in Lung 
Cancer Patient Song Xu, Yi Wu, Renwang Liu, Haiyang Fan, Sen Wei, Gang Chen, Jun 
Chen Tianjin Medical University General Hospital, Tianjin/China
Background: Lung cancer is the leading cause of cancer mortality worldwide. About 
30–40% of patients with lung cancer developed bone metastasis during the course of 
their disease, with the median survival time of 7 months approximately. Bone lesion is 
characterized by the imbalance of osteoblastic and osteoclastic activity induced by the 
tumor cells. Mesenchymal stem cells (MSCs) are the progenitor cells of osteoblast cells, and 
therefore it is interesting to investigate whether and how MSCs have biological alterations 
in the tumor microenvironment of lung cancer patients with bone lesion. Methods: We 
tested miR-139-5p and Notch1 expression during MSC osteogenic differentiation, and 
validated the effect of miR-139-5p in MSC osteogenesis by transfection of miR-139-
5p mimic and inhibitor. We also collected blood samples of healthy donors and lung 
cancer with bone metastasis, and tested serum miR-139-5p expression. Results: We 
demonstrated that during MSC osteogenic differentiation in vitro, the expression of miR-
139-5p increased significantly while Notch1 and its downstream factors decreased. By
gain and loss of function studies we showed that miR-139-5p could positively regulate
MSC osteogenic differentiation. And luciferase and western blot assays confirmed that
miR-139-5p targeted Notch1 expression directly. Moreover, Notch1 knockdown by
siRNA could no longer confer miR-139-5p induced MSC osteogenic differentiation. Lung
cancer cell A549 and L9981 secreted factors upregulated miR-139-5p expression and
meanwhile downregulated Notch1 expression in MSC, as well as impaired ALP activity,
the early osteogenic marker of MSCs. More importantly, we observed that serum miR-
139-5p was significantly lower in lung cancer patients with lytic bone lesion compared to 
healthy donors. Conclusion: We demonstrate for the first time, that miR-139-5p could
regulate osteogenic differentiation of MSC by targeting Notch1 mediated signalling
pathway. Lung cancer cells could decrease miR-139-5p expression and inhibit MSC
osteogenic potential. Importantly, serum miR-139-5p is significantly lower in lung cancer
patients with lytic bone lesion compared to healthy donors. Therefore, miR-139-5p might
be a biomarker of bone metastasis in lung cancer patients and treatment with miR-139-
5p mimic might be an interesting strategy to restore the impaired MSC osteogenic
differentiation and to control bone disease in lung cancer patients with bone lesion.
Keywords: miR-139-5p, Notch1, bone metastasis, lung cancer
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MINI34.06 MicroRNA 10b, 27a and 27b Are Upregulated in Lung Cancer Cell 
with Epidermal Growth Factor (EGFR) Mutation Resistant to EGFR TKI Hannah 
Montes1, Emma B. - D. Reyes1, Jared Kevern2, Peter J. Van Veldhuizen3, Chao H. Huang4 
1Kansas City VA Medical Center, Kansas City/MO/United States of America, 2University of 
Kansas Medical School, Kansas City/KS/United States of America, 3Kansas City VA Medical 
Center, Kansas City/United States of America, 4Division of Hematology/Oncology, University 
of Kansas Medical Center, Westwood/KS/United States of America
Background: EGFR Tyrosine Kinase Inhibitor (TKI) is now standard of care in lung cancer 
patients with EGFR mutation. Invariably, these patients develop resistance and would 
require treatment with another EGFR TKI or chemotherapy. The gate keeper mutation 
T790M is responsible for about 50% of resistance cases. There are other mechanisms 
that could confer resistance in these patients. High expression of microRNA (mir) 
10 is associated with worse prognosis in resected lung cancer patients with EGFR 
mutation. The mir 27a and 27b is associated with increased expression of c-met which 
is a potential mechanism of resistance to EGFR. We explored the expression of mir 10b 
and 27a and 27b in lung cancer cell lines with EGFR mutation that were resistant to 
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and actin dynamics. A significantly different pattern of ESYT2 alternative splicing was 
found in primary lung tumors as compared to normal lung tissue (p<0.001). In particular, 
an isoform containing an extra exon was overexpressed in cancer tissues, while the 
expression of the canonical isoform was decreased. We found a significant correlation 
between the splicing pattern of ESYT2 and the expression of FGFR1 in a panel of 43 
lung cancer cell lines (r=-0.724, p<0.001). Using siRNA downregulation, we analyzed the 
implication of the ESYT2 isoforms in tumor biology and demonstrated a distinct role of 
the splice isoforms in actin and tubulin cytoskeleton organization. We also searched for 
splicing factors responsible for the splicing of ESYT2. We found that the ratio of ESYT2 
isoforms correlated with the expression of the splicing factor QKI in lung cancer cell 
lines (r=-0.793, p<0.001). Moreover, in vitro downregulation of QKI markedly affected 
ESYT2 splicing. Interestingly, we found a significant enrichment of QKI targets in the list 
of differentially spliced genes identified by ExonPointer (p<0.001), suggesting that this 
factor is a critical regulator of splicing in lung cancer. Finally, we observed a significant 
downregulation of QKI expression in primary NSCLC compared to adjacent normal lung 
cancer cells (p<0.001), and an association between the nuclear expression of this factor 
and disease-free survival (HR=0.61; 95%CI=0.35-1.05) or overall survival (HR=0.44; 
95%CI=0.21-0.94). Conclusion: Using a novel analytical tool we have identified new 
splicing variants with functional relevance in lung cancer. Moreover, changes in splicing 
events in lung primary tumors were found to be largely regulated by the splicing factor 
QKI, a potential tumor suppressor gene downregulated in NSCLC and associated with the 
prognosis of the disease.
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MINI34.12 Oncofetal miRNA Expression Inactivates Nuclear Factor I/B, 
a Critical Regulator of Lung Development and Lung Adenocarcinoma 
Pathogenesis Daiana D. Becker-Santos1, KelsieL. Thu1, Larissa A. Pikor1, Calum E. 
Macaulay1, William W. Lockwood1, John C. English2, Wendy P. Robinson3, Igor Jurisica4, 
Stephen Lam1, Wan L. Lam1 1Department of Integrative Oncology, British Columbia Cancer 
Research Centre, Vancouver/BC/Canada, 2Department of Pathology, Vancouver General 
Hospital, Vancouver/BC/Canada, 3Department of Medical Genetics, University of British 
Columbia, Vancouver/BC/Canada, 4Princess Margaret Cancer Center, University Health 
Network, Toronto/ON/Canada
Background: Fetal development shares many biological similarities with tumourigenesis 
such as high rates of cell proliferation and vasculature restructuring. Particularly in 
the lung, a number of genes and pathways involved in the development of this organ 
play important roles in the malignant transformation of adult lung cells. Despite 
these biological similarities, there is a paucity of information regarding how specific 
molecular regulators involved in fetal lung development become oncogenes in lung 
cancer. This is the case for micro RNAs (miRNAs), which have a pivotal role in regulating 
gene expression during organ development and tumourigenesis. Therefore, a better 
understanding of the human fetal lung miRNA-transcriptome has the potential to reveal 
key players in lung cancer development and progression. Methods: 131 pairs of non-
small cell lung cancer (NSCLC) tumour and adjacent non-malignant lung tissues and 15 
human fetal lung tissue samples were profiled by miRNA-sequencing. Mann–Whitney U 
tests were performed with Benjamini-Hochberg multiple testing corrections to identify 
miRNAs abundantly expressed in fetal and tumour tissues but scarce in non-malignant 
adult lung (i.e. oncofetal miRNAs). To investigate protein-coding genes controlled by 
the oncofetal miRNAs identified, miRDIP was applied followed by gene reporter luciferase 
assay experiments. The assessment of associations between patient survival and mRNA 
expression of selected genes targeted by the oncofetal miRNAs was evaluated in multiple 
NSCLC cohorts (>1,400 tumour cases). To validate the protein expression of the most 
prominent gene regulated by the oncofetal miRNAs identified, immunohistochemical 
(IHC) analysis was performed on a lung adenocarcinoma (LUAD) tissue microarray 
(TMA). Results: We describe for the first time a comprehensive, unbiased 
characterization of miRNA expression in human fetal lung tissue by miRNA sequencing. 
Through comparison to a large cohort of NSCLC, we identified numerous miRNAs that 
recapitulate their fetal expression patterns in lung cancer. Strikingly, assessment of the 
genes potentially regulated by these oncofetal miRNAs led us to identify Nuclear Factor 
I/B (NFIB), a transcription factor essential for lung development, as being frequently 
targeted by oncofetal miRNAs. Concordantly, analysis of NFIB expression using RNA-
sequencing data for multiple NSCLC cohorts revealed its frequent underexpression 
in tumours (>60%). Remarkably, low expression of NFIB was significantly associated 
with poorer survival in LUAD patients but not in squamous cell carcinoma patients, 
consistent with the functional role of NFIB in distal lung cell differentiation (i.e. cells 
that are the precursors of LUAD). Furthermore, an NFIB-related gene signature was 
identified in LUAD tumours and included several well-known lung differentiation markers 
(TTF-1, ABCA3, GPR116, SFTPB). Finally, the underexpression of NFIB protein was 
validated on a LUAD TMA, which also revealed that tumours presenting lower levels of 
this transcription factor are associated with higher grade, biologically more aggressive 
LUAD (invasive mucinous, micropapillary and solid subtypes). Conclusion: This work 
has revealed a prominent mechanism for the downregulation of a crucial gene for lung 
development, which we found to be associated with aggressive phenotypes of LUAD 
and consequently, poor patient survival. Elucidating the specific role of NFIB in lung 
cancer biology will likely lead to the identification of targetable tumour vulnerabilities. 
Keywords: miRNAs, lung developmental transcription factors, Adenocarcinoma
luciferase reporter gene assays. Western blot, qRT-PCR, immunofluorescence were used 
to compare the expression levels of ZEB1, E-cad, Vim and β-catenin in A549 cells which 
were transfected miR-33b or miR-NC, anti-miR-33b or anti-miR-NC and in vivo. MTT was 
used to analysis growth curves of transfected cells with miR-33b or miR-NC, anti-miR-33b 
or anti-miR-NC, siRNA-NC or siRNA -ZEB1, siRNA-NC or siRNA-β-catenin. The transfected 
cells were subjected to Transwell migration and invasion assays. Results: Mean miR-33b 
levels were significantly lower in lung adenocarcinoma tissues compared with matched 
non-cancerous tissues (0.024± 0.028 vs 0.063 ± 0.074, P < 0.0001). The level of 
miR-33b in NSCLC was strongly correlated with lymph node metastasis (P < 0.0001). 
ZEB1 levels were significantly higher in lung adenocarcinoma tissues compared with 
matched non-cancerous tissues (0.447± 0.371vs0.084 ± 0.112, P <0.0001). The level 
of miR-33b in lung adenocarcinoma was negative correlated with ZEB1 (P < 0.0001,r=-
0.6077). MiR-33b significantly inhibited EMT in lung adenocarcinoma metastasis in vitro 
and vivo (P < 0.05).MiR-33b directly targets the ZEB13’UTR(P < 0.01).β-catenin was 
down regulation by overexpression of miR-33b (P < 0.01). MiR-33b overexpression and 
ZEB1 inhibition suppressed lung adenocarcinoma migration and invasion in vitro (P < 
0.01). Conclusion: On the basis of our results, we propose that miR-33b suppress EMT 
in lung adenocarcinoma through direct targeting of ZEB1 in vitro and in vivo. Moreover, 
we found that Wnt/β-catenin/ZEB1 pathway regulated by miR-33b might involved 
in lung adenocarcinoma EMT. These findings provide new insights into the molecular 
functions of miR-33b as well asthe role of ZEB1 in lung adenocarcinoma metastasis. 
Keywords: EMT, ZEB1, lung adenocarcinoma, MiR-33b
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MINI34.09 The Long Non-Coding RNA AK126698 Modulates Wnt/β-Catenin 
Signaling Through FZD-8 Silencing in Non-Small-Cell Lung Cancer Xiao Fu, 
Hui Li Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical 
University, Beijing/China
Background: Recent evidence indicates that long non-coding RNAs (lncRNAs) play a 
critical role in the regulation of cellular processes, such as differentiation, proliferation 
and metastasis. These lncRNAs are found to be dysregulated in a variety of cancers. 
In our previous study, we have demonstrated that lncRNA AK126698 regulated A549 
cells cisplatin resistance partly through Wnt/β-catenin signaling. However, the clinical 
significance of lncRNA AK126698, and its’ molecular mechanisms of controlling 
cancer cell proliferation and migration are still unclear. Methods: Expression of 
lncRNA AK126698 was analyzed in 55 non-small cell lung cancer (NSCLC) tissues 
and 3 NSCLC cell lines using quantitative polymerase chain reaction (qPCR) assays. 
Gain and loss of function approaches were used to investigate the biological role 
of AK126698 in NSCLC cells. The effects of AK126698 on cell proliferation were 
evaluated by CCK-8 and colony formation assays. Apoptosis was evaluated by flow 
cytometry. Protein levels of AK126698 targets were determined by western blotting and 
fluorescent immunohistochemistry. Results: AK126698 expression was significantly 
decreased in NSCLC tumor tissues compared with normal lung tissues. Additionally, 
reduced AK126698 expression was associated with larger tumor size and advanced 
pathological staging of NSCLC patients. Ectopic expression of AK126698 impaired 
cell proliferation and migration and induced apoptosis in vitro. However, knockdown 
of AK126698 expression promoted cell migration and invasionin in vitro. In addition, 
the expression of FZD8 was inversely correlated with AK126698 in both NSCLC 
tissues and cell lines and that over-expression of AK126698 could significantly down-
regulate the expression of gene downstream of FZD8, including β-catenin, CyclinD1 and 
c-Myc. Conclusion: The results of present study indicate that lncRNA AK126698 might
serve as a suppressor that regulates the pathogenesis of NSCLC through Wnt/β-catenin
signaling pathway. It may provide a new target for therapeutic intervention of NSCLC.
Keywords: long non-coding RNA, Wnt/β-catenin, FZD-8, NSCLC
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MINI34.11 Identification and Functional Characterization of Non-Small Cell 
Lung Cancer-Associated Splice Variants and Splicing Factors Fernando De 
Miguel1, Maria J. Pajares1, Elena Martinez-Terroba1, Xabier Morales1, Ravi D. Sharma2, 
Ana Rouzaut1, Angel Rubio2, Luis Montuenga1, Ruben Pio1 1Cima-University of Navarra, 
Pamplona/Spain, 2Ceit-University of Navarra, San Sebastian/Spain
Background: Deregulation of alternative splicing has become a hallmark of cancer. In 
non-small cell lung cancer (NSCLC), the biological importance of splicing is evidenced by 
the identification of aberrant RNA transcripts associated with somatic mutations in genes 
encoding splicing factors. We have previously developed ExonPointer, an algorithm 
optimized to detect differential splicing cassette events from data obtained in microarrays 
containing probes in exons and junctions. Our present objective was to apply this 
technology for the identification and characterization of cancer-associated splice variants 
and splicing factors in NSCLC. Methods: We applied ExonPointer for the identification of 
differential splice forms in lung cancer tissues (8 adenocarcinomas, 13 squamous cell 
carcinomas and 1 large cell carcinoma) and matched normal lung. We validated the events 
by RT-PCR and used bioinformatics tools, such as DAVID and Ingenuity Pathway Analysis, 
for cluster enrichment analyses. siRNA knockdown of specific splice isoforms was used 
for functional analyses. Prognostic studies were performed by immunohistochemistry 
in 127 primary tissues from patients with NSCLC. Results: The validation rate for the 
top 20 differentially expressed splice events identified by ExonPointer was 70%. Gene 
cluster analyses using the first 250 events showed a significant enrichment of cancer-
related clusters such as Cellular Growth and Proliferation, or Cell Death and Survival. 
Among the validated genes, we identified Extended synaptotagmin-2 (ESYT2). ESYT2 is a 
membrane protein that mediates fibroblast growth factor receptor-1 (FGFR1) endocytosis 
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a cellular model for in vitro studies of biological role of three prognostic miRNAs in 
SCC. Genes regulated by miR-662 and/or miR-192 may be involved in maintaining 
the chemoresistance and clonogenic potential of SCC, and these features may be 
inhibited in a miR-dependent specific manner. Further studies may elucidate predictive 
value of these genes and a possibility of their targeting with novel therapeutics. 
Keywords: microRNA, squamous lung carcinoma, chemoresistance
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MINI35.01 Genetic Alterations in the Fanconi Anemia Pathway in Lung Cancers  
Wenrui Duan, Li Gao, Kathleen Dotts, Arjun Kalvala, Brittany Aguila, Gregory Otterson, 
Miguel Villalona The Ohio State University, Columbus/United States of America
Background: The FA pathway contains 17 complementation groups, referred to as FA 
subtypes A, B, C, D1/BRCA2, D2, E, F, G, I, J, L, M, N, O, P, Q and S. Cells with FA 
deficiency are hypersensitive to DNA damaging agents such as cisplatin and mitomycin 
C (MMC). Disruptions of the FA pathway may involve epigenetic silencing of the FA-core 
complex, mutations or deletion of one or several FA genes. Recently we developed a 
FA triple-staining immunofluorescence (FATSI) method to detect FANCD2 foci formation 
using formalin fixed paraffin embedded (FFPE) tumor samples. We screened 139 non-
small cell lung cancer (NSCL) FFPE tumors for FANCD2 foci formation by FATSI analysis. 
Based on the FATSI analysis, 104 of 139 tumor samples were evaluable (lack of Ki67 was 
defined as non-evaluable samples) for FANCD2 foci status. Among 104 evaluable tumors, 
23 (22%) were FANCD2 foci negative. However, further investigation and confirmation of 
the genetic and epigenetic alterations involved in the FANCD2 foci defective tumors is 
critical for supporting application of this selection process to justify subsequent clinical 
treatment strategies for cancer patients. Methods: The aim of the study is to investigate 
the genetic alterations in the FANCD2 foci defective lung tumors and matching non-tumors. 
The FANCD2 foci defective tumors were identified with the FATSI method. DNA samples 
isolated from frozen tumor and matching non-tumor tissues were analyzed with whole 
exome sequencing. All 17 genes involved in the FA pathway were analyzed. Results: To 
investigate the gene involved in disrupting the FA pathway in patient tumors, we applied 
exome sequencing to 18-paired DNA samples (15 paired foci-negative non-small cell lung 
tumor and non-tumor frozen tissues, and 3 paired foci-positive non-small cell lung tumor 
and non-tumor frozen tissues). Among the 15 foci negative tumors, 7 tumors contain 9 
somatic mutations including FANCA, FANCC, FANCD2, FANCM, FANCM, FANCP/ SLX4 
and FANCS/BRCA1. There was no mutation detected among the three foci positive 
tumors. Loss of heterozygosity (LOH) events were detected in nine tumors, including 
one foci positive and eight foci negative tumors. The LOHs occurred in FANCA, FANCD1, 
FANCD2, FANCM, FANCI, FANCP/SLX4, FANCQ/ERCC4. LOHs on FANCA gene were found 
in three tumors and LOHs on FANCD2 gene were detected in four tumors including one 
foci positive tumor. Conclusion: Based on our preliminary study, 7 of the 15 FANCD2 
foci negative lung tumors contained somatic mutation and 8 of the 15 foci negative 
tumors contained LOHs in the FA genes. A higher frequency of somatic mutation (2 of 7 
tumors) and LOHs (3 of 9 tumors) was detected in FANCA gene. In addition, 4 of 9 tumors 
contained LOHs on FANCD2 indicating the importance of this gene in maintaining FA 
foci formation. However, we are uncertain if these alterations are functional. Given that 
FA pathway disruptions may also involve epigenetic silencing of the FA-core complex, 
plus its collaboration with other proteins, it is necessary to investigate the genetic 
alteration in the FA associated proteins and promoter methylation status of these genes. 
Keywords: Fanconi Anemia genes, exome sequencing
BIOLOGY 
WEDNESDAY, SEPTEMBER 9, 2015 - 18:30-20:00
MINI35.02 Inhibitor of Differentiation 1 (Id-1) Gene Silencing Reduces Liver 
Metastases Formation in a NSCLC Animal Model Eduardo Castanon1, Ines 
Lopez2, Mariano Ponz-Sarvise1, María Collantes3, Margarita Ecay3, Isabel Gil-Aldea4, 
Christian Rolfo5, Alfonso Calvo2, Ignacio Gil-Bazo1 1Oncology, Clinica Universidad de 
Navarra, Pamplona/Spain, 2Solid Tumors and Biomarkers, Center for Applied Medical 
Research. Universidad de Navarra, Pamplona/Spain, 3Nuclear Medicine Department, 
Clinica Universidad de Navarra, Pamplona/Spain, 4Biobank, Fundacion Miguel Servet-
Navarrabiomed, Pamplona/Spain, 5Thoracic Oncology, Multidisciplinary Oncology Centre 
Antwerp, University Hospital Antwerp, Edegem/Belgium
Background: Around 30% of non-small cell lung cancer (NSCLC) patients present LM 
during the disease course causing a negative clinical impact on survival and quality of life. 
The expression of certain genes in cancer cells might be crucial for allowing tumor cells 
to spread to the liver. According to this hypothesis Id1 and Id3 genes, part of the signature 
that facilitates breast cancer cells to disseminate to the lungs, might be determinant 
for NSCLC LM development. Methods: Three cohorts including totally 80 mice were 
compared; Id1 wild-type C57BL/6 (WT) female mice (n = 40) vs. Id1 knock out (IDKO) 
female animals (n = 28) vs Id1/Id3 knock out mice (Id1Id3KO) (n = 12). In both groups 
of mice 500,000 Lewis Lung Carcinoma cells (LLC) Id1 WT (Id1+/+) Id3 WT (Id3+/+), or 
Id1 homozygously deficient (Id1-/-) and Id3 WT (Id3+/+) or Id1-/- and Id3 heterozygously 
deficient (Id3+/-) were generated through gene silencing, and intrasplenically injected. 
Thereafter, both groups of mice were weekly monitored with FDG-micro-positron emission 
tomography (mPET) scans for LM formation. Animals were sacrificed (and tissues 
microscopically analyzed) by the time LM were developed and clinical deterioration was 
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MINI34.13 Long Noncoding RNA BC070487 Represses ZNFX1 during Tobacco-
Induced Lung Carcinogenesis Sichuan Xi1, Jigui Shan2, Hong Xu3, Zuoxiang Xiao4, Yin 
Xiong1, Shakirat Oyetunji11, Leandro Mercedes1, Mary Zhang1, Julie A Hong1, David S. 
Schrump1 1TGIB, NCI/CCR/NIH, Bethesda/MD/United States of America, 2National Cancer 
Institute, Frederick, Frederick/MD/United States of America, 3National Cancer Institute, 
Frederick, Frederick/United States of America, 4Cancer and Inflammation Center for Cancer 
Research, National Cancer Institute, Frederick, Frederick/United States of America
Background: Limited information exists regarding regulation of gene expression by 
long noncoding RNAs (lncRNAs) during initiation and progression of tobacco-associated 
lung cancers. In the present study, an in-vitro model system was used to examine 
the effects of cigarette smoke on lncRNA expression in human respiratory epithelia 
and lung cancer cells. Methods: Micro-array and qRT-PCR techniques were used to 
assess lncRNA and gene expression profiles in normal human small airway epithelial 
cells (SAEC) and immortalized human bronchial epithelial cells (HBEC) cultured in the 
presence or absence of cigarette smoke condensate (CSC). Quantitative chromatin 
immunoprecipitation (ChIP), methyl-DNA immunoprecipitation (MeDIP), and cross-link 
immunoprecipitation (CLIP) techniques were used to assess promoter occupancy, DNA 
methylation, and interaction of lncRNAs with target proteins. Formaldehyde-Assisted 
Isolation of Regulatory Elements (FAIRE) assays were used to identify a regulatory 
sequence for lncRNA BC070487. Results: Micro-array analysis demonstrated that 
under relevant exposure conditions, CSC consistently mediated a 2.5 fold increase in 
BC070487 expression, and 3.6 fold decrease in its immediate downstream target gene, 
ZNFX1, in SAEC. qRT-PCR experiments confirmed a 4-7 fold up-regulation of BC070487, 
with a 4-8 fold down-regulation of ZNFX1 in SAEC and HBEC, as well as Calu-6 and 
H841 lung cancer cells following CSC exposure. BC070487 expression correlated 
inversely with expression of ZNFX1 (BC070487: 1.38-10.31 fold up vs ZNFX1: 2.26-
26.29 fold down) in primary lung cancers relative to adjacent normal lung parenchyma. 
Overexpression or depletion of BC070487 inhibited or enhanced expression of ZNFX1, 
respectively in normal respiratory epithelia and lung cancer cells. CSC as well as 
BC070487-mediated repression of ZNFX1 coincided with increased occupancy of EZH2, 
SUZ12, BMI1, and increased levels of H3K27Me3, with decreased H3K4Me3 within the 
ZNFX1 promoter region. CSC as well as BC070487 overexpression enhanced binding 
of BC070487 with EZH2, SUZ12 and BMI1 proteins in SAEC and Calu-6 cells. CSC 
exposure significantly increased DNA methylation in one of three CpG islands spanning 
the regulatory elements of ZNFX1. In addition, CSC enhanced binding of BC070487 with 
DNMT3A and DNMT3B with site-specific de novo DNA methylation of ZNFX1 in SAEC 
and Calu-6 cells. FAIRE assays identified a 800 bp regulatory sequence for BC070487; 
CSC-mediated activation of BC070487 coincided with increased levels of H3K4Me3, 
H3K27Ac, H3K36Me3, Sp1, and Ago proteins, with decreased levels of H3K27Me3 and 
H3K9Me3 within this regulatory region. miR-31, an oncomiR specifically induced by CSC, 
modulated the transcriptional activity of BC070487 via remodeling the distribution of 
histone modification marks (Up: H3K4Me3, H3K27Ac, H3K36Me3; Down: H3K27Me3 
and H3K9Me3) in the regulatory region of BC070487. Overexpression or depletion of 
BC070487 increased or inhibited proliferation and invasion of lung cancer cells, and 
similarly modulated growth of SAEC and HBEC cells. In contrast, ZNFX1 overexpression 
or depletion decreased or enhanced growth of normal respiratory epithelial cells and 
lung cancer cells. BC070487 overexpression enhanced growth of lung cancer cells 
xenografts in athymic nude mice, while forced expression of ZNFX1 arrested growth 
of these xenografts. Conclusion: Collectively, these data suggest that CSC-mediated 
up-regulation of BC070487 suppresses ZNFX1 to promote pulmonary carcinogenesis. 
Keywords: ZNFX1, cigarette smoke, lung cancer, BC070487
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MINI34.14 Biological Role of Prognostic MicroRNAs (MiRNAs) in Squamous 
Lung Cancer Cell Lines Martyna Filipska1, Marcin Skrzypski2, Jacek J. Bigda1, Jacek 
Jassem2 1Cell Biology Unit, Medical University of Gdansk, Gdansk/Poland, 2Department and 
Clinics of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk/Poland
Background: The benefit from postoperative chemotherapy in non-small cell lung 
cancer (NSCLC) is modest and there are no reliable tools allowing for individual selection 
of high-risk patients for this management. We earlier demonstrated that overexpression 
of three miRNAs: miR-662, -192 and -192* may correlate with the risk of distant 
relapse in squamous cell lung cancer (SCC) patients undergoing pulmonary resection 
(Skrzypski et al. 2014, Br J Cancer). However, the role of these miRNAs in maintaining 
aggressive phenotype and/or chemoresistance of SCC is unknown. The aim of this 
study was to assess the biological role of three abovementioned miRNAs in SCC cells 
in vitro. Methods: In the search for appropriate in vitro model we screened by reverse 
transcription quantitative PCR 11 NSCLC cell lines (H1703, H520, H662, SK-MES-1, A549, 
H23, H1975, HCC 827, PC9, H460 and Calu-6) for miRNA expression profiles and analyzed 
their phenotypic features including migration, invasion and clonogenic potential. H520 
and H1703 SCC cell lines were transfected with locked nucleic acid miRNA inhibitors. The 
sensitivity of transfected and wild type cells to cisplatin and etoposide was compared 
using cytotoxic MTT test. Soft agar colony formation assay was performed to assess 
the clonogenic potential of transfected vs. non-transfected cells. Results: Among the 
analyzed NSCLC cell lines, H520 cells showed natural overexpression of miR-662, -192 
and -192*. These cells were resistant to both chemotherapeutics and exhibited an ability 
to form colonies in soft agar. The inhibition of miR-662 and miR-192 sensitized these cells 
to etoposide (p=0.004 and 0.016, respectively) but not to cisplatin. Similar results were 
obtained for H1703 cells (p=0.002 and 0.02, respectively). H520 cells treated with miR-
192 and miR-662 inhibitors, compared to negative control, also demonstrated reduced 
number of colonies in soft agar (p<0.001). Conclusion: We developed and optimized 
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evident. Results: Expression of Id1 in both the host and the tumor cell line injected were 
independent predictive factors for the presence of LM. In fact, silencing Id1 expression in 
tumor cells (OR = 0.04; CI 95% 0.2 (0.04-0.9) or knocking down Id1 in the host tissues (OR: 
0.2; CI 95% 0.06-0.7), impaired LM presentation. Silencing Id3 seemed not to diminish 
the risk of LM presentation. Conclusion: Absence of Id1 expression in the host partially 
impairs LM presentation. Silencing Id1 in tumor cells diminish the odds of presenting LM. 
Knocking down Id1 in the host or targeting Id1 in the tumor cell may represent a new 
approach to prevent LM presentation, and thus, improving the outcome in NSCLC patients. 
Keywords: Mouse model, Inhibitor of differentiation 1, Liver Metastasis, Gen silencing
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MINI35.03 N-Myc Downstream Regulated Gene 1(NDRG1) Promotes the 
Stem-Like Properties of Lung Cancer Cells Through Stabilized C-Myc 
Yongfang Wang, Kai Wang Respiration Medicine, The Second Affiliated Hospital of the 
Zhejiang University School of Medicine, Hangzhou/China
Background: Tumor-initiating cells (TIC) which were defined their ability to generate 
tumor play a critical role in tumorigenesis and development of lung cancer. However, 
the mechanism underlying how TICs keep self-renewal needs to be clarified. We 
investigated the biological function and clinical significance of N-myc downstream 
regulated gene 1 (NDRG1) in lung TICs. Methods: Recombinant NDRG1 shRNA lentivirus 
or NDRG1-overexpressed lentivirus was employed to knock down or reinforce NDRG1 
expression respectively. Biological functions of NDRG1 silenced and overexpressed 
cells were investigated using in vitro and in vivo methods. Results: NDRG1 was much 
highly expressed in lung tumor-initiating cells compared with parental lung cancer cells 
in both human NSCLC cell lines and primary NSCLC cells. Immunohistochemical on 
the lung cancer tissues showed that NDRG1 was highly expressed. The GSEA analysis 
showed that patients with increased expression of NDRG1 had a worse survival and 
prognosis in the analysis of 226 cases of lung cancer specimens. Enhanced expression 
of NDRG1 promoted stem-like properties of NSCLC cells in A549 and H1975 cells 
while the knockdown of NDRG1 decreased the expression of iPS factors (OCT4、SOX2
、KLF4、C-MYC), the spheres-forming ability in vitro and tumorigenecity and mass of 
lung cancer H1299 and HCC827 cells in vivo. Furthermore, we revealed that c-Myc 
was a key molecule of which NDRG1 involved in the self-renewal of TICs. NDRG1 
was positively correlated with c-Myc expression. NDRG1 inhibited the ubiquitylation 
degradation of c-Myc to promote self-renewal of lung TICs through interaction with 
Skp2. The Interaction between NDRG1 and Skp2 was enforced in lung TICs. Moreover, 
the distribution of NDRG1 was generally in cellular membrane, cytoplasm and nucleus 
of lung cancer cells and its nuclear localization was positively regulated by the 79th 
tyrosine phosphorylation of NDRG1. Phosphorylated NDRG1 at Y79 which was positively 
regulated by PI3K-AKT pathway increased the expression of c-Myc. Conclusion: NDRG1 
promotes the self-renewal of lung TICs through stabilizing c-Myc by interaction with Skp2. 
Our study indicates that NDRG1 is one of potential targets for eradication of lung TICs. 
Keywords: NDRG1, c-Myc, Skp2, lung tumor initiating cell
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MINI35.04 Degradation of FGFR1/Akt/Src/C-Raf/Erk by Arsenic Trioxide and 
FGFR Inhibitor in Squamous Cell Lung Cancer Sze Kwan Lam, James Chung Man 
Ho Department of Medicine, The University of Hong Kong, Hong Kong Sar/Hong Kong
Background: Lung cancer is one of the top cancer killers. Squamous cell lung carcinoma 
(SCC) represents the second most common histologic subtype of lung cancer. Arsenic 
trioxide (ATO) inhibits tumor growth and initiates apoptosis in lung adenocarcinoma and 
acute promyelocytic leukemia. Fibroblast growth factor receptor (FGFR) amplification 
has been shown in some SCC. FGFR inhibitor (e.g. PD173074) has been developed to 
inhibit FGFR. Methods: The combination effect of ATO and PD173074 (PD) was studied 
using a SCC cell line (SK-MES-1) with FGFR1 amplification. The effect of ATO and/or 
PD on cell viability and protein expression was studied by MTT assay and Western blot 
respectively. Cell cycle analysis, phosphatidylserine externalization and mitochondrial 
membrane depolarization were monitored by flow cytometry. Proteasome inhibitor (MG-
132) was used to study the degradation mechanism. The in vivo effect of ATO and/or 
PD was investigated with a nude mice xenograft model. Results:Combination of ATO 
and PD reduced cell viability along with increased sub-G1 population, phosphatidylserine 
externalization and mitochondrial membrane depolarization, more significantly than 
single agents alone. Downregulation of FGFR1, p-Akt, Akt, p-Src, Src, p-c-Raf, c-Raf, Erk 
and survivin as well as upregulation of cleaved PARP were observed upon ATO and/
or PD treatment. MG-132 partially reversed the degradation of Akt, Src, c-Raf and Erk 
induced by ATO/PD, suggesting the involvement of proteasome degradation system 
(Fig 1). Nonetheless, the mechanism of FGFR1 downregulation remained unknown. 
Downregulation of FGFR1, Akt, Src, c-Raf and Erk as well as cleaved PARP elevation 
induced by ATO and/or PD were confirmed in vivo (Fig 2). 
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are less understood. Methods: Primary cultures of CAFs and noncancer fibroblasts 
were established from 28 independent resected non-small cell lung cancers and their 
corresponding non-neoplastic lung parenchyma. Collagen gel contraction, xCELLigence 
Real-Time Cell Analysis of proliferation and in vivo tumorigenicity were studied to assess 
the CAF activity. Percent area of desmoplasia among total tumor stroma was used to 
define high desmoplasia (HD) versus low desmoplasia (LD). Gene expression data on 
RNA extracted from contracted gels following 8 hours incubation was obtained using 
Illumina Human HT-12v4 Bead Chips array and was preprocessed and normalized using 
RMA and values were log2 transformed. Two-fold change cutoff was applied to identify 
differentially expressed genes in CAF-HD versus CAF-LD. Results: High desmoplasia 
correlates with higher ability to contract collagen gel, increased cell proliferation and 
tumor growth. Microarray gene expression analysis of the 24 CAF cell lines identified 23 
genes that were differentially expressed between 12 CAF-HD versus 12 CAF-LD lines and 
were correlated significantly (p ≤ 0.05) with the gel contraction. 23 differentially gene 
expression were evaluated in gene expression microarray data (Affymetrix HG-U133 Plus 
2 Array) from 181 NSCLC patients. We found 7 out of 23 differential gene expression to 
be significantly in concordant with the cohort of 181 NSCLC patients. Taking 7 prioritized 
genes, we have generated physical protein-protein interaction network by quering I2D ver. 
3 and visualizing it in NAViGaTOR ver 2.3 (http://ophid.utoronto.ca/navigator). To study 
the degree of desmoplasia and outcome, we used the cohort of 181 NSCLC patients data 
set. We observed that desmoplasia appears to be associated with the time to relapse 
in univariable analysis. The association was far stronger in the adenocarcioma group 
with significance for both univariable and multivariable analysis. Conclusion: We provide 
evidence for a functional heterogeneity of CAFs in NSCLC patients based on the level 
of desmoplasia in tumor stroma. Furthermore, we develop desmoplasia-specific gene 
signature that could subgroup CAFs and contribute to their functional heterogeneity. 
Keywords: Gene Expression, CAF, Heterogeneity, desmoplasia
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MINI35.09 Sonic Hedgehog Is Required for Tumor Progression in a Mouse 
Model of Small Cell Lung Cancer Anette Szczepny1, Samantha Jayasekara1, Amali 
Mudiyanselage1, D. N. Watkins2 1Centre for Cancer Research, MIMR-PHI Institute of Medical 
Research, Clayton/VIC/Australia, 2Kinghorn Cancer Centre, Garvan Institute of Medical 
Research, Darlinghurst/NSW/Australia
Background: Activation of the Hedgehog (Hh) signaling pathway is well documented 
in many cancers including Small Cell Lung Cancer (SCLC). Whilst it has been shown 
that Smoothened, the central Hh pathway mediator, is required for the initiation 
and progression of SCLC in a mouse model, it is unclear what drives activation 
of this pathway in these tumors. As these tumors commonly express the Sonic 
Hedgehog (Shh) ligand and lack pathway activating mutations, it was hypothesized 
that production of the Shh ligand by SCLC cells could be causing cell-autonomous 
pathway activation and thereby driving tumorigenesis. Methods: To address this 
question, we used a well-characterized conditional genetic mouse model of SCLC in 
which inhalation of recombinant adenovirus expressing Cre can trigger recombination 
at loxP sites in the airway epithelium. When the virus is administered to mice double 
homozygous for the conditional p53 and Rb knockout alleles (p53lox/lox;Rblox/lox), 
mice develop multiple tumors over 9 months. To define the role of the Shh ligand in 
the initiation and progression of SCLC in this tumor model, p53lox/lox;Rblox/lox animals 
were further crossed with a conditional Shh-overexpressing transgenic mouse 
(ShhTg). Reciprocally, genetic deletion of Shh was achieved by crossing p53lox/lox;Rblox/
lox mice with a conditional Shh knockout mouse (Shhlox). Results: Aged cohorts of 
AdenoCre-infected p53lox/lox;Rblox/lox;ShhTg mice developed more frequent and 
significantly larger tumors compared to their p53lox/lox;Rblox/lox littermate controls, 
with tumors exhibiting a highly malignant and proliferative phenotype. Conversely, 
genetic deletion of Shh resulted in a dramatic reduction in tumor size inp53lox/
lox;Rblox/lox;Shhlox/lox mice compared to littermate controls. Conclusion: Together, 
these findings demonstrate that Shh plays a crucial role in driving the progression 
of SCLC, suggesting that Shh may be a potentially useful therapeutic target. 
Keywords: mouse models, Sonic Hedgehog, SCLC
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MINI35.11 Mutant ARAF Drives Lung Carcinogenesis Through a Distinct 
Oncogenic Mechanism Luiz H. Araujo1, Joseph M. Amann1, Marcin Imielinski2, Heidi 
Greulich2, Matthew Meyerson2, David P. Carbone1 1The Ohio State University Medical 
Center, Columbus/OH/United States of America, 2Dana Farber Cancer Institute, Broad 
Institute of Harvard and MIT, and Massachusetts General Hospital, Boston/MA/United States 
of America
Background: We recently identified a novel somatic mutation in ARAF in a lung 
adenocarcinoma from a patient that demonstrated a remarkable response to sorafenib. 
The S214C lies in a negative regulatory domain of ARAF, distinct from the catalytic 
domain mutations commonly found in BRAF. The aim herein was to characterize the 
biochemical and functional aspects of ARAF S214C. Methods: ARAF constructs were 
generated and ectopically expressed in an immortalized bronchial epithelial cell line 
(BEAS-2B). We evaluated the acquisition of anchorage independence, MEK activation, 
and cell morphology. COS7 cells were used for co-immunoprecipitation (IP) and 
kinase assays. Results: Cells expressing ARAF S214C substantially increased soft 
agar colony formation relative to vector, wild-type, kinase-dead (D429A), and double-
mutant (S214C+D429A) variants. Accordingly, ARAF S214C cells exhibited increased 
phospho-MEK levels, suggesting that the transforming potential is dependent on its 
kinase activity. Interestingly, ARAF S214C cells acquired an elongated, fibroblast-like 
Conclusion: Massive protein degradation (FGFR1, Akt, Src, c-Raf and 
Erk) was induced by ATO and/or PD treatment mainly via proteasomal 
degradation in a SCC cell line (SK-MES-1) in vitro and in vivo. Potential role 
of combined ATO with FGFR inhibitor in SCC warrants further exploration. 
Keywords: FGFR1/Akt/Src/c-Raf/Erk Degradation, Squamous cell lung cancer, arsenic 
trioxide, FGFR inhibitor
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MINI35.07 ATM Mutations in Cancer Cell Lines Predict Higher Mutation Rates 
and Genetic Instability Lars F. Petersen1, Yaoqing Shen2, Alexandra Fox2, Janessa 
Laskin2, D. Gwyn Bebb1 1Oncology, TBCC Translational Labs, University of Calgary, Calgary/
AB/Canada, 2Michael Smith Genome Science Centre, BC Cancer Agency, Vancouver/BC/
Canada
Background: Ataxia telangiectasia-mutated (ATM) is a critical first responder in the cell to 
DNA damage. Individuals lacking ATM are extremely sensitive to DNA-damaging ionizing 
radiation, and are predisposed to develop cancers. The mechanism for ATM dysfunction 
in A-T patients, or cancer patients that are ATM-deficient, is unknown. ATM has been 
sequenced in lung cancer patient samples, but no specific mutation hotspots have been 
linked with disease development, despite ATM being one of the most mutated genes 
in lung cancer. Our own quantitative analysis of ATM protein levels in patient samples 
suggests that expression is lost in 20-25% of cases and that this loss correlates with 
poor overall survival and increased response to adjuvant chemotherapy treatments. We 
believe that this may be the result of increased genomic instability within the cancer cells 
caused by a lack of adequate DNA repair. Given that ATM-deficient cancer cells may have 
higher genetic instability, and that ATM is so highly mutated in lung cancer, we sought to 
quantify the relationship between ATM mutations and genomic instability, as measured 
by total somatic mutations. Methods: Using data available from the Broad Institute’s 
Cancer Cell Line Encyclopedia (CCLE), we correlated mutations in ATM and other genes 
involved with the DNA repair response with the total number of mutations annotated 
in ~900 cancer cell lines. We also analyzed total mutations per cell line against the 
functional impact score of single nucleotide variations (SNVs) within ATM. To determine 
the clinical relevance of the cancer cell line observations, we partnered with the BC 
Genome Sciences Centre (BCGSC) to perform similar analyses on ~100 whole-genome-
sequenced patient samples. Results: We show that in cell lines across all cancer types, 
mutations in ATM correlate with a significantly higher number of total mutations. When 
analyzed by site of origin, the greatest differences in total mutations were found in lung, 
breast, intestinal, and esophageal cancer cells. We examined additional genes associated 
with the DNA-repair response, including direct response genes (i.e. ATR, BRCA1&2) and 
downstream targets (i.e. p53). Only mutations in the direct response genes appeared to 
associate with total mutations, whereas p53 – while more commonly mutated – did not 
correlate with higher mutations. In 10 lung cancer patients, one had a truncating mutation 
and had the second highest number of somatic mutations, and highest among non-
smokers. Conclusion: We have identified a potential relationship between ATM mutation 
and total somatic mutations in cancer cell lines and patient tumour genomes, which may 
be indicative of overall genetic instability in these samples. Analysis of the ATM mutations 
in cell lines and patient samples clearly shows that there are no specific hotspots for 
mutation in ATM that correlate with increased total mutations. Thus screening for ATM 
mutations alone may not be sufficient to indicate loss of function or instability. However, 
this data may prove useful in developing panels of targets to screen as mutation hotspots 
of instability, and ultimately to help identify patients that may benefit from targeted 
or modified therapy options based on ATM-deficiency or higher genetic instability. 
Keywords: mutation, sequencing, ATM, Genome instability
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MINI35.08 Functional Role of Cancer Associated Fibroblasts in Non-Small 
Cell Lung Cancer Patients Roya Navab1, Jing Hao2, Melania Pintilier3, Tao Wang2, 
Igor Jurisica2, Ming S. Tsao2 1Research, Princess Margaret Hospital, MG L/ON/
Canada, 2Research, Princess Margaret Hospital and Ontario Cancer Institute, MG L/ON/
Canada, 3Research, Princess Margaret Hospital and Ontario Cancer Institute, MG M/ON/
Canada
Background: Cancer-associated fibroblasts (CAFs) are well known to strongly 
influence tumor development, progression and metastasis. Their characteristics and 
prognostic role in non-small cell lung cancer (NSCLC) patients have been recognized. 
However, the functional heterogeneity of CAFs between patients and their genetic basis 
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SFN might also have the potential to initiate peripheral-type lung adenocarcinoma. 
Keywords: Tg-SPC-SFN, malignant progresssion, SFN(14-3-3 sigma), Adenocarcinoma
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MINI35.13 Targeting Cancer Stem Cell Factor BMI1 to Sensitize Non-Small 
Cell Lung Cancer to Chemotherapy and Radiation Therapy Kunal R. Chaudhary1, 
Balazs Halmos2, Haiying Cheng3, Jose M. Silva4, Tom K. Hei5, Simon K. Cheng1 
1Department of Radiation Oncology and Center for Radiological Research, Columbia 
University Medical Center, New York/NY/United States of America, 2Division of Hematology/
Oncology, Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital-
Columbia University Medical Center, New York/AL/United States of America, 3Department 
of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York/NY/
United States of America, 4Department of Pathology, Icahn School of Medicine at Mount 
Sinai, New York/NY/United States of America, 5Department of Radiation Oncology and 
Center for Radiological Research, Columbia University Medical Center, New York/United 
States of America
Background: Lung cancer is known to be the most frequent disease and the leading 
cause of cancer-related death in men and women worldwide. Despite treatment advances, 
patient outcomes remain dismal and overall survival at 5 years is only 15%. The resistance 
mechanisms for concurrent chemoradiation therapy are poorly studied. Cancer stem cells 
have been proposed to be the driver for many cancers including lung cancer and may be 
also responsible for therapy resistance. Methods: We sought therefore to identify therapy 
resistance pathways in lung cancer by using genome-wide RNAi high-throughput screen 
via a shRNA viral library pool containing approx. 60,000 individual shRNAs targeting 
alomost 80% of human genome on a human lung adenocarcinoma cell line (PC9) treated 
with cisplatin alone, radiation alone and combined radiation and cisplatin. Results: From 
the cisplatin and radiation screen, analysis of top 100 potential hits interestingly showed 
several cancer stem cells markers including Sox, Lrg6, and members of the Hedgehog 
signaling pathway Patched and Bmi1. FACS analysis showed increased stem cell markers 
CD133, ABCG2 and CXCR4 expression on PC9 cells treated multiple times with cisplatin 
and radiation compared to non-treated cells, pointing towards acquired stemness of 
lung cancer cells after treatmentent and subsequently resistanve to treatment. Further 
FACS and real time PCR analysis revealed evlevated EMT marker such as CD44 and 
SNAIL and decreased expression of E-Cadherin and Vementin in treated cells compared 
to non-treated cells. Cells treated with cisplatin and radiation in combination with PTC-
209 showed increased cleaved-PARP staining compared to cells treated with combined 
chemoradiation. We further determined the effects of Bmi1 on therapy resistance with 
survival assays by treating PC9 cells with Bmi1 inhibitor PTC-09. MTT cell survival and 
colonogenic assays was performed by treating PC9 cells with PTC-09 in triplicate and 
then treated with increasing dosage of cisplatin (0.1, 1 and 10 µM) or X-ray radiation (2, 4 
and 6 Gy). Significantly decreased cell survival was observed in PTC-09 treated PC9 cells 
treated with cisplatin or radiation compared to control and cisplatin or radiation alone 
treated cells. Further colonogenic assay of PC9 cells treated with 2Gy+1 um cisplatin and 
increasing dosage of PTC-09 showed significant decrease in the ability of cells to form 
colonies compared to control. Conclusion: By performing an unbiased genome wide 
RNAi screen for therapeutic resistance, we have successfully identified and validated a 
molecular regulator of cancer stem cell pathway which enabled us to successfully test 
the revelance of the cancer stem cell model in lung cancer. Our study provides evidence 
for the concept that targeting cancer stem cells can be therapeutically beneficial. We are 
further evaluating effect of Bmi1 using CRISPR knock out model and downstream target. 
Keywords: Functional genomics, resistance biomarkers, NSCLC stem cells, Targeted 
therapy
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MINI35.14 Microthrombosis Enhances Extravasation via Myeloid Hypoxia-
Inducible Factors Colin E. Evans1, Alice Prodger1, Cristina Branco-Price1, Asis 
Palazon1, Petros Tyrakis1, Jingwei Sim1, Helene Rundqvist2, Par-Ola Bendahl3, 
Mattias Belting3, Randall S. Johnson1 1University of Cambridge, Cambridge/United 
Kingdom, 2Karolinska Institutet, Stockholm/Sweden, 3Lund University, Lund/Sweden
Background: Mechanisms that regulate the positive association between thrombosis and 
pulmonary metastasis are incompletely understood. It was hypothesised that thrombus 
formation stimulates a hypoxic response, which in turn promotes extravasation. The 
primary aim was to determine whether thrombosis of the pulmonary microvasculature 
(Tpm) increases extravasation via myeloid (neutrophil and macrophage) hypoxia-inducible 
factor (HIF). Methods: Pulmonary microthrombosis was induced in wildtype and 
conditional HIFα knockout mice by administration of intravenous polystyrene microbeads 
(n=15/group). Murine lung cancer cell extravasation was quantified, and both murine 
pulmonary and human breast tumors (n=221) were characterised by immunostaining and 
image analysis. Results: Tpm was induced in wild type mice via tail vein administration 
of polystyrene microbeads (15µm diameter, 1000/mouse). Tpm led to chronological 
increases in pulmonary HIF1α expression (P=0.01), HIF2α expression (P<0.01), 
neutrophil infiltration (P<0.05), and macrophage infiltration (P<0.05; 1-5days post-
Tpm vs. non-thrombosed vehicle controls, n=8/group/time point); these increases were 
comparable with changes observed following vena cava thrombosis (assessed via image 
analysis of immunostained tissue throughout). In wild type mice with circulating Lewis 
lung cancer cells (LLCs, 1million/mouse i/v), Tpm led to increases in pulmonary fibrin 
deposition (P<0.0001), HIF1α expression (P<0.05), HIF2α expression (P<0.05), and LLC 
extravasation (P<0.0001; 14days post-LLCs vs. non-thrombosed controls, n=15/group). 
Using conditional HIFα knockout mice (vs. wild type littermates), it was shown that Tpm-
induced increases in pulmonary fibrin deposition and LLC extravasation were dependent 
shape, characteristic of MEK-active cells, whereas none of other variants presented this 
morphology. We also demonstrated that cells expressing ARAF S214C with an additional 
RAS-binding domain mutation (R52L) or dimerization interface mutation (R362H) lacked 
MEK activation, showing that RAS binding and RAF-RAF dimerization are essential for 
activity. To elucidate the role of BRAF and RAF1 as dimerization partners of ARAF 
S214C, we performed knockdowns of BRAF, RAF1, or both. ARAF S214C-induced MEK 
activation was not reversed by the BRAF knockdown, however both RAF1 and double 
knockdowns (BRAF and RAF1) led to loss of MEK activation, suggesting that RAF1 is 
required. Subsequently, COS7 cells were co-transfected with tagged constructs of ARAF 
and either BRAF or RAF1, followed by co-IP. We showed that mutant ARAF presents a 
higher rate of dimerization than wild-type ARAF in the presence of sorafenib. Importantly, 
sorafenib-induced heterodimers lacked kinase activity, compatible with the clinical 
response reported. Conclusion: ARAF S214C demonstrates the in vitro features of a 
driver oncogene, and also a distinct mechanism of action. This oncogenic process can 
be successfully suppressed by RAF inhibitors like sorafenib, and could represent a new 
target for personalized therapy in advanced lung adenocarcinoma. 
 
Figure: Summary of the ARAF S214C oncogenic mechanism. 
Keywords: Targeted therapy, Lung neoplasms, oncogene, ARAF
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MINI35.12 Stratifin Accelerates Progression of Lung Adenocarcinoma at an 
Early Stage Aya Shiba, Yunjung Kim, Masayuki Noguchi Department of Pathology, 
Faculty of Medicine, University of Tsukuba, Ibaraki/Japan
Background: Adenocarcinoma in situ (AIS) of the lung has an extremely favorable 
prognosis. However, early but invasive adenocarcinoma (eIA) sometimes has a fatal 
outcome. We had previously compared the expression profiles of AIS with those of eIA 
showing lymph node metastasis or a fatal outcome, and found that stratifin (SFN, 14-3-3 
sigma) was a differentially expressed gene related to cell proliferation (Aya Shiba-Ishii, IJC. 
2011). We also found that SFN expression was totally suppressed in normal lung tissue, 
whereas demethylation of its promoter triggered aberrant SFN overexpression in eIAs in 
a p53-independent manner (Aya Shiba-Ishii, AJP. 2012). SFN has been linked to cancer 
most directly, possibly having tissue-specific functions and regulating progression of the 
cell cycle. Here, we performed an in vivo study to clarify the role of SFN in progression 
of lung adenocarcinoma. Methods: We induced stable knockdown of SFN using two 
individual shRNAs (shSFN). To evaluate the oncogenic activity of SFN, we injected A549-
shSFN intrabronchially or intravenously into SCID mice. Additionally, we generated SFN-
transgenic mice (Tg-SPC-SFN+/-) showing lung-specific expression of human SFN (hSFN) 
under the control of a tissue-specific enhancer, the SPC promoter. In order to observe 
the tumorigenic activity of SFN, Tg-SPC-SFN+/- and WT ICR mice were intraperitoneally 
administered 4 mg 4-(methylnitrosamino) -1- (3-pyridyl) -1-butanone (NNK, a pulmonary 
carcinogen) or saline as a control, and tumorigenicity was assessed for 20 weeks. Lungs 
of representative mice were periodically examined using animal CT. Results: Although 
control A549 cells formed advanced tumors in the lungs of SCID mice after intrabronchial 
and/or intravenous injection, we also found pleural dissemination in the control group (in 
75% after intravenous injection and in 25% after intrabronchial injection). However, A549-
shSFN did not form any tumors. Next, we confirmed the lung-specific expression hSFN in 
Tg-SPC-SFN+/- using RT-PCR and IHC. In a chemical carcinogenesis experiment, animal 
CT revealed several pulmonary tumors in some Tg-SPC-SFN+/- from 15 weeks after 
NNK administration, and at 20 weeks 47.8% of Tg-SPC-SFN+/- (11/23) had developed 
lung tumors, whereas only 11.1% of WT ICR (3/27) had done so (statistically significant). 
Surprisingly, two of seven Tg-SPC-SFN+/-mice (28.6%) developed tumors even though 
they were not administered NNK. All of the tumors that developed in Tg-SPC-SFN+/- lung 
expressed hSFN abundantly. Conclusion: Here, we showed that suppression of SFN 
expression in lung adenocarcinoma A549 cells was significantly reduced in terms of not 
only lung tumor formation but also metastatic potential. Additionally, it was found that Tg-
SPC-SFN+/- mice developed lung tumors at a significantly higher rate than control mice 
after NNK administration. Interestingly, several Tg-SPC-SFN+/- mice developed lung 
tumors without carcinogen. Because these tumors showed high hSFN expression, SFN 
was thought to facilitate not only tumor progression but also tumor initiation, and to work 
as an oncogene. Soda et al. found that 100% of Tg-EML4-ALK mice developed hundreds 
of adenocarcinoma nodules in both lungs within a few weeks after birth (Nature 2007). 
Although the oncogenic activity of SFN is weaker than that of EML4-ALK fusion kinase, 
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the Dutch Ministry of Health. All participants gave written informed consent. In total, 
7,557 individuals underwent baseline LDCT screening. Incidence-screening rounds 
took place after 1, 3 and 5.5 years. This study included participants with solid non-
calcified nodules, newly detected after baseline and also in retrospect not present on 
any previous screen. Lung cancer diagnosis was based on histology, and benignity was 
based on either histology or a stable size for at least two years. Nodule volume was 
generated semi-automatically by Lungcare software (Siemens, Erlangen, Germany), and 
the nodule detection limit was 15mm3. Results: During the incidence screening rounds, 
1,484 new solid nodules were detected in 949 participants (77% male), with a median 
age of 59 years (interquartile-range 55-63 years). At the second screening round (1 
year after baseline), at least one new solid nodule was present in 4.7% (344/7,295) 
of participants, and at the third screening round (2 years after the second screening 
round) additional new nodules were found in 7.1% (491/6,922) of participants. Eventually, 
a new solid nodule was proven to be lung cancer in 7.9% (75/949) of participants with 
new solid nodules (77 cancers). A higher number of pack-years smoked increased the 
risk of a new nodule being cancer significantly (P=0.004). Age and gender distribution 
were comparable between participants with and without lung cancer detected in a 
new solid nodule (P=0.236 and P=0.157 respectively). The majority of cancers was 
diagnosed at stage I (48/77 [62.3%]). Most of the lung cancers were adenocarcinoma 
(30/77 [39.0%]), squamous cell carcinoma (20/77 [26.0%]) or small cell lung cancer 
(9/77 [11.7%]). Conclusion: New solid nodules are common findings in LDCT lung 
cancer screening and possess a comparably high risk of malignancy. Guidelines 
may need to consider a more stringent follow-up for new nodules. More research 
concerning new nodules is necessary to determine a sufficient follow-up strategy 
and evaluate distinguishing nodule features of benign and malignant new nodules. 
Keywords: Lung neoplasms, new solitary pulmonary nodule, lung cancer screening, 
incidence screening
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MINI36.03 Multi-Nodularity in Baseline CT Lung Cancer Screening and 
Relationship with Lung Cancer Probability Robin Peters1, Marjolein A. 
Heuvelmans2, Pim De Jong3, Peter Van Ooijen1, Matthijs Oudkerk2, G. H. De Bock1, R 
Vliegenthart2 1University Medical Center Groningen, Groningen/Netherlands, 2Department 
of Radiology, University of Groningen, University Medical Center Groningen, Groningen/
Netherlands, 3University of Utrecht, University Medical Center Utrecht, Utrecht/Netherlands
Background: Currently, there is little known about prevalence of multi-nodularity 
in a high risk screening population. Radiologists often find more than one nodule per 
screenee. Whether the number of lung nodules plays a role in the probability of lung 
cancer, remains still largely unknown. Methods: In the Dutch-Belgian randomized lung 
cancer screening trial (NELSON), launched in 2003, participants were selected with 
at least one non-calcified nodule at baseline. The NELSON trial was approved by the 
Ministry of Health and the ethics board of each participating center. All participants 
gave written informed consent. The per-participant number of baseline nodules was 
determined. The probability of lung cancer was compared for categories based on 
the number of baseline nodules, using chi-square testing. Lung cancer diagnosis was 
confirmed by histology. Nodules were classified as benign if they did not show growth 
for up to six years after baseline. Results: 3,392 participants (84,4% male, median age 
58 years, median pack years 37,9) with 7,258 nodules at baseline CT screening were 
included. Of these 3,392 screenees, 1,746 (51,5%) had one nodule, 800 (23,6%) had 
two nodules, 354 (10,4%) had three nodules, 191 (5,6%) had four nodules, and 301 
(8,9%) had five or more nodules. The probability of lung cancer was 61/354 (3.5%) in 
subjects with one nodule, 37/800 (4.6%) in those with two nodules, 17/354 (4.8%) for 
three nodules, 12/191 (6.3%) for four nodules and 10/301 (3.3%) when a participant had 
over four nodules (p=NS). In the baseline screening round, 62 subjects had a malignant 
nodule. Lung cancer diagnosis was made in the nodule with the largest volume in 60/62 
(96.8%) cases. Overall, lung cancer was diagnosed in 137/3,392 subjects (4.0%) in 
whom nodules were found at baseline. Mean nodule count in screened subjects with 
only benign nodules was 2.1±1.8, compared to 2.3±2.2 in those with a malignant 
nodule. Conclusion: At baseline CT lung cancer screening, nearly half of screened 
participants with lung nodules have more than one lung nodule. Nodule count did not 
have predictive value in the determination of lung cancer probability in lung cancer 
screening participants. In the first screening round, of all detected nodules per screenee, 
lung cancer was detected most frequently in the nodule with the largest volume. 
Keywords: Lung cancer probability, Multinodularity, Lung cancer sreening
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MINI36.04 Automated Measurement of Malignancy Risk of Lung Nodule 
Detected by Screening Computed Tomography Alexander J. Ritchie1, Martin 
Tammemägi2, Colin Jacobs3, John Mayo4, Wei Zhang5, Heidi Roberts6, Michel 
Gingras7, Sergio Pasian7, Lori Stewart8, Scott Tsai8, Daria Manos9, Jean M. Seely10, 
Paul Burrowes11, Rick Bhatia12, Sukhinder Atkar-Khattra13, Bram Van Ginneken3, Ming 
S. Tsao6, Stephen Lam13 1Royal Brisbane Hospital, Brisbane/QLD/Australia, 2Brock 
University, St. Catherines/ON/Canada, 3Radboud University Medical Center, Nijmegen/
Netherlands, 4Vancouver Coastal Health, Vancouver/BC/Canada, 5Peking University 
First Hospital, Beijing/China, 6University Health Network Princess Margaret Cancer 
Centre, Toronto/ON/Canada, 7Institut Universitaire de Cardiologie Et de Pneumologie de 
Québec, Quebec/QC/Canada, 8Juravinski Hospital and Cancer Center, Hamilton/ON/
Canada, 9Dalhousie University, Halifax/NS/Canada, 10Ottawa Hospital Cancer Centre, 
Ottawa/ON/Canada, 11University of Calgary, Calgary/AB/Canada, 12Memorial University, St. 
John’s/NL/Canada, 13BC Cancer Research Centre, Vancouver/BC/Canada
upon HIF1α or HIF2α in neutrophils and macrophages; myeloid HIFs were also responsible 
for Tpm-induced increases in pulmonary tumour proliferation and vascularisation (n=15/
group). In human tumour samples (n=221), fibrin deposition was positively correlated 
with HIF2α expression (RS=0.22, P<0.001), while increases in HIF2α were associated 
with reductions in metastasis-free survival (P<0.05). Conclusion: Thrombus formation 
in mouse pulmonary microvasculature enhances cancer cell extravasation via neutrophil- 
and macrophage-specific HIF1α or HIF2α. In human tumours, HIF2α is associated 
with increased fibrin deposition, and reduced survival. Pulmonary microvascular 
thrombosis can enhance cancer cell dissemination via myeloid cell-specific HIFs. 
Keywords: Hypoxia, HIF, Extravasation, Thrombosis
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MINI36.01 Three-Dimensional Quantitative Computed Tomography Evaluation 
of Pulmonary Adenocarcinoma Using Image-Analysis Software Kazunori Hata1, 
Keiju Aokage1, Hironobu Ohmatsu2, Junji Yoshida1, Genichio Ishii3, Tomoyuki Hishida1, 
Masahiro Tsuboi1 1Division of Thoracic Surgery, Department of Thoracic Oncology, National 
Cancer Center Hospital East, Kashiwa/Japan, 2Thoracic Oncology, National Cancer Center 
Hospital East, Kashiwa, Chiba/Japan, 3Pathology, Resarch Center of Innovative Oncology, 
National Cancer Center Hospital East, Kashiwa, Chiba/Japan
Background: Several 2-dimensional computed tomography (CT) -based evaluation 
methods of small-sized lung adenocarcinomas have been reported as predictors of the 
disease invasiveness. They include the ratio of the maximum diameter of consolidation 
to the maximum entire tumor diameter (C/T ratio), tumor shadow disappearance rate 
on mediastinal window images (TDR), and visual estimation of the ratio of ground-glass 
opacity area (GGO-R). However, these measurements can be poorly reproducible due to 
possible inter-observer discrepancy, and can be unrepresentative because measuring is 
done only on one section of a lesion. We have developed a 3-dimensional quantitative 
entire-nodule evaluation method using novel image-analysis software. The aim of this 
study is to compare the new method to these 2-dimensional evaluation methods as a 
predictor of small-sized invasive lung adenocarcinomas. Methods: There were 101 
consecutive patients with clinical stage IA adenocarcinoma of the lung who underwent 
complete resection between 2002 and 2005 at our institution, excluding patients 
undergoing preoperative treatment and those with multiple lung nodules or with 
a past history of other cancers. Of them, 75 had a nodule separated from the chest 
wall and mediastinum depicted on preoperative thin section CT scan without contrast 
enhancement, and they were the subject of this study. The reconstruction interval 
of the CT scans was 0.2mm and the reconstructed slice thickness was 0.5mm. The 
image analysis software recognizes a nodule as a collection of cubic voxels. Ground 
glass opacity (GGO) was defined as the area of increased attenuation in the lung with 
preservation of the bronchial and vascular margins. As the average CT value of pulmonary 
arteries on non-contrast-enhanced CT was 50 Hounsfield Unit (HU), we measured the 
percentage of the voxels over 50 HU in a nodule to identify voxels representing solid 
component, and the percentage was defined as R-50. Invasive cancer was defined as a 
nodule with pathological lymphatic permeation, vascular invasion or node involvement. 
The correlation between invasive lung cancer and clinicopathological factors, including 
the image findings (C/T ratio, TDR, GGO-R and R-50) was evaluated using multivariate 
analysis. The areas under the curve (AUC) of receiver operating characteristics curves 
were compared among the image evaluation methods. Results: There were 17 invasive 
cancers. C/T Ratio, TDR, GGO-R and R-50 were independent predictors of invasive lung 
cancers (p<0.01). R-50 was equivalent in AUC to the other evaluation methods (AUC: R-50, 
0.807; C/T Ratio, 0.800; TDR, 0.809; GGO-R, 0.792, respectively). Conclusion: Our 
new 3-dimensional quantitative evaluation method using image-analysis software had 
invasive cancer predictability similar to the other 2-dimensional evaluation methods. 
As this method enables entire-tumor evaluation quantitatively and objectively, 
it should be more reproducible and reliable than the conventional methods. 
Keywords: Three-dimensional quantitative computed tomography evaluation, ground-
glass opacity, predictability, computed tomography
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MINI36.02 Newly Detected Solid Nodules at Incidence CT Lung Cancer 
Screening Rounds: Occurrence and Lung Cancer Probability Joan E. 
Walter1, Marjolein A. Heuvelmans1, Geertruida H. De Bock2, Pim A. De Jong3, Rozemarijn 
Vliegenthart1, Matthijs Oudkerk1 1Department of Radiology, University of Groningen, 
University Medical Center Groningen, Groningen/Netherlands, 2Department of Epidemiology, 
University of Groningen, University Medical Center Groningen, Groningen/Netherlands, 
3Department of Radiology, University of Utrecht, University Medical Center Utrecht, Utrecht/
Netherlands
Background: Lung cancer screening by low-dose computed tomography (LDCT) is 
now recommended for high-risk individuals by US guidelines. New nodules detected 
after initial baseline screening may complicate management. So far, reported results 
of new nodules have been inconsistent as different definitions were used. The purpose 
of this study was to determine the occurrence of new solid nodules and their respective 
lung cancer rate at incidence screening rounds of the Dutch-Belgian Randomized 
Lung Cancer Screening Trial (NELSON). Methods: The NELSON trial was approved by 
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accurately abnormal scans for review by a radiologist. Pre-screening by a technician 
and CV software is a promising strategy for reducing workload, improving the speed, 
consistency and quality of scan interpretation of screening chest CTs. Supported by 
the Terry Fox Research Institute, The Canadian Partnership Against Cancer and the BC 
Cancer Foundation on behalf of the Pan-Canadian Early Detection of Lung Cancer Study 
Group.
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MINI36.07 Diagnostic Value of Electromagnetic Navigation Bronchoscopy for 
Peripheral Pulmonary Lesions : A Randomized Controlled Trial Sun Jiayuan1, 
Yi Xin2, Zhang Xin3, Baohui Han4 1Department of Endoscopy, Shanghai Jiaotong University, 
Shanghai Chest Hospital, Shanghai/China, 2Suzhou Lung Care Technologies Co., Ltd., 
Suzhou/China, 3Department of Respiratory Medicine, Shanghai Fudan University, Shanghai 
Zhongshan Hospital, Shanghai/China, 4Department of Pulmonary Medicine, Shanghai 
Jiaotong University Shanghai Chest Hospital, Shanghai/China
Background: Navigational bronchoscope including conventional electromagnetic 
navigation bronchoscope(ENB) and endobronchial ultrasound(EBUS) with a guide 
sheath(GS) for transbronchial lung biopsy (TBLB) has improved the diagnostic 
outcome for peripheral pulmonary lesions (PPLs). However, ENB required the 
bronchoscope for large diameter of the working channel(>2.6mm) which could limit 
the deep of the insertion and EBUS-GS could be regarded as the confirmation tool 
other than navigation system. A new, realtime electromagnetic guidance system for 
bronchoscopy using a thin bronchoscope(4.0mm) with a GS(1.95mm) for TBLB is 
a novel method to increase diagnostic yield of PPLs. Methods: A prospective, open 
label, two centers, randomized controlled pilot study involves two diagnostic arms: 
ENB-GS-TBLB and traditional GS-TBLB which was conducted to determine the ability and 
safety.ENB-GS-TBLB is performed using an electromagnetic navigation system with a 
GS and an internal locatable guide with diameter of 1.45 mm. Primary outcome was 
diagnostic yield. Secondary outcomes were yields by total procedure time, the time 
for finding lesions and the X-ray time using during operation. Complications were also 
documented. Results: Of the 86 patients recruited, 81 had a definitive histological 
diagnosis and were included in the final analysis. The diagnostic yield of the ENB-GS-
TBLB (87%) was greater than GS-TBLB (64%; p<0.05). The time for finding lesions of the 
ENB-GS-TBLB(3min 43s) was significantly less than GS-TBLB(4min 44s; p<0.05). ENB-
GS-TBLB was independent of lesion size or lobar distribution. No complications were 
found in both two groups. Conclusion: ENB-GS-TBLB seems to be an accurate and safe 
procedure. It allowed us to improve the diagnostic yield of flexible bronchoscopy in PPLs. 
Keywords: Electromagnetic Navigation Bronchoscopy, guide sheath, transbronchial 
lung biopsy, peripheral pulmonary lesion
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MINI36.08 18F-FDG PET Imaging Utilization in the National Lung Screening 
Trial Viswam S. Nair1, Vandana Sundaram1, MichaelK. Gould2, Sanjiv S. Gambhir3, 
Manisha Desai1 1Medicine, Stanford University School of Medicine, CA/United States of 
America, 2Department of Research and Evaluation, Kaiser Permanente Southern California, 
Pasadena/AL/United States of America, 3Radiology, Stanford University School of Medicine, 
Ca/United States of America
Background: The National Lung Screening Trial (NLST) showed that chest CT screening 
for patients at risk for lung cancer reduces lung cancer mortality compared to Chest X-Ray 
(CXR) screening, but with considerable costs due to a high rate of false positive findings. 
The use of FDG PET has been advocated as a diagnostic tool to aid clinicians in evaluating 
nodules that may or may not be cancer, but no investigations to date have ascertained 
current practice patterns in a large group of patients across the U.S. Methods: Using 
data from the NLST, we determined the appropriateness and characteristics of diagnostic 
FDG PET use in patients with an abnormal finding (defined as a ≥ 4 mm nodule) during 
lung cancer screening via CT or CXR. Diagnostic FDG PET consisted of either a PET 
alone or combined PET/CT, which was done prior to a lung cancer diagnosis but after an 
abnormal finding. Appropriateness was defined as diagnostic FDG PET use for nodules ≥ 
8 mm. We used multivariable logistic regression techniques to assess factors associated 
with diagnostic FDG PET use. Results: Of 9,964 patients with an abnormal finding during 
any of the three rounds of screening, 1,206 (12%) had a diagnostic FDG PET scan at 33 
different medical centers across the U.S. (Table 1). Forty percent (n = 484) of these 
scans were recommended by a radiologist as a follow-up for an abnormal finding. Twenty-
seven percent (n = 331) were performed for nodules less than 8 mm, and of these 24% 
(n = 81) were recommended by radiologists. There were no regional differences in PET 
use across U.S. areas with endemic fungal disease but patients from the Northeast and 
Southeast were twice as likely as the West to have a PET scan after a positive screen. 
Older age, nodule size ≥ 0.8 –2.0 cm, upper lobe location and a spiculated nodule border 
were associated with increased diagnostic FDG PET use. Conclusion: This is the first 
study to describe differential FDG PET use across the U.S and by medical specialty. 
Importantly, PET imaging was used inappropriately for small nodule evaluation in one out 
of four cases. Future studies should characterize associated costs and whether better 
adherence to current national guidelines can reduce such costs. 
Background: We have previously reported a practical predictive tool that accurately 
estimates the probability of malignancy for lung nodules detected at baseline screening 
LDCT (New Engl J Med. 2013;369:908-17). Manual measurement of nodule dimensions 
and generation of malignancy risk scores is time consuming and subjected to intra- and 
inter-observer variability. The goal of this study is to prepare a nodule malignancy risk 
prediction model based on automated computer generated nodule data and compare 
it to an established model based on radiologists’ generated data. Methods: Using the 
same published PanCan dataset (New Engl J Med. 2013;369:908-17) with the number of 
lung cancers updated, we prepared a logistic regression model predicting lung cancer 
using computer-generated imaging data from the CIRRUS Lung Screening software 
(Diagnostic Imaging Analysis Group, Nijmegen, The Netherlands). Ninety-one of the 
2,537 baseline (first) scans were not available or could not be processed by CIRRUS. 
The remaining 2,446 scans were first annotated by the CIRRUS software. A human non-
radiologist reader then accepted/rejected the annotated marks and manually searched 
the LDCT for nodules missed by CIRRUS or the study radiologist. New nodules found 
that were not recorded by the study radiologist were reviewed by a subspecialty trained 
chest radiologist with 14 years experience in lung cancer screening (JM). Nodule 
morphometric measurements (maximum and mean diameter, volume, mass, density) 
and total nodule count per scan irrespective of size were automatically generated by 
the CIRRUS software. The nodule type (nonsolid, part-solid, or solid), nodule description 
(lobulated, spiculated or well defined) and nodule location (upper versus middle or lower 
lobe) were manually entered. The variables were evaluated in models as untransformed 
and natural log transformed variables. Nonlinear relationships with lung cancer were 
also evaluated. Socio-demographic and clinical history predictors were not included in 
the model. Results: Radiologists evaluation identified 8,570 pulmonary nodules of any 
size in 2063 individuals - 124 nodules in 119 individuals were diagnosed as cancer in 
follow-up. Based on CIRRUS software annotated marks that were accepted by a human 
reader, computer analysis identified 11,520 pulmonary nodules in 2174 individuals - 121 
nodules in 115 individuals were diagnosed as cancer in follow-up. Thirty-six percent of 
new nodules found by CIRRUS and/or second human reader were ≥4 mm (mean±SD, 
5.9± 3.5 mm). Both the computer generated imaging data model (Model-CIRRUS) and 
the radiologist generated data model (Model-RAD) demonstrated excellent discrimination 
and calibration. Their predictive performances were also similar. Comparing Model-CAD 
to Model-RAD, the AUCs were 0.9537 versus 0.9541, the 90th percentile absolute 
errors were 0.0008 versus 0.0007, and the Brier scores were 0.0093 versus 0.0137. 
Mean nodule diameter is a better risk predictor than maximum nodule diameter, nodule 
density or mass. Conclusion: The predictive performances of computer and radiologist 
generated data models were similar. The model can be integrated to the CIRRUS Lung 
Screening software to automatically generate a nodule malignancy risk score to facilitate 
nodule management recommendation. Supported by the Terry Fox Research Institute, 
The Canadian Partnership Against Cancer and the BC Cancer Foundation on behalf of the 
Pan-Canadian Early Detection of Lung Cancer Study Group.
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Background: The recommendation by the US Preventive Services Task Force to screen 
high-risk smokers with low-dose computed tomography (LDCT) and the recent decision 
by the Centers for Medicare and Medicaid Services to fund LDCT screening under the 
Medicare program mean that LDCT screening will be implemented at the population 
level in the US and likely in other countries. With the large volume of scans that will be 
generated, accurate and efficient interpretation of LDCT images is key to providing a 
cost-effective implementation of LDCT screening to the large at risk population. Objective 
To evaluate an alternative workflow to identify and triage abnormal LDCT scans in which a 
technician assisted by Computer Vision (CV) software acts as first reader with the aim to 
reduce workload, improve speed, consistency and quality of interpretation of screening 
LDCT scans. Methods: A test dataset of baseline Pan-Canadian Early Detection of Lung 
Cancer Study LDCT scans (New Engl J Med. 2013;369:908-17) was used. This included: 
136 scans with lung cancers, 556 scans with benign nodules and 136 scans without 
nodules. The scans were randomly assigned for analysis by the CV software (CIRRUS 
Lung Screening, Diagnostic Imaging Analysis Group, Nijmegen, The Netherlands). 
The annotated scans were then reviewed by a technician without knowledge of the 
diagnosis. The scans were classified by the technician as either normal (no nodules or 
benign nodules only, potentially not requiring radiologist review) or abnormal (suspicious 
of malignancy or other abnormality requiring radiologist review). The results were 
compared with the Pan-Can Study radiologists. Nodules found by CIRRUS but not by 
the radiologist were reviewed by a subspecialty trained chest radiologist with 14 
years experience in lung cancer screening (JM). Results: The overall sensitivity and 
specificity of the technician to identify an abnormal scan were: 97.7% (95% CI: 96.3 - 
98.7) and 98.0% (95% CI: 89.5 - 99.7) respectively. The technician correctly identified 
all the scans with malignant nodules. The time taken by the technician to read a scan 
was 208±120 sec. Conclusion: A technician assisted by CV software can categorize 
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Fig.2. A case of CT-guided cutting needle lung biopsy using “Liquid Withdarw” technique 
A: The co-axial inducer needle is located at the margin of the lesion B&C:after biopsy, the 
lidocaine can be seen in the needle passage and no pnemothorax is found. Conclusion: CT-
guided percutaneous lung biopsy using co-axial and liquid withdraw is an accurate, 
safe，reliable technique. Compared to co-axial technique without liquid withdraw, the 
incidence of pneumothorax was reduced from approximately 35% to 10.5%. More 
studies according to liquid withdraw technique will be conducted in our future work. 
Keywords: CT, Lung biopsy, Pneumothorax, lung cancer
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MINI36.11 Pre-Operative Fine Needle Aspiration (FNA) for Diagnosis of 
Suspected Early Stage Lung Cancer Reduces Non-Malignant Resection Rate 
Julie A. Barta1, ClaudiaI. Henschke2, Raja Flores3, David F. Yankelevitz2, Charles A. 
Powell1 1Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount 
Sinai, New York/NY/United States of America, 2Radiology, Icahn School of Medicine at Mount 
Sinai, New York/NY/United States of America, 3Thoracic Surgery, Icahn School of Medicine 
at Mount Sinai, New York/NY/United States of America
Background: Rates of resection of non-malignant lung nodules suspected pre-operatively 
to be lung cancer vary widely and are reported to be as high as 40%. Commonly used 
modalities in the pre-operative workup of new lung nodules suspicious for lung cancer 
include positron emission tomography (PET), bronchoscopy, and computed tomography 
(CT) -guided fine needle aspiration (FNA). We evaluated the non-malignant resection rate 
(NMRR) and the frequency of benign resections among patients with pre-operative FNA in 
our lung cancer center. Methods: The study population was identified using databases 
of the Mount Sinai Departments of Thoracic Surgery and Radiology. Eligible patients 
included those with a CT-guided FNA and/or surgical resection performed during the 
12-month period between July 2013 – July 2014 for known or suspected first primary 
early stage lung cancer presenting with a lung nodule or mass. Cases were included if 
patients were >18 years of age with no history of cancer treated within 5 years. Patient 
data were abstracted from the electronic medical records. Results: A total of 283 
nodules from 264 patients met inclusion criteria. Of these, FNA was performed in 217 
(77%) of the 264 patients, with 131 results (60%) categorized as malignant. Similarly, 
228 nodules (81%) were PET imaged, and 141 (62%) of these were positive (Standard 
Uptake Value >2). Sensitivity and specificity of FNA and PET for diagnosis are reported 
in Table 1. Post-FNA pneumothorax requiring a chest tube occurred in 11/193 FNAs 
performed at Mount Sinai (6%). Of 208 surgically resected nodules, 27 cases (13.0%) 
had a non-malignant diagnosis on pathologic examination. The non-malignant resection 
rate (NMRR) ranged from 0% to 39% by different surgeons and did not correlate with 
surgical case volume. Among the 142 resections preceded by FNA, 11 (7.7%) were found 
to have non-malignant pathology. In contrast, among the remaining 66 resections without 
a pre-operative FNA, 16 (24.2%) were benign (OR 3.81, 95%CI 1.52-9.69; p = 0.001). 
Conclusion: In this single center retrospective analysis, the overall NMRR was lower than 
in previously published reports. Furthermore, the NMRR was significantly lower in 
thoracic operations preceded by a CT-guided FNA compared with those without a pre-
operative FNA. Diagnostic accuracy of FNA in this cohort of patients at moderate to high 
risk for lung cancer is higher than that of PET, with an acceptably low complication rate. 
These findings suggest that pre-operative diagnostic confirmation by FNA results in a low 
rate of non-malignant resection. Keywords: lung cancer, Lung cancer resection, 
Screening for lung cancer, fine needle aspiration
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MINI36.09 CT-Guided Cutting Needle Lung Biopsy Using “Liquid Withdraw” 
Technique: Prominently Reduced Incidence of Pneumothorax Rutian Li, Wei Ren, 
Hang Zhang, Lifeng Wang, Baorui Liu The Comprehensive Cancer Center, The Drum Tower 
Hospital of Nanjing University, Nanjing/China
Background: CT-guided cutting needle lung biopsy is important for the diagnosis of 
lung cancer. The co-axial method is now widely used. However, co-axial method failed 
to decrease the incidence of pneumothorax. This study is to investigate whether our 
new-developed “Liquid withdraw” technique (to inject small amount of lidocaine during 
withdraw of the needle) can reduce incidence of pneumothorax when combined with 
co-axial technique. 
 
Fig.1.What is liquid withdraw 
Methods: From Jan 2013 to Dec 2014, We retrospectively studied 38 CT-guided 
percutaneous lung biopsy using co-axial and liquid withdraw techniques. The 
pathologies and complications secondary to biopsy procedure (pneumothorax, bleeding 
and hemoptysis) were noted. Pneumothorax was graded as mild, moderate, and 
severe. Results: 37 cases was diagnosed out of 38 biopsies, of which 23 cases were 
adenocarcinoma (21 patients consented EGFR mutation test, and 15 cases had EGFR 
mutaions)，2 squamous cell carcinoma, 1 non-small cell lung cancer (cannot be further 
classified after IHC), 1 small-cell lung cancer, 2 primary lung cancer of other types, 5 
metastatic lung cancer and 3 benign diseases. 4 cases (10.5%) happened pneumothorax 
(all were mild pneumothorax), bleeding during biopsy happened in 1 (2.6%) case, 6 
cases with a small amount of hemoptysis (15.8%). No infection, tumor implantation or 
aeroembolism happened.
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Table2. Operative factors in relation to cardiopulmonary complications












<0.001 0.242 0.107 0.128 
<0.001 0.096
 
Conclusion: LAA% is useful for predicting cardiopulmonary complications in patients 
with COPD undergoing lobectomy for lung cancer.In patients with COPD undergoing 
lobectomy for lung cancer, 70 years of age or older, the LAA% 1% or more of the cases, 
more careful intraoperative, and postoperative management are required.
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MINI36.14 Improving Pathways to Early Lung Cancer Diagnosis: Process 
Mapping and Qualitative Analysis Nicole M. Rankin1, Tim Shaw2, Sarah York1, 
Deborah Mcgregor1, Phyllis Butow1, Jane Young1, Kate White1, David Barnes3, Rob 
Zielinski4, Emily Stone5 1Sydney Catalyst, The University of Sydney, Camperdown/NSW/
Australia, 2Faculty of Health Sciences, The University of Sydney, Camperdown/NSW/
Australia, 3Royal Prince Alfred Hospital, Camperdown/NSW/Australia, 4Medical Oncology, 
Orange Health Services, Orange/NSW/Australia, 5St Vincent’s Hospital, Darlinghurst/NSW/
Australia
Background: Lung cancer is one of the most difficult cancers to diagnose in primary 
care settings. Lung symptomatology alone is a poor indicator of likelihood of diagnosis 
and in Australia; most primary care practitioners (general practitioners, GPs) will see only 
one or two lung cancer cases annually. Early diagnosis leads to improved survival with 
5-year lung cancer survival much higher in localised disease (30% versus 16% overall). 
Australia has a mixed public-private model of health services and referral pathways 
from primary to secondary and tertiary services are based on traditional or informal 
networks resulting in wide variations in practices. This presentation will report results 
from diagnostic pathway mapping in lung cancer across three multidisciplinary teams 
(MDTs) to inform future intervention strategies to reduce variation and improve patient 
outcomes. Methods: We conducted process-mapping workshops with each team to 
identify the barriers to delivering diagnostic and treatment services. We also developed 
qualitative interview schedules for GPs and patients. We recruited participants through 
multiple strategies (mail out, personal invitation from the clinical champion) with local 
ethics approval. Results: Forty-six lung cancer clinicians and four consumers participated in 
process mapping workshops across three sites. The resulting process maps highlight health 
system delays and complexities for patients navigating health services, particularly for 
those living in regional and rural areas. The provision of specialist services for lung 
cancer diagnosis varies significantly geographically with potential for patients to be 
lost to follow up. Twelve GPs completed in-depth qualitative interviews or participated 
in a focus group to identify barriers and enablers in diagnostic pathways. Qualitative 
analysis reveals that GPs need tailored information about appropriate referrals to 
specialist pulmonologists or oncologists at the time of a suspicious lung cancer. For 
GPs without established referral networks, there can be significant uncertainty about 
the most appropriate referral pathways. Analysis from qualitative interviews with 20 
lung cancer patients and their carers indicates that they perceive their GP as having an 
advocacy role in coordinating their care across specialists’ appointments and diagnostic 
investigations. Patients reported that personal contact and networking across clinicians 
in primary, secondary and tertiary settings was a significant factor in the timeliness of 
investigations or being referred for treatment. In particular, the urgency or severity of 
symptoms significantly impacted timeliness in securing appointments for investigative 
diagnostic tests. Patients reported that GPs willing to coordinate their care played an 
enabling or facilitating role in their care pathway. Conclusion: This collaborative project 
between clinicians and researchers has identified significant barriers and enablers in 
diagnostic pathways in lung cancer. Primary care practitioners play a significant role in 
managing patient care and require timely and tailored information about how to refer to a 
specialist who actively participates in a MDT. We have subsequently developed a protocol 
to implement a referral decision prompt at the time of CT investigation for those people 
with a suspicious lung lesion. This prompt will be directed at primary care practitioners 
and we are currently undertaking a pilot study to examine its feasibility and acceptability. 
Keywords: early diagnosis, multidisciplinary teams, qualitative methods, implementation 
& dissemination research
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MINI36.12 Diagnosis of Peripheral Lung Nodules: Cost Analysis of EMB/EBUS 
Compared to TTNB K. Adam Lee Thoracic Surgery and Lung Center, Jupiter Medical 
Center, Jupiter/FL/United States of America
Background: This analysis compares the cost–effectiveness of radial endobronchial 
ultrasound (EBUS) and electromagnetic navigation (ENB) to transthoracic needle biopsy 
(TTNB) to achieve diagnosis of suspicious lung lesions. As more centers develop lung 
screening and lung nodule clinics, there will be a need for diagnosis of small pulmonary 
nodules. The National Lung Screening Trial (NLST) showed a probable positive Low Dose 
Computer Tomography (LDCT) incidence of 25%, indicating the number of patients 
requiring a diagnostic evaluation will increase. The expectation of increased lung cancer 
screening due to the Centers of Medicare and Medicaid Services approving coverage 
for LDCT for eligeable patients, and the American College of Chest Physicians (ACCP) 
recommendation for improved techniques to diagnose peripheral lung lesions necessitate 
utilizing clinical and economic assessment tools that support clinical decisions. The study 
seeks to identify the most cost-effective biopsy protocol to reduce costs, and deliver 
improved diagnostic accuracy. Methods: The study reviewed the NLST which enrolled 
over 50,000 people aged 55–74 years with at least a 30-pack/year smoking history, 
in fairly good health and non-symptomatic of lung disease. The study found low-dose 
computed tomography of the chest resulted in a 20% lower mortality from lung cancer 
compared with those who had chest x-rays. Approximately 25% of the LDCT-screened 
patients had a positive screen requiring confirmation of the lung lesion. Using an estimate 
of 5.2 million annual chests CT scans in the USA as a basis for the number of patients 
seeking a confirmative result before being recommended for surgery for possible 
benign lung lesions. The cost–effectiveness models employed estimate the direct costs 
to the hospital and to the patient. Direct costs were calculated using the Medicare 
Median cost files by Current Procedural Terminology (CPT) code for 2012. Additional 
costs were added to account for the fee of the procedure room, nursing and clinical 
support staff, and observation room time. Reimbursement reflects the 2013 Medicare 
allowable payment exclusive of the geographic adjustment factor. Reimbursement 
from commercial insurers is constructed upon a conservative multiple of the Medicare 
allowable. CPT codes subject to the multiple procedure discounts were properly reduced 
by 50% as they would be for reimbursement purposes for both Medicare and commercial 
insurance reimbursement. Results: Modeling 200 representative patients delegated to; 
TTNB, bronchoscopy, or R-EBUS-/ENB-enabled endobronchial percutaneous (Endo-Perc) 
when comparing procedure fees, insurance payment and clinical outcomes, the Endo-
Perc technique lead to the most cost-effective option to biopsy the lung lesion. The 
lower adverse event profile of pneumothorax and reduced cost exhibited by the Endo-
Perc procedure; resulted in a benefit of $130,464 compared with a loss of $562,863 
for TTNB, or a loss of $103,487 for routine bronchoscopy. Conclusion: The results 
suggest combining R-EBUS with ENB provides a high-diagnostic yield at a lower cost 
due to the lower risk of a pneumothorax when compared with transthoracic lung biopsy. 
Keywords: electromagnetic navigation, peripheral lung nodule, cost effectiveness, 
Screening
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MINI36.13 Quantitative Computed Tomography as Predictor of 
Cardiopulmonary Complication after Lobectomy for Lung Cancer in COPD 
Patients Yoshiyuki Yasuura, Tomohiro Maniwa, Naoko Miyata, Reiko Shimizu, Hiroyuki 
Kayata, Hideaki Kojima, Shoji Takahashi, Mitsuhiro Isaka, Yasuhisa Ohde Division of 
Thoracic Surgery, Shizuoka Cancer Center, Shizuoka/Japan
Background: In lung cancer resection, COPD is a risk factor for postoperative 
complications. There are few reports about postoperative complications that 
assume a pictorial emphysematous change an index. We examine a relationship 
of an emphysematous regional ratio in preoperative CT in patients with COPD who 
underwent lung cancer resection and cardiopulmonary complication. Methods: One 
hundred fifty-nine patients with COPD who underwent lobectomy for lung cancer in our 
hospital from 2002 to 2011 were retrospectively evaluated in this study. Preoperative 
factors, including proportion of emphysematous area measured by CT (percentage of 
low attenuation area: LAA%), and operative factors were analyzed. Cardiopulmonary 
complications include pyothorax, pneumonia, atelectasis, acute pulmonary injury, chest 
tube indwelling, O2 long supply and arrythmia. Results: Cardiopulmonary complications 
were observed among 61 patients (38%). Ages, FEV1.0%, LAA% and amounts of 
blood lost were significantly relevant to cardiopulmonary complications by univariate 
analysis. Multivariate analysis indicated that patient’s age and LAA% could be significant 
independent predictors. Table1.Complications incidence by LAA%
LAA% N complications: n=61
no complica-
tions: n=98 p value
~1% 1~10% 
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without side effects. In most cases, three doses administered at weekly intervals caused 
complete regression of established tumors, with response durable for > 2 months. Those 
tumors that regrew were responsive to re-dosing with STA-12-8666, and were subsequently 
eliminated. Further, STA-12-8666 induced complete or partial regression of tumors that 
progressed following fi rst or second line treatment with standard of care agents for SCLC. 
Low dose (50 mg/kg) STA-12-8666 inhibited tumor growth and enhanced the anti-tumor 
activity of 30 mg/kg carboplatin, resulting in complete tumor regression. Pharmacokinetic 
and proteomic analysis confi rmed STA-12-8666 concentration in tumors, and identifi ed 
a signature of DNA damage response biomarkers in STA-12-8666-treated tumors that 
is different from that induced by irinotecan. Conclusion: The fi ndings that HSP90i-drug 
conjugate STA-12-8666 is highly active in preclinical models of SCLC (in both frontline 
and second line settings) support the evaluation of this novel compound in clinical trials. 
Keywords: small cell lung cancer, STA-12-8666, HSP90 inhibitor-SN-38 conjugate, mass 
spectrometry kinome beads
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MINI37.03 Survival after Surgery for pN1 and pN2 Small Cell Lung Cancer: A 
Comparison with Surgical Treatment of Non-Small Cell Lung Cancer Chi-Fu J. 
Yang, Derek Y. Chan, Brian C. Gulack, Paul J. Speicher, Matthew G. Hartwig, Mark F. 
Berry, Betty C. Tong, Mark W. Onaitis, Thomas A. D’Amico, David Harpole
Surgery, Duke University, Durham/NC/United States of America
Background: With the advent of modern chemotherapy and radiotherapy, we 
hypothesize that patients who undergo surgery followed by adjuvant therapy for 
locally advanced small cell lung cancer (SCLC) may have signifi cantly better long-term 
survival compared to historical data suggesting 2-year overall survival of 4-20% for 
patients undergoing surgery for SCLC. Methods: Prospectively-collected perioperative 
outcomes and survival data of patients with pathologic T1-3, N1 and (limited) N2 SCLC 
and non-small cell lung cancer (NSCLC) who underwent complete resection with adjuvant 
chemotherapy ± radiation and no induction therapy were reviewed from the US National 
Cancer Data Base from 2003-2011 using Kaplan-Meier method and propensity-score 
matching. Groups were matched for common prognostic co-variates including year 
of diagnosis, age, sex, race, education, insurance status, facility type, distance from 
facility, Charlson/Deyo co-morbidity score, T and N status, tumor size, and tumor 
location. These prospective data were acquired by certifi ed tumor registrars and include 
over 70% of cancer diagnoses annually in the U.S. Results: During the study period, 369 
and 12,152 patients underwent complete resection for pathologic T1-3 N1-2 M0 SCLC 
and pT1-3 N1-2 M0 NSCLC, respectively. Median follow-up time was 43 months. Five-year 
overall survival was 37% for SCLC pN1 patients and 26% for SCLC pN2 patients (Table). 
Matched patients with pN1/N2 NSCLC had better 5-year survival compared to patients 
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MINI37.01 Chk1 Inhibition Enhances Cisplatin Cytotoxicity Regardless of p53 
Status in Human Small Cell Lung Cancer Cells Wei-Hsun Hsu, Shuo-Tse Hsu, 
Guanhua Rao, In-Gyu Kim, AnnaT. Alberobello, Yisong Wang, Giuseppe Giaccone
Oncology, Lombardi Cancer Center, Washington, DC/United States of America
Background: Small cell lung cancer (SCLC) has a poor prognosis and harbors complex 
genetic alterations including frequent loss-of-function mutations of p53 and Rb, which 
impair the G1/S checkpoint control. Checkpoint Kinase 1 (Chk1) is a vital serine/
threonine specifi c protein kinase responsible for halting the cell cycle in check after 
DNA damage. With abrogation of Chk1-mediated cell cycle checkpoint control, cancer 
cells may enter mitosis with extensive DNA damage leading to mitotic catastrophe and 
apoptotic cell death. Previous in vitro studies showed that p53 defi cient cancer cells 
benefi t from Chk1 inhibition. Here we demonstrate that a combination of Chk1 inhibition 
and cisplatin causes more growth inhibition and caspase activation in SCLC cell lines 
compared to cisplatin alone, regardless of p53 status. Methods: Chk1 inhibition was 
achieved by siRNA knockdown (Qiagen) and AZD7762 (Selleckchem) in p53 mutant SCLC 
cell lines (GLC4, NCI-H82) and p53 intact SCLC cell lines (NCI-H128, NCI-H209). Cell 
viability was measured by Cell-Titer Glo assay (Promega) after 72hrs of drug treatment. 
Synergism was defi ned by combination index (CI)>1 using the Chou-Talalay method. Cell 
cycle analysis was performed by PI staining and detected by FACS. Western blotting and 
immunofl uorescent staining were used to evaluate caspase activation and other signaling 
proteins. Results: SCLC cell lines were treated with cisplatin 24hrs at each IC50 dosage 
after Chk1 siRNA transfection. In GLC4 after 2.5uM cisplatin treatment, cell viabilities of 
control siRNA-treated and Chk1 siRNA-treated cells were 28% and 10.6% (p=0.006, by 
paired t-test), respectively. Similar signifi cant reduction of cell viability was observed in 
1uM cisplatin-treated NCI-H82 cells (44.6% vs. 29.7%; p=0.0632) and in 3uM cisplatin-
treated NCI-H128 cells (62.5% vs. 45.3%; p=0.0155), respectively. More cleaved 
caspase-2 and caspase-3 were noted in Chk1 knockdown plus cisplatin-treated GLC4 
cells than in cisplatin alone. The IC50 (72hrs) of single agent AZD7762 (Chk1 inhibitor) 
treatment was 240nM, 211nM, 266nM and 215nM in GLC4, NCI-H82, NCI-H128 and 
NCI-H209 respectively. The combination indexes of AZD7762 and cisplatin (both given at 
around IC50s) calculated by Chou-Talalay method indicated synergism in all these 4 cell 
lines. Cell cycle analysis revealed that AZD7762 abrogated cisplatin-induced G2/M arrest 
in GLC4 and G1 arrest in NCI-H128. Inhibition Chk1 by AZD7762 was associated with 
reduction of CDC25C and CDC2 phosphorylation. Phospho-Histone H3 (mitotic marker) 
was increased in AZD7762 and cisplatin combined treatment compared to cisplatin alone 
in a p53 independent fashion. Intriguingly, inhibition of Chk1 by AZD7762 alone in GLC4 
cells activated caspase-2. Conclusion: Chk1 inhibition both by siRNA knockdown and 
AZD7762 enhances cisplatin cytotoxicity. The synergism was primarily due to increased 
apoptosis and abolished cell cycle arrest. Although p53 is frequently mutated in SCLC, 
growth inhibition was seen in a p53 independent manner. In GLC4, single agent AZD7762 
treatment can cause caspase-2 activation through an as yet unidentifi ed mechanism. 
Our fi ndings suggest that Chk1 is a potential therapeutic target in small cell lung 
cancer and is synergistic with chemotherapy. The effects of Chk1 inhibitor and its 
combination with chemotherapy agents in SCLC animal models are currently underway. 
Keywords: small cell lung cancer, Chk1, p53
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MINI37.02 The Novel HSP90 Inhibitor-SN-38 Conjugate (STA-12-8666), Is 
Highly Active in Preclinical Models of Small Cell Lung Cancer (SCLC) Yanis 
Boumber1, Anna Gaponova2, Anna Nikonova2, Alexander Deneka2, Alexander Kudinov2, 
Meghan Kopp2, BrianL. Egleston2, Sam Litwin2, JamesS. Duncan2, Kelly Duncan2, 
Hossein Borghaei1, Ranee Mehra1, David Proia3, Erica Golemis2 1Medical Oncology, Fox 
Chase Cancer Center, Philadelphia/PA/United States of America, 2Fox Chase Cancer Center, 
Philadelphia/PA/United States of America, 3Synta Pharmaceuticals, Lexington/MA/United 
States of America
Background: Small cell lung cancer (SCLC) is a highly aggressive disease representing 
12-13% of all lung cancers, with 5 year survival rate of only 6%. While most patients 
respond initially to cytotoxic chemotherapies such as irinotecan, etoposide, or carboplatin, 
resistance rapidly emerges and response to second line agents such as topotecan is limited. 
In contrast to non-small cell lung cancer, few targetable oncogenes have been identifi ed 
in SCLC. STA-12-8666 is a small molecule drug, which binds the tumor-concentrated 
active form of heat shock protein 90 (HSP90), with a cleavable linker attached to SN-
38, the active metabolite of irinotecan. Cleavage of the linker within the tumor provides 
time-release of SN-38 at high local concentration, while signifi cantly limiting drug 
exposure and toxicity in non-transformed tissue. The goal for this work was to evaluate 
STA-12-8666 for potential use as a new second line monotherapy, or as adjuvant in the 
frontline setting for SCLC. Methods: Three dose levels of STA-12-8666 were evaluated in 
comparison to irinotecan, ganetespib, carboplatin, etoposide, cisplatin and chemotherapy 
combinations in 4 independent SCLC xenograft models, including parental and cisplatin-
resistant derivative cell lines (SCLC1, SR2), and a patient-derived xenograft (PDX). STA-
12-8666 was also evaluated in drug combinations. Intratumoral responses were profi led 
using a mass spectrometry based approach to evaluate kinase pathway activation, and 
results confi rmed by immunohistochemistry and western blot analysis. Pharmacokinetic 
analysis was performed to benchmark retention of STA-12-8666 to irinotecan in lung 
tumors. Results: In all four models, high dose (150 mg/kg) STA-12-8666 was tolerated 
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(n=3) 20/56 (n=3) (N=17)
Best overall response, n (%)a
CR 0 1 (33.3) 0 0 0 1 (5.9)
PR 2 (40.0) 2 (66.7) 3 (100.0) 0 0 7 (41.2)
SD 3 (60.0) 0 0 2 (66.7) 1 (33.3) 6 (35.3)
Not evaluable 0 0 0 1 (33.3) 2 (66.7) 3 (17.6)
Overall response rate (CR+PR), n (%)
All patients 2 (40.0) 3 (100.0) 3 (100.0) 0 0 8 (47.1)
Response-evalu-
able patients 2 (40.0) 3 (100.0) 3 (100.0) 0 0 8 (57.1)
aPer RECIST, v1.1
Keywords: etoposide, small cell lung cancer, Carfi lzomib, carboplatin
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MINI37.06 Randomized Phase II Trial of CODE or Amrubicin Plus Cisplatin 
Chemotherapy after Chemoradiotherapy for Limited-Disease Small Cell Lung 
Cancer Ikuo Sekine1, Hideyuki Harada2, Noboru Yamamoto3, Toshiaki Takahashi4, 
Koichi Goto5, Naoyuki Nogami6, Takashi Seto7, Fumihiro Oshita8, Hiroaki Okamoto9, 
Hiroshi Tanaka10, Masashi Wakabayashi11, Yuichiro Ohe3 1Department of Medical 
Oncology, University of Tsukuba, Tsukuba/Japan, 2Radiotherapy Division, Shizuoka Cancer 
Center, Shizuoka/Japan, 3Department of Thoracic Oncology, National Cancer Center 
Hospital, Tokyo/Japan, 4Thoracic Oncology Division, Shizuoka Cancer Center, Shizuoka/
Japan, 5Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 
Chiba/Japan, 6Department of Pulmonary Medicine, National Hospital Organaization, Shikoku 
Cancer Center, Matsuyama/Japan, 7Department of Thoracic Oncology, National Kyusyu 
Cancer Center, Fukuoka City/Japan, 8Department of Thoracic Oncology, Kanagawa Cancer 
Center, Yokohama/Japan, 9Department of Respiratory Medicine, Yokohama Municipal 
Citizen’s Hospital, Yokohama/Japan, 10Department of Internal Medicine, Niigata Cancer 
Center Hospital, Niigata/Japan, 11JCOG Data Center, National Cancer Center Hospital, Tokyo/
Japan
Background: Four cycles of etoposide plus cisplatin (EP) concurrently with accelerated 
hyperfractionation thoracic radiotherapy (AHTRT) is the standard treatment for limited-
disease small cell lung cancer (LD-SCLC). The objectives of this study were to evaluate 
effi cacy and toxicities of CODE or amrubicin plus cisplatin (AP) chemotherapy following 
one cycle of EP and AHTRT in patients with LD-SCLC, and to select the promising arm for 
subsequent phase III trials. Methods: Eligibility criteria included patients with previously 
untreated LD-SCLC with measurable lesion, ECOG PS of 0-1, and 20-70 years of age. 
Eligible patients received one cycle of EP (etoposide 100 mg/m2 on days 1-3 and cisplatin 
80mg/m2 on day 1) plus AHTRT (45Gy/ 30 fractions in 3 weeks). Patients who achieved 
CR, PR or SD were secondarily registered and randomized to receive either 3 cycles of 
CODE (cisplatin 25 mg/m2 on days 1 and 8, doxorubicin 40 mg/m2 on day 1, etoposide 
80 mg/m2 on days 1-3, and vincristine 1 mg/m2 on 8 every 2 weeks) or 3 cycles of AP 
(amrubicin 40 mg/m2 on days 1-3 and cisplatin 60 mg/m2 on day 1 every 3 weeks). 
G-CSF was administered on the days when chemotherapy was not administered in CODE, 
or on day 5 to the day when a neutrophil count exceeded 5,000/µL in AP. Patients with 
CR after CODE or AP received prophylactic cranial irradiation. The primary endpoint 
was the one-year progression-free survival (PFS) after the second registration. Tumor 
responses were assessed with RECIST version 1.1 by the central review committee. 
A better regimen for phase III trial is determined with a randomized phase II selection 
design. The sample size was 72 randomized patients to detect >= 10% difference in 
one-year PFS with a probability of 80%. Results: From May 2011 to Jan 2014, 85 patients 
from 28 institutions were registered. After the induction EP plus AHTRT, 75 patients were 
randomized to CODE (n=39) or AP (n=36). Patient demographics were well balanced 
between the arms. One patient did not receive CODE and 34 (89%) of the 38 patients 
received 3 cycles of CODE, whereas 33 (92%) of the 36 patients received 3 cycles of 
AP. Grade 4 neutropenia, anemia and thrombocytopenia were observed in 47%, 21% 
and 16% of patients in CODE, and in 78%, 6% and 17% of patients in AP, respectively. 
Grade 3 non-hematological toxicities with the incidence of 5% or higher included febrile 
neutropenia (16%), hyponatremia (8%), hypokalemia (5%), fatigue (5%), and anorexia 
(5%) in CODE, and febrile neutropenia (42%), nausea (11%), anorexia (11%), fatigue (8%), 
esophagitis (6%) in AP. CR and PR were noted in 13 and 25 patients in CODE, and in 
10 and 24 patients in AP, respectively. The median overall survival in the 74 patients 
was 42.8 months. The one-year PFS (95% CI) was 41.0 (25.7 - 55.8) % in CODE and 
54.3 (36.6 - 69.0) % in AP. Conclusion: The one-year PFS seemed better in AP than in 
CODE. AP arm is considered to be the test regimen for the subsequent phase III trial. 
Keywords: small cell lung cancer, weekly chemotherapy, Amrubicin, Cisplatin
Conclusion: SCLC T1-3 N1-2 patients who undergo complete resection followed by 
adjuvant chemotherapy ± radiation have 5-year survival greater than 26%. Compared to 
NSCLC, SCLC patients with N1/N2 disease have worse survival; however, the differences 
in survival between NSCLC and SCLC patients with N1/N2 disease are much smaller than 
previously reported. These results support a re-evaluation of the role of surgery in 
multimodality therapy for locally advanced small cell lung cancer. 
Keywords: small cell lung cancer, Surgery, limited stage SCLC, locally advanced SCLC
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MINI37.05 Carfi lzomib, Carboplatin and Etoposide for Previously Untreated 
Extensive-Stage Small Cell Lung Cancer: Initial Results from a Phase 
1b/2 Study Firas Badin1, Elhamy Eskander2, Harry Harper3, Anne Chiang4, Daniel 
Haggstrom5, Wael Harb6, Sanjay Aggarwal7, Eren Demirhan7, William Fisher8 1Baptist 
Healthcare, Lexington/KY/United States of America, 2Frederick Memorial Hospital, Frederick/
MD/United States of America, 3Hackensack University Medical Center, Hackensack/
NJ/United States of America, 4Yale Cancer Center, New Haven/CT/United States of 
America, 5Levine Cancer Institute; Carolinas Healthcare System, Charlotte/NC/United 
States of America, 6Horizon Oncology Center, Lafayette/IN/United States of America, 7Onyx 
Pharmaceuticals, Inc., An Amgen Subsidiary, South San Francisco/CA/United States of 
America, 8Indiana University Health Ball Memorial Hospital, Muncie/IN/United States of 
America
Background: Proteasome inhibitors synergize with topoisomerase inhibitors (eg, 
etoposide), which are frequently used to treat extensive-stage small cell lung cancer (ES-
SCLC; Takigawa et al. Anticancer Res 2006;26:1869–76). Results from study PX-171-007 
(NCT00531284) suggest that carfi lzomib has activity in relapsed SCLC (Papadopoulos 
et al. Cancer Chemother Pharmacol 2013;72:861–8), and clinical experience in myeloma 
suggests that carfi lzomib may be added to other agents with limited additive toxicity. 
Preliminary results are presented from the phase 1b portion of the CFZ004 trial 
(NCT01987232) intended to determine the maximum tolerated dose (MTD) and safety 
of carfi lzomib with carboplatin and etoposide in patients with previously untreated ES-
SCLC. Methods: Patients received carfi lzomib (30-minute intravenous infusion) on days 
2, 3, 9, and 10 (20 mg/m2 [days 2 and 3 of cycle 1]; 20–56 mg/m2 thereafter) and fi xed 
doses of carboplatin (target area under the concentration-time curve: 5 mg/mL/min) 
on day 1 and etoposide (100 mg/m2) on days 1, 2, and 3 of a 21-day cycle for up to 6 
cycles. Assessment of dose-limiting toxicities (DLTs) in cycle 1 was used to determine 
dose escalation up to the MTD or recommended phase 2 dose. Disease response 
was assessed using Response Evaluation Criteria in Solid Tumors (RECIST), version 
1.1. Patients achieving ≥stable disease (SD) after 6 cycles could receive single-agent 
carfi lzomib until disease progression or unacceptable toxicity. Results: As of March 31, 
2015, 17 patients (median age: 59.0 years) had been treated in the phase 1b portion 
in 5 dosing cohorts; enrollment in the 56-mg/m2 cohort is ongoing. Patients initiated 
a median of 6 cycles of carfi lzomib; the median treatment duration was 16.3 weeks. 
One patient (56-mg/m2 cohort) experienced a DLT. There were no on-study deaths. 
Two patients discontinued carfi lzomib due to an adverse event (AE; metastatic pain: 
n=1; decreased neutrophil count: n=1). All-grade AEs were generally consistent with the 
profi les of the agents under study. Thirteen patients (76.5%) had a grade ≥3 AE; the most 
common (≥3 patients) were anemia (n=4), neutropenia (n=4), decreased neutrophil 
count (n=4), and leukopenia (n=3). The preliminary overall response rate (≥partial 
response) in 14 response-evaluable patients was 57.1%, with 1 complete response (Table 
1). All response-evaluable patients achieved ≥SD. Conclusion: The MTD of carfi lzomib 
with carboplatin and etoposide has not been reached. Patients are showing encouraging 
responses to treatment, with AEs generally consistent with the profi les of the agents 
under study. Response data, currently immature, will be updated at the meeting. Table 
1. Phase 1b Best Overall Responses per Investigators
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MINI37.10 Factors Associated with Severe Pneumonitis for Limited Stage Small 
Cell Lung Cancer Ritsuko U. Komaki1, Xiong Wei1, Pamela K. Allen1, Emma B. Holliday1, 
Ahsan Farooqi1, Steven H. Lin1, Peter Balter2, Radhe Mohan2, Zhongxing Liao1, James 
D. Cox1 1Radiation Oncology, MD Anderson Cancer Center, Houston/TX/United States of 
America, 2Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston/
TX/United States of America
Background: Pneumonitis is a major side effect for the treatment of limited stage small 
cell lung cancer with concurrent chemotherapy and radiotherapy (CChRT). Prevention 
is more important than treatment when patients develop grade 3-5 severe pneumonitis 
(SP). We investigated factors causing SP among patients with limited stage small cell 
lung cancer (SCLC) treated by CChRT. Methods: This is a retrospective analysis of 559 
patients with limited-stage SCLC treated at a single institution from 1986-2009 with 
definitive CChRT to a total dose of 45-70 Gray (Gy). Candidate variables included tumor 
size, year of diagnosis & treatment period (1986-1999 vs. 2000-2009), gender, age, 
Karnofsky’s Performance Status (KPS), ethnicity, radiation dose, cycles of induction 
chemotherapy, use of intensity-modulated-radiation-therapy (IMRT) and fractionation. 
CTCAE v2 before 2003 and CTAE v3 in 2003-2009 were used to evaluate SP Grade 
3-5 which were similar. Chi-square test was used for between group comparisons for 
categorical variables and the median test was used for between group comparisons for 
continuous variables. Kaplan-Meier estimates were constructed for overall survival (OS), 
disease-free survival (DFS), local-recurrence-free survival (LRFS), distant metastasis-free 
survival (DMFS). Analysis was performed using Logistic regression analysis with SP as 
the primary endpoint. Results: Of the 559 patients included in this analysis, tumor size 
was available for 520 patients. Median follow-up was 21.2 months (range 1.2-240.8). 
Thirty-five (6.2%) patients developed SP (26 Grade-3, 8 Grade-4 & 1 Grade-5). 2D or 
3DCRT was used before 2000 and IMRT was usually used for small cell lung cancer 
in 2000-2009. Univariate analysis (UVA)showed that SP was associated with treatment 
given in 2000-2009 ( OR 3.93, P<001) ,age ≥ 60 (OR 7.72, P=0.001) ,KPS < 90 (OR 
2.22, P=0.02), IMRT (OR 2.3, P= 0.026) and twice daily fractionation( OR 2.38, P=0.03).
Induction Chemotherapy reduced SP (OR 0.39, P= 0.023) compared to immediate CChRT. 
Tumor size (at cut points 3 cm & 5 cm) did not make significant difference regarding SP. 
Multivariate analysis (MVA) has shown that significantly higher SP was associated with 
treatment given in 2000-2009 (OR 3.42, P=0.006), age ≥ 60 (OR 7.77, P= 0.001), male 
(OR 2.12, P=0.047)and twice daily RT (OR 2.45, P=0.026) . OS was significantly reduced 
among SP group vs. Pneumonitis ≤ Grade 2 (MST 17.9 vs.25 months, P= 0.038) (5-year 
OS 16 % vs. 27%), respectively. SP were not significantly correlated with DFS, LRFS and 
DMFS. Conclusion: Significantly higher SP was seen among patients with limited stage 
small treated in 2000-2009, age ≥ 60, male and twice daily RT. OS was significantly 
reduced SP. UVA showed IMRT causing significantly higher SP. MVA did not show IMRT was 
a significant factor for SP. Tumor size did not show significant difference regarding SP. 
Keywords: Factors, Severe Pneumonitis, Limited Stage Small Cell Lung Cancer
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MINI37.11 Inter-Observer Variability in Hippocampus Delineation on MRI Scans 
for Hippocampal Avoidance Prophylactic Cranial Irradiation Trial Chun Chen1, M. 
De Ruiter2, F. Bartel1, F. Vandaele3, S. Sunaert4, K. De Jaeger5, N. Dollekamp6, Margriet 
Kwint1, E. Dieleman7, Y. Lievens8, Dirk De Ruysscher9, S. Schagen2, Jose Belderbos1 
1Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam/
Netherlands, 2Division of Psychosocial Research and Epidemiology, Netherlands Cancer 
Institute, Amsterdam/Netherlands, 3Department of Radiation Oncology, Multidisciplinary 
Oncology Center Antwerp University Hospital, Antwerp/Belgium, 4Department of 
Radiation Oncology, University Hospital Leuven, Leuven/Netherlands, 5Department 
of Radiation Oncology, Catharina Hospital, Eindhoven/Netherlands, 6Department of 
Radiation Oncology, University of Groningen, University Medical Center Groningen, 
Groningen/Netherlands, 7Department of Radiation Oncology, Academic Medical Center, 
Amsterdam/Netherlands, 8Department of Radiation Oncology, Ghent University, Ghent/
Netherlands, 9Experimental Radiation Oncology, KU Leuven, Leuven/Belgium
Background: Prophylactic cranial irradiation (PCI) is the standard treatment in patients 
with small-cell lung cancer (SCLC) without progression after chemo-radiotherapy in stage 
I-III disease and after having a remission after chemotherapy in stage IV. In an international 
phase III trial (NCT01780675), patients with SCLC are randomised to receive PCI with or 
without Hippocampal Avoidance (HA). Accurate delineation of the hippocampus is crucial 
for this trial. In this study we evaluate the hippocampus delineation variability among 
radiation oncologists in multi-institutions for SCLC patients. Methods: The left and right 
hippocampus from 5 randomly selected patients (10 structures) were delineated by 5 
radiation oncologists and 2 neuroradiologist in 7 institutions according to the RTOG 
atlas (http://www.rtog.org/CoreLab/ContouringAtlases/HippocampalSparing.aspx), 
together with a questionnaire. For each patient, a high resolution 3D inversion recovery 
T1 weighted MRI-scan was first registered to the planning CT-scan (1mm slicing). The 
observer then delineated the hippocampus according to the atlas on axial slices of the 
MRI. The mapped delineations on the CT were then used in dose planning with a 5mm 
margin. The mean and standard deviation (SD) of 1) volume and 2) range in medio-lateral, 
superior-inferior and anterior-posterior directions were computed for each structure. 
The corresponding inter-observer reliability was estimated by the intra-class correlation 
coefficient (ICC absolute agreement) using a linear mixed model. A median surface was 
computed and the overall delineation variability per structure was calculated by the root-
mean-square (rms) of the local SD per sampled points on the median surface, while 
the local SD corresponds to the perpendicular distance between each observer and a 
sampled point. Results: The standard deviation of the delineated volume per structure 
varied from 0.14 to 0.48cm3. The corresponding inter-observer reliability (ICC) was 0.19, 
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MINI37.07 PCI Survival Improvement for Extensive Stage SCLC Limited 
to Patients on Maintenance Systemic Therapy: A Secondary Analysis of 
CALGB 30504 Joseph K. Salama1, Lin Gu2, Xiaofei Wang3, Jeffrey Bogart4, Jeffrey 
Crawford3, Steven Schild5, Neal Ready2, Everett Vokes6 1Radiation Oncology, Duke 
University, Durham/United States of America, 2Duke University Medical Center, Durham/
NC/United States of America, 3Duke University Medical Center, Durham/United States of 
America, 4Suny-Upstate Medical Center, Syracuse/AL/United States of America, 5Radiation 
Oncology, Mayo Clinic, Scottsdale/United States of America, 6Univ of Chicago, Chicago/IL/
United States of America
Background: PCI has become standard of care for extensive stage small cell lung 
cancer (ES-SCLC) patients. However, one recent randomized study establishing this 
standard did not require brain imaging prior to enrollment, and another, which did, failed 
to show a benefit for PCI. CALGB 30504 (Alliance) was a randomized phase II study of 
sunitinib vs placebo in ES-SCLC patients responding to at least 4 cycles of platinum 
based therapy requiring baseline brain imaging at enrollment. As this study spanned 
the introduction of PCI for ES-SCLC, PCI was left to the discretion of the treating team. 
Therefore, we performed a secondary analysis of CALGB 30504 to determine the impact 
of PCI on ES-SCLC patients. Methods: CALGB 30504 was a phase II randomized study in 
ES-SCLC comparing maintenance sunitinib versus placebo following SD or CR/PR to 4-6 
cycles of etopside 100 mg/m2 d1-3 and either carboplatin AUC=5 or cisplatin 80 mg/
m2 d1 q 21 days. Sunitinib was 150 mg PO d 1 then 37.5 mg PO qd until progression. 
The primary objective was to determine if maintenance sunitinib would improve PFS, 
as was recently reported. PCI was recommended at 25 Gy in 2.5 Gy fractions, within 
4-6 weeks of chemotherapy, but not required. Sunitinib was to be held 2 days prior, 
during, and 2 days after the completion of PCI. All statistical analyses were performed 
by the statisticians at Alliance/CALGB Statistical and Data Center on the platform of SAS 
(version 9.3; SAS Institution Inc., Cary, North Carolina). Results: 85 patients received 
maintenance therapy(41placebo, 44 sunitinib). 41 (48%) received PCI, 44 didn’t. All 
patients and tumor characteristics were balanced between PCI and no-PCI patients. 
PCI dose was 25 Gy for 31 patients (range: 25-37.5 Gy). Median time to PCI was 21 
wks (range: 12-27 wks) from enrollment. For all patients, PCI was associated with an 
improvement in PFS (median 7.8 vs 6.5 mo HR=0.63 (95% CI: 0.41-0.98), p=0.037), but 
not OS (median 12.9 vs 13.2 mo, HR=1.01 (95% CI: 0.64-1.62), p=0.955). In placebo 
patients, there was no PFS or OS difference between patients receiving PCI or not. In 
patients randomized to sunitinib, PCI conferred a PFS benefit (9.7 vs 6.8 mo, HR=0.49 
(95% CI: 0.26-0.92), p=0.024), but not an OS benefit (14.1 vs 13.5 mo, HR=0.85 (95% 
CI: 0.44-1.66), p=0.636). When restricted to patients who did not receive PCI, there was 
no difference in survival between sunitinib or placebo patients. In PCI patients, those 
receiving sunitinib had non-significant improvement in PFS (9.7 vs 6.7 months, HR=0.63 
(95% CI: 0.34-1.20), p=0.158) and trended towards an improvement in OS (14.1 vs 10.6 
months, HR=0.56 (95% CI: 0.29-1.10), p=0.087), which was magnified and approached 
significance when crossover patients were excluded (14.1 vs 10.0 mo, HR=0.49 (95% 
CI: 0.22-1.06), p=0.064). Conclusion: PFS, and trends for OS improvement were 
limited to patients receiving the combination of PCI and maintenance sunitinib. Placebo 
patients did not benefit from PCI. Improved outcomes for ES-SCLC patients with PCI are 
likely limited to patients who achieve both intracranial and extracranial disease control. 
Keywords: extensive stage small cell lung cancer, prophylactic cranial irradiation
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MINI37.08 Pazopanib as Second Line Treatment of Platinum Sensitive SCLC 
Patients: A Multicenter Phase II Trial of the Hellenic Oncology Research Group 
Athanasios Kotsakis, Vasilios Karavasilis, Sofia Agelaki, Nikolaos Kentepozidis, Stavros 
Peroukidis, Epaminontas Samantas, Charalambos Christophyllakis, Eleftheria Kleio 
Dermitzaki, Filippos Koinis, George Fountzilas, Vassilis Georgoulias Hellenic Oncology 
Research Group (Horg), Athens/Greece
Background: Pazopanib is a small anti-angiogenic molecule inhibiting the tyrosine 
kinase of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit. An increased angiogenesis 
and VEGF expression has been reported in SCLC which is correlated with disease 
dissemination and poor prognosis. A multicenter phase II study of second line pazopanib 
in patients with SCLC was conducted. Methods: Patients with histologically confirmed 
SCLC who relapsed at least 3 months after the completion of front line VP-16/CDDP 
chemotherapy (platinum sensitive disease) were enrolled. Eligible patients should have 
measurable disease and ECOG performance status (PS) 0-2. Treatment consisted of 
daily p.o. pazopanib 800 mg in cycles of 28 days until disease progression. The primary 
endpoint was progression-free rate (PFR) at 8 weeks since anti-angiogenic factors are 
not associated with objective tumor shrinkage. Results: Thirty seven out of 39 enrolled 
patients (2 pts are still ongoing) were evaluable for response and toxicity. The median 
age was 65 years (range 39-82); male=33 pts; PS 0=22 pts; PS 1=15 pts. Eleven 
(28.2%) patients had only local relapse. The median interval from previous treatment was 
5.4 months (3.0-38.2). One (3%) CR, 10 (26%) PR and 10 (26%) SD were documented, 
for an overall progression free rate (PFR) of 55% (95% CI: 39.4- 71.2%). The median 
PFS and OS was 3.7 and 10.6 mo, respectively, while the estimated 1-year survival was 
58% (median follow up= 18.9 mo). Grade 4 adverse events (AEs) included neutropenia 
(n=2 pts) and diarrhea (n=2 pts) whereas grade 3 AEs were fatigue (n=4pts), nausea 
(n=1 pt), diarrhea (n=2 pts), hand-foot syndrome (n=1 pt) and transaminasaemia 
(n=1 pt). Epistaxis (gr 2) was reported in 3 pts, proteinuria (gr 2) and hypertension 
(gr 2) in 2 pts each. There were no treatment-related deaths. Conclusion: Second line 
treatment with pazopanib of patients with sensitive SCLC, was well-tolerated and resulted 
in a promising overall survival and disease control rate, including objective responses. 
Keywords: pazopanib, SCLC, 2nd line, platinum sensitive
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Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor in the 
pleural lining of the lung and peritoneum with median overall survival with standard of 
care (SOC) chemotherapy only 12 months from diagnosis. This poor prognosis may be 
attributed at least in part to cancer stem cells (CSCs) that are resistant to chemotherapy 
and can mediate cancer recurrence and progression. Focal adhesion kinase (FAK) plays 
an essential role in the survival, self-renewal and tumor-initiating capability of CSCs. 
The FAK inhibitor VS-6063 (defactinib) is currently being tested in patients with MPM 
following disease control on standard pemetrexed/platinum chemotherapy (COMMAND, 
ClinicalTrials.gov NCT01870609). Methods: An Aldefluor assay, previously validated as 
a CSC assay (Shapiro et al., 2014), was used to assess the effects of chemotherapy or 
VS-6063 on CSCs in vitro. Tumor initiating potential of MPM cells after treatment with 
SOC agents, and VS-6063 alone or in combination with pemetrexed was measured in 
vivo. CSC marker expression in MPM patient tumor samples was measured by IHC, Q-PCR 
and RNASeq analysis. Novel CSC markers were validated in an in vivo limiting dilution 
assay. Results: Treatment of a human MPM cell line with pemetrexed or cisplatin, the 
SOC therapy for mesothelioma, resulted in a 6-fold enrichment of ALDH-positive CSCs. 
In direct contrast, the FAK inhibitor VS-6063 markedly reduced the proportion of CSCs. 
Control and pemetrexed-treated MPM cells showed robust tumor initiation in vivo, while 
cells treated with VS-6063 alone or VS-6063 plus pemetrexed had decreased tumor 
initiating capacity. FAK inhibitor was found to selectively induce apoptosis in CSCs, 
indicating that the mechanism of their elimination is cell death. In addition to ALDH, 
several new mesothelioma CSC markers were validated in in vivo limiting dilution assay 
and their clinical utility was assessed. An increase in CSC markers, including ALDH1, 
CD133 and CXCR2, was observed in tumor samples from 11 patients following first line 
pemetrexed-cisplatin chemotherapy. In tumor biopsies from MPM patients treated for 12 
days with VS-6063, tumor pFAK (Y397) and expression of CSC markers was reduced. 
Interestingly, gene expression analysis of these samples revealed an inhibition of CSC 
pathways after VS-6063 administration. VS-6063 maintained the effect of chemotherapy 
in patient-derived xenograft (PDX) mouse model. Treatment with pemetrexed/cisplatin 
resulted in tumor growth inhibition followed by rapid tumor re-growth upon cessation 
of the treatment. Tumor re-growth was substantially delayed when FAK inhibitor was 
administered after chemotherapy. Conclusion: These data provide a strong rationale 
for the current clinical testing of VS-6063 following treatment with pemetrexed plus 
platinum to potentially prolong time to progression in patients with mesothelioma. 
Keywords: Mesothelioma, FAK Inhibitor, Cancer Stem Cells
BIOLOGY AND PROGNOSIS 
WEDNESDAY, SEPTEMBER 9, 2015 - 18:30-20:00
MINI38.02 BAP1 Inactivation in Mesothelioma Is Highly Prevalent Marjorie 
Zauderer, Andrea Cercek, Andreas Rimner, Valerie Rusch, Prasad S. Adusumilli, Garrett 
M. Nash, Andre Moreira, Julija Hmeljak, Marc Ladanyi, Lee M. Krug
MSKCC, New York/NY/United States of America
Background: Efforts to elucidate tumorigenic mutations in mesothelioma are essential 
to advance therapy. Prior efforts to characterize the molecular heterogeneity of this 
disease have been limited by sample condition and testing platforms. Herein, we 
describe efforts to prospectively test patients using next-generation sequencing with 
matched patient germline controls. Methods: Sequential mesothelioma patients were 
approached for consent to our IRB protocol NCT01775072 to perform MSK-IMPACT 
(Integrated Mutation Profiling of Actionable Cancer Targets), a comprehensive molecular 
profiling platform based on solution-phase exon capture and next generation sequencing 
to detect somatic genetic alterations in FFPE tumor specimens. MSK-IMPACT involves 
hybridization capture and deep sequencing of all protein-coding exons of 341 key cancer-
associated genes, including all genes that are druggable by approved therapies or are 
targets of experimental therapies being investigated in clinical trials at MSKCC. Results: 
51 patients with mesothelioma underwent MSK-IMPACT testing (see Table 1). 12 samples 
had low tumor content. Among 39 samples with reliable results, BAP1 was the most 
common alteration (46%). Another 3 samples had changes also thought to inactivate 
BAP1 (2 samples had gene copy number changes just below the cutoff for whole gene 
deletions and 1 had an inversion of LIMD-BAP1 thought to inactivate BAP1), making the 
incidence of BAP1 alterations possibly as high as 56%. In 4 samples with sufficient tumor 
content, no alterations were identified. Table 1
N=39 (%)
Gender M/F 26/13 (67/33)
Primary site of disease * Pleural * 
Peritoneal * Testicular 32 (82) 6 (15) 1 (3)
# identified alteration, average 3
Alterations present in >6% * BAP1 
* NF2 * CDKN2Ap16INK4A * 
SETD2 * CDKN2Ap14ARF * LATS1
* CREBBP * WT1 * CDKN2B *
PI3KCA * PBRM1 * TP53
18 (46) 8 (21) 5 (13) 5 (13) 4 (10) 4 (10) 4 (10) 
4 (10) 3 (8) 3 (8) 3 (8) 3 (8)
Conclusion: Using MSK-IMPACT, BAP1 inactivation is the most common alteration. 
Other aberrations previously reported at high frequency were identified but 
albeit at lower frequencies (NF2 and p16, previously reported as 40% and 75% 
respectively). For multiple samples with deep coverage, no alterations were 
identified. The high incidence of BAP1 mutations in this systematic testing 
makes this pathway ideal for developing and testing targeted therapies. 
Keywords: Mesothelioma, BAP1, NF2, molecular alterations
implying a high variability among the observers. The overall delineation variability per 
structure varied from 0.6 to 1.0mm. Areas with good agreements were the superior and 
inferior part of the hippocampus. The difficult area (Fig.1) was in the anterior medial area, 
close to the amygdala and uncus. The ICC in medio-lateral, superior-inferior and anterior-
posterior directions were 0.55, 0.64 and 0.80, respectively. A large spread of the SD of 
range in medio-lateral direction and the relative low ICC imply that a better instruction, or 
training is desirable to improve the delineations. 
Conclusion: There was a substantial variability in hippocampus delineation among 
the observers. Stricter adherence to the RTOG guidelines and (web-based) training are 
needed. The implication of the variations on the dose distribution is currently verified. 
Keywords: Hippocampal Avoidance Prophylactic Cranial Irradiation, small cell lung 
cancer, Inter-observer variability, hippocampus delineation
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MINI37.12 Survival Trends of Small Cell Lung Cancer (SCLC) in the United 
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Center, Omaha/NE/United States of America, 2Biostatistics, University of Nebraska Medical 
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Center, Omaha/United States of America, 4Internal Medicine/ Oncology-Hematology, VA-
Nebraska Western Iowa Health Care System; University of Nebraska Medical Center, Omaha/
NE/United States of America
Background: Small cell lung cancer (SCLC) has poor outcomes. The past thirty years have 
seen some advances in the management options for SCLC. However the impact of these 
advances on outcomes in the general population with SCLC is unclear. Methods: The 
Surveillance, Epidemiology, and End Result (SEER) registry 18 was used to identify SCLC 
cases from 1988 to 2011. Patients were classified either limited stage (LS) or extensive 
stage (ES) disease at diagnosis. Cox regression model was used to compare overall 
survival after adjustment for confounding covariates. Results: A cohort of 83,396 SCLC 
patients was analyzed. A higher proportion of males had ES-SCLC compared to females 
(72.7% vs. 67.4%; p<0.0001) Males had worse median overall survival (OS) compared 
to females (LS-SCLC: 10 vs. 12 months, HR: 1.11; 95% CI, 1.08-1.14; ES-SCLC: 6 vs. 7 
months; HR: 1.16, 95% CI, 1.14-1.18). A higher proportion of younger patients (≤70 years) 
compared to older patients (>70 years) had ES-SCLC at diagnosis (70.76 vs. 68.02%; 
p<0.0001). However, median OS was worse in older patients for both stages (LS-SCLC: 
10 vs. 13 months; HR 1.31, 95% CI 1.27-1.34; ES-SCLC: 6 vs. 8 months, HR: 1.19, 95% 
CI 1.16-1.21). A higher proportion of whites presented with ES-SCLC as compared to 
blacks or others (70.1% vs. 66.5% and 65.9%; p<0.0001). Blacks had worse median 
OS compared to whites (LS-SCLC: 10 vs. 11 months; HR: 1.07, 95% CI, 1.02-1.12; ES-
SCLC: 6 vs. 7 months, HR: 1.07, 95% CI 1.02-1.12). Compared to the reference period 
1993-1997, patients diagnosed with ES-SCLC during the latter time periods had worse 
OS: 1998-2002 (HR: 1.12; 95% CI, 1.08-1.15), 2003-2007 (HR: 1.23, 95% CI 1.20-1.27) 
and 2008+ (HR: 1.53, 95% CI, 1.49-1.58). A similar difference was not seen in patients 
with LS-SCLC, where only the most recent time period 2008+, had a worse survival 
compared to 1993-1997 period (HR: 1.37, 95% CI, 1.30-1.43). Conclusion: Females, 
whites, and younger patients with SCLC had better OS compared to males, blacks 
and older patients, respectively. Unfortunately, survival from SCLC has not improved 
significantly and may actually have worsened, during the past 20 years. The reason 
for this discord between clinical trial evidence and real-world evidence need to be 
investigated further. Newer treatment approaches are urgently needed for this disease. 
Keywords: SEER database, survival, outcomes, SCLC
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MINI38.01 FAK Inhibitor VS-6063 Targets Mesothelioma Cancer Stem Cells: 
Rationale for Maintenance Therapy after Conventional Chemotherapy Vihren 
Kolev1, Irina Shapiro1, Paul Baas2, Raphael Bueno3, Jonathan Pachter1, David Weaver1 
1Verastem, Boston/MA/United States of America, 2Department of Thoracic Oncology, 
Netherlands Cancer Institute, Amsterdam/Netherlands, 3Division of Thoracic Surgery, 
Brigham and Women’s Hospital/ Harvard Medical School, Boston/MA/United States of 
America
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MINI38.06 FP1039/GSK3052230 with Chemotherapy in Patients with 
Fibroblast Growth Factor (FGF) Pathway Deregulated Squamous NSCLC or 
MPM Pilar Garrido1, Ignacio Delgado2, Enriqueta Felip3, Manuel Domine4, Paul Paik5, 
Jose Trigo6, Jan Schellens7, Shirish Gadgeel8, Hedy Lee Kindler9, Primo Lara Jr.10, 
Sergey Orlov11, Johan Vansteenkiste12, Evgeny Levchenko13, Ulrik Lassen14, Santiago 
Viteri15, Julie Hambleton16, Katherine Baker-Neblett17, Li Yan18, Chenxi Wang18, Donna 
Sedoti18, Gray Kirby17, Ionel Mitrica18, Jeffrey Botbyl18, Daniel Morgensztern19 
1Medical Oncology Department, Hospital Ramón Y Cajal, Madrid/Spain, 2Oncology 
Department, Hospital Infanta Cristina, Badajoz/Spain, 3Servicio de Oncologia, Hospital 
General Universitario Vall D’Hebron, Barcelona/Spain, 4Fundación Jiménez Díaz, Madrid/
Spain, 5Memorial Sloan Kettering Cancer Center, New York/NY/United States of America, 
6Hospital Virgen de La Victoria, Malaga/Spain, 7Antoni Van Leeuwenhoek Ziekenhuis, 
Amsterdam/Netherlands, 8Karmanos Cancer Institute, Detroit/MI/United States of 
America, 9Medicine, University of Chicago, Chicago/IL/United States of America, 10University 
of California, Davis Medical Center, Sacramento/CA/United States of America, 11Pavlov State 
Medical University, St Petersburg/Russian Federation, 12University Hospital Gasthuisberg, 
Leuven/Belgium, 13Petrov Research Institute of Oncology, St. Petersburg/Russian 
Federation, 14Department of Oncology, Rigshospitalet, Koebenhavn/Denmark, 15Hospital 
Univ. Quirón Dexeus, Barcelona/Spain, 16Five Prime Therapeutics, San Francisco/CA/
United States of America, 17Glaxosmithkline, Research Triangle Park/NC/United States 
of America, 18Glaxosmithkline, Philadelphia/PA/United States of America, 19Oncology, 
Washington University School of Medicine in St. Louis, St. Louis/MO/United States of 
America
Background: GSK3052230/FP1039 is a soluble fusion protein with the ECD of FGFR1c 
linked to the hinge and Fc regions of human IgG1 and acts as a ligand trap by sequestering 
FGFs involved in tumor growth and angiogenesis. In contrast to small molecule FGFR 
kinase inhibitors, GSK3052230 spares the hormonal FGF ligands, namely FGF19, 21 
and 23. GSK3052230 combined with chemotherapy was efficacious in xenograft 
models of FGFR1-amplified NSCLC and malignant pleural mesothelioma (MPM) with FGF2 
mRNA overexpression. A phase I monotherapy study determined 20mg/kg weekly as 
the maximum feasible dose (MFD) achieving the desired blood concentration, with no 
maximum tolerated dose (MTD) reached. Methods: This study (NCT01868022 funded by 
GSK) will evaluate the safety and efficacy of GSK3052230 weekly infusion in combination 
with paclitaxel + carboplatin in previously untreated FGFR1 amplified metastatic sqNSCLC 
(Arm A), in combination with docetaxel in FGFR1 amplified metastatic sqNSCLC that 
has progressed after at least 1 line of chemotherapy (Arm B), or in combination with 
pemetrexed + cisplatin in patients with untreated and unresectable MPM (Arm C). Each 
arm involves a dose escalation phase utilizing the 3+3 design, followed by an expansion 
phase up to 30 patients (pts). Key endpoints include the MTD/MFD of GSK3052230 
with chemotherapy, safety, response rates and duration. Results: Thirty-four pts 
have been dosed with GSK3052230 at dose levels ranging from 5mg/kg to 20mg/
kg in combination with chemotherapy across three Arms, n=15 (A), n=6 (B) and n=13 
(C). Baseline characteristics: males/females 29/5; mean age 68.5 years; ECOG PS 0 
(n=20), 1 (n=13), 2 (n=1). Most common AEs were: Arm A: asthenia, neutropenia; Arm 
B: neutropenia, diarrhea, rash; Arm C: decreased appetite, nausea, infusion reaction. 
Infusion reactions were seen in 8/34 (24%) pts (n=3 Grade (Gr)1, n=3 Gr2, n=2 Gr3). 
Serious AEs included: Arm A- neutropenia (n=4), fatigue (n=1), asthenia (n=1), fever 
(n=1), respiratory infection (n=1); Arm B- neutropenia (n=1), abdominal pain (n=1); Arm 
C-bowel perforation/ischemia (n=1), infusion reaction (n=1), elevated creatinine (n=1). 
No DLTs have been observed in sqNSCLC pts (Arms A and B). Three DLTs were reported 
in mesothelioma pts (Arm C 20mg/kg): Gr5 bowel perforation/ischemia, Gr4 elevated 
creatinine levels and Gr3 infusion reaction. MFD for Arm A is determined at 20mg/
kg. Dose escalation is ongoing for Arms B and C. Preliminary PK results revealed no 
drug-drug interactions. At time of data-cutoff, 10 PR were observed among 23 patients 
evaluable for efficacy (ORR = 43%) and a clinical benefit rate of 78% with two ongoing 
subjects on study >300 days. Preliminary efficacy is as follows: Arm A (6 PR, 2 SD, 1 
PD, 6= not-yet-evaluable (NE)), Arm B (4 SD, 1 PD, 1 NE), and Arm C (3 PR, 3 SD, 3 
PD, 4 NE). Conclusion: GSK3052230 is in general well tolerated in combination with 
chemotherapy. The MFD for GSK3052230 is 20mg/kg in combination with paclitaxel 
+ carboplatin in first line sqNSCLC patients. Toxicities typically associated with small-
molecule FGFR inhibitors, namely hyperphosphatemia and retinal, nail, and skin changes, 
were not observed. The initial activity and safety profile of GSK3052230  warrant further 
study.
BIOLOGY AND PROGNOSIS 
WEDNESDAY, SEPTEMBER 9, 2015 - 18:30-20:00
MINI38.07 RITA Enhances Mithramycin-Mediated Growth Arrest and Apoptosis 
of Malignant Pleural Mesothelioma Cells In-Vitro and In-Vivo Mahadev Rao1, Vivek 
Shukla1, David Straughan1, Saïd Azoury1, Paul Feingold1, Scott M. Atay1, Young Hong1, 
Trevor Upham1, Julie A Hong1, Mary Zhang1, Xinmin Li2, R. T. Ripley1, David S. Schrump1 
1Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda/United States of 
America, 2Clinical Microarray Core, UCLA, Los Angeles/AL/United States of America
Background: Malignant pleural mesotheliomas (MPM) are relatively rare tumors for 
which there are no effective treatment options. Previously we reported that mithramycin 
(MM) dramatically inhibits growth and tumorigenicity of MPM cells in part via depletion of 
Specificity Protein 1 (SP1) and activation of p53 signaling. We also demonstrated that 24h 
MM treatment induces G0/G1arrest and senescence with subsequent apoptosis of MPM 
cells. The present study was undertaken to examine the effects of RITA (Reactivation of 
p53 and Induction of Tumor cell Apoptosis- a p53 activator and MDM2 inhibitor) with or 
without MM in cultured MPM cells in vitro and in vivo. Methods: NCI-SB-MES1 and NCI-SB-
MES7 (MES1 and MES7, respectively) with wild-type p53 were cultured in the presence 
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MINI38.03 Validation of a Specific Missense GTF2I Mutation in More Indolent 
Thymic Epithelial Tumours Spyridon Gennatas1, Hima Anbunathan1, Angeles 
Montero2, Andrew G. Nicholson3, Sanjay Popat4, Anne M. Bowcock1 1Genomic Medicine 
Section, Imperial College, London, London/United Kingdom, 2Histopathology, Royal 
Brompton & Harefield NHS Foundation Trust, London/United Kingdom, 3Department 
of Histopathology, Royal Brompton and Harefield NHS Trust, London/United 
Kingdom, 4Department of Medicine - Lung, Royal Marsden NHS Foundation Trust, Surrey/
United Kingdom
Background: Thymic epithelial tumours (TETs) are rare intrathoracic cancers 
that can be invasive and very difficult to treat. There is currently a huge gap in the 
understanding of the basic science behind their development as well as great clinical 
need for development of effective treatments. Recently a missense mutation (T>A, at 
the same position on chromosome 7, 74146970) was identified in GTF2I at high frequency 
(78%) in the more indolent type A and AB thymomas. We examined the frequency of 
this alteration in an independent cohort of well clinically characterized patients from 
the UK. Methods: Tumour samples were collected from 94 patients from a single 
tertiary cardiothoracic centre in the UK, the Royal Brompton & Harefield NHS Foundation 
Trust (London). These were subject to histological assessment by expert Consultant 
Histopathologists to confirm the diagnosis and determine tumour abundance. DNA was 
extracted with Quiagen’s QIAamp DNA FFPE Tissue Kit (Catalogue No. 56404). PCR and 
Sanger sequencing was performed with semi-nested primers. Results: We assessed 
the frequency of the GTF2I mutation in a total of 94 TETs with a tumour abundance of at 
least 70%. The mean age for all patients was 57 and the male: female ratio was 1:1.25 
The GTF2I mutation was seen in 25 of 87 evaluable TETs (29%) and was present more 
commonly in type A (85%) and AB (46%) thymomas. The frequency decreased to 9% 
in type B1 (1/11) and 5% in type B2 thymomas (1/19). In our cohort the mutation was 
not detected in any B3 thymomas or carcinomas, including neuroendocrine tumours 
or two cases of thymic hyperplasia. Interestingly all AB thymomas with the mutation 
had a much lower percentage of mutant alleles compared to the majority of the A 
thymomas. Twenty-three of the 25 patients (92%) with the mutation had Stage I – II 
disease at presentation and had complete resection of their thymoma. Conclusion: Our 
results confirm the presence of the GTF2I mutation at a high frequency in type A and AB 
thymomas in an entirely different patient cohort. Although the frequency of the mutation 
in type A thymomas in our cohort is very similar to what was reported originally (85% 
and 82% respectively) it was lower in the AB thymomas (46% and 74% respectively). 
Explanations for this include the smaller sample number in our cohort and a higher 
percentage of the lymphocytic component in our samples than that in the original series. 
The lower mutation frequency in the B subtypes and carcinomas compared to the original 
series could be due to the smaller numbers in our cohort. We aim to address these 
issues by expanding our validation series to over 200 samples. Whole exome and RNA 
sequencing of TETs is ongoing and will allow us to further confirm and extend this finding. 
Keywords: thymic tumours, Thymoma, Gene mutation
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MINI38.04 BRCA1/OCT1/MAD2L1 Axis Regulates a Bifurcating Apoptotic 
Pathway Induced by Vinorelbine in Mesothelioma Sara Busacca1, AnnabelJ. 
Sharkey1, David Waller2, Apostolos Nakas2, Laura O’Regan1, Keith Kerr3, Michael Sheaff4, 
Andrew Fry1, DeanA. Fennell1 1University of Leicester, Leicester/United Kingdom, 2Glenfield 
Hospital, Leicester/United Kingdom, 3Department of Pathology, Aberdeen Royal Infirmary, 
Aberdeen/United Kingdom, 4Barts and the London NHS Trust, London/United Kingdom
Background: There is currently no licenced second line therapy for mesothelioma patients 
upon relapse after pemetrexed cisplatin. The vinca alkaloid spindle poison, vinorelbine, 
exhibits useful activity in mesothelioma, warranting evaluation in a new UK randomised 
clinical trial, VIM. However the molecular determinants of efficacy are unclear. We have 
reported that BRCA1 is an essential regulator of vinorelbine-induced apoptosis, and loss of 
detectable BRCA1 occurs in 39% of mesotheliomas. However the mechanisms governing 
BRCA1 dependent lethality has been lacking. We have utilized a functional genetic 
approach to uncover critical genes required for vinorelbine efficacy. Methods:Apoptosis 
was analysed by PARP cleavage and caspase 3/7 activity assay. Focused RNAi targeting 
Caspase 8, BAX and BAK was conducted to delineate critical death activators. Mouse 
embryonic fibroblasts (MEFs) wild type (WT) or double knockout (DKO) for BAX/BAK 
cells were also used. MAD2L1 expression was studied by western blot and qRT-PCR. 
Tumour explants were derived from 10 MPM patients. Results: Mitochondrial and 
caspase-8 dependent apoptosis pathways were shown by triple knockdown of BAX, 
BAK and Caspase 8 to be required to rescue completely from vinorelbine-induced 
apoptosis. Loss of BRCA1 recapitulated this apoptosis block and was associated with 
loss of Oct1 dependent MAD2L1 associated transcriptional upregulation. RNAi mediated 
silencing of MAD2L12 phenocopied BRCA1 loss. In cells selected for resistance to 
vinorelbine, MAD2L1 failed to upregulate, secondly to constitutive downregulation of 
BRCA1. Using mesothelioma explants derived at extrapleural decortication, exhibited 
either marked resistance or sensitivity to vinorelbine induced apoptosis; correlation with 
regulation of BRCA1/Oct1/MAD2L is ongoing and will be presented. Conclusion: BRCA1 
functions through an Oct1/MAD2L1-dependent activation of both mitochondria 
dependent and independent pathways to induce apoptosis. This implicates a 
requirement for a functional spindle assembly checkpoint, with implications for 
expanding the biomarker repertoire governing vinorelbine efficacy in mesothelioma 
Keywords: explants, vinorelbine, Mesothelioma, apoptosis
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MINI38.09 The Prognostic Signifi cance of Nodal Metastatic Burden in Survival 
following Radical Surgery for Malignant Pleural Mesothelioma
Annabel J. Sharkey, Apostolos Nakas, David Waller University Hospitals of Leicester, 
Leicester/United Kingdom
Background: The staging of malignant pleural mesothelioma (MPM) remains 
undetermined. But it is still important for informing prognosis and selection for high risk 
surgery. The specifi c lymphatic drainage of the pleura implies that nodal staging based on 
that used in lung cancer may not be accurate for MPM. We have evaluated an alternative 
nodal staging strategy. Methods: We retrospectively analysed the pathology and 
outcome of 282 patients who survived for over 30 days following radical surgery for MPM: 
190 extended pleurectomy decortication(EPD), 92 extrapleural pneumonectomy(EPP). 
All patients underwent intraoperative systematic nodal dissection. Nodal stations were 
assigned to all nodes, and patients were staged according to the current UICC system. 
The status and number of nodes in each station were recorded. Survival was calculated 
for the standard nodal stages (N0, N1, N2). We derived nodal groups Na, Nb, Nc based 
on the percentage of sampled nodes containing tumour, irrespective of nodal station: Na 
= N0, Nb ≤ median %, Nc > median %. Results: The type of surgery did not infl uence 
median survival; EPD 12.3 vs. EPP 14.5 months, p=0.46. The median survival of the 
standard nodal stages were: N0(113 patients), 16.5 months; N1(13 patients), 13.0 
months; N2(156 patients), 11.8 months. There was no signifi cance difference in survival 
between N1 and N2, p=0.65 but there was between N0 and N1/N2, p=0.04. The median 
percentage of nodal metastases was 43%. There were signifi cant differences in median 
survival between Na, Nb and Nc, p=0.03. There were signifi cantly more positive N2 
nodes in group Nc (98%), than in group Nb (86%) p=0.001.




Na - no metastases 113 16.5
Nb - </= 43% metastases 86 13.5
Nc - > 43% metastases 83 9.9
Conclusion: There appears to be greater accuracy in a nodal staging system based on 
the nodal burden of metastases rather than an anatomically based system. There may 
be less accuracy in nodal staging in lung sparing radical surgery for MPM due to less 
extensive nodal sampling.
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MINI38.11 Tumor Volume and Epithelioid Differentiation Are Independent 
Predictors of Survival in  Malignant Pleural Mesothelioma Diana Kircheva, Aliya 
Husain, Sydeaka Watson, Arif Qudsia, Amy Durkin Celauro, Samuel Armato, Hedy Lee 
Kindler, Wickii T. Vigneswaran University of Chicago, Chicago/IL/United States of America
Background: Maximal cyto-reductive surgery with adjuvant therapy provides 
survival advantage in selected patients with malignant pleural mesothelioma (MPM). 
Extended pleurectomy and decortication (EPD), a lung sparing procedure, provides 
an opportunity to measure the tumor volume. We hypothesized that tumor volume is 
of mithramycin (24h) and/or RITA (48h). DNA damage, senescence and autophagy were 
assessed by immunoblot/immunofl uorescence analysis of g-H2A-X phosphorylation 
and foci formation, ß-gal staining, and immunoblot/immunofl uorescence analysis 
of LC3 proteins. Propidium iodide and APO-BrdU techniques were used to determine 
cell cycle kinetics and quantify apoptosis. qRT-PCR and immunoblot techniques were 
used to examine signal transduction, cell cycle-related and apoptosis-related protein 
levels in MPM cells. Murine subcutaneous xenograft models were used to evaluate the 
combinatorial antitumor effects of RITA and MM in-vivo. Results: MM treatment (10-100nM 
x 24h) mediated dose-dependent depletion of SP1 and markedly increased p53 levels in 
MPM cells; these effects coincided with DNA damage, G0/G1 arrest, senescence and an 
autophagy phenotype as evidenced by induction of LC3 puncta/proteins and p-AMPK and 
inhibition of p-S6 kinase. Senescence or autophagy phenotype coincided with up-regulation 
of CDKN1A, MDM2/TP53INP1, MAPLC3B, and down-regulation of EZH2, SP1/MTOR. 
RITA (100-1000nM x48h) alone mediated low-level, dose-dependent growth inhibition 
in MPM cells. However treatment with subtherapeutic doses of MM for 24h followed 
by RITA for 48h resulted in synergistic growth inhibition and apoptosis in MPM cells, 
detected by fl ow cytometry, as well as immunoblot analysis of cleaved PARP and cleaved 
caspase 3. Sequential intraperitoneal treatment with MM (1mg/kg/week) followed by 
RITA (2 mg/kg/3d/week) signifi cantly reduced volumes/masses of subcutaneous MES1 
xenografts in athymic nude mice. Conclusion: Sequential mithramycin/RITA treatment 
signifi cantly reduces mesothelioma tumor burden via induction of apoptosis. These 
fi ndings provide preclinical rationale for evaluation of this drug regimen in MPM patients. 
Keywords: Mithramycin,RITA,Mesothelioma,apoptosis
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MINI38.08 Contemporary Analysis of Prognostic Factors in Patients with 
Unresectable Malignant Pleural Mesothelioma (MPM) Andrea Bille1, Marjorie 
Zauderer2, Kaitlin Woo3, Valerie W. Rusch4, Lee M. Krug5 1Thoracic Surgery, Memorial 
Sloan Kettering Cancer Center, New York/AL/United States of America, 2Medicine/Thoracic 
Oncology, MSKCC, New York/NY/United States of America, 3Epideimiolgy and Biostatistics, 
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Background: The CALGB and EORTC have previously developed prognostic scoring 
systems for patients with MPM, but these included patients managed surgically 
and predated the use of pemetrexed. We sought to identify prognostic factors in a 
contemporary cohort of patients with unresectable MPM. Methods: We retrospectively 
reviewed the charts of patients with histologically proven MPM managed non-surgically 
at MSKCC from 2000-2012. Variables analyzed and correlated with overall survival (OS) 
included: sex, age at diagnosis, smoking history, asbestos exposure, tumor laterality, 
initial performance status (PS), tumor histology, clinical TNM, initial PET maximum 
Standardized Uptake Value (SUVmax), hemoglobin level, platelet, lymphocyte and 
neutrophil counts, treatment type (chemotherapy and/or radiotherapy), and response 
to treatment. OS was analyzed by Kaplan-Meier method, and signifi cance (p<0.05) of 
prognostic factors was analyzed by log-rank test and Cox regression. Results: 191 
patients met study criteria: median age 71 years (range 46-90), 147 (77%) male, 128 
(67%) epithelioid , 20 (10.5%) biphasic, and 28 (14.6%) sarcomatoid. 34 patients were 
stage I-II at presentation and 157 (82%) stage III-IV. First line chemotherapy included 
pemetrexed in 159 (90.3%) patients. Median time from diagnosis to treatment was 1.2 
months. With a median follow-up of 13.2 months, median OS for all patients was 13.4 
months. By univariate analysis, histology (p<0.001), platelet count (≤450 vs. >450, 
p<0.001), initial PS, maximum PET SUV (> or ≤8.1, p=0.037) were signifi cant. Clinical 
staging (I/II vs III/IV) did not correlate with OS (p=0.35). By multivariable analyses, only 
histology, platelet count and PS were independent prognostic factors. 1-year OS was 
69% (95%CI 62%-78%) for epithelioid versus 30% (95%CI 15%-59%) and 29% (95%CI 
16%-51%) for biphasic and sarcomatoid tumors, respectively. Patients with PS 0-1 
had a 1-year OS of 64% (95%CI 56%-73%) versus 42% (95%CI 31%-57%) for PS 2 or 
greater. Epithelioid histology, PS 0-1 and elevated neutrophil count at diagnosis were 
signifi cantly associated with response to fi rst line chemotherapy. Patients with response 
or stable disease after the fi rst two cycles of chemotherapy had signifi cantly better OS, 
median OS was 16.8 (95% CI 14.8 – 20.1) versus 6.5 (95% CI 5.4-8.5) months (p<0.001). 
Patients receiving more than one line of chemotherapy had better OS, median OS 14.2 
(95% CI 12.1 – 16.8) versus 8.7 (95% CI 6.6 – 11.0 ) months (p=0.013). There was 
no signifi cant association between use of radiotherapy and OS (p=0.058), but patients 
who received radiotherapy showed a 1-year OS of 60.5% vs 44.0% of patients who 
did not receive radiotherapy. Conclusion:This analysis in patients with unresectable 
MPM confi rms that some elements of the CALGB and EORTC prognostic scoring 
systems (platelet count, PS, histology) correlate with OS, and identifi es factors (PS, 
elevated neutrophil count, histology) associated with response to chemotherapy. Our 
analysis emphasizes the impact of histology and response to fi rst-line chemotherapy 
on outcomes, but also the lack of predictability with the use of clinical staging. 
Keywords: malignant pleural mesothelioma, chemotherapy, prognostic score, overall 
survival
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Background: The value of surgical treatment for malignant pleural mesothelioma is still 
an open question. We analysed a surgical series of MPM patients undergoing surgery 
for MPM in a single institution. Methods: A retrospective analysis was carried out of all 
surgical patients treated in our Department from 2000 to February 2015. Selection criteria 
were age<75, performance status 0-1, non-sarcomatoid histology, pretreatment stage 
I-III, and fit for major surgery. The procedure of choice was extrapleural pneumonectomy 
(EPP) until 2010 and radical pleurectomy/decortication (PD) thereafter. Patients that 
were found to be unresectable underwent palliative pleurectomy. The IMIG system was 
used for pathological staging, complications were scored based on WHO-derived criteria 
and the Charlson Co-morbidity Index was used to stratify patients. Results: Radical 
surgery was attempted in 163 patients: 91 received EPP, 47 underwent PD (1 with 
macroscopic residual disease) and 25 a palliative pleurectomy. Their main features 
and survival outcomes are summarized in table 1. Mean age and Charlson score were 
higher in PD than in EPP patients. A mixed histology was more prevalent in those who 
received palliative pleurectomy. Complications were equally frequent after EPP and PD 
but less frequent after palliative surgery. However, EPP patients had a high frequency of 
early- and late-occurring (30-600+ days postop) pleural sepsis (p=0.002) that had an 
unfavorable effect on OS (p=0.035). Induction chemotherapy was associated with better 
outcomes in PD but not in EPP. At multivariate analysis, epithelial histology (p=0.0419, 
grade 3+ complications (p=0.001) and Charlson index (p=0.001) were associated with 
better overall survival (OS). PD was associated with better OS compared with palliative 
pleurectomy (p=0.05), while EPP was not. 
EP (%) P/D (%) R2 (%)
N° 91 47 25
Mean Age (95% CI) 60 (58 - 61) 65 (62 - 67) 63 (60 - 66)
Males 66 (72) 31 (66) 22 (88)
Trimodal** 28 (30.77) 33 (70.21) 6 (24.00)
Epithelioid 81 (89.01) 46 (97.87) 20 (80.00)
p-Stage 0-II 18 (19.8) 18 (38.3) -
p-Stage III 68 (74.73) 20 (42.55) 2 (8.00)
p-Stage IV 5 (5.49) 9 (19.15) 21 (92.00)
Grade 3+ Compli-
cations 25 (25.47) 12 (25.53) 2 (8.00)
30-Day Mortality 3 (3.30) 1 (2.13) -
Median OS (IQI) 19.0 (9.3 - 35.6) 29.9 (13.7 - 35.2) 13.3 (4.7 - 31.6)
Median DFS (IQI) 11.5 (7.1 - 21.8) 12.1 (6.4 - 19.2) -
 
Title table: Patients’ features and survival outcomes in surgical MPM patients * Surgery 
+ either chemo or RT, **induction + Surgery + Postoperative radiotherapy, IQI= 
Interquartile Interval 
a better predictor of survival than the T and N, because it represents tumor burden 
more accurately. Currently the significance of epithelioid differentiation in the biphasic 
histology also remains poorly understood. We report our experience with patients 
undergoing EPD and the implication of tumor volume and epithelioid differentiation in 
overall survival. Methods: We evaluated 116 patients who underwent EPD for MPM. 
The following variables were assessed: age, gender, histology, tumor volume and 
pathological T and N stage. The tumor volume of resected specimens was measured 
using a water displacement method. All histological examinations were performed by 
a single pathologist, and the percent epithelioid histology was estimated in all patients. 
A Cox regression model was used to identify significant predictors of survival. Kaplan-
Meier was used to summarize overall and subgroup survival. Results: There were 95 
males and 21 females with a median age of 68 years (range 43-88 years). Epithelioid 
differentiation was 100% in 60 patients, 50-95% in 35 patients, and less than 50% in 
21 patients (no patient with pure sarcomatoid histology was included in this report). 
Mean tumor volume was 642+/- 400ml. Tumor volume was between 100-299cc in 20 
patients, between 300-599cc in 37 patients, and >600cc in 54 patients. In 5 patients 
the volume was not estimated. Six patients (5%) died within 30 days. Two-year survival 
from EPD was 28%. Median survival was 15.7 months. Percent epithelioid differentiation 
(p=0.0004) and tumor volume (p=0.001) were significant predictors of survival. T 
(p=0.05) stage, but not N stage, was a significant predictor of survival. Tumor volume 
was a predictor of T stage (p=0.05). No relationship between N stage and either tumor 
volume or histology was observed. Conclusion: Percent epithelioid differentiation and 
tumor volume are independent predictors of survival in MPM patients undergoing EPD. 
Keywords: malignant pleural mesothelioma, Epithelioid, Pleurectomy and Decortication, 
Tumor volume
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MINI38.12 Multiplex Immunofluorescence Identifies Differences in Immune 
Microenvironment & Prognostic Biomarkers between Mesothelioma Subtypes 
Tanguy Seiwert1, Stephanie Mcgregor2, Chengyi Shu3, Igor Feldman4, Tong Zi3, Zhixiang 
Zuo5, Arun Khattri2, Aliya Husain6, Hadi Duraid2, Wickii T. Vigneswaran2, Thomas N. 
Krausz2, Sriram Sathyanarayanan3, Hedy Lee Kindler1 1Section of Hematology/Oncology, 
University of Chicago, Chicago/IL/United States of America, 2University of Chicago, 
Chicago/United States of America, 3Jounce Therapeutics, Boston/MA/United States of 
America, 4Jounce Therapeutics, Boston/United States of America, 5University of Chicago, 
Chicago/AL/United States of America, 6University of Chicago, Chicago/IL/United States of 
America
Background: Malignant mesothelioma (MM) is a universally lethal disease, which 
develops in the pleura, peritoneum, pericardium, and tunica vaginalis. MM is commonly 
associated with a prominent inflammatory reaction, including extensive macrophage 
infiltration. Early reports indicate presence of tumor infiltrating lymphocytes (TILs), 
PD-L1 expression (Kindler et al ASCO 2014), and activity of anti-PD-1 therapy (Alley et 
al AACR 2015). However, quantitative evaluation of multiple immune markers in a large 
mesothelioma cohort and evaluation of prognostic and biologic implications has not 
been reported. Methods: We performed multiplex immunofluorescence (IF) staining 
and automated, quantitative density assessments in a clinically annotated cohort of 109 
malignant mesotheliomas (58 epithelioid, 43 biphasic, 8 sarcomatoid). Staining for PD-1, 
PD-L1 (immune checkpoint), FOXP3 (T-regulatory cells), and CD8 (TILs) was performed 
using a quantitative, multiplex IF system (TissueFax), and a multi-tumor-validated, 
quantitative StrataQuest analysis algorithm in order to identify specific immune cells 
and respective densities. Gene expression data (TCGA) was analyzed to confirm 
individual correlations. Staining for CD206 (macrophages) is ongoing. Results: PD-L1 
density correlated with more aggressive histology, and was highest in sarcomatoid 
(median density score of 3016), and biphasic (2720) tumors compared with epithelioid 
tumors (1740). Using a cutoff of 5% PD-L1 density by area 19% of epithelioid, 38% of 
sarcomatoid, and 44% of biphasic tumors were deemed PD-L1 positive. PD-L1 expression 
exhibited a bimodal distribution (peaks at both high and low PD-L1 densities). Also with 
the biphasic tumor cohort expression of PD-L1 correlated with worse outcome (P=0.02), 
while PD-1 and CD8 did not have prognostic implications (and could not distinguish 
histologic subtypes). By contrast in epithelioid MM CD8 infiltration density showed a 
trend towards improved prognosis (P=0.06) (and correlated with PD-1 expression), while 
PD-L1 expression was not prognostic. Interestingly, PD-1/CD8 and PD-L1 expression 
did not correlate regardless of histology (R=0.02-0.08), suggesting macrophage-driven 
PD-L1 expression. Gene expression data supported this hypothesis and staining for M2-
related macrophage markers is ongoing. In epithelioid tumors FOXP3 T-regulatory cell 
density showed a trend towards worse prognosis (P=0.07). In biphasic and sarcomatoid 
tumors prognosis was poor regardless of FOXP3 expression. Data on stromal versus 
tumor expression patterns is being processed. Conclusion: In mesothelioma CD8, 
PD-1, PD-L1 and FOXP3 are widely expressed, with 19% of epithelioid, and 38-44% of 
sarcomatoid and biphasic tumors showing elevated PD-L1 density. PD-L1 expression 
correlates with a worse prognosis by subtype and in the biphasic tumor population. In 
epithelioid tumors PD-1 may indicate better outcome. PD-1 and PD-L1 expression do not 
correlate with each other in malignant mesothelioma, which relates to pro-tumorigenic 
macrophages leading to potentially interferon gamma independent PD-L1 expression. 
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MINI38.13 Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit 
for Surgery According to Type of Procedure and Completeness of Resection 
Maurizio Infante1, Edoardo Bottoni1, Emanuela Morenghi2, PaoloA. Zucali3, Daoud 
Rahal4, Andrea Morlacchi1, Anna Maria Ascolese5, Pierina Navarria5, Alberto Testori1, 
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Conclusion: In this study of 14,228 patients over 36 years, cancer-directed 
surgery was associated with better survival in MPM, independent of other 
forms of therapy, including radiation. These data support the role of surgery-
based therapy as the cornerstone for treatment in this challenging disease. 
Keywords: mesothelioma, SEER, surgery, radiation
 
Conclusion: EPP does not offer a significant benefit while PD may offer 
an advantage over palliative pleurectomy. The Charlson index is a major 
independent prognosticator in patients undergoing surgery for MPM. 
Keywords: malignant pleural mesothelioma, pneumonectomy, radical pleurectomy/
decortication
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MINI38.14 Surgery and Not Radiation Improves Survival in Malignant Pleural 
Mesothelioma Andrea Wolf1, Emanuela Taioli1, Marlene Camacho-Rivera2, Andrew 
Kaufman1, Dong-Seok Lee1, Daniel Nicastri1, Kenneth Rosenzweig3, Raja Flores1 
1Department of Thoracic Surgery, The Mount Sinai Health System, New York/NY/United 
States of America, 2Department of Population Health, North Shore/Long Island Jewish Health 
System, New York/AL/United States of America, 3Department of Radiation Oncology, The 
Mount Sinai Health System, New York/NY/United States of America
Background: Surgery has a controversial role in the treatment of malignant pleural 
mesothelioma (MPM) as no trial has demonstrated independent survival benefit of 
surgery. Likewise, there is lack of consensus regarding the role of radiation in MPM. 
We evaluated whether cancer-directed surgery and/or radiation independently influenced 
MPM survival in a large population-based dataset. Methods: The Surveillance, 
Epidemiology, and End Results database was explored from 1973 to 2009 to identify 
all cases of pathologically-proven MPM. Age, sex, race, diagnosis year, stage, cancer-
directed surgery, radiation, and vital status were analyzed (chemotherapy data not 
available). The association between prognostic factors and survival was estimated using 
a Cox proportional hazards model. Results: There were 14,228 patients with pathologic 
diagnosis of MPM. On multivariable analysis, female gender, younger age, localized 
stage, and cancer-directed surgery were independently associated with longer survival 
(Table). Survival was longer for patients who underwent surgery or surgery and radiation 
but not for those who underwent radiation only (Figure).
Table. Association between Patient and Disease Characteristics and Survival
Variable Category Adjusted HR (95% CI) *
Sex Male 1 (Ref)
Female 0.78 ( 0.75-0.82)
Race White 1 (ref)
Black 1.07 (0.98-1.16)
Other 0.99 (0.89-1.09)
Age (years) continuous 1.24 (1.22-1.26)
Stage Localized 1 (ref)
Regional 1.30 (1.21-1.40)
Distant 1.34 (1.26-1.42)





Therapy No radiation or surgery 1 (ref)
Radiation only 1.17 (1.10-1.25)
Surgery only 0.65 (0.62-0.68)
Radiation and surgery 0.69 (0.63-0.75)
